{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"]},"docs":[{"location":"","title":"Home","text":"<p>This is the online home of the Vanderbilt Internal Medicine Residency Handbook.</p>"},{"location":"#dedication","title":"Dedication","text":"<p>The authors and editors dedicate the fourth edition of the Housestaff Handbook to the memory of Dr. Michael Fowler, whose compassion, sincerity, and commitment to education continue to guide and inspire us.\u00a0</p> <p>Michael J. Fowler, MD, Associate Professor of Medicine and Associate Professor, Office of Teaching and Learning in Medicine in the Vanderbilt University School of Medicine, was an inspiring teacher and educator, an outstanding physician, and a wonderful colleague who passed away on February 20, 2022. As a Master Clinical Teacher at Vanderbilt, Mike was the Course Director for Physical Diagnosis and taught physical diagnosis to more than 1500 Vanderbilt medical students. As Co-director of the Shade Tree Clinic, he touched the lives of many patients and inspired Vanderbilt medical students to understand how to be a physician who cared for the entire patient. He was a wonderful, passionate teacher and advocate for all students in the clinical setting, in the classroom and in life, and touched many, many people with his kindness, humor, intellect, humility, and medical and teaching skills.</p> <p>\u2013 Alvin C. Powers, MD, Nashville, TN, May 2022</p> <p> </p> QR code link for this online VIMBook"},{"location":"appendices/appendices-discharge-va/","title":"How to Discharge a Patient at VA","text":"<p>Complete the following steps in this order to ensure info will be accurately reflected on the DIPN.</p> <ul> <li>Medication reconciliation</li> <li>The list of outpatient medications at the end of your reconciliation is the final medication discharge list.</li> <li>In the medication tab, transfer new inpatient medications to the outpatient medication list by right-clicking and select \u2018Transfer.\u2019</li> <li>Select \u201cPick up at window,\u201d as this will ensure the patient will have the medication prior to leaving the hospital.</li> <li>Order new supplies (wound care, tube feeds, etc) by placing new outpatient \"med\" order.</li> <li>Review the existing outpatient medications to determine if they need to be continued and if the pt has an adequate supply at home - refill meds if necessary.</li> <li>Discontinue any outpatient medications that you do not want the pt to continue taking. Right-click and select \u2018Discontinue.\u2019</li> <li>Return to clinic (Primary care).</li> <li>Critical to tag PCP on discharge summary to ensure they are alerted to hospital stay. Can also tag consultants and office coordinators (RNs) can be cc\u2019d to DC summary by resident.</li> <li>For PCP follow-up, no longer need to place an RTC, will be coordinated by PACT on the clinic side.</li> <li>Ask VA Inpatient Chief for \"welcome to VA wards\" info with instructions to place subspecialty hospital follow up appts, as there is variation (page fellow vs e-consult vs RTC).</li> <li>Complete DIPN</li> <li>The DIPN contains all of the discharge instructions.</li> <li>Start a new note and select \u2018DIPN\u2019 template. This will open a pre-templated note - follow the prompts and select finish. All sections need to be addressed to proceed.</li> <li>Discharge related orders will generate after you finish the DIPN prompts, which includes vaccinations, removing IV, removing Foley catheter, etc.</li> <li>The DIPN is valid for 24 hrs; thus the DIPN may be pre-signed one day prior. If DIPN is pre-signed, final changes to pt instructions and medications need to be addended.</li> <li>[Optional but strongly recommended] Provide personal instructions to the patient at the top of the DIPN (coach your interns to do this!), such as:<ul> <li>A simple statement for why the pt was admitted.</li> <li>Changes made to pt\u2019s medications that you feel are important to highlight.</li> <li>Home instructions (daily weights, diet changes, wound care, etc).</li> <li>Key follow-up plans (main appointments, labs, or tests).</li> </ul> </li> <li>Sign the DFF (discharge from facility) order:</li> <li>The DFF order is found under the \u201cDischarge Orders\u201d tab in CPRS orders.</li> <li>Once all steps are completed, DFF can be signed and pt will be discharged from facility.</li> <li>Discharge summary: right click dropdown menu \"identify additional cosigner\" ALWAYS add the patient's PCP, may add other consultants or subspecialists for continuity.</li> </ul>"},{"location":"appendices/appendices-discharge-vumc/","title":"How to Discharge a Patient at VUMC","text":"<ul> <li>Verify the correct pharmacy with the patient (Vanderbilt MCE     pharmacy if using meds-to-beds) and if refills of existing     medications are needed</li> <li>Select \u2018Transfer-Discharge\u2019 on the navigator panel on eStar select     \u2018Discharge\u2019 tab on the top of the page</li> <li>Select \u2018Rx Routing\u2019 on the left panel. Choose one of the three     options. This choice will set the default prescribing choice for new     medications at discharge or refilled medications. This can be     changed manually within each Rx order</li> <li>Default = will e-prescribe to pt\u2019s pharmacy</li> <li>Print = will print all Rx\u2019s and not e-prescribe (printed to nursing     station on pt\u2019s floor)</li> <li>Do not print and do not e-prescribe (This is used for pt going to     SNF or IPR)</li> <li>Select \u2018Discharge Orders\u2019 on the left panel. This will open a     reconciliation navigator</li> <li>Reconcile the home medications with the current inpatient     medications. The red tab on the right side of the screen will become     green when all medications are addressed</li> <li>For new medications or refills, make sure the \u2018Class\u2019 in the     prescription is set to \u2018Normal\u2019 for electronic prescriptions.     Otherwise, to add the medication to the list without a prescription,     choose \u2018No Print\u2019</li> <li>The medications will e-prescribe to the pharmacy selected at the     bottom of the order panel on the right side of your screen</li> <li>To send to multiple pharmacies, select the primary pharmacy at the     bottom of the order panel on the right side of your screen, then     choose \u2018Send to Multiple Pharmacies\u2019</li> <li>Note that meds-to-beds will arrange to deliver meds AFTER the     \"discharge\" order is signed; if discharge is time-sensitive, can     call to ask if meds can be delivered in advance</li> <li>Next, select \u2018Order Sets\u2019 at the top of the Discharge Orders panel</li> <li>In the order box on the right, type \u201cAdult General Discharge\u201d</li> <li>Right-click on the option and select \u201cAdd to Favorites\u201d. Now, this     option will be available on the Order Set page for future patients.</li> <li>Open Adult General Discharge order set<ul> <li>Select the appropriate choices pertinent to current pt<ul> <li>For SNF/LTC, include RN orders like diet, activity     order/restriction, wound care, etc.</li> </ul> </li> <li>On the right side of the screen, you can add Ad Hoc orders such     as:<ul> <li>Hospital Follow-up with \"X\" service (place these as soon as     you know!)</li> <li>Ambulatory Referrals</li> <li>Post-discharge labs</li> <li>Important for ID labs in addition to INR checks, place fax     number for which provider that will be following up results     in the comments section. If labs will be done outside of     Vanderbilt system, must select \"External Non-VMG\"</li> <li>Medications not listed on reconciliation list</li> </ul> </li> </ul> </li> <li>When all sections are completed, click \u2018Sign \u2013 Print and/or     E-prescribe Now\u2019</li> <li>Select \u2018Follow-up Providers\u2019 on the left panel.</li> <li>Select the providers that you want to receive the discharge summary.     Provide personal instructions to the patient</li> <li>Select \u2018Instructions\u2019 on the left-hand panel</li> <li>Free-text your personal comments and instructions to the patient,     such as:<ul> <li>A simple statement for why the pt was admitted</li> <li>Changes made to pt\u2019s medications that you feel are important to     highlight</li> <li>Home instructions (daily weights, diet changes, wound care, etc)</li> <li>Key follow-up plans (main appointments, labs, or tests)</li> </ul> </li> <li>This section appears FIRST in the pt\u2019s printed AVS</li> </ul>"},{"location":"appendices/appendices-door-codes/","title":"Appendices door codes","text":"<p>Please see print version and/or login through SSO (forthcoming)</p>"},{"location":"appendices/appendices-phone-numbers/","title":"Appendices phone numbers","text":"<p>Please see print version and/or login through SSO (forthcoming)</p>"},{"location":"appendices/appendices-rotations-va/","title":"Interns' Guide to Rotations at VA","text":""},{"location":"appendices/appendices-rotations-va/#structure-overview","title":"Structure Overview","text":"Teaching Service Structure Patient Cap Morgan 1-6 1 resident, 1 intern 10 Geriatrics 1 resident, 1 intern 10 Rogers (Hep, ID, Pulm, Renal) 1 resident, 1 intern 10 Heart Failure (CHF 1 &amp; 2 ) (one team) 1 resident, 2 interns 8 per intern (16 total) Cardiology (Harrison 1 &amp; 2) (two teams) 1 resident, 1 intern 10 Hematology (Brittingham A &amp; B) (one team) 1 resident, 2 interns 8 per intern (16 total) Oncology (Onc A &amp; B)  (two teams) 1 resident, 1 intern 10 VU MICU 1 &amp; 2   (two teams) 3 residents, 3 interns no cap (typically 10-12) VU CCU 3 residents no cap (typically 10-12) VU Night: Admitting Morgan/Rogers 1 resident, 2 interns 10 VU Night: Admitting Harrison/Heme/Onc 1 resident, 1 intern 10 VU Night: Crosscover 1 resident, 1 intern N/A VA Wards 1-5 1 resident, 2 interns 8 per intern (16 total) VA Wards 6 2 residents 8 per resident (16 total) VA MICU 3 residents, 3 interns no cap (typically 10-12) VA Night: Admitting 1 resident, 2 interns 10 VA Night: Crosscover 1 resident N/A"},{"location":"appendices/appendices-rotations-va/#va-veterans-affairs-rotations","title":"VA: Veterans Affairs Rotations","text":""},{"location":"appendices/appendices-rotations-va/#va-general-wards-1a-6b","title":"VA General Wards (1A \u2013 6B)","text":"<ul> <li>Always make sure that your VA login works a few days before you are     scheduled to start!</li> <li>Team: 1 Res, 2 Interns with soft patient cap of 8 each (16 total)</li> <li>Pagers: See VA Phone/Pager Directory Section for pager numbers</li> <li>Pick up list by 6:30 AM In the pulm/ID fellows workroom on the 2nd     floor (between team 4 workroom and the MICU), sign-out at 6 PM</li> <li>Admitting: Teams 1-3-5 &amp; 2-4-6 alternate admitting days and admit     until 5:30 PM</li> <li>Non-admitting teams can sign out once their work Is complete as     early as 2PM on weekdays and 12PM on weekends</li> <li>Rounds alternate at 7 AM on admitting days, 8 AM on non-admitting     days, meet at workrooms; night admitting team presents to attendings     at 7 AM (depending on team)</li> <li>Work rooms:<ul> <li>Team 1 on 2N hallway, past RN station</li> <li>Team 2 on 2N hallway, past RN station</li> <li>Team 3 on 2N hallway, between main elevators and RN station</li> <li>Team 4 at 2nd floor adjacent to main elevators</li> <li>Team 5 on 3N hallway</li> <li>Team 6 in pulm &amp; ID fellow workroom outside MICU on 2G</li> </ul> </li> <li>Tips: Admission days can be very busy and anything you can get done     on the non-admitting days will make your life easier (ex: DIPNs).     Ensure that you tag PCP on EVERY H&amp;P so they know patient is     admitted (right click signed H&amp;P -&gt; dropdown menu -&gt; \"identify     additional co-signer\"), make documents in OneDrive (it's     HIPAA-compliant!) to use as your pre-rounding sheet and sign-out     sheet and share these with your team (for days off); roll your     pagers via Vanderbilt operator (same as at VU); ensure all orders on     patients still in the ED are \u201cdelayed\u201d or they will disappear once     on the floor (ask your resident); all consults must be accompanied     by page to the covering fellow (use Synergy for medicine     subspecialties consult schedule, TVHS website for surgery/other),     beware that medications disappear after 1 month of admission (your     pharmacist can help!), beware that diets disappear when converting     obs to inpatient, enjoy a complimentary VA square!</li> </ul>"},{"location":"appendices/appendices-rotations-va/#va-micu","title":"VA MICU","text":"<ul> <li>Team: 3 Res, 3 Interns, no specific patient cap</li> <li>Combined CCU and MICU; 7AM CCU rounds followed by 8AM MICU rounds</li> <li>Day Intern: 7 AM - 9 PM; Night Intern 8 PM - 10 AM; MICU between 2N     and 2G (2nd floor)</li> <li>Tips: Night intern presents all of the old patients in the morning     and signs the notes. The day intern owns the A&amp;P of the notes by     keeping them updated. Never hesitate to relay information to your     resident overnight if you are concerned (wake him/her up!)</li> </ul>"},{"location":"appendices/appendices-rotations-va/#va-nights","title":"VA Nights","text":"<ul> <li>Team: 1 Res, 2 Interns, total of 10 admissions overnight</li> <li>Pager: NIGHT ADMIT RESIDENT must roll the night admitting pager     317-0227</li> <li>Start at 7 PM, Admit until 5 AM, present new patients to teams at 7     AM, leave by 8 AM</li> <li>Start Sunday night for interns, Wednesday night for residents; off     day is Saturday night for interns/cross-cover resident (covered by     clinic resident), Friday night for admitting resident (covered by     BMT resident)</li> <li>Tips: Admissions typically bolus at the start of shift and slow     later in the night, so worry about seeing pts, formulating plans     with resident and putting in orders first as notes can be finished     once it slows down, cafeteria at VU closes at 2 AM, communicate     everything you do with your resident who is supervising a second     intern as well, ensure all orders on pts still in the ED are     \u201cdelayed\u201d or they will disappear once on the floor (ask your     resident), enjoy a complimentary VA square for breakfast!</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/","title":"VUMC Rotations","text":""},{"location":"appendices/appendices-rotations-vumc/#structure-overview","title":"Structure Overview","text":"Teaching Service Structure Patient Cap Morgan 1-6 (Gen med) 1 resident, 1 intern 10 Geriatrics 1 resident, 1 intern 10 Rogers (Hep, ID, Pulm, Renal) 1 resident, 1 intern 10 Heart Failure (CHF 1 &amp; 2 ) (one team) 1 resident, 2 interns 8 per intern (16 total) Cardiology (Harrison 1 &amp; 2) (two teams) 1 resident, 1 intern 10 Hematology (Brittingham A &amp; B) (one team) 1 resident, 2 interns 8 per intern (16 total) Oncology (Onc A &amp; B)  (two teams) 1 resident, 1 intern 10 VU MICU 1 &amp; 2   (two teams) 3 residents, 3 interns no cap (typically 10-12) VU Night: Admitting Morgan/Rogers 1 resident, 2 interns 10 VU Night: Admitting Harrison/Heme/Onc 1 resident, 1 intern 10 VU Night: Crosscover 1 resident, 1 intern N/A VA Wards 1-5 1 resident, 2 interns 8 per intern (16 total) VA Wards 6 2 residents 8 per resident (16 total) VA MICU 3 residents, 3 interns no cap (typically 10-12) VA Night: Admitting 1 resident, 2 interns 10 VA Night: Crosscover 1 resident N/A <p>Non-comprehensive list of non-teaching services you may interact with:</p> Non-Teaching Service Type Riven General medicine Scoville General medicine (NP, night admitting) Page Campbell Cardiology Advanced Lung Disease Service (ALDS) Lung transplant Browning Hematology (benign + malignant) Stem Cell Transplant Stem Cell Transplant"},{"location":"appendices/appendices-rotations-vumc/#morgan-1-6-general-medicine","title":"Morgan (1 \u2013 6) (General Medicine)","text":"<ul> <li>Team: 1 Res, 1 Intern with patient cap of 10</li> <li>Pagers: Morgan 1: 831-4765, Morgan 2: 831-4766, Morgan 3: 831-4767,     Morgan 4: 831-4768, Morgan 5: 831-8481, Morgan 6: 831-4781</li> <li>Pick up list at 6 AM in res library on 8N (code 431), admit until     5:30 PM, sign-out 6 PM</li> <li>Admitting: Teams 1-3-5 &amp; 2-4-6 alternate admitting days (just like     VA)</li> <li>Non-admitting teams can sign out once their work is complete as     early as 2PM on weekdays and 12PM on weekends</li> <li>Rounding time and meeting location varies by attending (typically     between 7 to 8 AM)</li> <li>Work room: team-specific rooms labelled on hall behind 7N Nursing     station (Code 24300)<ul> <li>Morgan 5, 6 7755 (no code)</li> </ul> </li> <li>Huddle<ul> <li>Morgan 1</li> <li>Morgan 2</li> <li>Morgan 3</li> <li>Morgan 4</li> <li>Morgan 5 - 1340 on Teams</li> <li>Morgan 6 - 1350 on Teams</li> </ul> </li> <li>Tips: get pharmacist's phone number 1st day, get case     management/social work phone numbers, place consults as soon as     possible (preferably before rounds once consult teams arrive at 7     AM)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#geriatrics","title":"Geriatrics","text":"<ul> <li>Team: 1 Res, 1 Intern with patient cap of 10</li> <li>Rounds at 8 AM, team meets in the Round Wing workroom</li> <li>Work room: 7434</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#rogers-subspecialty-services","title":"Rogers (Subspecialty Services)","text":""},{"location":"appendices/appendices-rotations-vumc/#all-rogers-services","title":"All Rogers services","text":"<ul> <li>Team: 1 Res, 1 Intern with patient cap of 10</li> <li>Pick up list at 6 AM, admit daily until 5:30 PM, sign-out 6 PM</li> <li>Each HPI usually requires special info about the patient\u2019s     subspecialty diagnosis; refer to primer documents that are available     for most subspecialty services in the chief's \"welcome to the wards\"     email, and see tips below</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#rogers-hepatology","title":"Rogers Hepatology","text":"<ul> <li>Rounds typically at 8 AM, team meets on 6MCE</li> <li>Pager: 831-4782</li> <li>Work room: 6MCE, room 6755 near the elevators (no code)</li> <li>Review: Hepatology Section, Paracentesis (Procedures), and     'Surviving Rogers Hep' primer</li> <li>Tips: structure one-liner as \u201ccirrhosis secondary to ___     decompensated by ___ (EV bleed, ascites, SBP, HE, or HRS) who     follows with ___ (hepatologist) and is ___ (listed /     undergoing workup for / not listed) for transplant\u201d; know patient     MELD-Na scores (use the MELD-Na dot phrase or patient list column);     anticipate at least diagnostic paracentesis on admission if any     concern for SBP (abdominal pain, AMS, etc.)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#rogers-id","title":"Rogers ID","text":"<ul> <li>Rounds typically at 8 AM, team meets in Resident Library (8N)</li> <li>Pager: 831-4779</li> <li>Work room: 6 Round Wing, 2nd door on left after coming out of     elevator (no code)</li> <li>Tips: Each HPI for pt with HIV should include most recent CCC     provider, CD4/Viral Load, prior AIDS-defining illnesses and     compliance to ART; Use \u2018Notifications\u2019 tab on main screen in Epic to     keep track of lab orders as patients can have long stays with     send-out labs that can take up to two weeks to result (can also hit     \u2018Notify Me\u2019 in dropdown box of Order)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#rogers-pulmonology","title":"Rogers Pulmonology","text":"<ul> <li>Rounds typically at 8 AM, team meets at 8N nursing station</li> <li>Pager: 831-4777</li> <li>Work room: 8 South 8216 (code 2430)</li> <li>Tips: Each HPI should include most recent PFTs (FEV1% most     important, include other relevant data or recent changes); For CF,     Use the CF admission order set, know typical organisms in patient\u2019s     sputum (ex: MDR Pseudomonas, Burkholderia, MRSA)\u00a0and consult CF     team; for PH know the therapies they are on (typically Flolan or     Veletri)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#rogers-renal","title":"Rogers Renal","text":"<ul> <li>Rounds typically start 7-7:30 AM, team meets at resident/fellow work     room on 6MCE</li> <li>Pager: 831-4783</li> <li>Work room: 6MCE 6772, behind nursing station with renal fellows (no     code)</li> <li>Tips: Each HPI should have renal transplant history with year, type     of transplant, PRA, Ag MM, CMV D/R; 6MCE charge nurse can get pts     transferred there; alert the night cross-cover resident to patients     with recent renal biopsy and low threshold to contact renal fellow;     transplant pts should have daily tacro level one hour before AM     tacro dose (5:00 am), regardless of pt\u2019s home schedule and be     cautious with first dose timing of immunosuppression to keep on     schedule</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#cardiology-services-chf-harrison-and-ccu","title":"Cardiology Services (CHF, Harrison, and CCU)","text":""},{"location":"appendices/appendices-rotations-vumc/#chf-heart-failure-1-2","title":"CHF - Heart Failure (1 &amp; 2)","text":"<ul> <li>Team: 1 Res, 2 Interns on one team with pt cap of 8 per intern (16     total)</li> <li>Pagers: CHF-A: 831-6485, CHF-B: 831-6486</li> <li>Pick up list at 6 AM, admit daily until 5PM (alternate admissions,     resident to help assign)</li> <li>Rounds typically at 7 AM, team meets at 7MCE nursing station</li> <li>Workroom: 7N room 7024 right before bridge to 7MCE (code 145)</li> <li>Tips: Know each patient\u2019s dry weight (usually found in outpatient     cards notes or at last discharge), know current outpatient diuretic     regimen, know most recent TTE, RHC, and LHC results (keep this info     accessible on rounds), order strict I&amp;Os; Daily Standing Weights,     and fluid restriction of 2L/day, obtain iron studies to assess need     for IV iron, perform volume exams on patients before rounds</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#harrison-1-2","title":"Harrison (1 &amp; 2)","text":"<ul> <li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li> <li>Pagers: Harrison 1: 831-4769, Harrison 2: 831-4770</li> <li>Pick up list at 6 AM, admit until 5 PM (Long) or 2 PM (Short)</li> <li>Alternate long and short days with other Harrison team</li> <li>Weekends: Only long team admits new patients</li> <li>Rounds typically at 7 AM, team meets at 7MCE Nursing station</li> <li>Work room: 5MCE 5181 (code 0701); hard to hear stats so keep door     propped</li> <li>Tips: To order heart cath, must be in the cardiology context in Epic     \u201cVUMC Cardiology VIR\u201d (order listed as \u201cCase Request Cath Lab\u201d and     use provider \u201cSurgeon, Generic\u201d)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#ccu","title":"CCU","text":"<ul> <li>Team: 3 Res, dedicated cards fellow, no specific patient cap</li> <li>Pager: 831-6487</li> <li>Rounds start at 7 AM on 5N with Interventional rounds, then Advanced     Heart Failure rounds</li> <li>Call room: 5229AA, on 5S behind the nursing station (code 1234#)</li> <li>Supply room: on 5N (code 512), equipment/US room: on 5N (code 512)</li> <li>Tips: make sure you have access to the Swan sheet folder, have     someone show you how to fill in Swan numbers, make a new Swan     document daily, make a schedule so you stay on top of q4h Swan     numbers and frequent I/O assessments, familiarize yourself with IABP     monitors and Impella care, have pre-call update any hospital courses     the post-call resident wasn't able to do since post-call is busy     presenting on rounds</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#hematology-brittingham-oncology","title":"Hematology (Brittingham) &amp; Oncology","text":""},{"location":"appendices/appendices-rotations-vumc/#hematology-brittingham","title":"Hematology (Brittingham)","text":"<ul> <li>Team: 1 Res, 2 Interns with patient cap of 8 per intern (16 total)</li> <li>Pagers: Brittingham 1: 831-4785, Brittingham 2: 831-4788</li> <li>Pick up list at 6 AM, admit daily until 5 PM (alternate admissions     between interns)</li> <li>Rounds at 8 AM, team meets on 10T</li> <li>Work room: 7MCE conference room (code 0701)</li> <li>Tips: Each HPI should include malignancy history (dx, prior tx,     current tx), utilize the 'treatment' tab to keep on track with chemo     cycle/day, know the febrile neutropenia algorithm, if possible,     enter orders/write notes while the other intern and attending are at     bedside, low threshold to work any complaints up as bleeds,     infections, and fevers are common and can be rapidly lethal</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#oncology-a-b","title":"Oncology (A &amp; B)","text":"<ul> <li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li> <li>Pagers: Oncology A: 831-4786, Oncology B: 831-4787</li> <li>Pick up list at 6 AM, admit daily until 5 PM, sign-out 6 PM</li> <li>Rounds at 8 AM, team meets on 11N at nursing station</li> <li>Workroom: Varied; typically resident library, 11N or 10T, or 7MCE     Conference room</li> <li>Tips: Each HPI should have Onc history (Dot Phrase \u201c.onchist\u201d)     including dx, prior treatments, most recent imaging; 10T and 11N     charge nurse can get pts transferred there, know that patients     admitted from infusion clinic must be seen and have orders placed     (write delayed admission orders in advance of their arrival to floor     bed)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#vu-micu","title":"VU MICU","text":"<ul> <li>Team: 3 Res, 3 Interns, no specific patient cap</li> <li>Pagers: MICU 1 Intern Pager: 831-4759, MICU 2 Intern Pager:     831-4757. Need to also carry the team phone</li> <li>Day Intern: 8 AM - 10 PM; Night Intern 9 PM - 11 AM</li> <li>Rounds at 8 AM (start with half hour teaching most days)</li> <li>Work areas: team 1 sits at computers across from pt room 8641; team     2 sits at computers across from pt room 8613; ultrasound/equipment     room code is 4321#; break room code 4321</li> <li>Tips: Day 1, figure out if you're the code team and where the I/O     kit is. Night intern presents all the old patients in the morning     and signs the notes. The day intern owns the A&amp;P of the notes by     keeping them updated. Trust the nurses and never hesitate to relay     info to your resident overnight if you\u2019re concerned (wake him/her     up!)</li> </ul>"},{"location":"appendices/appendices-rotations-vumc/#vu-nights","title":"VU Nights","text":"<ul> <li>Start on Sunday night for interns, Wednesday night for residents;     off Saturday night</li> <li>Team: 1 Res, 2 Interns with patient cap of 10 for Morgan/Rogers     admitting; 1 Res + 1 Intern w/ cap of 10 for Harrison/Heme/Onc (Res     and Intern split admissions)</li> <li>Harrison/Heme/Onc: Start at 6 PM, admit until 5 AM, sign-out by 6 AM</li> <li>Morgan/Rogers: Start at 6:30 PM, admit until 5:30 AM, sign-out by     6:30 AM</li> <li>Cross cover: Start at 6 PM (Be on time!), sign-out 6:30 AM</li> <li>Tips: ensure you communicate all orders and plans with the resident,     writing \u201cTo do\u201d boxes on the first pages of each printed H&amp;P might     help you communicate the important aspects of each plan to the day     intern when they arrive the next morning, cafeteria closes at 2 AM.     For cross cover, make sure to document any significant events in     Epic. Useful to follow-up on pts admitted previous nights to reflect     on your diagnosis and workups.</li> </ul>"},{"location":"appendices/appendices-uploading-records/","title":"Uploading Records to EPIC","text":"<ul> <li>Request outside records to your Doximity account fax</li> <li>Open Doximity in Epic virtual desktop browser window (internet     explorer)</li> <li>Open faxed documents, and save your document as PDF to desktop of     the virtual desktop</li> <li>Return to Epic</li> <li>Click the \"Epic\" dropdown menu (the same one where you \"Change     Context\")</li> <li>Hover over \u201cPatient Care\u201d than click \"Media Manager\" (pin to avoid     extra clicks next time)</li> <li>Select your pt</li> <li>Click \"Scan;\" a popup window will appear</li> <li>On the popup window, click \"File\" &gt; \"Import File\"</li> <li>In the bottom right-hand corner, change the file type from \"Image     Files\" to \"PDF Files\"</li> <li>Search for your saved document under \"Downloads\" or \u201cDesktop\u201d and     select \"Open\"</li> <li>The documents should appear in the popup window. On the right-hand     side, under \"Store Images As:\" scroll down and select \"Outside     Medical Records\"</li> <li>Click \"Upload Images;\" name them as you choose</li> <li>Exit out of Media Manager and refresh chart</li> </ul>"},{"location":"cardiology/cardiology-acs/","title":"Acute Coronary Syndromes","text":"<p>Anna Berry</p>"},{"location":"cardiology/cardiology-acs/#background","title":"Background","text":"<ul> <li>Completely or partially occluding thrombus on a disrupted     atherothrombotic coronary plaque leading to myocardial     ischemia/infarction</li> <li>STEMI: Elevated troponin &amp; elevation in ST segment or new LBBB with     symptoms<ul> <li>&gt; 0.1 mV in at least 2 contiguous leads</li> <li>Exception, in V2-V3:</li> <li>&gt; 0.2 mV in men older than 40 y/o</li> <li>&gt; 0.25 in men younger than 40 y/o</li> <li>&gt; 0.15 mV in women</li> </ul> </li> <li>NSTEMI: Evidence of myocardial necrosis (elevated troponin) w/o ST     segment elevation</li> <li>Unstable Angina: Angina without evidence of myocardial necrosis     (normal troponin)</li> <li>Other causes of myocardial injury: coronary spasm, embolism,     imbalance of oxygen demand and supply 2/2 fever, tachycardia,     hypo-/hypertension</li> </ul>"},{"location":"cardiology/cardiology-acs/#presentation","title":"Presentation","text":"<ul> <li>Classic Angina: dyspnea on exertion, substernal, pressure or     vice-like quality, improved with rest. Note that response     nitroglycerin is no longer in the guidelines.</li> <li>Anginal Equivalents: nausea, weakness, epigastric pain (esp. in age     &gt; 65 y/o, women, diabetics)</li> <li>Change in patient\u2019s baseline angina, especially onset at rest</li> <li>Physical Exam: sinus tachycardia, diaphoresis</li> <li>If large infarct, can present with symptoms of acute heart failure</li> </ul>"},{"location":"cardiology/cardiology-acs/#evaluation","title":"Evaluation","text":"<ul> <li>EKG: Compare to prior EKG and assess for<ul> <li>New ST elevations or ST depressions</li> <li>T wave inversions: not specific but more concerning if deep (&gt;     0.3mV)</li> <li>Biphasic T waves and deep T wave inversions in leads V2 &amp; V3     (Wellens' sign [LAD])</li> </ul> </li> <li>Cardiac biomarkers: troponin I is most sensitive for myocardial     injury</li> <li>ACC/AHA guidelines recommend both EKG and trop q2-6 hours<ul> <li>Consider this if high suspicion for ACS despite normal initial     markers</li> <li>If negative x2, OK to stop trending</li> </ul> </li> <li>Other labs: lipid panel, TSH, A1C</li> </ul>"},{"location":"cardiology/cardiology-acs/#management","title":"Management","text":""},{"location":"cardiology/cardiology-acs/#stemi","title":"STEMI","text":"<ul> <li>STAT page Cardiology on call via Synergy (whether in VA or     Vanderbilt)</li> <li>ASAP: aspirin 325mg, heparin drip (high nomogram, with bolus)</li> <li>Hold P2Y12 receptor blocker until discussed with cards fellow</li> </ul>"},{"location":"cardiology/cardiology-acs/#nstemi","title":"NSTEMI","text":"<ul> <li>Medical management followed by left-heart catheterization within 48     hours</li> <li>General: bedrest, telemetry, repeat EKG with recurrent chest pain,     NPO at midnight</li> <li>Place cath case request (see \u201cpre-catheterization\u201d management below)</li> </ul>"},{"location":"cardiology/cardiology-acs/#anti-thrombotic-therapy","title":"Anti-thrombotic therapy","text":"<p>Antiplatelet agents</p> <ul> <li>ASA 325 mg loading dose then 81 mg daily after</li> <li>Do not give P2Y12 receptor blocker until discussed with         cardiology fellow</li> <li>Clopidogrel: prodrug that is metabolized to active form (can             have undermetabolizers), irreversible inhibition</li> <li>Ticagrelor: reversible inhibitor</li> <li>Prasugrel: prodrug but more rapidly metabolized than             clopidogrel with less variation, irreversible inhibition, do             not use w/ age &gt; 75 or weight \\&lt; 60 kg</li> <li>Prasugrel and ticagrelor are superior to clopidogrel but             have higher bleeding risk</li> <li>Cangrelor: IV, rarely used</li> </ul> <p>Anti-coagulants</p> <ul> <li>Unfractionated heparin drip</li> <li>Type this in Epic and select \u201cnursing managed\u201d protocol for         \u201cACS\u201d</li> <li>VA: it can be found under the \u201cOrders\u201d tab along the left-hand         column.</li> <li>Enoxaparin (LMWH) can be used but requires preserved renal         function (CrCl &gt; 30) and most interventionalists prefer heparin         prior to LHC</li> </ul>"},{"location":"cardiology/cardiology-acs/#pre-catheterization-care","title":"Pre-Catheterization Care","text":"<ul> <li>Ensure pt. is NPO at MN for planned cath</li> <li>Continue anticoagulation with heparin gtt</li> <li>Place cardiac catheterization request (must be in cardiology     context). Can also call cath lab to ensure pt. is scheduled     appropriately</li> </ul>"},{"location":"cardiology/cardiology-acs/#post-catheterization-care-catheterization-documentation","title":"Post-Catheterization Care Catheterization Documentation","text":"<ul> <li>The most appropriate guidance for post-cath care is in the cardiac     catheterization report</li> <li>VUMC: Epic Cardiac tab Cardiac Catheterization/Intervention Report</li> <li>VA: Note tab Post-Procedure note and Cardiac Catheterization note</li> <li>If there is a delay in filing the final report at VUMC: Review the     Cardiac Catheterization Nursing Documentation which shows if stents     were deployed</li> </ul>"},{"location":"cardiology/cardiology-acs/#post-catheterization-heparin","title":"Post-Catheterization Heparin","text":"<ul> <li>Medical management w/o intervention: stop heparin unless directed in     report</li> <li>If indication for CABG (ex: Left main, proximal LAD), continue     heparin gtt until surgery</li> <li>PCI placed: stop heparin and continue/start DAPT as directed by     cardiology</li> <li>Other medical indication for anticoagulation (DVT/PE, atrial     fibrillation): restart ~ six hours after catheterization</li> </ul>"},{"location":"cardiology/cardiology-acs/#cath-site-checks","title":"Cath Site Checks","text":"<ul> <li>6 - 8 hours post catheterization (typically can be signed out as     0000 cath check), only needed for femoral arterial access</li> <li>Look, listen, feel: evaluate for hematoma &amp; pseudoaneurysm; call     fellow if concerned</li> <li>Small amount of bruising and mild tenderness at the site is normal</li> <li>Listen above and below the site for a bruit; the area should be soft</li> <li>Hypotension after femoral access is concerning for RP bleed<ul> <li>STAT CBC, CT A/P &amp; call the cardiology fellow</li> </ul> </li> <li>Femoral oozing: Cardiology fellow, will need to hold pressure</li> <li>Radial oozing: instruct nurse to re-inflate the TR band and restart     the clock on deflation</li> </ul>"},{"location":"cardiology/cardiology-acs/#post-acs-care","title":"Post ACS Care","text":"<ul> <li>Echo prior to discharge</li> <li>DAPT: Aspirin 81 mg daily and P2Y12 agent</li> <li>Beta blocker in all patients within 24 hours</li> <li>Metoprolol, carvedilol &amp; bisoprolol have proven mortality benefit       with reduced EF</li> <li>High intensity statin (ex: rosuvastatin 40 or atorvastatin 80). See     outpatient lipids section</li> <li>ACEi/ARB if anterior STEMI</li> <li>Lifestyle Modification: weight loss, smoking cessation, diabetes     control</li> <li>See heart failure section for management of HFrEF</li> </ul>"},{"location":"cardiology/cardiology-acs/#acs-complications","title":"ACS Complications","text":"<ul> <li>VT/VF, sinus bradycardia, third-degree heart block, new VSD, LV     perforation, acute mitral regurgitation, pericarditis and     cardiogenic shock; More common with STEMI CCU post-cath</li> </ul>"},{"location":"cardiology/cardiology-acs/#additional-information","title":"Additional Information","text":"<ul> <li>Initiate treatment if there is true concern for ACS and bleeding     risk acceptable, medications can always be discontinued</li> <li>TIMI score: &gt;2 correlates with \u2191 mortality, indicating a need for     aggressive treatment</li> <li>ACC Guideline Clinical App is a useful resource with summaries of     guideline-based recs</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/","title":"Arrhythmias","text":"<p>Kunal Patel, Madeline Rukavina</p>"},{"location":"cardiology/cardiology-arrhythmias/#acute-management-of-arrhythmias","title":"Acute management of arrhythmias","text":"<ul> <li>12-lead EKG if possible and have defib pads on patient</li> <li>Is the patient unstable (hypotensive, signs/symptoms of     hypoperfusion)?</li> <li>Is the information real?</li> <li>Review tele strips if stable: VUMC Web Resources -&gt; VUH PIICiX     Philips Web -&gt; patient selection -&gt; alarm review     (vuhphilipsweb.app.vumc.org)</li> <li>Review past EKGs to determine if patient has had this rhythm before</li> <li>Ensure pt has good IV access</li> <li>Labs: BMP, Mg, TSH, and \u00b1 troponin, tox screen</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#bradyarrhythmias","title":"Bradyarrhythmias","text":"<p>Kunal Patel</p>"},{"location":"cardiology/cardiology-arrhythmias/#background","title":"Background","text":"<ul> <li>Broadly classified as sinus node dysfunction (pacing defect) or     atrioventricular block (conduction defect)</li> <li>Clinical presentation varies widely based on underlying cause,     timing, degree of block/dysfunction</li> <li>Unlikely to cause symptoms if HR &gt;50</li> <li>Symptoms include syncope/presyncope, dyspnea, angina</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#etiologies","title":"Etiologies","text":"<ul> <li>Infection/sepsis</li> <li>Ischemia</li> <li>Rheumatologic/Inflammatory</li> <li>Post-cardiac surgery</li> <li>Hypothyroidism</li> <li>Sleep apnea</li> <li>Infiltration (amyloid, hemochromatosis)</li> <li>High vagal tone (pain, nausea)</li> <li>Medications: Antihypertensives, antiarrhythmics, psychoactive meds,     anesthetics, cannabis, muscle relaxants, etc.</li> </ul> <p>Sinus node dysfunction</p> <ul> <li>Symptomatic sinus bradycardia, tachy-brady syndrome, chronotropic     incompetence, sinus pause, SA exit block</li> <li>Asymptomatic sinus bradycardia (esp in young/healthy patient) is     unlikely to be true bradyarrhythmia</li> </ul> <p>AV Block</p> <p></p>"},{"location":"cardiology/cardiology-arrhythmias/#evaluation","title":"Evaluation","text":"<ul> <li>TTE if structural disease suspected</li> <li>Ambulatory cardiac monitoring if frequently symptomatic</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#management","title":"Management","text":"<ul> <li>Avoid nodal blocking agents \u2013 Adenosine, Beta-blockers, CCBs,     Digoxin</li> <li>Observation if asymptomatic</li> <li>Treat identified underlying causes</li> <li>If symptomatic or high-grade block (Mobitz II or complete heart     block), EP consult for pacemaker evaluation</li> <li>If unstable:</li> <li>Atropine (0.5 mg every 3 to 5 minutes; maximum total dose: 3 mg)<ul> <li>Do NOT use in heart transplant</li> <li>Call CCU Fellow</li> <li>Dopamine (5 to 20 mcg/kg/minute) OR Epi (2 to 10 mcg/min)</li> <li>Transvenous pacing   (Pacer pads on the defib device are capable of pacing,   but don\u2019t forget to sedate!)</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#tachyarrhythmias-narrow-complex","title":"Tachyarrhythmias - Narrow complex","text":"<p>Kunal Patel</p>"},{"location":"cardiology/cardiology-arrhythmias/#background_1","title":"Background","text":"<ul> <li>Three causes of tachyarrhythmias<ul> <li>Re-entry: patient with structural heart disease (ex post-infarction scar)</li> <li>Abnormal Automaticity: electrolyte abnormalities or acute ischemia (Purkinje fibers)</li> <li>Triggered Activity: early and late after depolarizations. Ex: Hypokalemia, ischemia, infracts, excess calcium and drug toxicity</li> </ul> </li> </ul> <p>Tachyarrhythmia differential</p> <p></p>"},{"location":"cardiology/cardiology-arrhythmias/#evaluation_1","title":"Evaluation","text":"<ul> <li>Unstable tachyarrhythmia</li> <li>Start with treatment, determine type later</li> <li>Synchronized cardioversion: place defibrillator pads, consider     0.5-2mg IV midazolam for sedation, prepare for synchronized     cardioversion at 200J (can \u2191 to 300-360 J)</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#management_1","title":"Management","text":"<ul> <li>Sinus tachycardia<ul> <li>Almost always secondary</li> <li>Address underlying causes: fever/sepsis, hypo/hypervolemia, anxiety,   anemia, PE, ACS, hypoxia, pain, urinary retention, withdrawal</li> </ul> </li> <li>Atrial Fibrillation/Flutter \u2013 See Atrial fibrillation section</li> <li>AVNRT/Orthodromic AVRT<ul> <li>Look for p buried in QRS, rate 150-250, AVRT will have delta waves when NSR</li> <li>Vagal maneuvers (1st line): Sit patient upright have them blow into tip of 10cc syringe for 10-15 seconds rapidly lay supine and raise legs</li> <li>Adenosine (2nd line): therapeutic (break AVRT/AVNRT) and diagnostic (allows visualization of underlying rhythm)<ul> <li>Do NOT give in heart transplant, severe COPD, pre-excitation causing wide complex tachycardia (WPW antidromic AVRT)</li> <li>Peripheral line at AC or above w/ arm elevated:   6mg x1, 6mg x1 (if not effective after 1-2 min),   12mg x1 (if refractory to 6mg)</li> <li>Central line: cut dose in half to 3mg x1, 3mg x1, 6mg x1</li> </ul> </li> </ul> </li> <li>Multifocal atrial tachycardia<ul> <li>3 or more p wave morphologies. Seen in cardiac and pulmonary disease</li> <li>Usually does not cause hemodynamic instability</li> <li>BBs and non-DHP CCBs can be effective, need to address underlying   issue</li> </ul> </li> </ul> Drug Dosing Benefits Side Effects Metoprolol <p>5mg IV q5m x3</p> <p>PO metoprolol tartrate 12.5mg q6 hours \u2191 every 6 hr to target</p> <p>Good 1st line agent</p> <p>Less BP effect than dilt</p> <p>Hypotension,</p> <p>Negative inotropy</p> Diltiazem <p>10-20 mg IV over 2m q15m x2</p> <p>drip = 5-15 mg/hr</p> Good 1st line w/ normal EF with drip needed <p>Hypotension</p> <p>Avoid in HFrEF</p> Esmolol <p>500 mcg/kg bolus</p> <p>drip = 50-200 mcg/kg/min</p> <p>Rapid onset/offset</p> <p>RBC metabolism</p> Hypotension Amiodarone 150 IV over 10-30m, then 1 mg/m for 6h, then 0.5mg/m for 18h <p>Minimal BP effects</p> <p>Long lasting; Relatively fast onset (acute effect is mostly beta blockade)</p> <p>Pulmonary and thyroid toxicity</p> <p>Cardioversion</p> Digoxin 500mcg IV x1, then 250mcg IV q6h x2-3 Great for reduced EF, positive inotropy <p>Slow onset</p> <p>Depends on vagal tone \u2013 poor in hyper- adrenergic states</p> Procainamide 20-50 mg/min loading, 1-4 mg/min maintenance Use in pre-excitation syndromes (i.e. WPW), does not inhibit AV nodal conduction <p>Lupus-like syndrome</p> <p>Hypotension</p>"},{"location":"cardiology/cardiology-arrhythmias/#tachyarrhythmias-wide-complex","title":"Tachyarrhythmias - Wide Complex","text":"<p>Madeline Rukavina</p>"},{"location":"cardiology/cardiology-arrhythmias/#definitions","title":"Definitions","text":"<p>Ventricular tachycardia (VT): a run of 3+ PVCs</p> <ul> <li>Sustained VT: VT for 30 seconds or shorter if it requires     intervention</li> <li>Nonsustained VT (NSVT): VT for \\&lt; 30 seconds</li> <li>VT storm: 3+ separate episodes of sustained VT within 24 hrs.</li> </ul> <p>VT Morphologies</p> <ul> <li>Monomorphic VT: similar QRS configuration from beat to beat<ul> <li>Usually 2/2 scar-mediated VT from prior infarction</li> </ul> </li> <li>Polymorphic VT: a continuously changing QRS configuration from beat     to beat<ul> <li>Ischemia until proven otherwise</li> </ul> </li> <li>Torsades de Pointes (TdP): a form of polymorphic VT with a continually     varying QRS that appears to spiral around the baseline of the ECG in     a sinusoidal pattern</li> <li>Ventricular fibrillation (VF): chaotic rhythm characterized by     undulations that are irregular in timing and morphology, without     discrete QRS complexes</li> </ul> <p>Ventricular Tachycardia vs. SVT with aberrancy</p> <ul> <li>VT: The action potential originated in the ventricles (ex: VT)</li> <li>Supraventricular tachycardia with aberrancy: the action potential     originates from a focus above the ventricles &amp; conducts through the     AV node with a delay or block resulting in a wide QRS (mimics VT)</li> <li>Ex: sinus tachycardia w/ bundle branch block (block may be rate     dependent), AF w/ LBBB</li> </ul> <p>Many ways to differentiate VT vs. SVT w/ aberrancy</p> <ul> <li>Consult cardiology for assistance</li> <li>Look for ECG features suggestive of VT</li> <li>Very broad complexes &gt;160 ms</li> <li>RsR\u2019 complex with a taller left rabbit ear In V\u00bd</li> <li>AV dissociation (P/QRS dissociation)</li> <li>Capture Beats: native QRS complexes making a cameo during the VT</li> <li>Fusion Beats: QRS which appears like a signal average of VT and         native complex</li> </ul> <p> </p> <ul> <li>There are more advanced criteria to help distinguish. The aVR     (Vereckie) criteria is one example that is fast and accurate</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#management_2","title":"Management","text":"<p>Unstable</p> <ul> <li>Sedate with midazolam 1-2mg</li> <li>Cardioversion for monomorphic VT. Synchronized shock at 100-200J</li> <li>Defibrillation if VF/polyVT</li> </ul> <p>Stable</p> <ul> <li>Medications (as below)</li> </ul> Drug Name Dosing Mechanism Side Effects Amiodarone 150mg IV over 10 min, then 1mg/min for 6 hours; repeat bolus if VT recurs <p>Class III</p> <p>-K+ channel blocker; has class Ia, II, &amp; IV effects</p> Bradycardia, hypotension (acutely) Lidocaine 1-1.5 mg/kg (usually 75-100 mg) at a rate of 25-50mg/min; lower doses of .5-.75mg/kg can be repeated every 5-10 min as needed <p>Class IB</p> <p>-fast Na+ channel blocker-&gt; slows conduction</p> Slurred speech, AMS, seizures, bradycardia Procainamide 20-50mg/min until arrhythmia terminates or max dose 17mg/kg is reached <p>Class IA</p> <p>-fast Na+ channel blocker -&gt; slows conduction</p> <p>-K+ channel blocker-&gt; prolongs repolarization</p> <p>Bradycardia, hypotension, torsades, drug-induced lupus</p> <p>Avoid in HF pts, prolonged QT</p> <ul> <li> <p>Cardioversion If refractory to medical management</p> </li> <li> <p>Treatment of underlying cause if identifiable</p> <ul> <li>Ischemia, electrolyte disturbances, heart failure, drugs</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#premature-ventricular-complexes-pvcs","title":"Premature Ventricular Complexes (PVCs)","text":"<p>Madeline Rukavina</p>"},{"location":"cardiology/cardiology-arrhythmias/#background_2","title":"Background","text":"<ul> <li>Premature Ventricular Complex (PVC): early ventricular     depolarization \u00b1 mechanical contraction</li> <li>PVC burden: % of beats of ventricular origin / total beats over a     24h period</li> <li>PVCs are common: Up to 80% of apparently healthy people have PVCs</li> <li>Normal number of PVCs in an adult is \\&lt;500 in 24h</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#etiologies_1","title":"Etiologies","text":"<ul> <li>HTN with LVH, prior MI/scar, HF, myocarditis, ARVC, HCM, idiopathic     VT, OSA, pHTN, COPD, thyroid disease, substance use (EtOH, nicotine,     stimulants, caffeine)</li> </ul>"},{"location":"cardiology/cardiology-arrhythmias/#inpatient-evaluation-management","title":"Inpatient Evaluation &amp; Management","text":"<ul> <li>12 lead EKG: conduction disease, long QT syndrome, Brugada syndrome,     ARVC</li> <li>Labs: K, Mg, TSH, drug screen</li> <li>Evaluate for QT prolonging agents (risk of Torsades)</li> <li>Evaluate tele for PVC burden</li> <li>Inpt consult to EP for PVCs rarely warranted unless significant PVC     burden (&gt;5 PVC/min, consistently) in setting of reduced LVEF.</li> <li>For pts with &gt;5 PVC/min or pts with symptoms, discharge with     Ziopatch (VA) or mobile cardiac telemetry (VU) and obtain TTE if     none recent.</li> </ul>"},{"location":"cardiology/cardiology-atrial-fibrillation-and-flutter/","title":"Atrial Fibrillation &amp; Flutter","text":"<p>Brittany Saldivar</p>"},{"location":"cardiology/cardiology-atrial-fibrillation-and-flutter/#background","title":"Background","text":"<ul> <li>AF: 12-lead EKG with absence of p-waves and irregularly irregular     QRS complexes</li> <li>Flutter: sawtooth atrial F waves (300 BPM) with regular or regularly     irregular QRS complexes</li> <li>Ventricular rate ratio of F waves: V waves ~150 (2:1), ~100 (3:1),     or ~75 (4:1)</li> <li>3 classifications<ul> <li>Paroxysmal (terminates within 7 days)</li> <li>Persistent (persisting beyond 7 days)</li> <li>Permanent (normal rhythm cannot be restored)</li> </ul> </li> <li>Rapid ventricular response (RVR) is HR &gt; 100 (ie AF/Flutter w/     tachycardia)</li> <li>AF/RVR is far more often a consequence of hypotension than the cause     of it</li> </ul>"},{"location":"cardiology/cardiology-atrial-fibrillation-and-flutter/#evaluation","title":"Evaluation","text":"<ul> <li>Causes: Mnemonic \u201cH PIRATES\u201d<ul> <li>Hypertension</li> <li>Pneumonia, Pericarditis, Post-op</li> <li>Ischemia (rare)</li> <li>Rheumatic Valve</li> <li>Atrial Myxoma or Accessory Pathway</li> <li>Thyrotoxicosis</li> <li>Ethanol or Excess Volume</li> <li>Sick sinus, Sepsis</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-atrial-fibrillation-and-flutter/#management","title":"Management","text":"<ul> <li>Treatment goals<ul> <li>Rate control, Goal HR \\&lt; 110 (RACE II)</li> <li>Rhythm control (if indicated)</li> <li>Stroke prevention</li> </ul> </li> </ul> <p>Rate control (inpatient)</p> <ul> <li>RVR ~ sinus tach of AF; Always work to address the underlying cause     (infection, volume overload, etc). Rate control is rarely an     emergency unless the patient is unstable</li> <li>If stable with RVR (SBP &gt;90)<ul> <li>IV if HR &gt; 130 or symptomatic (metop 5 mg IV or dilt 15-20 mg     IV), otherwise do PO</li> <li>AV nodal blocking agents<ul> <li>B-blockers: Start with metop tartrate (titratable)   consolidate to succinate. Avoid in decompensated or   borderline HF</li> <li>Calcium channel blockers (diltiazem): avoid in HFrEF</li> </ul> </li> </ul> </li> <li>Peri stable (SBPs 80s-90 with preserved perfusion)<ul> <li>Amiodarone: Consider if decompensated HF, accessory pathway,     anti-coagulated. Caution that you may cardiovert pt (stroke     risk)</li> </ul> </li> <li>Unstable (SBPs \\&lt;80)<ul> <li>Cardioversion</li> </ul> </li> </ul> <p>Rate control (outpatient)</p> <ul> <li>typically achieved with beta blocker therapy,   metoprolol is most frequently used</li> </ul> <p>Rhythm control (inpatient)</p> <ul> <li>New onset a-fib (first time diagnosis): most pts will be a candidate     for trial of cardioversion</li> <li>If onset clearly within 48 hours, can proceed without TEE. Often TEE     is done anyway (pt may have had intermittent asymp AF)</li> <li>If onset &gt;48 hours or unclear, will need TEE to rule out LAA     thrombus</li> <li>Pharmacologic options include class 1C: flecainide, propafenone     (avoid in structural heart disease) and class 3: Amiodarone,     dronedarone, sotalol, ibutilide, dofetilide (some require loading     inpt)<ul> <li>Caution using antiarrhythmics in any pt you wouldn't     electrically cardiovert without TEE</li> </ul> </li> </ul> <p>Rhythm control (outpatient)</p> <ul> <li>Consider EP consult for ablation in symptomatic paroxysmal or     persistent AF refractory to anti-arrhythmic drugs, AF in HFrEF, or     flutter</li> <li>Stroke Prevention (for AF and flutter)<ul> <li>CHA2DS2-VASc risk score &gt;2 in M or &gt;3 in F should prompt long term AC in AF persisting &gt;48 hours</li> <li>NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred to warfarin except in moderate to severe MS or mechanical valve</li> </ul> </li> <li>If cardioversion planned for new onset AF, start AC as soon as     possible<ul> <li>Post-cardioversion, anticoagulate for at least 4 weeks due to     atrial stunning and stroke risk</li> </ul> </li> <li>If no contraindications or procedures, continue anticoagulation     while inpatient</li> <li>Typically do not need to bridge AC for AF in the setting of     procedures unless mechanical valve is present. Decide on a case     by-case basis</li> <li>Left atrial appendage closure can be considered in those with     increased risk of bleeding</li> </ul>"},{"location":"cardiology/cardiology-autonomics-and-orthostatics/","title":"Autonomics and Orthostatic Hypotension","text":"<p>Leonard Chiu</p>"},{"location":"cardiology/cardiology-autonomics-and-orthostatics/#background","title":"Background","text":"<ul> <li>Orthostatic Hypotension: SBP \u2193 &gt; 20 mmHg, DBP \u2193 &gt; 10 mmHg), or HR     Increase &gt; 30 within 3 min of standing up or head-up tilt to 60% on     a tilt table</li> <li>Etiologies: Neurogenic OH (nOH) vs non-neurogenic OH</li> <li>nOH associated with autonomic failure<ul> <li>Blunted tachycardia during hypotension characteristic of     autonomic failure</li> <li>nOH: If HR rise is \\&lt;15</li> <li>nOH also associated with periods of high BP (supine     hypertension)</li> <li>Ex: Neurodegenerative disease, neuropathy (diabetes, amyloid,     paraneoplastic, etc)</li> </ul> </li> <li>Other causes: volume depletion (most common), medications     (diuretics, alpha-1 blockers, BB, etc), pump failure (severe AS,     arrhythmia)</li> </ul>"},{"location":"cardiology/cardiology-autonomics-and-orthostatics/#evaluation","title":"Evaluation","text":"<ul> <li>Orthostatic vitals signs (checking supine, sitting, and standing     with 5-minute wait in each position)</li> <li>Volume status exam</li> <li>Labs: CBC, CMP, EKG, TSH, B12, , LFTs,</li> <li>Consider SPEP/UPEP, paraneoplastic panel, autonomic function testing     depending on clinical context</li> <li>Autonomic Function Testing: Available at 4:15pm Tues, Wed, Thurs NPO     4 hours prior</li> <li>Hold oral pressors and antihypertensives 12 hours prior</li> </ul>"},{"location":"cardiology/cardiology-autonomics-and-orthostatics/#management","title":"Management","text":"<ul> <li>Conservative:</li> <li>TED hose and abdominal binder for ambulation</li> <li>Drink 16oz of fluid 15 min prior to standing</li> <li>If they have supine HTN, keep HOB 30-45 degrees at all times</li> <li>Add 2.3-4.6g of salt per day to diet (if no contraindications)</li> <li>Avoid high temperatures (which cause peripheral vasodilation)</li> <li>Supine HTN therapies: transdermal nitroglycerin (preferred);     minoxidil, hydralazine, or clonidine in select patients</li> </ul> <p>Orthostatic hypotension pharmacologic therapies</p> Drug Dose Mechanism Side effects Fludocortisone (Florinef) <p>0.1mg QD</p> <p>\u2191 by 0.1 mg</p> <p>Max: 0.3 mg QD</p> Mineralocorticoid increase blood volume. Enhances sensitivity to circulating catecholamines <p>Edema</p> <p>HTN</p> <p>HypoK</p> <p>Do not use in CHF</p> Midodrine <p>2.5mg TID</p> <p>\u2191 by 2.5mg</p> <p>Up to 10mg TID</p> Peripheral-selective \u03b11 agonist \u2192 constricts both aa &amp; vv <p>Supine HTN</p> <p>Pilomotor reactions</p> <p>Pruritus</p> <p>GI upset</p> <p>Avoid in uncontrolled HTN, urinary retention, heart disease</p> Droxidopa <p>100mg</p> <p>\u2191 by 100mg</p> <p>Up to 600mg TID</p> NE precursor \u2192 carboxylated to NE. Can cross BBB. Supine HTN, less than midodrine Atomoxetine 10mg or 18mg SNRI Do not use w/ glaucoma or MAOI"},{"location":"cardiology/cardiology-bedside-echocardiography/","title":"Bedside Echocardiography","text":"<p>Jamie Pfaff</p>"},{"location":"cardiology/cardiology-bedside-echocardiography/#finding-an-ultrasound","title":"Finding an Ultrasound","text":"<ul> <li>MICU: radiology room behind charge nurse\u2019s desk in middle hallway</li> <li>VA ICU: In front of resident workspace</li> <li>8N: Behind nurses station before entering cleaning supply room</li> <li>8S: In supply closet to left as your walk toward nursing station -     (door code is 1-3-5)</li> <li>6MCE: COVID restricted (ask nurses)</li> <li>CCU/5N only: supply room on left as entering CCU</li> <li>Round wing: 5th floor, ask nurses</li> </ul>"},{"location":"cardiology/cardiology-bedside-echocardiography/#tte-standard-views","title":"TTE Standard Views","text":""},{"location":"cardiology/cardiology-bedside-echocardiography/#parasternal-long","title":"Parasternal long","text":"<ul> <li>Probe position: Rotate probe 180 degrees with right edge of     probe/probe marker pointing toward patient\u2019s left shoulder</li> <li> <p>Make sure probe is centered over mitral valve (In right spot if you     can see MV and AV)</p> <ul> <li>Distance separating the anterior MV leaflet from the septal wall     as measure of LV systolic function (easy evaluation of systolic     function)</li> <li>Place M mode spike at tip of mitral leaflet and hit M mode     (perpendicular to septum)</li> <li>Identify E point (passive filling of LV) and determine distance     from interventricular septum (IVS)<ul> <li>&lt;7mm = Normal</li> <li> <p>10mm = HF</p> </li> </ul> </li> <li>Confounders that elevate EPSS: AR, MS</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-bedside-echocardiography/#parasternal-short","title":"Parasternal short","text":"<ul> <li>Probe position: Rotate probe 180 degrees with right edge of     probe/probe marker pointing toward patient\u2019s left shoulder</li> <li>Good position to assess EF by visualizing wall thickening</li> </ul> <p>Apical four chamber</p> <ul> <li>Probe position: Slide down and look near patient\u2019s left nipple (or     in the intermammary fold after lifting up breast tissue if needed -     at PMI if able to palpate)</li> <li>Good to assess EF by visualizing cardiac shortening</li> </ul>"},{"location":"cardiology/cardiology-bedside-echocardiography/#subxiphoid","title":"Subxiphoid","text":"<ul> <li>Probe position: Push probe head into patient\u2019s abdomen just below     xiphoid and flatten probe to make nearly parallel to patient\u2019s     position, marker to pt\u2019s left</li> <li>Troubleshooting: shift probe slightly left of midline (toward     patient\u2019s right) and angle toward heart/right to use liver as     acoustic window or ask patient to take big breath (moves heart     closer to probe)</li> <li>Best window to visualize pericardial effusion</li> </ul>"},{"location":"cardiology/cardiology-bedside-echocardiography/#ivc","title":"IVC","text":"<ul> <li>Probe position: subxiphoid area with probe marker facing toward     patient\u2019s head tilted slightly left of midline, trace IVC into RA to     verify correct vessel (vs aorta)</li> <li>IVC size and collapsibility used as a surrogate for CVP and RAP<ul> <li>&lt;2.1 cm and &gt;50% collapse: RAP ~3mmHg</li> <li>&lt;2.1 cm and &lt; 50% collapse or &gt;2.1cm and &gt;50% collapse: RAP ~8mmHg</li> <li>&gt;2.1cm, &lt;50% collapse: RAP ~ &gt;15mmHg</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-bedside-echocardiography/#resources","title":"Resources","text":"<ul> <li>https://www.coreultrasound.com/basic-cardiac-function/</li> <li>http://pie.med.utoronto.ca/tte</li> <li>https://www.echocardiographer.org/TTE.html</li> <li>App: FATE CARD (Focus Assessed Transthoracic Echocardiography)</li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/","title":"Cardiac Devices","text":"<p>Marcus Threadcraft</p>"},{"location":"cardiology/cardiology-cardiac-devices/#types-of-cardiac-implantable-electronic-devices-cied","title":"Types of Cardiac Implantable Electronic Devices (CIED)","text":"<ul> <li>For Controlling Arrhythmias: Implantable Pulse Generators</li> <li>Pacemakers: Anti-bradycardia pacing</li> <li>ICDs: Anti-tachycardia pacing and defibrillation</li> <li>Biventricular Pacemakers: CRT for ventricular dyssynchrony (LBBB &amp;     Heart Failure)</li> <li>Loop Recorders: implantable devices for monitoring arrhythmias (most     often Afib)</li> <li>LVADs: augment cardiac output for end-stage heart failure (not     covered here)</li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/#pacemakers","title":"Pacemakers","text":"<ul> <li>Provide anti-bradycardia pacing by stimulating myocardium</li> <li>Peripheral permanent pacemakers (PPMs)</li> <li>SubQ generator, transvenous leads<ul> <li>Single chamber RV lead</li> <li>Dual chamber RV and RA leads</li> <li>BiV: RV, RA, and LV (coronary sinus) leads</li> </ul> </li> <li>Leadless pacemaker<ul> <li>Implanted generator in RV</li> </ul> </li> </ul> <p>Indications</p> <ul> <li>Symptomatic Bradycardia</li> <li>Heart Block: 2nd Degree Type II w/ sx or 3rd Degree</li> <li>Sick Sinus Syndrome</li> <li>Carotid Sinus Syndrome</li> <li>After catheter ablation of AV node for AF</li> <li>CRT</li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/#implantable-cardioverterdefibrillators-icds","title":"Implantable Cardioverter/Defibrillators (ICDs)","text":"<ul> <li>Pacing lead + defibrillation coil</li> <li>Detect and treat VT/VF v<ul> <li>Anti-tachycardia pacing (ATP)- attempts to entrain and terminate     VT</li> <li>Defibrillation If ATP unsuccessful</li> </ul> </li> </ul> <p>Indications</p> <ul> <li>Primary prevention<ul> <li>HFrEF<ul> <li>EF \\&lt;35% and NYHA II-III or EF \\&lt;30% and NYHA I</li> <li>Must be &gt;90d from revasc, &gt;40d from MI, and on GDMT</li> </ul> </li> <li>Arrhythmogenic syndromes<ul> <li>Arrhythmogenic RV cardiomyopathy, Brugada syndrome, HCM and     cardiac sarcoid with specific risk factors</li> </ul> </li> </ul> </li> <li>Secondary prevention<ul> <li>Hx VF arrest or VT</li> <li>Inducible VT on EP study with history of syncope</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/#cardiac-resynchronization-therapy-crt","title":"Cardiac Resynchronization Therapy (CRT)","text":"<ul> <li>BiV pacer that coordinates LV/RV contraction through synchronized     activation of each ventricle following atrial contraction.</li> <li>-P: CRT pacing only</li> <li>-D: ICD function</li> </ul> <p>Indications</p> <ul> <li>Class I: LBBB and QRS\u2265150 with EF\\&lt;35%, NYHA II- IV, on GDMT, NSR</li> <li>Class IIa: EF\\&lt;35%, NYHA II- IV, on GDMT, NSR AND<ul> <li>LBBB &amp; QRS 120-149, non-LBBB &amp; QRS\u2265150, or EF\\&lt;35% and expected     to require &gt;40% ventricular pacing</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/#interpreting-pacemaker-codes","title":"Interpreting Pacemaker Codes","text":"1st Letter 2nd Letter 3rd Letter 4th Letter A: atrial, V: ventricular, D: dual, O: none, I: inhibition, R: rate-adaptive Chamber Paced Chamber Sensed Response to Sensed Beat Program Features"},{"location":"cardiology/cardiology-cardiac-devices/#examples-of-common-pacing-modes","title":"Examples of Common Pacing Modes","text":"<ul> <li>VVI: Single RV lead that delivers a beat if no beat sensed. Often     used with chronic AF with bradycardia</li> <li>DDDR: Senses and paces both the atria and ventricle. If beat not     sensed within a predefined interval, beat delivered. R indicates     rate responsivity (changes rate based on changes in patient     activity)</li> <li>Magnet: Paces at a fixed rate without respect to native electrical     activity (AOO,VOO,DOO). Deactivates ICD shock. Often used in surgery     or at end of life to avoid ICD shocks</li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/#additional-configurations","title":"Additional Configurations","text":"<ul> <li>Epicardial Leads- pacemaker/defibrillator leads attached to outside     of the heart (requires OR) vs traditional transvenous lead     placement, which are inserted in the Cath Lab<ul> <li>Epicardial Leads generally placed in smaller children or during     cardiac surgery with expected need for pacing/defibrillation</li> </ul> </li> <li>Abandoned leads<ul> <li>Absolute contraindication to MRI (ungrounded, produces heat and     thermal Injury In setting of magnetic field)</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-cardiac-devices/#placement-complications","title":"Placement Complications","text":"<ul> <li>Acute: pocket hematoma, pneumothorax, myocardial perforation,     cardiac tamponade, infection, lead displacement or disconnection</li> <li>Long-term: secondary device infection, lead fracture (lead lifetime     10-15 years), insulation failure</li> </ul>"},{"location":"cardiology/cardiology-chest-pain/","title":"Chest Pain","text":"<p>Nicholas King</p>"},{"location":"cardiology/cardiology-chest-pain/#chest-pain-angina-framework","title":"Chest Pain / Angina Framework","text":"<ul> <li>Determining likelihood that chest pain has a cardiac etiology     depends on symptoms and lies on a spectrum</li> <li>Cardiac &gt; possible cardiac &gt; noncardiac is more useful than     typical vs atypical angina</li> </ul>"},{"location":"cardiology/cardiology-chest-pain/#diagnoses-not-to-miss-the-serious-six","title":"Diagnoses Not to Miss: \u201cThe Serious Six\u201d","text":"<ul> <li>Acute Coronary Syndrome</li> <li>Mediastinitis (e.g, esophageal perforation)</li> <li>Aortic Dissection/Aneurysm</li> <li>Cardiac Tamponade</li> <li>Pulmonary Embolus</li> <li>Pneumothorax</li> </ul>"},{"location":"cardiology/cardiology-chest-pain/#other-differential-diagnoses","title":"Other Differential Diagnoses","text":"<ul> <li>Skin: Laceration, herpes zoster</li> <li>Subcutaneous: cellulitis, abscess</li> <li>Musculoskeletal: Costochondritis, fracture, myositis, sprain/strain</li> <li>Pleural space (no pain receptors in the lung): PNA, tumor, pleuritis</li> <li>Pericardium: Pericarditis</li> <li>Heart: Myocarditis, spontaneous coronary artery dissection (SCAD),     coronary vasospasm, aortic stenosis, stress-induced cardiomyopathy     (Takotsubo), decompensated heart failure</li> <li>Esophagus: GERD, esophagitis</li> <li>Trachea: Tracheitis, tracheal tear</li> </ul>"},{"location":"cardiology/cardiology-chest-pain/#physical-exam","title":"Physical Exam","text":"<ul> <li>Vitals: BP in both arms (do while interviewing - quick, easy,     inexpensive)</li> <li>Hemodynamic profile (warm/dry, warm/wet, cold/dry, cold/wet)</li> <li>Palpate chest: evaluate costochondral junction, subcutaneous     emphysema, examine skin</li> <li>Cardiac: murmurs, rub for pericarditis, JVD for heart failure or PE     with RV strain</li> <li>Pulm: absent breath sounds for PTX, crackles for left heart failure,     PNA</li> <li>Abdomen: abdominal pain mistaken or referred as chest pain</li> <li>Extremities: asymmetric leg swelling (&gt;2 cm difference) for DVT/PE</li> </ul>"},{"location":"cardiology/cardiology-chest-pain/#diagnostic-studies","title":"Diagnostic Studies","text":"<ul> <li>EKG: ACS (STEMI, new LBBB, ST depressions, T wave Inversions,     Wellens' sign), pericarditis, pericardial effusion</li> <li>Labs: Troponin (ACS, PE, myocarditis), CBC, BNP, lactate</li> <li>CXR: PTX, PNA, dissection, esophageal rupture</li> <li>Bedside ultrasound: pericardial effusion, R heart strain for PE,     wall motion abnormality for infarct/ischemia or stress-induced CM,     valvular disease, lung sliding/PTX</li> <li>CTA: gold standard for PE. Dissection can be diagnosed w/ CTA, MRA,     or TEE</li> </ul>  Evaluation for Coronary Disease Test Indications Benefits Risks Considerations EKG Stress <p>Low to Intermediate risk patients</p> <p>Do not stress active or suspected ACS</p> <p>Serves as screening with high NPV</p> Functional status w/ Bruce treadmill protocol <p>Exercise tolerance</p> <p>limits use</p> <p>Cannot have LBBB,</p> <p>nondiagnostic if 85% target HR not achieved</p> Dobutamine Echo Stress More sensitive than EKG Contraindicated: arrhythmias, LVOT obstruction, HTN, AS <p>Can be useful to eval low grade low flow AS</p> <p>Hold BB</p> SPECT stress <p>More sensitive than echo,</p> <p>Assess viability</p> Adenosine or Regadenason contraindicated in reactive airway disease No caffeine or theophylline prior PET stress <p>Better PPV than Echo</p> <p>Assess viability</p> Better for pts with larger abdominal girth (less diaphragmatic attenuation) Cardiac MRI Assesses viability Can assess nonischemic vs ischemic cardiomyopathy; HR must be &lt; 70, gold standard for structure and function Coronary CT Very high NPV for stenosis <p>Contrast media reactions</p> <p>CIN lower risk than cath</p> <p>Might have poor lumen visualization if heavy calcium burden</p> <p>HR &lt; 70</p> Coronary Angiogram <p>STEMI</p> <p>High risk NSTEMI:</p> <p>Refractory angina, new arrhythmia, cardiogenic shock (HF)</p> <p>Suspected true ACS</p> <p>Diagnostic and Therapeutic</p> <p>Direct visualization of lumen</p> <p>Therapeutic PCI</p> <p>CIN with contrast</p> <p>Cath site complications</p> <p>Rare: SCAD, cholesterol emboli</p> <p>Positive Screen (above) necessitates LHC</p> <p>Case request cath lab</p> <p>NPO MN prior</p> <p>Groin check if femoral access</p>"},{"location":"cardiology/cardiology-chf/","title":"Heart Failure","text":"<p>Brittany Saldivar</p>"},{"location":"cardiology/cardiology-chf/#background","title":"Background","text":"<p>ACC/AHA Stages of HF</p> <ul> <li>Stage A: At risk but without structural heart disease or symptoms</li> <li>Stage B: + structural HD, - symptoms</li> <li>Stage C: + structural HD, + prior or current symptoms</li> <li>Stage D: refractory HF requiring specialized intervention</li> </ul> <p>NY Heart Association (NYHA) Functional Classes of HF</p> <ul> <li>Class I: Normal physical activity is not limited</li> <li>Class II: Comfortable at rest; normal physical activity results in     HF symptoms</li> <li>Class III: Comfortable at rest; less than normal activity leads to     HF symptoms</li> <li>Class IV: Inability to perform any physical activity without     symptoms</li> </ul>"},{"location":"cardiology/cardiology-chf/#etiologies","title":"Etiologies","text":"<ul> <li>HFrEF (Clinical diagnosis + LVEF \\&lt; 40%)<ul> <li>Ischemic: Obstructive CAD, previous/current myocardial     infarction</li> <li>Non-ischemic:<ul> <li>Load: HTN, valvulopathy</li> <li>Arrhythmia: tachyarrhythmia, pacemaker induced</li> <li>Myocardium</li> </ul> </li> <li>Toxins (EtOH, drugs, chemo, radiation),</li> <li>Inflammatory (infections, AI),</li> <li>Metabolic (thyroid, thiamine deficiency),</li> <li>Infiltrative (amyloid, sarcoid, hemochromatosis)</li> <li>Stress induced/takotsubo CM<ul> <li>Genetic</li> <li>Idiopathic</li> </ul> </li> </ul> </li> <li>HFpEF: HTN, CAD, obesity, DM, infiltrative, hypertrophic     cardiomyopathy</li> </ul> <p>Causes of Heart Failure Exacerbations (FAILURES)</p> <ul> <li>Forgetting medications or taking drugs that can worsen HF (e.g. BB,     CCB, NSAIDs, TZDs), chemo (anthracyclines, trastuzumab)</li> <li>Arrhythmia/Anemia: AF, VT, PVCs; Increased arrhythmia burden on     device check?</li> <li>Ischemia/Infarction/Infection: myocarditis; Acute vascular     dysfunction (e.g. endocarditis), especially mitral or aortic     regurgitation.</li> <li>Lifestyle choices: Dietary indiscretions - high salt, EtOH,     excessive fluid intake. Obesity.</li> <li>Upregulation (of CO): pregnancy and hyperthyroidism</li> <li>Renal failure: acute, progression of CKD, or insufficient dialysis     (Increased preload)</li> <li>Embolus (pulmonary) or COPD (leads to increase right-sided     afterload)</li> <li>Stenosis (worsening AS, RAS) leading to hypertensive crisis high     left-sided afterload</li> </ul>"},{"location":"cardiology/cardiology-chf/#presentation","title":"Presentation","text":"<ul> <li>Volume overload: shortness of breath, dyspnea on exertion,     Orthopnea, PND</li> <li>Nausea/poor po intake (hepatic and gut congestion)</li> <li>Confusion (decreased CO)</li> <li>Exam: Edema (legs, sacrum), rales, S3, S4, murmur (AS, MR), elevated     JVD, + hepatojugular reflex, ascites</li> </ul>"},{"location":"cardiology/cardiology-chf/#evaluation","title":"Evaluation","text":"<ul> <li>CBC, CMP, Magnesium, Lactate, TSH, iron studies</li> <li>Troponin, ECG</li> <li>BNP (Pro-BNP if on Entresto) \u2013 high negative predictive value for HF     (false negative can occur in obese patients)</li> <li>CXR \u2013 differentiate other causes of dyspnea</li> <li>TTE</li> <li>Determine hemodynamic and volume profile<ul> <li>Cold vs warm</li> <li>Dry vs wet</li> </ul> </li> </ul> Cardiac Index Euvolemia Hypervolemia Low <p>Warm Extremities</p> <p>Adequate UOP</p> <p>Normal PPP</p> <p>Warm and Dry</p> <p>Forrester Class I</p> <p>Tx: GDMT as tolerated</p> <p>Warm and Wet</p> <p>Forrester Class II</p> <p>Tx: Diuresis, Vasodilators</p> Normal <p>Cardiogenic Shock</p> <p>Cool Extremities</p> <p>Renal Failure</p> <p>Narrow PP</p> <p>Cold and Dry</p> <p>Forrester Class III</p> <p>Tx: Inotropes</p> <p>Cold and Wet</p> <p>Forrester Class IV</p> <p>Tx: Diuresis +Tailored therapy (+/- vasodilators, inotropes)</p>"},{"location":"cardiology/cardiology-chf/#management","title":"Management","text":"<ul> <li>Telemetry, Daily STANDING weights, 2 L fluid restriction, 2g sodium     diet, strict I/Os</li> <li>Diuresis: Place on 2.5 x home dose of IV diuretic, dose BID-TID     (DOSE Trial)</li> <li>Goal is to be net negative (generally 1-2 L per day but patient     dependent)</li> <li>Check BMP BID and Mg QD, keep K&gt;4 and Mg&gt;2</li> <li>Low threshold for substantial increase (double) in loop vs     transition to drip if not diuresing adequately</li> <li>Can also augment with sequential nephron blockade (thiazides,     acetazolamide)</li> <li>Continuation/optimization of GDMT (below)</li> </ul>"},{"location":"cardiology/cardiology-chf/#guideline-directed-medical-therapy-for-hfref","title":"Guideline-Directed Medical Therapy for HFrEF","text":"<p>Brittany Saldivar</p>"},{"location":"cardiology/cardiology-chf/#general-principles","title":"General Principles","text":"<ul> <li>Starting patients on low dose of multiple agents preferred to max     dose of single agent</li> <li>D/C summary should have discharge weight, diuretic regimen, and     renal function</li> <li>Daily weights at home with rescue diuretic plan (pm dose for 3 lbs     in 1 day, 5 lbs in 3 days</li> </ul> Drug Indication Mechanism/ Benefits Precautions Beta Blockers <p>Carvedilol</p> <p>Metoprolol succinate</p> <p>Bisoprolol</p> <p>HFrEF &lt;40 %</p> <p>Stage C HF (NYHA class I \u2013 IV)</p> Reduces catecholamine stimulation. Decreased HR, myocardial energy demand, less adverse remodeling. <p>Avoid if pt is decompensated (cold); \u201cstart low and go slow\u201d</p> <p>Can continue during exacerbation if patient compensated</p> ARNIs Sacubitril/ valsartan <p>HFrEF &lt; 40%</p> <p>NYHA class II \u2013 IV</p> <p>Used in place of ACE/ARB</p> Prevents vasoactive natriuretic peptide degradation involved in pathogenesis of HF (+ action of ARB) <p>Need a 36 hr wash-out period if transitioning from ACEi to ARNI</p> <p>Hypotension</p> <p>Risk of angioedema</p> ACEIs <p>Lisinopril</p> <p>Enalapril</p> <p>Captopril</p> <p>Ramipril</p> <p>HFrEF &lt;40 %</p> <p>Stage C HF (NYHA class I \u2013 IV)</p> Blocks harmful effects of RAAS activation and attenuates adverse cardiac and vascular remodeling <p>Risk of angioedema</p> <p>Monitor renal function and K</p> ARBs <p>Losartan</p> <p>Valsartan</p> <p>Candesartan</p> <p>HFrEF &lt;40 %</p> <p>Stage C HF (NYHA class I \u2013 IV)</p> See ACEIs <p>See ACEIs</p> <p>Preference for ARB &gt; ACEi if plans to start ARNI</p> MRAs <p>Eplerenone</p> <p>Spironolactone</p> <p>NYHA class II-IV and</p> <p>GFR &gt;30</p> Diuretic and blood pressure lowering effects and blocks deleterious effects of aldosterone on the heart (including hypertrophy and fibrosis) Hyperkalemia \u2013 avoid if CrCl &lt;30 or K &gt;5 SGLT2i <p>Dapagliflozin</p> <p>Empagliflozin</p> <p>HFrEF &lt;40% with and without DM</p> <p>NYHA class II-IV</p> <p>In conjunction with background GDMT</p> Osmotic diuresis and natriuresis, improve myocardial metabolism, inhibit sodium-hydrogen exchange in myocardium, reduce cardiac fibrosis <p>UTI/ GU infections</p> <p>Risk of ketoacidosis (both DKA and euglycemic)</p> Vasodilators <p>Hydralazine</p> <p>Isosorbide Dinitrate</p> <p>Persistently symptomatic black patients despite ARNI/ BB/ MRA/ SGLT2i</p> <p>NYHA class III-IV</p> <p>Reduces cardiac afterload and preload and may also enhance nitric oxide bioavailability</p> <p>Reduction in mortality for African American patients</p> Hypotension Ivabradine Ivabradine <p>HFrEF &lt;35%, on maximally tolerated BB, sinus rhythm with HR &gt; 70</p> <p>NYHA class II or III</p> <p>If current inhibitor involved in SA node activity</p> <p>Decr HR associated with improved outcomes</p> <p>Need sinus rhythm</p> <p>Caution in sinus node disease and conduction defects</p> Iron Repletion (IV) <p>Iron sucrose</p> <p>Ferric carboxymaltose</p> <p>Iron dextran</p> Ferritin &lt;100 \u00b5g/L or ferritin 100-299 \u00b5g/L AND transferrin saturation &lt;20% <p>Decreases HF hospitalizations</p> <p>Improves exercise function and QOL</p> Risk of anaphylaxis higher in iron dextran"},{"location":"cardiology/cardiology-chf/#device-therapies-after-optimization-of-medical-gdmt","title":"Device therapies (after optimization of medical GDMT)","text":"<ul> <li>Cardiac resynchronization therapy (CRT)<ul> <li>Class I indication: NYHA class II to IV, LVEF \u226435% with QRS \u2265150 ms and left bundle branch block (LBBB)</li> <li>Class II (consider) If EF \\&lt; 35% and:<ul> <li>QRSd &gt; 150, without LBBB</li> <li>AF that requires ventricular pacing and AVN ablation</li> <li>Undergoing placement of device with anticipation of &gt;40% ventricular pacing</li> </ul> </li> </ul> </li> <li>ICD<ul> <li>Class I indication: NYHA class II \u2013 VI with LVEF \\&lt;35% (must have &gt;1yr expected survival and 40+ days from MI)</li> </ul> </li> <li>Mitra Clip<ul> <li>Criteria: moderate to severe mitral regurgitation (3-4+), on maximally tolerated GDMT, an ejection fraction &gt;20%, and a left ventricle end-systolic dimension of less than 7 cm</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-ekg/","title":"Approach to the ECG","text":"<p>Melis Sahinoz</p> <p>Method = mastery, approach each EKG the same.</p>"},{"location":"cardiology/cardiology-ekg/#rate","title":"Rate","text":"<ul> <li>Regular rhythms = \u201cRule of 300\u201d = 300 \u00f7 (large boxes between QRS     complexes)</li> <li>300, 150, 100, 75, 60, 50</li> <li>Irregular rhythms or severe bradycardia = (total number of QRS     complexes on ECG) x 6</li> </ul>"},{"location":"cardiology/cardiology-ekg/#rhythm","title":"Rhythm","text":"<ul> <li>Determine regular vs irregular: calipers or march out QRS complexes     on paper</li> <li>Criteria for Sinus rhythm: P before every QRS; Upright P in Lead I,     II; Negative in aVr</li> </ul>"},{"location":"cardiology/cardiology-ekg/#axis","title":"Axis","text":"<ul> <li>Normal: - 30o to + 90o</li> <li>Quick method: Leads I and II</li> <li>Normal Axis: Upright in I and II</li> <li>Left Axis Deviation: Upright in I, down in II<ul> <li>Causes: LVH, LBBB, Left anterior fascicular block, prior     inferior MI</li> </ul> </li> <li>Right Axis Deviation: Down in I, up in II<ul> <li>Causes: RVH, RBBB, Left posterior fascicular block, prior     lateral MI, PE</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-ekg/#intervals","title":"Intervals","text":"<ul> <li>PR Interval: normal 120 \u2013 200 ms<ul> <li>If \\&lt; 120 ms, consider pre-excitation with accessory pathway (i.e.     WPW)</li> <li>If &gt; 200 ms, first degree AV block</li> </ul> </li> <li>QRS Complex: 60 \u2013 100 ms (normal)<ul> <li>100-120 ms: Incomplete BBB or non-specific intraventricular     conduction delay (IVCD)</li> <li>&gt; 120ms: complete BBB, ventricular tachycardia, hyperkalemia</li> </ul> </li> <li>QT interval: Normal duration \\&lt; 450ms in men and \\&lt; 460ms in women<ul> <li>QT is inversely proportional to HR (QT interval shortens at faster     HRs)</li> <li>Quick estimate: normal QT is less than half the preceding RR     interval</li> <li>QTc estimates the QT interval at a HR of 60 bpm (to allow for     comparison across HRs)</li> <li>A couple formulas exist to calculate QTc:<ul> <li>QTcB= most commonly used due to simplicity, most accurate HR of     60</li> <li>QTcF= more accurate when HR is outside the range of 60-100</li> </ul> </li> <li>Clinically significant when generally QTc &gt; 500 ms</li> <li>Causes of Prolonged QTc: hereditary, medication-induced     (anti-emetics, ABX, psychiatric meds), hypokalemia, hypomagnesemia,     hypocalcemia, ischemia</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-ekg/#morphology","title":"Morphology","text":"<ul> <li>P wave: P waves in limb leads should be \u22642.5 small box high and \u22642.5     small box wide<ul> <li>Right Atrial Enlargement: Peaked P Wave in Lead II that measures     &gt;2.5 mm</li> <li>Left Atrial Enlargement<ul> <li>Lead II: Bifid P Wave (two humps) with total duration &gt; 110 ms</li> <li>Lead V1: Biphasic P wave, terminal deflection &gt; 1mm wide and     deep</li> </ul> </li> <li>If \u2265 3 different P wave morphologies in same lead: wandering atrial     pacemaker (HR \\&lt; 100) or multifocal atrial tachycardia (HR &gt; 100)</li> </ul> </li> <li>QRS complex<ul> <li>Voltage<ul> <li>Low voltage: QRS amplitude \\&lt; 5mm in limb leads or \\&lt; 10mm in     precordial<ul> <li>Causes: pericardial effusion, infiltrative cardiomyopathy,     obesity</li> </ul> </li> <li>Right Ventricular Hypertrophy: Tall R Waves in V1 (&gt; 7mm) and     right axis deviation</li> <li>Left Ventricular Hypertrophy: multiple criteria exist<ul> <li>Sokolow-Lyon criteria\u00a0is a common example: S in V1 + R in V5     or V6 &gt;35mm, R in aVL &gt;1.1 mV</li> </ul> </li> </ul> </li> </ul> </li> <li>Conduction delays<ul> <li>RBBB: Wide QRS and RSR\u2019 in V1 or V2; deep broad S In lateral     leads</li> <li>LBBB: Wide QRS, large S in V1, broad monophasic R wave in     lateral leads (I, aVL, V6)</li> </ul> </li> <li>R wave progression<ul> <li>R wave normally gets progressively larger from V1 to V6</li> <li>If the transition does not occur by V4, this is called \"poor R     wave progression\". This is seen in chronic lung disease, LVH,     left anterior fascicular block, and anterior MI.</li> </ul> </li> <li>Q-wave: Small Q waves are normal in most leads<ul> <li>Never normal in V1-V3</li> <li>Pathologic Q waves: &gt; 1 box wide and 2 boxes deep or &gt; 25% height     of R wave</li> </ul> </li> <li>ST Segment<ul> <li>ST Elevation: STEMI, LBBB (ST elevation in leads with deep S waves),     LVH, Ventricular paced rhythm, Pericarditis (associated with PR     depression), coronary vasospasm, Brugada syndrome</li> <li>ST Depression: ischemia, reciprocal change in STEMI, posterior     myocardial infarction (V1-V3), digoxin, hypokalemia</li> <li>See ACS section for STEMI criteria, Wellens Syndrome</li> </ul> </li> <li>T wave<ul> <li>Normal T waves are upright in all leads except aVR and V1</li> <li>Inverted T Waves<ul> <li>Acute ischemia (if present in contiguous leads), LBBB (in     lateral leads), RBBB (V1-V3), LVH (\u2018strain\u2019 pattern similar to     LBBB), RVH (RV \u2018strain\u2019 in V1-V3 or inferior leads), PE (right     heart strain or part of S1,Q3,T3), intracranial pathology</li> </ul> </li> <li>Peaked T Waves<ul> <li>Hyperkalemia vs \u2018hyperacute\u2019 T waves that precede ST elevation     and Q waves in STEMI</li> </ul> </li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-inpatient-hypertension/","title":"Inpatient Hypertension","text":"<p>Lee Richardson</p>"},{"location":"cardiology/cardiology-inpatient-hypertension/#background","title":"Background","text":"<ul> <li>Hypertensive urgency: SBP &gt; 180mmHg/DBP &gt; 120mmHg</li> <li>Hypertensive emergency: SBP &gt; 180mmHg/DBP &gt; 120mmHg + end organ     damage</li> </ul>"},{"location":"cardiology/cardiology-inpatient-hypertension/#evaluation","title":"Evaluation","text":"<ul> <li>Are there signs/symptoms of end organ damage?</li> <li>Neurologic symptoms: agitation, delirium, stupor, seizures, visual     disturbances</li> <li>Focal neurologic deficits</li> <li>Chest pain</li> <li>Back pain (consider aortic dissection)</li> <li>Dyspnea (consider pulmonary edema)</li> <li>BMP, LFTs, Troponin, BNP: Lab findings suggestive of end-organ     damage</li> </ul>"},{"location":"cardiology/cardiology-inpatient-hypertension/#management","title":"Management","text":"<ul> <li>Goal is to lower BP back to normal over 24-48 hours</li> <li>Initial lowering should be 10-20% in minutes if HTN emergency; goal     should be 10-20% in 2-4 hours if HTN urgency</li> <li>Typically aim for initial goal BP near 160/110</li> <li>Exceptions to gradual lowering include:<ul> <li>Acute stroke: call code stroke, lower ONLY if BP &gt; 185/110 in     pts under consideration for reperfusion therapy; or BP &gt;     220/120 in pts not candidates for reperfusion therapy</li> <li>Aortic dissection: Goal = rapidly lower BP in minutes to target     of 100-120 systolic to avoid aortic shearing forces</li> </ul> </li> <li>Pharmacologic therapy<ul> <li>If pt was previously on anti-HTN meds, ensure their home medicines     have been restarted at appropriate doses, formulation (long acting     vs. short), and dosing intervals</li> <li>If pt has a rapid acting anti-HTN med, can consider giving a dose     early or an \u201cextra dose\u201d and then up titrating their overall daily     dose</li> </ul> </li> <li>Rescue therapies<ul> <li>Captopril PO (12.5mg or 25mg dosed Q8H; conversion ratio of     captopril:lisinopril = 5:1)</li> <li>Hydralazine PO (10-20mg initial dosing Q6H)</li> <li>Isosorbide dinitrate PO (5-20mg TID)</li> <li>Nifedipine XL PO (dose at 30mg initially, max 90 mg BID; NOT     sublingual)</li> <li>Labetalol IV (10-40mg initially; dosed up to every 20-30mins)</li> <li>Hydralazine IV (10-20mg initially; dosed up to every 30 mins).</li> <li>Nitropaste 1\u201d (can add/wipe away for titration; dose Q6H until     oral meds can be started for better long-acting control)</li> </ul> </li> <li>Dialysis if missed session</li> </ul>"},{"location":"cardiology/cardiology-inpatient-hypertension/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Refractory HTN: try additional agents listed above vs. escalation of     care for drip (nicardipine, nitroglycerin, nitroprusside, esmolol).</p> </li> <li> <p>Most drips that can be done for this indication are done in stepdown     and usually require no-titration of the infusion and occasionally     the MD to be bedside to initiate the infusion.</p> </li> <li> <p>This includes diltiazem, labetalol, nitroglycerin, and verapamil     drips. Nicardipine, esmolol, and nitroprusside drips are not allowed     on step down.</p> </li> </ul>"},{"location":"cardiology/cardiology-pe/","title":"Pulmonary Embolism","text":"<p>Anna Berry</p>"},{"location":"cardiology/cardiology-pe/#background","title":"Background","text":"<p>A thrombus originating in a deep vein (LE &gt; UE) embolizing to the     pulmonary arterial circulation.</p> <ul> <li>Risk Factors = Virchow\u2019s Triad<ul> <li>Stasis: immobilization, hospitalization, spinal cord injury, or long     travel</li> <li>Hypercoagulable state: cancer, prothrombotic genetic conditions such     as Factor V Leiden, OCPs, antiphospholipid syndrome, nephrotic     syndrome, pregnancy, infection, etc.</li> <li>Endothelial Injury: surgery, trauma</li> </ul> </li> </ul> <p>Most originate from a DVT in the iliac, femoral, and popliteal veins</p>"},{"location":"cardiology/cardiology-pe/#presentation","title":"Presentation","text":"<ul> <li>Dyspnea and tachypnea</li> <li>Respiratory alkalosis on blood gas from hyperventilation</li> <li>Hypoxemia</li> <li>Sinus Tachycardia or atrial arrhythmias</li> <li>Hemoptysis</li> <li>Lower extremity pain, swelling, and redness \u2013 occurs in 50% of pts     with DVT</li> <li>RV Failure (large PE) \u2013 elevated JVP, hypotension, syncope, R     parasternal heave, accentuated P2, hepatomegaly</li> </ul>"},{"location":"cardiology/cardiology-pe/#evaluation","title":"Evaluation","text":"<ul> <li>If hemodynamically unstable and PE suspected, provide hemodynamic     support (ie. O2, pressors, etc.) and perform emergent bedside TTE</li> <li> <p>If no RV strain evident on TTE, low likelihood of hemodynamically     significant PE. Consider other causes of shock.</p> </li> <li> <p>Hemodynamically stable</p> <ul> <li>EKG<ul> <li>Most commonly sinus tachycardia</li> <li>Less commonly and indicative of large PE: RAD, RVH, RBBB, RA     enlargement, S1Q3T3 (deep S in lead I, deep Q and inverted T in     lead III), TWI in V1-V3</li> </ul> </li> <li>CXR: Typically normal. May see linear atelectasis, pleural effusion,     PA cutoff sign</li> <li>Labs: ABG, troponin, BNP</li> <li>May consider lower extremity dopplers</li> <li>Imaging vs d-dimer based on pre-test probability:<ul> <li>Low pre-test probability (use Wells Criteria) d-dimer</li> <li>For moderate to high pre-test probability CTA Chest PE protocol<ul> <li>If high pre-test probability or moderate pre-test     probability with &gt;4 hour delay in work-up, start empiric     anticoagulation if bleeding risk is acceptable while work-up     is ongoing</li> </ul> </li> </ul> </li> <li>TTE</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-pe/#management","title":"Management","text":"PE Class: Low risk Submassive Massive Definition <p>Hemodynamically stable</p> <p>No evidence of right heart strain or myocardial necrosis on labs or TTE</p> <p>Hemodynamically stable</p> <p>Evidence of right heart strain or myocardial necrosis: RV strain on TTE (ex: D-sign), BNP &gt;150, trop &gt;0.05</p> <p>Hemodynamically unstable (ex: SBP&lt;90)</p> <p>Evidence of RV strain</p> Management <p>Start anticoagulation</p> <p>LWH or heparin gtt (if renal impairment)</p> <p>Can also use NOAC. Rivaroxaban &amp; apixaban can be used as initial management. Edoxaban &amp; dabigatran can be used after 5-10 days of parenteral therapy</p> <p>Provide hemodynamic support, monitor for decompensation</p> <p>Start anticoagulation with unfractionated heparin gtt</p> <p>STAT consult cardiology for consideration of catheter directed thrombolysis (EKOS) or embolectomy</p> <p>Provide hemodynamic support.</p> <p>Start anticoagulation with unfractionated heparin gtt</p> <p>Page CCU fellow STAT. Consider systemic tPA (this is a fellow/attending level decision).</p> <p>Discuss with cardiology catheter directed thrombolysis (EKOS) or embolectomy</p>"},{"location":"cardiology/cardiology-pe/#tpa-considerations","title":"tPA Considerations","text":"<ul> <li>Dose is 100mg tPA over 2hrs</li> <li>Most effective within 24 hours but effective up to 14d</li> <li>Contraindications:<ul> <li>Absolute:<ul> <li>CNS Pathology: hemorrhagic or ischemic CVA within 3 mo, AVM,     CNS neoplasm, recent surgery</li> <li>Trauma: Recent head trauma w/ fx or injury</li> </ul> </li> <li>Relative<ul> <li>Surgery: surgery w/in 3 wks</li> <li>Heme: active bleeding, bleeding diathesis, plt \\&lt; 100, oral     AC</li> <li>Age: &gt;75 yo, dementia</li> </ul> </li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-pe/#long-term-management","title":"Long-term management","text":"<ul> <li>Anticoagulation: see \u201cVenous Thromboembolism\u201d in Hematology/Oncology</li> </ul>"},{"location":"cardiology/cardiology-rhc/","title":"Right Heart Catheterization","text":"<p>Pakinam Mekki</p>"},{"location":"cardiology/cardiology-rhc/#background","title":"Background","text":"<ul> <li>Pulmonary artery catheter (PAC): Multilumen catheter that sits in     the right heart to provide invasive measurement of hemodynamic     parameters</li> <li>Indications for PAC placement<ul> <li>Diagnose undifferentiated shock</li> <li>Severe cardiogenic shock</li> <li>Diagnose pulmonary hypertension</li> <li>Diagnose left -&gt; right shunting</li> <li>Diagnose valvular and pericardial disease</li> <li>Titrating medications, specifically inotropes, pulmonary     vasodilators, diuresis</li> </ul> </li> <li>Contraindications to PAC placement<ul> <li>RA/RV mass or thrombi</li> <li>Tricuspid or pulmonic valve endocarditis</li> <li>Mechanical tricuspid or pulmonic valves</li> <li>Presence of RV assist device</li> </ul> </li> <li>Complications of PAC placement<ul> <li>Arrythmias: VT, RBBB, 3rd degree AV block if preexisting LBBB</li> <li>Infection (endocarditis of the pulmonary valve)</li> <li>Bleeding</li> <li>Pulmonary embolism and pulmonary Infarct</li> <li>Pneumothorax</li> <li>Air embolism</li> <li>Pulmonary artery perforation / rupture</li> <li>Endocardial/valvular damage</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-rhc/#pac-pressure-tracings","title":"PAC Pressure Tracings","text":"Definition Normal \"Rule of 5s\" <p>Interpretation</p> <p>Central Venous Pressure</p> <p>(CVP)</p> Pressure in superior vena cava, often an indicator of volume status 0 - 5 mmHg Elevated CVP is indicative of cardiac dysfunction and/or fluid retention  Low CVP is indicative of volume depletion or decreased venous tone Right Atrial Pressure (RAP) Surrogate for preload, should be same as CVP 0 - 5 mmHg Elevated with disruption in forward cardiac flow or increase in intravascular volume Right Ventricle Pressure ( Right ventricular systolic and diastolic pressures; RVSP can be surrogate for PASP 25/5 mmHg Elevated with diseases that elevate PA pressure and pulmonic valve disorders. Severe RVP elevations are generally chronic while acute conditions typically have RVSP &lt;40-50. Pulmonary Artery Pressure (PAP) Measured as systolic, diastolic, and mean pressures. Diagnoses pHTN. <p>25/10 mmHg</p> <p>Mean: 10 - 19 mmHg</p> Elevated In acute conditions (PE, hypoxemia induced pulmonary vasoconstriction) or pHTN (mean PAP &gt; 20 mm Hg) Pulmonary Artery Wedge Pressure (PAWP or wedge) Pressure measured by wedging the PAC into a small pulmonary arterial branch; surrogate for left atrial pressures and LVEDP 10 mm Hg Increased with elevated LVEDP: systolic or diastolic heart failure, mitral and aortic valve disorders, hypervolemia, R to L shunts, tamponade, constrictive/restrictive cardiomyopathy Thermodilution Cardiac Output &amp; Index Amount of blood pumped in one min. CI is the cardiac output divided by body surface area (to standardize for body size) <p>CO: 3.4-15 L/min</p> <p>CI: 2.8-4.2 L/min/m^2</p> <p>Low CI: systolic/diastolic heart failure, severe valvular disorder (MR, AS), RV failure, pHTN, cardiogenic shock.</p> <p>Elevated CI (high-output state): sepsis, anemia, thyrotoxicosis, A-V shunt</p> <p>Mixed central venous oxyhemoglobin</p> <p>saturation (SvO2)</p> % of oxygen bound to Hgb in blood returning to the right side of the heart, reflects total body O2 extraction 65-70% <p>High SvO2 (&gt; 65%) = decreased O2 demand or \u201chigh flow\u201d states seen in distributive shock (sepsis)</p> <p>Low SvO2 (&lt; 50%) = decreased O2 delivery seen in cardiogenic or hypovolemic shock. In low SvO2 states, there is less O2 supply to same demand)</p>"},{"location":"cardiology/cardiology-rhc/#calculating-hemodynamic-parameters-from-pac-pressures","title":"Calculating Hemodynamic Parameters from PAC Pressures","text":"Definition Normal Values Interpretation Fick CO and CI Calculated CO based on Oxygen consumption (VO2), Hbg, and O2 sats of arterial and venous blood <p>4-7 L/min</p> <p>2.5-4 L/min/m2</p> See \"Cardiac Index\" above. Systemic Vascular Resistance (SVR) Measurement of afterload; helpful in delineating the etiology of shock as well as guiding afterload-reduction therapy in HFrEF 700-1200 dynes*s*cm-5 <p>Elevated SVR is seen in hypovolemic, cardiogenic, and obstructive shock</p> <p>Decreased SVR is seen in distributive shock (sepsis, anaphylaxis, neurogenic)</p> Transpulmonary gradient (TPG) Differentiates between pre- and post-capillary pulmonary hypertension. &lt; 12 mmHg A TPG value greater than 12 mmHg indicates that a component of the pHTN is secondary to pulmonary vascular disease Pulmonary Vascular Resistance (PVR) Gold standard in the estimation of the severity of pre-capillary pHTN  Reflects the pressure drop across the pulmonary system only and is independent of the LA, mitral valve and the LV <p>&lt; 3 Wood Units</p> <p>30-90 dynes*sec*cm5</p> <p>Elevated PVR (&gt;3 Wood units) suggests pre-capillary pHTN</p> <p>Normal PVR seen in pulmonary venous hypertension (diastolic dysfunction)</p> Pulmonary artery pulsatility index (PAPi) Pulmonary pulse pressure relative to preload (RAP), Indicator of RV function &gt; 0.9 PAPi &lt; 0.9 predicts in-hospital mortality and/or need for RVAD in acute MI. Can be decreased in pure RV failure or biventricular failure Cardiac Power Cardiac output relative to afterload, a measure of LV contractile reserve Normal &gt; 1 <p>CP&lt; 0.6 strongly suggestive of LV failure</p> <p>Found to be a strong independent hemodynamic correlate in pts with cardiogenic shock. Predictor of mortality in CCU</p>"},{"location":"cardiology/cardiology-shock/","title":"Cardiogenic Shock","text":"<p>Ashley Cozart</p>"},{"location":"cardiology/cardiology-shock/#definition","title":"Definition","text":"<p>Impairment of cardiac output due to primary cardiac disorder that     results in end-organ hypoperfusion and hypoxia</p>"},{"location":"cardiology/cardiology-shock/#etiology","title":"Etiology","text":"<ul> <li>Cardiomyopathic: myocardial infarction with LV dysfunction,     exacerbation of heart failure, myocarditis, myocardial contusion,     drug-induced</li> <li>Arrhythmic: atrial tachycardias (atrial fibrillation/flutter, AVRT,     AVNRT), ventricular tachycardia and fibrillation, complete heart     block, second degree heart block</li> <li>Mechanical: valvular insufficiency, valvular rupture, critical     valvular stenosis, ventricular septal wall defect, ruptures     ventricular wall aneurysm, atrial myxoma</li> </ul>"},{"location":"cardiology/cardiology-shock/#presentation","title":"Presentation","text":"<ul> <li>Cold (decreased perfusion) due to reduced cardiac output (can be     wet- increased PCWP OR dry normal PCWP)</li> <li>Symptoms of volume overload + end-organ hypoperfusion (altered     mental status, nausea, abdominal pain, decreased urine output)</li> <li>Hypotension; narrow pulse pressure</li> </ul>"},{"location":"cardiology/cardiology-shock/#evaluation","title":"Evaluation","text":"<ul> <li>EKG</li> <li>Labs: CBC, CMP, BNP, troponin, lactate</li> <li>Evidence of end organ damage: lactic acidosis, acute kidney injury,     acute liver injury</li> <li>Echocardiogram: assess EF and valves</li> <li>LHC If ischemia (see ACS)</li> <li>Hemodynamic monitoring via Swan-Ganz or PA catheter:<ul> <li>No benefit for general shock but does improve in-hospital mortality for those with cardiogenic shock</li> <li>PA catheter hemodynamic profile:<ul> <li>Cardiac index \\&lt; 2.2, cardiac power \\&lt;0.6, SVR 800-1600, SVO2 \\&lt;60%</li> <li>LV-dominant: RA (CVP) \\&lt;15, PCWP &gt;18, PAPi &gt;1.5 (pulmonary artery pulsatility index)</li> <li>RV-dominant: RA &gt;15, PCWP \\&lt;18, PAPi &gt;1.5</li> <li>Bi-V-dominant: RA &gt;15, PCWP &gt;18, PAPi &gt;1.5</li> <li>PAPi \\&lt; 1 indicates that patient will likely need RV support</li> <li>CP \\&lt; 0.5 strongest independent hemodynamic correlate of mortality in CS</li> <li>See right heart cath section for interpreting PA catheter profiles</li> </ul> </li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-shock/#management-medical-mechanical-circulatory-support","title":"Management (medical &amp; mechanical circulatory support)","text":""},{"location":"cardiology/cardiology-shock/#medical-management","title":"Medical management","text":"<p>Focus on optimizing preload, afterload, and contractility.</p> <ul> <li>Preload: IV diuresis</li> <li>Afterload: IV \u2013 nitroglycerine, nitroprusside; PO \u2013 hydralazine,     isosorbide dinitrate; vasoconstricting pressors (phenylephrine,     vasopressin) if needing BP support</li> <li>Contractility - Inodilators (increase contractility, decrease     afterload \u2013 milrinone, dobutamine) or inoconstrictors (increase     contractility and afterload \u2013 epinephrine, norepinephrine)</li> </ul>"},{"location":"cardiology/cardiology-shock/#mechanical-circulatory-support-indications","title":"Mechanical circulatory support indications","text":"<ul> <li>Shock refractory to &gt;1 pressor</li> <li>Shock 2/2 MI (physiology: unloads LV, increases systemic perfusion,     increases myocardial perfusion, and provides hemodynamic support     during PCI)</li> </ul> <p>Types of mechanical circulatory support (MCS)</p> Intra-aortic Balloon Pump V-A ECMO Tandem Heart Impella Dynamics Inflates during diastole, deflates during systole Blood from femoral vein is oxygenated and pumped to femoral artery <p>LV: blood aspirated from LA to femoral artery</p> <p>RV: blood aspirate from RA to PA</p> <p>Impella 2.5, 5.0 &amp; CP: Blood aspirated from LV to aortic root</p> <p>Impella RP: Blood aspirated from IVC and delivered to PA</p> Flow 1 LMP 4.5 LPM 4-5 LPM <p>2.5: 2.5 L/min</p> <p>CP: 3.33 L/min</p> <p>5.0: 5 L/min</p> <p>RP: 4 L/min</p> Support LV BiV LV, RV, or BiV LV or RV (RP) Effects <p>Reduces afterload</p> <p>Increases stroke volume (SV)</p> <p>Increases coronary perfusion</p> <p>Reduces LV preload and PCWP</p> <p>Increases afterload</p> <p>Reduces SV</p> <p>Reduces LV preload and PCWP</p> <p>Improves tissue perfusion</p> <p>Increases afterload</p> <p>Reduces SV</p> <p>Reduces LV preload and PCWP</p> <p>Improves tissue perfusion</p> <p>Reduces SV</p> <p>Reduces preload and PCWP</p> <p>Improves tissue perfusion</p> Complications <p>Thrombocytopenia</p> <p>Thrombosis</p> <p>Arterial obstruction</p> <p>Aortic rupture or dissection</p> <p>Air embolism</p> <p>Circuit thrombosis</p> <p>LV dilation</p> <p>Hypothermia</p> <p>Gas embolism</p> <p>Tamponade d/t perforation</p> <p>Thrombosis</p> <p>Embolism (gas or thrombus)</p> <p>Arterial Shunt</p> <p>Pump migration</p> <p>Hemolysis</p> <p>Aortic regurg</p> <p>LV perf</p> <p>VT/VF</p> <p>Daily management of MCS devices:</p> <ul> <li>Ensure optimal placement of device with daily CXR</li> <li>Anticoagulation (based on device)</li> <li>Hematoma monitoring at device site</li> <li>Check distal pulses to monitor for limb ischemia</li> </ul> <p>Pearls for MCS</p> <ul> <li>MCS devices are contraindicated in following situations: aortic     regurgitation or metallic aortic valve, aortic aneurysm or     dissection, severe aortic or peripheral artery disease, left     ventricular or left atrial thrombi, bleeding diathesis, uncontrolled     sepsis</li> <li>ECMO is placed by the cardiac surgery team, once a patient is     cannulated they will move onto the cardiac surgery team</li> <li>Impella, tandem heart, and IABPs are placed in the cath lab</li> <li>MCS is a bridge to recovery/definitive therapy, durable cardiac     support (VAD), or transplant</li> </ul>"},{"location":"cardiology/cardiology-syncope/","title":"Syncope","text":"<p>Sarah Myers</p>"},{"location":"cardiology/cardiology-syncope/#background","title":"Background","text":"<ul> <li>Definition: abrupt, transient loss of consciousness with rapid &amp;     spontaneous recovery\u00a0\u00a0</li> <li>Presyncope \u2013 symptoms occurring before syncope including     lightheadedness, tunnel vision/other visual disturbances</li> </ul>"},{"location":"cardiology/cardiology-syncope/#classification","title":"Classification","text":"<ul> <li>Cardiac syncope\u00a0</li> <li>Tachyarrhythmias: VT, SVT\u00a0</li> <li>Bradyarrhythmias: sinus node dysfunction, AV blocks (high grade)\u00a0</li> <li>Structural: Aortic Stenosis, HCM, cardiac tamponade, congenital     anomalies, masses/tumors\u00a0</li> <li>Vascular: Pulmonary embolism, aortic dissection, severe pHTN\u00a0</li> <li>Noncardiac syncope</li> <li>Reflex mediated<ul> <li>Vasovagal; most common form of reflex mediated syncope<ul> <li>Can occur sitting/standing or with trigger (stress, pain,     medical settings)</li> <li>Classically has prodrome of nausea, diaphoresis, tunnel     vision followed by hypotension and/or bradycardia</li> </ul> </li> <li>Situational (micturition/defecation/coughing)</li> <li>Carotid sinus sensitivity syndrome</li> </ul> </li> <li>Orthostatic</li> <li>Medications (diuretics, nitrates/CCB/alpha blockers, TCAs)</li> <li>Volume depletion (hemorrhage, dehydration)</li> <li>Autonomic dysfunction</li> </ul>"},{"location":"cardiology/cardiology-syncope/#differential-diagnosis","title":"Differential diagnosis","text":"<ul> <li>Seizure, stroke, metabolic derangements, Intoxication/withdrawal,     hypoglycemia, head trauma</li> <li>With rare exceptions, these do not result In complete LOC with     spontaneous recovery</li> </ul>"},{"location":"cardiology/cardiology-syncope/#evaluation","title":"Evaluation","text":"<ul> <li>History and physical are essential for evaluation of a syncopal     event\u00a0</li> <li>Characteristics associated with cardiac syncope\u00a0</li> <li>Male, &gt;60, known structural/ischemic heart disease, brief/no     prodrome, syncope while supine/at rest or during exercise, family hx     of SCD/premature death, abnormal exam\u00a0</li> <li>Characteristics associated with noncardiac syncope</li> <li>Younger age, syncope while standing or with positional changes,     prodrome (nausea, vomiting, warmth), specific triggers, previous     episodes that have been similar\u00a0\u00a0</li> </ul>"},{"location":"cardiology/cardiology-syncope/#workup","title":"Workup","text":"<ul> <li>EKG on all patients with syncope, monitor those who are admitted on     telemetry</li> <li>CBC, CMP, troponin, BNP (If cardiac cause suspected), POC glucose,     UDS, orthostatic VS</li> <li>EEG and neuroimaging if concern for seizure activity or focal neuro     deficit\u00a0\u00a0</li> <li>TTE and consider stress testing particularly in exertional syncope\u00a0\u00a0</li> </ul>"},{"location":"cardiology/cardiology-syncope/#management","title":"Management","text":"<ul> <li>Cardiac: managed as indicated based on pathology\u00a0</li> <li> <p>If arrhythmia is suspected but not captured on admission, consider     discharge with event monitor \u00a0</p> </li> <li> <p>Noncardiac</p> </li> <li> <p>Reflex</p> <ul> <li>Vasovagal- consider tilt table testing If recurrent or diagnosis     not clear</li> <li>Situational- mainly avoiding triggers</li> <li>Carotid sinus syndrome- may require PPM</li> </ul> </li> <li> <p>Orthostatic</p> <ul> <li>Medication related<ul> <li>Appropriate to hold potentially offending medications     (diuretics, vasodilators) during evaluation</li> <li>Monitor for worsening supine hypertension, arrhythmias, or     heart failure when holding</li> </ul> </li> <li>Volume depletion; resuscitate as appropriate</li> <li>Autonomic dysfunction: see autonomics section</li> </ul> </li> <li> <p>Driving: TN law does not require any MD to inform the state of TLOC\u00a0</p> </li> <li>Should still recommend patients not drive while work-up ongoing.     Document all conversations about driving with patients</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/","title":"Valvular Heart Disease","text":"<p>Jonathan Napper, Marcus Threadcraft</p>"},{"location":"cardiology/cardiology-valvular-heart-disease/#aortic-stenosis","title":"Aortic stenosis","text":"<p>Jonathan Napper\u00a0</p>"},{"location":"cardiology/cardiology-valvular-heart-disease/#etiology","title":"Etiology","text":"<ul> <li>Degenerative calcification of the aortic cusps</li> <li>Congenital bicuspid aortic valve</li> <li>Chronic deterioration (calcific)</li> <li>Prior rheumatic fever/inflammation</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#presentation","title":"Presentation","text":"<ul> <li>Angina, syncope, exertional dyspnea, heart failure (HF carries worse     prognosis)</li> <li>Typically aged 70 \u2013 80 y/o; if bicuspid aortic valve expect 10-20     yrs earlier</li> <li>Physical exam: Systolic crescendo-decrescendo murmur that radiates     towards the carotids</li> <li>Late peaking murmur, faint or absent S2, or delayed carotid upstroke     suggest severe AS</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#evaluation","title":"Evaluation","text":"<ul> <li>TTE with doppler is test of choice</li> </ul> Severity \u00a0 Valve Area (cm2)\u00a0 Mean Gradient (mmHg)\u00a0 <p>Velocity \u00a0</p> <p>(m/s)\u00a0</p> Indexed Valve Area (cm2/m2) \u00a0 Mild \u00a0 &gt;1.5\u00a0 &lt;20\u00a0 2.0-2.9\u00a0 &gt;0.85\u00a0 Moderate \u00a0 1.0-1.5\u00a0 20-39\u00a0 3.0-3.9\u00a0 0.60-0.85\u00a0 Severe\u00a0 &lt;1.0\u00a0 &gt;40\u00a0 &gt;4.0\u00a0 &lt;0.6\u00a0 Critical \u00a0 &lt;0.5\u00a0 --\u00a0 --\u00a0 --\u00a0 <p>AS stages</p> <ul> <li>A: at risk of AS (those with bicuspid anatomy or calcification</li> <li>B: Asymptomatic non-severe AS</li> <li>C: asymptomatic AS<ul> <li>C1: normal EF</li> <li>C2: abnormal EF<ul> <li>This stage might benefit from exercise or stress testing to   elicit symptoms</li> </ul> </li> </ul> </li> <li> <p>D: Symptomatic AS</p> </li> <li> <p>Some with symptomatic AS might not have enough LV reserve to produce     high velocities and gradients (ex EF of 10% w/ critical valve area)     = low flow/low gradient AS; consider dobutamine to unmask AS</p> </li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#management","title":"Management","text":"<ul> <li>No proven effective medical therapy</li> <li>Definitive treatment is valve replacement for:<ul> <li>Stage D</li> <li>Stage C with inducible symptoms on stress testing, low EF, or     undergoing other cardiac procedure</li> <li>Rapid progression (increase in velocity &gt;0.3m/sec per year)</li> </ul> </li> <li>Consult cardiac surgery for determination of SAVR vs TAVR<ul> <li>In general, high risk surgical patients benefit most from TAVR</li> <li>At VUMC: If determined to be intermediate to high operative risk by     Cardiac Surgery, they will often recommend contacting the TAVR team     for evaluation</li> </ul> </li> <li>Avoid rapid hemodynamic shifts and aggressive changes in preload or     afterload</li> <li>Aim for normotension<ul> <li>Avoid preferential vasodilators such as hydralazine or nitroglycerin</li> <li>Significant vasodilation may \u2193 coronary filling pressures -&gt; myocardial ischemia</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#monitoring","title":"Monitoring","text":"<ul> <li>Severe AS: TTE q 6-12 months</li> <li>Moderate AS: TTE q 1-2 years</li> <li>Mild AS: TTE q 3-5 years</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#post-avr-anticoagulation","title":"Post AVR anticoagulation","text":"<ul> <li>All patients will get 3-6 months of AC s/p AVR</li> <li>Continued duration based on type of AVR<ul> <li>Bioprosthetic (TAVR and some SAVRs): antiplatelets alone after     Initial AC</li> <li>Mechanical: lifelong AC with warfarin only</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#aortic-regurgitation","title":"Aortic Regurgitation","text":"<p>Jonathan Napper\u00a0</p>"},{"location":"cardiology/cardiology-valvular-heart-disease/#etiology_1","title":"Etiology","text":"<ul> <li>Primary valve disease (rheumatic disease, bicuspid aortic valve,     infective endocarditis, syphilis)</li> <li>Primary aortic root disease (medial degeneration, aortic dissection,     Marfan\u2019s syndrome, bicuspid aortic valve, syphilis, non-syndromic     familial)</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#presentation_1","title":"Presentation","text":"<ul> <li>Acute AR: LV cannot respond to increased volume to maintain stroke     volume pulmonary edema and cardiogenic shock</li> <li>Chronic AR: indolent presentation, often patient will develop     symptoms of heart failure including DoE, orthopnea, PND</li> <li>Physical exam: \u201cWater-hammer\u201d pulses, wide pulse pressure, laterally     displaced PMI, high pitched \u201cblowing\u201d decrescendo murmur best heard     at third intercostal space at left sternal border, S3</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#management_1","title":"Management","text":"<ul> <li>Acute severe AR<ul> <li>Prompt surgical repair</li> <li>Vasodilators such as nitroprusside and diuretics can be used to     stabilize patient</li> </ul> </li> <li> <p>Chronic severe AR</p> <ul> <li>Medical management</li> <li>Early symptoms of exercise intolerance can be treated with     diuretics</li> <li>Systolic BP should also be controlled with goal SBP \\&lt; 140 in     chronic AR</li> </ul> </li> <li> <p>Repeat imaging should be performed 3-6 month to assess for depressed     LVEF or LV dilation</p> </li> <li> <p>Stages of Chronic AR: Ranging from Stage (A): Asymptomatic but \u201cAt     Risk\u201d AR to Stage (D) Symptomatic Severe AR</p> <ul> <li>If symptoms are present, automatically Stage D, otherwise     Progression through stages is determined by AR Jet Width</li> </ul> </li> <li>Class I indications for Valve Repair:<ul> <li>Stage D (Symptomatic) or Stage C (Asymptomatic Severe AR)   with LVEF \\&lt; 55%, or are undergoing other   cardiac surgery</li> <li>If LVEF &gt; or equal 55%, patients should be considered for         surgery if LV is dilated (LVESD &gt; 50 mm (class IIa) or LVEDD &gt;         65 mm (class IIb))</li> <li>Any patient with progressive AR, even if they do not meet criteria     for severe AR, should consider valve replacement if undergoing     cardiac surgery for other reasons</li> <li>Note: TAVI for isolated chronic AR is challenging 2/2 dilation         of the aortic annulus and root</li> </ul> </li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#mitral-regurgitation","title":"Mitral Regurgitation","text":"<p>Marcus Threadcraft</p>"},{"location":"cardiology/cardiology-valvular-heart-disease/#etiology_2","title":"Etiology","text":"<ul> <li>Primary MR \u2013 caused by direct involvement of the valve apparatus     (leaflets or chordae tendineae)</li> <li>Degenerative/myxomatous mitral valve disease (mitral valve prolapse     with flail leaflet, mitral annular calcification, chordal rupture)</li> <li>Rheumatic fever</li> <li>Infective endocarditis</li> <li>Papillary muscle rupture following acute (inferior) MI</li> <li>Secondary MR- caused by changes of the LV that lead to valvular     incompetence</li> <li>Dilated Cardiomyopathy</li> <li>HOCM with systolic anterior motion</li> <li>Coronary Artery Disease or prior MI leading to papillary muscle     tethering</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#presentation_2","title":"Presentation","text":"<ul> <li>Acute MR- sudden onset reduction in forward cardiac flow and left     atrial/pulmonary vein volume overload</li> <li>Dyspnea with flash pulmonary edema</li> <li>Left-sided heart failure</li> <li>Chronic MR- progressive symptoms d/t cardiac remodeling to     compensate for mitral flow reversal</li> <li>Progressively worsening heart failure: dyspnea, orthopnea, PND</li> <li>LV dilation from volume overload</li> <li>LA remodeling/dilation leading to afib</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#auscultation","title":"Auscultation","text":"<ul> <li>Holosystolic Murmur</li> <li>Best heard at Apex</li> <li>Radiation to the Axilla</li> <li>Frequently associated with S3</li> <li>Murmur may be absent in acute MR due to large regurgitant     orifice/low velocity regurgitant jet</li> <li>Increases w/ increased preload or afterload</li> <li>Pulmonary Rales</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#evaluation_1","title":"Evaluation","text":"<ul> <li>CXR: assess for pulmonary edema, r/o other causes of acute dyspnea</li> <li>ECG: often non-specific, LVH</li> <li>Echocardiography: assess valve apparatus, size, and function of     LA/LV, grade severity of MR</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#chronic-mr-stages","title":"Chronic MR stages","text":"<ul> <li>A: No symptoms</li> <li>B: &gt;mild MR w/o hemodynamic changes or symptoms</li> <li>C: Severe MR w/o symptoms<ul> <li>C1: preserved EF and normal LV size</li> <li>C2: reduced EF (\\&lt;60%), dilated LV (LVESD &gt; 40mm)</li> </ul> </li> <li>D: Severe/symptomatic</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#management_2","title":"Management","text":"<p>Acute hemodynamically significant MR</p> <ul> <li>Urgent surgical repair or replacement</li> <li>Medical stabilization as a bridge to surgery<ul> <li>Afterload reduction is key to promote forward flow</li> <li>Vasodilators (nitroprusside, nitroglycerin) reduce afterload</li> <li>Diuresis to reduce preload and improve pulmonary edema</li> <li>IABP placement can be used as mechanical afterload reduction</li> </ul> </li> </ul> <p>Chronic severe primary MR</p> <ul> <li>Surgical repair favored over valve replacement</li> <li>Class I:<ul> <li>Asymptomatic patients w/ LVEF 30-59% or LVESD &gt; or equal 40mm</li> <li>Symptomatic patients w/ EF &gt; 30%</li> </ul> </li> <li>Class II:<ul> <li>A: asymptomatic patients with progressive EF decline or LV     dilation on serial monitoring; or very severe MR</li> <li>B: new onset AF</li> </ul> </li> <li>Secondary MR can consider MV repair with persistent class III-IV     symptoms while on guideline directed medical therapy</li> <li>In HFrEF, consider MitraClip after volume optimization (see Heart     Failure section)</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#mitral-stenosis","title":"Mitral Stenosis","text":"<p>Marcus Threadcraft</p>"},{"location":"cardiology/cardiology-valvular-heart-disease/#etiology_3","title":"Etiology","text":"<p>Characterized by thickened mitral valve leaflets and fused leaflet tips.</p> <ul> <li>Rheumatic Fever (leading cause worldwide)</li> <li>Calcification of the mitral valve annulus (common in high income     countries)</li> <li>Autoimmune Diseases: SLE, Rheumatoid arthritis</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#presentation_3","title":"Presentation","text":"<ul> <li>Progressive symptoms: Asymptomatic Heart Failure</li> <li>Orthopnea</li> <li>PND</li> <li>Hoarseness/Dysphagia (compression of recurrent laryngeal     nerve/esophagus by enlarged left atrium from pressure overload)</li> <li>Symptoms of Right Heart Failure</li> <li>Acute Symptoms may present in settings of increased cardiac output     (pregnancy, sepsis, or exercise) or tachyarrhythmias</li> <li>Dyspnea</li> <li>Fatigue</li> <li>Palpitations</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#physical-exam","title":"Physical exam","text":"<ul> <li>Low-pitched rumbling, diastolic Murmur, best heard at apex,     low-pitched, rum<ul> <li>Loud S1, opening snap after S2</li> <li>Prominent P2 if pulmonary HTN develops</li> </ul> </li> <li>Pulmonary Rales</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#evaluation_2","title":"Evaluation","text":"<ul> <li>CXR: LA enlargement, increased pulmonary vasculature</li> <li>Echocardiography: thickening of mitral valve leaflets, decreased     area of valve leaflets, left atrial enlargement</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#management_3","title":"Management","text":"<ul> <li>Varies between rheumatic MS and calcific MS (in general,     intervention of calcific MS is very challenging and high risk)</li> <li>Severe, symptomatic rheumatic MS:<ul> <li>Percutaneous mitral balloon commissurotomy (PMBC)</li> <li>Surgical repair/replacement if patient failed PMBC or undergoing other cardiac surgery</li> </ul> </li> <li> <p>Calcific MS has a poor prognosis with 5-year survival \\&lt;50%,     Intervention is higher risk and should be reserved for severely     symptomatic patients</p> </li> <li> <p>No role for commissurotomy with calcific MS</p> </li> <li>Surgical valve replacement may be considered for severely     symptomatic patients (technically challenging)</li> </ul>"},{"location":"cardiology/cardiology-valvular-heart-disease/#anti-coagulation","title":"Anti-Coagulation","text":"<ul> <li>Anti-coagulation is indicated if:<ul> <li>Mechanical prosthetic mitral valve<ul> <li>Warfarin, goal INR 3-4 lifelong</li> </ul> </li> <li>Bioprosthetic mitral valve replacement<ul> <li>Warfarin, goal INR 2-3 for first 3-6 months</li> </ul> </li> <li>Atrial Fibrillation regardless of CHADS2VASC score</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-abcdef-a2f-bundle/","title":"ABCDEF (A2F) Bundle","text":"<p>Kaele Leonard</p>"},{"location":"critical-care/critical-care-abcdef-a2f-bundle/#background","title":"Background","text":"<ul> <li>Post-Intensive Care Syndrome (PICS): complex constellation of     cognitive, physical, and psychological impairments that impact most     survivors of critical illness, leading to disability, frailty, and     poor quality of life</li> <li>Predicted by (1) duration of immobility and (2) delirium</li> <li>Both are reduced by &gt;80% compliance with ABCDEF (A2F) Bundle     concepts</li> <li>ABCDEF (A2F) Bundle: Interprofessional, evidence-based safety bundle     of care principles to help reduce LOS, mortality, bounce-backs, and     the duration of ICU delirium and coma</li> <li>Goal: allow pt to \u201cprove us wrong\u201d about readiness for liberation     from devices, sedatives, etc.</li> </ul> <p>**A**ssess, prevent, and manage pain</p> <ul> <li>Tools to assess pain using facial expressions, body movements,     muscle tension, compliance with ventilator, or vocalization for     extubated pts</li> <li>Ex: Critical Care Pain Observation Tool (CPOT): scale 0-8,     uncontrolled pain 3</li> <li>Uncontrolled pain increases risk for delirium, limits inspiratory     effort &amp; weaning from ventilator, and limits ability to mobilize</li> <li>Treatment: multi-modal: parenteral opioids, neuropathic meds (e.g.,     gabapentin, ketamine), adjunctive non-opioids analgesics (e.g.,     acetaminophen, NSAIDs), nonpharmacologic interventions     (repositioning, heat/cold)</li> </ul> <p>**B**oth spontaneous awakening trials (SATs) and spontaneous breathing trials (SBTs)</p> <ul> <li>SATs = daily sedative interruptions</li> <li>RN-driven protocol involving safety checklist: no active seizures,     alcohol withdrawal, agitation, paralytics, myocardial infarction, or     increased ICP</li> <li>If pass SAT, then proceed to SBT</li> <li>If fail SAT (anxiety, agitation, pain, resp distress) restart     sedation at \u00bd doses</li> <li>SBTs = PS ventilation (Fi02 \u2264 50%, PEEP \u2264 7.5; typically 40% and     5/5) for \u2265 30 minutes</li> <li>RT or physician/APP-driven protocol with safety screen: passed SAT,     O2 sat \u2265 88%, inspiratory efforts, no myocardial ischemia, no/low     vasopressor support</li> <li>If pass SBT, physician/APP judgment on extubation</li> <li>If fail SBT (RR &gt; 35 or \\&lt; 8, O2 sat \\&lt; 88%, resp distress, mental     status change) restart full ventilatory support</li> <li>Evidence:<ul> <li>Liberated pts from mechanical ventilation 3 days sooner, decreased     ICU and hospital length of stay by 4 days, and 14% absolute     reduction in mortality at 1 year</li> </ul> </li> </ul> <p>**C**hoice of analgesia and sedation</p> <ul> <li>Richmond Agitation-Sedation Scale (RASS): sedation &amp; level of     arousal assessment tool (Figure 1)</li> <li>Target light sedation of RASS -1 to 0 with goal of (1) pt following     commands without agitation and (2) limiting immobilization</li> <li>Over-sedation: hold sedatives till target, then restart at \u00bd prior     dose</li> <li>Analgosedation with focus on treating pain first and then adding     sedation meds PRN</li> <li>Sedatives: dexmedetomidine (dex) or propofol &gt;&gt;&gt; benzodiazepines</li> <li>Benzodiazepines increase risk of delirium in a dose-dependent     fashion</li> </ul> <p> </p>  Figure 1: Richmond Agitation-Sedation Scale (RASS) Delirium - assess, prevent, and manage <p>**D**elirium- assess, prevent, and manage</p> <ul> <li>Screening for delirium: q4hr using CAM-ICU (Figure 2)</li> <li>Affects 60-80% of ventilated pts and associated with increased     morbidity and mortality, longer ICU and hospital length of stay,     long-term cognitive dysfunction</li> <li>Risk factors and treatment: see Delirium section in Psychiatry</li> </ul> <p>**E**arly mobility and exercise</p> <ul> <li>Prolonged immobilization during critical illness leads to     ICU-acquired weakness, associated with worse outcomes: \u2191 mechanical     ventilation, increased hosp length of stay, greater mortality, and     greater disability</li> <li>Consult PT/OT to initiate rehab at the beginning of critical illness</li> <li>Can be done safely in pts receiving advanced support</li> </ul> <p>**F**amily engagement and empowerment</p> <ul> <li>Especially important when pts are unable to communicate themselves</li> <li>Incorporate family at the bedside and on rounds to learn pt     preferences and values, engage in shared-decision making, and     address questions and concerns</li> </ul> <p> </p>"},{"location":"critical-care/critical-care-ards/","title":"Acute Respiratory Distress Syndrome (ARDS)","text":"<p>Judd Heideman</p>"},{"location":"critical-care/critical-care-ards/#background","title":"Background","text":"<ul> <li>A syndrome of diffuse inflammation and injury of the alveoli and     capillary endothelium leading to fluid and protein accumulation in     the interstitium and alveoli, pulmonary edema, and hypoxemic     respiratory failure; 30-50% mortality rate</li> <li>Triggers:</li> <li>Pulmonary<ul> <li>Pneumonia (viral and bacterial) \u2022 Lung contusion</li> <li>Direct inhalation injury \u2022 Aspiration</li> <li>Primary graft dysfunction of pulmonary transplant</li> </ul> </li> <li>Extra-pulmonary<ul> <li>Sepsis (most common cause) \u2022 HSCT</li> <li>Trauma \u2022 Burns</li> <li>Massive blood transfusions/TRALI \u2022 Pancreatitis</li> <li>Drugs (amiodarone, chemotherapy, cocaine, opioids)</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-ards/#evaluation","title":"Evaluation","text":"<ul> <li>Diagnosis: Berlin Criteria</li> <li>New or worsening respiratory symptoms beginning within one week of     diagnosis</li> <li>New bilateral opacities present on chest radiograph or CT chest<ul> <li>Not explained by effusions, collapse of lobe/lung, or nodules</li> </ul> </li> <li>Absence of left heart failure or volume overload</li> <li>Severity: based on PaO2/FiO2 ratio with a PEEP \u2265 5 cm H2O</li> <li>PaO2 = arterial partial pressure of O2 (requires ABG)</li> <li>FiO2 = fraction of inspired oxygen (expressed as a decimal between     0.21 and 1.0)</li> </ul> PaO2/FiO2 ratio PEEP Mild 201-300 \u22655 Moderate 101-200 \u22655 Severe \\&lt;100 \u22655"},{"location":"critical-care/critical-care-ards/#management","title":"Management","text":"<ul> <li>Frequently requires intubation; non-invasive ventilation not a great     treatment</li> <li>Low tidal volume (Vt) ventilation mortality benefit</li> <li>Goal Vt = 4-8 mL/kg of predicted body weight (obese patients don\u2019t     have bigger lungs)</li> <li>Plateau pressure goal: \u226430 cm H2O</li> <li>Oxygenation goal: PaO2 55-80 or SpO2 88-95%</li> <li>pH goal: \u22657.20, \u201cpermissive hypercapnia\u201d</li> <li>Treat the underlying cause (see \u201cTriggers\u201d above)</li> </ul>"},{"location":"critical-care/critical-care-brain-death/","title":"Brain Death","text":"<p>Anna Berry</p>"},{"location":"critical-care/critical-care-brain-death/#background","title":"Background","text":"<ul> <li>Brain death= complete and permanent loss of brain function. Defined     by coma with loss of capacity for consciousness, brainstem reflexes,     and the ability to breathe independently</li> </ul> <p>Checklist for Determination of Brain Death (American Academy of Neurology)</p> <ol> <li>Prerequisites (all must be checked)<ul> <li>Coma, irreversible and cause known</li> <li>Neuroimaging explains coma \u2013 usually CT or MRI</li> <li>Absence of CNS depressing drugs</li> <li>No evidence of residual paralytics (electrical stimulation if     paralytics used)</li> <li>Absence of severe acid-base, electrolyte, endocrine abnormality</li> <li>Normothermia or mild hypothermia (core temp &gt;36\u00b0C)</li> <li>SBP \u2265100 mm Hg</li> <li>No spontaneous respirations</li> </ul> </li> <li>Examination (all must be checked) \u2013 Attending MUST be present for brain death exam</li> </ol> <p> </p> <p>Greer DM, Determination of\u00a0Brain\u00a0Death. NEJM.\u00a02021;385;2554-61. DOI: 10.1056/NEJMcp2025326</p> <ol> <li>Apnea testing (all must be checked) \u2013 Attending MUST be present<ul> <li>Pt is hemodynamically stable</li> <li>Ventilator adjusted to provide normocarbia (PaCO2 35\u201345 mm Hg)</li> <li>Preoxygenate with 100% FiO2 and PEEP of 5 cm water for &gt;10 minutes     to PaO2 &gt;200 mmHg</li> <li>Provide oxygen via a suction catheter to the level of the carina at     6 L/min or attach T-piece with continuous positive airway pressure     (CPAP) at 10 cm H2O</li> <li>Disconnect ventilator</li> <li>Spontaneous respirations absent</li> <li>Arterial blood gas drawn at 8\u201310 minutes, patient reconnected to     ventilator</li> <li>PCO2 \u226560 mm Hg, or 20 mm Hg rise from normal baseline value; OR:</li> <li>Apnea test aborted due to spontaneous respirations present,     hemodynamic instability, or hypoxia</li> </ul> </li> <li>Ancillary testing (Order one test if clinical examination cannot be fully performed due to patient factors or if apnea testing inconclusive/aborted)<ul> <li>Cerebral angiogram</li> <li>HMPAO SPECT (Single photon emission computed tomography)</li> <li>EEG &amp; TCD (transcranial Doppler)</li> </ul> </li> </ol>"},{"location":"critical-care/critical-care-brain-death/#organ-donation-caveats","title":"Organ donation caveats","text":"<ul> <li>Discussions about organ donation should take place between Tennessee     Donor Services (TDS) and the surrogate. You SHOULD NOT be having     conversations with the surrogate about donation. Direct questions to     TDS.</li> </ul>"},{"location":"critical-care/critical-care-codes/","title":"Running Codes","text":"<p>Jacqueline Visina</p>"},{"location":"critical-care/critical-care-codes/#arrival-to-a-code","title":"Arrival to a Code","text":"<ul> <li>Questions to answer when you arrive: Is someone running the code?     Who is doing compressions? Do we have pads on the patient? What is     our IV access?</li> <li>Take charge: establish if anyone is actively running the code, if     someone is running the code, introduce yourself and ask how you may     be helpful. If someone is NOT, have someone begin chest compressions     IMMEDIATELY and assume responsibility for the running the code</li> <li>IV access: IV access preferred, if no immediate IV access, place IO</li> <li>Obtain a brief medical history and events surrounding the code and     the patient\u2019s code status</li> <li>Have someone find the nearest crash cart and get pads on the patient     as soon as possible</li> </ul>"},{"location":"critical-care/critical-care-codes/#running-the-code","title":"Running the Code","text":"<ul> <li>Assess the rhythm</li> <li>If Vfib/VT- immediately shock</li> <li>For polymorphic VT, this is ischemia until proven otherwise unless     the patient is on a large amount of QTc prolonging medications.</li> <li>If PEA/Asystole- resume compressions, give Epi 1mg ASAP</li> <li>Strong ACLS</li> <li>Q2min- pulse check, rhythm check, shock?</li> <li>Remember the two interventions with proven mortality benefit are     high quality chest compressions and early defibrillation. Do not     interrupt these actions for other things</li> <li>Monitor the quality of chest compressions</li> <li>Warn resuscitators when shock is being delivered</li> <li>Consider Advanced Airway</li> <li>Remember chest compressions save lives. Not intubation. Do not stop     compressions for intubation</li> <li>Stay Calm</li> <li>Closed Loop communication- continue giving instructions, use names,     minimize interruptions</li> <li>Do not move from foot of bed if you are running the code</li> <li>Ensure delivery of adequate compressions. Avoid excessive     ventilation</li> <li>If you are running the code, it is helpful to maintain a constant     verbal running summary of interventions that have been tried and the     course of the code</li> <li>Have a member of the team locate an ultrasound for line placement     and diagnostics</li> <li>Allow family to be present</li> <li>H\u2019s and T\u2019s: Treat Reversible Factors</li> <li>Some of the fellows here will empirically give 2 grams of magnesium,     1 amp of D50, 1 amp of bicarb, and 1g calcium chloride at the onset     of the code irrespective of presenting rhythm</li> <li>Can send Labs \u2013 ask for a \u201cloaded gas\u201d. This will usually be a     VBG/ABG with lactate, K, Ca, and Hgb. Often information does not     result quick enough to change immediate management. Have someone     look up most recent labs in Epic (looking for recent hyperK,     acidosis)</li> </ul>"},{"location":"critical-care/critical-care-codes/#terminating-a-code","title":"Terminating a Code","text":"<ul> <li>Consider initial rhythm, patient comorbidities, cardiac vs     non-cardiac arrest, bedside echo findings. ROSC or rhythm changes     during code?</li> <li>Persistent ETCO2\\&lt; 10mmHg after 20min CPR has minimal survival</li> <li>Ask your team if they have any other therapies that they feel would     be indicated</li> <li>Ask if anyone remains in favor of continuing CPR</li> <li>When unanimous, terminate the code and announce time of death. Thank     your team. Take a moment of silence for the deceased patient</li> </ul>"},{"location":"critical-care/critical-care-codes/#post-arrest-care","title":"Post-Arrest Care","text":"<ul> <li>Immediately following ROSC is the most dangerous point of ACLS</li> <li>Airway: Secure airway if not done during code, ensure RT avoids     hypoxia or hyperoxia</li> <li>BP: MAPs&gt;65, IVF and/or pressors if needed</li> <li>If on floor, prioritize moving patient to a unit for ongoing care     once hemodynamically stable enough for transfer. Would not delay for     other diagnostics/interventions (lines, CXR, etc)</li> <li>Cardiac: obtain EKG. Assess if urgent cardiac intervention is     required for STEMI vs unstable cardiogenic shock vs VT storm or Vfib</li> <li>Neuro: if not following commands, consider TTM. TTM is still     performed at VUMC with a strict protocol and inclusion criteria. If     there is any question about TTM eligibility, page the CCU fellow</li> <li>Send rainbow labs (CBC, CMP, Mg, coags, trop, lactate, VBG/ABG).     Treat rapidly reversible causes</li> <li>CXR</li> <li>Propofol/fentanyl infusion if the patient is intubated. Pressor of     choice post ROSC is usually levophed</li> <li>If not done during the code, usually central access will be obtained     and an arterial line will be placed</li> </ul>"},{"location":"critical-care/critical-care-codes/#intern-role-during-codes","title":"Intern role during codes","text":"<ul> <li>maintain hand on femoral pulse</li> <li>place IO if needed</li> <li>have access to the patient\u2019s chart to answer questions that arise during the code.</li> <li>If family is not available, looking up primary contact information is invaluable.</li> <li>In the MICU, your role is to grab the yellow IO kit prior to leaving for the code</li> </ul>"},{"location":"critical-care/critical-care-codes/#family-presence-during-cpr","title":"Family presence during CPR","text":"<p>Studies show that it reduces the frequency of PTSD-related symptoms and does not interfere with medical efforts</p> Treatable Causes of Cardiac Arrest: The H\u2019s and T\u2019s H\u2019s T\u2019s Hypoxia Toxins Hypovolemia Tamponade H+ Tension Pneumothorax Hypo/Hyper K Thrombosis: Pulmonary Hypothermia Thrombosis: Coronary"},{"location":"critical-care/critical-care-drips/","title":"MICU/CCU Drips","text":"<p>Patrick Barney</p> <p>Most have order sets in Epic. Typically choose \u201cTitration Allowed\u201d in ICU</p> Vasopressors: Drug Dose Receptors Indications Considerations Norepinephrine (Levophed) 1 \u2013 100 mcg/min \u03b1\u03b11 &gt; \u03b21 1st line septic shock Peripheral ischemia, skin necrosis Phenylephrine (Neosynephrine) <p>Bolus: 0.05 \u2013 0.5 mg q 10-15 min</p> <p>Infusion: 40-360 mcg/min</p> \u03b1\u03b11 Periprocedural hypotension (Neostick), pts w/ tachyarrhythmias, Critical AS or HOCM with severe LVOT obstruction and shock Reflex bradycardia, Peripheral ischemia, skin necrosis Epinephrine 1 \u2013 40 mcg/min \u03b1\u03b11=\u03b21=\u03b22 Post PEA arrest, Anaphylaxis, Septic shock (severe), Cardiogenic shock Tachy-arrhythmias, Peripheral ischemia, skin necrosis Vasopressin 0.04 U/min (no titration) V1, V2, V3 2nd line septic shock, Right heart failure Hyponatremia, Bradycardia <p>ANG II</p> <p>needs approval from MICU leadership</p> 20 \u2013 40 ng/kg/min ANG II Refractory vasodilatory shock Thrombosis pt MUST have chemical DVT ppx. Contraindicated in heart failure Dopamine 2 \u2013 20 mcg/kg/min Dopamine (1-5 mcg) &gt; \u03b21 (5-10 mcg) &gt;\u03b11 (&gt;10mcg) Hypotension, Cardiogenic shock Tachy-arrhythmias, peripheral ischemia, skin necrosis Dobutamine 2.5 \u2013 20 mcg/kg/min \u03b21 &gt;&gt;&gt; \u03b22 Cardiogenic shock Vasodilation Hypotension, Tachycardia, Tachyphylaxis Milrinone 0.375 \u2013 0.75 mcg/kg/min PDE-3 Cardiogenic shock Hypotension, renally cleared Sedatives/Anxiolytics: Drug Dose Class Side effects Propofol Infusion: 5 \u2013 150 mcg/kg/min General anesthetic (GABA R agonist) <p>Severe hypotension, bradycardia, hypertriglyceridemia, propofol infusion syndrome (rare)</p> <p>Monitor for toxicity with q4 day TGs and CK</p> Dexmedetomidine (Precedex) Infusion: 0.1 \u2013 1.5 mcg/kg/h Central \u03b1\u03b12 agonist Hypotension, bradycardia Midazolam (Versed) <p>Push: 0.5 \u2013 5 mg</p> <p>Infusion: 0.25 \u2013 5 mg/h (no max dose)</p> Benzodiazepine Hypotension, risk of BNZ withdrawal if used for long periods with sudden discontinuation Lorazepam (Ativan) <p>Push: 0.5 \u2013 10 mg</p> <p>Infusion: 0.5 \u2013 5 mg/h (no max dose)</p> Benzodiazepine Hypotension, propylene glycol carrier - AGMA Ketamine <p>Push: 1-2mg/kg</p> <p>Infusion: 0.2mg/kg/hr, titrate by 0.1 q15min</p> NDMA antagonist <p>Delirium/hallucination \u2013 use caution in patients with psychiatric hx, hypertension, tachycardia</p> <p>Pretreat with 0.4mg IV glycopyrrolate to avoid hyper-salivation</p> Analgesic: Drug Dose Side effects Fentanyl <p>Push: 25 \u2013 100 mcg</p> <p>Infusion: 25 \u2013 400 mcg/h</p> Hypotension, Serotonin syndrome, chest wall rigidity at high doses Morphine <p>Push: 1 \u2013 5 mg q1-2h prn</p> <p>Infusion: 1 \u2013 5 mg/h</p> Hypotension (profound), itching, constipation, HA; avoid in renal failure Hydromorphone (Dilaudid) <p>Push: 0.25 \u2013 1 q1-2h prn</p> <p>Infusion: 0.5 \u2013 3 mg/h</p> Hypotension, respiratory depression, itching Anti-hypertensives Drug Class/MOA Dose Indications Side effects Comments Esmolol Beta blocker <p>Bolus: 1mg/kg over 30s</p> <p>Infusion: 50-300mcg/kg/min (max 300)</p> Aortic dissection, HTN emergency Bradycardia, hypotension Titrate to desired BP or HR. Caution in HFrEF Nicardipine CCB Infusion: 5-15mg/hr (max 15) HTN emergency Bradycardia, hypotension Titrate to desired BP, avoid in HFrEF Nitroprusside Metabolized to NO vasodilatory effect (arterial roughly = venous) Infusion: 0.3mcg/kg/min; titrate q2min to max 10mcg/kg/min HTN E, flash pulmonary edema, HFrEF for afterload reduction Hypotension, cyanide toxicity Contraindicated in hepatic and renal failure Nitroglycerin NO mediated venous &gt; arterial vasodilation Infusion: start 0.25mcg/kg/min, titrate by 1mcg/kg/min q15min (max 10mcg/kg/min) Refractory angina, flash pulmonary edema, HTN emergency Hypotension, headache, palpitations Contraindicated in severe RHF and concurrent use of PDE-5 inhibitor Anti-Arrhythmics: Drug Dose Indications Side effects Comments Adenosine 6 \u2013 12 mg IV rapid push and flush; may repeat x2 PSVT conversion Complete AV nodal blockade <p>10 second half-life</p> <p>\u00a0Must have continuous EKG/tele monitor</p> Amiodarone <p>ACLS: 300 mg IV push</p> <p>Non-emergent: 150 mg over 10 min then 0.5 mg/min</p> Vtach/Vfib, Afib Pulm, ophthalmic and thyroid toxicity w/ chronic use Less hypotension than other agents, safe in heart failure. May chemically cardiovert patients, caution if off therapeutic AC Diltiazem <p>Push: 10 \u2013 20 mg q15 min x 2 if no response</p> <p>Infusion: 5 \u2013 15 mg/h</p> Afib, Aflutter, PSVT Bradycardia, hypotension Avoid use in pts with HFrEF Lidocaine <p>ACLS: 1 mg/kg x 1</p> <p>Infusion: 1 \u2013 4 mg/min</p> Vtach Bradycardia, Heart block Avoid use in liver failure/ Okay for HFrEF. Often 1st line CCU med for VT/ May need to check levels if using for longer than 24 hours Procainamide 15 mg/kg over 30 min then 1 \u2013 6 mg/min Vtach, refractory afib Bradycardia, hypotension Drug-induced lupus, cytopenias"},{"location":"critical-care/critical-care-intubation-extubation/","title":"Intubation and Extubation","text":"<p>Daniel Motta-Calderon</p>"},{"location":"critical-care/critical-care-intubation-extubation/#intubation","title":"Intubation","text":""},{"location":"critical-care/critical-care-intubation-extubation/#background","title":"Background","text":"<ul> <li>Intubation is the definitive therapy for patients with worsening     respiratory failure</li> <li>Indications for intubation- hypoxic or hypercarbic respiratory     failure, airway protection</li> </ul>"},{"location":"critical-care/critical-care-intubation-extubation/#intubation-checklist","title":"Intubation checklist","text":"<ul> <li>Prepare the patient<ul> <li>IV access: at least two large bore IV access sites.</li> <li>Optimize position: Supine sniffing position</li> <li>Assess the airway: Assess for difficult intubation predictors     (opening mouth \\&lt;3cm, Mallampati \u2265 III, neck circumference &gt;40cm,     thyromental distance \\&lt;6cm, head-neck extension \\&lt;30 degrees)</li> <li>Optimal pre-oxygenation: using FiO2 100% (facemask, high flow     nasal cannula)</li> <li>Optimize medical status: resuscitation, temporize hyperkalemia,     Hb &gt;7</li> </ul> </li> <li>Prepare the equipment<ul> <li>Monitoring: SpO2, capnography, telemetry, BP</li> <li>Equipment: bag valve mask, 2 endotracheal tubes (ETT) with cuffs     checked, direct laryngoscope, videolaryngoscope, bougie/stylet,     working suction, supraglottic airway, oropharyngeal airway</li> <li>Medications: paralytic (ex: rocuronium, succinylcholine),     induction sedative (ex: etomidate, ketamine, propofol), analgesics     (ex: fentanyl), maintenance sedative, IVF hanging in room, pressors     (ex: Neostick)</li> </ul> </li> <li>Prepare the team<ul> <li>First and second intubators, RT, RN, someone to monitor hemodynamics</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-intubation-extubation/#rapid-sequence-intubation-rsi","title":"Rapid-sequence intubation (RSI)","text":"<ul> <li>Preferred method of induction, associated with increased     first-attempt success and fewer intubation-related complications</li> <li>Simultaneous IV administration of rapidly acting paralytic and     induction agents to achieve sedation and paralysis</li> </ul>"},{"location":"critical-care/critical-care-intubation-extubation/#post-intubation","title":"Post-intubation","text":"<ul> <li>Ensure correct placement of ETT with capnography and confirming     bilateral breath sounds</li> <li>Secure ETT with taping, tying or tube holder</li> <li>Obtain post-placement CXR</li> </ul>"},{"location":"critical-care/critical-care-intubation-extubation/#immediate-complications-of-intubation","title":"Immediate complications of intubation","text":"<ul> <li>Aspiration: Suction airway, ideally prior to initiation of positive     pressure ventilation to prevent distal movement of aspirated     contents. Cricoid pressure maneuver historically used to reduce risk     but unclear if it works so often not performed</li> <li>Cardiovascular collapse: May be hypotension or sympathetic surge     (hypertension, tachycardia, arrhythmias). Manage with     fluids/pressors if need, rule out other causes (ex: hypoxia, PTX)</li> <li>Hypoxemia: Preoxygenate with 100% FiO2 to minimize risk. Rescue     maneuvers with bag mask ventilation if needed</li> <li>Mechanical injury: Dental, soft tissue, tracheal, laryngeal.     Retrieve any dislodged teeth, suction blood</li> </ul>"},{"location":"critical-care/critical-care-intubation-extubation/#extubation","title":"Extubation","text":""},{"location":"critical-care/critical-care-intubation-extubation/#is-the-patient-ready-to-be-extubated","title":"Is the patient ready to be extubated?","text":"<ul> <li>Are they oxygenating well? SpO2 \u226590% with FiO2 \u226450% and PEEP \u22648cm     H20</li> <li>Has the underlying cause of their respiratory failure improved?</li> <li>Did patient pass their SBT?<ul> <li>See ABCDEF Bundle section for details on SBT</li> </ul> </li> <li>Is patient able to protect their airway?</li> <li>Is the patient on a stable pressor requirement or no pressors?</li> <li>Is patient coughing and clearing secretions?</li> <li>Is patient off sedation, alert and following commands?</li> <li>Positive cuff leak? (See below for steps)</li> <li>Consider calculating the rapid shallow breathing index (RSBI):     RR/tidal volume (L)<ul> <li>Set PS at 0cm H2O, and PEEP at 5cm H2O and, measure VT &amp; RR for     one minute.</li> <li>RSBI \u2265 105 predicts likely failure to wean. The use of a RSBI is     attending dependent at Vanderbilt and is not frequently     calculated when assessing readiness for extubation</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-intubation-extubation/#post-extubation-complications","title":"Post-extubation complications","text":"<ul> <li>Post-extubation stridor: 2/2 laryngeal edema</li> <li>Positive cuff leak test= high risk methylprednisolone 20 mg IV q4h     x 4 prior to extubation to prevent</li> <li>If after extubation: Methylprednisolone 40 mg IV x1 dose + inhaled     racemic epinephrine. If stridor &gt;60minutes, consider reintubation</li> <li>Cuff leak test:<ul> <li>Suction secretions and set the ventilator into the AC mode</li> <li>Inflate the cuff and record inspiratory and expiratory VT to     evaluate for differences between the two volumes</li> <li>Deflate the cuff record the expiratory VT over the next six     breathing cycles. Average the three lowest expiratory VT values</li> <li>The cuff leak volume is the difference between the inspiratory     VT (measured before the cuff was deflated) and the averaged     expiratory VT. If the difference is \\&lt;100cc, this is considered     failure but is not an absolute contradiction to extubation</li> </ul> </li> <li>Post-extubation respiratory failure<ul> <li>Recurrent hypoxic or hypercarbic respiratory failure</li> <li>Assess for aggravating factors (volume overload, shock, AMS, etc)</li> <li>For hypercarbic respiratory failure, may trial BiPAP. If     unsuccessful reintubate</li> <li>Preventative post-extubation BiPAP not routinely used in all     patients but consider in select populations at high risk for     failure: severe COPD with preexisting chronic hypercarbia during     SBT, patients intubated for cardiogenic pulmonary edema</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-modes-oxygen-delivery/","title":"Modes of Oxygen Delivery","text":"<p>Blake Funke</p> System L/min % O2 Comments Blow by (ex: Trach collar) 21-100% Nasal cannula 1-8 25 \u2013 45% Large bore nasal cannula Up to 15 Up to 65% Can be identified by larger bore tubing (often green) and nose piece. Colloquially referred to as HFNC at VUMC, but true HFNC = optiflow Venturi mask 4 to 15 24 \u2013 50% Actual FiO2 is dependent on patient effort Non-rebreather 10 to 15 65-95% Often used as a bridge to higher level of O2 therapy HFNC: Optiflow (VUMC), AirVo (NAVA) Up to 60 30-100% Delivers 0.5-1 cm/H2O of PEEP per 10L of flow Use of all of these modes requires a spontaneously breathing patient"},{"location":"critical-care/critical-care-modes-oxygen-delivery/#non-invasive-positive-pressure-ventilation","title":"Non-invasive positive pressure ventilation","text":"<ul> <li>CPAP<ul> <li>Indications: obstructive sleep apnea, tracheomalacia</li> <li>Settings: CPAP, FiO2</li> </ul> </li> <li>BiPAP<ul> <li>Indications: hypercapnic respiratory failure (RF), hypoxic RF,     pulmonary edema, obstructive sleep apnea, obesity hypoventilation     syndrome, RF 2/2 neuromuscular disease</li> <li>Settings: IPAP, EPAP, FiO2, RR (sometimes)</li> </ul> </li> </ul> Invasive positive-pressure ventilation Mode You set Not set Comments Pressure support (PS) <p>PEEP</p> <p>PS above PEEP</p> <p>FiO2</p> <p>TV</p> <p>RR</p> <p>Inspiratory flow</p> Similar to Bipap. Frequently used for vent weaning / SBT. Requires spontaneously breathing pt Volume Control (AC/VC) <p>PEEP</p> <p>RR</p> <p>TV</p> <p>Inspiratory flow</p> <p>FiO2</p> Inspiratory pressure <p>Mandates a minute ventilation; limits volutrauma (i.e. can guarantee low tidal volume ventilation)</p> <p>Primary mode used in MICU (mode used in major ARDS trials)</p> <p>SIMV</p> <p>Synchronized Intermittent Mandatory Ventilation</p> <p>PEEP</p> <p>RR</p> <p>TV</p> <p>PS above PEEP</p> <p>FiO2</p> Pt gets VC breath for set rate, but if tries to breath over this will get PS breath; VC and PS breaths are synchronized when able Pressure Control (AC/PC) <p>RR</p> <p>Inspiratory Pressure</p> <p>PEEP</p> <p>Inspiratory Time (or I:E ratio)</p> <p>FiO2</p> TV <p>Minimizes barotrauma (i.e. sets a max inspiratory pressure) does not guarantee a specific minute ventilation (must monitor PCO2 with blood gases)</p> <p>Does not have natural ventilator alarms for protection \u2013 need to increase low minute ventilation alarm threshold</p> <p>PRVC</p> <p>Pressure Regulated Volume Control</p> <p>PEEP</p> <p>RR</p> <p>TV</p> <p>Inspiratory flow</p> <p>Pressure max</p> <p>FiO2</p> <p>Adaptive pressure control (NOT actually a volume control mode); tries to limit both barotrauma and volutrauma but if in conflict, minute ventilation will drop (i.e. need to monitor PCO2 with blood gases like any other PC mode)</p> <p>Con: More the pt works, the less the ventilator does</p> APRV / Bilevel <p>PEEP (PLow)</p> <p>Pressure High</p> <p>Time Low</p> <p>Time High</p> <p>FiO2</p> TV <p>Long periods of inspiratory holds and very brief expirations (i.e. releases), for refractory hypoxemia.</p> <p>Often difficult to ventilate pts on this mode</p>"},{"location":"critical-care/critical-care-refractory-hypercapnia/","title":"Refractory Hypercapnia","text":"<p>Amelia Muhs</p>"},{"location":"critical-care/critical-care-refractory-hypercapnia/#background","title":"Background","text":"<ul> <li>Inadequate clearance of CO2 leading to respiratory acidosis (pH \u2264     7.20) despite maximum RR&amp;TV (i.e. minute ventilation) tolerated     without causing barotrauma or autoPEEP</li> <li>Common causes:<ul> <li>Obstructive lung disease (COPD, emphysema, asthma)</li> <li>Hypoventilation (sleep apnea, obesity, sedative medications (ie     opiates), neuromuscular weakness, chest wall trauma, ascites/pleural     effusion)</li> <li>Increased CO2 load (shock, sepsis, malignant hyperthermia)</li> </ul> </li> <li>Presentation:<ul> <li>Shortness of breath</li> <li>AMS, somnolence</li> <li>Hypoxemia</li> <li>Tachycardia, hypertension (in some cases)</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-refractory-hypercapnia/#evaluation","title":"Evaluation","text":"<ul> <li>Physical exam, mental status, recent medications</li> <li>ABG or VBG \u2013 if increased PCO2 and normal pH, always treat the pH     and not the PCO2 (i.e., may be compensated chronic hypercarbia and     blowing off more CO2 may be harmful)</li> </ul>"},{"location":"critical-care/critical-care-refractory-hypercapnia/#management-algorithm","title":"Management Algorithm","text":"<ul> <li>Special considerations<ul> <li>If history of OSA, make sure they are on home CPAP/BiPAP</li> <li>If opiate related trial narcan</li> <li>Bronchodilators for reactive airway diseases</li> </ul> </li> <li>BiPAP<ul> <li>Contraindicated if pt unable to remove BiPAP mask on their own</li> <li>Increase MV by increasing \u0394 between IPAP/EPAP or increasing RR</li> </ul> </li> <li>Mechanical ventilation<ul> <li>Allows you to control rate and tidal volume (in Volume Control     modes)</li> <li>NOTE: some pts have higher minute ventilation on their own compared     to mechanical ventilation (e.g., DKA); pt-specific considerations     regarding intubation</li> <li>To increase minute ventilation and CO2 clearance:<ul> <li>Increase RR<ul> <li>30-35 is about as high as you can go</li> <li>Need to keep in mind I/E time to avoid breath     stacking/autoPEEP (gas trapped in lungs)</li> <li>Some signs of autoPEEP include worsening hypotension and the     expiratory limb on the flow waveform on the vent not     returning to zero</li> </ul> </li> <li>Increase TV we usually start at 4-6mL/kg IBW. You can consider     increasing to 8mL/kg IBW as long as plateau pressures remain \\&lt;     30 cm H2O<ul> <li>Goal peak pressures \u2264 35 cm H2O / plateau pressures \u2264 30 cm     H2O</li> </ul> </li> </ul> </li> </ul> </li> <li>ARDS permissive hypercapnia (goal pH \u2265 7.2)</li> <li>V-V ECMO / Extracorporeal carbon dioxide removal (ECCO2R)</li> <li>Indications for hypercapnia:<ul> <li>Severe dynamic hyperinflation and/or severe respiratory acidosis</li> <li>pH \u2264 7.25 with PaCO2 \u2265 60 for 6 hr with RR at 35/min and TV     increased to target maximum MV while keeping plateau pressure \u2264     32 cm H2O</li> <li>Similar considerations and contraindications as refractory hypoxemia (see above)</li> <li>Benefits: Reduces work of breathing, promotes early ventilator     weaning/extubating allows early mobilization and recovery</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-refractory-hypoxemia/","title":"Refractory Hypoxemia","text":"<p>Amelia Muhs</p>"},{"location":"critical-care/critical-care-refractory-hypoxemia/#background","title":"Background","text":"<ul> <li>Inadequate arterial oxygenation despite high levels of inspired O2     or the development of barotrauma in mechanically ventilated pts</li> <li>Generally start to consider the interventions below if needing FiO2     &gt;80%</li> <li>Differential:<ul> <li>Worsening underlying primary process (e.g. progressive ARDS)</li> <li>PE</li> <li>Pneumothorax</li> <li>Fluid overload</li> <li>Ventilator-associated Pneumonia</li> <li>New ARDS</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-refractory-hypoxemia/#evaluation","title":"Evaluation","text":"<ul> <li>Always get CXR STAT if pt has new or worsening O2 requirement</li> <li>ABG is frequently helpful as well</li> <li>Can use POCUS to check for lung sliding (pneumothorax) or RV     enlargement/septal bowing/McConnell\u2019s sign (RV strain in PE)</li> </ul>"},{"location":"critical-care/critical-care-refractory-hypoxemia/#initial-management","title":"Initial management","text":"<ul> <li>Remember \u2013 if at any point the pt is rapidly decompensating, you can     always disconnect them from the vent and bag them until they     recover/while calling for help</li> <li>Early consideration of ECMO consult in appropriate pts (discuss with     MICU fellow)</li> <li>Optimize fluid status consider diuresis/dialysis if not making urine</li> <li>Consider higher PEEP strategy</li> <li>Increased PEEP higher mean airway pressure, generally improves     oxygenation especially with diffuse pulmonary pathologies<ul> <li>Exceptions may include certain focal/shunt pathologies (e.g.     dense lobar PNA)</li> <li>Worsening oxygenation may occur with overdistension of alveoli     increase dead space ventilation; generally determined     empirically at the bedside</li> </ul> </li> <li>Titrate up slowly; generally do not exceed PEEP 18<ul> <li>Limited by high plateau pressures/barotrauma,     overdistension/dead space ventilation, decreased preload/venous     return</li> </ul> </li> <li> <p>ARDSnet FiO2/PEEP Tables: At VUMC we typically use the Lower PEEP     table</p> </li> <li> <p>Other recruitment maneuvers</p> <ul> <li>Reposition pt \u2013 can try elevating HOB or positioning so \u201cgood lung\u201d     is down</li> <li>If concern for mucus plug, consider need for bronch</li> <li>If concern for significant atelectasis can try recruitment maneuvers     with the vent including sustained inflation (setting expiratory     pressure to ~30 for ~30 seconds) and PEEP titration (setting PEEP     to 20-25 and decreasing by 2cm at a time) \u2013 call the fellow before     attempting</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-refractory-hypoxemia/#management-algorithm-for-refractory-hypoxemia","title":"Management Algorithm for Refractory Hypoxemia","text":"<ul> <li>Inhaled vasodilators: Distribute preferentially to well-ventilated     alveoli local vasodilation improved V/Q matching</li> <li>VUMC formulary preference: inhaled epoprostenol (aka Flolan)</li> <li>Alternatives: inhaled milrinone, inhaled nitric oxide</li> <li>Data suggest improved PaO2/FiO2; large RCT without evidence for     mortality benefit</li> <li>Deep sedation (RASS -4 or -5)<ul> <li>Promotes ventilator synchrony</li> </ul> </li> <li>Neuromuscular blockade (paralysis) \u2013 call your fellow before doing     this<ul> <li>Rationale: maximal vent synchrony (eliminates residual chest     wall/diaphragm tone)</li> <li>Pt MUST be RASS -5 (need analgesia + sedation)</li> <li>Trial one time IV push of vecuronium 0.1 mg/kg</li> <li>If improved vent synchrony/oxygenation, consider cisatracurium     (Nimbex) drip</li> <li>Data are mixed ACURASYS 2010 (improved 90-day mortality but     underpowered likely overestimating benefit); ROSE 2019 (no     difference in 90-day mortality)</li> </ul> </li> <li>Prone positioning (Need attending approval)<ul> <li>Pts with moderate to severe ARDS (PaO2/FiO2 ratio \\&lt; 150)</li> <li>At VUMC, we use regular ICU beds and manually flip pts; cycle prone     16 hrs/supine 8 hrs</li> <li>When proning or supining a pt, always have a provider who can     intubate in the room in case unplanned extubation occurs</li> <li>Considerations: need a team of people to reposition, high risk of ET     tube malposition, difficult to access lines/perform procedures, high     risk of pressure injuries</li> <li>Data: PROSEVA 2013 proning improved 28-day mortality; study     complicated by imbalances between groups</li> </ul> </li> <li>Alternative ventilator modes (usually Pressure Control or     APRV/BiLevel/BiVent)</li> <li>APRV/BiVent should be avoided in people with bad obstructive lung     disease, hemodynamic instability, refractory hypercarbia</li> <li>Venovenous (V-V) ECMO<ul> <li>Indications for hypoxemia:<ul> <li>PaO2/FiO2 \\&lt; 50 with FiO2 &gt;80% for &gt;3 hrs OR</li> <li>PaO2/FiO2 \\&lt; 80 with FiO2 &gt;80% for &gt;6 hrs AND</li> <li>Mechanical ventilation \u2264 1 week</li> </ul> </li> <li>Absolute Contraindications:<ul> <li>Poor short-term prognosis (e.g. metastatic cancer)</li> <li>Irreversible, devastating neurologic pathology</li> <li>Chronic respiratory insufficiency without the possibility for     transplant</li> </ul> </li> <li>Can calculate RESP score predicts in-hospital survival with ECMO</li> <li>CONSULT EARLY if a pt may be a candidate; allows ECMO team to assist     with evaluation</li> <li>Data:<ul> <li>CESAR 2009: improved 6-month survival without severe disability</li> <li>EOLIA 2018 : no mortality benefit but 28% crossover from control     to ECMO arm dilutes potential effects</li> </ul> </li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-sepsis/","title":"Sepsis","text":"<p>Charlie Oertli</p>"},{"location":"critical-care/critical-care-sepsis/#background","title":"Background","text":"<p>Most recent definition (Sepsis-3): organ dysfunction from     dysregulated host response to infection</p> <ul> <li>2021 Surviving Sepsis Guidelines: SIRS, MEWS, NEWS superior to qSOFA     for screening sepsis</li> <li>SIRS \u22652 of any of: 1) RR&gt;20, 2) T \\&lt;36 or &gt;38, 3) HR &gt;90, 4) WBC     \\&lt;4 or &gt;12 or &gt;10% bands</li> <li>Septic Shock = sepsis + vasopressors + lactate &gt;2 meq/dL (Sepsis 3     definition)</li> <li>Alternate screening systems you may see which are more     specific and better at prognosis of in hospital mortality     than SIRS:<ul> <li>Acute change in baseline SOFA score \u22652: P/F ratio, Plts, Tbili, SBP,     GCS, Cr</li> <li>\"Quick\" SOFA (qSOFA): \u22652 of AMS (GCS\u226413), SBP\u2264100 mmHg, RR\u226522/min</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-sepsis/#evaluation","title":"Evaluation","text":"<ul> <li>Cultures prior to antibiotics if possible (but don\u2019t delay     antibiotics just to get cultures)</li> <li>Consider sputum Cx, paracentesis, thoracentesis, wound Cx, LP, joint     aspiration</li> <li>Lactate (even if not hypotensive)</li> <li>Imaging: x-ray, CT, or US of potential source</li> </ul>"},{"location":"critical-care/critical-care-sepsis/#management","title":"Management","text":"<p>Source control: Remove old lines, chest tube for empyema, drain     abscesses, etc</p> <p>Antibiotics</p> <ul> <li>Early antibiotics: within 1 hour if septic shock, within 3 hours if     sepsis</li> <li>Target organisms most likely to cause infection in suspected organ;     if source unknown, start empiric broad-spectrum</li> <li>MRSA coverage - vancomycin/daptomycin/linezolid/ceftaroline</li> <li>Pseudomonas coverage - zosyn/cefepime/meropenem /cipro/gentamicin</li> <li>Pneumonia: add atypical coverage (azithromycin/levaquin; 2nd line     doxycycline if prolonged QTC or elderly) if severe or being admitted     to the ICU</li> <li>Fungal coverage for Candida: if neutropenic, TPN, abdominal surgery,     prior antibiotics</li> <li>De-escalation: Once source is controlled, if abx duration is unknown     use procalcitonin, culture susceptibilities, and clinical evaluation     to help guide de-escalation</li> </ul> <p>Resuscitation</p> <ul> <li>Give 1-3 L (\u226530 mL/kg of body weight) of IV balanced crystalloid     within first 3 hours</li> <li>Only give blood if Hb \\&lt; 7, unless evidence of bleeding or     myocardial ischemia</li> <li>Monitor HR, BP, mental status, urine output \u2013 do NOT give     beta-blockers to slow HR in the setting of sepsis unless dangerously     high and limiting diastolic filling (discuss with fellow), this is     an appropriate stress response</li> <li>Assess fluid responsiveness by leg raise (if BP improves with leg     raise, give more fluids). Other options US IVC (mixed data), pulse     pressure</li> </ul> <p>Vasopressors</p> <ul> <li>Start if MAP not responsive to fluid resuscitation</li> <li>Target MAP &gt; 65mmHg, also monitor mental status, serum lactate, and     urine output; may need higher goal for pts with chronic HTN</li> <li>Start with norepinephrine -- via central line, PICC, or port. Can     run through peripheral IV (at least 18g, proximal to wrist) up to 15     mcg/min for up to 48 hours if no central access<ul> <li>SOAP II trial: norepinephrine &gt; dopamine (less arrhythmias)</li> <li>No upper limit of NE but can cause peripheral ischemia with     prolonged use</li> </ul> </li> <li>Add vasopressin at fixed dose of 0.04 units/min when NE dose &gt;= 50     mcg/min<ul> <li>VASST trial: possible benefit for pts on 5-15 of NE; however,     this was opposite of hypothesis and vasopressin is expensive</li> </ul> </li> <li>Add epinephrine or dobutamine if low cardiac output</li> <li>Add phenylephrine for pts with tachyarrhythmias (reflex bradycardia)</li> <li>Consider Angiotensin II (discuss with fellow, needs MICU leadership     approval) contraindicated with CHF and     DVT/PE/clots/hypercoagulability</li> <li>Consider steroids if vasopressors failing or on steroids chronically     hydrocortisone 100mg IV q8hr or 50mg IV q6hr for 5 to 7 days</li> </ul>"},{"location":"critical-care/critical-care-shock/","title":"Management of Shock","text":"<p>Alex Toporex, Soibhan Kelley</p>"},{"location":"critical-care/critical-care-shock/#distributive-shock","title":"Distributive Shock","text":""},{"location":"critical-care/critical-care-shock/#background","title":"Background","text":"<ul> <li>Pathophysiology: severe, peripheral vasodilation</li> <li>CO/CI increased, SVR decreased, PCWP and RAP normal to low</li> <li>Etiologies: sepsis (most common), anaphylaxis, neurogenic, adrenal     insufficiency, pancreatitis</li> <li>Signs/symptoms:<ul> <li>Sepsis: localizing signs of infection; tachycardia, tachypnea, may     be hypo/hyperthermic; POCUS with hyperdynamic cardiac function</li> <li>Anaphylaxis: history of anaphylaxis; urticaria, edema, diarrhea,     wheezing on exam</li> <li>Neurogenic: history of CNS trauma; focal neurologic deficits on exam</li> <li>Adrenal insufficiency: hx chronic steroid use, may have GI symptoms,     hyponatremia (common), hyperkalemia (rare), hypoglycemia,     hypo/hyperthermia, NAGMA</li> <li>Pancreatitis: abdominal pain, elevated lipase, evidence on CT scan</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-shock/#management","title":"Management","text":"<ul> <li>Sepsis: see sepsis section</li> <li>Anaphylaxis: 0.3mg IM epinephrine ASAP to be repeated q5-15min x 3;     after third IM epi, consider IVF and epi gtt if persistent     hypotension. Adjuncts: albuterol nebs for bronchospasm, H1 and H2     blockers, \u00b1 glucocorticoids (methylprednisolone 1mg/kg).     EPINEPHRINE SAVES LIVES.</li> <li>Neurogenic: caution with IVF resuscitation, can worsen cerebral and     spinal cord edema; preferred pressors are norepinephrine and     phenylephrine; for neurogenic shock 2/2 spinal cord pathology,     consider higher MAP goal 85-90 mmHg</li> <li>Adrenal insufficiency: stress dose steroids with hydrocortisone     100mg IV q8hr or 50mg q6hr</li> <li>Pancreatitis: IVF + pressors; trend H/H and Ca; treat complications     (necrotizing pancreatitis, abdominal compartment syndrome); address     underlying etiology (see GI section)</li> </ul>"},{"location":"critical-care/critical-care-shock/#cardiogenic-shock","title":"Cardiogenic Shock","text":""},{"location":"critical-care/critical-care-shock/#background_1","title":"Background","text":"<ul> <li>Pathophysiology: CO/CI decreased, SVR increased, PCWP and RAP     elevated (left heart failure) or PCWP low/normal and RAP elevated     (right heart failure)</li> <li>Etiologies: Cardiomyopathy (LHF, RHF or biventricular), arrhythmia,     mechanical such as acute AR (ex: dissection) or MR (ex: ruptured     papillary muscle)</li> </ul>"},{"location":"critical-care/critical-care-shock/#presentation","title":"Presentation","text":"<ul> <li>Edematous, elevated JVP, \u201ccold and wet\u201d; hypoxia w/crackles and pulm     edema; mixed venous sat \\&lt; 50-60%; POCUS with plump,     non-compressible IVC, reduced EF, and B-lines</li> </ul>"},{"location":"critical-care/critical-care-shock/#management_1","title":"Management","text":"<p>See cardiogenic shock in cardiology section</p>"},{"location":"critical-care/critical-care-shock/#hypovolemic-shock","title":"Hypovolemic Shock","text":""},{"location":"critical-care/critical-care-shock/#background_2","title":"Background","text":"<ul> <li>Etiologies: Hemorrhagic and non-hemorrhagic</li> <li>Signs/symptoms:<ul> <li>Hemorrhagic: Common sources include GI, retroperitoneal (*needs     high index of suspicion), traumatic, intraabdominal, thighs, thorax</li> <li>Non-hemorrhagic: 2/2 GI losses or decreased PO intake</li> </ul> </li> <li>POCUS with thin, collapsible IVC</li> </ul>"},{"location":"critical-care/critical-care-shock/#management-hemorrhagic","title":"Management (Hemorrhagic)","text":"<ul> <li>Ensure good access with two large-bore (at least 18G) IVs ideally in     AC or above; Cordis or MAC CVC (can also use dialysis catheter, if     necessary)</li> <li>Hyperacute bleed:<ul> <li>1:1:1 ratio FFP:Plt:RBC (balanced resuscitation), massive     transfusion protocol (MTP)</li> <li>Monitor iCa and replete (citrated blood products will deplete Ca)</li> <li>Minimize crystalloid if possible, w/primary use to prevent immediate     hemodynamic collapse (contributes to coagulopathy, hypothermia,     acidemia, trauma/surgery)</li> <li>Permissive hypotension until source control/transfusions with     arterial bleeds (high MAP/SBP -&gt; clot destabilization); trend POC     lactate/exam to guide</li> <li>Acute traumatic arterial bleed or post-partum hemorrhage consider     TXA (1-2 gm bolus)</li> <li>Reverse anticoagulation, if applicable</li> <li>Vasopressors -&gt; generally poorly effective, would start with     norepinephrine</li> <li>Source control -&gt; GI, IR, or EGS</li> </ul> </li> <li>Variceal bleed: See GI Bleeding section for specific management</li> </ul>"},{"location":"critical-care/critical-care-shock/#management-non-hemorrhagic","title":"Management (Non-Hemorrhagic)","text":"<ul> <li>Aggressive IVF resuscitation (balanced crystalloid); target MAP \u226565</li> <li>Can support BP during resuscitation with pressors (usually     norepinephrine)</li> </ul>"},{"location":"critical-care/critical-care-shock/#obstructive-shock","title":"Obstructive Shock","text":""},{"location":"critical-care/critical-care-shock/#background_3","title":"Background","text":"<ul> <li>Etiologies: Massive pulmonary embolism, tension pneumothorax, and cardiac     tamponade</li> <li>Signs/symptoms:<ul> <li>Pulmonary embolism: acute hypotension, known DVT, evidence of R     heart strain on EKG, POCUS w/enlarged RV, septal bowing, McConnell\u2019s     sign, \u2191 BNP, PE on CTA</li> <li>Tension pneumothorax: history of COPD or fibrotic lung disease,     ventilated pts w/ high peak pressures, unilateral decreased BS on     auscultation and tympany on percussion, POCUS without lung sliding,     CXR w/ PTX and mediastinal shift</li> <li>Cardiac tamponade: elevated JVP, muffled heart sounds, pulsus     paradoxus, POCUS with diastolic collapse of RV and large pericardial     effusion (best in subcostal window)</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-shock/#management_2","title":"Management","text":"<ul> <li>Massive pulmonary embolism: see Pulmonary Embolism Section for     specific management</li> <li>Tension PTX: needle decompression using 14-16G needle into the     second intercostal space at the midclavicular line; call trauma     surgery or fellow for chest tube ASAP</li> <li>Cardiac tamponade: STAT page cardiology or cardiothoracic surgery;     can temporize hypotension with IVF resuscitation\u2014500-1L IVF boluses     (may not work if pt is euvolemic or hypervolemic); no proven benefit     from inotropy (e.g., dobutamine)</li> </ul>"},{"location":"critical-care/critical-care-temperature-abnormalities/","title":"Temperature Abnormalities","text":"<p>Soibhan Kelley</p>"},{"location":"critical-care/critical-care-temperature-abnormalities/#hypothermia","title":"Hypothermia","text":""},{"location":"critical-care/critical-care-temperature-abnormalities/#background","title":"Background","text":"<ul> <li>Core temperature \\&lt;35\u00b0C (95\u00b0F). Mild 32-35C (90-95F), moderate     28-32C (82-90F), or severe \\&lt;28C (82F) \u00b1 pulseless</li> <li>Ensure thermometer is \u201clow-reading,\u201d standard thermometers not     accurate</li> <li>Core temperature can be measured w/ bladder catheter probe or     esophageal probe (may be falsely \u2191 if heated oxygen being     delivered). Rectal temp can be used but is less accurate</li> <li>Etiologies:<ul> <li>Heat loss: Environmental, burns, iatrogenic (CRRT, cold IVF, massive     transfusion protocol), vasodilatory drugs/toxins</li> <li>Decreased heat production: endocrinopathies (hypothyroidism, adrenal     insufficiency, hypopituitarism, hypoglycemia), thiamine deficiency</li> <li>Impaired regulation: Spinal cord injury, hypothalamic lesions, drugs     (classes including antihyperglycemics, beta blockers, sedatives,     ETOH, alpha agonists, general anesthetics)</li> <li>Multiple mechanisms: sepsis, pancreatitis, DKA</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-temperature-abnormalities/#evaluation","title":"Evaluation","text":"<ul> <li>Infectious work-up</li> <li>POC blood glucose, TSH/FT4, cortisol, lipase, UA, UDS, EtOH level,     additional tox as appropriate, DKA work-up if relevant</li> <li>Physical exam + history for exposures and trauma</li> <li>CBC, CMP, Lactate, ABG, CK, PT/PTT, Fibrinogen</li> <li>EKG</li> </ul>"},{"location":"critical-care/critical-care-temperature-abnormalities/#management","title":"Management","text":"<ul> <li>Treat underlying cause [see appropriate sections]</li> <li>Mild hypothermia:<ul> <li>Passive external rewarming (PER): blankets, increase ambient     temperature</li> <li>Note that PER requires sufficient underlying physiologic reserve to     generate heat. This is often impaired in elderly pts, malnutrition,     sepsis</li> </ul> </li> <li>Moderate hypothermia, refractory mild hypothermia, or cardiovascular     instability:<ul> <li>Active external rewarming (AER): forced warm air (ie Bair Hugger),     heated blankets, heat lamps, hot packs (consider burn risk)</li> </ul> </li> <li>Severe hypothermia or refractory moderate hypothermia:<ul> <li>Active core rewarming: Warmed IV crystalloid (limited rewarming     potential unless large volume but will decrease ongoing losses),     warmed humidified inspired air, warmed bladder lavage</li> <li>More extreme methods such as peritoneal/thoracic lavage more likely     to be used in severe environmental cases in ED</li> </ul> </li> <li>Pulseless severe hypothermia (\u201cYou aren't dead unless you are warm     and dead\u201d)<ul> <li>Continue CPR until re-warmed as severe hypothermia is     neuroprotective and pts can have good neurologic outcomes despite     hours of CPR</li> <li>ACLS medications and shocks will have poor effectiveness; prioritize     circulation (i.e. chest compressions) and rewarming</li> <li>Consider ECMO (likely venoarterial if pulseless); would need     transfer to CVICU</li> </ul> </li> <li>Identify and manage complications: bradycardia/heart block,     arrhythmias, shock, coagulopathy/DIC, rhabdo; rebound     hyperkalemia/hypoglycemia with rewarming</li> </ul>"},{"location":"critical-care/critical-care-temperature-abnormalities/#fever-and-hyperthermia","title":"Fever and Hyperthermia","text":""},{"location":"critical-care/critical-care-temperature-abnormalities/#background_1","title":"Background","text":"<ul> <li>Fever: T &gt;38.0\u00b0C (100.4\u00b0F) driven by hypothalamus activity in     response to systemic triggers (i.e. cytokines); may use lower     threshold for immunocompromised pts</li> <li>Hyperthermia: T &gt;41.0 C (105.8\u00b0F) uncontrolled heat production with     failure of thermoregulation</li> <li>Infectious etiologies:<ul> <li>Considerations in the ICU include central-line associated blood stream infection, catheter-associated UTI, pneumonia (including ventilator-associated), sinusitis (esp in pts with NGT or ETT), clostridium difficile, acalculous cholecystitis</li> </ul> </li> <li>Non-infectious etiologies:</li> <li>Drug fever<ul> <li>Difficult to distinguish from other causes; Can begin hrs-wks     after starting a drug</li> <li>Sources: antibiotics (penicillins, cephalosporins,     sulfonamides), anticonvulsants (phenytoin, carbamazepine,     phenobarbital), allopurinol, heparin, dexmedetomidine</li> <li>Drugs of abuse with sympathomimetic activity (cocaine, meth,     ecstasy)</li> <li>Anticholinergic or salicylate intoxication</li> </ul> </li> <li>Idiosyncratic drug reactions<ul> <li>Serotonin syndrome</li> <li>Neuroleptic malignant syndrome</li> <li>Malignant hyperthermia</li> </ul> </li> <li>Transfusion reactions</li> <li>PE/DVT</li> <li>Endocrine: hyperthyroidism/thyroid storm, adrenal insufficiency</li> <li>CNS pathology (intracranial bleed/stroke, particularly hypothalamic     region)</li> <li>Malignancy</li> <li>Heat stroke (exertional or non-exertional)</li> <li>Other inflammatory states: Pancreatitis, gout, pericarditis,     pneumonitis</li> </ul>"},{"location":"critical-care/critical-care-temperature-abnormalities/#evaluation_1","title":"Evaluation","text":"<ul> <li>Infectious work-up \u00b1 LP; may consider pan-scan if unable to     identify source</li> <li>POC glucose, BMP, LFT, Mg/Phos, CBC w/diff</li> <li>Consider coags + fibrinogen (DIC), CK/UA (rhabdo), UDS,     acetaminophen and salicylate levels, TSH/FT4, cortisol, lipase, ABG</li> <li>Review medication list: antibiotics, serotonergic drugs,     anti-psychotics, recent sedation for OR or recently intubated with     succinylcholine, dexmedetomidine</li> <li>Consider CT/MRI head</li> </ul>"},{"location":"critical-care/critical-care-temperature-abnormalities/#management_1","title":"Management","text":"<ul> <li>Treat underlying etiology [see appropriate sections]</li> <li>Serotonin syndrome -&gt; stop serotonergic drugs; add cyproheptadine</li> <li>Malignant hyperthermia -&gt;activate malignant hyperthermia team; add     dantrolene</li> <li>Cooling<ul> <li>Target \\&lt;38.0\u00b0C (100.4\u00b0F)</li> <li>Surface cooling: Ice (bath, or ice packs more likely in our MICU),     evaporative cooling with misted lukewarm water and fan</li> <li>Internal cooling:     Cold IV fluids     (pharmacy keeps ~3L of cold LR on-hand, they will cool more if you call down and ask),     dry ventilation (evaporative) with non-humidified nasal cannula or vent circuit</li> <li>Avoid shivering -&gt; give opiates (except in serotonin syndrome),     precedex, propofol, benzos, ketamine</li> </ul> </li> <li>Antipyretics<ul> <li>Acetaminophen, NSAIDs</li> <li>Block prostaglandin-mediated temperature elevations</li> <li>Effective for most causes of fever- infection, pancreatitis, DVT/PE,     pneumonitis</li> <li>AVOID for true hyperthermia (ineffective and potentially harmful)     -&gt; neuroleptic malignant syndrome, malignant hyperthermia,     serotonin syndrome, heat stroke</li> </ul> </li> <li>Monitor for complications<ul> <li>Rhabdo, DIC, arrhythmias</li> </ul> </li> <li>If high suspicion for infection and not improving on antibiotics,     consider other infectious etiologies including fungal (ex: candida)</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/","title":"Tracheostomy","text":"<p>Jared Freitas</p>"},{"location":"critical-care/critical-care-tracheostomy/#indications","title":"Indications","text":"<ul> <li>Prolonged mechanical intubation and weaning</li> <li>Tracheal stenosis</li> <li>Acute airway obstructions (head and neck cancers)</li> <li>Trauma</li> <li>Neuromuscular disease</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#benefits-of-tracheostomy-vs-et-tube","title":"Benefits of Tracheostomy vs ET tube","text":"<ul> <li>Improved pt comfort and decreased need for sedation</li> <li>Reduced laryngeal damage</li> <li>Increased ability to communicate (i.e. speaking valve)</li> <li>May decrease risk of developing ventilator associated pneumonia     (mixed data)</li> <li>May reduce time to wean from the vent and decrease time in the     hospital (mixed data)</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#timing","title":"Timing","text":"<ul> <li>No mortality difference or \u2193 in hospital length of stay for early     (day 4) vs late (day 10)</li> <li>Generally performed after 2 weeks of intubation, but not backed by     data</li> <li>Pts that might get tracheostomy earlier: anticipated prolonged     mechanical ventilation (i.e. those with acute neurologic injury     affecting spinal cord)</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#types-of-tracheostomy-tubes","title":"Types of Tracheostomy Tubes","text":"<ul> <li>Different brands: most common in hospital = Shiley</li> <li>Components:<ul> <li>Faceplate: keeps tube in place, has the model and size on it</li> <li>Inner cannula: can be removed, cleaned and replaced in case of     obstruction</li> <li>Cuff (may or may not have): allows for pt to be ventilated; may     prevent some aspiration</li> <li>Fenestration (may or may not have): allow speaking without valve</li> </ul> </li> <li>Common sizes:<ul> <li>Initial: 8-0; Standard downsizing: 6-0</li> <li>Lengths: standard vs larger XLT (P = longer proximal end, D =     longer distal end)</li> </ul> </li> <li>Presenting on ICU rounds = size/cuff status/brand (e.g. 8-0 cuffed     shiley)</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#speaking-valves","title":"Speaking Valves","text":"<ul> <li>Passy Muir Valve (PMV): one-way valve placed on the outer portion of     the trach; air moves in with inspiration but is blocked and thus     funneled up through the vocal cords during exhalation allowing for     phonation</li> <li>Contraindication: severe upper airway obstruction or aspiration     risk, copious secretions, decreased cognitive status, severe medical     instability, or inability to tolerate cuff deflation</li> <li>IMPORTANT SAFETY PRINCIPLE: cuff must be deflated, since air needs     to be able to travel back up the airway, if the cuff is not deflated     and you put the PMV on, then pt cannot exhale</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#maintenance-of-tracheostomy-tubes","title":"Maintenance of Tracheostomy Tubes","text":"<ul> <li>Inner cannula should be cleaned 2-3 times per day</li> <li>Daily stoma care should be initiated to prevent pressure ulcers and     stoma infections</li> <li>As needed suctioning for secretions</li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#complications-and-airway-emergencies-in-a-tracheostomy-pt","title":"Complications and airway emergencies in a tracheostomy pt","text":"<ul> <li>Hemorrhage (mild bleeding from surface vessels and granulation     tissue is common, major bleeding is rare think erosion into     brachiocephalic [innominate] artery)</li> <li>Airway damage subglottic or tracheal stenosis; tracheobronchitis</li> <li>Fistulas (tracheoarterial, tracheoesophageal)</li> <li>Unintended tracheostomy tube dislodgement:<ul> <li>Bag mask (use hand/gauze to occlude stoma) or intubate from above     (i.e. through the mouth); if complete laryngectomy then must use     stoma</li> <li>Fresh trach (\u2264 14 days): do NOT replace due to risk of misplacement     into the mediastinum and loss of airway; airway management from     above</li> <li>Older trach: can be replaced at bedside with obturator by trained     staff</li> <li>All pts with trachs have a yellow sign above bed with date, type,     size of trach as well as a replacement trach with obturator in the     room</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-tracheostomy/#secretion-management","title":"Secretion Management","text":"<ul> <li>Respiratory hygiene (\u201cpulmonary toilet\u201d): heated vent, guaifenesin,     hypertonic saline, duonebs, cough assist device, appropriate     suctioning (too much = worsen secretions), acapella, inspiratory     spirometer</li> </ul>"},{"location":"critical-care/critical-care-ultrasound/","title":"Ultrasound in Critical Care","text":"<p>Audrey White</p>"},{"location":"critical-care/critical-care-ultrasound/#volume-assessment","title":"Volume assessment","text":"<ul> <li>IVC measurements</li> <li>Clinical Questions: Will the patient respond to fluid resuscitation?     Is CVP low or high?</li> <li>Protocol: See cardiology POCUS section</li> <li>Limitations: Non applicable in patients with elevated abdominal     pressure or abdominal contractions during measurement</li> <li>Troubleshooting: Use the liver as a window to the IVC to avoid bowel     gas. Start at the right mid-axillary line with the leading edge     toward the head of the patient, and fan to view the IVC in     longitudinal axis.</li> </ul>"},{"location":"critical-care/critical-care-ultrasound/#lung-assessment","title":"Lung Assessment","text":"<ul> <li>Lung ultrasound relies on recognition of ultrasound artifacts to     identify normal and pathologic findings.</li> <li>Normal findings<ul> <li>\u201cBat sign\u201d: Ultrasound cannot penetrate reflective rib surface,     casting a vertical shadow</li> <li>A- lines: hyperechoic horizontal lines descending from the     pleural line at regular intervals. This reverberation artifact     occurs in normal aerated lung</li> </ul> </li> <li>Pathologic findings<ul> <li>B-lines, comet tails: Vertical hyperechoic lines which (1)     extend from the pleural line through the depth of the image, (2)     move with lung sliding, and (3) obliterate A lines. Multiple B     lines indicates excess interstitial fluid</li> <li>Lung rockets: &gt;3 B lines indicates interstitial syndrome. Most     common cause is acute pulmonary edema, also consider ARDS, PNA,     pulmonary fibrosis, &amp; pulmonary contusion. Helps distinguish CHF     vs COPD exacerbation in patients with dyspnea</li> <li>Loss of lung sliding, barcode sign: The shimmering, twinkling     appearance of the dynamic aerated lung is lost. Can confirm in     M-mode with barcode sign- smooth homogenous lines indicating no     movement of lung tissue. Lung sliding=suspicion for PTX but NOT     specific unless can identify lung point</li> <li>Lung Point: The precise location where the lung detaches from     the pleura can sometimes be identified. Can confirm in M-mode     which will show \u201cbarcode\u201d and \u201cseashore\u201d patterns adjacent. 100%     specific for pneumothorax</li> <li>Pleural effusion, jellyfish sign: Anechoic fluid is visualized     between the diaphragm and dynamic lung</li> </ul> </li> <li>Probe: linear or phased array</li> <li>Protocol<ul> <li>Adjust the depth to ~10cm to start. Position the probe vertically     on the midclavicular line. Slide the probe so that the hyperechoic     pleural line is visualized between rib shadows. Note     presence/absence of A lines, B lines, lung sliding, and alveolar     consolidation</li> <li>Repeat on the opposite side and lower anterior lung fields</li> <li>Repeat on the right and left mid-axillary line, upper and lower         lung fields. Look for pleural effusion between the diaphragm and         lung</li> <li>Repeat on the posterior lung fields if indicated to complete a         12-zone lung examination</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-ultrasound/#cardiovascular","title":"Cardiovascular","text":"<p>Goal-directed echocardiography for acute shock</p> <ul> <li>Pericardial tamponade<ul> <li>Apical 4 chamber (A4C): pericardial effusion, may see end diastolic     collapse of right atrium</li> <li>Parasternal long (PLAX): pericardial effusion will appear anterior     to thoracic descending aorta, may see collapsing right ventricle</li> <li>False positives: pericardial cyst, pericardial fat pad, pleural     effusion (posterior to thoracic descending aorta on PLAX)</li> </ul> </li> <li>Acute cor pulmonale<ul> <li>PLAX, PSAX: paradoxical septal motion, D shaped left ventricle,     dilated RV</li> <li>A4C: end-diastolic RV area : LV area &gt; 1</li> <li>Subxiphoid (SUX): dilated IVC</li> </ul> </li> <li>LVEF- see cardiology section</li> </ul>"},{"location":"critical-care/critical-care-ultrasound/#abdominal-assessments","title":"Abdominal assessments","text":"<ul> <li>FAST exam</li> <li>Clinical questions: Is there fluid in the peritoneal or pericardial     spaces?</li> <li>Probe: curvilinear or phased array</li> <li>Protocol<ul> <li>Start on abdominal mode at depth 21-25cm. Assess for pericardial     effusion in SUX view</li> <li>Reduce depth to 12-16cm and place probe on the right anterior     axillary line between ribs 8-12 with the indicator toward the     patient\u2019s head. Sweep medially to identify the right kidney.     Assess for anechoic fluid in Morrison\u2019s pouch between the kidney     and liver, subdiaphragmatic space, and paracolic gutter. Rock     the probe to assess for fluid cephalad to the diaphragm. Slide     inferiorly to confirm no fluid around the inferior pole of the     kidney</li> <li>Place probe on the left anterior axillary line between ribs 8-11     with the leading edge toward the patient\u2019s head. Sweep medially     to identify the left kidney. Assess for anechoic fluid in the     splenorenal interface, subdiaphragmatic space, pleural space,     paracolic gutter, and left kidney inferior pole</li> <li>Place probe midline just superior to the pubic symphysis.     Identify the bladder in longitudinal and transverse view. Assess     for fluid outside the bladder wall and in the pouch of Douglas     (females) or rectovesicular space (males)</li> </ul> </li> <li>Limitations: Cannot detect retroperitoneal bleed. False positives     from ascites, pleural effusion, subcapsular hematoma, ruptured     cysts, physiologic fluid in pouch of Douglas, epicardial fat pad.     Exam may be indeterminant if significant bowel gas or obesity</li> <li>Small bowel obstruction assessment<ul> <li>Overall SBO ultrasound has ~92% sensitivity and ~97% specificity     to detect SBO and greater diagnostic accuracy than abdominal XR</li> <li>Probe: curvilinear</li> <li>Protocol: Have the patient lie supine and relax the abdominal wall.     Place the probe vertically on the abdomen and sweep across all four     quadrants in sagittal view. Repeat in transverse view. Measure small     bowel wall thickness and diameter using the caliper tool</li> <li>Signs of SBO:<ul> <li>Diameter &gt; 2cm \u2022 Decreased peristalsis</li> <li>Wall thickness &gt; 4mm \u2022 Back and forth stool movement</li> <li>Tanga sign: In severe SBO, may see triangular pocket hypoechoic     free fluid surrounding the small bowel near the obstruction</li> </ul> </li> </ul> </li> <li>Renal ultrasound<ul> <li>Protocol is similar to FAST exam. Fan the probe through each kidney     in sagittal and transverse view to assess for dilation of the     collecting ducts. To move the kidney inferiorly, ask the patient to     take a deep breath</li> <li>Bilateral hydronephrosis and full bladder suggests urinary     obstruction distal to the ureter</li> <li>Unilateral hydronephrosis suggests nephrolithiasis or ureteral     obstruction</li> <li>Limitations: Renal US has a reported sensitivity of 70% and     specificity of 75% to detect nephrolithiasis compared to CT</li> </ul> </li> </ul>"},{"location":"critical-care/critical-care-vent-settings/","title":"Introduction to Vent Management","text":"<p>Jared Freitas</p>"},{"location":"critical-care/critical-care-vent-settings/#ventilator-settings","title":"Ventilator Settings","text":"<ul> <li>See table in Modes of Oxygen Delivery for variables adjusted     in each ventilator mode</li> <li>Trigger: what initiates a breath; time, flow, or pressure (pt     triggers are flow and pressure)</li> </ul>"},{"location":"critical-care/critical-care-vent-settings/#static-ventilator-readouts","title":"Static Ventilator Readouts","text":"<ul> <li>Plateau pressure (Pplat): measure with inspiratory hold, assesses     static lung compliance</li> <li>Auto-PEEP: measure with expiratory hold; occurs when volume of     previous breath is not entirely expelled before the next breath is     initiated</li> </ul>"},{"location":"critical-care/critical-care-vent-settings/#dynamic-ventilator-readouts","title":"Dynamic Ventilator Readouts","text":"<ul> <li>Measured RR: in most modes, pt may trigger breaths above set RR; if     set and measured RR match consider \u2193 respiratory drive (sedation,     neurologic injury) or iatrogenic over-ventilation</li> <li>VTi / VTe: tidal volume of inspiration (VTi) and expiration (VTe)</li> <li>VTi should approximately equal VTe, if not then concern for air leak     (e.g. cuff leak or pneumothorax) or auto-PEEP</li> <li>Minute ventilation: calculated from VTe x RR; higher MV = more CO2     clearance</li> <li>Peak pressure: highest pressure reached in the entire ventilator     cycle</li> </ul>"},{"location":"critical-care/critical-care-vent-settings/#critical-non-ventilator-hemodynamic-readouts","title":"Critical Non-ventilator hemodynamic readouts","text":"<ul> <li>SpO2: if poor waveform or discordant with PaO2, may need serial ABG</li> <li>HR: quickest indicator of emergencies such as pneumothorax, PE,     ventilator disconnection</li> <li>Blood pressure: positive pressure ventilation decreases preload and     afterload; depending on the underlying pt physiology, increases in     positive pressure may be detrimental or beneficial for BP</li> </ul> Alarm Type What is causing the alarm? Troubleshooting High Peak Pressure Static compliance issue (stretch of the lung - doesn't change with airflow) versus dynamic compliance issue (resistance of the circuit when there is air flowing) <p>Step 1: Check plateau pressure by performing inspiratory hold. Must be in VC mode.</p> <p>High Peak and Low Plateau = Dynamic compliance issue High Resistance</p> <ul> <li><p>Check circuit tubing for excess water condensation or a kink. Ask RT to disconnect and clear circuit</p></li> <li><p>Check if patient is biting ETT bite block, pain control/sedation</p></li> <li><p>Incline suction to clear secretions or proximal mucous plug</p></li> <li><p>Auscultate for wheezing or stridor to indicate bronchospasm or airway obstruction-&gt;give bronchodilators</p></li> </ul> <p>High Peak and High Plateau = Static compliance issue Worsening alveolar process</p> <ul> <li><p>Emergencies to quickly assess for:</p></li> </ul> <ul> <li><p>Tension pneumothorax (exam, US for lung sliding, CXR)</p></li> <li><p>Main stem intubation (ask about any tube migration, listen to breath sounds, CXR)</p></li> </ul> <ul> <li><p>Consider worsening alveolar process leading to decreased lung compliance: worsening pulmonary edema, PNA, DAH, ARDS or other non-alveolar process such as new pleural effusion, obesity, intraabdominal hypertension/compartment syndrome</p></li> </ul> <ul> <li><p>CXR, US to assess for b-lines, tracheal aspirate, bronch, etc</p></li> <li><p>Treat according to etiology (chest tube, reposition ETT, diuresis, abx, etc)</p></li> </ul> Low Tidal Volume/Low Minute Ventilation (VE) Pt is not getting the desired tidal volume/VE that was set in the vent parameters. The alarm reports exhaled VE. May cause inadequate ventilation, CO2 retention, potentially hypoxia <p>Compare inspiratory tidal volumes (Vti) with expiratory tidal volumes (Vte) on the ventilator. If Vti&gt;Vte, check for a leak in the system</p> <ul> <li><p>Have RT check all connections</p></li> <li><p>Listen for a cuff leak \u2013 can have RT check a cuff pressure and if low then re-inflate-&gt;sometimes need to do an ETT exchange</p></li> <li></li> </ul> <p>If low tidal volumes and no leak (ie. Vti = Vte) and RR WNL</p> <ul> <li><p>Pt may need more support, ie switching to a different vent mode (PS to PRVC). Discuss with RT or fellow</p></li> </ul> <p>If low RR and no leak and Vt at goal</p> <ul> <li><p>Patient may be oversedated</p></li> <li><p>Ensure pt has a back-up rate in case they aren't triggering the vent-&gt;may need to switch vent modes for this (i.e. take off pressure support) or increase set/ventilator respiratory rate</p></li> </ul> Apnea No breaths are being triggered by the vent your patient is NOT breathing this is an emergency <p>***Check that patient hasn't self-extubated, trach hasn't fallen out, or been unhooked from vent***</p> <p>If self-extubated or tracheostomy decannulated, then immediately start bagging the patient (may need to bag from trach stoma if s/p laryngectomy). Have nurse call staff assist so that patient can be re-intubated if necessary or have trach team called to replace a fresh (&lt;7 days old) trach</p>"},{"location":"demo/demo-lights/","title":"Pleural Effusions","text":"<p>Eddie Qian</p>"},{"location":"demo/demo-lights/#background","title":"Background","text":"<p>There is a normal influx of fluid into the pleural space due to     leaky capillary membranes and the pleural space\u2019s negative pressure.     This fluid is constantly reabsorbed by lymphatics. An imbalance in     the system will result in accumulation.</p> <ul> <li> <p>Some examples:</p> <ul> <li> <p>Increased influx: increased filtration from the capillaries from     high intravascular hydrostatic pressure (i.e., heart failure, renal     failure) or low intravascular oncotic pressure</p> </li> <li> <p>Other liquid entry into the pleural space through anatomic deficits:     CSF, chyle, urine, blood, ascites (the diaphragm is naturally     porous)</p> </li> <li> <p>Decreased efflux: obstruction of the parietal pleural stoma (from     protein or cellular debris in exudative pleural effusions)</p> </li> <li> <p>Increased systemic venous pressure (lymphatic system drains into the     systemic venous circulation so high venous pressure prevents     lymphatics from draining appropriately)</p> </li> </ul> </li> </ul>"},{"location":"demo/demo-lights/#evaluation","title":"Evaluation","text":""},{"location":"demo/demo-lights/#imaging","title":"Imaging","text":"<ul> <li>CXR: lateral decubitus position (if effusion moves with gravity,         suggests free flowing)</li> <li>Ultrasound: assess size, location, loculations (fibrinous         septations which may prevent simple drainage)</li> <li>CT Chest with contrast (not always indicated; helpful to eval         septations)</li> </ul>"},{"location":"demo/demo-lights/#thoracentesis-see-procedures-section","title":"Thoracentesis (see Procedures section)","text":"<p>Will it change management?</p> <p>If septated or empyema,\u00a0 consider pulm consult for chest tube.</p> <p>Orders:</p> <ul> <li>Always: Pleural LDH, protein, cell count/diff, culture</li> <li>Don\u2019t forget serum LDH &amp; protein!</li> <li>Consider: pleural cytology, hematocrit, triglycerides, glucose,         amylase</li> </ul> <p>Interpretation:</p> Lights Criteria &gt;=1 of the following = exudative pleural protein : serum protein &gt; 0.50 pleural LDH : serum LDH &gt; 0.60 pleural LDH : upper limit of normal of serum LDH &gt; 0.66 <ul> <li>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis         (caused by increased intrapleural negative pressure),         hypoalbuminemia, renal failure</li> <li>Exudative: infections (bacterial, TB, fungal), malignant,         rheumatologic, PE</li> </ul> <p>Pearls about initial tests:</p> <ul> <li>Protein: &gt;5 think TB or malignancy, =&lt; 0.5 think urine, CSF,             peritoneal dialysate</li> <li>Glucose: =&lt; 60 think about malignancy, TB,                 rheumatologic, and less specific hemothorax or                 parapneumonic</li> <li>Cell count/differential: polys represent an acute                 process, monocytes represent a chronic process,                 lymphocytes think about TB or malignancy, eosinophils                 think about air/blood, TB, malignancy, asbestos, drugs</li> <li>Two separate processes may co-occur and a transudate may mask an                 exudative effusion; if\u00a0 concerned for this and you have clinical                 stability, trial diuresis prior to thoracentesis.</li> </ul> References <p>Lights Criteria Original Paper</p>"},{"location":"endocrinology/endocrinology-adrenal-incidentalomas/","title":"Adrenal Incidentalomas","text":"<p>Matthew Gonzalez</p>"},{"location":"endocrinology/endocrinology-adrenal-incidentalomas/#background","title":"Background","text":"<ul> <li> <p>Adrenal mass &gt;1cm, discovered by chance on radiographic imaging</p> </li> <li> <p>Less than 1% are malignant</p> </li> <li> <p>Supportive of benign: &lt;4 cm in size, smooth borders, homogenous appearance, &lt;10 HU (Hounsfield units), rapid contrast washout (on \"adrenal phase\" imaging)</p> </li> <li> <p>Supportive of malignancy: &gt;4 cm in size, irregular borders, &gt; 20 HU on unenhanced CT, delayed contrast washout, tumor calcifications, increase in size over time, presence in young pts and hx cancer</p> </li> </ul>"},{"location":"endocrinology/endocrinology-adrenal-incidentalomas/#evaluation","title":"Evaluation","text":"<ul> <li> <p>All incidentalomas should be screened for pheochromocytoma (~3% incidence) before operative intervention </p> </li> <li> <p>Cortisol secreting adenoma (~6% incidence) causing Cushing's syndrome: baseline serum DHEAS, low dose (1mg) overnight dexamethasone suppression test</p> </li> <li> <p>Aldosterone secreting adenoma (&lt;1% incidence) causing hyperaldosteronism: if hypertensive (HTN) or hypokalemic order plasma aldosterone and renin, confirmatory testing with sodium loading (oral vs IV) and 24-hour urine aldosterone, sodium, and creatinine</p> </li> </ul>"},{"location":"endocrinology/endocrinology-adrenal-incidentalomas/#management","title":"Management","text":"<ul> <li> <p>If benign appearing and not hormone producing: interval imaging in ~1 year, and repeat hormone work up</p> </li> <li> <p>Unilateral adrenal incidentaloma</p> <ul> <li>If progression free (stable size, and not hormone producing) can consider monitoring cessation after 4 years</li> </ul> </li> <li> <p>Pheochromocytomas should undergo surgical evaluation for removal</p> <ul> <li>Alpha blockade (phenoxybenzamine) + propranolol prior to resection to avoid HTN crisis</li> </ul> </li> <li> <p>Aldosteronoma: should undergo surgical evaluation for definitive treatment; if unable to undergo surgery can treat with medical management with long term mineralocorticoid antagonist (e.g. spironolactone)</p> </li> <li> <p>Cortisoloma: if clinically significant should undergo surgical removal, will need perioperative glucocorticoid administration to avoid iatrogenic adrenal insufficiency</p> </li> <li> <p>Macroadenomas (masses &gt;4 cm) are usually malignant and should be considered for surgical resection due to higher risk of carcinoma</p> </li> </ul>"},{"location":"endocrinology/endocrinology-adrenal-insufficiency/","title":"Adrenal Insufficiency","text":"<p>Griffin Bullock</p>"},{"location":"endocrinology/endocrinology-adrenal-insufficiency/#background","title":"Background","text":"<ul> <li>Differential: Primary (Adrenals) vs Secondary (Pituitary):<ul> <li>Exogenous steroid use (&gt;10 mg for &gt;3wks) undergoing severe physiologic stress or sudden discontinuation of steroid</li> <li>Autoimmune adrenal insufficiency</li> <li>Infection/Infiltration: tuberculosis, sarcoidosis, malignancy</li> <li>Hemorrhage (Waterhouse-Friderichsen syndrome)</li> <li>Pituitary mass/tumor, infarct, infiltration, surgery, trauma </li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-adrenal-insufficiency/#presentation","title":"Presentation","text":"<ul> <li> <p>Generalized weakness, lightheaded, abdominal pain, nausea, weight loss, fatigue</p> </li> <li> <p>Lab Abnormalities: hyponatremia, hyperkalemia, hypoglycemia</p> </li> </ul>"},{"location":"endocrinology/endocrinology-adrenal-insufficiency/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Inpatient Setting</p> <ul> <li>Draw AM cortisol and ACTH (ideally 8am) -&gt; 0.25mg cosyntropin -&gt; cortisol 1 hour after <ul> <li>Cortisol level \u226518-20 rules out primary adrenal insufficiency (and most secondary)</li> </ul> </li> </ul> </li> <li> <p>Outpatient Setting</p> <ul> <li>Draw AM cortisol level for screening (&gt;15 rules typically rules out adrenal insufficiency)</li> <li>ACTH stimulation for confirmation</li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-adrenal-insufficiency/#management","title":"Management","text":"<ul> <li>Consult endocrine if ACTH stimulation test is abnormal</li> <li>Adrenal crisis (if concerned, treat first, test later)<ul> <li>BMP, glucose monitoring, ACTH level, serum cortisol</li> <li>Fluid resuscitation: NS or D5NS. Do not use hypotonic saline</li> <li>Hydrocortisone 100mg x1 followed by 50mg q8h </li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-diabetes-inpatient-management/","title":"Inpatient Diabetes Mellitus (DM)","text":"<p>Will Bassett</p>"},{"location":"endocrinology/endocrinology-diabetes-inpatient-management/#background","title":"Background","text":"<ul> <li> <p>Blood glucose (BG) goal</p> <ul> <li>Wards: &lt;140 mg/dL fasting; &lt;180 mg/dL random; increase for elderly, \u201csicker\u201d patients</li> <li>ICU: 140-180 mg/dL (NICE-SUGAR Trial)</li> <li>Avoiding hypoglycemia in critically ill patients is more important than targeting ideal BG</li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-diabetes-inpatient-management/#management","title":"Management","text":"<ul> <li> <p>Initial orders</p> <ul> <li>HOLD all home oral diabetes medications (except consider continuing empagliflozin in heart failure pts)</li> <li>Typically recommend dose reducing home insulin (usually 50% of home dose for type 2; varies for type 1) for changes in diet. If AKI present, consider reducing by more.<ul> <li>Patients with Type 1 DM always need basal insulin, even if NPO or else will lead to DKA</li> <li>If patients with Type 1 DM are eating, they will need prandial insulin as well </li> </ul> </li> <li>Order set \u201cSUBCUTANEOUS INSULIN ORDER(S)\u201d<ul> <li>Hemoglobin A1c. Can consider if none in last 3 months and concern for poor outpatient control. A1c does not routinely affect inpatient management</li> <li>Fingerstick blood glucose: Typically AC/HS (before meals and nightly)</li> <li>Hypoglycemia management: Select all of these</li> <li>Basal insulin:<ul> <li>Type 2 DM, consider \u2193 home dose (50-60% to home dose) as often inpatients have reduced PO intake and \u2193 renal function</li> <li>Type 1 DM, DO NOT hold basal insulin, and avoid \u2193 &lt; 80% of home dose</li> <li>Unnecessary if no home basal insulin</li> </ul> </li> <li>Insulin lispro meal: \u2193 home dose by \u00bd, do not give while NPO</li> <li>Lispro insulin correction scale: Start with Low or Medium sliding scale and \u2191 prn</li> <li>Carb-controlled or carb-restricted diet</li> </ul> </li> </ul> </li> <li> <p>Insulin adjustments</p> <ul> <li>If BGs persistently &gt;200<ul> <li>Calculate all insulin needs over 24h (basal + mealtime + sliding scale)<ul> <li>Give 50% as basal and other 50% as 3 divided mealtime doses</li> <li>E.g. 10 basal + 0 mealtime + 14 sliding scale total = 24 units total daily = 12u basal + 4u TID with meals</li> <li>If new to basal, safe start is 0.2 u/kg daily if normal GFR</li> </ul> </li> </ul> </li> <li>If BGs &lt; 70<ul> <li>If overnight/AM, reduce basal insulin dose</li> <li>If daytime/post-prandial hypoglycemia, reduce mealtime and sliding scale</li> <li>Less is more! Blood glucose in the low 200s is better than the 50s</li> <li>If endocrine consulted for inpatient glucose management, please notify &gt;24h prior to discharge if you want recommended discharge regimen</li> </ul> </li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-diabetes-inpatient-management/#steroid-induced-hyperglycemia","title":"Steroid-induced Hyperglycemia","text":"<ul> <li> <p>Steroids increase insulin resistance causing elevated postprandial BG</p> </li> <li> <p>Insulin adjustments</p> <ul> <li>Double mealtime + correction dose with leaving the basal the same</li> <li>Modified basal bolus regimen (30% basal, 70% bolus)</li> <li>Add NPH once daily (weight + dose based, per below*) if on daily prednisone<ul> <li>Prednisone 10 mg = 0.1 u/kg NPH</li> <li>Prednisone 20 mg = 0.2 u/kg NPH up to 0.4 u/kg daily</li> <li>lower dose if AKI, administer at the same time as prednisone dosing</li> </ul> </li> <li>On discharge, if steroids will be longstanding, increase home insulin regimen per inpatient requirements. If steroids will be tapered or discontinued soon after, either continue hospital regimen for remainder of steroid course or return to home regimen (hyperglycemia is better than hypoglycemia)</li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-diabetes-inpatient-management/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Tube feeds</p> <ul> <li>Dose regular insulin q6h (not TID AC as they don\u2019t have distinct \u201cmeals\u201d)</li> <li>Consolidate for bolus feedings based on 24-hour insulin needs prior to discharge</li> </ul> </li> <li> <p>Insulin pumps</p> <ul> <li>If a patient has a pump and supplies, reasonably controlled BG, is willing and able to manage pump then s/he can keep the pump on. This requires a Diabetes Consult.</li> <li>Still order POC BG checks AC/HS for nurse to chart and fill out MedEx pump contract</li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-dka/","title":"Diabetic Ketoacidosis (DKA)","text":"<p>Will Bassett, Matthew Gonzalez</p>"},{"location":"endocrinology/endocrinology-dka/#background","title":"Background","text":"<ul> <li> <p>Classically in type 1 diabetes but can also occur in insulin-dependent type 2 diabetes</p> </li> <li> <p>Definition: \u2191 blood glucose (typically &gt;350) w/ high anion gap and ketones in blood/urine</p> </li> <li> <p>If glucose is significantly elevated but little to no ketones/anion gap present, you likely have HHS, which is typically associated with \u2191 serum osm and BG &gt; 600</p> </li> </ul>"},{"location":"endocrinology/endocrinology-dka/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Labs: BMP with anion gap (AG), CBC, phos, blood gas, serum osms, UA, consider beta-hydroxybutyrate</p> </li> <li> <p>Workup aimed at discovering the underlying cause (The \"I\u2019s\"):</p> <ul> <li> <p>Infection/ Inflammation: CBC, CXR, UA/UCx, LFTs; consider BCx, lipase (pancreatitis). Note: Leukocytosis will be present in DKA, even if infection isn\u2019t the precipitating factor</p> </li> <li> <p>Ischemia (MI, CVA, mesenteric ischemia): EKG, Troponin, CT(A) if clinical suspicion</p> </li> <li> <p>Intoxication - Ethanol (can cause ketosis with or without acidosis), cocaine, MDMA</p> </li> <li> <p>Impregnation - Beta HCG if appropriate</p> </li> <li> <p>Insulin-openia/Iatrogenic: steroids, SGLT2 inhibitors, other meds, insulin delivery failure (pump failure, insulin degraded by heat, etc.)</p> </li> </ul> </li> </ul> <p>Remember to correct sodium for hyperglycemia (Na + 2.4 mEq * (BG-100))</p>"},{"location":"endocrinology/endocrinology-dka/#management","title":"Management","text":"<ul> <li> <p>Initial monitoring: q2-4h BMPs (monitor K closely), q1h BG fingersticks</p> <ul> <li>Can space less frequently once gap is closed x 2 and patient off insulin infusion</li> </ul> </li> <li> <p>Ensure IV access</p> </li> <li> <p>Start IV fluids, insulin, and potassium as below</p> <ul> <li> <p>Start insulin gtt</p> </li> <li> <p>Start subcutaneous long-acting insulin as soon as insulin drip/IV insulin is started</p> <ul> <li>Either start home long-acting (dose reduce as needed) or if insulin na\u00efve, lantus 0.2-0.3u/kg/day</li> </ul> </li> <li> <p>Lactated ringers\u2019 preferred fluid if no contraindication</p> </li> <li> <p>Dextrose should be added when BG &lt;200 (or clear liquid diet)</p> </li> <li> <p>Turn off insulin drip when anion gap is closed on two consecutive BMPs. Make sure your long acting insulin has been given at least four hours prior to drip being turned off</p> </li> </ul> </li> <li> <p>Consult endocrinology early</p> </li> <li> <p>Management algorithm below (Diabetes Care. 2009 Jul; 32(7): 1335\u20131343)</p> </li> <li> <p>Note: pts are usually deficient in total body potassium even if their serum potassium is high</p> </li> </ul>"},{"location":"endocrinology/endocrinology-dka/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Pts on insulin drip can be admitted to stepdown (8MCE) with order set</p> </li> <li> <p>Pts can be admitted to stepdown on a subcutaneous insulin protocol with mild DKA with endocrinology guiding insulin management</p> </li> <li> <p>Avoid ordering C-peptide if concern for new type 1 diabetes, beta islet cells can be \"stunned\" with recent hyperglycemic states and may be falsely low</p> </li> <li> <p>SGLT2 inhibitors are being prescribed much more often and can cause a euglycemic DKA, where acidosis and ketosis present but no elevated BG. These patients still require an insulin gtt until their acidosis has improved and their gap closed, regardless of BG level</p> </li> </ul> <p></p>"},{"location":"endocrinology/endocrinology-hyperthyroidism/","title":"Hyperthyroidism","text":"<p>Griffin Bullock</p>"},{"location":"endocrinology/endocrinology-hyperthyroidism/#background","title":"Background","text":"<ul> <li> <p>Low TSH and High T4 and/or T3 (primary): Graves\u2019 disease, Toxic goiter, TSH-producing adenoma, hyperemesis gravidarum, subacute granulomatous thyroiditis, amiodarone, radiation, excessive replacement, struma ovarii</p> </li> <li> <p>Low TSH/Normal T4 and T3: Subclinical hyperthyroidism, central hypothyroidism, non-thyroidal illness, recovery from hyperthyroidism, pregnancy (physiologic)</p> </li> <li> <p>Subclinical Hyperthyroidism: repeat testing to verify abnormality is not transient</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hyperthyroidism/#presentation","title":"Presentation","text":"<ul> <li>Anxiety, emotional lability, heat intolerance, tremor, palpitations, increased appetite, unexplained weight loss, new onset atrial fibrillation, myopathy, menstrual disorder, exophthalmos, tachycardia, pretibial myxedema, hyperreflexia, lid lag, changes to hair or skin</li> </ul>"},{"location":"endocrinology/endocrinology-hyperthyroidism/#evaluation","title":"Evaluation","text":"<ul> <li> <p>TSH, free T4, free T3 (only T3 or T4 may be elevated, though both often are)</p> </li> <li> <p>Biotin affects assay, causes falsely \u2193 TSH and falsely \u2191 FT4/FT3</p> </li> <li> <p>CBC: May have a normocytic anemia due to increased plasma volume</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hyperthyroidism/#management","title":"Management","text":"<ul> <li> <p>Thyrotropin antibodies (Graves-specific test, not sensitive)</p> </li> <li> <p>Radioiodine uptake scan if thyrotropin antibodies negative</p> <ul> <li>Note: if pt has had a contrasted study wtih radioactive iodine in the past 6 weeks, the RAI update scan will not be helpful </li> </ul> </li> <li> <p>Treatment: methimazole, PTU, beta blockers, radioiodine ablation, surgery</p> </li> <li> <p>Pts should be referred to endocrinology for treatment plan based on work up</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypoglycemia/","title":"Hypoglycemia","text":"<p>Will Bassett</p>"},{"location":"endocrinology/endocrinology-hypoglycemia/#background","title":"Background","text":"<ul> <li> <p>Definition: BG &lt;70 mg/dL in a patient on insulin or an oral hypoglycemic; &lt;55 mg/dL for other patients</p> <ul> <li>Generally worse outcomes than hyperglycemia</li> </ul> </li> <li> <p>Causes: infection, liver failure, iatrogenic (e.g. insulin not adjusted for AKI or being NPO)</p> </li> <li> <p>Symptoms vary from tremor, palpitations, delirium, dizziness, AMS, coma</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypoglycemia/#management","title":"Management","text":"<ul> <li> <p>Give PO carbohydrate load (15-20g oral glucose) if pt is alert and tolerates PO</p> </li> <li> <p>Give IV D50 if severe (&lt;50), or cannot take PO</p> </li> <li> <p>Repeat measurements after 15 minutes and treat again as needed</p> <ul> <li>As a rule of thumb, 15g of carbs should raise BG within 15 minutes</li> </ul> </li> <li> <p>Give glucagon 0.5-1mg SQ/IM if no IV access and impaired consciousness</p> <ul> <li>Effect is transient and IV access should be obtained ASAP for glucose infusion</li> </ul> </li> <li> <p>Do NOT hold basal insulin for T1DM: treat the low, then reduce dose if needed</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypothyroidism/","title":"Hypothyroidism","text":"<p>Griffin Bullock</p>"},{"location":"endocrinology/endocrinology-hypothyroidism/#background","title":"Background","text":"<ul> <li>Elevated TSH and low FT4 (primary hypothyroidism)<ul> <li>Hashimoto\u2019s (autoimmune) thyroiditis, iodine deficiency, drugs (amiodarone, dopamine antagonists), adrenal insufficiency, thyroid hormone resistance (genetic), non-thyroidal illness (recovery phase), post-surgery or ablation for hyperthyroidism</li> </ul> </li> <li> <p>Elevated TSH and normal FT4: subclinical hypothyroidism</p> </li> <li> <p>Low-Normal TSH, low FT4: central hypothyroidism, sick euthyroid</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypothyroidism/#presentation","title":"Presentation","text":"<ul> <li> <p>Often non-specific and vague: fatigue, cold intolerance, weight gain, constipation, dry skin, myalgia, edema menstrual irregularities, depression, mental dysfunction</p> </li> <li> <p>Goiter, bradycardia, diastolic hypertension, delayed relaxation following reflex testing</p> </li> <li> <p>Lab abnormalities: microcytic anemia, hypercholesterolemia, hyponatremia, elevated CK</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypothyroidism/#evaluation","title":"Evaluation","text":"<ul> <li> <p>TSH: If elevated repeat TSH and obtain T4</p> </li> <li> <p>Lipid panel, CBC, BMP</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypothyroidism/#management","title":"Management","text":"<ul> <li> <p>Treatment required if \u2193 T4, significantly \u2191 TSH (&gt;10), or symptoms with any lab abnormality</p> </li> <li> <p>Titrate therapy to a normal TSH (unless central hypothyroidism, then target free T4 levels)</p> </li> <li> <p>Observation of asymptomatic pts with subclinical hypothyroidism (normal T4, mild \u2191 TSH)</p> </li> <li> <p>Treatment is with formulation of T4 (full replacement is approximately 1.6 mcg/kg/day)</p> </li> <li> <p>Initial Dose:</p> <ul> <li> <p>Young/healthy patients: full anticipated dose</p> </li> <li> <p>Older patients or patients with CAD: 25-50 mcg daily</p> </li> </ul> </li> <li> <p>Increased doses required for: pregnancy, estrogen therapy, weight gain, PPI therapy, GI disorders (\u2193 absorption), ferrous sulfate therapy</p> </li> </ul>"},{"location":"endocrinology/endocrinology-hypothyroidism/#additional-information","title":"Additional information","text":"<ul> <li> <p>Pts should take Levothyroxine alone, 1 hr prior to eating to ensure appropriate absorption</p> </li> <li> <p>Of note, missed doses can be taken along with the next dose</p> </li> <li> <p>Symptoms improve in 2-3 weeks. TSH steady state requires 6 weeks</p> </li> <li> <p>Dose can be titrated every 6 weeks based on TSH</p> </li> <li> <p>Pregnancy: Pregnancy causes lab changes due to differing levels thyroid binding globulin. Use tables based on trimester to interpret values</p> <ul> <li>TPO antibody testing should be conducted if abnormal as this affects risk of complications</li> </ul> </li> <li> <p>Hypothyroid pts are at increased risk for preeclampsia, placental abruption, preterm labor/delivery</p> </li> <li> <p>Refer to endocrine for close monitoring and adjustment to avoid fetal complications</p> </li> <li> <p>Inpatients who are pregnant and have abnormal TFTs warrant endocine consult. </p> </li> </ul>"},{"location":"endocrinology/endocrinology-severe-hypertriglyceridemia/","title":"Severe Hypertriglyceridemia (HTG)","text":"<p>Chloe de Crecy</p>"},{"location":"endocrinology/endocrinology-severe-hypertriglyceridemia/#background","title":"Background","text":"<ul> <li> <p>Elevated triglycerides (TG) on a fasting lipid panel</p> <ul> <li>Normal: &lt;150 mg/dL</li> <li>Moderate HTG: 150-499 mg/dL</li> <li>Moderate to severe HTG: 500-999 mg/dL</li> <li>Severe HTG: &gt;1000 mg/dL</li> </ul> </li> <li> <p>Nearly all patients with severe HTG have a genetic predisposition and an additional factor known to raise serum TGs (e.g. diabetes, alcohol abuse, oral estrogen therapy, hypothyroidism, nephrotic syndrome, propofol, ART, pregnancy)</p> </li> <li> <p>Risks of hypertriglyceridemia: pancreatitis (can occur if serum TG &gt;500 mg/dL), ASCVD</p> </li> <li> <p>Signs: xanthomas, hepatosplenomegaly, lipemia retinalis, milky appearance of plasma</p> </li> <li> <p>Symptoms: short-term memory loss, abdominal pain, flushing with alcohol</p> </li> </ul>"},{"location":"endocrinology/endocrinology-severe-hypertriglyceridemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Order lipid panel for: usual outpatient screening, acute pancreatitis, cutaneous xanthomas, family members with familial HTG, monitoring HTG treatment</p> </li> <li> <p>Note: Sodium, glucose, amylase, LDL readings can be affected by HTG</p> </li> <li> <p>Consider sending A1c, Cr, TSH</p> </li> <li> <p>Assess medication list for secondary causes</p> </li> </ul>"},{"location":"endocrinology/endocrinology-severe-hypertriglyceridemia/#management","title":"Management","text":"<ul> <li> <p>HTG induced pancreatitis</p> <ul> <li> <p>If pt has hypocalcemia, lactic acidosis, or multi-organ dysfunction</p> <ul> <li>Initiate plasmapheresis and monitor serum TG after each cycle until &lt;500</li> <li>Severe dietary fat restriction (&lt;5%) until TG &lt;1000</li> </ul> </li> <li> <p>If none of the above and pt is hyperglycemic</p> <ul> <li>Start insulin gtt, IVF, monitor q1h BG and q12h TG</li> <li>Discontinue insulin when serum TG &lt;500</li> <li>Severe dietary fat restriction (&lt;5%) until TG &lt;1000</li> </ul> </li> <li> <p>If none of the above and patient is euglycemic</p> <ul> <li>Monitor q12h TG until &lt;500</li> <li>Severe dietary fat restriction (&lt;5%) until TG &lt;1000</li> <li>Consider initiation of insulin gtt as well (regardless of BG level) as insulin will help metabolize TG particles</li> </ul> </li> </ul> </li> <li> <p>Long-term Management (once TG &lt;1000, otherwise decreased efficacy)</p> <ul> <li>Pharmacologic: fibrates (most commonly fenofibrate), statins, niacin, omega-3 fatty acids</li> <li>Nonpharmacologic: discontinue alcohol use, dietary fat and sugar restriction (target fat intake at &lt;10% of calorie intake), exercise</li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-steroid-conversions/","title":"Steroid Conversions","text":"<p>Neil Phillips</p> Drug Name Equivalent doses (mg) Anti-inflammatory activity relative to hydrocortisone Duration of action (hrs) Hydrocortisone (cortisol) 20 1 8 to 12 Cortisone acetate 25 0.8 8 to 12 Prednisone 5 4 12 to 36 Prednisolone 5 4 12 to 36 Methylprednisolone 4 5 12 to 36 Triamcinolone 4 5 12 to 36 Dexamethasone 0.75 30 36 to 72 Betamethasone 0.6 30 36 to 72"},{"location":"endocrinology/endocrinology-stress-dose-steroids/","title":"Stress Dose Steroids","text":"<p>Griffin Bullock</p>"},{"location":"endocrinology/endocrinology-stress-dose-steroids/#primary-options","title":"Primary Options","text":"<ul> <li> <p>Dexamethasone 4 mg IV: does not affect cortisol assays, ideal if diagnosis uncertain</p> </li> <li> <p>Hydrocortisone 100 mg IV bolus then 50 mg q8h until stable: greater mineralocorticoid activity. Ideal if adrenal insufficiency known/confirmed or if hyperkalemic (K&gt;6.0)</p> </li> </ul>"},{"location":"endocrinology/endocrinology-stress-dose-steroids/#when-to-use","title":"When to Use","text":"<ul> <li>Concern for adrenal crisis</li> <li>Patients with known adrenal insufficiency:<ul> <li>Minor Illness: \u2191 dose x3 for 3 d or until clinically improved &amp; acute stress resolved</li> </ul> </li> <li>Surgery: dependent on severity of operation<ul> <li>Minor (e.g. hernia repair): hydrocortisone 25 mg for 1 day</li> <li>Moderate (e.g. cholecystectomy): 50-75 mg day of surgery and post-op day 1</li> <li>Major (e.g. CABG): 100-150 mg daily 2-3 days (would consult endocrine in this setting)</li> <li>Trauma, critical illness, or unclear give stress dose</li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-thyroid-nodules/","title":"Thyroid Nodules","text":"<p>Terra Swanson</p>"},{"location":"endocrinology/endocrinology-thyroid-nodules/#background","title":"Background","text":"<ul> <li> <p>~50% of adults will have a thyroid nodule on ultrasound</p> </li> <li> <p>Benign: goiter, cyst, inflammatory, Hashimoto\u2019s, follicular adenoma (microadenoma)</p> </li> <li> <p>Malignant: follicular, papillary, medullary, anaplastic, metastatic, thyroid lymphoma</p> </li> <li> <p>Risk factors for malignancy: age &lt;30, head or neck radiation, family history of thyroid cancer</p> </li> </ul>"},{"location":"endocrinology/endocrinology-thyroid-nodules/#evaluation","title":"Evaluation","text":"<ul> <li>TSH, Free T4, Thyroid U/S</li> </ul>"},{"location":"endocrinology/endocrinology-thyroid-nodules/#management","title":"Management","text":"<ul> <li> <p>If Low TSH: Likely a hyperfunctioning \"hot\" nodule (benign in 95% of cases)</p> <ul> <li> <p>Order Iodine-123 or technetium-99m thyroid scan</p> <ul> <li> <p>If hyperfunctioning \u2192 measure T3/free T4 if \u2191, treat for hyperthyroidism</p> </li> <li> <p>If non-functioning \u2192 proceed as if TSH were normal</p> </li> </ul> </li> </ul> </li> <li> <p>Normal or elevated TSH:</p> <ul> <li> <p>FNA indicated based on U/S findings listed below (determined by TI-RADS system)</p> <ul> <li> <p>Nodules &gt;1 cm that have high- or intermediate-suspicion pattern</p> </li> <li> <p>Nodules &gt;1.5 cm that have low-suspicion pattern</p> </li> <li> <p>Nodules &gt;2 cm that have very-low-suspicion pattern</p> </li> </ul> </li> </ul> </li> <li> <p>FNA cytology determines the plan of action:</p> <ul> <li> <p>Benign \u2192 periodic US monitoring at 12-24 months, then at increasing intervals</p> </li> <li> <p>Indeterminate \u2192 repeat FNA in 3-12 months</p> </li> <li> <p>Malignant \u2192 surgical referral</p> </li> </ul> </li> <li> <p>Nodules that do not meet FNA criteria, US findings determine the timing for follow-up imaging:</p> <ul> <li> <p>High suspicion: 6-12 months</p> </li> <li> <p>Low to intermediate suspicion: 12-24 months</p> </li> <li> <p>Nodules &gt;1 cm with very \u2193 suspicion OR pure cyst: &gt;24 months if at all</p> </li> </ul> </li> <li> <p>Nodules &lt;1 cm with very \u2193 suspicion OR pure cyst: no further imaging necessary</p> </li> </ul>"},{"location":"endocrinology/endocrinology-thyroid-storm/","title":"Thyroid Storm","text":"<p>Gaby Schroeder</p>"},{"location":"endocrinology/endocrinology-thyroid-storm/#background","title":"Background","text":"<ul> <li> <p>Diagnosis is based on recognition of exaggerated signs/symptoms of thyrotoxicosis leading to multi-organ dysfunction in the setting of precipitating event</p> </li> <li> <p>Common Precipitants: Grave\u2019s Disease, surgery, trauma, pregnancy, stress, infection, MI/PE, medication non-compliance, iodine loads</p> </li> <li> <p>Use Burch-Wartofsky Point Scale (BWPS); available on MD Calc</p> <ul> <li> <p>&gt; 45: highly suggestive</p> </li> <li> <p>25-44: impending storm</p> </li> <li> <p>\\&lt; Less than 25: unlikely to represent storm</p> </li> </ul> </li> </ul>"},{"location":"endocrinology/endocrinology-thyroid-storm/#management","title":"Management","text":"<ul> <li> <p>ENDOCRINE EMERGENCY - if suspected consult Endocrine ASAP</p> </li> <li> <p>Therapies directed towards thyroid gland</p> <ul> <li>PTU: Preferred because it inhibits peripheral conversion of T4 -&gt; T3 as well as production of T4, 500-1000mg loading dose, followed by 250mg q4 -6 hours (PO, rectal)</li> <li>Methimazole: q4-6 hours, dose varies (PO, rectal, IV)</li> </ul> </li> <li> <p>Therapies directed toward decreasing T4 to T3 conversion</p> <ul> <li>Propranolol (60-80mg PO q4)</li> <li>Hydrocortisone (300mg x1, 100mg q8) - treats high incidence of co-existing adrenal insufficiency</li> </ul> </li> <li> <p>Cholestyramine 4g QID can be considered to reduce enteric recirculation</p> </li> <li> <p>Refractory Storm: plasmapheresis and plasma exchange</p> </li> <li> <p>Close hemodynamic monitoring, may need vasopressors (consider transfer to ICU)</p> </li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-abdominal-pain/","title":"Acute Abdominal Pain","text":"<p>Alex Mamunes</p>"},{"location":"gastroenterology/gastroenterology-acute-abdominal-pain/#general-approach","title":"General Approach","text":"<ul> <li> <p>Rule out life threatening causes: Obstruction, Perforation,     Dissection, AAA rupture, Inferior MI, Ectopic Pregnancy</p> </li> <li> <p>History: pain quality/timing/location/severity, aggravating and     alleviating factors (eating, bowel movements, position),     nausea/emesis, bowel changes, flatus &amp; prior episodes</p> </li> <li> <p>Initial labs: CBC, BMP, LFTs, INR, lactate, lipase, U/A, urine hCG</p> </li> </ul> System Causes Common features Workup Esophagus Esophagitis \u2013 GERD, EOE, candida, HSV, CMV, pill, functional Epigastric pain, nocturnal reflux, odynophagia, dysphagia, thrush, immunocompromised Trial PPI, nystatin swish and swallow, consider EGD Stomach Dyspepsia Epigastric pain, indigestion, bloating H. pylori testing, Trial PPI, \u00b1 EGD Peptic ulcer disease NSAID use, better or worse w/ food, \u00b1 melena CBC, H. pylori testing, EGD Gastritis NSAID use, ETOH abuse, burning epigastric pain Liver Hepatitis: Ischemic, Viral, ETOH, trauma, toxins, autoimmune, congestive <p>RUQ pain \u00b1 jaundice</p> <p>EtOH, Tylenol or IVDU</p> LFTs, INR, ETOH, Tylenol lvl, viral panel, RUQ U/S + dopplers; CT Spleen Splenomegaly: increased size, infarct, abscess LUQ pain Physical exam, CT Biliary Biliary colic <p>Overweight, \u2640, 40\u2019s, lasts hrs, worse with food,</p> <p>RUQ pain scapula</p> LFTs, RUQ U/S Cholecystitis RUQ pain (Murphy\u2019s sign), nausea, emesis with fever Choledocholithiasis RUQ pain, N/V with jaundice CBC, LFTs, RUQ U/S, blood cx Ascending cholangitis RUQ pain, N/V, jaundice, fever; hypotension, AMS Pancreas Acute or chronic Pancreatitis; Complications (fluid, collection, necrosis, pseudocyst) <p>ETOH use, gallstones, epigastric pain back, N/V</p> <p>Chronic pancreatitis: calcifications on CT</p> Lipase, CT A/P (rarely necessary within 24-48 hrs), RUQ U/S for gallstones Intestines Gastroenteritis N/V, sick contact, undercooked food, travel Supportive care Diverticulitis Older, h/o diverticulosis, LLQ pain with fever <p>CBC (leukocytosis)</p> <p>CT A/P w contrast</p> Constipation h/o IBS, narcotic use, unable to pass stool, straining KUB Bowel Obstruction/Ileus Prior hernia, abd surgery or malignancy, pain, nausea, emesis, distention inability to pass stool or flatus <p>KUB (air fluid levels)</p> <p>CT is more sensitive</p> <p>If concerned, page EGS and consider NGT to suction</p> Acute Small Bowel Mesenteric Ischemia Vascular disease, A-Fib, dissection, thrombosis, rapid onset, severe, periumbilical with N/V, recent hypotensive episode, post-prandial <p>CBC (leukocytosis)</p> <p>BMP (metabolic acidosis), Lactate</p> <p>CT A/P w contrast (CTA if suspicion)</p> Colonic non-occlusive Mesenteric Ischemia: ischemic colitis Cramping pain, laterally (most often left), urge to defecate + hematochezia <p>CBC, BMP, Lactate</p> <p>CT A/P w contrast</p> <p>+/- colonoscopy</p> Appendicitis Periumbilical to RLQ with N/V, later fever CBC, Lactate, CT A/P w/contrast IBD Flare H/o Crohn\u2019s or UC, Abd pain, fever, diarrhea, hematochezia CBC, Lactate, CTE, ESR, CRP, C-diff, GIPP C. diff colitis Antibiotic exposure, diarrhea, abdominal cramping <p>C-diff PCR, CBC (leukocytosis)</p> <p>KUB (megacolon)</p> Ogilvie\u2019s syndrome Pseudo-obstruction in elderly pt, signs of obstruction w/o mechanical cause CBC, lactate, CT A/P w contrast Volvulus Progressive abdominal pain, nausea, distention, constipation, vomiting <p>CBC, lactate</p> <p>CT A/P w contrast</p> Typhlitis Neutropenia, abdominal pain (often RLQ), fever <p>CBC with diff, CT A/P w/ contrast, blood cx, C-diff;</p> <p>empiric abx</p> OBGYN Ectopic pregnancy Sexually active, 6-7 wks after LMP, RLQ or LLQ pain + vaginal bleeding Urine hCG, pelvic US, CBC, T&amp;S <p>Pelvic inflammatory disease, endometritis,</p> <p>Tubo-ovarian abscess</p> Sexually active, h/o STI, purulent discharge, cervical motion tenderness, \u00b1 fever Pelvic exam w/ culture, GC probe, pelvic US Ovarian torsion Young, sudden onset &amp; severe, often with N/V Pelvic US w/ doppler Kidney Nephrolithiasis h/o kidney stones, Crohn\u2019s disease, sharp flank pain, paroxysms, \u00b1 hematuria U/A, CT A/P without contrast UTI Suprapubic pain, dysuria, cloudy urine, new odor U/A with culture Pyelonephritis Flank pain, fever/chills, CVA tenderness, usually UTI symptoms <p>U/A with culture, BMP</p> <p>CT A/P w/contrast</p> Urinary Retention Older pt, male with BPH, anticholinergics Post-void residual Renal infarct h/o vascular disease or A-fib, acute flank pain with N/V, +/- fever, HTN <p>CBC, BMP, UA, ECG (r/o a-fib)</p> <p>CT A/P w contrast</p> Vascular Myocardial infarction CAD risk factors, DoE, epigastric, diaphoresis ECG, troponin Aortic Dissection Vascular Risk factors, sudden onset, tearing pain back CT dissection rule out AAA rupture Vascular risk factors, sudden onset back, hypotensive, pulsatile abdominal mass CT A/P w contrast, consult vascular surgery MSK/skin Herpes zoster Immunocompromised, dermatomal rash, burning pain <p>Physical exam</p> <p>Vesicle PCR for zoster</p> Muscle strain h/o trauma, overuse, heavy exercise, worse with twisting or bending Physical exam; rest, NSAIDs Hernia Bulge, worse w/valsalva CT A/P non con Pulmonary Pneumonia Productive cough, fever CXR, CBC, sputum cx Pulmonary embolus Tachycardia, tachypnea, hypoxemia <p>ECG, trop, BNP</p> <p>CTA chest</p> Functional IBS, depression, dyspepsia, anxiety abdominal migraine, functional <p>Imaging negative</p> <p>Otherwise negative workup</p> Above workup Other Adrenal crisis Hypotension, fatigue, lethargy, N/V, weight loss, hyperpigmentation BMP (\u2193Na, \u2191K, \u2193 Glu) Cort. stim Intra-abdominal abscess Prior intra-abdominal disease or surgery, fever <p>CBC, blood cx</p> <p>CT A/P w/ contrast</p> DKA Nausea, emesis, general abdominal pain <p>CBC, BMP, U/A</p> <p>\u03b2\u2013hydroxy butyrate</p> Hypercalcemia <p>N/V, constipation,</p> <p>\u2191 thirst, \u2191 urination, bone pain, muscle weakness, confusion, fatigue</p> BMP, ionized calcium, PTH, Vit D, PTHrp Acute intermittent porphyria Severe, poorly localized with motor/sensory neuropathy, red urine, tachycardia Urinary PBG"},{"location":"gastroenterology/gastroenterology-acute-diverticulitis/","title":"Acute Diverticulitis","text":"<p>Michael Koenig</p>"},{"location":"gastroenterology/gastroenterology-acute-diverticulitis/#background","title":"Background","text":"<ul> <li>Inflammation and/or infection of a diverticulum, a small     out-pouching along wall of colon</li> <li>Presence of colonic flora on urine culture or pneumaturia suggests     colovesical fistula</li> <li>Most pts with uncomplicated diverticulitis have significant     improvement 2-3 days after antibiotics</li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-diverticulitis/#presentation","title":"Presentation","text":"<ul> <li>Lower abdominal pain (85% LLQ), tenderness to palpation on exam,     N/V, low-grade fever, change in bowel habits (constipation or     diarrhea)</li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-diverticulitis/#evaluation","title":"Evaluation","text":"<ul> <li>CBC w/diff, CMP, Lipase, U/A, \u03b2 - hCG</li> <li>Imaging: CT abdomen/pelvis with oral and IV contrast</li> <li>CT findings: localized bowel wall thickening (&gt;4mm), paracolic fat     stranding, presence of colonic diverticula</li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-diverticulitis/#management","title":"Management","text":"<ul> <li>Bowel rest vs. clear liquids (advance diet as tolerated)</li> <li>PO or IV antibiotics: should cover GNRs and anaerobic organisms</li> <li>Zosyn, cefepime + metronidazole, or meropenem (if high risk for     organisms w/ESBL)</li> <li>Cipro/flagyl if PO</li> <li>If low risk and mild disease, may not need antibiotics</li> <li>Continue IV abx until abdominal pain/tenderness is resolved (usually     3-5 days), then transition to oral: cipro + metronidazole or     Augmentin to complete 10-14 d course</li> <li>Colonoscopy after complete resolution of symptoms (6 \u2013 8 weeks) to     definitively rule out presence of underlying colorectal cancer     (unless performed in last year)</li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-diverticulitis/#complications","title":"Complications","text":"<ul> <li>Pts who fail to improve or deteriorate require repeat imaging</li> <li>Abscess continue antibiotics &amp; percutaneous drainage (if possible)     for abscesses &gt; 4 cm</li> <li>Surgery if no improvement 2-3 days after drainage</li> <li>Obstruction: radiographic differentiation between acute     diverticulitis and colon cancer is difficult; thus surgical     resection of bowel is needed to relieve obstruction and rule out     cancer</li> <li>Fistula: Rarely heal spontaneously, require surgical correction</li> <li>Perforation:<ul> <li>Microperforation (contained perforation):</li> <li>Presence of small amount of air bubbles, but no oral contrast     outside of colon on CT</li> <li>Most treated with IV abx and bowel rest like uncomplicated     diverticulitis</li> <li>Frank perforation:<ul> <li>Intraabdominal free air, diffuse peritonitis requires emergency     surgery</li> </ul> </li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-pancreatitis/","title":"Acute Pancreatitis","text":"<p>Alex Wiles</p>"},{"location":"gastroenterology/gastroenterology-acute-pancreatitis/#background","title":"Background","text":"<ul> <li>Common causes: Gallstones (40%), EtOH (30%)</li> <li>Other causes: post-ERCP, pancreatic cancer/obstruction, blunt     abdominal trauma, hypertriglyceridemia (TG &gt;1000), hypercalcemia,     drugs (thiazides, protease inhibitors, azathioprine, 6MP), mumps,     Coxsackie, vasculitis, pregnancy, genetic (PRSS1, SPINK1, CFTR),     autoimmune (IgG4), scorpion venom</li> <li>Several scoring systems:<ul> <li>BISAP (BUN &gt;25, Impaired mental status, SIRS, Age &gt;60, Pleural effusion)<ul> <li>0\u20132 Mortality &lt;2%; 3-5 Mortality &gt;15%</li> </ul> </li> <li>APACHE II (MD Calc, several factors)<ul> <li>0\u20138 Mortality &lt;4%; &gt; 8 Mortality 11\u201318%</li> </ul> </li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-pancreatitis/#presentation","title":"Presentation","text":"<ul> <li>Must have 2 out of the three:<ul> <li>Pain characteristic of pancreatitis (sharp, epigastric, radiating to back)</li> <li>Imaging characteristic of pancreatitis (US, CT, MRI)</li> <li>Enzymes (lipase or amylase) &gt;3x ULN (use lipase, much more specific)</li> <li>*If pain is characteristic and lipase &gt; 3x ULN, no need for CT A/P</li> </ul> </li> <li>Grading Severity:<ul> <li>Mild: no organ failure or systemic complications</li> <li>Moderate: transient organ failure (&lt;48 hours)</li> <li>Severe: persistent organ failure (&gt;48 hours)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-pancreatitis/#evaluation","title":"Evaluation","text":"<ul> <li>Lipase, CBC, CMP, lipid panel, lactate, direct bilirubin</li> <li>Obtain RUQ U/S for all pts, evaluates for gallstones</li> <li>CT A/P w/ IV contrast if indicated<ul> <li>Reserved for patients not improving at 48-72 hour to assess for complications</li> <li>If performed at onset, underestimates severity (necrosis takes 72 hours from onset)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-pancreatitis/#management","title":"Management","text":"<ul> <li>Fluids, Fluids, Fluids:<ul> <li>First 12-24 hrs: IVF at 200 to 500 cc/hr, or 5-10 cc/kg / hr (2.5 \u2013 <p>4 L within first 24 hrs)</p> </li> <li>Follow HCT and BUN as markers for successful fluid resuscitation</li> <li>Aggressive IVF in first 24 hours reduces both morbidity and mortality</li> <li>Persistent hemoconcentration at 24 hr is associated with necrotizing pancreatitis</li> </ul> </li> <li>Pain Control:<ul> <li>Common starting narcotic regimen is oxycodone 10 mg q6h PRN and hydromorphone 0.5 mg q4h for breakthrough</li> </ul> </li> <li>Nutrition:<ul> <li>NPO but start PO diet as soon as patient can tolerate (even within 24 hours)</li> <li>Clear liquid diet or mechanical soft and advance as tolerated</li> <li>Low fat diet (Fatty acids \u2192 CCK \u2192 trypsinogen to trypsin)</li> <li>If NPO &gt; 72 hours, attempt PO and if fail, place Dobhoff for enteral nutrition at latest by day five\u2026 outcomes with NG/NJ &gt;&gt;&gt; TPN</li> </ul> </li> <li>Antibiotics:<ul> <li>Fever, leukocytosis common, not an indication for ABX as the necrosis is sterile</li> <li>Infection of the necrosis should be suspected with failure to improve 7 days after onset</li> <li>Cefepime + Flagyl or carbapenem</li> </ul> </li> <li>EUS or IR guided drain for aspirate: can be done on immature     collections for diagnostic purposes but typically only done if     collection is walled-off\u2014at least 4 weeks</li> <li>Endoscopic Intervention (cystogastrostomy) has emerged as first-line     therapy for symptomatic pseudocysts or walled-off pancreatic     necrosis , with step-up therapy to video assisted retroperitoneal     debridement (VARD) or surgery when needed</li> </ul>"},{"location":"gastroenterology/gastroenterology-acute-pancreatitis/#additional-information","title":"Additional Information","text":"<ul> <li>If choledocholithiasis on Imaging urgent ERCP for patients with     cholangitis or obstructive jaundice, otherwise elective ERCP</li> <li>If Intermediate probability for choledocholithiasis MRCP or EUS or     (for patients requiring cholecystectomy Intraoperative cholangiogram</li> <li>If biliary sludge but no stones on U/S, still consider     cholecystectomy (likely microlithiasis)</li> <li>Complications:<ul> <li>ARDS, abdominal compartment syndrome, AKI, DIC</li> <li>&lt; 4 weeks after pancreatitis: Peripancreatic fluid collection, acute necrotic collection</li> <li> <p>6 weeks after pancreatitis: Pancreatic pseudocyst, walled-off necrosis (WON)</p> </li> </ul> </li> <li>Most fluid collections should be followed over time as acute     collections can resolve and are unable to be sampled safely with EUS</li> <li>Gallstone pancreatitis:<ul> <li>All pts should have cholecystectomy once recovered (recurrence is 25-30%) with EGS</li> <li>Performed during initial admission in cases of mild acute pancreatitis</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-biliary-disease/","title":"Biliary Disease","text":"<p>Alex Wiles, Anton de Witte</p>"},{"location":"gastroenterology/gastroenterology-biliary-disease/#pearls","title":"Pearls","text":"<ul> <li>ERCP is not available at VA: requires fee-basis consult to VUMC,     contact GI to arrange</li> <li>Prior cholecystectomy CBD normally dilates to 10 mm, not pathologic</li> <li>Pneumobilia generally indicates performance of prior biliary     sphincterotomy and/or biliary stent</li> <li>CBD dilation classically &gt; 6mm, but CBD dilates with age: 70 yo     7mm, 80 yo 8mm; opiates can also cause biliary dilatation</li> </ul>"},{"location":"gastroenterology/gastroenterology-biliary-disease/#biliary-colic","title":"Biliary Colic","text":"<ul> <li>Transient biliary obstruction typically at the GB neck without GB     inflammation (no fever)</li> <li>Presentation: Constant (not colicky) intense, dull RUQ pain and N/V     for 30 minutes to 6 hours, then resolves, provoked by fatty foods     (CCK), absent Murphy\u2019s sign</li> <li>Biliary colic generally consists of discrete episodes separated by     weeks to months, and not daily pain</li> <li>Evaluation: Normal (CBC, LFTs, Lipase, Lactate)</li> <li>Imaging: RUQ U/S: cholelithiasis (stones in GB)</li> <li>Management: Elective cholecystectomy as outpatient</li> </ul>"},{"location":"gastroenterology/gastroenterology-biliary-disease/#acute-calculous-cholecystitis","title":"Acute Calculous Cholecystitis","text":"<ul> <li>Inflammation of the GB from an obstructing stone in the GB neck or     cystic duct</li> <li>Ddx: PUD, pancreatitis, choledocholithiasis, ascending cholangitis,     IBD, Fitz-Hugh Curtis</li> <li>Presentation: Severe constant RUQ pain, fever/chills, N/V, + Murphy     sign</li> <li>Evaluation: CBC (leukocytosis), CMP (mild AST/ALT \u2191), Lipase,     Lactate, BCx x2</li> <li>Imaging: RUQ U/S: gallstones + GB wall thickening or pericholecystic     edema<ul> <li>If U/S non-diagnostic (no stones or GB inflammation) HIDA Scan (lack of GB filling)</li> </ul> </li> <li>Management<ul> <li>NPO, IVF, IV Abx until resolved or surgical removal</li> <li>Urgent Cholecystectomy (&lt;72H) with EGS;</li> <li>If poor surgical candidate: Cholecystostomy with IR; endoscopic drainage options for selected patients (i.e. poor surgical candidates also with ascites)</li> </ul> </li> <li>Complications: gangrenous cholecystitis, perforation, emphysematous     cholecystitis, chole-cysto-enteric fistula, gallstone ileus</li> </ul>"},{"location":"gastroenterology/gastroenterology-biliary-disease/#acute-acalculous-cholecystitis","title":"Acute Acalculous Cholecystitis","text":"<ul> <li>Inflammation of the GB without obstructing stone (due to stasis and     ischemia)</li> <li>Presentation: Seen in critically ill/ICU pts; similar history as     above; may present as unexplained fever or RUQ mass (rarely     jaundice)</li> <li>Ddx: calculous cholecystitis, pancreatitis, hepatic abscess</li> <li>Evaluation: Same as acute calculous cholecystitis</li> <li>Imaging: GB wall thickening, pericholecystic edema, intramural gas,     GB distention</li> <li>Management<ul> <li>Supportive care, antibiotics, GB drainage</li> <li>IVF, correct electrolyte abnormalities, NPO</li> <li>Broad spectrum antibiotic coverage</li> <li>Place CT-guided procedure consult for cholecystostomy placement vs Endoscopic drainage (transpapillary cystic duct stent via ERCP or cholecystoduodenostomy by EUS)</li> <li>Consult EGS if necrosis, perforation, or emphysematous changes present</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-biliary-disease/#choledocholithiasis","title":"Choledocholithiasis","text":"<ul> <li>Obstruction of biliary outflow by CBD stone without inflammation (no     fever)</li> <li>Impacted cystic duct stone (cholecystitis) with compression of the     CBD (Mirizzi syndrome)</li> <li>Presentation: RUQ pain (can be painless), N/V and jaundice</li> <li>Evaluation:<ul> <li>CMP and D-bili (Bili/ALP/ GGT \u2191\u2191\u2191, AST/ALT mild \u2191), CBC (Leukocytosis suggests cholangitis), Lipase</li> <li>Imaging: RUQ U/S: dilated CBD (ULN is 6mm) MRCP/EUS vs ERCP (see below)<ul> <li>MRCP preferred given non-invasive but has lower sensitivity for smaller stones (consider EUS if still have suspicion despite negative MRCP or if patient contraindication to/intolerance of MRI)</li> </ul> </li> </ul> </li> <li>Management:<ul> <li>NPO &amp; IVF, pain control PRN</li> <li>Stratify risk to determine whether to pursue MRCP (noninvasive, diagnostic) vs ERCP</li> <li>If any one of the following, patient is HIGH risk consult GI for <p>ERCP + EGS to consider cholecystectomy</p> <ul> <li>CBD stone on imaging</li> <li>Acute cholangitis</li> <li>Tbili &gt; 4 AND dilated CBD (&gt;6mm with GB, &gt; 8mm without GB)</li> </ul> </li> <li>If any one of the following, patient is INTERMEDIATE risk consider     MRCP (or EUS or cholecystectomy with intraoperative cholangiogram)<ul> <li>Abnormal liver enzymes</li> <li>Age &gt; 55</li> <li>Dilated CBD on U/S with Tbili &lt; 4</li> <li>If CBD stone seen on MRCP or EUS ERCP,</li> <li>If no CBD stone but patient has GB sludge or cholelithiasis EGS     consult for cholecystectomy + intraoperative cholangiogram</li> </ul> </li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-biliary-disease/#acute-cholangitis","title":"Acute Cholangitis","text":"<ul> <li>Bacterial infection of biliary tract 2/2 obstruction (typically     stones) or prior instrumentation (ERCP)</li> <li>Pts with malignant obstruction typically do not develop cholangitis</li> <li>Presentation: Charcot triad (RUQ pain, fever, jaundice); Reynolds\u2019     Pentad (AMS, Hypotension)</li> <li>Evaluation<ul> <li>CBC, CMP (D bili, ALP \u2191\u2191\u2191) Blood Cultures, Lipase, Lactate</li> <li>CRP, AST/ALT can be \u2191\u2191 as well</li> <li>Imaging: RUQ U/S: dilated CBD (ULN is 6mm), no need for MRCP/EUS</li> <li>Consider MRCP overnight if ERCP is not being done emergently</li> </ul> </li> <li>Management<ul> <li>NPO, IVF</li> <li>Consult GI for urgent/emergent ERCP (generally within 24 hr)</li> <li>If ERCP not feasible or fails to establish biliary drainage, can consider EUS-guided biliary drainage, percutaneous transhepatic cholangiography, or surgical decompression</li> <li>Antibiotics for Biliary Disease (IDSA Guidelines):<ul> <li>Mild to moderate acute cholecystitis (stable):</li> <li>Ceftriaxone 2g daily, Cefazolin 1-2g q8H</li> </ul> </li> <li>Cholangitis or Severe acute cholecystitis (unstable or immunocompromised):<ul> <li>Zosyn 3.375g q8H, Meropenem 1g q8H or Cipro 500 q12H and Flagyl 500 q8H</li> </ul> </li> <li>Healthcare-associated Biliary infections: consider Vancomycin     (order w/ PK consult)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-c-diff/","title":"Clostridioides Difficile Infections","text":"<p>Anton de Witte</p>"},{"location":"gastroenterology/gastroenterology-c-diff/#background","title":"Background","text":"<ul> <li>Clostridioides difficile is the causative bacteria for     antibiotic-associated colitis</li> <li>Always consider C. diff in a hospitalized patient with unexplained     leukocytosis</li> <li>Microbiology: Anaerobic gram-positive, spore-forming,     toxin-producing bacillus</li> <li>Outside colon, exists in spore form \u2013 resistant to heat, acid, and     antibiotics (why we must wash our hands)</li> <li>Spores are transferred from environment to person, once in intestine     convert to functional vegetative, toxin-producing forms susceptible     to antibiotics</li> <li>To be pathogenic, must release toxin (A+B) to cause colitis and     diarrhea</li> <li>Risk Factors: Antibiotic use (during use or typically up to 1 month     after use), age &gt;65, hospitalization, enteral feeding, obesity,     stem cell transplant, chemo, IBD, cirrhosis, \u00b1 PPI use (no clear     causal relationship)</li> </ul>"},{"location":"gastroenterology/gastroenterology-c-diff/#presentation","title":"Presentation","text":"<ul> <li>Spectrum from asymptomatic carrier to fulminant colitis with toxic     megacolon</li> <li>Asymptomatic carrier: 20% of hospitalized patients (50% of adults in     long term care facilities)</li> <li>Non-severe disease: watery diarrhea (&gt;3 unformed stools in 24     hours), lower abdominal pain, nausea, \u00b1 fever, leukocytosis (WBC     &gt;15,000)</li> <li>Severe disease: diarrhea, diffuse abdominal pain, abdominal     distention, fever, lactic acidosis, AKI (Cr &gt; 1.5), marked     leukocytosis (sometimes &gt;40,000)</li> <li>Fulminant disease: Severe criteria + hypotension/shock, ileus     (rare), or megacolon (&gt;7cm colon diameter and/or &gt;12cm cecum     diameter)</li> <li>Recurrent disease (relapse &gt; reinfection): resolution of symptoms     on therapy followed by reappearance of symptoms within 2-8 weeks     after stopping therapy; (Up to 25% of patients have recurrence)</li> <li>If symptoms never resolve, consider refractory C. diff or     alternative diagnosis</li> </ul>"},{"location":"gastroenterology/gastroenterology-c-diff/#evaluation","title":"Evaluation","text":"<ul> <li>Stool PCR for toxigenic strains (very sensitive, can detect     asymptomatic carriers w/o toxin production); with reflex EIA (enzyme     immunoassay) for toxins A and B (specificity of 99%)<ul> <li>PCR (+)/Toxin (-) = carrier</li> <li>PCR (+)/Toxin (+) = treat</li> <li>PCR (-) = no treatment</li> </ul> </li> <li>Imaging<ul> <li>Nonsevere disease: no imaging necessary</li> <li>Severe or fulminant disease: CT a/p with oral and IV contrast</li> </ul> </li> <li>Endoscopy: Typically used when alternative diagnosis is suspected;     not warranted for classical symptoms, positive laboratory tests, or     clinical response to treatment</li> </ul>"},{"location":"gastroenterology/gastroenterology-c-diff/#management","title":"Management","text":"<ul> <li>Contact precautions until at least 48 hours after diarrhea resolves</li> <li>Classify patient disease severity to guide treatment algorithm</li> <li>Do not repeat stool testing \u2013 50% remain positive after treatment up     to 6 weeks later</li> </ul> Clinical Condition Treatment Non-fulminant disease Initial episode (non-severe or severe) <p>-First line: PO Vancomycin 125mg QID x 10 days OR PO Fidaxomicin 200mg BID x 10 days</p> <p>-Second line: (only for non-severe disease in low-risk patients): PO Metronidazole 500mg TID x 10-14 days</p> Recurrent episode <p>Consult GI</p> <p>First Recurrence:</p> <p>-First line: PO Fidaxomicin 200mg BID x 10 days</p> <p>-Second line: Vancomycin Taper (PO 125mg QID x 14 days PO 125mg BID x 7 days PO 125mg QD x 7 days PO 125mg q72h x 2-8 weeks)</p> <p>-Adjunctive therapy: IV Bezlotoxumab 10mg/kg x1</p> <p>Second or Further Recurrence:</p> <p>-Same as above</p> <p>-Consider Fecal Microbiota Transplantation (FMT)</p> Fulminant disease Fulminant disease <p>Consult GI and EGS</p> <p>Ileus Absent:</p> <p>-PO Vancomycin 500mg QID + IV Metronidazole 500mg TID</p> <p>Ileus Present</p> <p>-Same as above + consider Vancomycin enemas 500mg q6h</p> <p>Consider colectomy or FMT</p>"},{"location":"gastroenterology/gastroenterology-chronic-pancreatitis/","title":"Chronic Pancreatitis","text":"<p>AJ De Witte</p>"},{"location":"gastroenterology/gastroenterology-chronic-pancreatitis/#definition","title":"Definition","text":"<p>A syndrome characterized by irreversible chronic progressive pancreatic inflammation, fibrosis, and scarring, resulting in damage to and loss of exocrine (acinar), endocrine (islet cells), and ductal cells</p>"},{"location":"gastroenterology/gastroenterology-chronic-pancreatitis/#etiology","title":"Etiology","text":"<p>TIGAR-O mnemonic</p> <ul> <li>Toxic Metabolic: EtOH, tobacco use, hyperCa (Ca &gt; 12), HLD     (fasting TG &gt; 300, nonfasting &gt; 500), CKD 5, medications, toxins</li> <li>Idiopathic: early onset (age \\&lt; 35), late onset (age &gt; 35)</li> <li>Genetic: Autosomal dominant (PRSS1 gene), recessive (CFTR,     SPINK1, etc.)</li> <li>Autoimmune: IgG4-related (AIP type 1), AIP type 2</li> <li>Recurrent, severe acute pancreatitis</li> <li>Obstructive: pancreas divisum, ampullary stenosis, main duct     pancreatic stones or strictures, widespread calcifications, mass     causing duct obstruction</li> </ul>"},{"location":"gastroenterology/gastroenterology-chronic-pancreatitis/#presentation","title":"Presentation","text":"<ul> <li>Abdominal pain (most common)</li> <li>Exocrine insufficiency: diarrhea, steatorrhea, weight loss<ul> <li>Typically occurs later in disease process</li> </ul> </li> <li>Endocrine insufficiency: diabetes</li> <li>Occasionally asymptomatic</li> </ul>"},{"location":"gastroenterology/gastroenterology-chronic-pancreatitis/#evaluation","title":"Evaluation","text":"<ul> <li>Imaging: CT or MRI (may be negative early in course of disease)<ul> <li>If CT or MRI negative but suspicion for CP remains high,     consider EUS \u00b1 biopsy or secretin-enhanced MRCP</li> </ul> </li> <li>Labs:<ul> <li>BMP, LFTs, lipid panel, PeTH</li> <li>Consider genetic testing, especially in younger patients and/or     patients without clear etiology</li> <li>Pancreatic function testing diagnoses exocrine insufficiency but     is not necessary for diagnosis of CP<ul> <li>Gold standard = 72-hour fecal fat (&gt; 7g of fat per 100g     stool per day) - rarely done</li> <li>More practical = fecal elastase (&lt;100 = diagnostic, 100-200     = indeterminate)<ul> <li>Must be performed on formed stool, can be false positive     If watery specimen</li> <li>Do not have to stop pancreatic enzymes to measure</li> </ul> </li> </ul> </li> <li>Lipase and amylase levels can be elevated, but are usually     normal due to pancreatic scarring and fibrosis</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-chronic-pancreatitis/#management","title":"Management","text":"<ul> <li>Tobacco and EtOH cessation</li> <li>Pancreatic enzyme replacement therapy if evidence/diagnosis of     exocrine insufficiency<ul> <li>Usual dose: 50,000 units/meal + 25,000 units with snacks</li> <li>Should take with first bite of a meal and consider adding extra     enzymes or splitting up dose throughout meal if lasting longer     than 15 mins</li> <li>If lack of response: try increasing dose, confirm compliance,     add PPI, split up dose throughout meal, look for concurrent GI     disorders</li> </ul> </li> <li>Pain: Tylenol + NSAIDs &gt; Opioids (Tramadol), consider SSRI/SNRI/TCA     or gabapentin<ul> <li>For refractory pain, other options include celiac plexus     blockade or total pancreatectomy with islet auto transplant</li> </ul> </li> <li>Vitamin supplementation + Vit D + Ca</li> <li>Consider antioxidants (selenium, ascorbic acid, \u03b2-carotene, and     methionine, vitamin E) \u2013 mixed evidence but some studies have shown     improved pain control</li> <li>Routine testing for osteoporosis and fat-soluble vitamin     deficiencies</li> </ul>"},{"location":"gastroenterology/gastroenterology-constipation/","title":"Constipation","text":"<p>Chelsie Sievers</p>"},{"location":"gastroenterology/gastroenterology-constipation/#background","title":"Background","text":"<ul> <li>Definition: presence of lumpy/hard stools, straining, use of digital     maneuvers, sensation of incomplete evacuation, frequency \\&lt;3 BM per     week.</li> <li>Common etiologies: opioid-induced, medications (anti-depressants,     iron, anticholinergics) hypothyroidism, hypokalemia, pregnancy, IBS,     neurogenic (trauma, MS, Parkinson disease, diabetes, autonomic     dysregulation).</li> <li>Always think about risk of obstruction (prior abdominal surgeries,     oncology history or risk for GI/GU malignancies, history of     IBD/Crohn\u2019s).</li> </ul>"},{"location":"gastroenterology/gastroenterology-constipation/#evaluation","title":"Evaluation","text":"<ul> <li>Evaluate etiologies plus lifestyle factors (low fiber intake, low     fluid intake, reduced mobility, acute illness)</li> <li>Clinical diagnosis, no need for imaging unless concerned for     obstruction \u2192 KUB/ CT</li> <li>BMP + Mg to evaluate electrolytes, consider TSH if chronic</li> <li>Rectal exam to exclude rectal mass or fecal impaction     (constipation + diarrhea doesn\u2019t exclude impaction/obstruction.     Overflow around mass = encoparesis)</li> </ul>"},{"location":"gastroenterology/gastroenterology-constipation/#management","title":"Management","text":"<ul> <li>Stop or minimize offending medications if possible</li> <li>Optimize lifestyle factors: out of bed, walking hallways, increase     fluid intake, + cup of coffee if appropriate.</li> <li>Escalating pathway: ensure meds are scheduled not PRN<ul> <li>MiraLAX (PEG) 17g BID (can give TID) + Senna nightly (can     &gt; increase to BID and/or 2 tabs) \u2192 Bisacodyl suppository \u2192 enema     &gt; (tap water or SMOG) \u2192 stronger osmotic laxative (lactulose     &gt; 20mg once, Mag-citrate, Golytely) \u2192 escalate lactulose dosing     &gt; 20 \u2013 30 mg q2hrs</li> </ul> </li> <li>Other considerations:<ul> <li>Avoid Fleet enemas (sodium-phosphate) in CKD and geriatric     &gt; populations</li> <li>\u201cThe hand that writes for opioids also writes a bowel regimen\u201d<ul> <li>Generally, start with scheduled MiraLAX (PEG) 17g daily +   senna nightly</li> <li>If severe and unrelieved by escalating therapies, can try   methylnaltrexone</li> </ul> </li> <li>Lactulose can cause severe bloating and cramping</li> <li>In patients unable to take PO: place DHT to deliver meds or     rectal lactulose (important for patients with cirrhosis with     AMS/HE).</li> <li>In patients with CF (at risk for distal intestinal obstruction     syndrome): ensure have pancreatic enzymes ordered, managed     more like constipation than true obstruction: PO/ NGT MiraLAX     QID or Golytely.</li> <li>Acute colonic pseudo-obstruction (Ogilvie's syndrome): &gt;12cm     cecal diameter = severe dilation, risk of perforation. Treated     with neostigmine, 2mg IV over 3 to 5 minutes. Monitor for     bradycardia, hypotension, and dysrhythmias (relative     contraindications: recent MI, asthma, PUD, epilepsy).     Decompression with colonoscopy used in some cases.</li> <li>Consider pelvic floor dysfunction, pelvic floor PT may be     helpful</li> </ul> </li> </ul> Laxatives Mechanism Examples Effects Bulking-agent Psyllium seed (Metamucil), methylcellulose (Citrucel) Absorb water and increase fecal bulk Osmotic Laxatives Polyethylene glycol (PEG = MiraLAX and Golytely), lactulose, mag-citrate Hyperosmotic substances, pull fluid into GI tract Stimulant Laxative Senna, Bisacodyl (Dulcolax) Stimulates peristalsis Stool Softener Docusate (Colace) Generally ineffective Opioid antagonist Methylnaltrexone (Reslistor) Peripheral acting opioid antagonist, inhibits opioid-induced decreased gastrointestinal motility cGMP Agonist Linaclotide (Linzess), Plecanatide (Trulance) Stimulates intestinal secretion of Cl-/HCO3- Prostaglandin derivative Lubiprostone (Amitiza) Increases intestinal chloride-rich fluid secretion"},{"location":"gastroenterology/gastroenterology-diarrhea/","title":"Diarrhea","text":"<p>Charles Oertli</p>"},{"location":"gastroenterology/gastroenterology-diarrhea/#background","title":"Background","text":"<ul> <li> <p>3 BM/day OR abnormally loose stool</p> </li> <li>Acute (&lt;2 weeks), persistent (2-4 weeks), or chronic (&gt;4 weeks)</li> <li>95% of acute diarrhea is self-limited &amp; no additional treatment     needed</li> <li>Most cases of acute diarrhea are due to infections</li> <li>Non-infectious etiologies become more common with increasing     duration</li> <li>Voluminous watery diarrhea more likely disorder of small bowel</li> <li>Small volume frequent diarrhea more likely disorder of colon</li> <li>Nocturnal diarrhea suggests an inflammatory or secretory etiology</li> </ul>"},{"location":"gastroenterology/gastroenterology-diarrhea/#acute-diarrhea","title":"Acute Diarrhea","text":""},{"location":"gastroenterology/gastroenterology-diarrhea/#etiology","title":"Etiology","text":"<ul> <li>Watery diarrhea: viral gastroenteritis (norovirus, rotavirus,     enteric adenovirus), C. diff, C. perfringens, S. Aureus, Bacillus     cereus, enterotoxigenic E. coli, Cryptosporidium, Listeria,     Cyclospora, vibrio cholerae, (Giardia is typically more chronic),     Tropheryma whipplei, COVID</li> <li>Inflammatory diarrhea: Salmonella, Campylobacter, Shigella, EHEC,     Yersinia, E histolytica, invasive viruses (CMV, HSV), Non-cholera     vibrio. Look for red flag symptoms (see below).</li> <li>Medications, specifically antibiotics</li> </ul>"},{"location":"gastroenterology/gastroenterology-diarrhea/#presentation","title":"Presentation","text":"<ul> <li>Evaluate for red flags (BATS are Vulnerable vampires)<ul> <li>Bloody stools,</li> <li>Antibiotics/Recent hospitalization<ul> <li>Any antibiotic can cause C. diff; the longer the treatment, the   more likely</li> <li>Most common to cause C. diff: Clindamycin &gt;&gt;   Penicillins/Cephalosporins/Fluoroquinolones</li> </ul> </li> <li>Too many stools: &gt;6 unformed stools/day</li> <li>Sepsis (Fever) or Severe abdominal pain</li> <li>Vulnerable (Age &gt;70 yr, immunocompromised, IVDU, IBD, pregnant, travel)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-diarrhea/#evaluation","title":"Evaluation","text":"<ul> <li>All patients: CBC w/ diff and BMP to eval for leukocytosis (C.diff),     AKI, electrolyte abnormalities, thrombocytopenia/anemia (HUS),     eosinophilia (parasites)</li> <li>If red flag symptoms or diarrhea &gt; 7d: ESR/CRP, C.diff, GIPP</li> <li>If immunocompromised: consider CMV, MAC, microsporidia</li> <li>If abdominal pain: consider CT A/P with IV contrast</li> <li>If concern for IBD or hx of IBD: CT Enterography with PO and IV     contrast</li> <li>Blood Cultures if febrile/septic</li> </ul>"},{"location":"gastroenterology/gastroenterology-diarrhea/#management","title":"Management","text":"<ul> <li>All patients: supportive care with PO or IVF, electrolyte repletion</li> <li>If C.diff negative or treatment for C.diff started, ok for     symptomatic treatment with Loperamide<ul> <li>Start with Loperamide 4mg x1 then transition to 2mg QID (AC+HS)     (maximum 16mg/day)</li> <li>If fever or inflammatory symptoms and C.diff not back, ok for     Bismuth subsalicylate (Pepto-Bismol) 30mL or 2 tablets q30min x8</li> </ul> </li> <li>Indications for antibiotics:<ul> <li>GIPP negative for Shigella, 0157:H7 (can precipitate HUS) and salmonella (can prolong carrier state)</li> <li>Empiric antibiotic therapy ONLY if toxic appearance or high concern for progressive illness/decompensation</li> <li>Ciprofloxacin 500 mg BID or levofloxacin 500 mg daily x 3-5 days</li> <li>Azithromycin 500 mg daily x 3 days</li> <li>Ampicillin + gentamicin used for pregnant women to cover for     Listeria</li> <li>C. diff positive (see section below)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-diarrhea/#approach-to-chronic-diarrhea","title":"Approach to Chronic Diarrhea","text":"Causes of Watery Diarrhea Secretory Motility Osmotic <p>Microscopic colitis</p> <p>Bile acid malabsorption</p> <p>Carcinoid</p> <p>Crohn\u2019s disease</p> <p>Gastrinoma</p> <p>VIPoma</p> <p>Mastocytosis</p> <p>Addison\u2019s disease</p> <p>Hyperthyroidism</p> <p>Diabetes</p> <p>Amyloidosis</p> <p>Systemic scleroderma</p> <p>Lactose intolerance</p> <p>Bile salt diarrhea</p> <p>Sugar alcohols: sorbitol, mannitol, xylitol</p> Meds: antibiotics, caffeine, colchicine, NSAIDs, antineoplastics, antiarrhythmics (digoxin), metformin, carbamazepine Meds: macrolides, metoclopramide, bisacodyl, senna, pyridostigmine Meds: citrates, lactulose, magnesium-containing antacids, mycophenolate, antibiotics, propranolol, hydralazine, procainamide Functional: IBS Causes of Fatty Diarrhea (Steatorrhea) Malabsorption Inflammatory <p>Celiac disease</p> <p>Gastric bypass</p> <p>Short bowel syndrome</p> <p>Tropical Sprue</p> <p>Whipple disease</p> <p>Small intestinal bacterial overgrowth (SIBO)</p> <p>Post-infectious malabsorptive diarrhea</p> <p>Maldigestion</p> <p>Pancreatic insufficiency</p> <p>Hepatobiliary disorders</p> <p>Diverticulitis</p> <p>Ischemic colitis</p> <p>Neoplasia</p> <p>Radiation colitis</p> <p>Arsenic poisoning</p> <p>Microscopic colitis</p> <p>Invasive infections: bacterial (tuberculosis, yersinosis), viral (CMV, HSV),</p> <p>Parasites (amebiasis, strongyloidiasis)</p> <p>Inflammatory bowel disease</p>"},{"location":"gastroenterology/gastroenterology-diarrhea/#evaluation_1","title":"Evaluation","text":"<ul> <li>Labs: CBC w/ diff, CMP, ESR/CRP, TSH, celiac serologies if high     suspicion (anti-TTG)</li> <li>Spot fecal elastase Steatorrhea (greasy, malodorous stools that     float)</li> <li>Colonoscopy indicated if alarm symptoms are present ( &gt;45 yrs and     hasn\u2019t had one, or \\&lt;45 yrs and concern for IBD, CMV, ischemic     colitis or microscopic colitis)</li> <li>If concern for IBS: Rome IV criteria (see section on \u201cIBS\u201d below)</li> </ul>"},{"location":"gastroenterology/gastroenterology-diarrhea/#management_1","title":"Management","text":"<ul> <li>IBS: trial elimination diet/low FODMAP, antidiarrheals</li> <li>Pancreatic insufficiency: enzyme replacement (Creon), consult     nutrition for assistance</li> <li>Celiac: eliminate gluten, will need outpatient nutrition follow-up</li> <li>Bile acid malabsorption: can try cholestyramine (can affect     absorption of other meds)</li> </ul>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/","title":"Esophageal Disorders","text":"<p>Caroline Barrett</p>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/#dysphagias","title":"Dysphagias","text":"<ul> <li>Oropharyngeal dysphagia = difficulty initiating a swallow</li> <li>Associated with coughing, choking, nasopharyngeal regurgitation, and     aspiration</li> <li>Causes: Structural (Zenker\u2019s diverticula, malignancy, goiter,     stricture, radiation injury, infection), Neuromuscular (stroke,     Parkinson disease, dementia, ALS, MS)</li> <li>Esophageal dysphagia: Difficulty swallowing several seconds after     initiation; associated w/sensation of food getting stuck in     esophagus</li> <li>Dysphagia to solids = mechanical obstruction<ul> <li>Foreign body: Inability to swallow solids and/or liquids,     including oral secretions<ul> <li>Most common foreign body = food in esophagus</li> </ul> </li> <li>Progressive: esophageal stricture, peptic stricture, esophageal,     cancer</li> <li>Intermittent: esophageal ring/web, eosinophilic esophagitis     (particularly in young pts)</li> </ul> </li> <li>Dysphagia to solids and liquids = motility disorder<ul> <li>Causes: achalasia, scleroderma, distal esophageal spasm (DES),     hypercontractile (nutcracker) esophagus</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/#evaluation","title":"Evaluation","text":"<ul> <li>If oropharyngeal dysphagia: videofluoroscopic modified barium     swallow and fiberoptic endoscopic evaluation of swallowing (FEES)</li> <li>When to order barium esophogram:<ul> <li>Pre-endoscopy if clinical history suspicious for proximal esophageal     lesion (i.e. Zenker\u2019s) or known complex stricture (post-caustic     injury or radiation)<ul> <li>Don\u2019t order if a food impaction is suspected or if imminent     endoscopy</li> </ul> </li> <li>Post-endoscopy if mechanical obstruction is still suspected (EGD can     miss lower esophageal rings or extrinsic esophageal compression)</li> </ul> </li> <li>EGD if concerns for mechanical obstruction</li> <li>Manometry for motility disorders</li> </ul>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/#management","title":"Management","text":"<ul> <li>Food impaction: IV glucagon to relax lower esophageal sphincter to     allow food passage</li> <li>Otherwise, requires urgent upper endoscopy for removal</li> <li>Additional management is specific to the final diagnosis</li> </ul>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/#odynophagia","title":"Odynophagia","text":"<ul> <li>Pain with swallowing</li> <li>Associated with esophagitis</li> </ul> <p>PIECE mnemonic for esophagitis:</p> <ul> <li>Pill-induced: NSAIDs, ART, KCl, doxycycline, bisphosphonates<ul> <li>Discontinue culprit med or substitute with liquid formulation; prevent by taking culprit meds w/ 8oz water and sit upright for 30 mins after</li> </ul> </li> <li>Infectious: usually in immunosuppressed pts</li> <li>Candida Esophagitis: most common in HIV or heme malignancies, pts on     antibiotics and steroid use<ul> <li>Can exist without OP thrush</li> <li>Diagnosis: white mucosal plaque-like lesions on EGD biopsy and     culture</li> </ul> </li> <li>HSV Esophagitis. Occurs most commonly in solid organ, BMT transplant     recipients, and immunosuppressed patients<ul> <li>Diagnosis: well-circumscribed ulcers on EGD, biopsy or brushings     of ulcer edge</li> <li>Rx: acyclovir 400mg PO five times daily for 14-21 days     (immunocompromised) or acyclovir 5mg/kg IV q8h for 7-14 days if     unable to tolerate PO; 200mg PO five times daily or 400mg PO     three times daily for 7-10 days (immunocompetent)</li> </ul> </li> <li>CMV Esophagitis: suspect in HIV pts w/ CD4\\&lt;50<ul> <li>Diagnosis: linear/longitudinal ulcers on EGD, biopsy</li> <li>Rx: ganciclovir 5mg/kg IV q12h for 21-42 days; change to PO once     pt able to tolerate; If contraindication to ganciclovir     (leukopenia, thrombocytopenia) can use Foscarnet. PO     valganciclovir can be used in patients who can tolerate and     absorb oral medications. Treatment duration is 3-6 weeks based     on expert opinion and response to disease</li> </ul> </li> <li>Eosinophilic Esophagitis (see below)</li> <li>Caustic: alkali-induced injury, acid-induced injury, acute period     (several days) following esophageal radiofrequency ablation for     Barrett\u2019s.</li> <li>GERD (see below)</li> </ul>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/#gerd","title":"GERD","text":"<p>Background</p> <ul> <li>Condition that develops when reflux of stomach contents causes     symptoms and/or complications</li> <li>Classified base on appearance of esophageal mucosa on EGD</li> <li>Erosive esophagitis: endoscopically visible breaks in distal     esophageal mucosa + GERD</li> <li>Nonerosive reflux disease: presence of symptoms of GERD without     esophageal mucosal injury</li> </ul> <p>Presentation</p> <ul> <li>Esophageal symptoms: heartburn, regurgitation, chest pain,     dysphagia, globus sensation, odynophagia</li> <li>Extra-esophageal symptoms: chronic cough, hoarseness</li> <li>Complications: Esophageal stricture, Barrett\u2019s esophagus, esophageal     adenocarcinoma</li> </ul> <p>Evaluation</p> <ul> <li>Dx can often be made clinically in pts with classic heartburn and/or     regurgitation</li> <li>If dx uncertain, can perform ambulatory pH monitoring + impedance</li> <li>EGD indicated for the following:</li> <li>Presence of alarm features (dysphagia, persistent vomiting, GI     cancer in 1\u00ba relative, odynophagia, GI bleeding, weight loss, iron     deficiency anemia, \u2265age &gt; 60 y/o with new-onset GERD symptoms)</li> <li>Risk factors for Barrett\u2019s esophagus (duration of GERD at least 5-10     years [must be present], &gt;50 yo, male, white, hiatal hernia,     obesity, nocturnal reflux, tobacco use, first-degree relative w/     Barrett\u2019s and/or adenocarcinoma)</li> <li>Abnormal UGI tract imaging (i.e. luminal abnormalities).</li> <li>Continued symptoms despite adequate PPI therapy</li> </ul> <p>Management</p> <ul> <li>Lifestyle and dietary modifications in all pts (weight loss; elevate     HOB; avoid precipitants such as fatty foods, caffeine, alcohol,     spicy foods, large meals, late night meals)</li> <li>Mild/intermittent symptoms (\\&lt;2 episodes/wk) and no erosive     esophagitis step-up therapy q4-8 wks until symptoms are controlled,     then continue for at least 8 wks:</li> <li>Low-dose H2RA prn standard dose H2RA BID (min 2 wks) discontinue     H2RA and start daily low dose PPI standard dose PPI</li> <li>Frequent symptoms (&gt;2 episodes/wk, and/or severe symptoms that     impair QOL) step-down therapy in order to optimize symptom relief</li> <li>Standard-dose PPI daily (8 wks) low-dose PPI daily H2RA (if     mild/intermittent symptoms) stop if asymptomatic<ul> <li>PPIs should be prescribed at lowest dose and for shortest     duration appropriate</li> <li>Instruct patients on optimal PPI use: most effective at gastric     acid suppression when taken 30-60 minutes before a meal</li> <li>Taper if taking for &gt;6 months and plan to discontinue</li> </ul> </li> <li>Medications:<ul> <li>Low dose H2RA: famotidine 10mg BID</li> <li>Standard dose H2RA: famotidine 20mg BID</li> <li>Low dose PPI: omeprazole 10 mg daily</li> <li>Standard dose PPI: omeprazole 20 mg daily</li> </ul> </li> </ul> <p>Additional Information</p> <ul> <li>Erosive esophagitis and Barrett\u2019s esophagus:<ul> <li>Require maintenance acid suppression with a standard dose PPI daily     given likelihood of recurrent symptoms and complications if stopped</li> </ul> </li> <li>Recurrent Symptoms (\u2154 of pts with nonerosive reflux disease     relapse when acid suppression is discontinued):<ul> <li>If \u22653 months after discontinuing repeat 8-week course</li> <li>If &lt;3 months of discontinuing, EGD (if not already performed) to     rule out other etiologies or complications</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-esophageal-disorders/#eosinophilic-esophagitis","title":"Eosinophilic Esophagitis","text":"<p>Background</p> <ul> <li>Pt usually with a history of asthma/allergies/eczema</li> <li>Dysphagia (most commonly to solid foods), food impaction, central     chest pain, GERD/refractory heartburn, upper abdominal pain</li> </ul> <p>Evaluation</p> <ul> <li>Diagnostic criteria</li> <li>Symptoms related to esophageal dysfunction</li> <li>EGD with &gt;15 eos/hpf on biopsy and exclusion of other causes</li> <li>50-60% pts will have elevated serum IgE lvl; peripheral eosinophilia     can be seen but is generally mild.</li> </ul> <p>Management</p> <ul> <li>Standard dose PPI for 8 weeks \u00b1 elimination diet if still     symptomatic after 4 weeks, increase PPI to BID if responsive,     continue PPI at lowest dose possible for symptom control</li> <li>Alternative treatment is swallowed budesonide or fluticasone</li> <li>Intermittent dilation of strictures to relieve dysphagia, but no     effect on underlying inflammation</li> <li>Should undergo evaluation by allergist, given strong association     with allergies</li> </ul>"},{"location":"gastroenterology/gastroenterology-gastroparesis/","title":"Gastroparesis","text":"<p>Hashim Hayat</p>"},{"location":"gastroenterology/gastroenterology-gastroparesis/#background","title":"Background","text":"<ul> <li>Syndrome of objectively delayed gastric emptying in absence of     mechanical obstruction</li> <li>Etiology: Diabetes (most common), post-surgical (gastric or     bariatric surgery), thyroid dysfunction, autoimmune or neurologic     disorders, medication-induced (GLP-1 agonists, narcotics,     anticholinergic agents</li> </ul>"},{"location":"gastroenterology/gastroenterology-gastroparesis/#presentation","title":"Presentation","text":"<ul> <li>Nausea, vomiting (may contain food eaten several hours prior),     abdominal pain (dull, crampy; rarely a predominant symptom), early     satiety, postprandial fullness, bloating, weight loss in severe     cases</li> </ul>"},{"location":"gastroenterology/gastroenterology-gastroparesis/#evaluation","title":"Evaluation","text":"<ul> <li>Exclude mechanical obstruction and mucosal disease with CTE and EGD</li> <li>Scintigraphic gastric emptying study = gold standard for diagnosis     (measures gastric retention of solids at 4h)</li> <li>Stop medications that may affect gastric emptying 48 hrs prior to     testing</li> <li>Must have blood sugar \\&lt; 275 (Hyperglycemia delays gastric emptying)</li> </ul>"},{"location":"gastroenterology/gastroenterology-gastroparesis/#management","title":"Management","text":"<ul> <li>Support with IVF and electrolytes \u2013 PO intake preferred</li> <li>Glycemic control in diabetics</li> <li>Stop offending medications</li> <li>Nutrition consult for teaching on frequent small volume meals that     are low in fat and soluble fiber</li> <li>If continued symptoms after above, try prokinetics and antiemetics</li> <li>Prokinetics<ul> <li>Liquid formulations preferred for better absorption</li> <li>Give 15min before meals and at bedtime.</li> <li>First line is Reglan. If no response, try Domperidone and     subsequently erythromycin (not good for long term, pts develop     tachyphylaxis)</li> </ul> </li> <li>Antiemetics: helps symptoms but do not improve gastric emptying</li> <li>In severe cases patients may require enteral feeding (post pyloric     preferred) or venting g-tube</li> <li>Emerging endoscopic treatment options: G-POEM (gastric peroral     endoscopic myotomy)</li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-bleeding/","title":"GI Bleeding","text":"<p>Matthew Meyers</p>"},{"location":"gastroenterology/gastroenterology-gi-bleeding/#background","title":"Background","text":"<ul> <li>Intraluminal blood loss anywhere from the nasopharynx/oral cavity to     the anus</li> <li>Don\u2019t forget epistaxis or oropharyngeal bleeding as possible source     of melena</li> <li>IV PPI prior to endoscopy may \u2193 need for endoscopic therapy but does     not impact transfusion requirement, rebleeding risk, need for     surgical intervention, or mortality</li> <li>Classification: relative location to the Ligament of Treitz (LoT)</li> <li>Upper = proximal to LoT<ul> <li>PUD, gastritis (alcohol, stress, NSAIDs, ASA), esophagitis,     variceal bleed, Mallory-Weiss tear, AVM, Dieulafoy\u2019s lesion,     aorto-enteric fistula, gastric antral vascular ectasias,     malignancy</li> </ul> </li> <li>Lower = distal to LoT<ul> <li>Diverticular bleed, ischemic/infectious/IBD/radiation colitis,     malignancy, angiodysplasia, anorectal (hemorrhoids, anal     fissure), Meckel\u2019s diverticulum, post-polypectomy bleed</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-bleeding/#presentation","title":"Presentation","text":"<ul> <li>Hematemesis (very specific for upper GI bleed), hematochezia     (usually lower although brisk upper possible), melena (usually     upper), coffee-ground emesis, epigastric/abdominal pain, acute or     chronic, hx of GI bleed and prior endoscopies, NSAID use, alcohol     use, anticoagulant use, hx of cirrhosis</li> <li>Exam: VITALS \u2013 assess stability to determine resuscitation needs,     MICU vs. floor; orthostatic vs, rectal exam every time (smear stool     on white tissue paper to look for melena), look for signs of     cirrhosis (jaundice, palmar erythema, ascites, spider angiomata)</li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-bleeding/#evaluation","title":"Evaluation","text":"<ul> <li>CBC, PT/INR, CMP, Lactic Acid, Blood Gas</li> <li>EGD: usually best</li> <li>Difficulty localizing GIB: pill-capsule, balloon enteroscopy     Meckel\u2019s scan, tagged RBC scan</li> <li>Massive lower GI bleeds will require arteriography</li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-bleeding/#management","title":"Management","text":"<ul> <li>Secure airway (intubation) if comatose, extremely combative, or     massive hematemesis</li> <li>At least 2 large bore IV\u2019s (&gt; 18 gauge) \u2013 ask nurses directly to     ensure these are placed</li> <li>Maintain active type and screen</li> <li>Bolus IVF to maintain MAP &gt;65H/H monitoring q6-q12 hours;     transfusions as indicated</li> <li>IV PPI (pantoprazole) 40 mg BID if thought to be upper/possible     ulcer</li> <li>If cirrhotic, Ceftriaxone 1g daily for empiric SBP prophylaxis</li> <li>If possibility of variceal bleed: Octreotide IV 50 mcg x1 then 50     mcg/hr drip x 3-5 days</li> <li>NPO if unstable vs. clear liquids (no reds or purples) until morning     for EGD</li> <li>Never give prep to a patient for colonoscopy (GoLytely) without     discussing with GI fellow</li> <li>Consult gastroenterology to facilitate endoscopy</li> <li>If endoscopy is unable to stop bleeding IR is next who can embolize</li> <li>If embolization fails EGS for source removal</li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-covid/","title":"GI Manifestations of COVID","text":"<p>Taylor Riggs</p>"},{"location":"gastroenterology/gastroenterology-gi-covid/#background","title":"Background","text":"<ul> <li>GI manifestations are reported up to 60% of patients with COVID</li> <li>GI symptoms may be the only symptom or precede other symptoms</li> <li>GI manifestations are felt to be due to expression of ACE2 receptor     throughout the GI tract</li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-covid/#presentation","title":"Presentation","text":"<ul> <li>Diarrhea \u2013 more common in severe disease</li> <li>~20% have diarrhea as first symptom of COVID; on average, lasts     about 5 days</li> <li>Nausea and vomiting \u2013 associated with more severe disease</li> <li>Mesenteric ischemia \u2013 likely due to intestinal microvascular injury</li> <li>Elevated liver enzymes \u2013 likely due to inflammatory response and     direct virus-related toxicity</li> <li>Hepatocellular pattern of injury most common; elevated bilirubin     seen in severe disease</li> <li>Usually self-limited</li> <li>Pancreatitis has been reported in several cases, but no causal link     has been established</li> </ul>"},{"location":"gastroenterology/gastroenterology-gi-covid/#management","title":"Management","text":"<ul> <li>Largely supportive care</li> <li>Monitor LFTs, coags, consider checking lipase if abdominal pain</li> <li>If LFTs not improving after several days or underlying chronic liver     disease, obtain RUQ U/S, consider hepatitis serologies</li> <li>Consider medications/antiviral medications as culprit and     discontinue as indicated</li> </ul>"},{"location":"gastroenterology/gastroenterology-ibs/","title":"Irritable Bowel Syndrome","text":"<p>Hashim Hayat</p>"},{"location":"gastroenterology/gastroenterology-ibs/#background","title":"Background","text":"<ul> <li>Diagnose by the Rome IV criteria, no longer a diagnosis of exclusion</li> <li>Recurrent abdominal pain on average at least 1 day/week in the last     3 months with an onset at least 6 months prior, associated     with\u00a0two or more\u00a0of the following criteria<ul> <li>Pain related to defecation</li> <li>Change in frequency of stool</li> <li>Change in form (appearance) of stool</li> </ul> </li> <li>Patient has none of the following warning signs: &gt;50yrs, evidence     of GIB, nocturnal pain or BMs, unintentional weight loss, family hx     of colorectal cancer or IBD, palpable abdominal mass or LAD, IDA,     +FOBT</li> <li>Classified based on predominant bowel habits<ul> <li>Diarrhea: &gt;25% BMs with Bristol stool types 6 or 7</li> <li>Constipation: &gt;25% BMs with Bristol stool types 1 or 2</li> <li>Mixed: both of above</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-ibs/#evaluation","title":"Evaluation","text":"<ul> <li>Thorough H&amp;P for alarm symptoms as above</li> <li>Consider limited testing with CBC, CMP, CRP, celiac serology, fecal     calprotectin</li> </ul>"},{"location":"gastroenterology/gastroenterology-ibs/#management","title":"Management","text":"<ul> <li>Treatment involves lifestyle and dietary modifications, psychosocial     treatment, and pharmacologic treatment</li> <li>Pain:<ul> <li>Peppermint oil (smooth muscle relaxant) \u2013 IBGuard, Iberogast</li> <li>Antispasmodics: Hyosciamine acts faster than Dicyclomine</li> <li>TCAs: Amitriptyline or nortriptyline (causes less constipation so better in IBS-C)</li> </ul> </li> <li>Bloating:<ul> <li>Low FODMAP diet</li> <li>Rifaximin as empiric treatment for SIBO</li> <li>No evidence for probiotics (can potentially worsen bloating 2/2 SIBO)</li> </ul> </li> <li>Bowel regulation:<ul> <li>IBS-D: Start with Loperamide (up to 16g daily), consider Lomotil if refractory</li> <li>IBS-C: Miralax, fiber supplement (Ispaghula husk orange), Linzess (first line but can be expensive), Trulance, or Amitiza</li> </ul> </li> <li>Other<ul> <li>Psychotherapy, CBT</li> <li>SSRIs, SNRIs for concomitant mood disorders</li> <li>Gabapentin, lyrica</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-inflammatory-bowel-disease/","title":"Inflammatory Bowel Disease","text":"<p>Francesca Raffa</p>"},{"location":"gastroenterology/gastroenterology-inflammatory-bowel-disease/#background","title":"Background","text":"<ul> <li>Ulcerative colitis (UC): colon only (can have backwash ileitis);     contiguous lesions; mucosal inflammation</li> <li>Crohn\u2019s disease (CD): any part of the GI tract; \u201cskip lesions\u201d;     transmural inflammation</li> <li>Important historical considerations to include in your documentation     and presentation:<ul> <li>Location of disease (CD: LB/SB, LB only, SB only; UC: proctitis, left-sided or pancolitis)</li> <li>Complications: Fistulizing, strictures, perianal, prior surgeries, current IBD treatment</li> <li>Include last endoscopies and imaging findings; current and prior IBD treatment and reason for transition (SEs, failure), primary IBD provider</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-inflammatory-bowel-disease/#presentation","title":"Presentation","text":"<ul> <li>UC: frequent diarrhea (often bloody), tenesmus, urgency, abdominal     pain; may have fever, malaise, and weight loss<ul> <li>Complications: severe bleeding/anemia, fulminant colitis, toxic megacolon</li> </ul> </li> <li>CD: abdominal pain, nausea/vomiting, fever, malaise, weight loss;     May also have diarrhea (\u00b1 bloody depending on CD location)<ul> <li>Complications: fistulas (entero-enteric, entero-vesicular, entero-cutaneous, rectovaginal, perianal, retroperitoneal), abscesses, strictures, obstruction</li> </ul> </li> <li>Extra-intestinal (EI): arthritis, sacro-iliitis, uveitis,     episcleritis, aphthous ulcers, erythema nodosum, pyoderma     gangrenosum, PSC (esp. UC), nephrolithiasis, thromboembolism</li> </ul>"},{"location":"gastroenterology/gastroenterology-inflammatory-bowel-disease/#evaluation","title":"Evaluation","text":"<ul> <li>CBC w/diff, CMP, CRP, ESR, \u00b1 blood cultures</li> <li>If diarrhea: GI Pathogen panel and C. diff</li> <li>If anemic: obtain iron studies and type &amp; screen</li> <li>If weight loss or concern for malnutrition: albumin, pre-albumin,     Vitamin D, B12, folate</li> <li>Imaging:<ul> <li>CT Enterography (oral contrast) preferred in CD, for luminal/extra-luminal complications</li> <li>How to order CTE: \u201cCT abdomen pelvis enterography\u201d, order barium (Volumen) 0.1% oral suspension x2, 1st dose to be given by nurse 60 min before study, 2nd study to be given 30 min before (nurse should be in contact with CT tech)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-inflammatory-bowel-disease/#management","title":"Management","text":"<ul> <li>Acute Flare</li> <li>Pain control: usually a major component of hospital course<ul> <li>Avoid NSAIDs, oral pain medications are preferred</li> <li>If pain is difficult to control, consider Acute Pain Service     consult</li> <li>Narcotics and Imodium are contraindicated in toxic megacolon</li> </ul> </li> <li>Antibiotics: appropriately treat infections (intra-abdominal or     perianal abscess) with antibiotics (consider prior culture data,     often use cipro/flagyl)</li> <li>VTE Prophylaxis: All IBD patients, even if having blood in stool     (unless requiring transfusion) as they are at much higher risk of     VTE</li> <li>Nutrition: Nutrition consult for all IBD patients; For severe     malnutrition or if prolonged bowel rest is needed, TPN is sometimes     initiated</li> <li>Anemia: Ferritin \\&lt;100 or iron sat \\&lt;20 with ferritin \\&lt;300,     consider iron infusions (if no bacteremia) or transfuse for severe     anemia</li> <li>Smoking Cessation (esp. with CD): discuss smoking cessation &amp;     consult tobacco cessation</li> <li>Consult Colorectal Surgery (not EGS): SBO, toxic megacolon, bowel     perforation, peritonitis</li> <li>Immunosuppression: (Infections must be ruled out and/or treated     before starting)</li> <li>Steroids:<ul> <li>Methylprednisolone (Solumedrol); often 20 mg BID for three days</li> <li>Transition to oral (40 mg prednisone daily) once clinically     improved/tolerating PO; typically prescribe a prolonged taper on     discharge (often down by 5 mg every week)</li> <li>If severe proctitis: consider rectal steroids (hydrocortisone     enema/foam)</li> </ul> </li> <li>If lack of response to steroids: additional medical therapy     (biologics), bowel rest with TPN, or surgical intervention<ul> <li>Infliximab (Inflectra) is available at VUMC</li> <li>If patient fails to respond to steroids, should consider     possibility of CMV colitis (usually evaluated by biopsy on flex     sig or colonoscopy)</li> <li>Prior to initiating a biologic, all patients must have the     following negative studies within the last year: Quantiferon     Gold and CXR, Hepatitis B serologies, HIV, urine histoplasma Ag     (some providers)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/","title":"Intestinal Ischemia","text":"<p>Michael Koenig</p>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#acute-mesenteric-ischemia","title":"Acute Mesenteric Ischemia","text":"<ul> <li>Sudden onset \u2193 or absence of blood flow to the small intestines</li> <li>Mesenteric Arterial Occlusion:<ul> <li>Arterial Embolism: Associated with cardiac arrhythmias (atrial fibrillation), valvular disease, endocarditis, ventricular aneurysm, aortic atherosclerosis, and aortic aneurysm</li> <li>Arterial thrombosis: Most commonly from atherosclerotic disease; can also be 2/2 abdominal trauma, infection, or dissection</li> </ul> </li> <li>Venous thrombosis:<ul> <li>Associated w/ hypercoagulable states, malignancy, prior abdominal surgery, abdominal mass venous compression, intra-abdominal inflammatory processes</li> </ul> </li> <li>Non occlusive mesenteric ischemia:<ul> <li>Intestinal hypoperfusion and vasoconstriction; associated with decreased cardiac output, sepsis, vasopressor use</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#presentation","title":"Presentation","text":"<ul> <li>Early: Abdominal pain is most common symptom, abdominal distension</li> <li>Abdominal tenderness is not prominent early (\u201cpain out of proportion     to the exam\u201d)</li> <li>Arterial occlusion: Sudden onset, severe periumbilical pain, nausea,     and emesis</li> <li>Venous thrombosis: More insidious onset abdominal pain, waxing and     waning</li> <li>Nonocclusive mesenteric ischemia: variable location and severity of     abdominal pain; often overshadowed by a precipitating disorder</li> <li>Late: As transmural bowel infarction develops, abdomen becomes     distended, bowel sounds become absent, and peritoneal signs develop\u00a0</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#evaluation","title":"Evaluation","text":"<ul> <li>Type and Screen, Lactic acid, BMP, CBC</li> <li>Imaging: KUB: Normal in &gt; 25% of cases</li> <li>Ileus w/ distended bowel loops, bowel wall thickening, \u00b1 pneumatosis     intestinalis</li> <li>Free intraperitoneal air immediate abdominal exploration</li> <li>CT Angiography: no oral contrast, obscures mesenteric vessels, \u2193     bowel wall enhancement</li> <li>Focal or segmental bowel wall thickening, intestinal pneumatosis,     portal vein gas, porto-mesenteric thrombosis, mesenteric arterial     calcification, mesenteric artery occlusion</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#management","title":"Management","text":"<ul> <li>General: IVFs, NPO, hemodynamic monitoring and support (try to avoid     vasoconstricting agents), anticoagulation, broad-spectrum     antibiotics, pain control</li> <li>If develops peritonitis or evidence of perforation on CT EGS consult     for surgery</li> <li>Mesenteric arterial embolism: Embolectomy vs. local infusion of     thrombolytic agent</li> <li>Mesenteric arterial thrombosis: Surgical revascularization vs.     thrombolysis with endovascular angioplasty and stenting</li> <li>Venous thrombosis: Anticoagulation; possible thrombolysis if     persistent symptoms</li> <li>Nonocclusive occlusion: Treat underlying cause, stop     vasoconstriction meds, consider intra-arterial vasodilator infusion</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#chronic-mesenteric-ischemia","title":"Chronic Mesenteric Ischemia","text":""},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#background","title":"Background","text":"<ul> <li>\u2193 blood flow to intestines, typically caused by atherosclerosis of     mesenteric vessel</li> <li>High-grade mesenteric vascular stenoses in at least two major     vessels (celiac, SMA, or IMA) must be established</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#presentation_1","title":"Presentation","text":"<ul> <li>Recurrent dull, crampy, postprandial abdominal pain</li> <li>Pts develop food aversion and often have associated weight loss</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#evaluation_1","title":"Evaluation","text":"<ul> <li>CTA abdomen/pelvis is preferred (&gt;90% sensitivity and specificity)</li> <li>Can also consider duplex U/S and gastric tonometry</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#management_1","title":"Management","text":"<ul> <li>Conservative management if asymptomatic: smoking cessation and     secondary prevention to limit progression of atherosclerotic disease</li> <li>Nutritional evaluation</li> <li>Revascularization (open vs. endovascular) is indicated if symptoms     are present</li> <li>Mesenteric angioplasty and stenting is first-line therapy</li> <li>Goal is to prevent future bowel infarction</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#ischemic-colitis","title":"Ischemic Colitis","text":""},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#background_1","title":"Background","text":"<ul> <li>Sudden, transient reduction in blood flow to colon</li> <li>Typically at \u201cwatershed\u201d areas, such as the splenic flexure and     rectosigmoid junction</li> <li>Most often nonocclusive (95% of cases) and affects older adults</li> <li>Risk factors: ACS, hemodialysis, shock, aortoiliac instrumentation,     cardiopulmonary bypass, extreme exercise (marathon running)</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#presentation_2","title":"Presentation","text":"<ul> <li>Rapid onset, mild cramping abdominal pain, associated with urge to     defecate, hematochezia</li> <li>Tenderness present (typically over left side)</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#evaluation_2","title":"Evaluation","text":"<ul> <li>Lactic acid (nonspecific but elevated), LDH, CPK, CBC     (leukocytosis), BMP (metabolic acidosis)</li> <li>KUB; if peritonitis or signs of severe ischemia \u2192 surgery\u00a0</li> <li>CT A/P with IV contrast (and oral contrast if patient can tolerate)</li> <li>Consider CTA A/P if suspicion for vascular occlusion</li> <li>Colonoscopy confirms diagnosis.\u00a0</li> <li>Edematous, friable mucosa; erythema; and interspersed pale areas;     bluish hemorrhagic nodules representing submucosal bleeding</li> <li>Segmental distribution, abrupt transition between injured and     non-injured mucosa</li> </ul>"},{"location":"gastroenterology/gastroenterology-intestinal-ischemia/#management_2","title":"Management","text":"<p>General: IVFs, bowel rest, antibiotics (Zosyn vs CTX/flagyl)</p> Ischemic Colitis Management Classification Management Mild No risk factors (see below) <p>Supportive care and observation</p> <p>Antibiotics can be stopped if no ulceration</p> Moderate 1-3 risk factors <p>Same as mild ischemia if no vascular occlusion</p> <p>Systemic anticoagulation +/- vascular intervention if mesenteric occlusion</p> Severe &gt; 3 risk factors, peritoneal signs, pneumatosis, pneumoperitoneum, gangrene or pancolonic ischemia on colonoscopy Consult EGS for abdominal exploration and segmental resection Risk factors: male, SBP &lt;90, HR &gt;100, WBC&gt;15k, Hgb &lt;12, Na &lt;136, BUN &gt;20, LDH &gt;350, isolated right-sided colonic involvement, abdominal pain with rectal bleeding"},{"location":"gastroenterology/gastroenterology-nausea-vomiting/","title":"Nausea &amp; Vomiting","text":"<p>Taylor Riggs</p>"},{"location":"gastroenterology/gastroenterology-nausea-vomiting/#etiology","title":"Etiology","text":"<p>VOMMIIT mnemonic</p> <ul> <li> <p>Vestibular: Labyrinthitis, vestibular neuritis, meniere\u2019s     disease, cerebellar stroke</p> </li> <li> <p>Obstruction: adhesions, hernia, volvulus, constipation, gastric     outlet obstruction</p> </li> <li> <p>Motility: gastroparesis, GERD, autonomic dysfunction</p> </li> <li> <p>Medications: antibiotics, SSRI, opioids, cannabinoid     hyperemesis</p> </li> <li> <p>Infection: gastroenteritis, hepatitis, pyelonephritis,     cholecystitis</p> </li> <li> <p>Inflammation: PUD, pancreatitis</p> </li> <li> <p>Toxins: uremia, ketoacidosis, hypercalcemia, chemotherapy</p> </li> </ul>"},{"location":"gastroenterology/gastroenterology-nausea-vomiting/#evaluation","title":"Evaluation","text":"<ul> <li> <p>All patients: CBC (leukocytosis, Hgb), BMP (AG, Ca, lytes, AKI),     LFTs, lipase, lactate, UA</p> </li> <li> <p>If risk factors: consider TSH, AM cortisol, troponin, \u03b2 hCG, UDS</p> </li> <li> <p>EKG to eval for ischemia and baseline QTc</p> </li> <li> <p>Imaging:</p> <ul> <li>If concern for obstruction (abd distention, decreased BMs) KUB, consider CT A/P</li> <li>If concern for biliary pathology (RUQ pain, abnl LFTs) RUQ U/S</li> <li>If vestibular/concern for CNS pathology CTH vs MRI brain</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-nausea-vomiting/#management","title":"Management","text":"<p>Address underlying cause and stop medications as appropriate</p> <ul> <li>Many antiemetics prolong QTc, however in patients without underlying     cardiac conduction abnormality, electrolyte abnormality, or organ     failure the risk of QTc prolongation leading to significant     arrhythmia is low.</li> <li>Obtain screening EKG in patients with underlying heart disease,     electrolyte abnormalities, organ failure or on other QTc prolonging     meds (antiarrhythmics, antipsychotics, antibiotics)</li> <li>4-8 mg of IV Zofran is estimated to prolong QTc by ~6ms</li> <li>Try to pick a medication that will address the underlying etiology     of nausea</li> <li>If patient does not respond to a medication in a certain class, try     a medication from a different class (see below)</li> </ul> Anti-Emetics Med (by class) Typical Dose Side Effects Prolongs QT? Serotonin antagonists Ondansetron (Zofran) 4-8mg PO/IV q6h Constipation, headache, arrhythmia, serotonin syndrome Yes <p>Granisetron</p> <p>(Kytril)1</p> 1 mg PO BID, 2mg pre-chemo, OR 10mcg/kg IV pre-chemo \u2018\u2019 Yes Dopamine Antagonists Prochlorperazine (Compazine) 5-10 mg PO/IV q6h, 25 mg PR q6h EPS, less sedation than H-blockers (e.g. Phenergan) Yes <p>Haloperidol</p> <p>(Haldol)</p> 0.5-1 mg PO/IV q6h EPS, arrhythmia Yes Zyprexa (Olanzapine) 5 -10mg PO qdaily EPS, constipation, anticholinergic Mild ^ Dopamine and Serotonin Antagonists Metoclopramide (Reglan) 10 mg PO/IV q6h EPS/dystonia, arrhythmias, drowsiness/dizziness, diarrhea Yes GABA-A Agonist <p>Lorazepam</p> <p>(Ativan)</p> 0.5-1mg PO/IV q6h PRN Sedation, delirium, amnesia, respiratory depression No H1 Antagonists Promethazine (Phenergan) 12.5 - 25mg PO /PR /IV q6h (avoid IV use if possible) Sedation, EPS (D2 antagonist also), arrhythmias, blurry vision Yes Diphenhydramine (Benadryl) 25-50mg PO/IV q6h Sedation, delirium, urinary retention, ileus Yes <p>Meclizine</p> <p>(Antivert)</p> 12.5-25mg PO q6h Sedation, dizziness, falls, blurry vision Yes Anticholinergics Scopolamine 1 mg patch q3day Dry mouth, blurry vision, drowsiness No Glucocorticoids Dexamethasone 4-8mg PO/IV prior to chemo or XRT, typically use with other agents Hyperglycemia, fluid retention, delirium No NK1 Antagonists Aprepitant Given prior to/with chemo Fatigue, neutropenia No CBD Agonists Dronabinol 2.5-5mg BID Dizziness, increased appetite, Tachycardia, hypotension No"},{"location":"gastroenterology/gastroenterology-peptic-ulcer-disease/","title":"Peptic Ulcer Disease","text":"<p>Michelle Izmaylov</p>"},{"location":"gastroenterology/gastroenterology-peptic-ulcer-disease/#background","title":"Background","text":"<ul> <li>Ulceration in the GI tract wall extending through the muscularis     mucosa into deeper layers</li> <li>Most common in the stomach and proximal duodenum</li> <li>Less common in the lower esophagus, the distal duodenum, or the     jejunum<ul> <li>\u2191 suspicion for unopposed hypersecretory states, like     Zollinger-Ellison syndrome</li> </ul> </li> <li>Causes: NSAID use and Helicobacter pylori &gt;&gt; steroids, malignancy,     and acute stress</li> </ul>"},{"location":"gastroenterology/gastroenterology-peptic-ulcer-disease/#presentation","title":"Presentation","text":"<ul> <li>Episodic gnawing or burning epigastric pain, 2 - 5 hr after meals,     nausea, vomiting, heartburn, bloating, postprandial belching, and     loss of appetite</li> <li>Nocturnal pain: acid is secreted in absence of a food buffer</li> <li>Classic teaching for ulcers: Gastric (pain worse w/eating); Duodenal     (pain better w/eating)</li> <li>May be asymptomatic until complications such as hemorrhage or     perforation</li> <li>Alarm features: unintentional weight loss, persistent vomiting,     melena, progressive dysphagia, early satiety, recurrent vomiting,     palpable abdominal mass, lymphadenopathy, family history of upper     gastrointestinal cancer, and iron deficiency anemia</li> </ul>"},{"location":"gastroenterology/gastroenterology-peptic-ulcer-disease/#evaluation","title":"Evaluation","text":"<ul> <li>CBC and H Pylori testing if no strong NSAID use history</li> <li>Urea breath or stool antigen (pt needs to stop PPI for 1-2 weeks, to     avoid false - for both)</li> <li>EGD: if alarm features or patient is older than 55</li> </ul>"},{"location":"gastroenterology/gastroenterology-peptic-ulcer-disease/#management","title":"Management","text":"<ul> <li>General: treat underlying cause (i.e. H. pylori, stop NSAIDs, etc),     encourage smoking cessation, and limit alcohol intake to 1     drink/day.</li> <li>If complicated peptic ulcer (i.e. bleeding, perforation, or gastric     outlet obstruction):<ul> <li>EGD to determine etiology and for possible treatment</li> <li>IV PPI (if bleeding IV PPI for 72 hrs after endoscopic treatment oral PPI)</li> </ul> </li> <li>If uncomplicated peptic ulcer (not caused by H. pylori):<ul> <li>Antisecretory therapy with oral PPI (i.e. omeprazole 20 to 40 mg daily):<ul> <li>If caused by NSAIDs: Duration: \\&lt;1 cm ulcer 4-6 wks; \u22651 cm ulcer 6-8 wks</li> </ul> </li> <li>If not caused by NSAIDs, Duration:<ul> <li>Duodenal ulcer: 4 weeks</li> <li>Gastric ulcer: 8 weeks</li> </ul> </li> </ul> </li> <li>If ulcer caused by H. pylori:<ul> <li>Treat with PPI BID for 14 days with an appropriate combination antibiotic regimen.</li> <li>Confirm H. pylori eradication (via stool antigen test, urease breath test, or EGD &gt;4 weeks after completion of therapy). If not eradicated, retreat</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-peptic-ulcer-disease/#additional-information","title":"Additional Information","text":"<ul> <li>Continue maintenance PPI therapy (omeprazole 20 mg daily) for the     following:<ul> <li>Peptic ulcer &gt;2 cm and age &gt;50 or multiple co-morbidities</li> <li>Frequently recurrent peptic ulcers (&gt;2 in one year)</li> <li>H. pylori-negative, NSAID-negative ulcer disease</li> <li>Failure to eradicate H. pylori (including salvage therapy)</li> <li>Condition requiring long term aspirin/NSAID use</li> <li>Persistent ulcer on repeat EGD (if performed)</li> </ul> </li> <li>Indications for repeat EGD (8-12 weeks):<ul> <li>Persistent/recurrent symptoms despite medical therapy</li> <li>Complicated ulcer (bleeding), with evidence of ongoing bleeding</li> <li>Giant gastric ulcer (&gt;2 cm) or features of malignancy at index endoscopy</li> <li>Gastric ulcer that was not biopsied or inadequately sampled on initial EGD</li> <li>Gastric ulcer in pt w/risk factors for gastric cancer (&gt;50 yo, H. pylori, immigrant from high prevalence area [Japan, Korea, Taiwan, Costa Rica], FHx, presence of gastric atrophy, adenoma, dysplasia, intestinal metaplasia)</li> </ul> </li> </ul>"},{"location":"gastroenterology/gastroenterology-small-bowel-obstruction/","title":"Small Bowel Obstruction (SBO)","text":"<p>Alex Wiles</p>"},{"location":"gastroenterology/gastroenterology-small-bowel-obstruction/#background","title":"Background","text":"<ul> <li>Risk Factors: prior abdominal surgeries (adhesions), malignancy,     hernia, intestinal inflammation (IBD)/stricture, radiation, abscess,     foreign bodies</li> <li>Indicators for bowel ischemia: fever, leukocytosis, tachycardia,     peritonitis</li> <li>Ddx: early appendicitis, large bowel obstruction, Ogilvie\u2019s, DKA,     Pancreatitis, IBD, Gastric outlet obstruction</li> </ul>"},{"location":"gastroenterology/gastroenterology-small-bowel-obstruction/#presentation","title":"Presentation","text":"<ul> <li>Nausea, emesis, intermittent colic, bloating, constipation</li> <li>Obstipation if completely obstructed, loss of flatulence</li> <li>Exam: classically with \u201ctinkling\u201d bowel sounds, tympanic abdomen,     distended abdomen</li> </ul>"},{"location":"gastroenterology/gastroenterology-small-bowel-obstruction/#evaluation","title":"Evaluation","text":"<ul> <li>CBC, BMP, lipase, hepatic function panel, lactate (sensitive, not     specific for ischemia)</li> <li>Start with KUB to rule out perforation but typically will require CT     (x-ray only ~80% sensitive)</li> <li>CT abdomen/pelvis with IV contrast is optimal study if adequate     renal function<ul> <li>No oral contrast (American College of Radiology (ACR) Appropriateness Criteria) as it will not aid diagnosis and can lead to aspiration; IV helps evaluate ischemia</li> </ul> </li> <li>Key word: transition point</li> <li>Non-specific signs of bowel inflammation: bowel wall thickening,     submucosal edema</li> </ul>"},{"location":"gastroenterology/gastroenterology-small-bowel-obstruction/#management","title":"Management","text":"<ul> <li>Consult EGS: if any concern for SBO, evaluate need for urgent     surgery</li> <li>Surgical indications complete obstruction, CT with ischemia,     perforation</li> <li>Gastric decompression: place NGT (prevent aspiration)</li> <li>NPO until obstruction relieved and NGT removed</li> <li>Fluids: two large bore IVs (nursing communication); LR bolus +     maintenance while NPO</li> <li>If no resolution of partial obstruction at 48 hours:</li> <li>Fluoroscopy Upper GI small bowel ft (follow through)<ul> <li>In comments, write \u201cGastrografin contrast\u201d (water-soluble     contrast) which osmotically reduces bowel wall edema and aids     peristalsis</li> <li>If gastrografin reaches the colon within 24 hours, it predicts     clinical resolution of SBO without surgery</li> <li>Note: this can also be therapeutic for pSBO and get bowels moving</li> </ul> </li> </ul>"},{"location":"geriatrics/geriatrics-dementia/","title":"Dementia","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-dementia/#background","title":"Background","text":"<ul> <li>Alzheimer\u2019s Disease (AD): short-term memory deficits prominent</li> <li>Vascular Dementia: \u201cStepwise decline\u201d in memory and functional     status</li> <li>Lewy Body Dementia: hallucinations, memory difficulties with     atypical Parkinsonism early</li> <li>Frontotemporal Dementia: behavioral (aggressive or     disinhibited), language (primary progressive aphasias) or memory     (Alzheimer\u2019s/FTD overlap) variants</li> <li>Posterior Cortical Atrophy: visual difficulties and ocular     apraxia preceding memory problems</li> <li>Creutzfeldt-Jakob Disease (CJD): manifests with subacute     cognitive decline, seizures, vision loss, personality changes. Can     develop startle myoclonus</li> <li>Corticobasal degeneration: focal neurologic changes with     parkinsonism</li> <li>Neurosyphilis: rare, but treatable, present with a range of     cognitive changes. Develop meningovascular encephalitis. Pts can     develop an arteritis, headache, and hydrocephalus.</li> <li>Normal Pressure Hydrocephalus (NPH): \u201cwet, wacky and wobbly\u201d     meaning incontinence, gait apraxia and cognitive changes (usually     frontal symptoms)</li> <li>Autoimmune Dementias: includes limbic encephalitis (like NMDA)     where there are memory and personality changes, autonomic changes,     hallucinations, and seizures</li> </ul> Normal Aging Mild Cognitive Impairment <p>Alzheimer\u2019s Dementia</p> <p>(DSM V Diagnostic Crit.)</p> <p>Mild decline in working memory</p> <p>More effort/time needed to recall new info</p> <p>New learning slowed but well compensated by lists, calendars, etc.</p> <p>+</p> <p>No impairment in social &amp; occupation functioning</p> <p>Subjective complaint of cognitive decline in at least one domain</p> <p>+</p> <p>Cognitive decline is noticeable and measurable</p> <p>+</p> <p>No impairment in social &amp; occupation functioning</p> <p>Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains</p> <p>+</p> <p>Causes significant impairment in social &amp; occupation functioning</p> <p>+</p> <p>Other medical &amp; psychiatric conditions, including delirium, have been excluded</p> <p>+</p> <p>Insidious onset and gradual progression of impairment in at least two cognitive domains</p> Cognitive domains: learning/memory, language, executive function, complex attention, perceptual motor, social cognition Alzheimer\u2019s Disease Vascular Dementia Lewy Body Dementia Frontotemporal Dementia Onset Gradual Sudden or stepwise Gradual Gradual (age &lt; 60) Cognitive Domains &amp; Symptoms Memory, language, visuospatial Depends on location of ischemia Memory, visuospatial Executive dysfunction, personality changes, disinhibition, language, +/- memory Motor Symptoms <p>Rare early</p> <p>Apraxia later</p> Correlates with ischemia Parkinsonism None Progression Gradual (over 8-10 years) Gradual or stepwise with further ischemia Gradual, but faster than Alzheimer\u2019s disease Gradual, but faster than Alzheimer\u2019s disease Imaging Possible global atrophy Cortical or subcortical on MRI Possible global atrophy Atrophy in frontal &amp; temporal lobes"},{"location":"geriatrics/geriatrics-dementia/#evaluation","title":"Evaluation","text":"<ul> <li>MINI-COG: Screening test for cognitive impairment (highly sensitive)<ul> <li>Ask pt to remember three words (banana, sunrise, chair). Ask pt to repeat immediately</li> <li>Ask pt to draw clock. After numbers are on the face, ask pt to \u201cset hands to 10 past 11\u201d<ul> <li>Correct is all numbers in right position AND hands pointing to the 11 and the 2</li> </ul> </li> </ul> </li> <li>Ask pt to recall the three words</li> </ul> <p>MINI-COG Flowchart</p> <ul> <li> <p>MOCA: Montreal Cognitive Assessment</p> <ul> <li>Lengthier test of cognition (but highly specific for cognitive impairment)</li> <li>Useful for detecting subtle deficits as in Mild Cognitive Impairment (MCI)</li> <li>Scores:<ul> <li>18-25: Mild cognitive impairment</li> <li>10-17: Moderate cognitive impairment</li> <li>&lt;10: Severe cognitive impairment</li> </ul> </li> </ul> </li> <li> <p>Rule out reversible causes of dementia-like symptoms: DEMENTIA</p> <ul> <li>Drugs</li> <li>Emotional (depression)</li> <li>Metabolic (CHF, COPD, CKD, OSA)</li> <li>Endocrine (hypothyroidism, hyperparathyroidism, hyponatremia)</li> <li>Nutrition (B12 deficiency)</li> <li>Trauma (chronic SDH)</li> <li>Infection</li> <li>Arterial (vascular)</li> </ul> </li> <li>B12, thyroid studies</li> <li>RPR, HIV testing in at-risk patient groups</li> <li>Neuropsych testing can be done for more clear patterns of     dysfunction</li> <li>MRI brain with contrast if concerned for inflammatory or infectious     causes<ul> <li>CJD: cortical ribboning on DWI with T2 hyperintensity in the thalamus and basal ganglia</li> <li>Sulcal crowding and bowing of the corpus callosum can be seen in NPH on imaging</li> </ul> </li> </ul>"},{"location":"geriatrics/geriatrics-dementia/#management","title":"Management","text":"<ul> <li>Targeting Cognitive Impairment<ul> <li>Cholinesterase Inhibitors: Donepezil, rivastigmine<ul> <li>Indicated for any stage (except FTD)</li> <li>SE: GI (nausea, diarrhea), bradycardia, orthostasis</li> </ul> </li> <li>NMDA antagonists: Memantine<ul> <li>Indicated in moderate to severe AD in combination with     cholinesterase inhibitors</li> <li>Fewer SE than cholinergic medications</li> </ul> </li> </ul> </li> <li>Vitamin supplementation (i.e. Vitamin E)<ul> <li>Unclear benefit in delaying progression of dementia</li> </ul> </li> <li>Targeting Behaviors<ul> <li>Non-pharmacologic management has the best evidence of effectiveness</li> <li>Depression: Treat with antidepressants (SSRI\u2019s)</li> <li>Sleep Disturbance: Mirtazapine (7.5 mg nightly) or Trazodone (25 mg     nightly)</li> <li>Agitation: Try SSRI (citalopram, sertraline)<ul> <li>Consider antipsychotics (black box warning increased risk of     death in elderly)</li> </ul> </li> </ul> </li> </ul>"},{"location":"geriatrics/geriatrics-falls/","title":"Falls","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-falls/#background","title":"Background","text":"<ul> <li>Screen annually for falls in the past year</li> <li>History of fall is a strong risk factor for future falls</li> <li>Recommended History Screening Tool: CDC STEADI Algorithm</li> <li>Physical Exam Screening Tools:</li> <li>If potentially unstable injuries (new spine fracture or lower     extremity fracture): Ask ortho to clear the patient for mobility</li> <li>If no potentially unstable injuries, attempt to get the patient out     of bed<ul> <li>If lying down, have them lift each leg off the bed</li> <li>If they can do this, ask them to sit up on side of bed</li> <li>If they can do this, ask them to stand</li> <li>If they can do this without assistance, then observe them walk</li> </ul> </li> <li>The Timed \u201cup and Go\u201d Test (TUG) tool for fall risk<ul> <li>Have the patient rise from sitting in a chair, walk 10 feet     forward, turn around, walk back to chair, and sit down</li> <li>Patients who require &gt; 10 seconds are at increased risk for     falls</li> </ul> </li> <li>Med Rec:<ul> <li>Antipsychotics, antidepressants, anticholinergics, anxiolytics, sedatives/hypnotics, anti-hypertensives, antiarrhythmics, steroids, statins all can increase risk of falls</li> </ul> </li> </ul>"},{"location":"geriatrics/geriatrics-falls/#management","title":"Management","text":"<ul> <li>Rule out other causes: Cardiac, Neurologic, Infectious</li> <li>Check Vitamin D levels (goal &gt; 30) and supplement (800-1000 IU     daily) if at increased fall risk</li> <li>Assess visual acuity (e.g. expedite cataract surgery)</li> <li>Hearing assessment (audiology screen)</li> <li>Consult Inpatient PT/OT and refer for HH PT/OT for home safety     evaluation at discharge</li> <li>Recommend non-skid shoes with a backing (sneaker)</li> <li>Modify extrinsic risk factors for falls: removal of fall hazards,     placement of handrails</li> <li>Referral to Exercise programs: At VUMC = Dayani Center \u201cAmbulatory     Referral to Medical Fitness\u201d outpatient order</li> </ul>"},{"location":"geriatrics/geriatrics-frailty/","title":"Frailty","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-frailty/#background","title":"Background","text":"<ul> <li>Syndrome of physiological decline in late life, characterized by     marked vulnerability to adverse health outcomes</li> </ul>"},{"location":"geriatrics/geriatrics-frailty/#evaluation","title":"Evaluation","text":"<ul> <li>FRAIL Scale Identifies frailty in community dwelling elders (1 -2 =     prefrail; &gt; 3 = frail)<ul> <li>Fatigue: are you Fatigued more often than not?</li> <li>Resistance: are you able to climb a flight of stairs?</li> <li>Aerobic: are you bale to walk a block?</li> <li>Illness: Do you have more than five illnesses?</li> <li>Loss: Have you lost more than 5% of weight in 6 months?</li> </ul> </li> <li>Order Vitamin D and B-12 Levels.</li> </ul>"},{"location":"geriatrics/geriatrics-frailty/#management","title":"Management","text":"<ul> <li>Adapt interventions to the individual, incorporating patient     preferences and stage on the spectrum of frailty</li> <li>Exercise programs with additional physical and occupational therapy     input if indicated.</li> <li>Optimize nutrition via supplementation (Vit D, B12)</li> <li>Comprehensive Geriatric Assessment; Outpatient PACE</li> </ul>"},{"location":"geriatrics/geriatrics-functional-status/","title":"Functional Status","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-functional-status/#background","title":"Background","text":"<ul> <li>Functional status: Ability to perform activities necessary in daily     life (ADL)</li> </ul> Basic ADL\u2019s Instrumental ADL\u2019s Advanced ADL\u2019s <p>Dressing</p> <p>Eating</p> <p>Ambulating/transfer</p> <p>Toileting/continence</p> <p>Hygiene (bathing)</p> <p>Shopping</p> <p>Housekeeping &amp; laundry</p> <p>Handling medications</p> <p>Accounting (finances)</p> <p>Food preparation</p> <p>Telephone</p> <p>Transportation (driving)</p> <p>Fulfill societal, community and family roles</p> <p>Participate in recreational tasks</p>"},{"location":"geriatrics/geriatrics-functional-status/#evaluation","title":"Evaluation","text":"<ul> <li>Katz ADL scale, Lawton-Brody IADL scale, Get up and Go test, MMSE,     Geriatric depression scale.</li> <li>Vulnerable Elders Scale-13: Identifies community dwelling pts at     risk for decline over 5 yrs</li> <li>Functional decline is not normal with aging and warrants detailed     physical, cognitive, and psychosocial evaluations</li> </ul>"},{"location":"geriatrics/geriatrics-malnutrition/","title":"Malnutrition","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-malnutrition/#background","title":"Background","text":"<ul> <li>Needs to meet two or more of following criteria:<ul> <li>Insufficient calorie intake</li> <li>Weight loss</li> <li>Loss of muscle mass</li> <li>Loss of subcutaneous fat</li> <li>Localized fluid accumulation that may mask weight loss</li> <li>Diminished functional status as measured in handgrip strength</li> </ul> </li> <li>Reversible causes of malnutrition:<ul> <li>Food security (poverty), dental status (dentition, gum health), dietary restrictions, food-related functional status (shop, prepare meals, feed self), depression, dementia, alcoholism, swallowing ability</li> </ul> </li> </ul>"},{"location":"geriatrics/geriatrics-malnutrition/#evaluation","title":"Evaluation","text":"<ul> <li>Assess for depression</li> <li>Screening with Mini Nutritional Assessment (good sensitivity and     specificity)</li> <li>Order: CBC, CMP, TSH</li> <li>Nutritional deficiencies: B12, folate, vitamin D</li> <li>Consider CT C/A/P depending on history</li> <li>Refeeding: K, Phos, Mg BID until stable and no longer having to     replete</li> </ul>"},{"location":"geriatrics/geriatrics-malnutrition/#management","title":"Management","text":"<ul> <li>Manage reversible causes of malnutrition as above</li> <li>Medications: consider Remeron (7.5 mg nightly). Avoid Megace (NNH =     23 for death)</li> <li>Liberalize dietary restrictions</li> <li>Nutritional Supplementation: Oral enteral supplements (i.e.     nutritional shakes)</li> </ul>"},{"location":"geriatrics/geriatrics-medication-management/","title":"Medication Management","text":"<p>Thomas Horton</p> <ul> <li>Medication Reconciliation Upon Admission</li> <li>Evaluating for Polypharmacy \u2013 Beer\u2019s Criteria</li> <li>Pharmacologic changes in the elderly<ul> <li>Pharmacokinetic (PK): Decreased hepatic and renal clearance. Reduction in first pass metabolism. Drug distribution changes due to decreased TBW and lean body mass resulting in relative increase in fat.</li> <li>Pharmacodynamic (PD): Exaggerated responses to pharmacologic therapy (therapeutic and adverse effects).</li> </ul> </li> <li>Avoid Prescribing Defaults:<ul> <li>NSAIDs can lead to gastritis, which can lead to prescription of PPI</li> <li>Diuretics can lead to urinary incontinence, which can lead to prescription of oxybutynin</li> <li>HCTZ can lead to hyperuricemia which can lead to prescription of allopurinol</li> </ul> </li> <li>Discharge Tips for med adherence: provide pillboxes &amp; arrange     blister packs for meds</li> <li>Recommended Tools: deprescribing.org (App available); medstopper.com</li> </ul>"},{"location":"geriatrics/geriatrics-overview/","title":"Geriatrics Overview","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-overview/#4-ms-of-age-friendly-care","title":"4 M\u2019s of Age-Friendly Care","text":"<p>Endorsed by the IHI to provide best evidence-based care to older patients across all settings of care:</p> <ul> <li>What **M**atters Most: Understand each patients specific healthcare     goals in the short and long term. Ask \u201cwhat matters most\u201d and align     the care plan with what matters.</li> <li>**M**edication: Aim to reduce adverse drug events in the elderly by     thorough med rec and avoiding potentially inappropriate medications     (e.g. Beers Criteria) when possible</li> <li>**M**entation: Identify, treat, and manage dementia, depression, and     delirium across various settings of care.</li> <li>**M**obility: Assess and optimize mobility</li> </ul> <p>Vanderbilt\u2019s FACETS Inpatient Geriatrics Curriculum: https://sites.google.com/view/facetscourse</p>"},{"location":"geriatrics/geriatrics-overview/#physiological-changes-with-aging","title":"Physiological Changes with Aging","text":"<ul> <li>Cardiovascular: Decreased vascular compliance and increased     stiffness (intimal thickening). Decreased cardiac output. Maximum     achievable HR decreases. Increase in systolic BP with decrease in     diastolic BP (wider PP).</li> <li>Endocrine/Immune: Impairment of glucose tolerance (insulin     resistance). Decreased sympathetic response to stress. Impairment of     T-cell immunity and increased susceptibility to infection.</li> <li>Gastrointestinal: Decreased GI absorption, gastric emptying,     motility, acid secretion, and hepatic blood flow. Reduced appetite     and alterations of taste and smell.</li> <li>Musculoskeletal: Decreased bone density, muscle mass and     strength. Increased fracture risk.</li> <li>Neurologic: Reduced cortical volume. Blunted vision, auditory     function, and vibrotactile sensation. Decreased autonomic neural     response. Slowed cognition and reflexes.</li> <li>Pulmonary: Increased chest wall rigidity. Decreased respiratory     muscle strength. Decreased FEV1; FVC. Diminished ventilatory     response to hypercapnia and hypoxia.</li> <li>Renal: Increased glomerulosclerosis. Decreased GFR and renal     clearance of drugs/metabolites (\u2193 1mL/min per year after age 40; Cr     may stay the same due to reduced muscle mass). Reduced tubular     function.</li> </ul>"},{"location":"geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/","title":"Urinary Incontinence and Foley Catheters","text":"<p>Thomas Horton</p>"},{"location":"geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/#background","title":"Background","text":"Types of UI Mechanism Associated Symptoms Stress <p>Incompetent urethral sphincter</p> <p>(post-prostatectomy)</p> <p>UI with physical exertion</p> <p>(cough, laughter, sneeze)</p> Urge <p>\u2191 bladder contraction from detrusor instability</p> <p>(infection, stone, T2DM, caffeine, meds, BPH</p> Frequency, nocturia, sudden urge Overflow \u2193 contractility/outlet obstruction (BPH, anticholinergic medications, T2DM, pelvic trauma, spinal cord disease, MS, polio) Hesitancy, weak stream, sense of incomplete emptying Functional Physical, emotional, or cognitive disability Depression, pain, evidence of physical, sensory, or cognitive impairment"},{"location":"geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/#evaluation","title":"Evaluation","text":"<ul> <li>Medication Reconciliation:<ul> <li>Alcohol, \u03b1-Adrenergic agonists, \u03b1-Adrenergic blockers, ACE inhibitors, Anticholinergics, Antipsychotics, Calcium channel blockers, oral estrogen, GABAergic agents, NSAID\u2019s, narcotics</li> </ul> </li> <li>Order Hemoglobin A1C, Electrolytes (particularly calcium), UA</li> <li>Rule out retention using PVR</li> <li>Rectal exam to rule out fecal impaction</li> </ul>"},{"location":"geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/#management","title":"Management","text":"<ul> <li>Skin care for urinary incontinence:</li> <li>Barrier creams: Venelex, petroleum, zinc oxide</li> <li>Diapers only when up out of bed</li> <li>Chucks while in bed (don\u2019t hold moisture up close to the skin like     diapers do)</li> <li>Offer toileting Q1-2hours</li> <li>Indications for a foley:<ul> <li>Inability to void</li> <li>Need for accurate UOP monitoring when patient unable to comply</li> <li>Urinary Incontinence AND open sacral or perineal wound</li> <li>Perioperative Use</li> <li>Comfort care at end of life</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/","title":"Anemia","text":"<p>Margaret Wheless</p>"},{"location":"hematology-oncology/hematologyoncology-anemia/#presentation","title":"Presentation","text":"<ul> <li>Symptoms:<ul> <li>Fatigue/malaise, dyspnea on exertion, angina (if history of CAD)</li> </ul> </li> <li>Signs:<ul> <li>Pallor, tachycardia, orthostatic hypotension, purpura, glossitis, koilonychia (in IDA)</li> <li>Jaundice (if hemolysis)</li> <li>Splenomegaly: suggests extramedullary hematopoiesis or sequestration</li> <li>Neurologic symptoms: suggests B12 deficiency</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#evaluation","title":"Evaluation","text":"<ul> <li>CBC w/diff, reticulocyte count, peripheral blood smear, Iron studies     (TIBC, Ferritin)</li> <li>RI &gt; 2%: blood loss vs hemolysis; see below<ul> <li>Hemolysis labs: Bilirubin, LDH, haptoglobin</li> </ul> </li> <li>RI &lt; 2%: hypoproliferative stratify based on RBC size<ul> <li>Microcytic (&lt;80) vs. Normocytic (80-100) vs. Macrocytic (&gt;100)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#reticulocyte-index-2","title":"Reticulocyte Index &gt;2%","text":""},{"location":"hematology-oncology/hematologyoncology-anemia/#background","title":"Background","text":"<ul> <li>Etiology: Consumption vs Blood loss</li> <li>Loss: acute bleed vs iatrogenic from labs</li> <li>Hemolysis: Microangiopathic hemolytic anemia (MAHA), autoimmune     hemolytic anemia (AIHA), intrinsic RBC defects</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#evaluation_1","title":"Evaluation","text":"<ul> <li>LDH, \u2191indirect bilirubin, \u2193haptoglobin, PT/PTT</li> <li>Peripheral blood smear: evaluated for schistocytes, bite cells, spur     cells, spherocytes, etc.</li> <li>Direct antiglobulin test (DAT) to evaluate for autoimmune hemolytic     anemia</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#extrinsic-rbc-causes","title":"Extrinsic RBC causes","text":"<ul> <li>If schistocytes \u00b1 thrombocytopenia = MAHA: TTP, DIC, HUS, HELLP,     mechanical valves, malignant HTN, cocaine, scleroderma renal crisis</li> <li>If DAT positive = AIHA</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#intrinsic-rbc-causes","title":"Intrinsic RBC causes","text":"<ul> <li>Sickle cell disease: chronic hemolysis + splenic sequestration     crisis where RI is\u2191 vs aplastic crisis where RI is\u2193 (see sickle cell     section)</li> <li>Hereditary spherocytosis</li> <li>Hereditary elliptocytosis</li> <li>PNH</li> <li>G6PD: bite cells, Heinz bodies<ul> <li>Usually precipitated by drugs: nitrofurantoin, dapsone, sulfonamides, rasburicase, primaquine</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#management","title":"Management","text":"<ul> <li>MAHA</li> <li>DIC: sepsis, malignancy, pregnancy<ul> <li>Treat underlying cause</li> <li>If active bleeding: FFP, cryoprecipitate (to keep     fibrinogen &gt;100) and platelets</li> </ul> </li> <li>TTP: Order ADAMTS13 (prior to plasma transfusion or exchange)<ul> <li>If concern for TTP you should immediately consult Heme and     Nephrology</li> </ul> </li> <li>HUS: + shiga toxin, AKI, diarrhea</li> <li>AIHA:<ul> <li>Cold (rare): IgM binds at temp &lt;37<ul> <li>Caused by lymphoproliferative disorder (Waldenstr\u00f6m     Macroglobulinemia), mycoplasma, EBV, HIV</li> <li>Consult heme. Treat underlying. Consider rituximab (steroids     ineffective)</li> </ul> </li> <li>Warm: IgG<ul> <li>Idiopathic or associated with lymphoma, SLE, drugs, babesiosis,     HIV</li> <li>Can use steroids, IVIG, rituximab</li> </ul> </li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#reticulocyte-index-2-rbc-size-framework","title":"Reticulocyte Index &lt;2% (RBC Size Framework)","text":""},{"location":"hematology-oncology/hematologyoncology-anemia/#normocytic-anemia-mcv-80-100","title":"Normocytic Anemia: MCV 80-100","text":"<ul> <li>Etiologies<ul> <li>Anemia of inflammation: (may also be microcytic)</li> <li>Anemia of CKD: low Erythropoietin (EPO) levels</li> <li>Endocrine disease (hypothyroidism, adrenal insufficiency):     \u2193metabolic demand/O2 requirement</li> <li>Mixed macrocytic/microcytic disease may have a normal MCV: look for     \u2191RDW</li> <li>Pure red cell aplasia: associated with destructive Ab (CLL, thymoma,     parvovirus, autoimmune)</li> <li>Paroxysmal nocturnal hemoglobinuria (PNH)</li> <li>Bone marrow failure or infiltration (typically will see     pancytopenia)</li> <li>Bone marrow biopsy may be indicated if no identifiable cause or     anemia is associated with other cytopenia\u2019s</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anemia/#microcytic-anemia-mcv-80-mnemonic-salti","title":"Microcytic anemia: MCV &lt;80 (mnemonic: SALTI)","text":"<ul> <li>Sideroblastic, Anemia of chronic disease, Lead poisoning,     Thalassemia and Iron-deficiency</li> </ul> Disease Etiology Evaluation Considerations Sideroblastic <p>MDS</p> <p>Idiopathic</p> <p>EtOH, Lead, Isoniazid</p> <p>Cu deficiency</p> <p>Social hx, TB, consider Lead level</p> <p>Fe: \u2191\u2191</p> <p>Ferritin: \u2191 to nL</p> <p>TIBC: nL</p> <p>Smear: basophilic stippling</p> <p>BMBx: ringed sideroblasts</p> In clinical practice this is usually acquired; either due to alcohol (can resolved with cessation) or primary bone marrow disorder (e.g. MDS-RARS) Anemia of Inflammation (formerly chronic disease) Chronic inflammation, malignancy, HIV, autoimmune dz, heart failure, etc. <p>Fe/TIBC &gt;18%</p> <p>Fe: \u2193\u2193</p> <p>Ferritin: \u2191\u2191</p> <p>TIBC: \u2193\u2193</p> <p>Treat underlying disease</p> <p>Replete Fe if ferritin &lt;100 or TIBC &lt;20%</p> <p>EPO if Hgb &lt;10 and serum EPO &lt;10</p> Thalassemia <p>\u2193 synthesis of \u03b1 or \u03b2 chains leads to \u2193 erythropoiesis and \u2191 hemolysis</p> <p>Family Hx of anemia</p> <p>Mentzer\u2019s index: MCV/RBC &lt;13 = thalassemia</p> <p>Normal Fe studies; can mimic microcytic anemia and Fe overload from transfusions</p> <p>Diagnosis: Hb electrophoresis (\u03b1 will be normal)</p> <p>\u03b1-thal more common in Asian/African descent</p> <p>\u03b2 thal common in Mediterranean descent</p> <p>Tx: transfusions, folate, Fe chelator depending on severity</p> Iron (Fe) deficiency <p>Chronic bleeding: colon cancer, heavy menstrual periods, cirrhosis (portal gastropathy)</p> <p>Supply: malnutrition, Crohn\u2019s dz, Celiac dz, subtotal gastrectomy</p> <p>Demand: pregnancy</p> <p>Fe/TIBC &lt;18%</p> <p>Fe:\u2193\u2193 TIBC:\u2191 nl to \u2191</p> <p>Ferritin: &lt; 100</p> <p>Mentzer\u2019s index: &gt;13</p> <p>Consider celiac testing based on clinical suspicion</p> <p>Investigate for GIB or source of blood loss</p> <p>Oral Fe: 6wks to correct anemia, 6mo to replete stores; dose every other day (\u2191 absorption w/ \u2193 GI side effects); add Vit C for \u2191 absorption</p> <p>If can\u2019t tolerate PO consider IV Fe (Avoid when bacteremic)</p> <p>HFrEF: IV Fe if ferritin &lt;100 OR 100-300 w/ Fe sat &lt;20%</p>"},{"location":"hematology-oncology/hematologyoncology-anemia/#macrocytic-anemia-mcv-100","title":"Macrocytic Anemia: MCV &gt;100","text":"<ul> <li> <p>Non-megaloblastic</p> <ul> <li>ETOH, liver disease, hypothyroidism, MDS</li> <li>Medications that impair DNA synthesis: zidovudine, 5-FU,     hydroxyurea, ara-C, AZT, MTX</li> </ul> </li> <li> <p>Megaloblastic</p> <ul> <li>B12 deficiency<ul> <li>Presentation: neurologic changes (subacute combined     degeneration), paresthesia, ataxia, dementia (reversible with     early treatment)</li> <li>Etiology: malnutrition (alcoholics, vegan), pernicious anemia,     gastrectomy, Crohn\u2019s disease, chronic pancreatitis, celiac     disease</li> <li>Diagnosis: \u2193B12, \u2191MMA, \u2191homocysteine</li> <li>Treatment: either monthly IM or sublingual B12 (oral not     absorbed if no IF)</li> </ul> </li> <li>Folate deficiency<ul> <li>Etiology: malnutrition, decreased absorption (e.g. Celiac     disease), impaired metabolism (MTX, TMP), \u2191requirement     (hemolysis, malignancy, dialysis)</li> <li>Diagnosis: \u2193folate, \u2191homocysteine, MMA will be normal</li> <li>Treatment: PO folate 1-4 mg daily</li> </ul> </li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/","title":"Anticoagulation","text":"<p>Madeleine Turcotte</p> Agent Treatment Dose Renal\u00a0Dose Prophylaxis Monitoring Unfractionated heparin 80 U/kg bolus, then 18 U/kg/hr No change necessary 5000 U q8h PTT (automatic in order set) <p>Enoxaparin</p> <p>(Lovenox)</p> 1 mg/kg q12h 1 mg/kg daily <p>40 mg daily</p> <p>\u00a0\u00a0\u00a0\u00a0\u00a0 or</p> <p>30 mg BID</p> <p>LMWH level (anti-Xa level)</p> <p>Best checked 4 h after 4th dose</p> <p> </p> Warfarin (Coumadin) <p>Start 2-5mg daily and monitor INR</p> <p>Can consult Pharmacy</p> <p> </p> <p>No change</p> <p>necessary</p> N/A <p>PT/INR</p> <p>Use Chromogenic Factor X assay if pt has APLS</p> Dabigatran (Pradaxa) <p>After 5 days of a parenteral AC,</p> <p>150 mg BID</p> Avoid use N/A <p>Can test drug level if concerned</p> <p>(Any DOAC)</p> Rivaroxaban (Xarelto) 15 mg BID x21 d then 20 mg daily Avoid use in CrCl&lt;30 10mg QD Apixaban (Eliquis) 10mg BID x7d, then 5mg BID VTE: No adjustment 2.5 mg BID <p>A Fib:</p> <p>2.5mg BID, if 2 of the following:</p> <p>Cr 1.5, Age\u00a0&gt;\u00a080</p> <p>Weight\u00a0&lt;\u00a060kg</p> Edoxaban (Savaysa) <p>After 5 days of a parenteral AC,</p> <p>60 mg daily</p> <p>30 mg for</p> <p>CrCl 15-50</p> <p>Avoid if CrCl\u00a0&gt; 95</p> Best studied option in renal dysfunction"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#additional-information","title":"Additional Information","text":"<ul> <li>VA is starting to move towards rivaroxaban and apixaban for extended     secondary thromboprophylaxis<ul> <li>Write in your PADR for apixaban citing \u201cpatient uses a pillbox and cannot use dabigatran\u201d</li> </ul> </li> <li>Renal dysfunction: favor warfarin, apixaban or edoxaban</li> <li>Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have     higher risk of GI bleed)</li> <li>Pregnancy: UFH/LMWH (other agents may cross the placenta)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#transitioning-between-anticoagulants-with-doacs","title":"Transitioning Between Anticoagulants with DOACs","text":"<ul> <li>LMWH to Warfarin<ul> <li>Warfarin and LMWH given simultaneously until INR is therapeutic for 24 hours</li> </ul> </li> <li>Warfarin to DOAC<ul> <li>Start DOAC when INR &lt; 2.0</li> </ul> </li> <li>DOAC to Warfarin<ul> <li>High Risk DVT/PE \u2013 start LMWH or UFH, then start Warfarin</li> <li>Low to Moderate Risk DVT/PE \u2013 Start warfarin while patient on DOAC, Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4</li> </ul> </li> <li>LMWH to DOAC<ul> <li>Stop LMWH and start DOAC when due for next dose of LMWH (within 2 hrs)</li> </ul> </li> <li>DOAC to LMWH<ul> <li>Stop DOAC and start LMWH when due for next DOAC dose</li> </ul> </li> <li>UFH to DOAC<ul> <li>Start DOAC when IV stopped (30 min prior to cessation if high risk for thrombosis)</li> </ul> </li> <li>DOAC to UFH<ul> <li>Start IV heparin with bolus when next DOAC dose is due</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#peri-procedural-management-of-anticoagulation","title":"Peri-Procedural Management of Anticoagulation","text":"<ul> <li>Temporary IVC filter indicated in pts with very recent acute VTE     (within 3-4 weeks) if the procedure requires AC delay &gt;12 hours</li> <li>For those at high risk of thromboembolism:<ul> <li>Consider continuing AC for low-bleeding-risk procedures, i.e. dental     procedures, cutaneous biopsy/excision, ICD placement, endovascular     procedures.</li> <li>Can bridge with LMWH or heparin drip</li> </ul> </li> </ul> Stop before procedure Restart after procedure Warfarin 5 days prior, check INR day of 12 to 24 hours after Dabigatran <p>48 hours prior</p> <p>(longer if CrCl 30-50 or procedure is high bleeding risk)</p> <p>1 day after</p> <p>(2 days if high bleeding risk)</p> Rivaroxaban Apixaban Edoxaban Heparin Stop infusion 4-5 hours prior 24 hours after Enoxaparin 12 - 24 hours prior 24 hours after, (48-72 hours if high bleeding risk)"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#strategies-for-reversal-of-anticoagulation","title":"Strategies for Reversal of Anticoagulation","text":""},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#warfarin","title":"Warfarin","text":"<ul> <li>Vitamin K: onset within a few hours but takes 24-48 hrs for full     effect</li> <li>Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30 minutes</li> <li>Intracranial bleed, bleed with hemodynamic instability, emergent     procedure non-life threatening<ul> <li>INR &lt;5: Vitamin K not recommended</li> <li>INR 5-10: Vitamin K 1-5 mg IV or PO</li> <li>INR &gt;10: Vitamin K 5mg PO or 5 mg IV</li> </ul> </li> <li>Prior to surgery<ul> <li>Rapid reversal INR &gt; 5: 5mg Vit K IV (24 hours prior to     procedure)</li> </ul> </li> <li>FFP<ul> <li>15 ml/kg (i.e. 4 units/70 kg person) if need reversal &lt;24 hrs, plus     give Vitamin K</li> </ul> </li> <li>KCentra ($$$): Contains Factors II, VII, IX, and X with Protein C,     Protein S, and heparin<ul> <li>Given instead of plasma when insufficient time for plasma/Vit K to     work (i.e. for life threatening hemorrhage)</li> <li>Avoid giving this in HIT</li> <li>Administer with Vitamin K</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#dabigatran","title":"Dabigatran","text":"<ul> <li>Idarucizumab ($$$) will reverse if prolonged thrombin time (remember     to check!) \u2013 Consult Hematology</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-anticoagulation/#factor-xa-inhibitors-rivaroxaban-apixaban-edoxaban","title":"Factor Xa Inhibitors (rivaroxaban, apixaban, edoxaban)","text":"<ul> <li>FEIBA (Factor VIII inhibitor bypassing activity) \u2013 can promote     coagulation but is not a reversal agent; limited data to     support use</li> <li>Consult Hematology before using; andexanet alfa (FDA approved) is     not on VUMC formulary but is on the VA formulary</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-bone-marrow-transplant/","title":"Bone Marrow Transplant","text":"<p>Chelsie Sievers</p>"},{"location":"hematology-oncology/hematologyoncology-bone-marrow-transplant/#background","title":"Background","text":"<ul> <li>Donor selection<ul> <li>Autologous: self, no matching required (no GVHD risk, but also no     graft-vs-tumor effect)</li> <li>Allogeneic: non-self, matching based on HLA (more matched = less     GVHD risk)<ul> <li>Matched-related donor (MRD): fully matched sibling</li> <li>Matched-unrelated donor (MUD): From NMDP database</li> <li>Haploidentical: Half matched sibling or parent</li> </ul> </li> </ul> </li> <li>Source of stem cells:<ul> <li>Peripheral blood stem cells (PBSCs) vs bone marrow-derived cells vs umbilical cord</li> </ul> </li> <li>Conditioning regimens:<ul> <li>Myeloablative vs Reduced-intensity conditioning (RIC)</li> </ul> </li> <li>GVHD prophylaxis (for allo-SCT):</li> <li>Regimen varies, can include tacrolimus, MMF, MTX, or thymo and     alemtuzumab during conditioning</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-bone-marrow-transplant/#complicationsadverse-effects","title":"Complications/Adverse Effects","text":"<p>Infectious</p> <ul> <li>Neutropenic fever, neutropenic enterocolitis (typhlitis)</li> <li>Bacterial infections</li> <li>Viral infections<ul> <li>CMV: check weekly PCR levels post-allo-SCT<ul> <li>All CMV+ recipients are treated with letermovir     prophylactically regardless of donor status</li> </ul> </li> <li>EBV: check weekly PCR levels post allo-SCT. If EBV VL &gt;1000 on     two occasions, can treat with pre-emptive rituximab to reduce     the risk of PTLD</li> </ul> </li> <li>Invasive fungal infections (e.g. aspergillus, candida)</li> </ul> <p>Non-infectious</p> <ul> <li>Nausea, vomiting, diarrhea, mucositis, cytopenias</li> <li>Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome     (SOS)<ul> <li>Pathophysiology: sinusoidal endothelial cell damage from     conditioning chemo post-sinusoidal portal HTN cytokine release     multiorgan failure and death</li> <li>Diagnosis: T Bili &gt;2, hepatomegaly/RUQ pain, weight gain &gt;2-5%</li> <li>Evaluation: RUQ US with doppler</li> <li>Treatment: Per heme attending; generally supportive, consider     defibrotide</li> </ul> </li> <li>Graft failure:<ul> <li>Primary (persistent neutropenia without engraftment)</li> <li>Secondary (delayed pancytopenia 2/2 immune phenomena or     infection after engraftment)</li> </ul> </li> <li>Engraftment syndrome:<ul> <li>Pathophysiology: PMN recovery cytokine storm vascular leak</li> <li>Symptoms: fever, tachycardia, hypotension, SOB, pulmonary edema,     rash, weight gain, bone pain, confusion</li> <li>Diagnosis: Clinical</li> <li>Treatment: high-dose IV steroids</li> </ul> </li> <li>Acute GVHD:<ul> <li>Only in allogenic; Increased risk with more HLA mismatch</li> <li>Pathophysiology: donor T cells attack recipient (Th1-mediated)</li> <li>Symptoms: skin rash, cholestatic liver injury, diarrhea</li> <li>Treatment: IV steroids (methylprednisolone 1-2mg/kg x 5d)<ul> <li>If refractory: mycophenolate, etanercept, ruxolitinib,     antithymocyte globulin</li> </ul> </li> </ul> </li> <li>Chronic GVHD (typically after T+100)<ul> <li>Can involve all organs but typically see a scleroderma-like     picture (xerophthalmia, xerostomia dysphagia, arthritis, skin     changes, malar rash, obliterative bronchiolitis, cholestatic     liver injury, cytopenias)</li> <li>Treatment: steroids (also photophoresis for skin), consider     trials of ruxolitinib, ibrutinib, rituximab if refractory</li> </ul> </li> <li>PTLD (post-transplant lymphoproliferative disorders)<ul> <li>Pathophysiology: B-cell proliferative disease typically 2/2     latent EBV</li> <li>Symptoms: fever, weight loss, fatigue, lymphadenopathy,     extra-nodal masses, \u2191 EBV PCR</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-cart/","title":"CAR T-cell Therapy","text":"<p>Chelsie Sievers</p>"},{"location":"hematology-oncology/hematologyoncology-cart/#background","title":"Background","text":"<ul> <li>Chimeric antigen receptor T cells (CAR-T) are a type of autologous     T-cell therapy collected from the patient and genetically modified     to contain an extracellular tumor-specific antigen target linked to     the internal component of the T-cell receptor.</li> <li>Goal: patient's own T-cells can specifically target the tumor cell     population.</li> <li>FDA approved therapies: Kymriah (CD19), Abecema (BCMA), Breyanzi     (CD19), Tecartus (CD19), Yescarta (CD19)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-cart/#complications","title":"Complications","text":"<ul> <li>Cytokine Release Syndrome (CRS)<ul> <li>Pathophysiology: Supraphysiologic immune cell response with     release of inflammatory cytokines.<ul> <li>Grade 1: fever \u2265100.4, no hypotension, no hypoxia</li> <li>Grade 2: fever \u2265100.4, hypotension not requiring     vasopressors and/or hypoxia requiring &lt; 6L</li> <li>Grade 3: fever \u2265100.4, hypotension requiring a vasopressor,     hypoxia requiring &gt;6L or non-rebreather</li> <li>Grade 4: fever \u2265100.4, hypotension requiring multiple     vasopressors, hypoxia requiring positive pressure</li> </ul> </li> <li>Work-up: blood and urine cultures (IV abx if needed)</li> <li>Treatment: acetaminophen for fever, ICU transfer (grade 1 okay     for floor), Tocilizumab 8 mg/kg IV (max 800mg; up to 3 doses in     24 hours, 8 hours apart), Dexamethasone 10 mg IV q 6 hours     (grade 3-4).</li> </ul> </li> <li>ICANS: Immune Effector Cell-Associated Neurotoxicity Syndrome</li> <li>Pathophysiology: high systemic inflammation leaky blood brain     barrier encephalopathy \u00b1 cerebral edema.<ul> <li>Based on ICE score: Orientation: orientation to year, month,     city, hospital: 4 points; Naming: ability to name 3 objects (eg,     point to clock, pen, button): 3 points; Following commands:     ability to follow simple commands (eg, \u201cShow me 2 fingers\u201d or     \u201cClose your eyes and stick out your tongue\u201d): 1 point; Writing:     ability to write a standard sentence (eg, \u201cOur national bird is     the bald eagle\u201d): 1 point; Attention: ability to count backwards     from 100 by 10: 1 point.</li> <li>Grade 1: ICE score: 7-9</li> <li>Grade 2: ICE score: 3-6</li> <li>Grade 3: ICE score 0-2</li> <li>Grade 4: ICE score 0</li> </ul> </li> <li>Work-up: neuro consult, fundoscopic exam for papilledema, consider     MRI brain w/&amp;w/o contrast, consider EEG, consider non-con CT head if     headache/lethargy.</li> <li>Treatment: q4hr neuro checks (q1hr if grade &gt;2 \u2192 ICU transfer),     Keep Na 135-145 with hypertonic saline if necessary (Na 145-150 if     grade 4), consider thiamine supplementation 500mg q8hrs,     Dexamethasone 10 mg q 6 hours (if seizure give 20mg x 1, then 10mg     q6hrs) (grade 2-3), Methylprednisolone 1000 mg IV q 24 x 3 days     (grade 4).</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-coagulopathies/","title":"Coagulopathies","text":"<p>Jason Jones</p>"},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#overview","title":"Overview","text":"<ul> <li>Step one: determine if platelet vs coagulation disorder</li> <li>Platelet Disorders: Skin/mucous membrane bleeding; Petechiae; Often     mild bleeding following surgery and tends to immediately follow     surgery</li> <li>Coagulation defect: Bleeding deep in soft tissues (muscles/joints);     hemarthroses, hematomas; tendency to have delayed bleeding after     surgery that can be severe</li> <li>Coagulopathies can be divided into Hereditary vs Acquired causes</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#hereditary","title":"Hereditary","text":""},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#hemophilia-a-factor-viii-deficiency-and-hemophilia-b-factor-ix-deficiency","title":"Hemophilia A (Factor VIII Deficiency) and Hemophilia B (Factor IX Deficiency)","text":"<ul> <li>Inherited in X-linked Recessive pattern</li> <li>Diagnosis: Isolated prolonged PTT with normalization upon mixing     study</li> <li>Management: purified/recombinant Factor VIII or IX. Desmopressin for     mild disease</li> <li>Consult benign hematology every time these patients are admitted</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#von-willebrand-disease-vwd","title":"von Willebrand Disease (vWD)","text":"<ul> <li>Can be hereditary (common) or acquired</li> <li>Abnormal quantity or function of von Willebrand Factor (vWF) needed     for platelet function</li> <li>Type 1 (most common): Quantitative defect. Low quantity, normal     function of vWF</li> <li>Type 2: Qualitative defect. Normal quantity, abnormal function of     vWF.</li> <li>Type 3 (rare): Complete absence of vWF, phenotypically similar to     hemophilia A</li> <li>Order in Epic: vW Profile = vWF Ag, Factor VIII Activity, Ristocetin     Cofactor Activity</li> <li>Management: Desmopressin (DDAVP) can be useful as prophylaxis or     treatment; most patients are treated with factor concentrate     replacements</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#acquired","title":"Acquired","text":""},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#coagulation-factor-inhibitors","title":"Coagulation Factor Inhibitors","text":"<ul> <li>Associated with autoimmune disease (paraneoplastic vs. autoantibody)</li> <li>Seen in hemophilia due to frequent treatments with recombinant     factors (alloantibody)</li> <li>Diagnosis: Elevated PTT that does not normalize with mixing study</li> <li>Management: Immunosuppression with steroids; cyclophosphamide \u00b1     rituximab</li> <li>Consult Hematology always (rare disorder with major bleeding     complications)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-coagulopathies/#vitamin-k-deficiency","title":"Vitamin K Deficiency","text":"<ul> <li>Caused by malnutrition, liver disease, or iatrogenic with warfarin</li> <li>Diagnosis: elevated PT, if severe may have prolonged PTT as well</li> <li>Management: Replace vitamin K</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-dic/","title":"Disseminated Intravascular Coagulation (DIC)","text":"<p>Eric Singhi</p>"},{"location":"hematology-oncology/hematologyoncology-dic/#background","title":"Background","text":"<ul> <li>Concurrent activation of the coagulation pathway and fibrinolytic     pathway</li> <li>Consumption of platelets, fibrin, and coagulation factors     fibrinolysis end organ damage and hemolysis</li> <li>Etiologies:<ul> <li>Infection/Sepsis, Liver disease, Pancreatitis, Trauma</li> <li>Malignancies: mucin-secreting pancreatic/gastric adenocarcinoma,     brain tumors, prostate cancer, all acute leukemias, acute     promyelocytic leukemia</li> <li>Obstetric complications (i.e. preeclampsia/eclampsia, placental     abruption)</li> <li>Acute hemolytic transfusion reaction (i.e. ABO incompatible     transfusion)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-dic/#evaluation","title":"Evaluation","text":"<ul> <li>Exam: petechiae, bleeding (mucosal, IV site, surgical wound site,     hematuria), ecchymoses, thrombosis (i.e. cold, pulseless     extremities)</li> <li>CBC, PT/INR, aPTT, Fibrinogen, D-Dimer, Peripheral Blood Smear</li> <li>\u201cDIC labs\u201d = q6h fibrinogen, PT/INR, aPTT (space out when lower     risk)</li> <li>Findings suggestive of DIC: thrombocytopenia, prolonged aPTT and     PT/INR, hypofibrinogenemia, elevated D-dimer, fibrin degradation     products, schistocytes</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-dic/#management","title":"Management","text":"<ul> <li>Treat the underlying cause!</li> <li>Vitamin K for INR &gt; 1.7 or bleeding</li> <li>Hypofibrinogenemia treatment: Cryoprecipitate 5-10 units if     fibrinogen &lt; 100</li> <li>Thrombocytopenia treatment: plt transfusion as normally indicated</li> <li>DVT ppx if not bleeding and plt &gt; 50</li> <li>VTE: anticoagulation if plt &gt; 50 and no massive bleeding</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/","title":"Hypercoagulable States","text":"<p>Chris Cann</p>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#background","title":"Background","text":"<ul> <li>Virchow\u2019s triad: 1. Hypercoagulability 2. Stasis 3. Endothelial     injury</li> <li>Diagnostic thrombophilia testing indications:<ul> <li>Idiopathic or recurrent VTE</li> <li>First VTE at &lt;40 years old</li> <li>VTE in the setting of strong family history</li> <li>VTE in unusual vascular site (cerebral, renal, mesenteric)</li> <li>Recurrent pregnancy loss</li> </ul> </li> <li>Must consider if thrombophilia testing will change clinical     management</li> <li>If the unprovoked VTE warrants indefinite anticoagulation then     testing may not be helpful</li> <li>However, if VTE provoked by minor risk factor (OCPs) with an     underlying thrombophilia might change the decision, then testing may     be informative</li> <li>Separated into Acquired and Hereditary conditions:<ul> <li>Hereditary: Factor V Leiden mutation, Prothrombin mutation, Protein     C or S deficiency, Antithrombin deficiency</li> <li>Acquired:<ul> <li>Antiphospholipid Syndrome (APLS)</li> <li>Heparin induced thrombocytopenia (HIT)</li> <li>Major surgery/trauma</li> <li>Nephrotic Syndrome</li> <li>Smoking</li> <li>Pregnancy</li> <li>Oral Contraceptives</li> <li>Immobilization (bedridden, hip/knee replacement)</li> <li>Active malignancy</li> <li>Estrogen replacement therapy</li> <li>Note: Travel (plane, train, automobile) is NOT on this list and     this is NOT considered a provoking risk factor</li> </ul> </li> <li>Testing: all specific testing for hereditary disorders and APS     should be performed at least 4-6 weeks after an acute thrombotic     event or discontinuation of anticoagulant/thrombolytic therapies to     avoid interference</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#antiphospholipid-antibody-syndrome-apls","title":"Antiphospholipid antibody syndrome (APLS)","text":""},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#background_1","title":"Background","text":"<ul> <li>Most common acquired disorder (anti-phospholipid antibodies present     in 3-5% population)</li> <li>Recurrent pregnancy loss, provoked DVT in young, unprovoked VTE and     arterial thrombosis in young, thrombosis unusual sites, thrombosis     in autoimmune disease</li> <li>This is a clinicopathologic diagnosis (need both clinical and     laboratory criteria)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#evaluation","title":"Evaluation","text":"<ul> <li>Positive for at least 1 lab criterion on at least 2 occasions, at     least 12 weeks apart:<ul> <li>Lupus anticoagulant: can occur in relation to drugs or infection;     transient are associated with thrombotic risk</li> <li>Anticardiolipin antibodies</li> <li>B2GP1 (anti-beta2-glycoprotein) antibodies</li> </ul> </li> <li>Must also meet at least 1 of the following clinical criteria:<ul> <li>Vascular thrombosis: DVT, arterial thrombosis, or small vessel     thrombosis of any organ</li> <li>Pregnancy loss: there are specific criteria for this \u2013 consult     UpToDate or other resource</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#management","title":"Management","text":"<ul> <li>Aspirin for primary prevention; warfarin for treatment (INR 2-3)</li> <li>Do NOT use DOACs for triple positive APLS (see TRAPS trial:     rivaroxaban inferior to warfarin)</li> <li>Rituximab for recurrent thrombosis despite anticoagulation     (controversial) \u2013 call hematology</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#heparin-induced-thrombocytopenia-hit","title":"Heparin-induced thrombocytopenia (HIT)","text":"<p>Type 1: Mild and self-limited (not immune-mediated)</p> <ul> <li>Occurs within the first 2 days of first-time exposure</li> <li>Platelet count normalizes with continued heparin therapy</li> </ul> <p>Type 2 (what we typically refer to as HIT): Immune mediated</p> <ul> <li>Fall in plt 30% to over 50% (even if plt count &gt;150) and/or     thrombotic event has occurred</li> <li>4-10 days after new exposure to heparin derivative OR\u2264</li> <li>1 day after restarting heparin derivative that had been used 30-100     days prior<ul> <li>If exposed to heparin within 100 days, will have platelet drop     within 24 hr</li> </ul> </li> <li>Frequency: unfractionated heparin &gt; LMWH; Surgical wards &gt; medical     wards</li> <li>50% will have thrombotic event in 30 days if HIT is untreated, with     20% mortality</li> <li>Arterial thrombi are common in HIT</li> <li>HIT results from antibodies to complexes of platelet factor 4 (PF4)     and heparin, further activating platelets (the activated platelets     aggregate causing thrombocytopenia)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#evaluation_1","title":"Evaluation","text":"<ul> <li>4T score (0-8 points):<ul> <li>Thrombocytopenia (0-2 pts): degree and nadir of platelet count drop</li> <li>Timing (0-2 pts): timing of fall after initial or recurrent heparin     exposure</li> <li>Thrombosis (0-2 pts): thrombosis, skin necrosis, non-necrotizing     lesions, acute systemic reaction to heparin</li> <li>Other causes of thrombocytopenia (0-2 pts): more points if no     alternate cause</li> </ul> </li> <li>Solid-phase ELISA for heparin-PF4 antibodies:<ul> <li>0.2-0.4 is indeterminate</li> <li> <p>0.4 is positive</p> </li> <li> <p>1.4 HIT is likely</p> </li> <li> <p>2 confirms HIT</p> </li> <li>The lab at VUMC will perform functional SRA reflexively for all     values &gt;0.2</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#management_1","title":"Management","text":"<ul> <li>0-3 points: Low concern for HIT; can restart heparin</li> <li>4-5 points: Intermediate probability (~10%) - hold heparin, start     non-heparin anticoagulant</li> <li>6 points: High probability (~50%) - hold heparin, start non-heparin     anticoagulant</li> <li>Argatroban (direct thrombin inhibitor) for prophylaxis and treatment     of thrombosis</li> <li>Avoid platelet transfusions as can increase thrombogenic effect</li> <li>Avoid warfarin until complete platelet recovery as may cause     microthrombosis</li> <li>Hematology consult for all confirmed HIT</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#factor-v-leiden-mutation","title":"Factor V Leiden mutation","text":""},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#evaluation_2","title":"Evaluation","text":"<ul> <li>Activated protein C resistance assay<ul> <li>APC ratio in patient vs normal</li> <li>normal &gt;2.0, heterozygotes 1.5-2.0, homozygotes &lt;1.5</li> </ul> </li> <li>FVL mutation is then determined via PCR</li> <li>Screen with APC assay rather than PCR initially; cost effective</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#management_2","title":"Management","text":"<ul> <li>VTE treatment same as general population</li> <li>VTE 4-8x risk in heterozygotes; 80x risk in homozygotes</li> <li>Avoid OCPs: increased risk for VTE</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#prothrombin-gene-mutation","title":"Prothrombin gene mutation","text":""},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#evaluation_3","title":"Evaluation:","text":"<ul> <li>PCR of G20210A mutation (2-4% prevalence)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#management_3","title":"Management:","text":"<ul> <li>VTE treatment same as general population &amp; avoid OCPs</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#protein-c-s-deficiency","title":"Protein C &amp; S Deficiency","text":""},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#background_2","title":"Background","text":"<ul> <li>Autosomal dominant; first event occurs between 10-50 years of age</li> <li>Synthesized in liver and Vit K dependent, therefore low levels in     hepatic dysfunction and warfarin use/vitamin K deficiency</li> <li>Protein C: low in settings of thrombosis, DIC, nephrotic syndrome,     intra/post-op</li> <li>Protein S: low in infectious (HIV) and autoimmune processes (IBD)</li> <li>Protein S decreases during pregnancy (decreased free Protein S,     normal total Protein S)</li> <li>Do not misdiagnose a pregnant patient with PS deficiency</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#evaluation_4","title":"Evaluation","text":"<ul> <li>Functional Protein C &amp; S assays</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#management_4","title":"Management","text":"<ul> <li>VTE treatment same as general population</li> <li>Avoid OCPs</li> <li>High risk patients may require protein C concentrate prior to     surgery</li> <li>Increased risk of warfarin-induced skin necrosis</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#antithrombin-deficiency","title":"Antithrombin deficiency","text":""},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#background_3","title":"Background","text":"<ul> <li>Autosomal dominant, does not skip generations</li> <li>VTE in unusual sites (cerebral sinuses, renal veins)</li> <li>Present &lt; 50 y/o, but rarely in first two decades</li> <li>Decreased in liver disease, nephrotic syndrome, protein losing     enteropathy, burn, trauma, bypass surgery, metastatic tumors,     premenopausal, OCP use, pregnancy</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#evaluation_5","title":"Evaluation","text":"<ul> <li>Functional antithrombin activity (AT-heparin cofactor assay)</li> <li>Then perform antigen quantity testing</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-hypercoagulable-states/#management_5","title":"Management","text":"<ul> <li>Can use Argatroban as does not require antithrombin function</li> <li>Warfarin preferred in VTE (titrate up based on expression of     antithrombin deficiency)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/","title":"Acute Leukemia","text":"<p>Robert Corty</p>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#background","title":"Background","text":"<ul> <li>Hematological malignancy caused by unchecked proliferation of WBC     precursors in the bone marrow</li> <li>Pt\u2019s with suspected acute leukemia require hospitalization for     urgent diagnosis &amp; treatment</li> <li>Types:<ul> <li>AML = Acute Myeloid Leukemia<ul> <li>APL = Acute Promyelocytic Leukemia defined by translocation     (15;17) PML-RARA</li> </ul> </li> <li>ALL = Acute Lymphocytic Leukemia</li> </ul> </li> <li>Risk Factors:<ul> <li>radiation, chemical exposures (e.g benzene), chemotherapy (esp     alkylating agents)</li> <li>HIV, immunosuppression, smoking</li> <li>myeloproliferative disorders, aplastic anemia</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#presentation","title":"Presentation","text":"<ul> <li>Leukocytosis, leukemia cutis, gingival hypertrophy, leukostasis</li> <li>Functional Leukopenia, often neutropenia: recurrent infections</li> <li>Anemia: fatigue, pallor, dyspnea</li> <li>Thrombocytopenia: gingival bleeding, epistaxis, petechiae,     ecchymoses, menorrhagia</li> <li>Extramedullary hematopoiesis: splenomegaly, hepatomegaly,     lymphadenopathy</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#evaluation","title":"Evaluation","text":"<ul> <li>Diagnosis of acute leukemia requires one of the following:<ul> <li>20% blasts in peripheral blood</li> <li> <p>20% blasts in bone marrow biopsy</p> </li> <li>Any pathognomonic cytogenetic abnormality of t(8;21), inv(16),     t(15;17)</li> </ul> </li> <li>Check for the presence of these time-sensitive conditions.<ul> <li>DIC \u2013 check fibrinogen, PT, PTT, platelets</li> <li>TLS \u2013 check uric acid, phosphate, K+</li> <li>Neutropenic fever \u2013 check temp, neutrophil count</li> <li>Leukostasis (see below)</li> <li>Presumptive APL \u2013 promyelocytes on diff, DIC or Auer rods on smear</li> </ul> </li> <li>Confirm if peripheral flow cytometry ordered/in process</li> <li>Use hematology admission order set</li> <li>Set RBC and Plt transfusion thresholds</li> <li>Order nurse-driven electrolyte repletion</li> <li>ECG and TTE to establish pre-chemotherapy cardiac function</li> <li>Daily labs: CBC, TLS, DIC</li> <li>TLS prophylaxis</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#management","title":"Management","text":"<ul> <li>Consult hematology</li> <li>Discuss chemo plan and order double lumen PICC for reliable access</li> <li>If findings suggest APL start ATRA</li> <li>Subspecialized lab tests: bone marrow biopsy, cytogenetics, FISH</li> <li>Monitor for Common Complications/Emergencies: (see individual     sections)<ul> <li>TLS, DIC, Febrile Neutropenia, Leukostasis</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#additional-information","title":"Additional Information","text":"<ul> <li>Obtain blood product consent on admission</li> <li>APL Specific findings: promyelocytes on differential or Auer rods on     smear</li> <li>Differentiation syndrome: promyelocytes differentiate<ul> <li>Symptoms and signs: fever, SOB, Hypotn, peripheral edema, pleural     effusion, AKI</li> <li>Diagnosis: No defined criteria. If suspicious, discuss with     hematology fellow</li> <li>Management: steroids. If critically ill, hold ATRA and ATO and     consider hydroxyurea</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#leukemia-treatment-overview","title":"Leukemia Treatment Overview","text":"<ul> <li>General strategy is to use \u201cinduction\u201d chemo to try to induce     clinicopathologic (as opposed to molecular) \u201cremission\u201d</li> <li>Defined as absence of symptoms, normal CBC, and &lt;5% blasts in bone     marrow (on day 28)</li> <li>Then waiting in hospital until neutrophil count &gt;500 (typically ~3 weeks)</li> <li>From there, bone marrow transplant (for high-risk disease) or     \u201cconsolidation\u201d chemo for normal-risk or low-risk disease</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#aml-treatment","title":"AML Treatment","text":"<ul> <li>Induction<ul> <li>Typical is \u201c7+3\u201d i.e. idrarubicin on days 1-3 and cytarabine on days     1-7</li> <li>If therapy-related AML, MDS-related AML, or AML with cytogenetics     similar to MDS, use \u201cVyxeos\u201d which is liposomal daunorubicin and     cytarabine on days 1, 3, and 5</li> <li>If low-risk dz (t(8;21) or inv(16)), use cytarabine on days 1-7, and     3 days of low-dose daunorubicin + gemtuzumab-ozogamicin</li> <li>There are other induction regimens that can be used depending on     specific cytogenetics and patient frailty, which is beyond the scope     of the handbook</li> </ul> </li> <li>Consolidation<ul> <li>Typically \u201cHiDAC\u201d(high-dose Ara-C i.e. cytarabine)<ul> <li>Generally too toxic for pts with age &gt; 60, so a dose reduction     is used</li> </ul> </li> <li>In the case of relapse, typical treatment is a different high-dose     chemo and BMT if possible</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#all-treatment","title":"ALL Treatment","text":"<ul> <li>Typical induction is \u201cHyperCVAD\u201d (hyper-fractionated     cyclophosphamide, vincristine, doxorubicin (\u201cA\u201d due to trade name     Adriamycin), and dexamethasone</li> <li>If t(9;22) (known as Philadelphia chromosome), use tyrosine kinase     inhibitor (TKI)</li> <li>If CD20+, use rituximab</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukemia/#common-chemotherapy-regimens-for-leukemia-encountered-as-inpatient","title":"Common Chemotherapy Regimens for Leukemia Encountered as Inpatient","text":"Regimen Components Use <p>7+3</p> <p> </p> Cytarabine (Ara-C) x 7 d &amp; Anthracycline\u00a0 (e.g. idarubicin x3 d) AML induction Vyxeos Cytarabine + liposomal daunorubicin AML-MRC or t-AML CLAG-M Cladribine, cytarabine (Ara-C), Filgrastim (G-CSF), mitoxantrone AML induction (relapsed/refractory) HIDAC High-dose cytarabine AML consolidation ATRA <p>All-trans retinoic acid</p> <p>given with arsenic trioxide (ATO)</p> APL (APML) HyperCVAD/MA <p>CVAD = Cyclophosphamide, vincristine, doxorubicin, dexamethasone</p> <p>MA = methotrexate/cytarabine\u00a0</p> <p>(Given as alternating cycles)</p> ALL R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone NHL R-EPOCH <p>Etoposide plus the drugs above</p> <p>(dosing is different)</p> NHL ABVD Doxorubicin, bleomycin, vinblastine, dacarbazine HL"},{"location":"hematology-oncology/hematologyoncology-leukocytosis/","title":"Leukocytosis","text":"<p>Kenna Koehler</p>"},{"location":"hematology-oncology/hematologyoncology-leukocytosis/#background","title":"Background","text":"<ul> <li>Common progenitor cells (stem cells) are located in the bone marrow     and give rise to erythrocytes, myeloblasts, megakaryoblasts</li> <li>Normal WBC can vary by age and pregnancy, for the purpose of this     section will assume this is for an average, non-pregnant adult</li> <li>Chronic mild neutrophilic leukocytosis (10-20k) is common with     tobacco use and obesity, both due to mechanisms related to chronic     inflammation</li> <li>Reactive (typically 11k-30k) - surgery, exercise, trauma, burns,     emotional stress</li> <li>Leukemoid reaction (typically 50k-100k) - severe infections     (fulminant C difficile), organ rejection</li> <li>If greater than 100k, think leukemia or myeloproliferative disorder</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-leukocytosis/#evaluation","title":"Evaluation","text":"<ul> <li>Neutrophilia (neutrophil count &gt;7k)<ul> <li>Bacterial infection, pregnancy, rheumatologic disease, steroids, beta agonists, lithium, colony-stimulating factors, splenectomy or functional asplenia, congenital (hereditary/chronic idiopathic neutrophilia), Down syndrome, leukocyte adhesion deficiency, malignancy, smoking, obesity</li> </ul> </li> <li>Lymphocytosis (&gt;40% of WBC count or &gt;4,500k/mm3)<ul> <li>Infections (pertussis, syphilis, CMV, EBV, hepatitis A/B/C, toxo), hypersensitivity reactions, thyrotoxicosis, Addison's disease, hematologic malignancies, \u201creactive\u201d</li> </ul> </li> <li>Monocytosis (&gt;8% of WBC count or &gt;880/mm3)<ul> <li>Infections (TB, fungal disease, protozoa, tick-borne), autoimmune disease, malignancy (CMML)</li> </ul> </li> <li>Eosinophilia (&gt;500/mm3)<ul> <li>Hypersensitivity (asthma, urticaria, atopic dermatitis, eosinophilic esophagitis), drug reactions, malignancies, connective tissue disease, idiopathic hypereosinophilic syndrome, infections (helminths, Scarlet fever, Hansen's disease), sarcoidosis, SLE</li> <li>Hypereosinophilia if AEC&gt;1500, typically merits heme evaluation</li> <li>Hypereosinophilic syndrome: AEC&gt;1500 and organ dysfunction from eosinophils</li> </ul> </li> <li>Basophilia (&gt;100/mm3)<ul> <li>CML, thyroid disease, IBC, chronic dermatitis, infections (varicella)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-lymphoma/","title":"Lymphoma","text":"<p>Danielle Fishman</p>"},{"location":"hematology-oncology/hematologyoncology-lymphoma/#background","title":"Background","text":"<ul> <li>Classically characterized by lymphadenopathy &amp; constitutional \u201cB\u201d     symptoms: fevers, drenching night sweats and weight loss</li> <li>Hodgkin:<ul> <li>10%</li> <li>superficial, nodal disease with orderly spread</li> <li>Bimodal Distribution: 15-35 years and &gt;50 years; M&gt;F</li> <li>CD15+, CD30+ (Reed Sternberg cells \u201cowl eyes\u201d)</li> <li>Associated with EBV in immunocompromised patient</li> </ul> </li> <li>Non-Hodgkin:<ul> <li>90%</li> <li>diffuse, nodal and extranodal disease with     noncontiguous spread</li> <li>Average 65 years, M&gt;F, 85-90% B-cell</li> <li>Associated with immunodeficiency (HIV, post-transplant), autoimmune     disease, infection (EBV, HTLV-1, H pylori, HCV, Borrelia, C     psittacosis, Coxiella)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-lymphoma/#general-evaluation","title":"General Evaluation","text":"<ul> <li>History<ul> <li>B symptoms; pruritus (10-15% of pt with HL); history of radiation</li> </ul> </li> <li>Physical Exam<ul> <li>Head &amp; neck, tonsils, axilla, testes, liver, spleen</li> <li>Lymphadenopathy: painless, firm, fixed, &gt;1cm</li> </ul> </li> <li>Lab tests:<ul> <li>CBC, CMP, LDH, Uric Acid, Phosphorus</li> <li>Consider HBV, HCV, HIV, EBV, Quant gold, Treponemal Ab, ANA</li> </ul> </li> <li>Imaging:<ul> <li>CT chest, abdomen, pelvis</li> <li>Most will eventually need PET-CT; MRI brain if neuro symptoms</li> </ul> </li> <li>Consider LP for NHL with high risk of CNS involvement or presence of     neurological symptoms<ul> <li>Risk factors: Burkitt, Lymphoblastic, testicular involvement,     double/triple hit</li> <li>Multiple LPs may be required to diagnose CNS lymphoma</li> </ul> </li> <li> <p>Diagnosis requires tissue</p> <ul> <li>Excisional Lymph node biopsy (Surg Onc Consult)</li> <li>Core biopsy (CT guided procedure consult)</li> <li>Of note, steroids may impact value of biopsy results</li> </ul> </li> <li> <p>Lugano Classification: staging of lymphoma</p> <ul> <li>I. 1 LN region or single extra lymphatic organ/site without nodal involvement</li> <li>II. &gt;2 LN regions, same side of diaphragm</li> <li>III. LN regions on both sides of diaphragm</li> <li>IV. Disseminated disease w/ 1+ extralymphatic organ</li> </ul> </li> <li> <p>Hodgkin:</p> <ul> <li>IPS negative prognostic calculator: albumin &lt;4, hemoglobin &lt;10.5,     male, stage IV disease, age&gt;45, WBC count&gt; 15K,     lymphocyte &lt;8% of WBC count</li> </ul> </li> <li>Non-Hodgkin:<ul> <li>Good prognosis: Follicular, Marginal Zone, Mycosis     Fungoides/Sezary Syndrome</li> <li>Poor prognosis: DLBCL \u2013 can arise from low grade lymphoma     Richter transformation), Double/Triple Hit: bcl-2, bcl-6,     or myc aberrations, Mantle Cell, Burkitt, Lymphoblastic     Lymphoma, and Anaplastic Large Cell Lymphoma</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-lymphoma/#general-management","title":"General Management","text":"<ul> <li>ECG and TTE to establish pre-chemotherapy cardiac function \u2013 many     chemo regimens with anthracyclines</li> <li>Daily labs: CBC, TLS, LDH</li> <li>TLS prophylaxis: mIVF, allopurinol</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-lymphoma/#common-chemotherapy-regimens-for-lymphoma","title":"Common Chemotherapy Regimens for Lymphoma","text":"Regimen Components Use R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone NHL R-EPOCH <p>Etoposide plus the drugs above</p> <p>(dosing is different)</p> <p>NHL</p> <p>(Double/Triple hit)</p> Hyper-CVAD Cyclophosphamide, vincristine, doxorubicin, and dexamethasone NHL HD-MTX + R High Dose methotrexate + Rituxumab Primary CNS Lymphoma ABVD Doxorubicin, bleomycin, vinblastine, dacarbazine HL"},{"location":"hematology-oncology/hematologyoncology-medical-oncology-resources/","title":"Medical Oncology Resources","text":"<p>Eric Lander</p>"},{"location":"hematology-oncology/hematologyoncology-medical-oncology-resources/#resources","title":"Resources","text":"<p>NCCN (National Comprehensive Cancer Center Network, https://www.nccn.org/): consensus based treatment guidelines for most hematopoietic and solid tumors.\u00a0 Free for house staff.</p> <p>https://www.HemOnc.org - comprehensive, expert-curated, wiki-style resource, seeks to catalogue all treatment regimens across all cancers. Born at VUMC.</p>"},{"location":"hematology-oncology/hematologyoncology-medical-oncology-resources/#vumc-oncology-rotation-tips","title":"VUMC Oncology Rotation Tips","text":"<p>The inpatient oncology rotation involves complex decisions often resulting from advancing diseases. The question \u201cWhat do you want?\u201d is too simple. Rather, it should be \u201cGiven your current circumstance, and given our choices, which path would you prefer to take?\u201d Patients want advice from their outpatient doctors who have been caring for them for years. Therefore, treatment and goals discussions often must pass through the inpatient attending to the outpatient attending. Be sure to define how communication with this primary oncologist will be handled.</p> <p>Oncology summary sentence in presentation:</p> <ol> <li>Cancer type and stage (at diagnosis \u2013 stage never changes even if     progressed)</li> <li>Pertinent tumor genetic information</li> <li>Any relevant surgeries (e.g. resections)</li> <li>Most recent treatment</li> <li>Trajectory of disease (e.g. progressive, improving, or stable)</li> <li>Patient\u2019s primary oncologist</li> </ol> <p>Ex: Ms. X is a 64 y/o female w/ stage IIIa adenocarcinoma of the lung post resection now with metastases to the spine (patient of Dr. Y) admitted w/intractable back pain and leg weakness. Full NGS at diagnosis with no actionable mutations, and was 40% positive for PDL1. No previous chemo.</p>"},{"location":"hematology-oncology/hematologyoncology-myelodysplastic-syndromes/","title":"Myelodysplastic Syndromes","text":"<p>Peter Hanna</p>"},{"location":"hematology-oncology/hematologyoncology-myelodysplastic-syndromes/#background","title":"Background","text":"<ul> <li>MDS is a malignant clonal myeloid disorder resulting in ineffective     (dysplastic) hematopoiesis leading to peripheral cytopenia\u2019s and a     risk of transformation to acute myeloid leukemia (AML)</li> <li>Usually idiopathic, a disease of the elderly (median onset at age     70)</li> <li>The WHO has several classification schemes for MDS<ul> <li>Most important for classification is the percent of blasts in the     bone marrow</li> <li>Note &gt;20% blasts in marrow = AML. Thus MDS &amp; AML are on a continuum</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myelodysplastic-syndromes/#presentation","title":"Presentation","text":"<ul> <li>50% asymptomatic; Symptoms can include nonspecific but gradual     fatigue, weakness</li> <li>Dysplastic cells do not work properly infections and bleeding are     more likely</li> <li>Macrocytic anemia is most common finding; followed by bicytopenia or     pancytopenia</li> <li>Isolated neutropenia or thrombocytopenia are unusual but possible</li> <li>Ask about secondary causes:<ul> <li>Exposure to chemicals (benzene, crude oil/gasoline industry,     cigarette smoke), chemotherapy, radiation</li> <li>Medications, alcohol use, chronic infections (HIV)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myelodysplastic-syndromes/#evaluation","title":"Evaluation","text":"<ul> <li>Goal is to rule out reversible causes of dysplasia and cytopenias</li> <li>CBC w/differential, Peripheral Smear, B12, Folate, HIV</li> <li>May consider Copper &amp; Zinc (send out labs, are expensive and rare     but check when MDS is being considered)</li> <li>Dysplastic changes on peripheral smear: hypogranulated/hyposegmented     neutrophils, hypogranulated platelets and macrocytosis of RBCs</li> <li>Circulating myeloblasts can be seen</li> <li>Final diagnosis made by Bone marrow Biopsy</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myelodysplastic-syndromes/#management","title":"Management","text":"<ul> <li>Molecular characteristics define the \u201crisk\u201d of the disease and     dictates treatments</li> <li>Prognostic scoring tools: revised international prognostic staging     system (R-IPSS)</li> <li>Management general paradigm:<ul> <li>Asymptomatic: with low-risk disease = monitoring</li> <li>Low-risk disease + symptoms due to anemia only: transfusions,     erythrocyte stimulating agents, and treatment with Luspatercept</li> <li>MDS with isolated del(5q): treated with lenalidomide</li> <li>High-risk patients: treated with hypomethylating agents</li> <li>Only curative intervention = hematopoietic stem cell transplant     (HSCT)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/","title":"Myeloproliferative Neoplasms (MPNs)","text":"<p>Christina Snider</p>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#background","title":"Background","text":"<ul> <li>MPNs = chronic myeloid disorders caused by abnormal proliferation of     mature bone marrow cell lineages (granulocytes, erythrocytes, or     megakaryocytes)</li> <li>MPNs differ from myelodysplastic syndrome (MDS); cells in MPNs are     normally developed (i.e. not dysplastic)</li> <li>Four \u201cclassic\u201d MPNs: polycythemia vera, essential thrombocythemia,     primary myelofibrosis and chronic myeloid leukemia (CML)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#polycythemia-vera-pv","title":"Polycythemia Vera (PV)","text":""},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#background_1","title":"Background","text":"<ul> <li>Polycythemia is a general term: Men = Hb/Hct &gt; 16.5/49%; Women =     Hb/Hct &gt; 16/48%</li> <li>Relative polycythemia = Concentrated H/H due to decreased plasma     volume<ul> <li>Diuretic use, vomiting, diarrhea; H/H should normalize with fluid     resuscitation</li> </ul> </li> <li>Absolute polycythemia = Increased RBC mass</li> <li>Primary polycythemia: 2/2 Inherited/acquired mutation in RBC     progenitor</li> <li> <p>Secondary polycythemia: Increase in RBC mass due to elevated serum     EPO</p> <ul> <li>Hypoxia/cardiopulmonary associated (chronic pulmonary disease,     R-to-L cardiac shunts, sleep apnea, obesity hypoventilation     syndrome, chronic carbon monoxide poisoning, including heavy     smoking)</li> <li>Kidney associated causes (following renal transplant, renal     artery stenosis, hydronephrosis)</li> <li>Autonomous EPO production from an EPO-producing tumors (rare)</li> <li>Steroid Use</li> </ul> </li> <li> <p>Epidemiology: Median age of diagnosis is 60 years; 25% cases present     at age &lt;50 years.</p> </li> <li> <p>95% PV pts have JAK2 V617F mutation, but JAK2 V617F mutation is     not specific to PV and can be seen in other MPNs</p> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#presentation","title":"Presentation","text":"<ul> <li>Incidentally elevated H/H</li> <li>Splenomegaly, generalized pruritus (post-warm bath/shower), unusual     thrombosis</li> <li>Erythromelalgia: intermittent occurrence of red, hot, painful     extremities</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#evaluation","title":"Evaluation","text":"<ul> <li>CBC with differential and peripheral smear</li> <li>EPO level</li> <li>Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids</li> <li>Peripheral blood screen for JAK2 V617F mutation</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#management","title":"Management","text":"<ul> <li>PV treatment aims to prevent thrombosis and bleeding events.</li> <li>Phlebotomy: maintain Hct &lt;45% (One unit 500 mL decreases Hct by 3%)</li> <li>ASA 81 mg for thrombosis prevention and symptom control</li> <li>Hydroxyurea: indicated for high-risk patients (&gt;60 years old or     with history of thrombosis)</li> <li>Interferon-alfa, busulfan, or ruxolitinib: indicated in select     high-risk patients</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#essential-thrombocythemia-et","title":"Essential thrombocythemia (ET)","text":""},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#background_2","title":"Background","text":"<ul> <li>Clonal stem cell disorder w/ increased platelet counts (&gt;450k/uL)</li> <li>Risks of thrombosis and hemorrhage</li> <li>Median age of diagnosis: 60 years; Twice as common in females.</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#presentation_1","title":"Presentation","text":"<ul> <li>Incidental thrombocytosis on CBC</li> <li>Splenomegaly, unusual thrombosis, and erythromelalgia</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#evaluation_1","title":"Evaluation","text":"<ul> <li>Screen for conditions that cause reactive thrombocytosis: Chronic     inflammatory diseases, infections, bleeding/hemolysis, iron     deficiency, post splenectomy</li> <li>CBC with smear (platelet anisocytosis) ranging from very small to     giant platelets</li> <li>CMP, LDH, Uric Acid, iron studies</li> <li>BCR ABL1 testing should be sent to exclude CML</li> <li>Bone marrow biopsy with staining, cytogenetics, and molecular     testing for JAK2, CALR, MPL mutations</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#management_1","title":"Management","text":"<ul> <li>Avoid ASA 81 in patients with platelet counts &gt;1 million     complicated by acquired von Willebrand syndrome due to increased     risk of bleeding</li> </ul> Treatment of ET <p>\u00a0Risk Score</p> <p>(IPSET-thrombosis)</p> Features Treatment High Hx of thrombosis and/or &gt;age 60 with JAK2 V617F mutation Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation +/-antiplatelet agent Intermediate Age &gt;60, no JAK2 V617F mutation, no history of thrombosis Low Age =&lt;60 w/ JAK2 V617F mutation and no history of thrombosis <p>Observation vs. daily ASA 81</p> <p> </p> Very Low Age =&lt;60, no JAK2 V617F mutation, no history of thrombosis"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#primary-myelofibrosis-pmf","title":"Primary Myelofibrosis (PMF)","text":""},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#background_3","title":"Background","text":"<ul> <li>Clonal proliferation of myeloid cells with variable morphologic     maturity resulting in reactive marrow fibrosis and extramedullary     hematopoiesis</li> <li>Least favorable prognosis out of MPN</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#presentation_2","title":"Presentation","text":"<ul> <li>Fatigue, weight loss, low grade fever, bone pain, and night sweats</li> <li>Marked splenomegaly \u00b1hepatomegaly (due to extramedullary     hematopoiesis)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#evaluation_2","title":"Evaluation","text":"<ul> <li>smear: teardrop shaped RBCs (dacrocytes)</li> <li>Bone marrow biopsy: \u201cdry tap\u201d due to extensive reticulin and/or     collagen fibrosis mutually exclusive mutations in JAK2, MPL, or CALR</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#management_2","title":"Management","text":"<ul> <li>Low risk patients: Observe if asymptomatic</li> <li>Cure by allogenic HCT transplantation in young, high-risk patients</li> <li>Treatment of anemias include transfusion support</li> <li>Surgical splenectomy if abdominal pain or transfusion dependent     anemia (used very infrequently)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#chronic-myelogenous-leukemia-cml","title":"Chronic Myelogenous Leukemia (CML)","text":""},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#background_4","title":"Background","text":"<ul> <li>Definition: MPN characterized by the overproduction of myeloid stem     cells that can differentiate</li> <li>Chronic phase:<ul> <li>Fatigue, weight loss, bleeding</li> <li>Abdominal fullness and early satiety due to splenomegaly</li> <li>WBC on CBC is typically &gt;100k, and smear shows neutrophilic cells     in all stages of maturation with &lt;2% blasts</li> </ul> </li> <li>Accelerated phase: Refractory leukocytosis, 10-19% blasts in     peripheral blood or bone marrow, worsening peripheral basophilia,     thrombocytopenia</li> <li>Blast phase = acute leukemia. &gt;20% blasts in peripheral blood or     bone marrow, extramedullary proliferation of blasts</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#evaluation_3","title":"Evaluation","text":"<ul> <li>Typical findings in blood and bone marrow and confirmation of     Philadelphia chromosome (BCR-ABL1 fusion gene) via conventional     cytogenetics, FISH, or rt-PCR</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/#management_3","title":"Management","text":"<ul> <li>Hydroxyurea can be used to reduce WBC while awaiting confirmation</li> <li>Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib,     nilotinib, and ponatinib</li> <li>Allogenic hematopoietic cell transplantation: Curative option for     pts in accelerated and blast phase, as well as young pts w/chronic     phase CML who do not respond to TKI therapy</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/","title":"Neutropenia &amp; Neutropenic Fever","text":"<p>Jennifer Marvin-Peek</p>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#background","title":"Background","text":"<ul> <li>Neutropenia: absolute neutrophil count (ANC) &lt; 1500</li> <li>Severe neutropenia: absolute neutrophil count (ANC) &lt;500 (Use     manual count if available)</li> </ul> Mechanism Causes Example (s) Neutrophil production Drug associated <p>Cytotoxic or immunosuppressive agents</p> <p>Methimazole, PTU, Colchicine</p> <p>Macrolides, Bactrim, Dapsone, Vancomycin</p> <p>Amphotericin, Acyclovir, Ganciclovir</p> <p>TCAs, Clozapine, Carbamazepine, Valproate</p> <p>ACEI, Digoxin, Propranolol, Procainamide</p> Radiation exposure Malignancies Leukemias, MDS Infection <p>Hepatitis, HIV, EBV, CMV</p> <p>Rickettsia, Tularemia, Typhoid, TB</p> Nutritional deficiency Vitamin B12, Folate, Copper Other Aplastic anemia, Benign ethnic neutropenia Redistribution Splenomegaly Margination and sequestration Congenital Genetics Benign ethnic neutropenia, familial neutropenia Immune destruction Autoimmune disorders RA, SLE Other Autoimmune neutropenia"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#management","title":"Management","text":"<ul> <li>If ANC &lt;500<ul> <li>Check all lines/IVs for erythema and induration daily</li> <li>Check mouth for mucositis, mouth care after meals and before bed</li> <li>Assess for Neutropenic Fever &amp; Complications \u2013 see below</li> <li>Evaluate for indications for prophylaxis \u2013 see below</li> <li>No evidence to support use of neutropenic diet</li> <li>No digital rectal exams or enemas/suppositories (risk of bacterial     translocation)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#neutropenic-fever","title":"Neutropenic Fever","text":"<ul> <li>ANC &lt;500 and T &gt;100.4 \u00b0F or 38.0 \u00b0C</li> <li>Neutropenic pts are unable to mount an adequate immune response and     can become critically ill very quickly</li> <li>Do not wait for a temp re-check, you need to start antibiotics     immediately</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#evaluation","title":"Evaluation","text":"<ul> <li>Chest X-ray</li> <li>Two sets of blood cultures (one from PICC/port if present)</li> <li>Urinalysis AND urine culture (not the reflex order set)</li> <li>If diarrhea, get C. diff PCR</li> <li>If abdominal pain, get CT A/P with IV contrast</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#management_1","title":"Management","text":"<ul> <li>Empirically treat with Cefepime</li> <li>Indications for Vancomycin:</li> <li>Hemodynamically unstable</li> <li>Severe mucositis</li> <li>Focal consolidation on CXR</li> <li>Erythema/induration around line</li> <li>Concern for skin/soft tissue infection</li> <li>GPCs in blood</li> <li>Fever continues &gt;24h on cefepime</li> <li>Additional Coverage:<ul> <li>If abdominal pain/diarrhea: Flagyl 500mg q8h</li> <li>Concern for C-diff: PO Vancomycin 125mg q6h</li> <li>Still fevering on Cefepime at 72 hrs (differs by attending)     Meropenem</li> </ul> </li> <li>Fungal coverage: Consider if risk factors (TPN) or persistent fevers     (&gt;72hrs)<ul> <li>Micafungin 100 mg IV daily or Voriconazole 200mg PO BID</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#neutropenic-complications","title":"Neutropenic Complications","text":"<ul> <li> <p>Mucositis</p> <ul> <li>Presentation<ul> <li>Can range from mouth soreness to severe erosions preventing     eating/drinking</li> <li>Can become secondarily infected with Candida, HSV</li> </ul> </li> <li>Management<ul> <li>Routine oral care with a soft toothbrush to remove plaque</li> <li>Oral rinses with saline and/or sodium bicarbonate</li> <li>Magic mouthwash for symptomatic relief (or viscous lidocaine at     the VA)</li> <li>Typically recovers quickly when ANC &gt; 500</li> </ul> </li> </ul> </li> <li> <p>Neutropenic enterocolitis (Typhlitis)</p> <ul> <li>Life-threatening bacterial translocation due to breakdown of gut-mucosal barrier</li> <li>Presentation<ul> <li>Abdominal pain + fever</li> <li>\u00b1 abdominal distension, nausea, vomiting, watery and/or bloody diarrhea</li> </ul> </li> <li>Diagnosis<ul> <li>CT A/P with contrast, consider C. diff PCR if diarrhea</li> </ul> </li> <li>Treatment<ul> <li>Cefepime/Flagyl OR Zosyn</li> <li>If no perforation/abscess on CT scan, typically continue until 14     days after ANC recovers &gt;500 and abdominal pain resolves</li> <li>Can change to cipro/flagyl once ANC &gt;500</li> <li>If perforation/abscess: will need imaging to confirm resolution, and     longer duration of abx</li> </ul> </li> </ul> </li> <li> <p>Neutropenic Prophylaxis</p> <ul> <li>Used if ANC is expected to be \\&lt; 500 for &gt; 7 days</li> </ul> </li> </ul> Most Common Regimens Alternatives Bacterial Levofloxacin 500mg daily (renally dosed) Cefdinir 300mg BID Viral Valacyclovir 500mg BID Acyclovir 400mg BID (renally dosed) Fungal Fluconazole 400mg daily <p>Posaconazole 300mg BID x2 days 300mg daily (AML induction for aspergillus)</p> <p>Micafungin 50mg IV daily</p> PJP (if steroids) Inhaled pentamidine 300mg qmonthly <p>Dapsone (check G6PD)</p> <p>Avoid Bactrim (risk of myelosuppression)</p>"},{"location":"hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/#filgrastim-g-csf-neupogenzarxiogranix","title":"Filgrastim (G-CSF \u2013 Neupogen/Zarxio/Granix)","text":"<ul> <li>Induces bone marrow production of neutrophils</li> <li>Dose: either 300mcg or 480mcg (rounded from 5 mcg/kg/day)</li> <li>Common side effects: fatigue, nausea</li> <li>PEG-filgrastim (Neulasta): long-acting version that is only given as     an outpatient</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/","title":"Oncologic Emergencies","text":"<p>Bradley Christensen, Madeleine Turcotte</p>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#leukostasis","title":"Leukostasis","text":""},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#presentation","title":"Presentation","text":"<ul> <li>Primarily occurs with acute myeloid leukemia and acute lymphoblastic     leukemia. This is not common with CLL or CML with high leukocyte     counts in the absence of a significant increased portion of     peripheral blasts</li> <li>Respiratory: dyspnea, hypoxia (note CXR may be normal)</li> <li>PaO2 by ABG often falsely low from WBC consuming O2 in vitro. Trust     SpO2.</li> <li>CNS: headache, AMS, vision changes, dizziness, tinnitus, gait     instability, neuro deficit</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#evaluation","title":"Evaluation","text":"<ul> <li>CBC with diff and peripheral blood smear</li> <li>Imaging: CT head to evaluate neuro deficit and to check for ICH</li> <li>Chest X-Ray vs CT chest to evaluate dyspnea and air space     abnormalities</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#management","title":"Management","text":"<ul> <li>Call hematology</li> <li>Emergent cytoreduction</li> <li>Leukapheresis: page nephrology and place dialysis catheter</li> <li>Hydroxyurea and chemotherapy per hematology fellow</li> <li>Transfer/admit to ICU</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#tumor-lysis-syndrome","title":"Tumor Lysis Syndrome","text":""},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#background","title":"Background","text":"<ul> <li>Lysis of malignant cells either spontaneously or in response to     chemotherapy causing release of K, Phos, nucleic acids, and     cytokines</li> <li>Consequences:<ul> <li>Hyperkalemia: most urgent and immediately life threatening</li> <li>Hyperphosphatemia: binds Ca and leads to CaPhos crystal deposition     AKI, HypoCa</li> <li>Hyperuricemia (from breakdown of DNA) precipitation in renal tubules     AKI</li> <li>Hypotension, AKI from cytokine release</li> </ul> </li> <li>Laboratory TLS</li> <li>Uric acid \u2265 8, Ca2+ \u2264 7, K+, or PO43- \u2265 4.5</li> <li>or &gt; 25% change from baseline in these values</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#evaluation_1","title":"Evaluation","text":"<ul> <li>Risk Stratification:<ul> <li>Highest risk after starting chemotherapy, but can occur     spontaneously</li> <li>Tumor characteristics which confer a higher risk of developing TLS:<ul> <li>High (&gt;5% risk): ALL (WBC&gt; 100K or LDH 2x ULN), AML (WBC&gt; 100K),     Burkitt\u2019s (III/IV or LDH\u22652xULN, DLBCL with bulky disease,     intermediate risk + AKI/CKD</li> <li>Intermediate: ALL (WBC&lt;100K, LDH &lt;2x ULN), AML (WBC 25-100K),     Burkitt\u2019s LDH&lt;2x ULN), DLBCL (non-bulky, LDH&gt;ULN), CLL (if tx with     fludarabine, rituximab, lenalidomide, or venetoclax +LN 5-10 cm or     ALC\u226525K), plasma cell leukemia, rare chemo-sensitive solid tumors     (small cell)</li> <li>Low: all others</li> </ul> </li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#management_1","title":"Management","text":"<ul> <li>Prevention:<ul> <li>High risk: q6-8h TLS labs, IVF (\u00b1loop diuretic if volume overload),     allopurinol, \u00b1 rasburicase</li> <li>Intermediate \u2013 q8h TLS labs, IVF, allopurinol</li> <li>Low \u2013 daily TLS labs, IVF<ul> <li>Significant hydration: goal to maintain UOP 80-100 mL/hr</li> <li>Allopurinol: 300 mg PO BID for CrCl &gt; 20 mL/min, UpToDate renal     dosing if lower</li> <li>Rasburicase ($$$): contraindicated in G6PD (send G6PD if not     urgent and AA, Asian or Jewish descent)<ul> <li>Given if uric acid &gt; 8 mg/dL: get fellow approval before     ordering</li> </ul> </li> </ul> </li> </ul> </li> <li>Treatment: (Can use as night/cross cover handoff)<ul> <li>K+ &gt; 5.5: STAT EKG. Kayexalate 30g orally or 60g per rectum (unless     contraindicated) x1<ul> <li>Give 10 U insulin/1 amp D50</li> <li>If EKG changes, then calcium gluconate and D5W at 100 mL/hr with     repeat BG in 1 hr</li> </ul> </li> <li>Uric acid &gt; 8 with 25% change from baseline: page hematology fellow     to discuss rasburicase</li> <li>PO4 &gt; 4.5 with 25% change from baseline: start/\u2191 phos binder     (sevelamer)</li> <li>Dialysis may be necessary in patients with poor renal function.</li> <li>IV calcium: do not administer unless symptomatic AND     hyperphosphatemia is corrected<ul> <li>With high phos, IV calcium can lead to calcium deposition and     renal failure</li> </ul> </li> <li>Hemodialysis: pt with anuria, refractory hyperkalemia, and     symptomatic hypocalcemia</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#superior-vena-cava-svc-syndrome","title":"Superior Vena Cava (SVC) Syndrome","text":""},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#background_1","title":"Background","text":"<ul> <li>Commonly Associated Malignancies: Lung Cancer, Non-Hodgkin or     Hodgkin Lymphoma, Mediastinal Germ Cell Tumors, Thymic Malignancies</li> <li>Partial or complete obstruction of the SVC impedes blood return from     the upper extremities, head, neck, and brain resulting in upstream     congestion</li> <li>Can be 2/2 a mass in the mediastinum or thrombosis (foreign body     i.e. catheter)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#presentation_1","title":"Presentation","text":"<ul> <li>Facial or neck swelling without generalized edema</li> <li>Sense of head fullness, exacerbated by leaning forward or lying down</li> <li>Pulmonary symptoms including dyspnea, stridor, hoarseness, cough -     due to edema narrowing the nasal passages and larynx or mechanical     airway obstruction</li> <li>Physical Exam: facial and neck edema particularly of the eye lids in     the morning, distended neck and chest veins; can also sometimes see     upper extremity swelling, papilledema, plethora. Look for associated     lymph node enlargement anywhere particularly including     supraclavicular, cervical, and axillary region</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#evaluation_2","title":"Evaluation","text":"<ul> <li>CXR: may show mass, perihilar or mediastinal disease</li> <li>Contrasted CT scan \u00b1 CT Venography: Phased to get a view of clot     contribution to obstruction guides decision regarding     anticoagulation or stenting</li> <li>Radiology attending can coordinate with techs (requires verbal     direct request)</li> <li>MRI/MRV may provide additional information (often not possible due     to pt too sick)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#management_2","title":"Management","text":"<ul> <li>Assess airway and prepare for intubation if needed</li> <li>Keep head of bed elevated</li> <li>Thrombosis:<ul> <li>Removal of lines/catheters associated with thrombus</li> <li>Consideration of anticoagulation</li> </ul> </li> <li>Tumor compression: the type of tumor guides treatment (tissue biopsy     is key)</li> <li>Stat/urgent consultations:<ul> <li>Interventional radiology for possible stenting/dilatation</li> <li>Radiation oncology- for radiation therapy</li> <li>Interventional pulmonology \u2013 for help with tissue dx</li> <li>Medical oncology \u2013 for help with diagnosis and chemotherapy</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#spinal-cord-compression","title":"Spinal Cord Compression","text":""},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#background_2","title":"Background","text":"<ul> <li>Malignancies where cord compression is most common:<ul> <li>Multiple Myeloma, Lymphoma (both Hodgkin and NHL), Lung, Breast,     Prostate Cancer</li> </ul> </li> <li>Tumor mass &amp; compressed and often displaced bone impinges thecal sac     or nerve roots spinal cord or any spinal nerves including the cauda     equina</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#presentation_2","title":"Presentation","text":"<ul> <li>Back pain, motor, or sensory deficits</li> <li>Cauda Equina syndrome bowel or bladder incontinence, ataxia</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#evaluation_3","title":"Evaluation","text":"<ul> <li>Neurologic exam with sensation testing seeking level below an     identified dermatome</li> <li>Lab testing: If no known malignancy check CBC, CMP, SPEP, and (in     males) PSA</li> <li>Bladder US if suspicion or retention with or without overflow     incontinence</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#management_3","title":"Management","text":"<ul> <li>If suspected, order MRI without and with contrast; if patient unable     to have MRI, CT myelography may be considered</li> <li>Immediate high dose steroids (dosing is controversial with     recommendations ranging from 4 to 100 mg of dexamethasone q6h -     choice of dexamethasone is to minimize mineralocorticoid effects.     Most common dosing is 10mg IV x1 followed by 4mg IV q6h)</li> <li>Consider stat/urgent consultation with:<ul> <li>Neurosurgery for diagnostic/therapeutic intervention</li> <li>Radiation oncology- for radiation therapy</li> <li>Medical oncology \u2013 for help with diagnosis and chemotherapy</li> </ul> </li> <li>Ensure regular neuro-vascular checks and close monitoring.</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#brain-metastases","title":"Brain Metastases","text":""},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#background_3","title":"Background","text":"<ul> <li>Common malignancies: Lung (NSCLC), breast, kidney, colorectal     carcinomas &amp; melanomas</li> <li>Significantly more common than primary brain tumors</li> <li>80% of brain metastasis occur in the cerebrum at grey/white matter     junction</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#presentation_3","title":"Presentation","text":"<ul> <li>Highly variable: consider brain mets in any cancer pt w/ neurologic     or behavioral changes</li> <li>Headache: worse in the mornings, with bending over or with valsalva</li> <li>Nausea/vomiting</li> <li>Cognitive dysfunction: changes in memory, mood or personality</li> <li>Focal neurologic deficits</li> <li>Signs of elevated ICP: papilledema, vision changes, drowsiness,     presyncope</li> <li>Seizures</li> <li>Stroke (particularly in melanoma, choriocarcinoma, thyroid &amp; renal     carcinomas)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#evaluation_4","title":"Evaluation","text":"<ul> <li>STAT CT if concerned for stroke or elevated ICP</li> <li>MRI with contrast: most sensitive, can differentiate between     metastases vs. other lesions<ul> <li>Suggestive features: multiple lesions, location, circumscribed     margins, vasogenic edema</li> </ul> </li> <li>If pt has no known primary tumor: consider CT C/A/P \u00b1 PET to     identify primary</li> <li>Biopsy with histopathology &amp; IHC: if diagnosis in doubt or if only a     single lesion is present</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-oncologic-emergencies/#management_4","title":"Management","text":"<ul> <li>If severe HA, N/V, focal deficits: systemic glucocorticoids</li> <li>Dexamethasone 10mg IV x1 followed by 4mg IV q6h (can be PO if     tolerated)</li> <li>Stat/urgent consults:<ul> <li>Neurosurgery \u2013 for diagnostic/therapeutic intervention</li> <li>Radiation oncology \u2013 for radiation therapy</li> <li>Medical oncology \u2013 for help with diagnosis and chemotherapy</li> </ul> </li> <li>Ensure regular neuro-vascular checks and close monitoring</li> <li>Do not perform LP without input from neurology</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-pancytopenia/","title":"Pancytopenia","text":"<p>Thomas Gracie</p>"},{"location":"hematology-oncology/hematologyoncology-pancytopenia/#background","title":"Background","text":"<ul> <li>Framework for differential:<ul> <li>Impaired production (aplastic anemia, marrow infiltration, marrow     suppression, vitamin/nutritional deficiencies, sepsis, cirrhosis)</li> <li>Peripheral destruction (autoimmune hemolytic, hypersplenism)</li> <li>Combined process (PNH, SLE, leukemia, HLH, infections)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-pancytopenia/#evaluation","title":"Evaluation","text":"<ul> <li>Medications: NSAIDs, AEDs, steroids, chemotherapy, antivirals,     immunosuppression</li> <li>PMHx: autoimmune disease (SLE, RA), radiation, gastric surgery,     malabsorption, liver disease, hematologic malignancy</li> <li>Social Hx: EtOH use, malnutrition, occupational exposures, exposures     to TB or leishmaniasis</li> <li>Exam: lymphadenopathy, hepatosplenomegaly, neuropathy, petechiae,     stigmata of liver disease, cachexia</li> <li>Diagnostic studies: CBC w/ diff, CMP, reticulocyte count, peripheral     smear, viral studies (hepatitis A/B/C, EBV, CMV, HIV, parvovirus     B19), vitamin levels (B12, folate, copper, zinc), iron studies,     hemolysis labs (LDH, haptoglobin, Coombs), flow cytometry, bone     marrow biopsy, cytogenetics and FISH</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-pancytopenia/#management","title":"Management","text":"<ul> <li>For pancytopenia that is acute (hospital onset) often observation is     the best approach</li> <li>When pancytopenia is slow, progressive over time, or acute without     any other precipitating factors then would consult hematology for     consideration of a bone marrow syndromes</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/","title":"Paraneoplastic Syndromes","text":"<p>Justin Lo</p>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#hypercalcemia-of-malignancy","title":"Hypercalcemia of malignancy","text":""},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#background","title":"Background","text":"<ul> <li>Caused by PTHrP production, osteolytic lesions, and/or rarely     exogenous Vit D</li> <li>PTHrP: Breast cancer, NSCLC (squamous)</li> <li>Osteolysis: Multiple Myeloma, Breast Cancer</li> <li>Exogenous Vit D: Lymphoma</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#evaluation","title":"Evaluation","text":"<ul> <li>Correct [Ca+2] for hypoalbuminemia: add 0.8 x (4.0 \u2013 albumin)</li> <li>Send basic hyperCa+2 work-up \u2013 PTH, Vit D, etc. (see hypercalcemia     section)</li> <li>PTHrP is called \u201cParathyroid Hormone-related Peptide-ARUP\u201d in Epic</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#management","title":"Management","text":"<ul> <li>First-line: IVF without calcium such as Normosol; goal urinary     output of 150-200 mL/hr</li> <li>Strict I/Os; Cautious IV fluids if pt w/cardiac or renal dysfunction</li> <li>Add Furosemide if hypervolemic (do not empirically start)</li> <li>Second-line: Zoledronic acid 4mg IV (takes 24-48 hours to see     effect)</li> <li>AMS or severe hypercalcemia (&gt;14mg/dL): calcitonin 4 IU/kg (req.     attending approval)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#siadh","title":"SIADH","text":""},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#background_1","title":"Background","text":"<ul> <li>Euvolemic hypotonic hyponatremia with urine sodium &gt;20 and     typically urine Osm &gt;100</li> <li>Associated with: SCLC (most common), head/neck cancers, breast     cancer</li> <li>See \"Nephrology\" for additional information</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#management_1","title":"Management","text":"<ul> <li>Free water restriction to 800mL/day</li> <li>Refractory: salt supplementation (e.g. salt tabs) \u00b1 loop diuretic</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#carcinoid-syndrome","title":"Carcinoid Syndrome","text":""},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#background_2","title":"Background","text":"<ul> <li>Episodic flushing, diarrhea, wheezing/SOB due to secretion of     histamine &amp; serotonin</li> <li>Most common: Neuroendocrine tumors \u2013 GI (often with mets to liver     and lung)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#evaluation_1","title":"Evaluation","text":"<ul> <li>Urine: UR 5-HIAA (ARUP)</li> <li>Imaging to identify tumor(s) (CT chest/abdomen/pelvis)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#management_2","title":"Management","text":"<ul> <li>Short-term treatment: subQ or IV octreotide (see UpToDate for     dosing)</li> <li>Antidiarrheals (Imodium, Lomotil, etc.) to slow transit</li> <li>Long-term treatment: depot (IM) forms of octreotide and lanreotide</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#autoimmune-encephalitis-encephalomyelitis-and-myelitis","title":"Autoimmune encephalitis, encephalomyelitis, and myelitis","text":""},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#background_3","title":"Background","text":"<ul> <li>Encephalopathy (limbic or brainstem), \u00b1 myelitis (limb ataxia,     sensory deficits)</li> <li>Associated with small cell lung cancer and checkpoint inhibitor     therapy</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#evaluation_2","title":"Evaluation","text":"<ul> <li>LP: make sure to order CSF oligoclonal bands &amp; CSF IgG index</li> <li>\u201cParaneoplastic AutoAb Eval-MAYO\u201d (add \"CSF\" to the front of the     order name if for LP)</li> <li>NMDA-R can be ordered as a standalone test</li> <li>CT head</li> <li>EEG if concern for subclinical seizures</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#management_3","title":"Management","text":"<ul> <li>Consult Neurology, for possible immunosuppressive therapy (steroids,     IVIG)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#lambert-eaton-myasthenic-syndrome-lems","title":"Lambert-Eaton myasthenic syndrome (LEMS)","text":""},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#background_4","title":"Background","text":"<ul> <li>Muscle weakness due to autoantibody against calcium channels     resulting in \u2193 ACh release</li> <li>Associated with SCLC (most common) &amp; lymphoma</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#presentation","title":"Presentation","text":"<ul> <li>Proximal muscle weakness, diminished DTRs</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#evaluation_3","title":"Evaluation","text":"<ul> <li>Nerve conduction studies: EMG w/ NCV</li> <li>Serum \u201cParaneoplastic AutoAb Eval-MAYO\u201d</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-paraneoplastic-syndromes/#management_4","title":"Management","text":"<ul> <li>Consult Neurology</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/","title":"Plasma Cell Dyscrasias","text":"<p>Rahul Shah, Jennifer Marvin-Peek</p>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#background","title":"Background","text":"<ul> <li>A heterogenous group of benign, premalignant, and malignant     conditions characterized by clonal proliferation of plasma cells</li> <li>Results in over-production of monoclonal immunoglobulins or     polypeptides (i.e., M-protein) that can be detected in serum and/or     urine</li> <li>Includes monoclonal gammopathy of undetermined significance (MGUS),     smoldering myeloma (SMM), multiple myeloma (MM), Waldenstr\u00f6m     Macroglobulinemia (WM), extra-medullary plasmacytoma, AL     amyloidosis, POEMS syndrome</li> <li>Spectrum of MGUS, SMM, and MM represents natural progression of same     disease process</li> <li>Complications: Increased infectious risk, cytopenias, renal failure,     hyperviscosity syndrome, malignant hypercalcemia, pain crisis from     bony disease</li> <li>Elevated gamma/protein gap (serum total protein minus albumin &gt;4)     often prompts work-up for an underlying plasma cell dyscrasia (high     specificity but low sensitivity)</li> </ul> Symptoms Signs <p>Fatigue, weakness, weight loss</p> <p>Bone pain</p> <p>Paresthesias, neuropathy, radiculopathy</p> <p>Visual disturbances</p> <p>(if hyperviscosity present)</p> <p>Lymphadenopathy (uncommon)</p> <p>Fever (uncommon)</p> <p>Anemia (Hgb &lt;10)</p> <p>Renal insufficiency (Cr &gt; 2)</p> <p>Hypercalcemia (Ca &gt; 11.5)</p> <p>Elevated protein gap (Total protein - Alb &gt; 4)</p> <p>Osteolytic bone lesions (typically central)</p> <p>Unexplained heavy proteinuria</p> <p>Rouleaux formation on blood smear</p>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#evaluation","title":"Evaluation","text":"<ul> <li>CBC w/ diff, peripheral blood smear, CMP (for Ca, Cr, albumin), LDH,     CRP, urinalysis</li> <li>SPEP with immunofixation, UPEP (24-hour urine) with immunofixation,     serum free light chains (FLC)</li> <li>Quantitative immunoglobulins (IgA, IgM, IgG, IgD, IgE)</li> <li>If Hgb &lt;10, Cr &gt;2, Ca &gt;11.5, M-protein &gt;1.5, non-IgG M-spike,     abnormal FLC ratio:</li> <li>Bone marrow biopsy + cytogenetics</li> <li>\u03b22-microglobulin, serum viscosity (in WM)</li> <li>Skeletal imaging to identify bone lesions: skeletal survey (x-ray)     often done initially, then more sensitive CT/PET-CT/MRI if biopsy     shows SMM/MM</li> <li>If considering amyloidosis: abdominal wall fat pad biopsy with Congo     red staining typically sufficient     (call pathology to arrange, can typically be done same-day or next-day)     vs direct biopsy of amyloid-involved tissue</li> </ul> Additional Tips for Lab Interpretation SPEP/UPEP Free light chains (FLC) Urinalysis <p>Initial screening test to look and quantify M-protein</p> <p>Serum immunofixation determines clonality</p> <p>(e.g. mono or polyclonal)</p> <p> </p> <p>Monoclonal spike &gt;1.5 is indicative of underlying dyscrasia</p> <p> </p> <p>Polyclonal spike suggests infectious, inflammatory, or reactive etiology</p> <p>Ratio of kappa/lambda &gt;3 highly suggestive of plasma cell dyscrasia or amyloidosis</p> <p> </p> <p>Ratio 1.65 to 3 can be due to infectious process or renal insufficiency</p> <p> </p> <p>Helpful in pts that only produce Bence-Jones protein (FLC w/o heavy chain) which isn't seen on SPEP</p> <p>Detects albumin, not light chains</p> <p> </p> <p>In myeloma cast nephropathy, dipstick will be negative since proteinuria is from FLC (i.e. Bence-Jones proteinuria)</p> <p> </p> <p>In AL amyloid, dipstick will be positive 2/2 albumin loss from nephrotic syndrome</p> <p>Monoclonal Gammopathy of Unknown Significance</p> <p>(MGUS)</p> <p>Smoldering Multiple Myeloma</p> <p>(SMM)</p> <p>Multiple Myeloma</p> <p>(MM)</p> % Plasma Cells in BM &lt;10% 10-60% \u2265 10% (typically &gt;30%) Monoclonal Protein IgG, IgA, IgM: 1.5 -3 IgG or IgA &gt;3 IgG or IgA &gt;3 Laboratory studies Normal Hgb, Ca, Cr Normal Hgb, Ca, Cr \u2193Hgb, \u2191Ca, \u2191Cr Symptoms None None Lytic bone lesions, fatigue Prognosis 1% / year progression to MM 10% / year progression to MM R-ISS staging (see below) Monitoring and/or Treatment <p>Monitoring only</p> <p>Yearly:</p> <p>Symptom check</p> <p>SPEP, FLC, CBC, BMP</p> <p>Monitoring only</p> <p>In 2-3 months, repeat SPEP, FLC, CBC, BMP</p> <p>Yearly skeletal survey</p> Chemotherapy, plus SCT for eligible patients"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#multiple-myeloma","title":"Multiple Myeloma","text":""},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#evaluation_1","title":"Evaluation","text":"<ul> <li>Diagnosis requires clonal bone marrow plasma cells \u226510% or     bony/extramedullary plasmacytoma AND one or more end-organ event     (CRAB criteria) or biomarker of myeloma</li> <li>CRAB criteria<ul> <li>Hypercalcemia, renal impairment, anemia, bone osteolytic lesions</li> </ul> </li> <li>Biomarkers of multiple myeloma<ul> <li>Clonal bone marrow plasma cells \u2265 60%</li> <li>Serum FLC ratio \u2265 100 or \u2264 0.01</li> <li> <p>1 focal lesion \u2265 5mm on MRI</p> </li> </ul> </li> <li>Skeletal imaging: Whole-body PET-CT or CT preferred, MRI, bone     survey (x-ray)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#management","title":"Management","text":"<ul> <li>First-line induction therapy typically is RVd: immunomodulatory     agent (lenalidomide [Revlimid]), proteasome inhibitor     (bortezomib [Velcade]) and dexamethasone</li> <li>Consolidation therapy includes autologous SCT for transplant     eligible patients</li> <li>Maintenance therapy is often given indefinitely, typically     lenalidomide or bortezomib</li> <li>Relapsed disease is often treated with anti-CD38 monoclonal Ab     (daratumumab) with a steroid and either immunomodulatory drug or     proteosome inhibitor; CAR-T also recently approved for relapsed MM</li> <li>Supportive Care<ul> <li>VTE prophylaxis with DOAC or LMWH if on an immunomodulatory agent     with 2 VTE risk factors; if only 0-1 VTE risk factors, aspirin</li> <li>EPO and G-CSF for treatment-related anemia and neutropenia</li> <li>Bisphosphonate (ideally zoledronic acid) to reduce risk of     fractures; analgesia \u00b1 radiotherapy for bone pain and palliation</li> <li>(Val)acyclovir if on bortezomib for VZV prophylaxis</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#lymphoplasmacytic-lymphomawaldenstrom-macroglobulinemia-igm","title":"Lymphoplasmacytic Lymphoma/Waldenstr\u00f6m Macroglobulinemia (IgM)","text":""},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#presentation","title":"Presentation","text":"<ul> <li>Hyperviscosity syndrome: blurred vision, dizziness, diplopia,     hypoxia, ataxia, vertigo, stroke, coma</li> <li>Peripheral neuropathy</li> <li>Retinal changes: dilated veins, hemorrhages, papilledema</li> <li>Cryoglobulinemia: large IgM complexes precipitate out in the cold,     causing Raynaud's, urticaria, purpura, acral cyanosis, tissue     necrosis</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#evaluation_2","title":"Evaluation","text":"<ul> <li>Requires: IgM monoclonal gammopathy on SPEP, BM biopsy w/\u226510%     lymphocytes with plasmacytoid differentiation (late stage B-cell     differentiation), and MYD88 mutation detected</li> <li>CBC, coagulation studies, cryoglobulins, IgM, \u03b22-microglobulin</li> <li>Serum viscosity (If &lt;4 symptoms are rare, If &gt;6 typically     symptomatic)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#management_1","title":"Management","text":"<ul> <li>Asymptomatic patients managed with close observation</li> <li>Symptomatic hyperviscosity is treated with plasmapheresis</li> <li>Induction: may include bendamustine \u00b1 rituximab if IgM level is     &lt;4000 (Rituximab can temporarily \u2191 IgM and \u2191 risk of hyperviscosity     syndrome)</li> <li>Monitor response with: IgM levels, monoclonal IgM on SPEP</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#other-plasma-cell-dyscrasias","title":"Other Plasma Cell Dyscrasias","text":""},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#light-chain-al-amyloidosis","title":"Light Chain (AL) Amyloidosis","text":"<ul> <li>Extracellular deposition of misfolded light chains (most commonly     kidney &amp; heart)</li> <li>Features: nephrotic syndrome, restrictive CM, peripheral neuropathy,     HSM, macroglossia, easy bruising/bleeding,     dysautonomia/orthostasis</li> <li>Diagnosis:<ul> <li>Need ALL 4: amyloid related systemic syndrome, positive congo     red staining on any tissue, evidence that amyloid is light     chain related, evidence of monoclonal plasma cell disorder</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#poems-syndrome","title":"POEMS Syndrome","text":"<ul> <li>Cause unknown, possibly chronic overproduction of pro-inflammatory     cytokines such as VEGF</li> <li>Features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal     protein (usually \u03bb light chain), Skin changes</li> <li>Diagnosis:<ul> <li>Mandatory Criteria: peripheral neuropathy, monoclonal plasma cell     disorder</li> <li>Major Criteria (need \u2153): osteosclerotic lesions, VEGF, Castleman     disease</li> <li>Minor Criteria (need \u2159): organomegaly, volume overload,     endocrinopathy, skin changes, papilledema, thrombocytosis or     polycythemia</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/#castleman-disease","title":"Castleman Disease","text":"<ul> <li>Angiofollicular lymph node hyperplasia</li> <li>Antibodies to HHV-8 implicated in &gt;50% of cases</li> <li>Features: Lymphadenopathy, fever, night sweats, fatigue, fluid     accumulation, violaceous lymph node biopsy w/ characteristic     hematopathology papules</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-sickle-cell-crisis/","title":"Sickle Cell Crisis","text":"<p>Michael J. Neuss</p>"},{"location":"hematology-oncology/hematologyoncology-sickle-cell-crisis/#background","title":"Background","text":"<ul> <li>Present with severe pain in bone, joints, chest, abdomen</li> <li>Causes: (HIDISC) Hypoxia, Ischemia, Dehydration, Infection, Stress,     Cold</li> <li>Can\u2019t Miss:<ul> <li>Acute chest: hypoxia + fever + chest pain + new infiltrate on CXR     (consult benign hematology immediately, do not wait until the next     day)</li> <li>PE (ACS less likely in these patients); avascular necrosis of hip,     priapism, stroke</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-sickle-cell-crisis/#evaluation","title":"Evaluation","text":"<ul> <li>Labs: LDH (high), Hgb/Hct (low; check vs baseline), retic, smear,     WBC</li> <li>If febrile: UA + Blood cultures</li> <li>Send Hgb S level, and compare to baseline w/ other hospital     admissions</li> <li>Imaging: CXR, MRI for hip pain, Abdominal U/S or CT abdomen</li> <li>Maintain active type and cross given probability of antibodies</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-sickle-cell-crisis/#management","title":"Management","text":"<ul> <li>General:<ul> <li>Look for a care coordination yellow note in the Summary Tab<ul> <li>Heme clinic will have specific management preferences for     individual patients</li> </ul> </li> <li>Maintain hydration, IVF at 150-200 cc/hr (if no contraindication)</li> <li>Oxygen: goal sat ~95% (higher O2 goal will help to prevent further     sickling!)</li> <li>Continue folic acid 1 mg qDay</li> <li>Continue hydroxyurea if uncomplicated pain crisis<ul> <li>Hold if counts suppressed or concern for infection</li> </ul> </li> <li>If in the MICU: consider discussion for plasma exchange (if Hgb SS     or SC or S-Thal)</li> <li>Transfuse: Simple transfusion if Hgb lower than baseline and/or     complications<ul> <li>Avoid transfusions when able, given risk of antibody formation</li> </ul> </li> </ul> </li> <li>Pain:<ul> <li>Will generally require opiates, likely initiation of PCA</li> <li>All SS patients should have pain plans; inpatient pain plans are in     the problem list under sickle cell disease or in the care     coordination section of Epic</li> <li>Outpatient plans (to which you will transition pts back prior to     discharge) are not standardized in location, but can be under Media     (with a pain contract) or found in notes</li> </ul> </li> <li>Acute chest:<ul> <li>Consult Hematology at time of admission</li> <li>D5 \u00bd NS @ 150-250 cc/hr</li> <li>Transfuse hgb to &gt;10</li> <li>PCA w/ dilaudid</li> <li>Abx for CAP (vs HAP if risk factors) \u00b1 bronchodilators</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-therapy-toxicities/","title":"Therapy Toxicities","text":"<p>Rahul Shah</p>"},{"location":"hematology-oncology/hematologyoncology-therapy-toxicities/#immune-checkpoint-inhibitor-toxicities","title":"Immune Checkpoint Inhibitor Toxicities","text":"<ul> <li>Immune checkpoint inhibitors augment the endogenous immune response     against tumors, which may lead to autoimmune-like toxicities, known     as immune-related adverse events (irAEs)</li> <li>Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild     adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg)     for severe adverse events</li> </ul> Adverse Event Type <p>Incidence with anti-CTLA-4</p> <p>(e.g. ipilimumab)</p> <p>Incidence with anti\u2010PD1/PD\u2010L1</p> <p>(e.g. nivolumab, pembrolizumab)</p> Skin (rash, pruritus, TEN) 30% 30% Colitis 25% 5% Hypothyroidism 20% 20% Hepatitis 10% 1% Hypophysitis 10% rare Pneumonitis 2-5% 2-5% Myocarditis &lt;1% &lt;1% Neurotoxicity (GBS, myasthenia gravis, encephalitis) &lt;1% &lt;1%"},{"location":"hematology-oncology/hematologyoncology-therapy-toxicities/#cytotoxic-agent-toxicities","title":"Cytotoxic Agent Toxicities","text":"Class Agent \u00a0Side Effect Alkylating Agents Busulfan Pulmonary fibrosis or diffuse alveolar hemorrhage Cyclophosphamide Myopericarditis, hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, tx: mesna) Ifosfamide Encephalopathy (tx: methylene blue), nephrotoxicity, hemorrhagic cystitis Antimetabolites 5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU) Myelosuppression, coronary vasospasm, palmar-plantar erythrodysesthesia, mucositis Cladribine, pentostatin Dose reduced for CrCl Cytarabine (Ara-C) Irreversible cerebellar ataxia (if high dose, neuro checks required), conjunctivitis (prevent with prophylactic steroid eye drops) Gemcitabine Transient transaminitis, peripheral edema, rash, rarely: pulmonary toxicity, hemolytic uremic syndrome, capillary leak syndrome Methotrexate Stomatitis, hepatotoxicity, renal failure, high dose requires leucovorin Antitumor antibiotics Anthracyclines (doxorubicin, daunorubicin, idarubicin) HFrEF (need TTE prior). Most notable with doxorubicin. Bleomycin Pulmonary fibrosis. Potentiated with G-CSF Monoclonal Antibodies Alemtuzumab Severe and prolonged cytopenias Bevacizumab HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage, GI bleeding/fistulas/perforation, wound healing complications Rituximab Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy; transfusion reaction during 1st time infusion Platinum Agents Cisplatin, oxaliplatin, carboplatin Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity (parasthesias, cold sensitivity, cramps, peripheral neuropathy), ototoxicity (high frequency hearing loss), constipation, hypomag Taxanes Docetaxel, paclitaxel Hypersensitivity reaction (often require premedication with steroids and H1/H2 blockers); peripheral neuropathy Topoisomerase Inhibitors Irinotecan, topotecan, etoposide Irinotecan- acute diarrhea can be treated with atropine; delayed with atropine Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Nilotinib, Bosutinib QTc prolongation, pulmonary effusion, hepatotoxicity Vinca alkaloid Vincristine Peripheral neuropathy and ototoxicity (vestibular system lost first)"},{"location":"hematology-oncology/hematologyoncology-thrombocytopenia/","title":"Thrombocytopenia","text":"<p>Robert Dunn</p>"},{"location":"hematology-oncology/hematologyoncology-thrombocytopenia/#background","title":"Background","text":"<ul> <li>Platelet count &lt;150k (mild), 50-100k (moderate), &lt;50k (severe)</li> <li>Framework for differential: consumption, sequestration, destruction,     production</li> <li>Causes to consider:<ul> <li>Can\u2019t Miss Diagnoses: TTP, HUS, HELLP, DIC, HIT</li> <li>Platelet clumping (lab artifact - pseudothrombocytopenia)</li> <li>Splenomegaly can represent: Plt sequestration, cirrhosis, portal     hypertension</li> <li>Drug-induced: (Antibiotics, heparin, chemo, GpIIb/IIIa antagonists,     H2-antagonists)</li> <li>Rheumatologic cause \u2013 SLE, sarcoidosis, scleroderma renal crisis</li> <li>Sepsis, independent of DIC</li> <li>Immune thrombocytopenia (ITP) is a diagnosis of exclusion</li> <li>Massive physiologic consumption: large hematoma, active hemorrhage</li> <li>Cirrhosis \u2013 results in low thrombopoietin (TPO) and increased     clearance</li> <li>Chronic alcohol use \u2013 direct marrow suppression</li> <li>Infections: HIV, HCV, EBV, Parvovirus, Rickettsia, H. pylori, CMV</li> <li>Bone marrow failure: aplastic anemia, MDS, leukemia, chemotherapy</li> <li>Dilutional: fluid resuscitation and massive transfusion</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-thrombocytopenia/#presentation","title":"Presentation","text":"<ul> <li>Petechiae \u2013 typically begins distally on lower legs (in mouth = wet     purpura), seen when \\&lt;10-20k</li> <li>Overt bleeding, mucosal bleeding, epistaxis (seen when \\&lt;20k)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-thrombocytopenia/#evaluation","title":"Evaluation","text":"<ul> <li>CMP, CBC w/diff, peripheral smear, citrated platelet count, immature     platelet fraction (IPF)</li> <li>LDH, Fibrinogen, d-dimer, PT/aPTT</li> <li>Determine timing of decline as well as prior values</li> <li>Look at other cell lines - never normal to have two cytopenia\u2019s</li> <li>Review recent initiation of drugs: (heparin, antibiotics, and     chemotherapy)</li> <li>Consider abdominal ultrasound to look for splenomegaly and liver     pathology</li> <li>Infectious work up (HIV, HCV)</li> <li>Calculate 4T Score and consider your pretest probability for HIT     testing</li> <li>HIT Ab: ELISA is first test \u2013 only run once/day at VUMC so order     early if considering</li> <li>Reflex Serotonin release assay (SRA) for confirmation (VUMC performs     reflexive testing)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-thrombocytopenia/#management","title":"Management","text":"<ul> <li>Plt &lt;50k<ul> <li>Discontinue pharmacologic DVT prophylaxis (unless HIT)</li> <li>If on anticoagulation: consider risk/benefits of continued     anticoagulation<ul> <li>Can transfuse plt\u2019s if AC is mandatory</li> </ul> </li> </ul> </li> <li>Plt &lt;10k<ul> <li>Transfuse platelets given risk of spontaneous intracranial     hemorrhage</li> <li>In pt\u2019s with HIT or TTP, there is theoretical concern that     transfusing plt can \u201cfuel the fire\u201d and lead to more thrombosis, but     if there is active bleeding then consider platelets<ul> <li>Therefore, bleeding with HIT or TTP, discuss with Hematology     before transfusion</li> </ul> </li> </ul> </li> <li>HIT<ul> <li>If pretest probability is high or HIT is confirmed</li> <li>Stop Unfractionated and low molecular weight heparin products</li> <li>Start Argatroban gtt</li> </ul> </li> <li>If schistocytes present on peripheral smear = concern for TTP<ul> <li>Draw ADAMTS13</li> <li>Contact Nephrology and Hematology for PLEX</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-thrombocytopenia/#additional-information","title":"Additional Information","text":"<ul> <li>Clumping on lab draws:<ul> <li>Obtain Citrated platelet (\u201cblue top\u201d tube \u2013 CPRS refers to it as a     blue top platelet count)</li> <li>If no resolution, obtain a \"Gold top\" LAB 301 in Epic (Named: Plt     count) (ACD tube)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-transfusion-medicine/","title":"Transfusion Medicine","text":"<p>R. Dixon Dorand</p>"},{"location":"hematology-oncology/hematologyoncology-transfusion-medicine/#overview","title":"Overview","text":"<p>For emergent transfusions:</p> <p>Call the blood bank (VUMC: 615-322-2233; VA: 67025, supervisor at 67029).</p> <p>For non-emergent transfusions:</p> <p>VUMC:</p> <ul> <li>RNs on 10T and 11N can follow transfusion protocols for pRBCs and     Plts \u2013 enter as a Nursing Communication or as part of the     Hematology/Oncology Admission Order set.</li> <li>At VUMC, all special processing of blood products (such as     irradiation) will be decided by blood bank based on special     considerations listed in order set. Examples include: stem cell     transplant, hematologic malignancy, or thalassemia</li> <li>Patients with frequent transfusions (e.g. sickle cell     hemoglobinopathy) should have an RBC Extended Phenotype ordered     (once) for minor RBC antigens to avoid immunization and antibody     development to these proteins</li> <li>You may ask the VUMC hematology lab to email you pictures of the     peripheral smear</li> </ul> <p>VA:</p> <p>Orders Tab \u2013 Blood Bank Orders \u2013 follow prompts to select appropriate product. Must order both the blood product AND the transfusion order (\u201cTransfuse blood\u201d)</p> <ul> <li>You need to specify all special processing such as irradiation</li> <li>To order a Type &amp; Screen as a lab, you must go to Blood Bank Orders</li> <li>Type &amp; Screen and Transfusion results are under the Blood tab in     Results</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-transfusion-medicine/#red-blood-cell-transfusion","title":"Red Blood Cell Transfusion","text":"<ul> <li>Volume 200-300 mL per unit prbc</li> <li>In general, 1 unit of packed RBCs increases Hgb by 1g/dL and HCT by ~3%</li> <li>Assessment of the post-transfusion Hgb can be performed 15 min     following transfusion, but ideally 1 hour after completion</li> </ul> <p>Indications:</p> <ul> <li>Hgb &lt;9-10 g/dL \u2013 Acute coronary syndrome</li> <li>Hgb &lt;8 g/dL or Hct &lt;25 \u2013 Bone marrow failure or receiving     antineoplastic therapy</li> <li>Also sometimes used in pts with pre-existing CAD</li> <li>Hgb &lt;7 g/dL or Hct &lt;21 \u2013 ICU, GI Bleeding, Oncology patient on     treatment</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-transfusion-medicine/#platelet-transfusion","title":"Platelet Transfusion","text":"<p>Indications:</p> <ul> <li>&lt;11 k/\u00b5L \u2013 all patients, reduce risk of spontaneous hemorrhage (use     on BMT, Brittingham)</li> <li>&lt;50 k/\u00b5L \u2013 active bleeding, scheduled to undergo select invasive     procedure</li> <li>&lt;100 k/\u00b5L \u2013 CNS hemorrhage, intrathecal catheter<ul> <li>This is also the threshold used for most Neurosurgical procedures</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-transfusion-medicine/#fresh-frozen-plasma-ffp-cryoprecipitate-cryo","title":"Fresh Frozen Plasma (FFP) &amp; Cryoprecipitate (Cryo)","text":"<p>Cryoprecipitate</p> <ul> <li>FFP enriched for von Willebrand factor, factor VIII, factor XIII,     and fibrinogen</li> </ul> <p>FFP</p> <ul> <li>Once thawed, must be used in 24 hrs (due to decline in labile     coagulation factors)</li> <li>Must be ABO compatible but not crossmatched or Rh typing</li> <li>Only administer FFP if INR \u22651.7 (the INR of FFP is ~1.7, so FFP will not fix an INR &lt; 1.7)</li> </ul> <p>Indications:</p> <ul> <li>Bleeding:<ul> <li>FFP If INR &gt;1.7</li> <li>Cryoprecipitate if fibrinogen &lt;100.</li> </ul> </li> <li>DIC:<ul> <li>Fibrinogen &lt;100: Transfuse 5 \u2013 10 units cryoprecipitate and repeat     fibrinogen. If bleeding, consider raising transfusion threshold of     cryoprecipitate to fibrinogen &lt;150</li> <li>For elevated INR, consider FFP transfusion. Thresholds for doing     this vary by attending</li> </ul> </li> <li>Cirrhosis:</li> <li>General concept: PT/INR, aPTT are unreliable markers for bleeding.     Fibrinogen \u2264100 \u2013 120 or thromboelastography are better surrogates     for bleeding risk</li> <li>Transfuse fibrinogen \u2264100 \u2013 120 if the patient is actively bleeding     or about to undergo a procedure or surgery other than paracentesis</li> <li>Transfuse FFP based on hepatology team preference (generally few     indications for FFP)</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-transfusion-medicine/#transfusion-premedication-reactions","title":"Transfusion Premedication &amp; Reactions","text":"<ul> <li>If you are concerned about a serious transfusion reaction, pause the     transfusion and contact the blood bank asap</li> <li>Order the transfusion reaction blood testing in Epic. You will send     a CBC, the bag of blood products, and the completed form to the     blood bank for analysis</li> </ul> <p>Premedication:</p> <ul> <li>Only if history of severe reaction</li> <li>Diphenhydramine 25-50mg IV</li> <li>Acetaminophen 650 mg PO</li> <li>Meperidine 25-50 mg IV (optional for chills)</li> <li>Hydrocortisone 50 mg IV (optional, for severe reactions or reactions     despite acetaminophen and diphenhydramine)</li> </ul> Reaction Signs &amp; Symptoms Etiology Clinical Action Allergic (mild) Pruritus, hives limited to small area Antibodies to transfused plasma proteins Pause transfusion. Administer antihistamines. Resume transfusion if improved; NO samples necessary. If no improvement in 30 min treat as moderate to severe. Allergic (moderate to severe) Generalized hives (&gt;2/3 body surface), bronchospasm &amp; dyspnea, abdominal pain, hypotension, nausea, anaphylaxis Antibodies to transfused plasma proteins usually IgE but can also be IgA, Possible allergen in blood product Administer antihistamines, epinephrine, vasopressors and corticosteroids as needed. Send product to blood bank. Febrile Non-Hemolytic Rise of temp &gt;1\u00b0C, chills, rigors, anxiety. Cytokines released from residual white blood cells in the blood product Mild: administer antipyretics as needed Acute Hemolytic Hemoglobinemia / uria, fever, chills, anxiety, shock, flank pain, chest pain, unexplained bleeding, cardiac arrest <p>Intravascular hemolysis usually due to ABO incompatibility; Recheck for patient ID or clinical error.</p> <p>This is an emergency.</p> Treat shock w/vasopressors; maintain airway; administer fluids and maintain brisk diuresis; monitor for AKI.. Administer blood products as needed after etiology is clear. Septic Rise of temp &gt; 2\u00b0C, sudden hypotension or hypertension, shock Micro-organism (i.e. bacteria) in donor bag (Greater risk in apheresis vs. RBC) Send bag/tubing to transfusion medicine. Order BCx. Broad spectrum abx \u00a0Pressor support if necessary. TRALI \u2013 Transfusion Related Acute Lung Injury Acute respiratory distress usually within 1-2 hours of transfusion. Non-cardiogenic pulmonary edema unresponsive to diuretics; Dx of exclusion. Usually donor HLA antibodies from transfused plasma. Recipient has corresponding antigens; causes neutrophil activation that results in extravasation of fluid into air spaces Respiratory support! Most will resolve within 24-96 hours. Steroids, diuretics: no known benefit."},{"location":"hematology-oncology/hematologyoncology-vte/","title":"Venous Thromboembolism","text":"<p>Kenna Koehler</p>"},{"location":"hematology-oncology/hematologyoncology-vte/#background","title":"Background","text":"<ul> <li>Includes both deep vein thrombosis (DVTs) and pulmonary embolism     (PE). See \u201cPulmonary Embolism\u201d section in cardiology for more     information on PEs</li> <li>Risk Factors for Provoked DVT/PE<ul> <li>Major risk factors: major surgery &gt;30 minutes, hospitalization &gt; 3     days, C-section</li> <li>Minor Risk Factors: Surgery &lt;30 minutes, Hospitalization &lt;3 days,     pregnancy, estrogen therapy, reduced mobility &gt;3 days</li> <li>Non-transient risk factors: Malignancy (active), IBD, liver disease,     hereditary thrombophilia</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-vte/#evaluation","title":"Evaluation","text":"<ul> <li>Asymmetric calf swelling of &gt;2cm sensitivity and specificity for     DVT of 60-70%</li> <li>Wells\u2019 Criteria for DVT can help guide diagnostic testing</li> <li>If a patient has a low pre-test probability, a negative D-dimer can     rule out DVT</li> <li>In a high pre-test probability patient a negative D-dimer is less     helpful</li> <li>Whole-leg ultrasounds with doppler</li> </ul>"},{"location":"hematology-oncology/hematologyoncology-vte/#management","title":"Management","text":"<ul> <li>Prophylaxis: Padua score</li> <li>Score &gt; 4 high risk, recommend pharmacologic prophylaxis<ul> <li>Subcutaneous Low Molecular Weight Heparin (LMWH) or Subcutaneous     Heparin</li> </ul> </li> <li>Score &lt;4 is low risk; recommend ambulation and SCDs</li> <li>Treatment (see anticoagulation section)<ul> <li>Subcutaneous low molecular weight heparin (LMWH)</li> <li>Oral factor Xa inhibitors (rivaroxaban, apixaban)</li> <li>Intravenous unfractionated heparin</li> <li>Warfarin (with bridge therapy)</li> </ul> </li> <li>Duration of treatment<ul> <li>Provoked: 3 months or until provoking factor (trauma, surgery,     malignancy) is removed</li> <li>Unprovoked: Typically requires life-long anticoagulation along with     assistance from hematology</li> </ul> </li> <li>Anticoagulation in malignancy:<ul> <li>LMWH or DOAC (most evidence for apixaban and rivaroxaban) while     malignancy still active</li> <li>Avoid rivaroxaban and edoxaban in GI malignancies (increased rates     of bleeding)</li> </ul> </li> </ul>"},{"location":"hematology-oncology/hematologyoncology-vte/#additional-information","title":"Additional Information","text":"<ul> <li>Should we get a follow up ultrasound?<ul> <li>A follow up ultrasound at the CONCLUSION of anticoagulation can help establish a post-treatment baseline and provide a baseline study for future comparison that can be critical for the diagnosis of recurrent/new DVT (which is very difficult to determine radiographically without a comparison imaging study)</li> </ul> </li> <li>What about IVC filters?<ul> <li>Select circumstances for these: In patients with acute DVT or PE and in whom anti-coagulation is absolutely contraindicated (thrombocytopenia, recent intra-cranial bleed, recent GI bleed) placement of a retrievable IVC filter should be discussed with Hematology and IR</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-acute-liver-failure/","title":"Acute Liver Injury and Failure","text":"<p>Hannah Lomzenski, and Lauren Chan</p>"},{"location":"hepatology/hepatology-acute-liver-failure/#background","title":"Background","text":"<ul> <li> <p>Acute liver injury (ALI): elevated liver enzymes + INR \u22651.5 but NO encephalopathy</p> </li> <li> <p>Acute liver failure (ALF): elevated liver enzymes + encephalopathy/AMS in the absence of pre-existing liver disease*</p> <ul> <li>*Chronic autoimmune hepatitis, HBV, Wilson disease, and Budd-Chiari syndrome can have ALF if they develop new AMS, despite the presence of a pre-existing liver disease</li> </ul> </li> <li> <p>Alcohol-associated hepatitis (AH) is not ALF (see above)</p> </li> </ul>"},{"location":"hepatology/hepatology-acute-liver-failure/#etiology","title":"Etiology","text":"<ul> <li> <p>R-factor (if history, exam, and diagnostic data are inconclusive i.e. R-factor is not a replacement to clinical judgement) = (ALT/uln ALT) / (ALP/uln ALP); See chart below</p> <ul> <li>R &gt; 5 = hepatocellular injury; R&lt;2 = cholestatic injury; R 2-5 = mixed injury</li> </ul> </li> <li> <p>Isolated hyperbilirubinemia: Differentiate direct versus indirect</p> <ul> <li>Direct: Refer to cholestatic pattern</li> <li>Indirect: Gilbert vs hemolysis</li> </ul> </li> <li> <p>Drugs Associated with liver injury</p> <ul> <li> <p>Hepatocellular pattern: acarbose, Acetaminophen, Allopurinol, Amiodarone, Baclofen, Bupropion, Fluoxetine, HAART (Nevirapine), Kava kava, Isoniazid, Ketoconazole, Lisinopril, Losartan, Methotrexate, NSAIDs, Omeprazole, Oxacillin/Nafcillin, Paroxetine, Pyrazinamide, Propylthiouracil, Rifampin, Risperidone, Sertraline, Statins, Tetracycline, Trazodone, Valproic Acid</p> </li> <li> <p>Mixed pattern: Amitriptyline, Azathioprine, Captopril, Carbamazepine, Clindamycin, Cyproheptadine, Enalapril, Flutemide, Nitrofurantoin, Phenobarbital, Phenytoin, Sulfonamides, Trazodone, Verapamil</p> </li> <li> <p>Cholestatic pattern: Amoxicillin-clavulanic acid, Anabolic steroids, Chlorpromazine, Clopidogrel, Oral contraceptives, Erythromycins, Estrogens, Irbesartan, Mirtazapine, Phenothiazines, Terbinafine, Tricyclics</p> </li> </ul> </li> </ul> Hepatocellular Injury: R factor &gt; 5 (Primary elevation of AST/ALT) Acetaminophen intoxication$ <p>Acetaminophen lvl</p> <p>Aspirin lvl</p> Acute Viral Hepatitis <p>Hep A$, B*$, C*, D, E</p> <p>EBV, CMV, HSV, VZV</p> Viral serologies (see below), hx of tattoos, IVDU, piercings, blood transfusion prior to 1990s, intranasal cocaine use and mass vaccinations (in 3rd world countries) Autoimmune hepatitis\\* Autoantibodies and high serum globulins Anti-smooth muscle (f-actin), ANA, ANCA, anti-liver kidney microsome (anti-LKM-1), anti-soluble liver antigen/liver-pancreas IgG Budd-Chiari Syndrome\\* Hepatic vein obstruction Ultrasound of abdomen w/ doppler, CT w/ contrast DILI \u2013 Drug Induced Liver Injury\\*$ Many drugs See above \\*Query NIH Liver Tox database: https://www.livertox.nih.gov HELLP Syndrome, Acute Fatty Liver of Pregnancy Pregnancy Requires urgent delivery regardless of gestational age Ischemic Liver Injury (Shock Liver)$ Shock (can be of any variety) AST and ALT can be in the thousands, high LDH, history of hypotension Toxins Ethanol, cocaine, mushroom (Amanita phalloides) UDS, ethanol level, PEth lvl Wilson\u2019s Disease\\* Copper overload Ceruloplasmin level (screening), 24h urine copper (confirmation), quantitative copper on liver biopsy \\*May present with chronic liver injury as well; $May present with AST/ALT &gt;100 Cholestatic Injury: R Factor \\&lt; 2 (Primarily elevated Alkaline phosphatase) Acute biliary obstruction Gallstones Abdominal ultrasound, MRCP, ERCP DILI \u2013 Drug-induced liver injury*$ Many drugs, consult livertox website Common: Augmentin, Bactrim, amiodarone, Imuran Malignancy* Pancreas, cholangiocarcinoma CT abdomen, ERCP Primary Biliary Cirrhosis* Autoimmune Anti-mitochondrial antibody Primary Sclerosing Cholangitis* Autoimmune, associated with IBD MRCP, ERCP Critical illness or COVID cholangiopathy Hypotension, COVID MRCP with biliary stenosis, appropriate history *May present with chronic liver injury as well; $May present with AST/ALT &gt;100"},{"location":"hepatology/hepatology-acute-liver-failure/#evaluation","title":"Evaluation","text":"<ul> <li>Consult hepatology early! (to assist with workup AND for transplant     evaluation)</li> <li> <p>Labs:</p> <ul> <li>CBC w/diff, CMP, Dbili, Mg, Phos, T&amp;S, BCx, UCx, PT/INR, aPTT, fibrinogen</li> <li>Amylase, lipase </li> <li>Beta-hCG for females of reproductive age</li> <li>ABG with arterial lactate, ammonia (arterial &gt;124 predicts mortality and CNS complications e.g. need for intubation, seizures, cerebral edema, &lt;75 very unlikely to develop ICH) </li> <li>Viral etiologies: Virtal hepatitis serologies (HAV panel, HBV panel, HCV IgG \u00b1 PCR quant, HDV if known HBV (with low or undetectable HBV load as Misc Reference Test, Hepatitis E PCR ent as miscellaneous if pregnant or travel to southeast Asia), HIV p24 Ag and HIV Ab, EBV Qt, CMV Qt, HSV \u00bd Qt, VZV IgM/IgG</li> <li>Toxins: UDS, ethanol level \u00b1 Peth, acetaminophen level (drawn &gt; 4 hours after last known ingestion), Salicylate level</li> <li>Autoimmune / genetic: ANA, ASMA, IgG, AMA (if predominantly elevated ALP), ceruloplasmin</li> </ul> </li> <li> <p>Imaging:</p> <ul> <li>RUQ abdominal ultrasound with doppler (important to assess     vasculature!)</li> <li>Consider CT with contrast in patients with normal renal function     and high suspicion of Budd-Chiari syndrome or malignancy with     negative ultrasound\u00a0 (better for assessing the hepatic veins)     and helps with transplant evaluation</li> <li>Consider TTE to rule out cardiac dysfunction; helpful for     transplant consideration</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-acute-liver-failure/#criteria-for-transplantation","title":"Criteria for Transplantation:","text":"<ul> <li>King\u2019s College criteria:     helps identify patients needing transplant referral/consideration<ul> <li>ALF due to acetaminophen:<ul> <li>Arterial pH \\&lt;7.3 after resuscitation and &gt;24 hr since     ingestion, OR</li> <li>Arterial Lactate &gt;3 after adequate fluid resuscitation, OR</li> <li>Grade III-IV HE, SCr &gt;3.4, and INR &gt;6.5 all within 24h period</li> </ul> </li> </ul> </li> <li>ALF not due to acetaminophen: INR &gt; 6.5 OR 3 of the 5 following     criteria:<ul> <li>Indeterminate etiology, drug-induced hepatitis</li> <li>Age \\&lt;10 or &gt;40</li> <li>Interval of jaundice to encephalopathy &gt;7 days</li> <li>Bilirubin &gt; 17.5 mg/dl (300 micromol/L) </li> <li>INR &gt;3.5</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-acute-liver-failure/#management","title":"Management","text":"<ul> <li>Any pt with concern for ALF should be cared for in MICU (even if mild change in mental status)</li> <li>Pts with ALF die acutely from hypoglycemia, cerebral edema, and     infection</li> <li>ABC\u2019s:<ul> <li>Intubate for GCS \\&lt;8, Grade 3 or 4 HE</li> <li>IVF resuscitation with isotonic crystalloid (most pts are volume     deplete; avoid hypotonic fluids due to risk of cerebral edema)</li> <li>Vasopressive agents for persistent hypotension (norepinephrine     preferred)</li> </ul> </li> <li>Monitoring:<ul> <li>Q1-2h neuro checks, Q1-2h glucose checks</li> <li>Closely monitor CMP, INR q6-8 hrs</li> </ul> </li> <li>Treatment of Primary Injury<ul> <li>IV N-acetylcysteine - improves transplant-free survival even in     patients WITHOUT acetaminophen induced acute liver failure<ul> <li>Initial loading dose = 150mg/kg over 1 hour, then 50mg/kg/hr     for 4 hours, then 100mg/kg/hr for 16 hours \u200b\u200b\u200b\u200b\u200b\u200b\u200b</li> <li>Patients with early stage hepatic encephalopathy (grade     I/II) have increased transplant free survival, while those     with grade III/IV do not</li> </ul> </li> <li>See below for etiology-specific treatment; hepatology consult     for LT eval</li> <li>Early toxicology consultation if suspected ingestion/overdose<ul> <li>For acute management contact Poison Control 800-222-1222</li> </ul> </li> </ul> </li> <li>Treatment of Secondary Complications<ul> <li>Infection: abx only if progressing HE, signs of infection, or     development of SIRS; ppx abx do not reduce mortality</li> <li>Cerebral edema/increased ICP:\u00a0 elevated HOB to 30 degrees, quiet     and dimly lit room, minimize IVF, goal Na 145-155,     hyperventilation if concern for impending herniation. Consider     3% saline (500mL) and/or mannitol (1g/kg, 20%) for pt at highest     risk (serum ammonia &gt;150, grade III/IV HE, ARF, vasopressor     support</li> <li>Seizures: phenytoin (no evidence to support seizure ppx)</li> <li>Renal Failure: early CRRT if persistent Metabolic Acidosis,     Volume Overload, Hyperammonemia, falling UOP</li> <li>Coagulopathy: IV Vit K; products for invasive procedures or     active bleeding only</li> </ul> </li> <li>Additional Supportive Care<ul> <li>PPI for bleeding ppx</li> <li>Enteral nutrition within 2-3 days; avoid TPN if possible; avoid     NG feeds if progressive HE; NG should only be placed w/     intubation as gagging increases ICP</li> <li>Prefer propofol for sedation for better neuro exams and may reduce cerebral blood flow</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-acute-liver-failure/#specific-management-by-etiology","title":"Specific Management by Etiology:","text":"<ul> <li>Acetaminophen<ul> <li>Early toxicology consultation if suspected ingestion/overdose</li> <li>For acute management contact Poison Control 800-222-1222</li> <li>Activated charcoal within 4 hours of ingestion, most effective within 1 hour</li> <li>IV N-acetylcysteine per protocol, look up Rumack-Matthew Nomogram and consult with toxicology<ul> <li>In Epic: search \u201cN-acetylcysteine\u201d and select order set \u201cAcetaminophen overdose\u201d</li> </ul> </li> </ul> </li> <li> <p>AFLP/HELLP \u2013 delivery</p> </li> <li> <p>Amanita phalloides \u2013 IV fluid resuscitation, PO charcoal, IV penicillin, IV acetylcysteine</p> </li> <li> <p>Autoimmune \u2013 IV steroids following approval by hepatology (and typically post biopsy). Azathioprine generally deferred until cholestasis resolved (Mycophenolate can be used instead)</p> </li> <li> <p>Budd-Chiari \u2013 anticoagulation, IR-guided endovascular therapy, transplant (must rule out underlying malignancy and evaluate for thrombotic disorders)</p> </li> <li> <p>HAV/HEV \u2013 supportive care, consider ribavirin for ALF due to HEV</p> </li> <li> <p>HBV \u2013 nucleos(t)ide analogue; orthotopic liver transplant</p> </li> <li> <p>HSV \u2013 acyclovir</p> </li> </ul>"},{"location":"hepatology/hepatology-alcoholic-hepatitis/","title":"Alcoholic Hepatitis","text":"<p>Julie Cui, Alex Wiles</p>"},{"location":"hepatology/hepatology-alcoholic-hepatitis/#background","title":"Background","text":"<ul> <li>Acute onset of rapidly progressive jaundice in pt with heavy EtOH intake (&gt;40g in females or &gt;60g in males EtOH/day for &gt;6 mos, or within &lt;60 days of abstinence)<ul> <li>May present after they have quit drinking due to immunosuppressive effects of alcohol</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-alcoholic-hepatitis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>AST &gt;60, AST/ALT &gt;1.5, both values &lt;400 IU/L; TBili &gt;3.0 mg/dL, documentation of heavy EtOH use until 8 weeks prior to presentation</p> </li> <li> <p>Prognostication with Maddrey\u2019s Discriminant Function: 4.6 * (PTpt \u2013 PTctrl) + Tbili</p> <ul> <li>Maddrey &gt; 32 = poor 30d prognosis &amp; may benefit from steroids (see below)</li> </ul> </li> <li> <p>RUQ U/S to rule out obstructive cause of jaundice</p> </li> <li> <p>Biopsy is not typically required but will show neutrophilic lobular inflammation, hepatocyte ballooning, steatosis, and pericellular fibrosis.</p> </li> <li> <p>Phosphatidylethanol (PEth) level is a biomarker of ethanol consumption over ~ 4wks; &gt;20 ng/mL can indicate chronic moderate/heavy alcohol intake</p> <ul> <li>A single episode consumption can result in detectable Peth for up to 12 days. Can be elevated for months with regular heavy alcohol intake</li> <li>EtOH levels may be negative unless acutely intoxicated</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-alcoholic-hepatitis/#management","title":"Management","text":"<ul> <li> <p>Supportive Care is essential! Consult nutrition, start high protein, high calorie diet, high dose Thiamine x 3d, Folate, MVI</p> </li> <li> <p>Full infection workup (CXR, UA, BCx, paracentesis) regardless of symptoms</p> </li> <li> <p>Steroids: STOP-AH Trial (NEJM 2015) showed improved mortality at 28 days but not at 90 days in patients with Maddrey &gt; 32 who received steroids; the decision to treat is very nuanced and should be discussed with hepatology attending.</p> <ul> <li>Prednisolone 40mg daily for pts who meet above criteria</li> <li>Contraindications to steroids include: presence of infection (must rule out first including TB, uncontrolled GI bleeding, AKI w/ Cr &gt;2.5 mg/dL)</li> <li>The Lille score can be used to guide continuation of steroids after 7 d of therapy</li> <li>NAC can be considered as adjunctive therapy to steroids and may decrease 30-day mortality, though has not demonstrated longer mortality benefit at 3 or 6 months</li> </ul> </li> <li> <p>Monitor on CIWA</p> <ul> <li>Psychiatry consultation as appropriate, consideration of medical therapy (see \u201cSubstance Use Disorders\u201d section in psychiatry)</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-ascites/","title":"Ascites and Hepatic Hydrothorax","text":"<p>Lauren Evers Carlini, Thomas Strobel</p>"},{"location":"hepatology/hepatology-ascites/#ascites","title":"Ascites","text":""},{"location":"hepatology/hepatology-ascites/#background","title":"Background","text":"<ul> <li> <p>Associated with a reduction in 5 year survival from 80% to 30%.</p> </li> <li> <p>Most often due to portal hypertension. Less common causes include peritoneal or metastatic cancer, heart failure, tuberculosis, nephrotic syndrome, Budd-Chiari, sinusoidal obstructive syndrome (S.O.S), or complications from procedures and pancreatitis</p> </li> </ul> Grade Definition Treatment Grade 1 Ascites Only seen on imaging 2g Na restriction Grade 2 Ascites Moderate, symmetric abdominal distension 2g Na restriction, diuretics Grade 3 Ascites Marked, tense abdominal distension LVP + Na restriction, diuretics (unless refractory)"},{"location":"hepatology/hepatology-ascites/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Bedside ultrasound on admission to confirm presence of ascites</p> </li> <li> <p>Diagnostic paracentesis in all pts with ascites on admission mainly to rule out occult SBP</p> <ul> <li>Initial paracentesis or when cause of ascites is uncertain: Total Protein, serum and BF Albumin, cell count w/diff, culture</li> <li>Subsequent/Serial paracenteses: cell count w/diff, culture, protein</li> <li>Always inoculate culture bottles at bedside (VA does not allow bedside innoculation)</li> </ul> </li> <li> <p>See Procedure section for guidance on paracentesis. </p> </li> <li> <p>Serum-ascites albumin gradient (SAAG) = serum albumin - ascites albumin.</p> </li> </ul> 0 1 2 Total Protein Ascites (not serum) SAAG &gt; 1.1 g/dL (Portal HTN ) SAAG \\&lt; 1.1 g/dL (Non-portal HTN ) \\&lt; 2.5 g/dL Cirrhosis Nephrotic Syndrome Myxedema &gt; 2.5 g/dL Post-hepatic portal HTN: Cardiac Ascites Budd-Chiari Malignant Ascites Pancreatic Ascites TB <ul> <li> <p>Calculate PMNs from fluid (see SBP below)</p> </li> <li> <p>Other tests:</p> <ul> <li>Triglycerides: if fluid is milky</li> <li>Cytology: if very concerned for peritoneal carcinomatosis. May need up to 3 separate samples (50ml or more) to be able to detect malignant cells</li> <li>ADA: if concern for peritoneal TB</li> <li>Hematocrit: For bloody appearing fluid (not just serosanguinous) to rule out hemoperitoneum. There needs to be a recent serum HCT for comparison.</li> <li>Amylase: If concerned for pancreatic ascites</li> <li>Glucose, LDH if concern about secondary peritonitis (see below)</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-ascites/#management","title":"Management","text":"<ul> <li> <p>2000mg sodium restriction per day for all ascites (Grade 1-3)</p> </li> <li> <p>Diuretics (spironolactone and typically furosemide)</p> <ul> <li>Start at 100mg of spironolactone with up titration to 400mg</li> <li>Furosemide is added if insufficient diuresis or if limited by hyperkalemia. Use more loop diuretics in patients with CKD</li> <li>If Urine Na:K ratio &lt;1, indicates insufficient natriuresis. Can \u2191 doses to a max of 400:160</li> <li>If poor response can change to torsemide 10mg and \u2191 to 40mg max (per single dose)</li> <li>Fluid restriction usually not necessary unless serum sodium &lt;125 mmol/L</li> </ul> </li> <li> <p>Large volume paracentesis should be performed for tense ascites or refractory ascites (grade 3), regardless of serum Cr. Pts should be tapped dry with each paracentesis</p> </li> <li> <p>Give 6-8g of albumin per liter of ascites removed, even if &lt; 5L</p> </li> <li> <p>Target weight loss of 0.5 kg/day when diuresing to avoid renal injury</p> </li> <li> <p>Discontinue NSAIDs and ACEI/ARB</p> </li> </ul>"},{"location":"hepatology/hepatology-ascites/#refractory-ascites","title":"Refractory Ascites:","text":"<ul> <li> <p>Two distinctions:</p> <ul> <li>Diuretic-resistant: lack of response to diuretics (max spironolactone 400mg/lasix 160mg), Na restriction and rapid recurrence following paracentesis</li> <li>Diuretic-intractable: unable to tolerate diuretic therapy 2/2 adverse drug effects (unexplained HE, AKI, K abnormalities, hypoNa, intractable muscle cramps)</li> </ul> </li> <li> <p>Management aside from liver transplant:</p> <ul> <li>Discontinue diuretics once refractory ascites has been established</li> <li>Consider oral midodrine; can be especially helpful if pt is also hypotensive</li> <li>Serial paracenteses, generally arranged OP with IR</li> <li>Consider TIPS (trans jugular intrahepatic portosystemic shunt; has survival benefit). Following TIPS, cessation or decrease in ascites should occur in 4-6 weeks</li> <li>Consider discontinuing beta blockers in patients with refractory ascites if sBP &lt;90, SCr &gt;1.5, or Na &lt;130</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-ascites/#hepatic-hydrothorax","title":"Hepatic Hydrothorax","text":""},{"location":"hepatology/hepatology-ascites/#background_1","title":"Background","text":"<ul> <li> <p>Transudative effusion, typically unilateral (75% right sided); reflects ascitic fluid that passes through defects in the diaphragm. 10% can develop without clinical ascites.</p> </li> <li> <p>Present in 4-12% of cirrhotics and portends a poor prognosis (75% mortality within 90 days)</p> </li> </ul>"},{"location":"hepatology/hepatology-ascites/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>Often suspected clinically, though must exclude pleural/cardiopulmonary process</p> </li> <li> <p>Thoracentesis will demonstrate a transudative effusion and should be evaluated with standard pleural fluid lab tests: cell count, protein, albumin, LDH, culture</p> <ul> <li>Other considerations: triglycerides, amylase, hematocrit, cytology</li> </ul> </li> <li> <p>Rule out SBE which is diagnosed the same as SBP (PMN&gt;250)</p> </li> </ul>"},{"location":"hepatology/hepatology-ascites/#management_1","title":"Management","text":"<ul> <li> <p>Similar management of ascites as noted above</p> </li> <li> <p>AVOID chest-tube placement. associated with increased morbidity and mortality due to extensive loss of fluid, electrolytes and protein as well as increased infection risk</p> <ul> <li>PleurX catheters can be considered for palliation (e.g., hospice patients)</li> </ul> </li> <li> <p>Refractory Hydrothorax is defined similarly and managed similarly with serial thoracentesis or TIPS. </p> </li> <li> <p>Management of spontaneous bacterial empyema is the same as in SBP (see below)</p> </li> </ul>"},{"location":"hepatology/hepatology-cirrhosis/","title":"Cirrhosis Overview","text":"<p>Hannah Angle, Lee Richardson </p>"},{"location":"hepatology/hepatology-cirrhosis/#background","title":"Background","text":"<ul> <li>Standard 1-liner for any patient with cirrhosis:</li> </ul> <ul> <li> <p>Example 1-liner: 65yo M with cirrhosis due to HCV decompensated by ascites and HE (MELD 25) who is listed for transplant and followed by Dr. Izzy</p> </li> <li> <p>Etiology of cirrhosis: HCV&gt;HBV, EtOH, NASH, Wilson\u2019s, hemochromatosis, A1AT deficiency, autoimmune hepatitis, PSC, PBC, congestive hepatopathy (right heart failure), medication-induced</p> </li> <li> <p>Complications that cause decompensation: overt ascites (or hepatic hydrothorax), overt hepatic encephalopathy (HE), esophageal variceal hemorrhage (EVH)</p> </li> <li> <p>Always calculate daily MELD-Na scores (predicts 3 mo survival based on Tbili, Cr, INR, Na)</p> </li> </ul>"},{"location":"hepatology/hepatology-cirrhosis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Goals: establish cause of cirrhosis, evaluate for complications and treat accordingly, determine prognosis, and consider transplant evaluation</p> </li> <li> <p>History:</p> <ul> <li>Symptoms suggesting decompensation: confusion, sleep disturbances, abdominal swelling, lower extremity edema, scleral icterus/jaundice, pruritus, easy bruising/bleeding (skin, mouth, GI tract), dyspnea</li> <li>Social history: EtOH and drug use hx, date of last drink, average # of drinks/day, duration of EtOH use, prior rehab, hx of DUI, if there has been continued EtOH use despite knowledge of liver disease; these factors all impact transplant candidacy</li> <li>Ascites: compliance with diuretics, compliance with salt restriction, frequency of paracentesis (volume removed, date of last para), h/o SBP</li> <li>HE: compliance with lactulose, # of BMs per day, any potential triggers (see HE section)</li> <li>GIB/EVH: hematemesis, coffee ground emesis, melena, hematochezia (duration, volume, # of bleeding episodes), last EGD (varices, banding) and colonoscopy, compliance with non-selective BBs</li> </ul> </li> <li> <p>Physical exam: asterixis, ascites, edema/anasarca, splenomegaly, muscle wasting, gynecomastia, testicular atrophy, palmar erythema, spider angiomata, scleral icterus/jaundice, petechiae/ecchymoses, caput medusa, Terry\u2019s nails</p> </li> <li> <p>Labs</p> <ul> <li>Initial Workup: CMP, CBC, coags, UA, HCV/HBV, Fe studies, PEth</li> <li>Unless requested by hepatology, defer to outpatient: AFP, ANA, IgG, A1AT, ceruloplasmin, AMA (PBC), ASMA (AIH), anti-SLA (AIH), anti-LKM (AIH)</li> </ul> </li> <li> <p>Imaging:</p> <ul> <li>Abdominal US with duplex </li> <li>For transplant eval, needs triple phase CT A/P (contrasted study, arterial and venous phases) or MRI abdomen with contrast</li> </ul> </li> <li> <p>Liver biopsy: gold standard for cirrhosis diagnosis but is not always needed if clinical presentation, labs, and imaging consistent with cirrhosis</p> </li> </ul>"},{"location":"hepatology/hepatology-cirrhosis/#lab-abnormalities","title":"Lab abnormalities","text":"<ul> <li> <p>Hyponatremia (see hyponatremia section below)</p> </li> <li> <p>Cirrhotic coagulopathy (increased INR): due to \u2193 coagulation factor production</p> </li> <li> <p>Thrombocytopenia: due to splenic sequestration, \u2193 TPO production</p> </li> <li> <p>Hypoalbuminemia: indications for 25% albumin transfusion \u2013 SBP (1.5g/kg on day 1, 1g/kg on day 3), LVP (6-8g/L of ascites), HRS (albumin challenge: 1g/kg/day with max 100 g/day x 2 days), hypoNa &lt;125 and refractory to fluid restriction</p> </li> </ul>"},{"location":"hepatology/hepatology-cirrhosis/#management","title":"Management","text":"<ul> <li> <p>Nutrition: high protein diet, 2g Na restriction (if ascites present)</p> <ul> <li>Mediterranean diet for NASH</li> <li>Fluid restriction if hyponatremic</li> </ul> </li> <li> <p>Immunizations: ensure up-to-date with HBV/HAV, PPSV23, Prevnar, Flu, COVID-19 vaccines</p> </li> <li> <p>Consider consulting Addiction Psych and Social Work for pts with EtOH use disorder - can assist with arranging Intensive Outpatient Program (IOP), Alcoholics Anonymous (AA)</p> </li> <li> <p>General screenings include: HCC screening (q6 months), EVH screening (see section below), monitor for other decompensations and treat accordingly, monitor MELD and consider transplant evaluation when &gt;15</p> </li> </ul>"},{"location":"hepatology/hepatology-cirrhosis/#medication-tips","title":"Medication Tips:","text":"<ul> <li> <p>Pain: 2g limit Tylenol, No NSAIDs, limit sedating medications especially with HE.</p> <ul> <li>Tramadol 25-50mg generally safe to use</li> </ul> </li> <li> <p>Pruritus: Sarna lotion, can spot dose antihistamines. Can discuss with pharmacist/attending about starting sertraline, cholestyramine (interacts with many medications), or rifampin.</p> </li> <li> <p>Anxiety/insomnia: hydroxyzine, avoid benzodiazepines</p> </li> <li> <p>If needed for EtOH withdrawal, use lorazepam (Ativan) instead of chlordiazepoxide (Librium) or diazepam (Valium) due to its shorter half life</p> </li> </ul>"},{"location":"hepatology/hepatology-coagulopathy/","title":"Coagulopathy in Cirrhosis","text":"<p>Garren Montgomery, John Laurenzano</p>"},{"location":"hepatology/hepatology-coagulopathy/#background","title":"Background","text":"<ul> <li>The liver is responsible for production of both pro- (factor II, V, VII, IV, X, and XI) and anti-coagulants (protein C, S) in hemostasis. Factor VIII is the only one not made by the liver.</li> <li>Thrombocytopenia is caused by splenic sequestration from portal HTN, failure to produce thrombopoietin (TPO), and bone marrow failure</li> </ul>"},{"location":"hepatology/hepatology-coagulopathy/#evaluation","title":"Evaluation","text":"<ul> <li> <p>INR/PT, and PTT are poorly reflective of bleeding risk</p> </li> <li> <p>TEG screens and other measures of comprehensive coagulation in cirrhotics</p> </li> </ul>"},{"location":"hepatology/hepatology-coagulopathy/#management","title":"Management","text":"<ul> <li> <p>Even in bleeding, there is no need to intervene on an INR or platelet value</p> </li> <li> <p>Pre-procedural FFP is not recommended, even in the presence of bleeding, but is frequently requested by different proceduralists</p> </li> <li> <p>Low risk procedures (i.e., paracentesis) do not require pre-procedural blood products</p> </li> <li> <p>In bleeding pts, the following are recommended per AASLD and AGA guidelines</p> <ul> <li>IV Vitamin K 10mg x 3 days</li> <li>FFP: Not recommended, unless as part of a balanced transfusion effort to avoid transfusion related coagulopathy, or if a TEG screen suggests potential benefit</li> <li>Cryoprecipitate: if fibrinogen &lt; 120</li> <li>Platelets: No specific targets regardless of bleeding. Pre-procedurally, recommend &gt;50</li> </ul> </li> <li> <p>Appropriate DVT ppx should be given with few exceptions (plts &lt;50k, active hemorrhage)</p> </li> <li> <p>For TEG transfusion recommendations are as follows:</p> <ul> <li>10 mg/kg FFP if R-time &gt;10 minutes</li> <li>1u Plts if maximum amplitude &lt;55 mm</li> <li>5u cryo if alpha angle &lt;45</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-hepatic-encephalopathy/","title":"Hepatic Encephalopathy (HE)","text":""},{"location":"hepatology/hepatology-hepatic-encephalopathy/#evaluation","title":"Evaluation","text":"<ul> <li>Asterixis: inability to maintain stable posture; many ways to assess<ul> <li>Check for clonus</li> <li>Have pt \u201chold out hands like you are stopping traffic\u201d (if following commands)</li> <li>Shine light in pupil (look up video of hippus)</li> </ul> </li> </ul> 0 1 2 3 Grade Behavior change Asterixis Cerebral Edema in Acute Liver Failure: I Mild confusion, changes in behavior, increased sleep No Asterixis No cerebral edema II Moderate confusion, lethargic Asterixis Rare cerebral edema III Marked confusion, arousable but falls asleep, incoherent speech Asterixis ~30% cerebral edema IV Coma No Asterixis ~75% cerebral edema <ul> <li>Identify precipitants<ul> <li>Infection (rule out SBP in addition to CXR, BCx, UA/Cx     regardless of sxs),</li> <li>Medication non-adherence (lactulose)</li> <li>GI bleed (perform rectal exam and observe hgb trend)</li> <li>Over-diuresis resulting in dehydration, lyte abnormalities     (especially hypoK)</li> <li>Sedatives/benzo/opiate administration (UDS)</li> <li>Post-TIPS, other large but spontaneous shunt (imaging can be     useful to determine if there is a shunt, and if an intervention     is feasible on such a shunt).</li> </ul> </li> <li>Ammonia (NH 3 ) levels do not play a role in the acute     management of hepatic encephalopathy; if pt has AMS or HE, you will     treat the HE regardless</li> <li>Arterial NH 3 is used in acute liver failure for     prognostication (not for management)</li> </ul>"},{"location":"hepatology/hepatology-hepatic-encephalopathy/#management","title":"Management","text":"<ul> <li> <p>Always determine precipitant and treat underlying condition</p> </li> <li> <p>Lactulose 30mL TID initially</p> <ul> <li>Titrate dose to at least 4 BMs daily, avoid excessive stool     output which may exacerbate HE due to dehydration and     electrolyte abnormalities</li> <li>Consider lactulose enemas vs DHT placement if pt unable to     tolerate PO<ul> <li>DHT are not contraindicated in patients with esophageal     varices, but should be avoided in patients with recent     hemorrhage or banding</li> </ul> </li> <li>Add Rifaximin after the second episode of HE, or if failure to     respond to lactulose<ul> <li>Frequently requires prior auth for OP approval and is     expensive</li> </ul> </li> </ul> </li> <li>Lactulose is generally continued indefinitely after first episode of     HE, though discontinuation can be considered if predisposing factors     (recurrent infection, EVH, EtOH use) have resolved</li> </ul>"},{"location":"hepatology/hepatology-hepatocellular-carcinoma/","title":"Hepatocellular Carcinoma (HCC)","text":"<p>Julie Cui, Lee Richardson </p>"},{"location":"hepatology/hepatology-hepatocellular-carcinoma/#background","title":"Background","text":"<ul> <li> <p>Pts with HCV cirrhosis are at greatest risk (incidence 2-4% per year)</p> </li> <li> <p>In chronic HBV and NASH, pts can develop HCC without having cirrhosis</p> </li> </ul>"},{"location":"hepatology/hepatology-hepatocellular-carcinoma/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Regular screening in pts with cirrhosis (or chronic HBV without cirrhosis) for HCC</p> <ul> <li>RUQ U/S q6mo (with or without AFP)</li> <li>Routine screening with CT or MRI is not recommended</li> </ul> </li> <li> <p>Options If U/S not satisfactory:</p> <ul> <li>CT A/P w/contrast, in comments specify triple phase for HCC screening</li> <li>MRI, specify Gadovist (preferred contrast agent)</li> <li>Contrast-enhanced ultrasound</li> </ul> </li> <li> <p>AFP trend is more useful than one value in time, though AFP &gt;20 should prompt multiphase CT or MRI for further evaluation</p> </li> <li> <p>Diagnosis can be made either by imaging (most common) or biopsy (rare)</p> </li> <li>Triple phase CT demonstrates strong early uptake in arterial phase, with subsequent wash-out in portal-venous phase</li> <li>If diagnosis remains unclear: can surveillance imaging or biopsy</li> <li>LI-RADS system notes risk of malignancy based on imaging characteristics</li> </ul> 0 1 2 LI-RADS What does it mean? What do we do? LR-1 to LR-2 Definitely/Probably benign Routine surveillance, consider diagnostic imaging within 6 mos LR-3 to LR-4 Indeterminate/Probably HCC Repeat or alternative diagnostic imaging in 3-6 mos. Consider Bx for LI-RADS 4 LR-5 Definitely HCC Plan treatment as noted below LR-M Cancer but may not be HCC NaN"},{"location":"hepatology/hepatology-hepatocellular-carcinoma/#management","title":"Management","text":"<ul> <li> <p>Lesions that meet Milan criteria can qualify for MELD exception points and are considered transplant candidates</p> <ul> <li>This accounts for pts with minimal synthetic dysfunction (and therefore low MELD)</li> </ul> </li> <li> <p>Milan criteria:</p> <ul> <li>Single tumor with diameter &gt;2cm but &lt;5 cm, no more than 3 tumors, each &lt;3 cm</li> <li>No signs of extra-hepatic involvement or vascular invasion</li> </ul> </li> <li> <p>Liver transplant is definitive treatment, although resection can also be curative (favored in pts with early cirrhosis i.e. Child Pugh A)</p> </li> <li>Locoregional therapies: Pts with unresectable disease, or who are not surgical candidates</li> </ul> 0 1 Therapy Details Radiofrequency ablation If in a favorable location and size, IR can percutaneously ablate with a large needle that emits microwave frequencies Trans-arterial chemoembolization (TACE) Chemotherapeutic agents injected into the tumor to occlude the feeding blood supply to the area. Trans-arterial radioembolization (TARE) Like TACE, though radioactive compound (i.e. Y-90) used to occlude the feeding blood supply. Stereotactic body Radiation Therapy (SBRT) Radiation therapy: can be used as an alternative to ablation and is generally performed in those meeting Milan criteria Systemic Chemotherapy For metastatic disease"},{"location":"hepatology/hepatology-hepatorenal-syndrome/","title":"Hepatorenal Syndrome","text":"<p>Garren Montgomery</p>"},{"location":"hepatology/hepatology-hepatorenal-syndrome/#background","title":"Background","text":"<ul> <li> <p>Portal HTN causes shear stress on portal vessels -&gt; endothelium release of vasodilators -&gt; splanchnic vasodilation and reduced effective blood volume (decreased MAP) -&gt; RAAS activation -&gt; sodium and water retention and severe renal vasoconstriction</p> </li> <li> <p>Bacterial translocation (as seen in SBP) -&gt; increased circulating pro-inflammatory cytokines -&gt; splanchnic vasodilation</p> </li> <li> <p>Definitions:</p> <ul> <li>HRS-AKI (formerly type I HRS): Rise in Cr \u22650.3 within 48h, rise in Cr \u226550% within 7 days, OR UOP &lt;0.5 mL/kg/hr for 6 hours</li> <li>HRS-NAKI (\u201cnon-AKI\u201d) (formerly type II HRS):</li> <li>HRS-AKD: eGFR&lt;60 for &lt;3 months in absence of other structural causes OR % rise in Cr \u226450% using last available Cr over last 3 months as baseline</li> <li>HRS-CKD: eGFR&lt;60 for \u22653 months in absence of other structural causes</li> </ul> </li> <li> <p>Diagnostic Criteria</p> <ul> <li>Diagnosis of AKI (see above) without other cause (see below</li> <li>No response or inadequate response at 48 hrs after volume expansion with albumin and withdrawal of diuretics</li> <li>Absence of proteinuria (&lt;500 mg/d), absence of hematuria (&lt;50 RBCs per HPF), normal renal ultrasound (exclude if patient has known CKD</li> <li>Suggestion of renal vasoconstriction with FeNa &lt;0.2, FeUrea &lt;20 (most sensitive diagnostic measure). UNa &lt;20 is suggestive but not diagnostic given baseline sodium avidity in cirrhosis and inability to calculate FeNa</li> <li>Cut off for ATN in cirrhosis is a FeNa &gt;0.5, rather than 1 in the general population</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-hepatorenal-syndrome/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Step 1: Exclude other obvious causes of renal injury such as hypovolemia or ATN</p> <ul> <li>Common precipitants of AKI: infection, overdiuresis, GI bleeding, recent LVP without subsequent volume expansion, nephrotoxic drugs/NSAIDs</li> <li>Workup: BMP, UA with microscopy, urine electrolytes (FeNa, FeUrea), urine protein/Cr ratio, renal ultrasound (to assess for chronicity), diagnostic para to rule out SBP</li> </ul> </li> <li> <p>Step 2: Diuretic cessation/albumin challenge</p> <ul> <li>STOP all diuretics, beta blockers, NSAIDs, ACE/ARBs, anti-hypertensives, vasodilators, nephrotoxins</li> <li>START volume expansion with albumin 1g/kg/day (up to a max of 100 g/day) x2 days</li> </ul> </li> <li> <p>Step 3: Diagnosis of HRS</p> <ul> <li>If no other clear cause of AKI is identified and SCr has not improved after 48 hours of diuretic cessation and volume expansion, proceed promptly to vasopressor treatment</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-hepatorenal-syndrome/#management","title":"Management","text":"<ul> <li>Pharmacologic therapies (in order of preference):<ul> <li>Terlipressin + albumin. Most effective combo based on clinical trials, NOW AVAILABLE (ongoing clinical trial at VUMC)</li> <li>Norepinephrine + albumin (25-50 g/day)<ul> <li>Most likely to be used at VUMC, requires central access (PICC vs triple lumen) but can be administered on stepdown unit</li> <li>Guidelines recommend NE to be dosed at 0.5-3 mg/hr. Would ask fellow, attending or pharmacist for baseline. VUMC protocol for ICU and stepdown:<ul> <li>Start NE gtt at 3mcg/min. If UOP is &lt;200 or MAP &lt;10mm Hg from baseline, increase by 3 mcg/min every 4 hours</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Continue to hold diuretics. LVP is still generally considered safe even in HRS if indicated by tense ascites (account for albumin repletion from LVP and HRS protocol). This can be attending specific and would confirm prior to performing</p> </li> <li> <p>Therapy is generally continued until HRS is reversed or the hepatology attending deems it refractory to medical treatment</p> </li> <li> <p>Patients with HRS-NAKI (formerly type II HRS) may respond to the above therapies, but recurrence of renal dysfunction after withdrawal of vasoconstrictors is the norm and thus current guidelines do not recommend them for this scenario</p> </li> <li> <p>RRT: Dialysis can be considered for those who fail to respond to pharmacologic therapy, particularly ONLY as a bridge to liver transplant. Decision to initiate should be individualized</p> </li> <li> <p>Liver transplant: The best and most definitive treatment regardless of response to pharmacologic therapy</p> </li> </ul>"},{"location":"hepatology/hepatology-hepatorenal-syndrome/#simultaneous-liver-kidney-transplant","title":"Simultaneous liver-kidney transplant:","text":"<ul> <li> <p>HRS often resolves with LT alone. Indications for kidney transplant are usually for patients with severe chronic renal dysfunction or on RRT. Must consult transplant nephrology.</p> </li> <li> <p>Criteria for SLKT:</p> <ul> <li>eGFR &lt;60 for &gt;30 days AND latest eGFR &lt;30</li> <li>eGFR &lt;25 for &gt;6 consecutive weeks with a documented eGFR q7 days</li> <li>Metabolic syndromes and polycystic disease</li> </ul> </li> <li> <p>Can qualify for safety net kidney transplant after liver transplant if eGFR &lt;20 2-12 months post-operatively (would be at higher priority than the rest of the kidney transplant list)</p> </li> </ul>"},{"location":"hepatology/hepatology-hyponatremia-cirrhosis/","title":"Hyponatremia in Cirrhosis","text":"<p>John Laurenzano</p>"},{"location":"hepatology/hepatology-hyponatremia-cirrhosis/#background","title":"Background","text":"<ul> <li> <p>Most commonly is hypervolemic hyponatremia, driven by release of ADH from decreased effective arterial blood volume (EABV) in the setting of portal hypertension</p> </li> <li> <p>Hyponatremia in cirrhosis is a marker of advanced disease and is associated with higher rates of SBP, HE, HRS, and mortality. </p> </li> </ul>"},{"location":"hepatology/hepatology-hyponatremia-cirrhosis/#evaluation","title":"Evaluation","text":"<ul> <li>Standard evaluation of hyponatremia, including Uosm, Sosm, UNa to rule out competing processes (e.g. beer potomania) </li> </ul>"},{"location":"hepatology/hepatology-hyponatremia-cirrhosis/#management","title":"Management","text":"<ul> <li> <p>Discontinue anti-hypertensives (including beta blockers) in patients with ascites and hyponatremia. Hold diuretics when Na &lt;125 </p> </li> <li> <p>Fluid restriction is recommended only in patients with Na &lt;125. Restriction is generally effective at 1-1.5L and must be less than daily urine output to increase free water excretion </p> </li> <li> <p>Replete potassium to 4.0, as potassium is as osmotically active and results in shifts in extra and intracellular fluids which lead to a net increase in serum sodium. </p> </li> <li> <p>25% albumin infusion (1g/kg split into BID dosing), has been shown to increase serum sodium and have higher rates of hyponatremia resolution at 30 days </p> </li> <li> <p>Other treatment considerations include vasopressors, vaptans, urea tabs</p> </li> <li> <p>Salt tabs should not be used to raise serum Na due to worsening hypervolemia</p> </li> <li> <p>Nephrology should be consulted if not improved after 48 hours</p> </li> </ul>"},{"location":"hepatology/hepatology-liver-transplantation/","title":"Liver Transplant (LT) Workup","text":"<p>Lauren Evers Carlini</p>"},{"location":"hepatology/hepatology-liver-transplantation/#background","title":"Background","text":"<ul> <li>Model for End-stage Liver Disease (MELD-Na) score: initially developed to predict survival following TIPS placement, though is now used to objectively rank patients in terms of priority for liver transplant (LT)<ul> <li>Factors in total bilirubin, creatinine, and INR. An updated version, the MELD-Na score, factors in the serum Na as well.</li> <li>Exception points given for complications like HCC and     hepatopulmonary syndrome (HPS), leading to score in mid to high     20\u2019s even if biologic MELD is low</li> </ul> </li> <li>Listing a patient for LT is determined by a multidisciplinary transplant     committee<ul> <li>Acute liver failure pts take precedence over decompensated     cirrhosis pts for LT</li> </ul> </li> </ul> Indications Contraindications* Cirrhosis with MELD \u2265 15 or evidence of decompensation (ascites, variceal bleed, HE, HPS, portopulmonary HTN) Ongoing substance abuse (must have documented abstinence \u2265 3 mos); some special considerations for pts who did not know of EtOH hepatitis or EtOH use d/o but highly variable Acute Liver Failure Untreated or recurrent malignancy HCC that meets Milan criteria Active Infection, AIDS Pts with early hilar cholangio-carcinoma that meets specific criteria Documented history of medical noncompliance Other rare dz (e.g., familial amyloid polyneuropathy or hyperoxaluria) Lack of Adequate social support Anatomic Contraindications; Chronic cardiac/pulmonary conditions that significantly increase perioperative risk (e.g., severe pulm HTN) * Advanced age (&gt;70) is not in itself a contraindication but candidates &gt; 70 should be almost free of comorbidities to be considered for LT*"},{"location":"hepatology/hepatology-liver-transplantation/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Abdominal CT (triple phase) or MRI (multiphase with contrast) to     evaluate for hepatic malignancy and vascular anatomy</p> </li> <li> <p>Infectious workup: TB testing, HIV, RPR, VZV, CMV, EBV, and     Hepatitis A, B, and C.</p> </li> <li> <p>Cardiac evaluation: EKG and TTE with bubble are required. Functional testing: CT coronaries with fractional flow, invasive angiography and intervention may be necessary depending on pre-test probability. </p> </li> <li> <p>PFT\u2019s, carotid ultrasound, panorex, etc. </p> </li> <li> <p>Appropriate cancer screenings (colonoscopy, pap smear, mammogram, and PSA     if applicable)</p> </li> <li> <p>DEXA scan</p> </li> <li> <p>Certification of completion of intensive outpatient program (IOP)     for substance abuse</p> </li> <li> <p>Evaluation by hepatobiliary surgical team after obtaining cross     sectional imaging</p> </li> <li> <p>Psychosocial evaluation (consult Psychiatry, social work)</p> </li> <li> <p>Current VUMC policy: pts should be abstinent from alcohol no less than 3-6 months, although exceptions may be m ade for early liver transplant based on a very strict protocol. Discuss exception criteria iwth attending if suspect patient unlikely to survive hospitalization without transplant </p> </li> <li> <p>Both living and deceased donor transplant are offered at VUMC. Donor     evaluation, however, cannot be started before the potential     recipient is deemed a candidate</p> </li> </ul>"},{"location":"hepatology/hepatology-nash-and-nafld/","title":"NASH and NAFLD","text":"<p>John Laurenzano</p>"},{"location":"hepatology/hepatology-nash-and-nafld/#background","title":"Background","text":"<ul> <li> <p>Non-alcoholic fatty liver disease (NAFLD): presence of hepatic steatosis in the absence of secondary causes (e.g, EtOH)</p> </li> <li> <p>Non-alcoholic steatohepatitis (NASH): evidence of active inflammation in conjunction with steatosis (elevated liver enzymes or evidence on bx)</p> </li> <li> <p>Strong association with metabolic syndrome, T2DM, HTN, obesity, prior cholecystectomy</p> </li> <li> <p>Generally asymptomatic</p> </li> <li> <p>Considered to be a common cause of cryptogenic cirrhosis</p> </li> </ul>"},{"location":"hepatology/hepatology-nash-and-nafld/#evaluation","title":"Evaluation","text":"<ul> <li> <p>NASH manifests with elevated liver enzymes, typically 2-5x the ULN, in a roughly 1:1 ratio (as opposed to alcoholic steatohepatitis), though ALT may be higher than AST</p> </li> <li> <p>NAFLD is asymptomatic and frequently found incidentally via imaging</p> </li> <li> <p>Exclusion of alternative causes and comorbid liver conditions: HCV, HBV, EtOH</p> </li> <li> <p>Note: Ferritin is frequently elevated, though not to the extent of hemochromatosis. Low level auto-antibodies are also frequently present</p> </li> <li> <p>Can be diagnosed based on imaging alone (and frequently is)</p> <ul> <li> <p>Ultrasound is used most frequently, though MRI and CT also are acceptable; use risk scores to determine the risk of advanced fibrosis and identify those who would benefit from biopsy</p> <ul> <li>Fibrosis-4 (FIB 4) score</li> <li>NAFLD fibrosis score</li> </ul> </li> <li> <p>More accurate, non-invasive fibrosis assessments can be done using elastography which can be vibration based (fibroscan), ultrasound based (sheer-wave), or MR-based</p> <ul> <li>Available at VUMC and can be ordered by anyone. Insurance will not cover MRE if BMI &lt;35</li> </ul> </li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-nash-and-nafld/#management","title":"Management","text":"<ul> <li> <p>Aggressive risk factor modification and management of comorbidities (HLD, HTN, T2DM)</p> </li> <li> <p>Weight loss: Mediterranean diet&gt;low fat diet (dose dependent improvement)</p> </li> <li> <p>No specific medications are FDA approved currently</p> <ul> <li>Pioglitazone has shown benefit in pts with T2DM and NASH</li> <li>Vitamin E has shown benefit in pts without T2DM and proven NASH</li> <li>Ongoing studies for SGLT-2i and GLP-1ra; some promise indicated for the latter</li> </ul> </li> <li> <p>While bariatric surgery is not a specific indication for NASH/NAFLD, increasing evidence demonstrates resolution of NASH and fibrosis in pts with clinically significant weight loss</p> </li> <li> <p>Referral to the surgical weight loss clinic should be considered in any patient who meets obesity guidelines for bariatric surgery (BMI &gt;40, or &gt;35 with metabolic comorbidities)</p> </li> </ul>"},{"location":"hepatology/hepatology-nash-and-nafld/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Statins: should be used for HLD in pts with NASH, NAFLD and NASH cirrhosis</p> </li> <li> <p>Statin use in decompensated NASH cirrhosis is controversial, and they are less likely to derive benefit given overall poor prognosis. There is an increased risk of rhabdomyolysis in pts with acute on chronic liver failure and are considered contraindicated</p> </li> <li> <p>Metformin is safe and may have a survival benefit in patients with diabetes and cirrhosis. Discontinue only in those who have increased risk for lactic acidosis (renal impairment and significant EtOH). Sulfonylureas are generally avoided.</p> </li> </ul>"},{"location":"hepatology/hepatology-portal-vein-thrombosis/","title":"Portal Vein Thrombosis (PVT)","text":"<p>John Laurenzano</p>"},{"location":"hepatology/hepatology-portal-vein-thrombosis/#background","title":"Background","text":"<ul> <li>Portal Vein Thrombosis (PVT) can worsen decompensation (i.e. variceal hemorrhage), however, worsening portal HTN -&gt; more sluggish flow -&gt; increased risk PVT</li> </ul>"},{"location":"hepatology/hepatology-portal-vein-thrombosis/#presentation","title":"Presentation","text":"<ul> <li>Often identified asymptomatically on U/S, but can be identified by new or worsening decompensation of portal HTN</li> <li>Variceal hemorrhage is the most common decompensating event associated with PVT</li> <li>Intestinal ischemia (abdominal pain, hematochezia) from PVT is exceedingly rare but associated with significant morbidity and mortality</li> </ul>"},{"location":"hepatology/hepatology-portal-vein-thrombosis/#evaluation","title":"Evaluation","text":"<ul> <li>RUQ U/S with doppler<ul> <li>Once identified, should be further assessed with triple phase CT or MRI with Gadovist contrast to exclude HCC with tumor thrombus</li> </ul> </li> <li> <p>Pts with newly identified PVT should undergo EGD to evaluate for high-risk varices, both for diagnostic and therapeutic considerations</p> </li> <li> <p>PVT in pts without cirrhosis should prompt evaluation for hypercoagulable disorders</p> </li> </ul>"},{"location":"hepatology/hepatology-portal-vein-thrombosis/#management","title":"Management","text":"<ul> <li> <p>Start anticoagulation if acute thrombus occludes &gt;50% of main portal vein, &lt;50% but extends into SMV, thrombus is symptomatic, or patient is a transplant candidate (irrespective of size). Requires discussion with attending/transplant team.</p> <ul> <li>Anticoagulation options: warfarin, LMWH, or DOAC</li> <li>DOAC\u2019s are safe in Childs Class A, can be used with caution in Childs B, and are contraindicated in Childs C</li> </ul> </li> <li> <p>Pts with chronic occlusive PVT (&gt;6 mos) or with cavernous transformation with collaterals do not generally benefit from anticoagulation</p> </li> <li> <p>Pts with high-risk varices should undergo endoscopic management or be on NSBB for prophylaxis for variceal hemorrhage, as noted above</p> </li> <li> <p>TIPS with portal vein recanalization has recently emerged as a therapeutic modality for PVT</p> </li> <li> <p>Pts should undergo follow up intermittently with ultrasound to assess for recanalization. AC may be stopped if there is failure to recanalize.</p> </li> <li> <p>If pts are not candidates for AC, they'll simply be treated for complications of portal HTN</p> </li> </ul>"},{"location":"hepatology/hepatology-sbp/","title":"Spontaneous Bacterial Peritonitis (SBP)","text":"<p>Patricia Checinski</p>"},{"location":"hepatology/hepatology-sbp/#background","title":"Background","text":"<ul> <li> <p>Infection of ascitic fluid without evidence of a surgical intra-abdominal source</p> </li> <li> <p>Presentation: fever, abdominal pain, encephalopathy, renal failure, acidosis, and/or leukocytosis</p> </li> </ul>"},{"location":"hepatology/hepatology-sbp/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Any pt with cirrhosis and ascites who is admitted should have diagnostic paracentesis to rule out SBP. Delaying paracentesis &gt; 12 hours is associated with a 2.7-fold increase in mortality.</p> </li> <li> <p>Obtain cell count with diff.</p> <ul> <li>Calculate the PMNs: total nucleated cells x % neutrophils.</li> <li>PMNs &gt; 250 cells is diagnostic of SBP. If there are greater than 100k RBCs, you should correct for them: for every 250 RBCs, subtract 1 PMN</li> </ul> </li> <li> <p>A positive ascitic bacterial culture with PMN &lt;250 is called bacterascites and asymptomatic patients should NOT receive antibiotics. You will also frequently see culture-negative SBP (neutrocytic ascites) which SHOULD be treated (see below).</p> </li> </ul>"},{"location":"hepatology/hepatology-sbp/#management","title":"Management","text":"<ul> <li> <p>Immediately start empiric antibiotics</p> </li> <li> <p>Guidelines recommend cefotaxime IV 2gm q8 hours x 5 days, but we commonly use ceftriaxone IV 2g q24h for 5-7 days at VUMC and Nashville VA.</p> <ul> <li>Most common culprits (E. coli, Klebsiella, streptococcal species, staphylococcal species)</li> <li>If SBP developed with recent hospital admission (90 days), recent exposure to BSA, diagnosed &gt;48 hours of admission, or with sepsis, consider zosyn or meropenem to cover MDROs</li> </ul> </li> <li> <p>IV albumin 1.5 g/kg on day 1 and 1g/kg on day 3</p> </li> <li> <p>Discontinue beta-blockers once SBP develops and do not restart until SBP is completely treated, Na &gt;130, and no AKI</p> </li> <li> <p>PPI\u2019s \u2191 risk for SBP in pts with cirrhosis, and should be reviewed for appropriateness</p> </li> <li> <p>Repeat diagnostic paracentesis two days after antibiotics initiated</p> <ul> <li>If &lt;25% decrease in PMNs, antibiotics should be broadened and consider secondary bacterial peritonitis</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-sbp/#prophylaxis","title":"Prophylaxis","text":"<ul> <li> <p>GI bleed: ceftriaxone 1g daily ciprofloxacin 500mg BID (preferred) or Bactrim one DS tablet BID x 5-7 days</p> </li> <li> <p>Outpatient lifelong ppx, indications:</p> <ul> <li>Prior SBP</li> <li>Ascitic protein &lt;1.5 AND<ul> <li>Child Pugh &gt;9 and bilirubin &gt;3 OR</li> <li>Renal dysfunction (Cr &gt;1.2, Na &lt;130, or BUN &gt;25)</li> </ul> </li> <li>Preferred: Bactrim DS tab daily or ciprofloxacin 500mg daily</li> <li>Alternatives: cefdinir 300mg daily, Augmentin 875/125 daily</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-sbp/#if-suspicion-is-high-for-secondary-bacterial-peritonitis","title":"If suspicion is high for secondary bacterial peritonitis:","text":"<ul> <li> <p>Examine serum-ascites albumin gradient (SAAG). SBP develops in pts with portal hypertension, defined by SAAG &gt; 1.1 g/dL. SBP is unlikely if SAAG is &lt; 1.1 g/dL.</p> </li> <li> <p>While not particularly sensitive, an ascitic leukocyte count of 5-10k should prompt consideration of secondary peritonitis</p> </li> <li> <p>Amylase from fluid can also be helpful to point towards pancreatic ascites, while bilirubin can indicate gallbladder perforation. Peritoneal fluid CEA and alkaline phosphatase can additionally help identify hollow viscus injury.</p> </li> <li> <p>Evaluate with cross-sectional imaging and surgical consultation as appropriate</p> </li> <li> <p>Runyon\u2019s Criteria to distinguish, requires \u2154 criteria below (protein, glucose, LDH)</p> </li> </ul> Spontaneous Secondary Protein (g/dL) &lt;1 &gt;1 Glucose (mg/dL) \u226550 &lt;50 LDH (U) Elevated, but &lt; 225 &gt;225 Organisms 0-1 Polymicrobial"},{"location":"hepatology/hepatology-tips/","title":"Transjugular Intrahepatic Portosystemic Shunt (TIPS)","text":"<p>Pakinam Mekki</p>"},{"location":"hepatology/hepatology-tips/#background","title":"Background","text":"<ul> <li> <p>A Transjugular Intrahepatic Portosystemic Shunt or TIPS procedure is done by interventional radiology to manage sequelae of portal hypertension (specifically variceal bleeding and ascites)</p> </li> <li> <p>A low-resistance shunt is created between an intrahepatic branch of the portal vein and the hepatic vein, allowing blood to bypass the high-resistance vessels within the fibrotic liver</p> </li> </ul>"},{"location":"hepatology/hepatology-tips/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Indications for TIPS</p> <ul> <li>Variceal hemorrhage (esophageal, gastric, etc.)</li> <li>Early \u201cpreemptive\u201d TIPS is an urgent TIPS placement within 72 hrs (preferably within 24 hours) of initial endoscopic hemostasis in pts at high risk for rebleeding (Child-Pugh Class B with active bleeding upon insertion of endoscope or Child-Pugh Class C with recent bleeding</li> <li>\u201cRescue\u201d TIPS is placed in pts with active, uncontrolled variceal bleeding or if bleeding recurs despite maximal endoscopic and pharmacologic therapy</li> <li>Refractory ascites (prolongs survival)</li> <li>Other: portal hypertensive gastropathy, PVT recanalization, Budd-Chiari syndrome, hepatic hydrothorax</li> </ul> </li> <li> <p>Contraindications to TIPS</p> <ul> <li>Absolute contraindications<ul> <li>Primary prevention of variceal bleeding, congestive heart failure, severe tricuspid regurgitation, severe pulmonary hypertension, multiple hepatic cysts or masses, Sepsis, unrelieved biliary obstruction</li> </ul> </li> <li>Relative contraindications<ul> <li>Hepatic encephalopathy, hepatic tumors (especially if centrally located), thrombocytopenia, moderate pulmonary hypertension</li> </ul> </li> </ul> </li> <li> <p>Pre-procedure preparation</p> <ul> <li>Labs: CBC, CMP, INR</li> <li>Liver imaging to assess portal system patency and exclude liver masses<ul> <li>Ideally triple phase CT with contrast</li> <li>In pts with renal impairment or active variceal bleeding, RUQ U/S with doppler is acceptable</li> </ul> </li> <li>TTE to evaluate for evidence of congestive heart failure, pulmonary hypertension, or valvular disease.</li> <li>Antibiotic ppx with ceftriaxone 1g IV once at the time of TIPS insertion as enteric bacteria within the static portal system can enter systemic circulation</li> <li>Patients with HE should receive rifaximin prophylaxis starting 2 weeks before procedure</li> </ul> </li> </ul>"},{"location":"hepatology/hepatology-tips/#management-post-tips","title":"Management Post-TIPS","text":"<ul> <li>Immediately following TIPS, pts are observed in the hospital overnight for complications<ul> <li>Monitor CBC and vitals closely. If hemodynamically unstable, STAT CBC and low threshold to obtain CTA A/P to evaluate for a bleeding source</li> </ul> </li> <li> <p>TIPS causes a substantial increase in venous return to the heart, which can unmask cardiac dysfunction that was previously compensated for</p> </li> <li> <p>Obtain RUQ U/S with Doppler to assess shunt patency 1 month of TIPS placement, or if ascites and/or variceal hemorrhage reoccur</p> </li> <li> <p>If patient with a TIPS develops refractory HE, can consider TIPS revision to lessen HE symptoms</p> </li> </ul>"},{"location":"hepatology/hepatology-upper-gi-bleed-cirrhosis/","title":"Gastroesophageal Varices and Hemorrhage","text":"<p>Patricia Checinski</p>"},{"location":"hepatology/hepatology-upper-gi-bleed-cirrhosis/#background","title":"Background","text":"<ul> <li> <p>Varices form due to portosystemic collaterals in the setting of portal HTN</p> </li> <li> <p>The risk of mortality with each episode of esophageal variceal hemorrhage (EVH) is 15-25%</p> </li> <li> <p>Recurrence occurs in 60% of patients within 1-2 years of the index event</p> </li> </ul>"},{"location":"hepatology/hepatology-upper-gi-bleed-cirrhosis/#variceal-screening","title":"Variceal Screening","text":"<ul> <li> <p>Not all pts with cirrhosis require screening. Can be omitted without clinically significant portal hypertension (e.g. low liver stiffness (on elastography) and platelets &gt;150) or if pt already on non-selective beta blocker (NSBB) with HR 55-60</p> </li> <li> <p>Compensated cirrhosis without varices: EGD q3yr, unless active liver injury (obesity, EtOH use, ongoing viral infxn), then q2yr</p> </li> <li> <p>Compensated cirrhosis with small varices: EGD q2yr unless active liver injury, then q1yr</p> </li> <li> <p>Decompensated cirrhosis with no or small nonbleeding varices: EGD q1yr, and at initial time of decompensation</p> </li> </ul>"},{"location":"hepatology/hepatology-upper-gi-bleed-cirrhosis/#management-non-bleeding-varices","title":"Management (Non-Bleeding Varices)","text":"<ul> <li> <p>Primary ppx with either NSBB (preferred) or endoscopic band ligation (EBL)</p> <ul> <li>Nadolol (given nightly as portal pressures are highest at night) or propranolol (BID)</li> <li>Carvedilol has greater portal pressures and may be preferred if tolerated (goal 6.25mg BID)</li> <li>For 2 \u00ba ppx, initiate ~72hr after acute bleed has resolved and octreotide discontinued</li> <li>Discontinue if: hypotension (sBP &lt;90), AKI, SBP or hyponatremia with refractory ascites</li> </ul> </li> <li> <p>Secondary ppx with both NSBB and EBL.</p> </li> <li>NSBB are associated with reduced mortality, while EBL is not</li> </ul>"},{"location":"hepatology/hepatology-upper-gi-bleed-cirrhosis/#management-bleeding-varices","title":"Management (Bleeding Varices)","text":"<ul> <li> <p>Place two large-bore IVs (18G or larger), resuscitate with blood products and albumin. Activate massive transfusion protocol if needed.</p> </li> <li> <p>Consider intubation if need for emergent EGD, change in mental status, ongoing hematemesis, concern of ability to protect airway</p> </li> <li> <p>Start octreotide 50 mcg IV bolus followed by continuous infusion of 50 mcg/h, to be continued for at least 2 days should EVH be confirmed on endoscopy</p> </li> <li> <p>Ceftriaxone 1g IV q24h for SBP prophylaxis (reduced mortality), then transition to PO ciprofloxacin for total 7-day course</p> </li> <li> <p>Consult GI for upper endoscopy. Endoscopic therapies performed include variceal band ligation and sclerotherapy.</p> </li> <li> <p>Consider balloon tamponade with Blakemore as temporizing measure before definitive management. Patient must be intubated before placement, and preferably GI should be made aware prior to placement.</p> </li> <li> <p>No role for the correction of INR, even in the presence of bleeding as excessive blood products and FFP can increase portal pressures and cause worsening bleeding</p> <ul> <li>Vitamin K can be given w/ \u2191 INR, though is unlikely to help in the acute setting</li> <li>Check TEG and fibrinogen and transfuse based on results</li> <li>AASLD does not recommend specific platelet targets during variceal hemorrhage</li> <li>Administer blood products in balanced ratio to avoid transfusion related coagulopathy (VUMC MTP is 6:4:1 of RBC:FFP:PLT)</li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-enteral-nutrition/","title":"Enteral Nutrition","text":"<p>Soibhan Kelley</p>"},{"location":"hospital-medicine/hospital-medicine-enteral-nutrition/#indications-for-enteral-feeding","title":"Indications for enteral feeding","text":"<ul> <li>Patients with high nutritional risk who are unable to maintain their own intake<ul> <li>Guidelines recommend calculating nutritional risk based on validated scoring tool (ex: Malnutrition Screening Tool). This is usually completed by the nutrition team</li> <li>Recognize who would benefit from nutrition consult to assist with risk determination<ul> <li>Patients with &gt;5% weight loss in past 1-3 months or decreased oral intake coupled with increased metabolic demands due to medical illness or surgery</li> </ul> </li> </ul> </li> <li>Patients with low nutritional risk may not need enteral feeding if it is anticipated they will resume intake in 5-7 days</li> <li>Critically ill patients: goal is early initiation of tube feeding (within 48 hours)</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-enteral-nutrition/#contraindications-to-enteral-nutrition","title":"Contraindications to enteral nutrition","text":"<ul> <li>Bowel obstruction or severe ileus</li> <li>Ischemic bowel</li> <li>Acute peritonitis</li> <li>Major gastrointestinal bleeding</li> <li>Intractable vomiting</li> <li>Significant hemodynamic instability<ul> <li>Patients who are not adequately volume resuscitated and have significant hemodynamic instability (i.e., have high pressor requirements) are thought to be at increased risk for bowel ischemia<ul> <li>Pressors in general are not a contraindication to tube feeds. Ok to start once pressors are down-trending or at a stable level</li> </ul> </li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-enteral-nutrition/#initiating-tube-feeds","title":"Initiating tube feeds","text":"<ul> <li> <p>Enteral access</p> <ul> <li>Nasogastric or orogastric feeding tube in acute setting. See procedures section for tips on placement</li> <li>For most patients, enteral feeding is safe with gastric tube placement<ul> <li>Consider post-pyloric placement for patients with high aspiration risk, impaired gastric motility, or patients who have demonstrated intolerance with gastric feeding</li> </ul> </li> <li>Consider percutaneous endoscopic gastrostomy (PEG) tube placement if anticipate enteral nutrition &gt;4 weeks</li> </ul> </li> <li> <p>Choice of formula and rate</p> <ul> <li>Place nutrition consult. RD will calculation caloric and protein needs to determine goal rate and formulation</li> <li> <p>OK to start tube feeds prior to recommendations and adjust later, especially if recommendations will be delayed. It only takes a simple calculation to make a reasonable tube feeding plan</p> <ul> <li>Use weight-based dosing for calorie requirements<ul> <li>Use 25-30 cal/kg (use ideal body weight for most patients, use actual weight for underweight patient) to estimate daily needs</li> </ul> </li> <li>Most common formula used at VUMC is Nutren 1.5 (1.5 cal/ml) or Novasource renal if significant renal impairment (2 cal/ml)</li> <li>Patients may need additional free water (most tube feed formulas are comprised of 80-85% water but varies with type). Typically dose as bolus of free water every 4-6 hours.<ul> <li>May empirically try 250cc free water every 4 hours and monitor Na trends. May need more if already with a large fluid deficit (ex: hypernatremia) or if high volume losses</li> <li>May use clinical calculators as below</li> </ul> </li> </ul> </li> <li> <p>Calculate hourly rate based on daily calorie need and formula calorie density</p> <ul> <li>Ex: Patient with IBW of 70Kg will need estimated 1,750 calories per day (70 x 25 cal/kg)</li> <li>If using Nutren 1.5, this will equal 1,167 ml per day (1,750 divided by 1.5 calories per ml). This would equal a goal rate of about 50ml per hour (rounded up) of Nutren 1.5</li> <li>Resources for quick calculations:<ul> <li>Search for \u201ctube feed cheat sheet\u201d on google and will find reference tables on EMCrit.org that gives you rate per hour for different weights and formula types</li> <li>Clincalc.com also has a useful enteral nutrition calculator</li> </ul> </li> </ul> </li> <li> <p>Start initially at a low rate (such as 10 mL/hr) to assess tolerability and advance to goal</p> <ul> <li>Advance quickly if no concern for refeeding syndrome (ex: increase by 10cc/hr q6h)</li> <li>If risk for refeeding syndrome or other issues with tolerability, typically advance more slowly over several days</li> </ul> </li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-enteral-nutrition/#potential-complications","title":"Potential Complications","text":"<ul> <li> <p>Aspiration</p> <ul> <li>Recommendation to keep head of bed elevated at 30 to 45 degrees (low quality, mixed evidence). Consider risks of this positioning (ex: formation of pressure ulcers)</li> <li>Consider post-pyloric placement if issues with aspiration (low quality, mixed evidence)</li> </ul> </li> <li> <p>Diarrhea or constipation</p> <ul> <li>Consider wheat dextrin fiber supplement (low quality evidence) but discontinue if not associated with clinical improvement. Avoid less soluble fibers such as psyllium due to risk of clogging tube. Avoid in patients with reduced GI motility due to rare risk of bezoar formation</li> </ul> </li> <li> <p>Hyperglycemia</p> <ul> <li>See endocrine section for management</li> </ul> </li> <li> <p>Refeeding syndrome</p> <ul> <li>Monitor q8 hour Mg, phos, K in high-risk patients (underweight, recent weight loss, prolonged poor intake) and advance to goal slowly</li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/","title":"Guidelines for Pregnant Patients","text":"<p>Ahmad Dbouk and Samuel Lazaroff</p>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#acute-cystitis","title":"Acute Cystitis:","text":"<ul> <li> <p>Significantly increased prevalence in pregnancy</p> </li> <li> <p>Symptoms: dysuria (urgency/frequency common in pregnancy)</p> </li> <li> <p>Diagnosis: evidence of pyuria and &gt;103 cfu/ml (note, if neg would test for g/c)</p> </li> <li> <p>Treatment: Empiric with cephalexin, cefpodoxime, amoxicillin-clavulanate, fosfomycin. Nitrofurantoin ok in second or third trimester. Avoid Bactrim in first trimester and near term. Tailor based on culture results.</p> </li> <li> <p>Note that asymptomatic bacteriuria is treated in pregnancy (in contrast with general public). Same antibiotic choices as above</p> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#pyelonephritis","title":"Pyelonephritis:","text":"<ul> <li>Symptoms: fever, flank pain, and nausea/vomiting, dysuria</li> <li>Diagnosis: clinical suspicion + pyuria and bacteriuria</li> <li>Treatment: IV antibiotics for 1 st 24-48hrs; beta-lactams     preferred</li> <li>Mild to moderate: ceftriaxone or cefepime</li> <li>Moderate to severe: piperacillin-tazobactam or meropenem</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#hyperemesis-gravidarum","title":"Hyperemesis Gravidarum:","text":"<ul> <li>Presentation: Hormone mediated nausea/vomiting typically starting     before 9wks GA</li> <li>Differential: gastroenteritis, hepatitis, biliary tract disease,     obstruction, pancreatitis, pyelonephritis, nephrolithiasis, ovarian     torsion, DKA, hyperparathyroidism, migraines, preeclampsia</li> <li>Workup: BMP, mg, phos, LFTs, lipase (may be mildly elevated in HG),     UA,</li> <li>Treatment:<ul> <li> <ul> <li>First Line: Ginger, doxylamine (25mg PO q6), pyridoxine         (20mg PO q6)</li> <li>Second Line: metoclopramide (10mg q6), Promethazine (12.5mg     q6)</li> <li>Third Line: ondansetron (8mg q12hrs, after 1st trimester)</li> <li>Hydration: 1L LR on admission + banana bag q24hrs</li> </ul> </li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#hypertension","title":"Hypertension:","text":"<ul> <li>Both gestational HTN and preeclampsia/HELLP are typically     diagnosed &gt;20w GA</li> <li>Tx options: nifedipine, labetalol, methyldopa, hydral (2     nd line), clonidine (2 nd line)</li> <li>Avoid: ACEs, ARBs, MRAs, Nitroprusside</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#diabetes","title":"Diabetes:","text":"<ul> <li>Due to hormonal changes associated with pregnancy, pregnant patients     are at higher risk for poor control and DKA</li> <li>Oral regimens are generally transitioned to insulin-based regimens.</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#gerd","title":"GERD:","text":"<ul> <li>1st Line: Can use antacids; avoid sodium bicarbonate and magnesium     trisilicate</li> <li>2nd Line: Sucralfate 1g PO TID</li> <li>3rd Line: Cimetidine 200mg (30min prior to eating)</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-guidelines-pregnant-patients/#asthma","title":"Asthma:","text":"<ul> <li>Similar rescue and controller medications as in non-pregnant patient</li> <li>Would favor using LABA over leukotriene receptor antagonists or     theophylline for additional therapy</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-lines-and-catheters/","title":"Lines and Catheters","text":"<p>Ahman Dbouk and Samuel Lazaroff</p>"},{"location":"hospital-medicine/hospital-medicine-lines-and-catheters/#foley-catheter","title":"Foley Catheter","text":"<ul> <li> <p>Indications: urinary retention, close urine output monitoring in critical illness or renal failure, need for strict I&amp;Os (ex: diuresis) and unable to be achieved without catheter, surgery, open sacral/perineal wounds with incontinence, patient comfort at end of life</p> <ul> <li>Urinary incontinence alone is not an indication for foley catheter</li> </ul> </li> <li> <p>Duration of use is biggest risk factor for CAUTI</p> <ul> <li>Best way to prevent CAUTI is to avoid inappropriate placement</li> <li>Assess daily whether foley can be removed</li> </ul> </li> <li> <p>Chronic Foleys generally should be exchanged at time of admission</p> </li> <li> <p>Any concern for catheter obstruction (particularly with blood clots) should prompt urgent urology consult for irrigation/intervention (typically after RN has attempted)</p> </li> <li> <p>Difficult foley placement</p> <ul> <li>Make sure an attempt has been made with a Coud\u00e9 catheter. This catheter has a curved tip that can be useful in patients with BPH</li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-lines-and-catheters/#picc","title":"PICC","text":"<ul> <li> <p>Single lumen: long term Abx, stable IV access with intermittent draws</p> </li> <li> <p>Double lumen: special populations (ICU or chemo), TPN w/ lipids (incompatible with many IV medications)</p> </li> <li> <p>Risk factors for CLABSI/VTE: \u2191\u2191duration, \u2191\u2191number of lumens, left arm, lower extremity</p> </li> <li> <p>A note on midlines:</p> <ul> <li>A midline is just a long PIV inserted into the deep veins in the arm, typically 6-15cm<ul> <li>For reference, when you place an US-guided IV, the \u201clong\u201d 18G needles at VUMC are 2.5 inches (~6.4cm)</li> <li>Not much benefit compared to US-guided IV. Useful for stable IV access for meds and fluids. Not a stable route for blood draws</li> </ul> </li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-lines-and-catheters/#g-tube","title":"G-Tube","text":"<ul> <li> <p>Troubleshooting: EGS consult for malposition/not functioning, wound consult for skin breakdown</p> </li> <li> <p>G-tube study: 30mL Gastrograffin via tube [resident often must push], and order KUB</p> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-telemetry/","title":"Telemetry","text":"<p>Ahmad Dbouk and Samuel Lazaroff</p>"},{"location":"hospital-medicine/hospital-medicine-telemetry/#background","title":"Background","text":"<ul> <li> <p>Many monitored pts do not have a true indication</p> <ul> <li>Leads to alarm fatigue, unnecessary workups, and is expensive</li> </ul> </li> <li> <p>Telemetry is not a substitute for more frequent vital signs</p> </li> <li> <p>Discuss frequently on rounds: always reassess need and indication</p> </li> <li> <p>Stable patients without troponin elevation or new arrythmias are typically appropriate for transfers without telemetry</p> </li> </ul> 0 1 Clinical Scenario Duration Cardiac Cardiac ACS Post-MI 24-48h 48h after revascularization Vasospastic angina Until symptoms resolve Any event requiring ICD shocks Remainder of hospitalization New/unstable atrial tachyarrhythmias Until stable on medical therapies Chronic AF w/ recurrence of RVR Clinical judgement Ventricular tachyarrhythmias Until definitive therapy Symptomatic bradycardia Until definitive therapy Decompensated CHF Until underlying cause treated Procedural Procedural Ablation (regardless of co-morbidities) 12-24h after procedure Cardiac surgery 48-72h, or until discharge if high risk for decompensation Non-cardiac major surgery in patient with AF risk factors Until discharge from step-down or ICU Conscious sedation Until patient awake, alert, HDS Miscellaneous Miscellaneous Endocarditis Until clinically stable CVA 24-48h Electrolyte derangement (K, Mg) Until normalization Hemodialysis Clinical judgement Drug overdose Until free of influence of substance <p>Notable non-indications:</p> <ul> <li>PCI for non-ACS indication (i.e. pre-transplant), non-cardiac chest     pain, Pt with AICD admitted for non-cardiac cause, non-cardiac     surgery, chronic AF and clinically stable</li> <li>Contraindicated in hospice/comfort care</li> <li>Nearly all noncardiac conditions (i.e.,     undifferentiated sepsis, stable GI bleed, alcohol withdrawal) upon     transfer out of ICU</li> </ul>"},{"location":"hospital-medicine/hospital-medicine-transitions-of-care/","title":"Transitions of Care: Tips for Safe Discharges","text":"<p>Soibhan Kelley</p> <ul> <li> <p>Discharge from hospital represents a period of vulnerability for patients. Medical errors (especially medication errors) following discharge are exceedingly common and can lead to adverse events</p> </li> <li> <p>At VUMC we are fortunate to have the Discharge Care Center</p> <ul> <li>Multidisciplinary team including nurses, social workers, care coordinators, and pharmacists</li> <li>Phone number is included on discharge paperwork and patients can contact them 24/7. The DCC also reaches out to patients through an automated system</li> </ul> </li> <li> <p>How residents can promote safe discharges:</p> <ul> <li>Communicate with patient\u2019s outpatient team (i.e. PCP)<ul> <li>Typically achieved through the discharge summary<ul> <li>Include a list of specific, actionable follow-up tasks and assign a responsible party.</li> <li>Place in easy-to-view spot at the top of the summary<ul> <li>Ex: Instead of writing \u201cfollow-up BMP after initiation of furosemide,\u201d write \u201cPCP to check BMP in 2 weeks after initiation of furosemide\u201d</li> <li>Include any pending studies and appointments from hospital admission</li> </ul> </li> <li>All relevant parties should receive a copy of the discharge summary (see appendices section for mechanics of discharge process)<ul> <li>It is useful to send patient with a printed copy of the discharge summary if they will follow-up outside VUMC</li> <li>For high-risk discharges (patients with poor health literacy, hx of being lost to follow-up, patients following up outside VUMC) consider calling PCP\u2019s office to set follow-up</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Complete an accurate and thorough medication reconciliation</p> <ul> <li>An accurate discharge medication list depends on having a complete admission medication reconciliation (utilize pharmacy consult!)<ul> <li>Three steps to medication reconciliation:<ul> <li>Verification: Performing a Best Possible Medication History</li> <li>Clarification: Checking that medications and doses are appropriate</li> <li>Reconciliation: Record all medication changes</li> </ul> </li> <li>Seek to use at least two sources of information</li> <li>Keep a list of any held or changed medications in your hospital course. Medication changes can be lost when not communicated during team transitions</li> <li>Review medication changes on rounds and with pharmacist on day of discharge (bonus points for day prior to discharge)</li> </ul> </li> <li>Highlight any significant medication changes on discharge summary<ul> <li>Can include as follow-up tasks if pertinent (ex: PCP to follow-up BP in 2 weeks. Losartan held on d/c due to AKI but anticipate need to reinitiate once Cr normalizes)</li> </ul> </li> <li>Be sure to communicate any changes with the patient and/or caregiver</li> </ul> </li> <li> <p>Ensure that appropriate resources and follow-up appointments have been requested (PT/OT, skilled or non-skilled nursing HH, PCP follow-up, etc.)</p> </li> <li> <p>Effectively communicate discharge plan to patient</p> <ul> <li>Discuss medication changes, tasks for patient to complete, follow-up appointments<ul> <li>Key points should also be written in the patient instructions box</li> <li>Useful to include educational sheets in the AVS (searchable in discharge navigator)</li> <li>Utilize the teach-back method to ensure your instructions were effectively communicated</li> </ul> </li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-wounds/","title":"Wounds \u2212 Adapted from Dr. Duggan\u2019s Geriatrics Guide","text":"<ul> <li> <p>To do when admitting a patient with wounds:</p> <ul> <li>Document ALL wounds that are present on admission. This affects reimbursement</li> </ul> </li> <li> <p>Use the Haiku app on your cell phone to document images of wounds in chart</p> </li> <li> <p>Wound Service hours are Monday through Friday, 6 AM - 2 PM</p> <ul> <li> <p>If there is an urgent/emergent wound need (i.e. needs surgical eval or management), consult the appropriate surgical service</p> </li> <li> <p>While awaiting consultation, initiate topical wound care orders (detailed below)</p> </li> </ul> </li> <li> <p>Consider contributing factors: nutritional, pressure-offloading equipment, wound supplies, PT/OT, home health nursing</p> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-wounds/#types-of-wounds","title":"Types of wounds","text":"<ul> <li> <p>Arterial wound - Calciphylaxis</p> </li> <li> <p>Venous leg wound - Fistula</p> </li> <li> <p>Diabetic foot wound - Abscess</p> </li> <li> <p>Vasculitis - Skin tear</p> </li> <li> <p>Pyoderma gangrenosum - Pressure injury</p> </li> <li> <p>Fungating lesion - Ischemic ulcers / gangrene</p> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-wounds/#vascular-wound-etiologies","title":"Vascular Wound Etiologies","text":"<ul> <li> <p>Arterial: located on distal ends of digits, shallow, well-defined borders, pale/necrotic wound bed, minimal exudate due to poor blood flow, cramping pain or a constant deep ache</p> </li> <li> <p>Diabetic: plantar surface of foot, callused wound margins; usually painless due to neuropathy</p> </li> <li> <p>Venous: located on medial malleolus or gravity dependent areas, irregular edges, ruddy red with yellow slough and copious exudate</p> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-wounds/#pressure-injury-staging","title":"Pressure Injury Staging","text":"Feature Deep Tissue Injury Stage 1 Stage 2 Stage 3 Stage 4 Skin Consistency Boggy Boggy Variable N/A N/A Skin color/nature of lesion Non-blanching purple or maroon, may appear as blood-filled blister Non-blanching erythema Abrasion, blister, or shallow crater Variable <p>Variable.</p> <p>If eschar, must be removed in order to stage, or is unstageable</p> Depth Epidermis intact Epidermis intact Through surface of epidermis and outer dermis SQ tissue to, but not through, fascia Full-thickness loss w/ destruction, necrosis, or damage to muscle, bone, supporting structures"},{"location":"hospital-medicine/hospital-medicine-wounds/#non-acute-wound-consult-guidelines","title":"Non-Acute Wound Consult Guidelines","text":"<ul> <li> <p>Order \u201cInpatient Consult to Adult Wound\" for these wound types: diabetic foot wounds*, venous, arterial, pressure injuries (consult required for DTI, stage 3, 4, and unstageable), IV infiltrate, skin tears, moisture-associated dermatitis, calciphylaxis, vasculitis, pyoderma gangrenosum, fungating lesion, abscess*, surgical wounds*, or wound VAC</p> </li> <li> <p>*Diabetic foot wounds: if pt being followed by podiatry, order \"Inpatient Consult to Podiatry\"</p> </li> <li> <p>*Abscess: if chronic due to IBD, consult colorectal surgery</p> </li> <li> <p>*Surgical wounds: if pt has VUMC surgeon, consult the respective surgical service</p> </li> <li> <p>Order \"Inpatient Consult to Adult Ostomy / Fistula / Tube\" for ostomy, trach, PEG, associated needs or complications (etc)</p> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-wounds/#acute-wound-consult-guidelines","title":"Acute Wound Consult Guidelines","text":"<ul> <li>Abscess, hematoma, or osteomyelitis with overlying wound \u2013 whom to consult for drainage/debridement:<ul> <li>Face \u2013 Face</li> <li>Chest/Sternum \u2013 CT surgery</li> <li>Breast \u2013 General surgery</li> <li>Spine \u2013 Spine</li> <li>Arm (hand to elbow) \u2013 Hand</li> <li>Lower leg (foot to knee) \u2013 Ortho</li> <li>Labial \u2013 OB/GYN</li> <li>Scrotal \u2013 Urology</li> <li>Buttock, thigh (knee to hip), arm (elbow to shoulder) \u2013 EGS consult</li> <li>Perirectal/Rectal acute abscess \u2013 EGS; (chronic due to IBD \u2013 Colorectal Surgery)</li> </ul> </li> <li>Necrotizing Fasciitis \u2013 whom to consult for URGENT/EMERGENT surgical eval:<ul> <li>Genitalia \u2013 Urology</li> <li>Buttocks, perineum, abdomen \u2013 EGS</li> <li>Upper extremity (shoulder to hand) \u2013 Hand</li> <li>Lower extremity (hip to toes) \u2013 Ortho</li> </ul> </li> </ul>"},{"location":"hospital-medicine/hospital-medicine-wounds/#wound-care-order-while-awaiting-consultant-recs","title":"Wound Care (order while awaiting consultant recs)","text":"<ul> <li>Superficial wounds<ul> <li>Stage 1 or 2 pressure injuries, moisture-associated skin damage, or skin tears<ul> <li>Order \u201cAdult Skin Care Guidelines\u201d and use the order set to guide you</li> </ul> </li> </ul> </li> <li>Shallow Stage 3 pressure injuries (i.e., &lt;1cm deep) or diabetic foot ulcers<ul> <li>Order \u201cWound Care\u201d: Frequency 2x weekly and prn; Cleanse with NS; protect periwound with Mepilex foam (type in comments)</li> </ul> </li> <li> <p>Painful superficial wounds with no infection (i.e. vasculitis, PG, calciphylaxis)</p> <ul> <li>Order \u201cWound Care\u201d: Frequency 2 times daily; Cleanse with NS; Apply Vaseline; Protect periwound with Xeroform and dry gauze (type in comments)<ul> <li>If wound is on the hand, arm, foot, or lower leg consider wrapping in Kerlix</li> <li>If wound is on the trunk (i.e., abdomen or buttocks), consider covering with an ABD pad and secure with medipore tape</li> </ul> </li> </ul> </li> <li> <p>Infected superficial wounds</p> <ul> <li>Odor alone does NOT indicate infection; wounds with necrotic tissue may have odor</li> <li>Order \u201cWound Care\u201d: Frequency 2 times daily; Cleanse with NS, Apply Silvadene; Protect periwound with Xeroform and dry gauze (type in comments)<ul> <li>If wound is on hand, arm, foot, or lower leg consider wrapping in a Kerlix</li> <li>If wound is on the trunk (i.e., abdomen or buttocks), consider covering with an ABD pad and secure with medipore tape</li> </ul> </li> </ul> </li> <li> <p>Medication order required: Silvadene q12h; in Admin Inst put \u201cper wound care orders\u201d</p> </li> <li> <p>Deep wounds (i.e., stage 3, 4, or deep diabetic foot wound (all &gt;1cm deep))</p> <ul> <li>Order \u201cWound Care\u201d: Frequency 2 times daily; Cleanse with NS, pack with Dakin\u2019s 0.025% (1/20 strength) soaked continuous Kerlix roll; Protect periwound with ABD pad &amp; medipore tape (type in comments)</li> <li>If wound care is painful, consider changing to daily dressing changes</li> <li>Medication order required: Dakin\u2019s 0.025% solution q12h; in Admin Inst put \u201cper wound care orders\u201d</li> </ul> </li> <li> <p>Deep tissue injury</p> <ul> <li>Medication order required: Venelex (balsam peru-castor oil) ointment q4h; in admin instructions put location to apply ointment and put \u201cno dressing\u201d</li> </ul> </li> <li> <p>Fungating mass</p> <ul> <li>Order \u201cWound Care\u201d: Frequency 2 times daily; Cleanse with baby shampoo and water, NS, Metrogel (type in comments); Protect with Xeroform, ABD pad, medipore tape</li> <li>Medication order required: metrogel q12h; in Admin Inst put \u201cper wound care orders\u201d</li> </ul> </li> <li> <p>Wound VAC</p> <ul> <li>Vanderbilt surgeon \u2013 consult Vanderbilt provider to provide care<ul> <li>Ensure connected to VUMC wound VAC. Pt shouldn't use home unit while admitted</li> <li>Order \u201cnursing communication\u201d to \u201cObtain wound VAC hospital machine and canister from service center to connect pt to hospital machine.\u201d</li> <li>Wound VAC should not be left without suction for more than 2 hours</li> <li>Settings: 125 mmHg continuous</li> </ul> </li> </ul> </li> <li> <p>Non VUMC surgeon (i.e., gets wound care at outside hospital/wound care center)</p> <ul> <li>Discontinue wound VAC as soon as possible</li> <li>Remove all of the clear plastic drape just like you would remove tape</li> <li>Remove all of the sponge just like you would remove gauze packing</li> <li>Examine the wound to ensure no residual sponge by gently probing site</li> <li>Rinse with saline, initiate care based wound type as above</li> </ul> </li> <li> <p>Leg wrap</p> <ul> <li>Ex: Unna's boot, ACE and 2, 3, or 4 layer compression</li> <li>Remove by cutting the wrap off</li> <li>Assess the wound and order dressing based on type of wound as above</li> <li>Order ACE bandage wrapped toe-to-knee. Remove q12h to assess skin</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-disease-overview-art/","title":"Overview of Antiretroviral Therapy","text":"<p>Kathryn Snyder and Quinton Taylor</p> Fixed Dose Combination regimens Renal Dosing Specific Considerations Biktarvy\u00ae Bictegravir/ Emtricitabine/ Tenofovir (Alafenamide) Discontinue if CrCl &lt; 30; ok w/HD <p>\u2191 Metformin levels</p> <p>Contraindicated with: rifampin, dofetilide, rifabutin</p> <p>Avoid close admin. with: laxatives, sucralfate, polyvalent cations (iron, calcium, etc.)</p> Dovato\u00ae <p>Doltegravir/</p> <p>Lamivudine</p> <p>CrCl 30-50: monitor for hematologic toxicities with lamivudine</p> <p>CrCl&lt;30: do not use combo pill; dose-adjust individual components</p> <p>\u2191 Metformin levels</p> <p>Dose adjustment needed with rifampin use</p> <p>Contraindicated w/dofetilide and multiple antiepileptic drugs</p> <p>Avoid close admin. with polyvalent cations (iron, calcium, etc.)</p> <p>Test all patients for HBV prior to initiation</p> Symtuza\u00ae <p>Tenofavir alafenamide/</p> <p>Emtricitabin/</p> <p>Darunavir/</p> <p>Cobistat</p> Discontinue if CrCl&lt;30; ok w/HD but dose after HD on dialysis days <p>Contraindicated w/rifampin, rifabutin, simvastatin, multiple antiepileptic drugs</p> <p>Note that cobistat can increase serum creatinine without affecting glomerular filtration so cautiously interpret serum creatinine levels</p> Triumeq\u00ae Abacavir/ Dolutegravir/ Lamivudine <p>CrCL 30-50: monitor for hematologic toxicities with lamivudine</p> <p>CrCl&lt; 30; do not use combo pill; dose-adjust individual components</p> <p>\u2191 Metformin levels</p> <p>Dose adjustment needed with rifampin use</p> <p>Contraindicated w/dofetilide and multiple antiepileptic drugs</p> <p>Avoid close admin. with polyvalent cations (iron, calcium, etc.)</p> <p>Test all patients for HBV prior to initiation</p> Genvoya\u00ae <p>Elvitegravir/ Cobicistat/ Emtricitabin/</p> <p>Tenofovir (Alafenamide)</p> Discontinue if CrCl &lt; 30; ok w/HD Many drug-drug interactions due to CYP 3A4 inhibition with cobicistat Nucleoside RTI Dose adj Specific Side Effects Major DDI Special Points Abacavir (ABC) Hepatic dysfunction <p>\u2191 LDL/TG</p> <p>\u2191 risk MI</p> Tenofovir Requires testing for HLA B5701 <p>Emtricitabine</p> <p>(FTC)</p> Renal Rash, insomnia, rhabdomyolysis, hyperpigmentation in palms/soles Lamivudine Active against HBV <p>Lamivudine</p> <p>(3TC)</p> Renal Nausea, HA, peripheral neuropathy, neutropenia, rash Emtricitabine Active against HBV Tenofovir Alafenamide (TAF) Discontinue if CrCl &lt; 15 \u2191 lipids AED\u2019s may \u2191 levels Tx of choice for HBV Tenofovir Disoproxil (TDF) Renal N/V, \u2191 LFTs, asymptomatic \u2191CK, renal dysfunction, bone mineral density loss <p>--</p> Active against HBV <p>NRTI Additional Information</p> <ul> <li> <p>Tenofovir alone is indicated for HBV, in which case you should be     mindful of renal clearance when dosing. In HIV, it is only used in     combination with emtricitabine and third agent. Contraindicated if     CrCl\\&lt;30</p> </li> <li> <p>Class-wide side effect: Lactic acidosis, steatosis and lipoatrophy     (though very rare with contemporary NRTIs)</p> </li> <li> <p>Resistance: M184V confers high resistance to emtricitabine and     lamivudine, mid-level resistance to abacavir, hypersusceptibility to     tenofovir</p> </li> </ul> Integrase Inhibitor Dose Adj. Specific Side Effects Major DDI Special Points Raltegravir (RAL) <p>--</p> <p>--</p> Rifampin, AED\u2019s <p>--</p> Dolutegravir (DTG) *see special points* <p>Hyperglycemia</p> <p>Weight gain</p> <p>Rifampin, Efavirenz</p> <p>\u2191Metformin</p> <p>Avoid close admin with laxatives, sucralfate, iron, calcium</p> <p>May \u2191Cr, without effect on renal function</p> NNRTIs Hepatic Adj Specific Side Effects Major DDI Special Points Efavirenz Stop if Child Pugh B/C <p>Psychosis, vivid dreams, SI, mania, seizures;</p> <p>\u2191 Lipids &amp; glucose</p> Azoles, antifungals, clopidogrel, some statins, clarithromycin, Buprenorphine Give before meals; discontinue if rash develops Etravirine (ETR) <p>Hypersensitivity</p> <p>\u2191 Lipids &amp; glucose</p> Clopidogrel, clarithromycin Nevirapine (NVP) Stop if Child Pugh B/C Steven Johnson Syndrome Azoles, OCP\u2019s, statins, clarithromycin <p>Don\u2019t start if CD4 &gt;250 in women, CD4 &gt;400 in men;</p> <p>Don\u2019t admin with antacids</p> Rilpivirine (RPV) None AED\u2019s, PPI\u2019s, dexamethasone <p>Must be taken with full meal; Don\u2019t use if HIV RNA &gt;100k + CD4 &lt; 200;</p> <p>Don\u2019t admin with antacids</p> <p>NNRTI Additional Information</p> <ul> <li> <p>Class-wide side effect: hepatitis, rashes</p> </li> <li> <p>Resistance: K103N resistance to efavirenz and nevirapine</p> </li> </ul> Protease inhibitors Hepatic Dose adj Specific Side Effects Major DDI Special Points Atazanavir (ATV) Based on Childs Pugh Jaundice, Kidney stones, AV block, Pancreatitis, Rhabdomyolysis <p>CYP3A4 Inhibitors</p> <p>PPI and H2 blockers</p> Admin with meals Darunavir (DRV) <p>Rashes</p> <p>Pancreatitis</p> <p>CYP3A4 Inhibitors</p> <p>Azoles can be used cautiously with drug level monitoring</p> Must stop if rash Lopinavir (LPV) <p>AV block, QT changes</p> <p>Pancreatitis</p> <p>Hepatitis</p> CYP3A4 Inhibitors Admin with meals <p>Protease Inhibitor Additional Information</p> <ul> <li>All protease inhibitors must be boosted:</li> </ul> <ul> <li> <p>Ritonavir: can cause MSK pain, rhabdomyolysis, although not expected     at usual doses</p> </li> <li> <p>Cobicistat: may increase Cr without effect on renal function</p> </li> </ul> <ul> <li>Class-wide side effects: hepatitis, hypersensitivity reactions,     increased cholesterol/TG, hyperglycemia, GI upset, lipodystrophy</li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/","title":"Sexually Transmitted Infections","text":"<p>Ashley Zeoli</p>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#gonorrhea","title":"Gonorrhea","text":""},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#background","title":"Background","text":"<ul> <li>Cause: gram-negative coccus Neisseria gonorrhoeae</li> <li>Gonorrhea causes a spectrum of disease including urethritis, cervicitis, epididymitis, proctitis, pharyngeal infections, conjunctivitis, PID, and disseminated gonococcal infection</li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#evaluation","title":"Evaluation","text":"<ul> <li>Microbial diagnosis is required to diagnose gonorrhea, rather than clinical diagnosis alone</li> <li>Test of choice: NAAT of the first-catch urine in men; NAAT of vaginal swab in women<ul> <li>Also perform co-testing for chlamydia</li> </ul> </li> <li>NAAT of pharyngeal or rectal swab should also be performed in patients with reported symptoms and recent sexual exposure. Note this is also routine testing in patients on PREP.</li> <li>Routine screening should be offered to sexually active patients, as many are asymptomatic</li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#management","title":"Management","text":"<ul> <li> <p>Ceftriaxone is the only current antibiotic that meets the strict treatment efficacy goals with single-dose therapy. CTX also has a low rate of drug resistance, which is becoming an increasing issue in the treatment of gonorrhea.</p> <ul> <li>High dose IM ceftriaxone (&lt;150kg 500mg IM; &gt;150mg 1g IM)<ul> <li>Same for pharyngitis or conjunctivitis</li> </ul> </li> <li>CTX allergies: Azithromycin (2g PO x1) + Gentamicin (240mg IM x1) or Gemifloxacin</li> </ul> </li> <li> <p>Treatment of chlamydia must also be accompanied with gonorrhea treatment when it has not been excluded with molecular testing.</p> <ul> <li>Doxycycline 100mg BID for 7 days</li> </ul> </li> <li> <p>Patients who have persistent symptoms despite treatment should be suspected of having resistant gonorrhea. Test with culture and antimicrobial susceptibility testing (with or without NAAT).</p> </li> <li> <p>Patients with recurrent symptoms after period of resolution should be re-evaluated for gonorrhea and other STIs</p> </li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#chlamydia","title":"Chlamydia","text":""},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#background_1","title":"Background","text":"<ul> <li> <p>Cause: gram negative bacteria Chlamydia trachomatis</p> </li> <li> <p>Most individuals are asymptomatic though causes a wide array of infections: urethritis, cervicitis -&gt; PID, conjunctivitis, perihepatitis (Fitz-Hugh-Curtis syndrome), pneumonia, proctitis, epididymitis, reactive arthritis, pharyngitis, lymphogranuloma venereum (LGV), endemic trachoma</p> </li> <li> <p>Differential diagnosis: Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium</p> </li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>Test of choice: NAAT of vaginal swab in females (first catch urine also adequate); NAAT of first catch urine in males.</p> </li> <li> <p>NAATs can detect both LGV and non-LGV chlamydia trachomatis, but cannot distinguish between them</p> </li> <li> <p>Any patient with signs and symptoms concerning for chlamydia should be tested. Testing should also routinely be offered to sexually active individuals since most patients are asymptomatic. Note this is also routine testing in patients on PREP.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#management_1","title":"Management","text":"<ul> <li> <p>Doxycycline 100mg BID x 7 days is the preferred treatment in non-pregnant patients (azithromycin is NOT preferred) Alternative treatment options (for allergies/severe contraindications): azithromycin (1g PO x 1), levofloxacin (500mg PO daily x7 days), and ofloxacin (300mg BID PO x7 days) Patients with recent potential or confirmed exposure within the last 1-2 weeks should be treated empirically</p> </li> <li> <p>Patients with persistent symptoms, confirmed infection, and who already underwent appropriate treatment, likely have a re-infection, rather than treatment failure. Test again.</p> </li> <li> <p>Patients with recurrent symptoms after resolution should be re-tested for chlamydia with a NAAT and other STIs (gonorrhea, BV, etc).</p> </li> <li> <p>Empiric therapy for gonorrhea should be given to patients unless NAAT is negative</p> </li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#syphilis","title":"Syphilis","text":""},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#background_2","title":"Background","text":"<ul> <li> <p>Caused by the spirochete, Treponema pallidum, which is visualized by dark field microscopy</p> </li> <li> <p>High rate of HIV co-infection among MSM with syphilis (~42%)</p> </li> <li> <p>Transmitted by direct contact with an infectious lesion during sex. Infection can occur anywhere inoculation occurs (i.e. contact with infected secretions can result in a lesion on any tissue site)</p> </li> <li> <p>Can readily cross the placenta -&gt; fetal infection</p> </li> <li> <p>Patients can present with a variety of symptoms, depending on their place in the disease course</p> </li> </ul>"},{"location":"infectious-diseases/infectious-disease-sexually-transmitted-diseases/#evaluation_2","title":"Evaluation","text":"<ul> <li> <p>Test all patients with signs and symptoms, as well as patients who are at increased risk for acquiring infection (patients with sexual partner with early syphilis, MSM, people living with HIV, high risk sexual behaviors, and history of commercial sex work or incarceration)</p> </li> <li> <p>HIV testing should be offered to all patients who test positive</p> </li> <li> <p>Pregnant patients should be screened for syphilis</p> </li> <li> <p>There are two types of serologic tests: treponemal-specific tests (FTA-ABS, MHA-TP, TPPA, TP-EIA, CIA) and nontreponemal tests (RPR, VDRL, TRUST). Either can be used as initial screening, but confirmatory testing with the other is needed due to false positives.</p> <ul> <li>Treponemal specific are usually used as confirmatory tests when nontreponemal tests are reactive. They are reported as reactive or non-reactive. Once positive, usually positive for life.</li> <li>Nontreponemal quantifies amount of antibody present and can be used to detect titers to assess for treatment. Titers should decline after a patient has been treated. A rise in titers in a previously treated patient should be concerning for new infection.<ul> <li>Requires a humoral response, so can be false negatives if immunocompromised</li> <li>False positives: autoimmune diseases, pregnancy, other infections</li> </ul> </li> </ul> </li> <li> <p>At VUMC, a positive treponemal IgG reflexes to a RPR titer.</p> </li> <li> <p>Neurosyphilis can occur at any time after infection. All newly diagnosed patients with syphilis should have a full neurologic exam and if any abnormalities should have an LP sent for CSF-VDRL.</p> </li> <li> <p>Any patients with syphilis and vision changes should undergo ophthalmology evaluation.</p> </li> </ul> <p>+ Treponemal</p> - Treponemal + Non-treponemal Diagnostic of syphilis (completely new, or potentially re-infected) Likely false positive - Non-treponemal Likely history of successfully treated syphilis Likely not syphilis, or false negative (due to prozone\\* effect) \\*Prozone effect: when there is an overabundance of antibodies and they interfere with clumping/formation of antigen-antibody complex so agglutination cannot be visualized <p>Management</p> <ul> <li>To assess treatment efficacy, we want to see a fourfold decrease in     titer after treatment</li> </ul> Symptoms Treatment Treatment Alternatives Primary Painless chancre at inoculation site with regional lymphadenopathy PCN G benzathine 2.4 million units IM x1 <p>Doxycycline 100mg PO BID x 14 days</p> <p>OR</p> <p>Ceftriaxone 1-2g daily IM or IV x 10-14 days</p> <p>OR</p> <p>Tetracycline 500mg PO QID x 14 days</p> <p>OR</p> <p>Amoxicillin 3g BID and probenecid 500mg BID x 14 days</p> Secondary Systemic illness with rash (palms, soles), fever, malaise, alopecia, hepatitis, mucous patches, condyloma, pharyngitis Early Latent Infected, but no symptoms. Occurs within one year of initial infection. Tertiary Symptomatic late syphilis (CV system, gummatous disease) PCN G benzathine 2.4 million units IM weekly x3 weeks <p>Doxycycline 100mg PO BID x 4 weeks</p> <p>OR</p> <p>Ceftriaxone 2g daily IM or IV x 10-14 days</p> Late Latent <p>Infected, but no symptoms. Occurs &gt;1 year after initial infection.</p> <p>Assume late latent with date of infection unknown</p> <p>Neuro</p> <p>syphilis</p> <p>Can occur at any time.</p> <p>Early: asymptomatic or symptomatic meningitis, vision loss, hearing loss</p> <p>Late: brain and spinal cord manifestations (dementia, tabes dorsalis)</p> <p>Treat ocular syphilis like neurosyphilis</p> <p>Aqueous PCN G 3-4 million units IV q4h x 10-14 days</p> <p>OR</p> <p>PCN G procaine 2.4 million units IM daily and probenecid 500mg PO QID x 10-14 days</p> <p>If PCN allergic, desensitize</p> <p>Ceftriaxone 2g daily IM or IV x 10-14 days</p>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/","title":"AIDS Defining Clinical Conditions","text":"<p>Rebecca Choudhury</p> <p>AIDS is defined by HIV infection with concurrent absolute CD4 count \\&lt;200, CD4 percentage \\&lt;14%, or one of the following conditions (predominately opportunistic infections and HIV associated malignancies):</p>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#neurologicophthalmologic","title":"Neurologic/Ophthalmologic","text":""},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#cns-toxoplasmosis","title":"CNS toxoplasmosis","text":"<ul> <li> <p>Presentation: Variable, depending on disease burden/location, may     include AMS, headache, seizure, ataxia, and focal neurologic     deficits, \u00b1 fever and flu-like symptoms</p> </li> <li> <p>Evaluation: MRI w/ring-enhancing lesions on brain imaging, serum     Toxoplasma IgG/IgM and (ideally) CSF Toxoplasma PCR (though CSF     Toxoplasma PCR has a low sensitivity). Response to empiric therapy     (~90% will have radiographic improvement after 14 days) can also be     diagnostic. Brain biopsy may be indicated if diagnostic uncertainty.</p> </li> <li> <p>Management: Pyrimethamine, sulfadiazine, and leucovorin is the     preferred regimen, discuss dosing with pharmacy. Alternative     regimens: clindamycin, Bactrim, atovaquone</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#progressive-multifocal-leukoencephalopathy-pml","title":"Progressive multifocal leukoencephalopathy (PML)","text":"<ul> <li> <p>Presentation: chronic (weeks to months), progressive neurologic     dysfunction, particularly incoordination and other motor     dysfunction, aphasia, sometimes cognitive impairment and personality     changes</p> </li> <li> <p>Evaluation: MRI brain w/patchy areas of demyelination in the     subcortical white matter; location is variable, but parietal,     occipital, and cerebellar involvement are common. JC virus PCR from     CSF. Brain biopsy.</p> </li> <li> <p>Management: Initiation of ART (there is no specific JC     virus-directed therapy), IRIS may occur in which case clinical     worsening before improvement may be seen. Fatal if HIV goes     untreated.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#hiv-related-encephalopathy","title":"HIV-related encephalopathy","text":"<ul> <li> <p>Presentation: Similar to other progressive dementias, with short     term memory loss followed by worsening global cognitive dysfunction,     motor deficits, sometimes seizures in late stages</p> </li> <li> <p>Evaluation: MRI w/diffuse cerebral atrophy and/or demyelinating     lesions similar to PML. CSF w/elevated protein \u00b1 lymphocytic     pleocytosis, with no alternative cause. Send HIV RNA from the CSF,     usually + in HIV encephalopathy</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#cryptococcal-meningitis","title":"Cryptococcal meningitis","text":"<ul> <li> <p>Presentation: Subacute to chronically worsening HA and fevers;     meningismus and photophobia may be present but are often absent;     rarely, focal neurologic deficits</p> </li> <li> <p>Evaluation: LP to check opening pressure and can send serum and CSF     Cryptococcus Ag. Brain imaging may be non-diagnostic</p> </li> <li> <p>Treatment: Induction therapy with amphotericin and flucytosine x14     days (at least), with repeat LP close to end of induction to confirm     CSF inflammation is improving and fungal culture is negative.     Consolidation therapy consists of high dose fluconazole for at least     8 weeks, followed by maintenance therapy with fluconazole for one     year. Pts may require serial LP or VP shunt to manage ICP.</p> <ul> <li>Delay ART for several weeks after start of treatment to avoid risk of IRIS.</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#cmv-retinitis-with-vision-loss","title":"CMV retinitis (with vision loss)","text":"<ul> <li> <p>Presentation: Blurry vision, focal blind spots, visual field     deficits, or scotomas and floaters. Typically begins unilateral,     though often progresses to bilateral involvement.</p> </li> <li> <p>Evaluation: Always consult ophtho if you suspect it! May cause     complete retinal detachment. Check serum CMV PCR (or vitreous if     able)</p> </li> <li> <p>Management: PO valgancyclovir (+intravitreous ganciclovir or     foscarnet in severe disease). If not on ART, must delay ART for at     least 2 weeks after start of CMV retinitis treatment to prevent     immune recovery uveitis</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#pulmonary","title":"Pulmonary","text":""},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#pneumocystis-jirovecii-pneumonia-pjp","title":"Pneumocystis jirovecii pneumonia (PJP)","text":"<ul> <li> <p>Presentation: fever, shortness of breath, cough (usually     non-productive), sometimes night sweats and weight loss. Hypoxia out     of proportion to exam.</p> </li> <li> <p>Evaluation: CT chest appearance usually bilateral and diffuse with     GGOs and cystic lesions of varying size. Large cysts can rupture,     causing pneumothorax.</p> <ul> <li>Transbronchial biopsy, BAL, or induced sputum with cytology and GMS stain.</li> <li>Sputum Pneumocystis PCR can be done, but this is a send-out with long turn-around-time</li> <li>Consider serum LDH and 1,3-BD-glucan: should be elevated, but are nonspecific.</li> </ul> </li> <li> <p>Management: Bactrim is the preferred treatment; PO is preferable as     Bactrim is 100% bioavailable. Check ABG on ROOM AIR to consider of     adding adjunctive steroids (If A-a gradient &gt;/=35mmHg and/or PaO2     \\&lt;70mmHg). Alternative regimens may include primaquine + clindamycin     or IV (NOT inhaled) pentamidine.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#pulmonary-tuberculosis","title":"Pulmonary tuberculosis","text":"<ul> <li> <p>Presentation: With low CD4, can have upper lobe cavities but also     atypical radiographic pattern, including a normal-appearing CXR.     Have a high degree of suspicion in any patient with advanced HIV and     respiratory complaints.</p> </li> <li> <p>Evaluation: TB skin tests and IGRAs have a high false negative rate     in advanced HIV. At VUMC, any pt with HIV and respiratory complaints     must be placed on airborne until TB ruleout- 3 sputum mycobacterial     cultures collected at least 8 hours apart. If concentrated smear is     negative x3, TB is unlikely (though have to follow up final culture     to be sure).</p> </li> <li> <p>Management: RIPE therapy is the standard initial treatment, with     adjustment if needed for drug resistance or contraindications</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#herpes-simplex-tracheobronchitis-andor-pneumonitispneumonia","title":"Herpes simplex tracheobronchitis and/or pneumonitis/pneumonia","text":"<ul> <li> <p>Evaluation: bronchoscopy with positive HSV PCR from BAL \u00b1 lung     biopsy. (Usually associated with HSV-1)</p> </li> <li> <p>Management: agent and duration not well defined for bronchopulmonary     disease; depending on severity of presentation, likely IV acyclovir     to start followed by transition to PO antiviral once evidence of     clinical improvement, for a total of 10-14 days.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#gastrointestinal","title":"Gastrointestinal","text":""},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#esophageal-candidiasis","title":"Esophageal candidiasis","text":"<ul> <li> <p>Presentation: Dysphagia, odynophagia or both. Concurrent     oropharyngeal candidiasis (\u201cthrush\u2019) is common but not universal.</p> </li> <li> <p>Evaluation: Typically presumptive. Treatment is the test; start     fluconazole and consider EGD if symptoms do not improve after     several days (in which case candidiasis may be severe, or it might     not be the cause)</p> </li> <li> <p>Management: Fluconazole; nystatin is ineffective, especially in the     severely immunocompromised</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#herpes-simplex-esophagitis","title":"Herpes simplex esophagitis","text":"<ul> <li> <p>Evaluation: EGD shows diffuse ulcerations throughout the esophagus;     in severe disease ulcers may coalesce into dark patches, \u201cblack     esophagus.\u201d Esophageal biopsy is definitive, but can infer based on     EGD appearance and serum studies.</p> </li> <li> <p>Management: Similar to other mucocutaneous infections, consider IV     acyclovir at first and transition to PO once clinically improved</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#cmv-esophagitisenteritiscolitis","title":"CMV esophagitis/enteritis/colitis","text":"<ul> <li> <p>Presentation: GI bleeding (colitis) or dysphagia and odynophagia     (esophagitis)</p> </li> <li> <p>Evaluation: serum CMV PCR, consult GI for consideration of     EGD/colonoscopy</p> </li> <li> <p>Management: (val)ganciclovir, foscarnet if ganciclovir resistance or     contraindication</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#chronic-1-mo-intestinal-isosporiasis","title":"Chronic (&gt;1 mo) intestinal isosporiasis","text":"<ul> <li> <p>Evaluation: Stool ova/parasite can capture Iospora belli (new name     Cystoisospora belli), may need serial analysis due to intermittent     shedding. Oocysts may also be seen on duodenal biopsy.</p> </li> <li> <p>Management: Bactrim; pyrimethamine + leucovorin if Bactrim is     contraindicated</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#chronic-intestinal-cryptosporidiosis","title":"Chronic intestinal cryptosporidiosis","text":"<ul> <li> <p>Presentation: Diarrhea; may infect respiratory tract, causing     nonproductive cough</p> </li> <li> <p>Evaluation: on GiPP or Cryptosporidium Ag</p> </li> <li> <p>Management: Early initiation or optimization of ART; Monotherapy     with nitazoxanide is preferred; raising CD4 count &gt;100 is necessary     to cure infection</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#recurrent-salmonella-septicemia","title":"Recurrent Salmonella septicemia","text":"<ul> <li>Generally sensitive to fluoroquinolones, but if not clinically     improving as expected you can request sensitivities from the     microbiology lab.</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#neoplastic","title":"Neoplastic","text":"<p>Non-Hodgkin\u2019s lymphoma</p> <ul> <li>DLBCL, Burkitt\u2019s, immunoblastic (subset of DLBCL), primary effusion     lymphoma, and 1\u00ba CNS</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#kaposis-sarcoma","title":"Kaposi\u2019s sarcoma","text":"<ul> <li> <p>Presentation: Distinctive mucocutaneous lesions, usually raised,     papular, violaceous or darkly colored, non-tender and non-pruritic.     Can also involve the visceral organs (esp lungs and GI tract) and     deep lymphatic system.</p> </li> <li> <p>Evaluation: clinical, tissue biopsy for staging, HHV-8 serum PCR.</p> </li> <li> <p>Management: Limited mucocutaneous disease may resolve with     initiation/optimization of ART, but widespread or resistant disease     may require additional local therapies (eg: radiation) or systemic     chemo</p> </li> <li> <p>Bacillary angiomatosis (caused by Bartonella) may present similarly,     but can be distinguished from KS on biopsy. It is neither a cancer     nor an AIDS defining clinical condition, and is usually treated with     doxycycline.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#cervical-cancer","title":"Cervical cancer","text":"<ul> <li>Presentation, diagnosis, and treatment are essentially the same as     in HIV-negative patients, but incidence is higher and disease     progression is often more rapid</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#multisystemmiscellaneous","title":"Multisystem/Miscellaneous","text":""},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#extrapulmonary-or-disseminated-mycobacterial-infection-tb-and-non-tb","title":"Extrapulmonary or disseminated Mycobacterial infection (TB and non-TB)","text":"<ul> <li> <p>TB can go everywhere; some notable extrapulmonary sites include     lymph nodes (e.g., scrofula), bones and joints (e.g., Pott\u2019s disease     of the spine), pleura and pericardium, GU tract, and CNS. Dx can     come from tissue culture and sometimes MTB PCR for more rapid     detection (needs ID approval).</p> </li> <li> <p>TB-IRIS may be severe (esp with high infection burden) and hard to     distinguish from TB treatment failure; can also be seen in     adequately treated TB (provoked by the presence of dead bacteria)     and undiagnosed latent TB.</p> </li> <li> <p>Disseminated MAC is usually diagnosed with AFB blood culture (only 1     positive needed). Think about it in patients with uncontrolled HIV     and severe immunosuppression (esp CD4 \\&lt;50), with unintentional     weight loss, chronic diarrhea and/or dyspnea, and evidence of GI     malabsorption or with bone marrow suppression</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#extrapulmonary-or-disseminated-histoplasmosis-cryptococcocosis-and-coccidiodomycosis","title":"Extrapulmonary or disseminated Histoplasmosis, Cryptococcocosis, and Coccidiodomycosis","text":"<ul> <li> <p>Can be difficult to distinguish based on clinical presentation and     imaging alone. Diagnosed by culture and/or antigen testing depending     on the organism and site of infection, and diagnosis may be     supported by serologic studies.</p> </li> <li> <p>Initial treatment of choice: liposomal amphotericin B in almost all     cases</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#chronic-mucocutaneous-hsv","title":"Chronic mucocutaneous HSV","text":"<ul> <li>Defined as mucocutaneous lesions present for &gt;1 month, can be     present at any site</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-aids-defining-conditions/#multicentric-castlemans-disease","title":"Multicentric Castleman\u2019s Disease","text":"<ul> <li>See \u201cPlasma Cell Dyscrasias\u201d section in Hematology/Oncology for more     details</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-antimicrobial-prophylaxis/","title":"Antimicrobial Prophylaxis per CD4 Counts","text":"<p>Rachel Pellegrino</p> 0 1 2 3 4 CD4 counts Opportunistic Infection Indication for Prophylaxis Medication Special Notes &lt;200 cells/mm3 Pneumocystis Pneumonia (PJP) CD4 &lt; 200, or CD4 &lt; 14%, or CD4 200-250 w/ delayed init. ART &amp; poor f/u TMP-SMX: 1 DS daily (qd), or TMP-SMX: 1SS qd TMP-SMX: 1 DS TIW If intolerant of TMP-SMX: dapsone*, or pentamidine, or atovaquone &lt;200 cells/mm3 Toxoplasma gondii encephalitis Toxoplasma IgG + and CD4 &lt; 100 TMP-SMX 1 DS tab daily Alternative regimens: Dapsone, or Atovaquone (all regimens effect. for PJP ) &lt;200 cells/mm3 Mycobacterium avium- intracellulare (MAC, MAI) Only if not on fully suppressive ART and active disseminated MAC is ruled out - Azithromycin 1200 mg weekly, or -Clarithromycin 500 mg BID, or - Rifabutin 300 mg daily NOT indicated for those initiating ART Infection Screening Indication Intervention Hepatitis A Virus (HAV) Non-immune w/ \u2191 risk for HAV infection (MSM, IVDU) or chronic liver disease HAV vaccine Hepatitis B Virus (HBV) Pts w/o chronic HBV or non-immune HBV vaccine. Ideally admin. before CD4 &lt; 350 Human Papilloma virus (HPV) Age 13-45 HPV vaccine series Influenza A and B Virus All patients Yearly inactivated influenza vaccine Latent Mycobacterium tuberculosis infection (LTBI) -Pts with positive screening test for LTBI w/ no evidence of active disease. -Pts w/ known exposure (INH 300mg + pyridoxine 25-50mg) PO daily for 9 months Streptococcus pneumoniae All patients PCV13 and PPV23 (order and timing depends on previous vaccination history and CD4) Syphilis All pts exposed to sex partner with syphilis diagnosis Screening for syphilis and gonorrhea/chlamydia with treatment if indicated. Varicella Zoster Virus (VZV) Pre-exposure: CD4 &gt;200, no previous vaccine.Shingrix (recombinant vaccine) is not live virus, only Zostavax (live virus) is contraindicated for CD4 &lt;200). Post-exposure: Close contact, particularly if CD4 &lt;200 Pre-exposure: Consider vaccination Post-exposure: Varicella-zoster immune globulin"},{"location":"infectious-diseases/infectious-diseases-bacteremia/","title":"Bacteremia: Interpreting GenMark ePlex\u00ae Results \u2013 VASP","text":""},{"location":"infectious-diseases/infectious-diseases-bacteremia/#background","title":"Background","text":"<ul> <li>When BCx turn positive, the lab reports Gram stain and GenMark     ePlex\u00ae results to help guide empiric therapy, while awaiting further     species identification and susceptibilities.</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-bacteremia/#management","title":"Management","text":"<ul> <li> <p>Start empiric antibiotic therapy (based on clinical picture and     table below)</p> </li> <li> <p>Consider ordering repeat BCx x2 based on organism to document     clearance</p> <ul> <li>Repeat for: Staph (MRSA or MSSA), Strep lugdunensis</li> <li>If source control &amp; no endovascular infxn, no need to repeat (most other strep and GNR\u2019s)</li> </ul> </li> <li> <p>VUMC     antibiograms     can be used to reference typical resistance patterns and most common     organisms in blood cultures.</p> </li> <li> <p>Candida in a blood culture is NEVER considered a contaminant</p> </li> </ul> <p>GRAM POSITIVE COCCI\u00a0</p> <p>Organism</p> <p>Resistance Marker</p> <p>Preliminary Recommendation</p> <p>Staphylococcus aureus</p> <p>or</p> <p>Staphylococcus lugdunensis</p> <p>ID Consult REQUIRED</p> mecA detected Start vancomycin IV No mecA detected <p>Start nafcillin or cefazolin</p> <p>Stop empiric vancomycin IV</p> <p>Staphylococcus epidermidis</p> <p>-Often skin contaminant</p> <p>-Repeat cultures, start therapy if uncertain</p> mecA detected Start vancomycin IV No mecA detected <p>Start nafcillin or cefazolin</p> <p>Stop empiric vancomycin IV</p> <p>Other coagulase negative Staph</p> <p>-Often skin contaminant</p> <p>-Repeat cultures, start abx if uncertain</p> Start vancomycin IV Streptococcus: agalactiae, pyogenes, anginosus <p>Start penicillin IV or CTX IV</p> <p>Stop empiric vancomycin</p> Streptococcus pneumoniae <p>Start ceftriaxone</p> <p>Stop empiric vancomycin</p> <p>Await PCN sensitivity data</p> <p>Other Streptococcus</p> <p>-May be contaminant</p> <p>Start ceftriaxone</p> <p>Stop empiric vancomycin</p> <p>Await PCN sensitivity data</p> <p>Enterococcus faecalis</p> <p>ID Consult REQUIRED</p> vanA or vanB detected <p>Start daptomycin 8-10mg/kg/day IV</p> <p>Don\u2019t treat w vancomycin IV</p> <p>Contact precautions</p> No vanA or vanB <p>Start ampicillin</p> <p>Stop empiric vancomycin IV</p> <p>Enterococcus faecium</p> <p>ID Consult REQUIRED</p> vanA or vanB detected <p>Start daptomycin 8-10mg/kg/day IV</p> <p>Don\u2019t treat w vancomycin IV</p> <p>Contact precautions</p> No vanA or vanB <p>Start vancomycin IV</p> <p>Follow-up ampicillin sensitivities</p> <p>Micrococcus</p> <p>-Often if in a single blood culture is skin contaminant</p> <p>Repeat BCx</p> <p>Start vancomycin IV if uncertain</p> <p>GRAM POSITIVE RODS</p> <p>Organism</p> <p>Preliminary Recommendation</p> Listeria monocytogenes <p>Start ampicillin</p> <p>Stop empiric vancomycin IV</p> <p>Other Gram positive rod (e.g. Bacillus cereus, Corynebacterium, Cutibacterium acnes, Lactobacillus)</p> <p>-Often skin contaminant</p> <p>-Repeat cultures, start therapy if uncertain</p> <p>Start vancomycin IV</p> <p>Follow-up sensitivities; some GPRs are resistant to vancomycin</p> <p>GRAM NEGATIVE RODS *Consult ID if carbapenem resistance detected*</p> Organism Preliminary Recommendation Acinetobacter baumannii Start ampicillin/sulbactam Bacteroides fragilis <p>Start metronidazole</p> <p>If polymicrobial infection, piperacillin/tazobactam, ampicillin/sulbactam, or meropenem based on other organisms</p> <p>Do NOT double cover anaerobes</p> Citrobacter spp. Start/continue cefepime Cronobacter sakazakii Start/continue cefepime Enterobacter (non-cloacae complex) Start/continue cefepime Enterobacter cloacae complex Start/continue cefepime Escherichia coli Continue empiric coverage and await susceptibilities <p>Fusobacterium nucleatum</p> <p>Fusobacterium necrophorum</p> Start ampicillin/sulbactam or start/continue metronidazole Haemophilus influenzae Start/continue ceftriaxone Klebsiella oxytoca Continue empiric coverage and await susceptibilities Klebsiella pneumoniae group Continue empiric coverage and await susceptibilities Morganella morganii Start/continue cefepime Neisseria meningitidis Continue empiric coverage and await susceptibilities <p>Proteus spp.</p> <p>Proteus mirabilis</p> Continue empiric coverage and await susceptibilities Pseudomonas aeruginosa Start/continue cefepime or piperacillin-tazobactam Salmonella spp Start/continue ceftriaxone <p>Serratia spp.</p> <p>Serratia marcescens</p> Start/continue cefepime Stenotrophomonas maltophilia Start trimethoprim-sulfamethoxazole (15-20mg/kg/day divided q8h for normal renal function) Gram-Negative Resistance Genes CTX-M Positive (ESBL) <p>Start meropenem</p> <p>Consider an Infectious Diseases consult</p> <p>Contact precautions (see Infection Prevention website)</p> <p>IMP Positive</p> <p>KPC Positive</p> <p>NDM Positive</p> <p>OXA (OXA-23 and OXA-48) Positive</p> <p>VIM Positive</p> <p>Carbapenemase-producing organism</p> <p>Obtain Infectious Disease consultation</p> <p>Contact precautions (see Infection Prevention website)</p>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/","title":"Central Nervous System Infection \u2013 VASP","text":""},{"location":"infectious-diseases/infectious-diseases-cns-infection/#bacterial-meningitis","title":"Bacterial Meningitis","text":""},{"location":"infectious-diseases/infectious-diseases-cns-infection/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Blood cultures prior to antibiotics if possible</p> </li> <li> <p>Head CT pre-LP, only if: Immunocompromised, hx of CNS diseases     (shunts, trauma, tumors), papilledema on exam or FND, AMS, or new     onset seizure.</p> </li> <li> <p>If there is a delay in obtaining head CT or LP, DO NOT delay     antibiotics.</p> </li> <li> <p>Lumbar puncture (See Procedures Section):</p> <ul> <li> <p>Obtain: Opening pressure, cell count + differential, glucose, protein, bacterial culture</p> </li> <li> <p>Send an extra tube or two of CSF to the lab, if possible, to be frozen in case extra testing is needed (Order \u2018Miscellaneous test\u2019 and for test name put \u201cPlease freeze CSF in virology;\u201d reference lab: VUMC, specimen type: CSF)</p> </li> <li> <p>Additional studies to consider in select pts: HSV 1, 2 PCR (NOT antibodies), VZV PCR, VDRL, Crypto Ag, fungal and/or AFB cultures, MTB PCR, West Nile Virus Ab, Enterovirus PCR, Histoplasma Ag, or Biofire Meningitis/Encephalitis Panel. These should not be performed routinely on all patients and consult ID where management questions exist.</p> </li> <li> <p>If Biofire Meningitis/Encephalitis Panel is performed, double check what is included to avoid sending duplicate individual tests (ie HSV, VZV, enterovirus, etc.) A negative cryptococcus on Biofire does not exclude disease (CSF Crypto Ag is more sensitive)</p> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/#management","title":"Management","text":"<ul> <li> <p>ANTIBIOTICS AS SOON AS POSSIBLE:</p> <ul> <li> <p>Ceftriaxone 2g IV q12h + Vancomycin, adjusted for renal function</p> </li> <li> <p>Piperacillin-tazobactam cannot be used due to poor CNS penetration</p> </li> <li> <p>IV ampicillin 2g q4h for optional coverage of Listeria for immunocompromised patients, pregnant women, or age &gt;50 (adjust based on renal function)</p> </li> <li> <p>IV acyclovir 10 mg/kg (based on adjusted body weight) q8h, if suspected HSV or VZV meningitis, make sure to run with adequate pre-hydration with NS</p> </li> <li> <p>Consider empiric PO/IV doxycycline 100mg BID if tick-borne illness is suspected</p> </li> </ul> </li> <li> <p>Steroids: Based on IDSA guidelines, steroids (dexamethasone 0.15     mg/kg q6h) should be given about 10-20 minutes before the first dose     of antibiotics, or at the same time, in patients with suspected     bacterial meningitis. IF pneumococcus is isolated, continue IV     steroids for 2-4 days; otherwise, can discontinue</p> </li> <li> <p>ID consultation: Duration should be guided by ID and varies based on     organism recovered</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/#encephalitis","title":"Encephalitis","text":""},{"location":"infectious-diseases/infectious-diseases-cns-infection/#background","title":"Background","text":"<ul> <li>The presence or absence of normal brain function/cognition is the     important distinguishing clinical feature between encephalitis and     meningitis</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>MRI more sensitive that CT, although imaging may or may not     demonstrate abnormal radiographic findings in patients with     encephalitis</p> </li> <li> <p>LP \u2013 similar studies as for meningitis (see above) + BioFire MEP for     ALL pts</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/#management_1","title":"Management","text":"<ul> <li> <p>Acyclovir 10mg/kg IV q8hr, consideration of antibacterial therapy if     unable to conclusively exclude a bacterial meningitis, consideration     of doxycycline if tick-borne infection is on the differential, and     further treatment as guided by ID</p> </li> <li> <p>ID consult is strongly encouraged for all patients with suspected     encephalitis</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/#brain-abscess","title":"Brain Abscess","text":""},{"location":"infectious-diseases/infectious-diseases-cns-infection/#evaluationmanagement","title":"Evaluation/Management","text":"<ul> <li> <p>Consult: Neurosurgery and ID</p> </li> <li> <p>Blood Cultures, HIV testing in any patient with a brain lesion</p> </li> <li> <p>Empiric antibiotics:</p> <ul> <li> <p>IV Vancomycin (target trough 15 - 20 mcg/mL) + ceftriaxone 2g IV q12h + metronidazole 500mg IV/PO q6h</p> </li> <li> <p>If concern for extension from otitis externa, use an antipseudomonal cephalosporin (cefepime 2g IV Q8h) instead of ceftriaxone</p> </li> <li> <p>Brain abscesses generally polymicrobial, thus broad-spectrum antibiotics indicated</p> </li> </ul> </li> <li> <p>Aminoglycosides, macrolides, tetracyclines (e.g. doxycycline),     clindamycin, beta-lactam/beta-lactamase combinations (e.g., Zosyn)     and 1st-generation cephalosporins (e.g., cefazolin) should NOT be     used as they do not cross BBB at high concentration.</p> </li> <li> <p>Antibiotic Duration: Based on surgical drainage and Infectious     Diseases guidance</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-cns-infection/#epidural-abscess","title":"Epidural Abscess","text":""},{"location":"infectious-diseases/infectious-diseases-cns-infection/#management_2","title":"Management","text":"<ul> <li> <p>If spinal lesion, consult \u2018Spine surgery\u2019 and it will be directed to     Ortho-Spine or Neurosurgery, depending on who is on call.</p> </li> <li> <p>Antibiotics should be started as soon as the diagnosis of epidural     abscess is suspected, immediately following the collection of two     sets of blood cultures</p> <ul> <li> <p>Vancomycin 15-20mg/kg IV q8-12h (adjusted for renal function) + ceftriaxone 2g IV q24h (or q12hr if there is secondary meningitis)</p> </li> <li> <p>Use cefepime 2g IV q8h instead of ceftriaxone if concern for Pseudomonas</p> </li> </ul> </li> <li> <p>ID consult is strongly encouraged and they will guide duration</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-diabetic-foot-infection/","title":"Diabetic Foot Infection \u2013 VASP","text":""},{"location":"infectious-diseases/infectious-diseases-diabetic-foot-infection/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Plain radiograph for all pts; MRI w/contrast if abscess/osteo     suspected</p> </li> <li> <p>BCx (prior to antibiotics) if systemic signs of infection, or severe     infection</p> <ul> <li>Do not culture swabs of lesions, as these generally only grow colonizing organisms.</li> </ul> </li> <li> <p>Consult podiatry if osteomyelitis present for bone specimen culture     and pathology (either from debridement specimen or bone biopsy)     prior to starting antibiotics.</p> </li> <li> <p>Consult surgery if concern for abscess, gas in tissue, joint     involvement</p> </li> <li> <p>Assess peripheral vasculature, consider arterial flow     studies/vascular surgery consult</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-diabetic-foot-infection/#management","title":"Management","text":"<ul> <li> <p>Assess Severity:</p> <ul> <li> <p>Mild: Local infxn, skin/subQ tissue only, erythema &gt;0.5 cm but \u22642cm from ulcer</p> </li> <li> <p>Moderate: Local infxn w/erythema &gt; 2 cm from ulcer or deeper structures included without SIRS</p> </li> <li> <p>Severe: Local infxn with systemic inflammation as evidenced by &gt;2 SIRS criteria</p> <ul> <li> <p>Consider anti-pseudomonal coverage if at risk for Pseudomonas infection (e.g. wet; failure of prior antibiotic therapy; chronic wound).</p> </li> <li> <p>Consider anaerobic coverage with metronidazole if foul-smelling and/or necrotic.</p> </li> </ul> </li> </ul> </li> </ul> <p>Non-purulent, no MRSA risk factors</p> <p>Purulent, MRSA risk factors</p> Mild <p>Cephalexin 500 QID OR</p> <p>Amoxicillin-clavulanate 875/125 BID</p> <p>TMP-SMX DS 1-2 tabs BID OR</p> <p>Doxycycline 100 BID</p> Moderate <p>Amoxicillin-clavulanate 875/125 BID OR</p> <p>Ampicillin-sulbactam 3g q6h OR</p> <p>Piperacillin-tazobactam 3.375g q8h ext infusion OR</p> <p>Levofloxacin 500 daily</p> <p>TMP-SMX DS 1-2 tabs BID + cephalexin 500 QID OR Amoxicillin-clavulanate 875/125 BID</p> <p>Vancomycin 15-20mg/kg q8-12h + ampicillin-sulbactam 3g q6h (anaerobic, but NO Pseudomonas cvg) OR cefepime 2g q8h (Pseudomonas cvg) + metronidazole 500 q8h (anaerobic cvg)</p> Severe Vancomycin 15-20 mg/kg q8-12h + cefepime 2g q8h + metronidazole 500 q8h"},{"location":"infectious-diseases/infectious-diseases-diabetic-foot-infection/#additional-information","title":"Additional Information","text":"<ul> <li> <p>If pt HDS, hold abx until deep tissue/operative cultures obtained.</p> </li> <li> <p>Most diabetic foot infections are polymicrobial in nature.</p> </li> <li> <p>Culture results may guide therapy, but all pathogens identified may     not require treatment.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/","title":"Endocarditis","text":"<p>Justin Smith</p>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/#background","title":"Background","text":"<ul> <li>Multiple etiologies of endocarditis:<ul> <li>Typical Bacterial<ul> <li>S. aureus, Enterococcus spp (E. faecalis most commonly),     viridans group streptococci, Strep gallolyticus (formerly S.     bovis)</li> <li>HACEK     : Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella,     Kingella</li> </ul> </li> <li>Other infectious<ul> <li>Culture negative: often recent antimicrobial exposure, slow     growing organism</li> <li>Coxiella, Brucella, Bartonella, Chlamydia, Legionella,     Mycoplasma, Tropheryma whipplei, Propionibacterium acnes</li> <li>Fungal: Candida and aspergillus most common</li> </ul> </li> <li>Non-infectious: a.k.a., marantic endocarditis, Libbman-Sacks     Endocarditis<ul> <li>Rare, most common in advanced malignancy, SLE, inflammatory     conditions</li> <li>Higher risk for embolization compared to IE</li> <li>Risk factors: IV drug use, congenital heart disease, valve     abnormalities, intracardiac devices, recent cardiac surgery</li> </ul> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/#presentation","title":"Presentation","text":"<ul> <li> <p>Fever (90%), Murmur (85%), Other: splenomegaly, splinter     hemorrhages, Janeway lesions, Osler Nodes, Roth Spots</p> </li> <li> <p>Persistent bacteremia despite appropriate treatment, new onset     cardiac dysfunction, new onset valve abnormalities, stroke, other     thromboembolic events, metastatic infections/abscesses, splenic     abscess, septic pulmonary emboli</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/#duke-criteria","title":"Duke Criteria:","text":"<ul> <li>Pathologic Criteria<ul> <li>Microorganisms: culture or histology proven: vegetation,     embolus, or intracardiac abscess</li> <li>Pathologic vegetations: vegetation of abscess with histology     proven endocarditis</li> </ul> </li> <li>Clinical Criteria<ul> <li>Major:<ul> <li>2x positive blood cultures from a typical organism</li> <li>Evidence of endocardial involvement</li> </ul> </li> </ul> </li> <li>Minor<ul> <li>Predisposing heart condition/IVDU</li> <li>Fever</li> <li>Vascular phenomena (Glomerulonephritis)</li> <li>Immunologic phenomena (Osler Nodes, Roth Spots, +Rheumatoid     factor, GN)</li> <li>Micro (Cultures that don\u2019t fit the above, or serologic evidence     of acute infection)<ul> <li> <ul> <li> <ul> <li>-</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Definite: 2 Major, 1 major and 3 minor, or 5 minor</li> <li>Possible: 1 major and 1 minor, or 3 minor</li> <li>Rejected: firm alternate diagnosis, resolution of evidence with \\&lt;4     days of antibiotics, or absence of pathologic evidence with \\&lt;4days     of antibiotics</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/#evaluation","title":"Evaluation","text":"<ul> <li>Physical exam: murmur, decreased peripheral perfusion, evidence of     heart failure, petechiae, splinter hemorrhages, Janeway     lesions/Osler nodes, organomegaly</li> <li>Blood cultures: at least three sets from different sites over a span     of several hours</li> <li>Echo (TTE vs TEE)<ul> <li>It can be reasonable to start with TEE if pretest probability is     high enough, if patient has known valvular abnormalities, or TTE     will be technically difficult -</li> </ul> </li> <li>EKG: new heart block or prolonged PR raises concern for     endocardial/perivalvular abscess. Endocarditis patients should be on     telemetry, monitored closely by team</li> <li>CXR: infiltrates suggestive of septic pulmonary emboli, pulmonary     edema, cardiomegaly</li> <li>Imaging of distant affected site if concerned for septic emboli</li> <li>Other advanced imaging in select scenario: cardiac CTA, cardiac MRI,     FDG-PET/CT</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/#management","title":"Management","text":"<ul> <li>Empiric antibiotics:<ul> <li>If bacteria isolated from blood, reference bacteremia section     for abx choice</li> <li>If awaiting cultures<ul> <li>Native valve: Vancomycin</li> <li>Prosthetic valve: Vancomycin and cefepime, consider     gentamicin</li> </ul> </li> </ul> </li> <li>Duration: determined by ID, often 4-6 weeks</li> <li>Surgical consult, if valve dysfunction, perivalvular abscess, large     (&gt;20mm) vegetations</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-endocarditis/#additional-information","title":"Additional Information:","text":"<ul> <li> <p>Complications: </p> <ul> <li> <p>Cardiac:</p> <ul> <li>Heart failure:\u00a0 usually secondary to valve dysfunction. Most     common when aortic valve involved, risk also depends on     organism (worst is Staph aureus )</li> <li>Perivalvular abscess: suspect when there are conduction     abnormalities on EKG; most likely when aortic valve     involved, less likely with mitral valve.</li> <li>Pericarditis: can be suppurative or non-suppurative</li> <li>Intracardiac Fistula</li> </ul> </li> <li> <p>Septic emboli and metastatic abscesses</p> </li> <li>Mycotic aneurysm: usually occurs at vessel branch points</li> </ul> </li> <li> <p>Follow Up</p> <ul> <li>Repeat TTE at completion of treatment to establish new baseline</li> <li>Followed for valvular dysfunction with frequency determined by     nature of the dysfunction. (MR caused by IE should be followed     on a timeline like other MR)</li> <li>Regular dental care, Prior IE is an indication for SBE     prophylaxis with dental work.</li> </ul> </li> <li> <p>Episode of IE is an indication for PDA or VSD closure</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/","title":"Fungal Infections","text":"<p>Justin Smith</p>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#histoplasmosis","title":"Histoplasmosis","text":""},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#background","title":"Background","text":"<ul> <li> <p>Endemic to Ohio and Mississippi river valley</p> </li> <li> <p>Pulmonary infiltrate with hilar or mediastinal LAD, pulmonary     nodule/cavitary lesion, pulmonary syndrome with erythema nodosum</p> </li> <li> <p>DDx: TB, malignancy, sarcoidosis (if considering sarcoidosis, rule     out histoplasmosis as sarcoidosis treatment can induce disseminated     histoplasmosis)</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Antigen (requires attending approval): For acute pulmonary     histoplasmosis, 65% urine sensitivity, 69% serum sensitivity, and     83% sensitivity when co-tested. Thus, both serum and urine Ag are     usually sent together</p> <ul> <li>Lower rates of positivity when disease is localized, versus diffuse throughout the lungs or disseminated.</li> <li>There are relatively high rates of cross-reactivity, where histoplasma antigen will be positive with blastomycosis; therefore, do not order blasto Ag if ordering histo Ag in MOST cases</li> </ul> </li> <li> <p>Serology: Consider Histoplasma Ab if evaluating for pulmonary     disease</p> </li> <li> <p>Culture: most useful in chronic infections, sensitivity is low in     acute/localized and may take &gt;6 weeks to grow.</p> </li> <li> <p>Bronchoscopy: If clinical suspicion is high and work up negative,     consider interventional pulmonology consult for consideration of     bronchoscopy</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#management","title":"Management","text":"<ul> <li> <p>Outpatient/Mild disease:</p> <ul> <li>Tx not required if symptoms \\&lt;4 weeks, initiate if symptomatic beyond 4 weeks</li> <li>Itraconazole: 200mg TID x3 days loading, then BID (adjusted by levels which are drawn 2 weeks post-start) for 6-12 weeks minimum</li> <li>Can use oral formulation or capsules (capsules require high acidity, give with food consumption or OJ or coke; do not use capsules if patient is on H2 blockers/PPI)</li> <li>Voriconazole, Posaconazole: used if not tolerating itraconazole or as salvage therapy</li> </ul> </li> <li> <p>Inpatient/Moderate to Severe Disease:</p> <ul> <li> <p>Amphotericin: 1-2 weeks induction, followed by PO itraconazole for 12 weeks (total)</p> </li> <li> <p>Methylprednisolone: help to prevent ARDS with significant lung involvement</p> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Complications: Pericarditis, arthritis/arthralgias with erythema     nodosum, chronic cavitary lesions, fibrosing mediastinitis,     broncholithiasis</p> </li> <li> <p>Disseminated Histoplasmosis:</p> <ul> <li>Typically found in immunocompromised populations</li> <li>Clinical presentations: FUO, weight loss, disseminated LAD, cutaneous manifestations, bone marrow suppression/pancytopenia, liver enzymes elevation, various solid organ involvement on imaging (liver, spleen, adrenals, nodes)</li> <li>Management<ul> <li>Mild: itraconazole</li> <li>Moderate to Severe: amphotericin induction followed by itraconazole</li> <li>CNS involvement: amphotericin for 4-6 weeks as induction</li> </ul> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#blastomycosis","title":"Blastomycosis","text":""},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#background_1","title":"Background","text":"<ul> <li> <p>Endemic to Mississippi/Ohio river valley, southern and midwestern     US, great lakes</p> </li> <li> <p>Pulmonary syndrome: cough, fever, hemoptysis, chest pain, dyspnea</p> <ul> <li>Can result in both an acute or chronic pneumonia, as well as ARDS</li> </ul> </li> <li> <p>Cutaneous: raised verrucous lesion, varying in color, with irregular     borders</p> </li> <li> <p>MSK: osteolytic lesion, draining sinus, soft tissue swelling</p> </li> <li> <p>Multi-system: up to 20-40% of cases, most typically lung/skin     involvement.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>Culture: typically takes 1-4 weeks</p> </li> <li> <p>Ag: urine &gt;serum. ~90% sensitive, but only 80% specific because of     cross-reactivity</p> </li> <li> <p>Serology: available, but not very useful because of high degree of     cross-reactivity</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#management_1","title":"Management","text":"<ul> <li> <p>Mild: PO itraconazole for 6-12 months with loading, check level at 2     weeks</p> </li> <li> <p>Moderate to Severe: induction with Amphotericin, followed by 6-12     months of PO itraconazole</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#candida","title":"Candida","text":""},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#background_2","title":"Background","text":"<ul> <li> <p>Oropharyngeal: white plaques in mouth, change in taste, erythema     without plaques</p> <ul> <li>Usually seen in infants, older adults, immunocompromised host (HIV or chemotherapy), inhaled steroid users</li> </ul> </li> <li> <p>Esophageal: odynophagia, especially retrosternal pain (AIDS defining     illness)</p> </li> <li> <p>Vulvovaginitis: itching, burning, vaginal discharge, vulvar     erythema, vulvar edema, dyspareunia, dysuria</p> </li> <li> <p>Balanitis: painful white plaques with burning and itching on the     glans penis</p> </li> <li> <p>Mastitis: erythema, tenderness in breast feeding woman.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#management_2","title":"Management","text":"<ul> <li> <p>Depends on specifics, but typically nystatin or fluconazole EXCEPT     C. glabrata (proof of fluconazole susceptibility needed) and C.     krusei (intrinsically resistant to fluconazole)</p> </li> <li> <p>Cx generally not indicated unless complicated pt with extensive tx     history for Candida</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-fungal-infections/#additional-information_1","title":"Additional Information","text":"<ul> <li>Disseminated disease<ul> <li>Presentation: Primarily immunocompromised populations (hematologic malignancies, solid organ transplant recipients, receiving chemotherapy, TPN, steroid use, broad spectrum antibiotics) and ICU settings (especially, burn, trauma, and neonatal)</li> <li>Diagnosis: Candida in a bacterial blood culture (NEVER contaminant)</li> <li>Start micafungin 100mg IV and consult ID for candidemia or if concerned for disseminated disease</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-general-tips/","title":"General Tips","text":"<ul> <li> <p>Vanderbilt Antibiotics Stewardship Program (VASP) has a     website     with much of the below guidance as well as Vanderbilt antibiograms, with     our resistance patterns</p> </li> <li> <p>Does your pt need to be on precautions?     Check the Infection Prevention Website     under \u2018isolation\u2019 tab or page the infection control pager in E-star     paging for additional questions</p> </li> <li> <p>Page 317-4376 for approval of restricted antimicrobials at VUMC     (page the VA ID fellow at the VA)</p> </li> <li> <p>The lab will automatically update the Tennessee health department     with reportable diseases</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/","title":"Genitourinary Infection \u2013 VASP","text":""},{"location":"infectious-diseases/infectious-diseases-gu-infection/#asymptomatic-bacteriuria","title":"Asymptomatic Bacteriuria","text":""},{"location":"infectious-diseases/infectious-diseases-gu-infection/#background","title":"Background","text":"<ul> <li>Isolation of bacteria in an appropriately collected urine specimen from an     individual without symptoms or signs of urinary tract infection.     Bacteriuria, foul odor, urine appearance, pyuria and/or bacteriuria     alone are not indicative of infection.</li> <li>Anuric ESRD patients may have bacteriuria from colonization due to     lack of flushing of bladder, avoid sending UA/Ucx unless patient is     symptomatic</li> <li>Treatment     only required for specific populations:<ul> <li>Pregnant women (screening performed at 12 \u2013 16 weeks)</li> <li>Anticipated urologic intervention</li> <li>Some     renal transplant recipients, depending on time since transplant</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#uncomplicated-urinary-tract-infection-uti","title":"Uncomplicated Urinary Tract Infection (UTI)","text":""},{"location":"infectious-diseases/infectious-diseases-gu-infection/#background_1","title":"Background","text":"<ul> <li>Clinical symptoms of UTI (dysuria/urgency/frequency/ hematuria) in     non-pregnant, immunocompetent, neurologically-intact pts with normal     urologic anatomy and no indwelling urinary catheters</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#management","title":"Management","text":"<ul> <li>Empiric therapy<ul> <li>Nitrofurantoin monohydrate: 100 mg PO BID x 5 days (avoid if any     concern for pyelonephritis or if creatinine clearance \\&lt;60)</li> <li>Cephalexin     250-500mg q6h x5-7 days</li> </ul> </li> <li>Alternative     therapies<ul> <li>Fosfomycin: 3 grams of powder mixed in water as a single PO dose     (avoid if any concern for ascending UTI or pyelonephritis).     Susceptibility test results must be requested of micro lab and     are only possible for E. coli and E. Faecalis.</li> <li>Amoxicillin-clavulanate: 875-125mg PO BID x5 days</li> <li>Ciprofloxacin: 250mg PO BID x3 days<ul> <li>FQ\u2019s should be reserved for more serious infections than     uncomplicated cystitis, and only after susceptibility     results are confirmed given high rates of resistance from     overuse (~25% of E. coli are resistant to ciprofloxacin     at VUMC)</li> <li>Adverse effect profile &gt;&gt; beta-lactams (i.e.     QT-prolongation, tendinopathies)</li> </ul> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#additional-information","title":"Additional Information","text":"<ul> <li>MDR cystitis: ESBL isolates are increasingly common due to antibiotic overuse<ul> <li>Before treating, decide if this is a TRUE UTI</li> <li>If true, consider Fosfomycin (if E. coli ) or nitrofurantoin (if susceptibility is confirmed \u2013 K. pneumoniae and Enterobacter spp are usually resistant), gentamicin or tobramycin 5-7mg/kg IV once, or ID consultation</li> <li>Ask the lab to check susceptibility results to these antibiotics, for the future reference</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#complicated-uti-and-pyelonephritis","title":"Complicated UTI and Pyelonephritis","text":""},{"location":"infectious-diseases/infectious-diseases-gu-infection/#background_2","title":"Background","text":"<ul> <li>Fever, pyuria, and costovertebral angle tenderness suggest     pyelonephritis. </li> <li>Consider it a complicated UTI if any of the following are present: <ul> <li>Renal calculi or other obstructive disease, immunosuppressed     host, abnormal urological anatomy or physiology (including stents), presence of a     urinary catheter</li> <li>Malse sex alone does NOT qualify as complicated </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#evaluation","title":"Evaluation","text":"<ul> <li> <p>UA with reflex urine culture</p> </li> <li> <p>BCx and UCx prior to antibiotics</p> </li> <li> <p>If there is no pyuria, consider an alternative diagnosis, or     proximal ureteral obstruction</p> <ul> <li>Pyuria is common in the presence of a urinary catheter, kidney stones,     urostomy, ileal conduit and other invasive devices, and may not     indicate infection</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#management_1","title":"Management","text":"<ul> <li>Duration: 7-14 days, depending on antibiotic choice</li> <li>Tailor therapy once/if cultures are available. If no improvement in     48h, consider imaging to rule out complications (e.g., perinephric     abscess)</li> </ul> 0 1 2 NaN First Line Alternative Outpatient Ciprofloxacin 750 BID (or 500 BID if bacteremia r/o) \u00a0x 7d NaN Inpatient - CTX 2g q24h - Cefepime 2g q8h - Meropenem 2g q8h (if h/o or confirmed ESBL w/in last 90 d) - Ertapenem 1g q24 instead of Meropenem if no Pseudomonas - Ciprofloxacin 750 PO BID (500 PO BID if bacteremia ruled out) OR 400 IV BID (if suscept confirmed)* <p>*FQ\u2019s have same bioavailability if given PO or IV so oral is preferred</p>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#catheter-associated-urinary-tract-infection-cauti","title":"Catheter Associated Urinary Tract Infection (CAUTI)","text":""},{"location":"infectious-diseases/infectious-diseases-gu-infection/#background_3","title":"Background","text":"<ul> <li>Culture growth of &gt; 10 3 cfu/mL of uropathogenic     bacteria + signs or symptoms consistent with infection (without     another identified etiology) + indwelling urethral/suprapubic     catheter or intermittent catheterization.<ul> <li>This includes pts with catheters in place during the preceding     48 hours</li> </ul> </li> <li>Duration = greatest risk factor (Increases 3-10% per day of     catheterization)<ul> <li>Other risks: female sex, diabetes, elderly, colonization of     catheter bag, poor care</li> </ul> </li> <li>Bacteriuria, foul odor, pyuria, urine appearance and/or bacteriuria     alone are not indicative of infection in patients who are otherwise     asymptomatic.</li> <li>Ensure clean sample collected<ul> <li>Ideally, catheter is removed and midstream sample obtained</li> <li>If catheterization required; removal of old catheter and sample     taken from new</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-gu-infection/#management_2","title":"Management","text":"<ul> <li> <p>Distinguish uncomplicated vs complicated UTI (see above)</p> </li> <li> <p>Antimicrobial management:</p> <ul> <li>Guided by cultures and susceptibilities</li> <li>Empiric guidance as per management of uncomplicated/complicated     UTI and per prior culture data/susceptibilities when available</li> <li>Duration: 7 \u2013 14 days depending on antibiotic, clinical response     and whether infection constitutes complicated vs uncomplicated     UTI</li> <li>Special note regarding Candida UTI management: Candida Is     generally not pathogenic</li> <li>Presence     in urine does not indicate infection (unless perinephric     abscess, renal transplant, or complex fistulous disease)</li> <li>Fluconazole     achieves excellent urinary penetration</li> <li>Echinocandins do not, and other azoles are not well studied in     UTIs</li> <li>If     fluconazole     resistant Candida cultured or suspected, consult ID</li> <li>Susceptibilities are not routinely run on Candida from urine     cultures and would need to be requested if concern for true     infection.</li> </ul> </li> <li> <p>Catheter management</p> <ul> <li>At the least, catheters should be replaced at the time of     antibiotic initiation (preferably removed) </li> <li>Preferably, catheters should be removed</li> <li>If catheterization is necessary, intermittent catheterization is     preferred over continuous use. Condom catheters and pure wicks also      preferred over foley catheter</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-hiv-art-general-concepts/","title":"HIV/AIDS and ART","text":"<p>Kathryn Snyder and Quinton Taylor</p>"},{"location":"infectious-diseases/infectious-diseases-hiv-art-general-concepts/#background","title":"Background","text":"<ul> <li> <p>Why is ART important?</p> <ul> <li>Clear morbidity and mortality benefits across all CD4 counts</li> <li>Decreases subsequent infections (both common and opportunistic)</li> <li>Decreased HIV related comorbid conditions, viral reservoirs, and transmission</li> </ul> </li> <li> <p>New HIV Diagnosis</p> <ul> <li>ID consult if patient is not on Rogers ID service (important for initiation, follow up [CCC], social work assistance)</li> <li>ART is indicated for all HIV+ patients, regardless of CD4; however, starting ART requires appropriate outpatient follow up</li> <li> <p>Lab evaluation:</p> <ul> <li> <p>HIV viral load, genotype, and resistance testing</p> </li> <li> <p>T cell subsets (CD4 Count), CBC with differential, CMP, UA</p> </li> <li> <p>HLA*B5701 testing before using abacavir containing regimen</p> </li> <li> <p>QuantiFERON Gold</p> </li> <li> <p>Pregnancy testing</p> </li> <li> <p>Viral hepatitis serologies</p> </li> <li> <p>Toxoplasma serologies</p> </li> <li> <p>Other STI screening (Syphilis, Gonorrhea/Chlamydia)</p> </li> </ul> </li> </ul> </li> <li> <p>Timing of ART initiation</p> <ul> <li>Factors affecting timing of initiation<ul> <li>Drug toxicity and interactions, risks for resistance, adherence barriers</li> <li>Treatment of opportunistic infections may delay initiation of ART given associated risk of immune reconstitution inflammatory syndrome (IRIS)<ul> <li>Delay ART for several weeks after initiation of therapy for cryptococcal meningitis, tuberculosis, and CMV retinitis</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>ART plan for overnight admits: okay to continue home ART, special     consideration for:</p> <ul> <li>Patients with hepatic or renal dysfunction may need dose adjustment</li> <li>Interactions with other newly initiated medications</li> <li>If there is concern for non-adherence, can hold morning dose</li> <li>Combination pills may need to be ordered as separate components</li> </ul> </li> <li> <p>Common key regimens for initiation</p> <ul> <li>Most regimens consist of an NRTI backbone (2 agents) plus a 3rd agent</li> <li>Some dual therapy regimens (such as Dovato@) are non-inferior to standard 3-drug therapy</li> <li>Many patients are started on combination pill regimens, including Integrase Inhibitor based regimens: Biktarvy\u00ae, Dovato\u00ae, Triumeq\u00ae, Genvoya\u00ae, dolutegravir + Descovy\u00ae</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-inpatient-covid19/","title":"Inpatient COVID-19 Management","text":"<p>Kathryn Snyder</p>"},{"location":"infectious-diseases/infectious-diseases-inpatient-covid19/#background","title":"Background","text":"<ul> <li>COVID-19 is the novel coronavirus responsible for the ongoing     pandemic that started in late 2019. The virus has ongoing mutations     resulting in new dominant strains.</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-inpatient-covid19/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Please see the most updated VUMC and VA guidance due to frequently     evolving recommendations.</p> </li> <li> <p>Please refer to the hospital\u2019s current maximum oxygen requirement     allowed on the floor to ensure patient is appropriately triaged.</p> </li> <li> <p>Basic admission workup for symptomatic, confirmed COVID-19</p> <ul> <li> <p>Labs: CBC with diff, CMP, d-dimer, ferritin, CRP, ESR, PT/INR, PTT, procalcitonin, RPP</p> </li> <li> <p>Imaging: portable CXR</p> </li> <li> <p>Nursing: Strict I/O</p> </li> <li> <p>Enhanced precautions (contact, airborne, eye protection)</p> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-inpatient-covid19/#management","title":"Management","text":"<ul> <li> <p>Fluid balance goal slightly net negative to even</p> </li> <li> <p>Anticoagulation/DVT prophylaxis:</p> <ul> <li>Please see latest VUMC or VA guidance based on clinical status (supplemental O2 requirements, ICU vs floor, etc.)</li> </ul> </li> <li> <p>Pharmacologic therapies</p> <ul> <li>Note: Therapies, indications, and contraindications are frequently changing, please see latest VUMC/VA guidelines for specific indications for these medications or others</li> </ul> </li> <li> <p>Remdesivir</p> <ul> <li> <p>Loading dose 200mg IV x1 then 100mg daily x 4 days</p> </li> <li> <p>For use in patients hospitalized for COVID within 7 days of     symptom onset</p> </li> <li> <p>Contraindications: known hypersensitivity, ALT &gt;/= 10x ULN,     high-flow NC, PPV, intubated, or on ECMO</p> </li> <li> <p>Monitoring: baseline CBC, INR, q48h CMP</p> </li> </ul> </li> <li> <p>Dexamethasone</p> <ul> <li> <p>6mg PO/IV x 10 days; consideration of longer taper if no     clinical improvement or persistently elevated CRP</p> </li> <li> <p>Contraindications: no hard contraindications, use clinical     judgement if concomitant serious bacterial/fungal infection</p> </li> </ul> </li> <li> <p>Antibiotics:</p> <ul> <li> <p>The incidence of superimposed bacterial infection in the setting     of COVID-19 is low</p> </li> <li> <p>The majority of patients do not need additional coverage for     bacterial pneumonia</p> </li> <li> <p>You can use procalcitonin to guide decision</p> </li> </ul> </li> <li> <p>Other pharmacologic therapies include baricitinib (JAK inhibitor),     tocilizumab (IL-6 inhibitor) and monoclonal antibodies</p> </li> </ul> <p>Additional Information</p> <ul> <li> <p>Complications and special considerations for COVID-19 patients</p> <ul> <li> <p>High PE/DVT risk</p> </li> <li> <p>Superimposed bacterial PNA</p> </li> <li> <p>AKI</p> </li> <li> <p>GI symptoms/abnormalities (see GI section on COVID-19)</p> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-orthopedic-infection/","title":"Joint Infections and Osteomyelitis \u2013 VASP","text":""},{"location":"infectious-diseases/infectious-diseases-orthopedic-infection/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Blood cultures prior to antibiotics</p> </li> <li> <p>MRI is the most sensitive and specific imaging modality for     osteomyelitis.</p> </li> <li> <p>Ortho consult for joint fluid aspirate or bone bx; send for culture     and send fluid for cell count/differential.</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-orthopedic-infection/#management","title":"Management","text":"<ul> <li> <p>Hold antibiotics until culture obtained, if patient is clinically     stable</p> </li> <li> <p>Osteomyelitis is a 6-week treatment course, can consider early     transition (at 2-3 weeks) to oral if good bioavailability and     susceptibility.</p> </li> <li> <p>For prosthetic joint infection, procedure/retention of hardware     determines duration</p> </li> <li> <p>First line empiric: Vancomycin + ciprofloxacin 750mg BID</p> </li> <li> <p>Antimicrobial therapy will ultimately be guided by culture data, ID     consult recommended for joint infection treatment due to need for     prolonged antibiotic therapy</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/","title":"Pulmonary Infections","text":"<p>VASP, Evan Schwartz</p>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#acute-bronchitis","title":"Acute Bronchitis","text":""},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#background","title":"Background","text":"<ul> <li>1-3 wks productive cough, often preceded by URI, may have wheezing/rhonchi</li> <li>Distinct from chronic bronchitis (&gt;3 mos of consecutive cough x 2 consecutive yrs)</li> <li>Distinct from PNA (parenchymal consolidation, fever &gt;100.4F, hypoxia, tachypnea)</li> <li>DDx: COVID-19, post-nasal drip, GERD, undertreated/new asthma, ACE-i induced bradykinin cough, undertreated CHF, acute PE, or new lung cancer</li> <li>Clinical dx; CXR/labs not necessary unless PNA suspected</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#management","title":"Management","text":"<ul> <li>Supportive: lozenges, cough suppressants (guaifenesin or dextromethorphan), smoking cessation. Consider albuterol inhaler for wheezing</li> <li>No indication for antibiotics</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#influenza","title":"Influenza","text":""},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#background_1","title":"Background","text":"<ul> <li>Dx often clinical w/cough, sore throat, #sputum/nasal discharge, HA, fever, myalgias, and malaise; \u00b1 N/V/D. Exam with increased flushing, rarely with lower respiratory symptoms</li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#evaluation","title":"Evaluation","text":"<ul> <li> <p>During flu season: Obtain COVID/RPP or dedicated influenza PCR; testing is more accurate if obtained within 96 hour of symptom onset</p> </li> <li> <p>CXR if concerned for bacterial superinfection</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#management_1","title":"Management","text":"<ul> <li> <p>Antivirals most effective when given &lt;48 hours from symptom onset; however, recommended to be given if symptomatic despite duration and to all hospitalized patients</p> </li> <li> <p>Oseltamivir 75mg BID x 5 days, peramivir 600mg IV x 1 (needs renal adjustment), or baloxavir (age \u226512) 40mg once (use 80 mg if &gt;80kg)</p> </li> <li> <p>Amantadine and rimantadine are no longer used due to emerging resistance</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#community-acquired-pneumonia-cap","title":"Community Acquired Pneumonia (CAP)","text":""},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#background_2","title":"Background","text":"<ul> <li> <p>All PNA that does not otherwise meet criteria for Hospital Acquired     Pneumonia (PNA that develops \u226548 hours after hospital admission),     Ventilator Associated Pneumonia (PNA that develops \u226548-72 hours     after endotracheal intubation), or aspiration PNA</p> </li> <li> <p>Healthcare-associated pneumonia is no longer a clinical entity per     2016 IDSA guidelines</p> </li> <li> <p>MRSA Risk Factors: recent history, cavitary lesion, post-influenza     bacterial PNA, pts with IDU, severe hypoxemia requiring intubation</p> </li> <li> <p>Pseudomonas: Double coverage is not indicated in general     population; LVQ has 82% sensitivity so not recommended unless     isolate proven susceptible</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>Sputum cultures prior to abx, consider BCx in select groups (severe     pneumonia, ICU admission, cavitary disease, immunosuppression).</p> </li> <li> <p>Rule out flu if the right season, COVID-19, consider RVP if it will     change management</p> </li> <li> <p>CURB-65 or PSI can aid in decision between outpatient vs inpatient     therapy</p> <ul> <li>CURB65: Confusion, Uremia (BUN &gt;=19 mg/dL), RR (&gt;30/min), BP(\\&lt;90/60 mmHg), Age \u2265 65 If \u2265 2, hospitalization is recommended.</li> </ul> </li> </ul> <ul> <li> <p>Consider urine pneumococcal Ag, urine Legionella Ag in severe CAP     and in certain pts (e.g., neutropenia, asplenia, obstructive lung     disease, hyponatremia, diarrhea, or heavy alcohol use); these are     performed at reference labs and will take several days to return.</p> </li> <li> <p>CRP, ESR, and pro-calcitonin have not been shown to reliably improve     outcomes; however, pro-calcitonin \\&lt; 0.25 suggests against bacterial     respiratory infection and antibiotic discontinuation is encouraged</p> </li> <li> <p>PA/ lateral CXR to evaluate for and localize infiltrate. If     immunocompromised, consider CT chest w/o contrast (does not improve     outcomes)</p> <ul> <li>Lobar Consolidation - likely bacterial</li> <li>Interstitial Infiltrate - likely atypical vs. viral vs. non-infectious</li> <li>Cavitation - concerning for fungal vs. necrotizing vs. mycobacterial</li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#management_2","title":"Management","text":"<ul> <li>Antibiotic Duration: 5-7 days (at least 5 days and improvement with     clinical stability)</li> </ul> <p>Outpatient</p> <p>Inpatient (Non- ICU &amp; ICU)</p> No MRSA or Pseudomonas suspected <p>Low Risk\\*:</p> <p>-Amoxicillin 1g TID</p> <p>High Risk:</p> <p>-Amoxicillin-clavulanate 875/125 BID + Macrolide</p> <p>-Cefdinir 300 BID + Macrolide</p> <p>-Amoxicillin 1g TID + Macrolide</p> <p>-Levofloxacin 750 daily</p> CTX 2g q24 + Azithromycin 500 daily OR Levofloxacin 750 daily MRSA or Pseudomonas suspected <p>MRSA: Vancomycin OR Linezolid</p> <p>(if no bacteremia)</p> <p>Pseudomonas: Cefepime 2g q8h</p> <p>*No chronic heart, lung, liver, renal disease, DM, alcoholism, immunocompromise</p>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#additional-information","title":"Additional Information","text":"<ul> <li> <p>MRSA nasal swab has reported negative predictive value for MRSA     pneumonia ranging 95% to &gt;99%; consider sending and if negative,     discontinue MRSA agent</p> </li> <li> <p>CTX is generally adequate coverage for aspiration PNA without     evidence of abscess, empyema, or cavitary lesion on imaging</p> </li> <li> <p>Aspiration pneumonia can be confused for aspiration pneumonitis     which does not need to be treated with antibiotics. Rapid resolution     of leukocytosis and stabilization of vitals suggest aspiration     pneumonitis and consideration of stopping antibiotics.</p> </li> <li> <p>There is low sensitivity of S. pneumoniae to azithromycin (42%) and     doxycycline (72%), so these should not be used as monotherapy</p> </li> <li> <p>Check for drug interactions with linezolid (e.g., SSRI, methadone,     methamphetamine use)</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#hospital-acquired-pneumonia-hap-and-ventilator-associated-pneumonia-vap","title":"Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)","text":""},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#background_3","title":"Background","text":"<ul> <li> <p>HAP: Pneumonia that develops &gt;48 hours after admission</p> </li> <li> <p>VAP: Pneumonia that develops &gt;48 hours after endotracheal     intubation</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#evaluation_2","title":"Evaluation","text":"<ul> <li> <p>Cultures of blood, sputum, endotracheal aspirate and/or bronchoscopy     specimen</p> </li> <li> <p>Consider MRSA nares to help with de-escalation</p> </li> <li> <p>If there is concern for respiratory viruses: send influenza, COVID,     RVP</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-pulmonary-infections/#management_3","title":"Management","text":"<ul> <li> <p>Initially cover for MRSA and Pseudomonas</p> </li> <li> <p>Antibiotic Duration: 7 days in uncomplicated cases, although     specific pathogens (e.g., Pseudomonas) may require longer duration     and ID guidance</p> </li> <li> <p>Consider ID consultation if the patient is not clinically improving     on empiric therapy or if an MDR pathogen grows from culture</p> </li> <li> <p>If no MRSA isolated and pt is improving, consider stopping     vancomycin ASAP</p> </li> <li> <p>There is concern for nephrotoxicity with combination Vancomycin and     piperacillin-tazobactam, but data controversial</p> </li> </ul> <p>MRSA Coverage</p> <p>Pseudomonas Coverage</p> First Line Vancomycin (Pharmacy dosing) Cefepime 2g q8h OR Piperacillin-tazobactam 3.375 q8h extended infusion OR Ceftazidime 2g q8h Alternative Vancomycin allergy: Linezolid 600 mg PO q12h True PCN allergy: Aztreonam 2g q8h"},{"location":"infectious-diseases/infectious-diseases-ssti/","title":"Skin and Soft Tissue Infection (SSTI) - VASP","text":""},{"location":"infectious-diseases/infectious-diseases-ssti/#cellulitis","title":"Cellulitis","text":""},{"location":"infectious-diseases/infectious-diseases-ssti/#background","title":"Background","text":"<ul> <li> <p>DDx: erysipelas, pyomyositis, necrotizing fasciitis, osteomyelitis,     venous stasis, shingles, gout</p> </li> <li> <p>Pathogens: Streptococcus species: Group A (most common), B, C, G,     Staphylococcus aureus (including MSSA and MRSA)</p> <ul> <li>Non-purulent, lymphangitis, or erysipelas? Think Streptococcus</li> <li> <ul> <li>Purulence (abscess or boil)? Think Staphylococcus</li> </ul> </li> </ul> </li> <li> <p>Unique clinical scenarios and associated organisms/organisms to     consider:</p> <ul> <li> <p>Dog/cat bite: Pasteurella multicoda, Capnocytophaga canimorsus</p> </li> <li> <p>Human bite: Eikenella corrodens, oral anaerobes, S. aureus</p> </li> <li> <p>Fresh water exposure: Aeromonas hydropholia, Plesiomonas shigelloides</p> </li> <li> <p>Saltwater exposure: Vibrio vulnificus</p> </li> <li> <p>Neutropenia, presence of ecthyma: Gram negatives (Pseudomonas aeruginosa)</p> </li> <li> <p>Immunocompromised: Fungal (Candida spp, Cryptococcus), Nocardia, non-tubercular mycobacteria)</p> </li> <li> <p>Burn patients: Pseudomonas, Acinetobacter, Fusarium</p> </li> </ul> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-ssti/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Outline border of erythema and obtain urgent surgery consultation if     rapid spread of infection, crepitus, air in tissues or pain     dramatically out of proportion to exam</p> </li> <li> <p>Blood cultures (BCx): ONLY needed if systemic signs/symptoms of     infection or immunocompromised (most pts will not need BCx or     imaging)</p> </li> <li> <p>Ultrasound for underlying abscess</p> </li> <li> <p>CT/MRI w/contrast: if necrotizing fasciitis, pyomyositis or     osteomyelitis suspected</p> </li> <li> <p>Bilateral lower extremity cellulitis is RARE and warrants further     consideration of other non-infectious etiologies</p> </li> <li> <p>Elevation test: if erythema improves after elevating leg above the     level of the heart for 1-2 minutes, less likely to be infectious     cellulitis</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-ssti/#management","title":"Management","text":"<ul> <li> <p>Antibiotics for 5 days for uncomplicated; can extend to 10-14 days     if little to no improvement, more extensive/serious infection, or if     immunosuppressed</p> </li> <li> <p>Typically improvement is not seen until &gt;48 hours of antibiotics,     usually longer</p> </li> <li> <p>Provide anti-Staphylococcal antibiotics for purulent cellulitis in     addition to I&amp;D, if abscess present</p> </li> <li> <p>Clinical appearance may often appear to worsen initially despite     adequate therapy</p> </li> <li> <p>Always elevate the extremity for more rapid clinical improvement!</p> </li> </ul> <p>No Staphylococcus suspected</p> <p>MSSA</p> <p>MRSA</p> <p>Mild/Moderate</p> <p>(Outpatient)</p> <p>Cephalexin 500 QID</p> <p>Amoxicillin 500 TID</p> <p>Cefadroxil 1g BID</p> <p>Cephalexin 500 QID</p> <p>Cefadroxil 1g BID</p> <p>Dicloxacillin 500 QID</p> <p>\\*Clindamycin 300-450 q6</p> <p>TMP/SMX 1-2 DS tabs BID</p> <p>Doxycycline 100 BID</p> Severe (Inpatient) <p>Cefazolin 2g q8h</p> <p>CTX 2g q24h</p> <p>Cefazolin 2g q8h</p> <p>Nafcillin 2g q4h</p> Vancomycin \\*Consider for PCN allergy; check antibiogram (VUMC vs VA) for Staph sensitivities; clindamycin should NOT be used for strep coverage"},{"location":"infectious-diseases/infectious-diseases-ssti/#necrotizing-fasciitis","title":"Necrotizing Fasciitis","text":""},{"location":"infectious-diseases/infectious-diseases-ssti/#background_1","title":"Background","text":"<ul> <li> <p>Infection of the deeper soft tissues that causes necrosis along the muscle fascia and overlying subcutaneous fat that is rapidly progressive and lethal if not addressed</p> </li> <li> <p>Clinical cues include rapid spread, pain out of proportion to exam, crepitus and hemorrhagic bullae</p> </li> </ul>"},{"location":"infectious-diseases/infectious-diseases-ssti/#evaluationmanagement","title":"Evaluation/Management","text":"<ul> <li> <p>SURGICAL EMERGENCY!</p> <ul> <li>STAT consult to surgical service for emergent debridement (generally EGS vs ortho)</li> <li>Imaging does NOT rule out necrotizing fasciitis and should not delay these consultations</li> </ul> </li> <li> <p>ID consult</p> <ul> <li>Blood cultures, but this should not delay antibiotic administration</li> <li>Contact and droplet precautions x first 24h of abx therapy; after this, contact precautions only if draining or contained wounds</li> <li>Vancomycin + either piperacillin-tazobactam 3.375g IV q8h extended infusion OR cefepime 2gm IV q8h + clindamycin 600mg-900mg IV q8h (for antitoxin effects)</li> </ul> </li> </ul>"},{"location":"introduction/introduction-acknowledgements/","title":"Acknowledgements","text":"<p>The Vanderbilt University Medical Center (VUMC) Internal Medicine Housestaff Handbook began with an Internal Medicine Resident Quality Improvement Project which was led by Michael J. Neuss, MD, PhD, under the guidance of Jennifer K. Green, MD, MPH in 2019.</p> <p>We would like to thank the following individuals for their contributions to the 4th edition of the Housestaff Handbook:</p> <ul> <li>The many VUMC residents (past and present) who have meticulously     authored each section of this handbook.</li> <li>The VUMC faculty who carefully reviewed each topic for its accuracy.</li> <li>Leah Brown, MD and Joseph Quintana, MD, the 3rd edition's     co-editors-in-chief, whose guidance was instrumental in the     transition between editions.</li> <li>Chase Webber, DO, who was a sounding board for our new ideas     throughout the year as the Handbook\u2019s faculty advisor.</li> <li>C. Beau Hilton, MD for his work in updating and improving the online     version of this handbook.</li> <li>John McPherson, MD, Kim Rathmell, MD PhD, Kristy Braden and Maria     Kasel, for their unwavering support.</li> </ul>"},{"location":"introduction/introduction-authors-editors-reviewers/","title":"Editors, Authors, and Reviewers","text":""},{"location":"introduction/introduction-authors-editors-reviewers/#editors-in-chief","title":"Editors-in-Chief","text":"<p>Lauren Chan, MD &amp; Jacqueline Visina, MD</p>"},{"location":"introduction/introduction-authors-editors-reviewers/#resident-editors","title":"Resident Editors","text":"<p>Cardiology:\u202fBrittany Saldivar, MD\u202f </p> <p>Critical Care:\u202f\u202fRaymond Dieter, MD </p> <p>Endocrinology:\u202fKinsley Ojukwu, MD\u202f </p> <p>Gastroenterology: Taylor Riggs, MD\u202f </p> <p>Geriatrics:\u202fThomas Horton, MD\u202f </p> <p>Hematology/Oncology: Michael LaPelusa, MD </p> <p>Hepatology:\u202fJulie Cui, MD\u202f </p> <p>Hospital Medicine: Soibhan Kelley, MD  </p> <p>Infectious Diseases:\u202fKaitlyn Reasoner, MD </p> <p>Nephrology: Trey Richardson, MD  </p> <p>Neurology:\u202fHunter Hewitt, MD </p> <p>Ophthalmology: Jonathan Barnett, MD </p> <p>Outpatient Medicine: Christina Snider, MD </p> <p>Palliative Care: Eli Cohen, MD </p> <p>Physical Medicine &amp; Rehabilitation:\u202fJakob Dovgan, MD, Douglas Bryant, MD, William Galbraith, DO, and Nicholas Abramson, MD </p> <p>Procedures: Katherine Heckman, MD\u202f </p> <p>Psychiatry:\u202fSoibhan Kelley, MD </p> <p>Pulmonary: Taryn Boyle, MD </p> <p>Radiology:\u202fJanesh Lakhoo, MD, MS  </p> <p>Rheumatology: Raeann Whitney, MD\u202f\u202f </p> <p>Toxicology:  Jennifer Marvin-Peek, MD  </p>"},{"location":"introduction/introduction-authors-editors-reviewers/#faculty-reviewers","title":"Faculty Reviewers","text":"<p>Cardiology:\u202f\u202fLisa Mendes, MD and Jared O\u2019Leary, MD\u202f </p> <p>Critical Care:\u202fTodd Rice, MD </p> <p>Endocrinology:\u202fLaura Heller, MD </p> <p>Gastroenterology: Patrick Yachimski, MD\u202f </p> <p>Geriatrics: Mariu Duggan, MD, MPH </p> <p>Hematology/Oncology: Rajiv Agarwal, MD and Benjamin Tillman, MD </p> <p>Hepatology: Manhal J. Izzy, MD </p> <p>Hospital Medicine: Chase J. Webber, DO </p> <p>Infectious Diseases:\u202fMilner Staub, MD, MPH and Sean Kelly, MD </p> <p>Nephrology: JP Arroyo, MD, PhD, </p> <p>Edward Gould, MD, and Beatrice Concepcion, MD </p> <p>Neurology:\u202fChristopher Lee, MD </p> <p>Ophthalmology: John Bond, MD </p> <p>Outpatient:\u202fJennifer K. Green, MD, MPH    </p> <p>Palliative Care:\u202fMohana Karlekar, MD </p> <p>Physical Medicine &amp; Rehabilitation:\u202fC. J. Plummer, MD </p> <p>Procedures: Garren Montgomery, MD </p> <p>Psychiatry:\u202fJonathan Smith, MD and Jose Arriola Vigo MD, MPH </p> <p>Pulmonary: Meredith Pugh, MD </p> <p>Radiology:\u202fVirginia Planz, MD </p> <p>Rheumatology: Kevin Byram, MD  </p> <p>Toxicology:\u202f Rebecca E. Bruccoleri, MD and Saralyn R. Williams, MD</p>"},{"location":"introduction/introduction-disclaimers/","title":"Disclaimers","text":"<p>The handbook is not a substitute for clinical judgment and is intended as an educational guide. Content reflects current national guidelines, as well as practice at VUMC and the Nashville VA. The handbook is not intended to replace more comprehensive references or guides.</p> <p>Images are used sparingly, but when used are created by the authors themselves, available by public domain, or reproduced under fair use.</p>"},{"location":"introduction/introduction-rationale/","title":"Rationale","text":"<p>The aim of this handbook is to provide specific, systems-based guidance  on practice at VUMC and the VA. We hope to provide readers with direct  and actionable guidance, consolidating the combined wisdom of  generations of residents and faculty experts.  </p> <p>The Handbook represents a coordinated effort to disseminate details of  our practice in a standardized, peer-reviewed format. The guidance  provided by the handbook makes legible evidence-based practice as well  as the oral tradition of a resident guiding an intern, or an attending a  resident. We hope that this handbook will inspire confidence and  learning, whether the reader is an intern on July 1 or a senior resident  who wishes to refresh their memory of a topic.  </p>"},{"location":"introduction/introduction-web-app-setup/","title":"Web App Setup","text":"<p>This site is optimized for use on mobile devices. It is possible to set up a link from your device's home screen that gives it the look and feel of a web app.</p> <ul> <li>iOS users: Go to VIMBook.org . At the bottom     of the screen, hit the \"Share\" icon (box with upward facing arrow).     Hit \"Add to Home Screen.\" Rename it to your liking. The gold     Vanderbilt icon will appear on your home screen, and you can click     this icon to be taken directly to the website.</li> <li>Android users:\u00a0 Go to VIMBook.org . Press     Menu, then select \"Bookmarks.\" Hold it down until \"Add Shortcut to     Home Screen\" appears, and click it. This will place an icon on your     home screen, and you can click this icon to be taken directly to the     website.</li> </ul>"},{"location":"nephrology/nephrology-acid-base/","title":"Acid-Base","text":"<p>Ned Hardison and Trey Richardson</p>"},{"location":"nephrology/nephrology-acid-base/#background","title":"Background","text":"<ul> <li> <p>Abnormal serum H+ concentrations lead to impaired cellular function     (cardiac arrest, vasodilation, decreased response to     catecholamines), electrolyte abnormalities (e.g. hypo- and     hyperkalemia, hypo- and hypercalcemia), impaired glucose metabolism,     impaired drug metabolism, and a whole host of other complications     that translate to increased morbidity and mortality</p> </li> <li> <p>ABG/VBG reference ranges:</p> <ul> <li> <p>pH = 7.36-7.44 (~7.32-7.40)</p> </li> <li> <p>PCO2 = 36-44 mmHg</p> </li> <li> <p>pO2: 60-100 mmHg</p> </li> <li> <p>HCO3 = 22-26 mEq/L</p> </li> </ul> </li> <li> <p>Useful formulas</p> <ul> <li> <p>pH on ABG = VBG pH + 0.035</p> </li> <li> <p>Anion Gap= Na-(Cl+Bicarb)</p> </li> <li> <p>Normal Anion Gap= 12-14</p> </li> <li> <p>Calculated Osmolarity= 2[Na]+ ([Glucose]/18) + ([BUN]/2.8)</p> </li> <li> <p>Osmolar gap= Measured osmolarity \u2013 Calculated osmolarity</p> </li> <li> <p>Winter\u2019s formula for respiratory compensation for AGMA: expected   pCO2 = 1.5 (serum bicarb) +8 \u00b1 2</p> </li> <li> <p>Shortcut: Expected       p**C**O2\u2004\u2248\u2004last two digits of pH</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#general-approach-to-acid-base-derangements","title":"General Approach to Acid-Base Derangements","text":"<ul> <li> <p>Step 1: Determine if the patient is acidemic or alkalemic (look at     the pH)</p> </li> <li> <p>Step 2: Determine the primary disorder (metabolic or respiratory)</p> </li> <li> <p>Step 3: Calculate anion gap (see section below)</p> </li> <li> <p>Step 4: Is there appropriate compensation?</p> </li> <li> <p>Step 5: Evaluate for secondary disorders</p> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#anion-gap-metabolic-acidosis","title":"Anion Gap Metabolic Acidosis","text":""},{"location":"nephrology/nephrology-acid-base/#background_1","title":"Background","text":"<ul> <li>Na+ is the predominant cation in normal plasma. Cl- and HCO3- are     the predominant anions. There are anions that are not directly     measured (e.g. most binding globulins, immunoglobulins, clotting     factors, and other proteins). These unmeasured anions are     responsible for the normal anion gap of ~12 meq/L. When there are     extra unmeasured anions within the plasma, the anion gap increases</li> </ul>"},{"location":"nephrology/nephrology-acid-base/#differential","title":"Differential","text":"<ul> <li>GOLDMARK: Glycols, oxyproline (acetaminophen metabolite), L-lactate,     D-lactate, methanol, ASA, renal failure/uremia, ketoacids</li> </ul>"},{"location":"nephrology/nephrology-acid-base/#evaluate-for-secondary-disorders","title":"Evaluate for secondary disorders","text":"<ul> <li>Corrected bicarbonate<ul> <li> <p>Corrected H**C**O3 = patient\u2019s H**C**O3 + (patient\u2019s anion gap - 12)</p> <ul> <li> <p>Corrected H**C**O3 &gt; 26, coexisting metabolic     alkalosis,</p> </li> <li> <p>Corrected HCO3 \\&lt;22 coexisting non-AG metabolic acidosis</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#osmolar-gap","title":"Osmolar Gap","text":"<ul> <li>If there is an anion gap, it is worthwhile to always calculate an     osmolar gap. You will be surprised the number of toxic ingestions     you catch this way</li> </ul>"},{"location":"nephrology/nephrology-acid-base/#non-anion-gap-metabolic-acidosis-nagma","title":"Non-anion gap metabolic acidosis (NAGMA)","text":"<ul> <li> <p>There are two places from which people can waste bicarbonate- the     kidneys and the gut</p> <ul> <li> <p>The urine anion-gap, which corresponds to unmeasured urinary NH4+     (primary means of renal acid excretion), can differentiate between     the two</p> </li> <li> <p>Urine anion gap = Unmeasured cations (NH4+) \u2013 unmeasured anions =     U\u00adNa + UK \u2013 UCl</p> </li> <li> <p>Positive value-&gt; low NH4+-&gt; renal losses</p> <ul> <li> <p>RTA</p> </li> <li> <p>Carbonic anhydrase inhibition: acetazolamide, topiramate</p> </li> <li> <p>Adrenal insufficiency</p> </li> <li> <p>Normal saline infusion</p> </li> </ul> </li> <li> <p>Ne-GUT-ive value-&gt;high NH4+-&gt;kidneys working     appropriately-&gt; GI losses</p> <ul> <li> <p>Diarrhea</p> </li> <li> <p>Pancreatic fistula</p> </li> <li> <p>Ureterosigmoidostomy</p> </li> </ul> </li> </ul> </li> <li> <p>Caveat: Proximal RTA has a normal distal urine acidification and has     a negative urine AG</p> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#managing-metabolic-acidosis","title":"Managing Metabolic Acidosis","text":"<ul> <li> <p>Lactic acidosis is the most common cause of anion gap metabolic     acidosis that we encounter</p> </li> <li> <p>In general, avoid use of bicarbonate to treat lactic acidosis</p> </li> <li> <p>Remember: H+ + HCO3- \\&lt;-&gt; H2CO3 \\&lt;-&gt; H2O +       CO2. While administering bicarbonate will transiently improve pH,       carbonic acid will eventually form and ultimately worsen acidemia</p> </li> <li> <p>In acute NAGMA, reasonable to give bicarbonate when bicarb \\&lt;12 or     pH \\&lt;7.1-7.2</p> </li> <li> <p>Pay close attention to other electrolyte levels, especially     potassium as it shifts back into cells</p> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#metabolic-alkalosis","title":"Metabolic Alkalosis","text":""},{"location":"nephrology/nephrology-acid-base/#background_2","title":"Background","text":"<ul> <li> <p>Metabolic alkalosis occurs as a primary disorder or as compensation     for respiratory acidosis. A thorough history and exam can usually     clarify which of these two scenarios is occurring</p> </li> <li> <p>In order for metabolic alkalosis to occur, there has to be both an     inciting phase (e.g. volume depletion) and a maintenance phase (e.g.     hypochloremia or hypokalemia)</p> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#presentation","title":"Presentation","text":"<ul> <li> <p>Most symptoms of metabolic alkalosis (confusion, nausea, vomiting,     tremors) occur as a result of other electrolyte abnormalities     (hypocalcemia, hypokalemia)</p> </li> <li> <p>Serum pH of &gt;7.55 is likely the threshold where symptoms will     develop</p> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#causes","title":"Causes","text":"<ul> <li> <p>Saline responsive (e.g. hypochloremia)</p> <ul> <li> <p>True volume depletion</p> </li> <li> <p>NG suction/Nausea/vomiting</p> </li> <li> <p>Diuretic use</p> </li> </ul> </li> <li> <p>Saline refractory</p> <ul> <li> <p>Hypokalemia</p> </li> <li> <p>Milk-Alkali syndrome</p> </li> <li> <p>Mineralocorticoid excess states</p> </li> <li> <p>Bartters Syndrome</p> </li> <li> <p>Gitelman\u2019s Syndrome</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-acid-base/#treatment","title":"Treatment","text":"<ul> <li> <p>Saline Responsive/Hypochloremia</p> <ul> <li> <p>If volume deplete, then normal saline is treatment of choice</p> </li> <li> <p>If alkalosis develops in setting of diuresis, then make sure replacing KCl and consider acetazolamide</p> </li> </ul> </li> <li> <p>Saline refractory</p> <ul> <li> <p>Hypokalemia- replenish potassium stores</p> </li> <li> <p>Hyperaldosteronism- covered in more detail in the endocrinology   section</p> </li> <li> <p>Bartter syndrome and Gitelman syndrome - replace electrolytes and   refer to nephrology</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-acute-rejection/","title":"Kidney Transplant Rejection","text":""},{"location":"nephrology/nephrology-acute-rejection/#background","title":"Background","text":"<ul> <li> <p>Rejection is divided into acute vs chronic and T-cell mediated or     antibody mediated</p> <ul> <li> <p>Pathologists can determine the type of rejection and the chronicity     by observing the structures that are acutely involved (e.g.     tubulitis, glomerulitis, arteritis, and capillaritis) as well as the     time course of involvement (e.g. presence of fibrosis)</p> </li> <li> <p>Structures exhibiting fibrosis represent chronic rejection that is     unlikely to respond to treatment, whereas acute inflammation may be     amenable to acute therapies</p> </li> <li> <p>This section will focus on acute rejection since this is the     clinical entity we will most likely manage while on the wards</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-acute-rejection/#acute-rejection","title":"Acute Rejection","text":"<ul> <li> <p>Acute T cell mediated rejection</p> <ul> <li> <p>Infiltration of the graft by lymphocytes and inflammatory cells     characterized by tubulitis, interstitial inflammation, and arteritis     (on occasion)</p> </li> <li> <p>Treatment:</p> <ul> <li> <p>High dose glucocorticoids (methyl prednisolone) is first line     (~ 5 days)</p> </li> <li> <p>Thymoglobulin (polyclonal Ig anti-T cell)</p> <ul> <li> <p>Use depends on severity of rejection</p> </li> <li> <p>Indicated if Cr fails to improve after steroids</p> </li> <li> <p>T cell subsets are measured during treatment until depleted</p> </li> </ul> </li> <li> <p>Tacro target levels are reset to ~8-10 if treated for acute T     cell mediated rejection</p> </li> </ul> </li> </ul> </li> <li> <p>Acute antibody mediated rejection (ABMR)</p> <ul> <li> <p>Donor specific antibody mediated rejection characterized by     glomerulitis, peri-tubular capillaritis (microcirculation     inflammation), complement deposition (C4d staining), and presence of     DSA</p> </li> <li> <p>Treatment = B-cell depletion therapy</p> <ul> <li> <p>IV methyl prednisone 500 mg IV x 3-5 days</p> </li> <li> <p>Plasmapheresis (If with high titers of DSA)</p> </li> <li> <p>IVIG 2 g/kg (max 140 g)</p> </li> <li> <p>Rituximab 375 mg/m2</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-aki/","title":"Acute Kidney Injury (AKI)","text":"<p>Terra Swanson</p>"},{"location":"nephrology/nephrology-aki/#background","title":"Background:","text":"<ul> <li>Definition based on 2012 KDIGO Guidelines:\u00a0<ul> <li>Rise in serum creatinine (sCr) &gt; 0.3 mg/dL within 48 hours, or increase &gt; 1.5 x baseline in 7 days\u00a0\u00a0</li> <li>Urine volume \\&lt;0.5 cc/Kg/H for at least 6 H</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-aki/#framework-for-aki","title":"Framework for AKI","text":"<ul> <li> <p>Pre-renal/hemodynamic AKI:</p> <ul> <li>Volume depletion: GI losses, hemorrhage, burns, critical illness increased insensible losses\u00a0</li> <li>Decreased effective circulating volume: cardiorenal, hepatorenal, hemodynamic effects of ACEi/ARB </li> <li>Afferent arteriole constriction [NSAIDs, Iodinated contrast]\u00a0</li> <li>Renal vein thrombus\u00a0</li> </ul> </li> <li> <p>Intra-renal: Glomerular, tubular, or interstitial diseases</p> <ul> <li>ATN = Most common form of intrinsic AKI. Can be Ischemic or toxic<ul> <li>Toxins can be broken down further into endogenous (e.g. rhabdo) and exogenous (e.g. drugs)</li> </ul> </li> <li>Acute Interstitial Nephritis (AIN): Usually drug induced (NSAIDs, PPIs, beta lactam abx)\u00a0\u00a0</li> <li>Glomerulonephritis</li> <li>Other causes:\u00a0\u00a0<ul> <li>Crystalline nephropathy: IV acyclovir, tumor lysis, ethylene glycol\u00a0</li> <li>Small vessel disease: MAHA, TTP, HUS</li> <li>Large vessel disease: Aortic dissection, renal artery stenosis\u00a0\u00a0</li> </ul> </li> </ul> </li> <li> <p>Post-renal: Can occur at any level of the GU system\u00a0</p> <ul> <li>Ureteral: stones, external compression (malignancy, LAD, abscess)\u00a0</li> <li>Bladder: neurogenic bladder, malignancy, obstructing blood clot\u00a0</li> <li>Urethra: BPH, prostate cancer, prostatitis\u00a0\u00a0</li> </ul> </li> <li> <p>Pre-renal azotemia and acute tubular necrosis comprise the majority     of inpatient acute kidney injuries</p> </li> </ul>"},{"location":"nephrology/nephrology-aki/#evaluation","title":"Evaluation","text":"<ul> <li> <p>History and volume exam</p> </li> <li> <p>Labs: CMP, urinalysis, protein/Cr ratio</p> </li> <li> <p>500cc-1L IV fluid challenge: If sCr improves to baseline in \\&lt;48H     then the insult was likely pre-renal. If not, then look for other     etiologies</p> </li> <li> <p>Evaluate for obstruction: I/O cath, Foley, Post Void Residual &gt;250     cc</p> </li> <li> <p>Who needs a renal ultrasound?\u00a0</p> <ul> <li>No obvious cause of AKI</li> <li>Abrupt oliguria or anuria\u00a0(think renal vein thrombus or obstruction)</li> <li>High suspicion for bladder outlet obstruction (PVRs might give you same data)\u00a0</li> <li>Add doppler to evaluate for renal artery stenosis (or if working up resistant hypertension)\u00a0</li> </ul> </li> <li> <p>Urine Electrolytes\u00a0</p> <ul> <li>FENa \\&lt;1% or FEUrea \\&lt;33% (if on diuretics) suggest pre-renal physiology</li> <li>Caveat, only validated in oliguric patients and more difficult     to interpret after fluids, diuretics, etc</li> <li>Not needed in the initial work-up of all patients with AKI. If     high suspicion for pre-renal etiology, trial fluid challenge and     assess response first</li> </ul> </li> <li> <p>Urine sodium can be used to assess Na avidity: UNa &gt; 40 suggests     ATN and UNa \\&lt; 20 suggests pre-renal</p> </li> </ul>"},{"location":"nephrology/nephrology-aki/#management","title":"Management","text":"<ul> <li> <p>All causes</p> <ul> <li>Minimize fluctuations in blood pressure</li> <li>Consider holding anti-hypertensive medications, especially ACEi/ARB (remember to determine plan to resume at/after discharge)</li> <li>Avoid unnecessary nephrotoxins</li> <li>Dose-adjust medications for changing renal function</li> </ul> </li> <li> <p>Pre-Renal</p> <ul> <li>True volume depletion- Intravenous volume expansion</li> <li>Cardiorenal syndrome- Decongestion/diuresis</li> <li>Hepatorenal syndrome- See Hepatology section for more information</li> </ul> </li> <li> <p>Post-renal</p> <ul> <li>Relieve Obstruction: I/O cath, foley, Urostomy (Urology), percutaneous nephrostomy (IR)</li> <li>Monitor for post-obstructive diuresis</li> </ul> </li> <li> <p>Intra-renal</p> <ul> <li>ATN- supportive care, monitor for post-ATN diuresis. If delayed recovery, may need outpatient dialysis</li> <li>Glomerulonephritis- Consult AKI service for assistance with biopsy and selecting immunosuppressive agents if needed</li> <li>AIN- Review meds, consult nephrology for possible biopsy and recommendations for steroids</li> </ul> </li> <li> <p>Monitor for renal recovery\u00a0</p> <ul> <li>Suspect concomitant ATN if sCr declines with volume expansion, diuresis, or relief of obstruction but remains a few points above baseline</li> </ul> </li> <li> <p>When to consult Nephrology</p> <ul> <li>Urgent indication for dialysis (see \u201cRenal Replacement Therapy\u201d)</li> <li>Abrupt anuria</li> <li>Cr worsening or urine output inadequate w/o clear cause</li> <li>Need for kidney biopsy\u00a0\u00a0</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-aki/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Rhabdomyolysis: UA positive for blood but no RBCs on microscopy</p> <ul> <li>Toxic damage due to myoglobin</li> <li>Serologic markers of muscle injury:\u00a0elevated CK, AST&gt;AST with normal ALK Phos\u00a0</li> <li>Fluids adjusted to urine output goal of 200-300 mL/hr until CK declines<ul> <li>Consider isotonic bicarb for initial 1-2L of IVF urine alkalinization to reduce precipitation</li> </ul> </li> <li>Avoid calcium repletion for hypocalcemia unless symptomatic\u00a0</li> </ul> </li> <li> <p>Post-obstructive diuresis\u00a0</p> <ul> <li>Necessary process to clear accumulated uremic toxins</li> <li>Replace ~50% of urine output to prevent pre-renal azotemia</li> <li>Monitor calcium, phosphorus, and magnesium in severe post-obstructive diuresis</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-aki/#contrast-induced-aki-ci-aki","title":"Contrast Induced AKI (CI-AKI)","text":"<p>Trey Richardson</p>"},{"location":"nephrology/nephrology-aki/#background_1","title":"Background","text":"<ul> <li> <p>When someone develops an AKI do your due diligence and evaluate for     the usual causes of AKI, regardless of when they were given contrast</p> </li> <li> <p>Mechanism of injury: direct toxic effect leading to tubular necrosis     and arteriolar vasoconstriction leading to medullary ischemia</p> </li> </ul>"},{"location":"nephrology/nephrology-aki/#kdigo-criteria-for-ci-aki","title":"KDIGO Criteria for CI-AKI:","text":"<ul> <li>sCr increase by 0.5mg/dl or 25% increase in sCr from baseline 48 H     after radiologic procedure where intravenous contrast was     administered</li> </ul>"},{"location":"nephrology/nephrology-aki/#who-is-at-risk-for-ci-aki","title":"Who is at risk for CI-AKI?","text":"<ul> <li> <p>Normal kidney function: incidence of CI-AKI is 1-3%</p> </li> <li> <p>Pre-existing CKD: Incidence of CI-AKI may be as high as 20% in     patients with CKD 4-5</p> </li> <li> <p>Other risk factors include: diabetes, heart failure, and advanced     age</p> </li> <li> <p>No real sCr or eGFR threshold below which iodinated contrast is     contraindicated, especially in patients for whom imaging will alter     management (e.g. acute stroke, PE, STEMI)</p> </li> </ul>"},{"location":"nephrology/nephrology-aki/#risk-reduction-strategies","title":"Risk reduction strategies","text":"<ul> <li> <p>Volume expansion with isotonic crystalloid (PRESERVE Trial) in     patients with AKI or eGFR \\&lt;30 ml/min/1.73m^2 who are clinically     hypo or euvolemic</p> <ul> <li>1cc/kg/hr for 6-12 hours before/during and 6-12 hours after the procedure in patients at high risk for CI-AKI. This rate can be decreased based on the risk for hypervolemia</li> </ul> </li> <li> <p>If the patient is volume overloaded, they probably should not     receive volume expansion prior to a contrasted study</p> </li> <li> <p>Never delay a necessary procedure out of concern for worsening renal     function. If in doubt, talk to nephrology</p> </li> </ul>"},{"location":"nephrology/nephrology-aki/#iodinated-contrast-in-ckd-5esrd-patients","title":"Iodinated contrast in CKD-5/ESRD patients","text":"<ul> <li> <p>Iodinated contrast does not need to be dialyzed immediately</p> </li> <li> <p>Avoid giving if you are trying to preserve residual kidney function     in ESRD on PD</p> </li> </ul>"},{"location":"nephrology/nephrology-aki/#gadolinium-contrast-for-mri","title":"Gadolinium contrast for MRI","text":"<ul> <li>Contraindicated in any AKI or if GFR \\&lt;30 in CKD given risk of     nephrogenic systemic fibrosis.</li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/","title":"Approach to Chronic Kidney Disease","text":"<p>Terra Swanson</p>"},{"location":"nephrology/nephrology-approach-ckd/#definition-of-ckd","title":"Definition of CKD","text":"<ul> <li> <p>Decreased kidney function or one or more markers of kidney damage     for 3 or more months</p> </li> <li> <p>History of kidney transplant</p> </li> <li> <p>GFR \\&lt; 60; Staging helps risk-stratify pts likely to progress or     develop complications of CKD</p> <ul> <li>CKD IIIa: eGFR 45-60</li> <li>CKD IIIb: eGFR 30-44</li> <li>CKD IV: eGFR 15-30</li> <li>CKD V: eGFR \\&lt; 15</li> </ul> </li> <li> <p>Markers of kidney damage</p> <ul> <li> <p>Albumin/Cr ratio</p> <ul> <li> <p>Mild: 0-30 mg/g</p> </li> <li> <p>Moderate: 30-300 mg/g</p> </li> <li> <p>Severe: &gt;300 mg/g</p> </li> </ul> </li> </ul> </li> <li> <p>Urine sediment: RBC casts, WBC casts, oval fat bodies or fatty     casts, granular casts</p> </li> <li> <p>Electrolyte derangements</p> </li> <li> <p>Abnormalities on histology</p> </li> <li> <p>Structural abnormalities: (cysts, hydronephrosis, scarring, masses,     renal artery stenosis)</p> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#when-to-refer-to-nephrology-clinic","title":"When to refer to nephrology clinic","text":"<ul> <li> <p>eGFR \\&lt; 45</p> </li> <li> <p>Persistent urine albumin/creatinine ratio &gt; 300 mg/g</p> </li> <li> <p>Urine protein/creatinine ratio greater than 500 mg/g</p> </li> <li> <p>Rapid loss of kidney function (&gt; 30% decline over 4 months)</p> </li> <li> <p>Hematuria not 2/2 urologic condition or if there are RBC casts on UA</p> </li> <li> <p>Inability to identify presumed cause of renal dysfunction</p> </li> <li> <p>Difficult to manage complications (hyperkalemia, anemia,     bone-mineral disease, HTN)</p> </li> <li> <p>Confirmed or presumed hereditary kidney disease (PCKD suspected)</p> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#complications-of-ckd","title":"Complications of CKD","text":"<ul> <li>Imbalance of water homeostasis<ul> <li>As renal mass declines the ability to both concentrate and dilute the urine is impaired</li> <li>This manifests as hyponatremia (no end-organ to respond to ADH) and edema</li> <li>Treat this with water restriction, diuretics or, eventually, ultrafiltration</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#metabolic-acidosis","title":"Metabolic acidosis","text":"<ul> <li> <p>Correcting serum bicarbonate to a goal of 23-30 meq/L slows decline     in renal function and protects against bone-mineral complications of     chronic metabolic acidosis</p> </li> <li> <p>Can calculate bicarbonate deficit to estimate dose of bicarbonate</p> </li> <li> <p>If bicarb \\&lt; 22, consider:</p> <ul> <li>Sodium bicarb 650 mg TID (8mEq bicarb per 650mg tablet) up to 5850mg/day (70 mEq or 3 tabs TID)</li> <li>Sodium citrate (Bicitra): 1mL = 1 mEq * Careful in cirrhosis since citrate cannot be metabolized</li> <li>Baking soda (sodium bicarbonate): 1 teaspoon = 59 mEq HCO3 (careful of Na load)</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#htn-in-ckd","title":"HTN in CKD","text":"<ul> <li> <p>Goal BP \\&lt; 120/80 (Class 2B recommendation) based on SPRINT trial,     ACC/AHA 2017, and KDIGO 2021 guidelines</p> </li> <li> <p>All comers: Diet (e.g. DASH) and lifestyle modifications</p> </li> <li> <p>CKD without albuminuria or DM:</p> <ul> <li>Start pharmacotherapy based on ASCVD risk as well as risk for other target organ damage</li> </ul> </li> <li> <p>CKD with moderate to severe albuminuria w/ or w/out DM</p> <ul> <li>ACEi or ARB titrated to maximally tolerated dose (Class 1B recommendation)</li> <li>Thiazide-like diuretics (see CLICK trial for chlorthalidone in advanced CKD)</li> <li>Loop diuretics can assist with volume driven HTN in patients with CKD 4-5</li> </ul> </li> <li> <p>HTN in kidney transplant</p> <ul> <li>CCBs or ARBs are first line (Class 1C recommendation)</li> </ul> </li> <li> <p>Consider stopping ACE-i/ARB if:</p> <ul> <li>GFR declines &gt;30% over 4 months. Consider evaluation for renal artery stenosis</li> <li>K &gt; 5.5 despite low K diet, optimizing dose of diuretics, or adding K-binders</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#anemia-in-ckd","title":"Anemia in CKD","text":"<ul> <li> <p>Multifactorial: decreased EPO production, impaired iron absorption,     uremic toxins suppressing bone marrow, loss of blood in dialysis     circuit, and from GI AVMs</p> </li> <li> <p>Indications for iron supplementation in non-dialysis patients:</p> <ul> <li>ALL patients with TSAT \\&lt;20% and ferritin \\&lt;100 ng/mL</li> <li>Patients with Hb \\&lt;13 and TSAT \\&lt;30% and ferritin \\&lt;500 ng/mL</li> <li>Can start with PO supplementation (see Anemia section). Reassess iron levels in 1-3 mos; if not appropriately \u2191, consider IV iron repletion</li> </ul> </li> <li> <p>Dialysis patients:</p> <ul> <li>IV Iron preferred method of repletion for HD patients with<ul> <li>TSAT \\&lt; 20% and ferritin \\&lt; 200</li> <li>TSAT \\&lt;30% and ferritin \\&lt;500 AND with Hb \\&lt; 10 OR are on EPO</li> </ul> </li> </ul> </li> <li> <p>Dosing: usually administered at HD sessions         - 125 mg ferric gluconate at consecutive HD sessions x 8 doses         - 100 mg iron sucrose at consecutive HD sessions x 10 doses         - Ferumoxytol 510mg at the end of two HD sessions 1-4 weeks apart</p> </li> <li> <p>Indications for EPO</p> <ul> <li>Pts w/ Hb \\&lt;10 who are not iron deficient (ferritin &gt;500) or     who\u2019s anemia persists despite adequate iron repletion</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#hyperkalemia-goal-k-55","title":"Hyperkalemia (Goal K \\&lt; 5.5)","text":"<ul> <li> <p>Patients with diabetic nephropathy (T4 RTA) and CKD 5-ESRD are at     the highest risk</p> </li> <li> <p>Strategies to mitigate hyperK</p> <ul> <li> <p>Low K diet (\\&lt; 40-70 mEq/day or 1500-2700 mg/day)</p> </li> <li> <p>Loop diuretics</p> </li> <li> <p>GI cation exchangers</p> <ul> <li> <p>Patiromer (Veltassa): binds K in colon in exchange for calcium</p> </li> <li> <p>Sodium zirconium cyclosilicate (Lokelma): binds K throughout intestine in exchange for sodium and H+</p> </li> <li> <p>Do not use Kayexelate as chronic therapy</p> </li> </ul> </li> </ul> </li> <li> <p>Treat metabolic acidosis</p> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#mineral-bone-disease-in-esrd","title":"Mineral bone disease in ESRD","text":"<ul> <li> <p>Avoid calcium supplementation in mild or asymptomatic hypocalcemia</p> </li> <li> <p>Replace vitamin D to &gt;20 (weak evidence)</p> </li> <li> <p>Phos goal \\&lt; 5.5</p> <ul> <li> <p>Sevelamer: use lowest dose effective to achieve Phos \\&lt; 5.5</p> <ul> <li> <p>Phos 5.5-7.5: initial dose 800 TID with meals</p> </li> <li> <p>Phos 7.5-9.0: initial dose 1200-1600 TID with meals</p> </li> <li> <p>Phos &gt; 9: initial dose 1600 TID</p> </li> <li> <p>Can titrate dosing by 400 to 800 mg per meal at 2-week intervals</p> </li> </ul> </li> <li> <p>Restrict dietary phos to 900 mg/day</p> </li> </ul> </li> <li> <p>PTH goal in CKD3: 2x ULN</p> </li> <li> <p>PTH Goal in ESRD: 2-10x ULN</p> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#diabetes-in-ckd","title":"Diabetes in CKD","text":"<ul> <li> <p>Individualize A1C goals. Both the ADA and VA-DOD have guidelines for     selecting A1C targets</p> </li> <li> <p>Treatment:</p> <ul> <li> <p>Metformin remains first-line but should be dose-reduced based on eGFR</p> <ul> <li> <p>eGFR &gt; 45: Maximum daily dose of 2000mg/day (1000mg bid)</p> </li> <li> <p>eGFR \\&lt; 45: Reduce max daily dose to 1000mg/day (500mg bid)</p> </li> <li> <p>eGFR \\&lt; 30: Discontinue if high risk for volume mediated AKI/chronically ill</p> </li> </ul> </li> <li> <p>SGLT-2 inhibitors for patients with eGFR &gt; 30 reduces progression to ESRD and death from renal or cardiovascular cause (Evidence: DAPA-CKD, CREEDENCE)</p> </li> <li> <p>Finerenone (non-steroidal MRA)- would ask nephrology for help if considering this option since relatively new and increased risk for hyperkalemia. (Evidence: FIDELIO)</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-approach-ckd/#dialysis-initiation","title":"Dialysis initiation","text":"<ul> <li> <p>Early (CKD3a or 3b) referral to nephrology has better outcomes</p> </li> <li> <p>Uremic symptoms: fatigue, sleep disturbance, N/V, decreased     appetite, dysgeusia, itching, hiccupping</p> </li> <li> <p>Refractory hyper K</p> </li> <li> <p>Refractory hypertension</p> </li> <li> <p>Plot your patient\u2019s eGFR using the graph function in EPIC or CPRS to     determine trajectory (normal age-related decline after age 60 is ~     1ml/min/m2)</p> </li> </ul>"},{"location":"nephrology/nephrology-hematuria/","title":"Hematuria","text":"<p>Laura Binari/Patrick Steadman</p>"},{"location":"nephrology/nephrology-hematuria/#background","title":"Background","text":"<ul> <li> <p>Definition: 3 urinalyses with three or more RBC/hpf; 1 urinalysis     with 100 RBC/hpf or gross hematuria (1 cc blood/L urine can induce     color change)</p> </li> <li> <p>Causes:</p> <ul> <li> <p>Can be transient (exercise-induced, menses, trauma)</p> </li> <li> <p>Concurrent pyuria/dysuria: consider urinary tract infection or     bladder malignancy</p> <ul> <li>Malignancy risk factors: male sex, age &gt; 50, smoking Hx,     exposures to benzene/aromatic amine, cyclophosphamide,     indwelling foreign body, pelvis irradiation, chronic UTIs, heavy     NSAID use, urologic disorders (nephrolithiasis, BPH)</li> </ul> </li> <li> <p>Recent URI: think infection related glomerulonephritis, IgA,     vasculitis, anti-GBM</p> </li> <li> <p>Positive Family Hx of Hematuria: consider PKD, Sickle Cell Disease</p> </li> <li> <p>Bleeding from other sites: think inherited/acquired bleeding     disorder, anticoagulation</p> </li> <li> <p>Unilateral Flank Pain: Ureteral calculus, renal malignancy, IgA     Nephropathy</p> </li> </ul> </li> </ul> Glomerular Extraglomerular (Non-Glomerular Source) Kidney <p>Ureter/</p> <p>Bladder</p> <p>Prostate/</p> <p>Urethra</p> Other <p>IgA Nephropathy</p> <p>IgA Vasculitis</p> Pyelo Cystitis BPH Exercise-Induced Lupus Nephritis Renal Cell Carcinoma Urothelial Malignancy Prostate Cancer Bleeding Diathesis Infection-related glomerulonephritis PKD Nephrolithiasis TURP Meds (AC) Anti-GBM Disease (Goodpasture\u2019s) <p>Sickle Cell</p> <p>Papillary Necrosis</p> Ureteral Stricture Urethritis (STI) Menses ANCA-associated Malignant HTN Hemorrhagic Cystitis (chemo/rads) <p>TB</p> <p>Schistoso-miasis</p> Genetic (Thin Basement Membrane Nephropathy/Alport Syndrome) <p>Arterial embolism</p> <p>Vein thrombus</p> Traumatic Foley/procedure <p>Evaluation</p> <ul> <li> <p>Step 1: Confirm the presence of hematuria</p> <ul> <li> <p>Dipstick positive heme: urinary RBCs (hematuria), free myoglobin or     free hemoglobin</p> </li> <li> <p>Centrifuge the urine</p> <ul> <li> <p>Red sediment -&gt; true hematuria (urinary RBCs)</p> </li> <li> <p>Red supernatant +</p> <ul> <li> <p>Positive dipstick: myoglobulin or hemoglobin</p> </li> <li> <p>Negative dipstick porphyria, Pyridium, beets, rhubarb, or     ingestion of food dyes</p> </li> </ul> </li> </ul> </li> </ul> </li> </ul> Glomerular Extraglomerular Color (if gross hematuria) Red, Cola, Smoky Red/Pink Clots Absent Present/Absent Proteinuria May be &gt;500 mg/day \\&lt;500 mg/day RBC morphology Dysmorphic RBCs present Normal (isomorphic) RBC casts May be present Absent <ul> <li> <p>Step 2: Determine if there is a GLOMERULAR or NON-GLOMERULAR source     of bleeding</p> <ul> <li> <p>Glomerular Bleeding:</p> <ul> <li> <p>Isolated Hematuria: Differential includes IgA Nephropathy, thin     BM dx, Alport\u2019s</p> </li> <li> <p>Nephritic syndrome (new proteinuria, pyuria, HTN, edema, rise in     Cr): post-infectious GN, MPGN, ANCA vasculitis, Goodpasture\u2019s,     lupus nephritis</p> </li> <li> <p>Workup: anti-GMB, anti-DNase/ASO, ANA, ANCA, C3, C4, cryo, Hep B     &amp; C, HIV</p> </li> <li> <p>Indications for Renal Biopsy: glomerular bleeding + risk factors     for progressive disease, including albuminuria &gt; 30 mg/day, new     hypertension &gt; 140/90 or significant elevation over baseline     BP, rise in serum creatinine</p> </li> </ul> </li> <li> <p>Extraglomerular Bleeding (Imaging Section)</p> <ul> <li> <p>If historical clues suggest nephrolithiasis, start with non-con     CT A/P</p> </li> <li> <p>Gross Hematuria otherwise should be evaluated with CT A/P w/ and     w/o contrast (CT urography); consult urology for cystoscopy     (often done as outpatient referral)</p> </li> <li> <p>If clots are passed, more likely to be secondary to lower     urinary source, and if a high burden of clots poses a risk of     obstruction (urologic emergency)</p> </li> <li> <p>If extraglomerular bleeding with clots: hematuria catheter needs     to be placed ASAP (2 valve catheter, 20-24 Fr (!); page urology     if nursing unable to obtain)</p> </li> </ul> </li> </ul> </li> <li> <p>CT Urography is more sensitive than IV pyelogram for renal masses     and stones.</p> </li> <li> <p>Prefer Renal and Bladder Ultrasound in pregnant patients</p> </li> <li> <p>All pts w/gross hematuria that is non-glomerular in source, in whom     infection has been ruled out, warrant cystoscopy. Additionally, all     patients with clots need cystoscopy</p> </li> </ul>"},{"location":"nephrology/nephrology-hypercalcemia/","title":"Hypercalcemia","text":"<p>Rebecca Choudhry and Trevor Stevens</p>"},{"location":"nephrology/nephrology-hypercalcemia/#background","title":"Background","text":"<ul> <li> <p>Total serum Calcium &gt;10.5</p> </li> <li> <p>Most (99%) Ca+2 is anhydrous and stored in bone. The remaining 1% is     60% bound (mostly to albumin), and 40% ionized and able to exert a     physiologic effect</p> </li> <li> <p>Remember, there is an inverse relationship between pH and Ca2+. As     pH declines, serum Ca increases due to H+ binding to albumin and     releasing Ca2+</p> </li> <li> <p>Don\u2019t forget to correct calcium level if hypoalbuminemia (or check     ionized calcium level),</p> <ul> <li> <p>Corrected Ca2+ = ((Normal albumin \u2013 Patient\u2019s albumin) x 0.8)) +     Patient\u2019s Ca2+</p> <ul> <li>This equation Is less reliable at very low albumin</li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypercalcemia/#presentation","title":"Presentation","text":"<ul> <li> <p>Ca+2 &gt; 12 can cause shortened QT interval, 2nd and 3rd degree heart     block, ventricular arrhythmias, and ST elevations mimicking MI</p> </li> <li> <p>Severe manifestations uncommon at Ca+2 \\&lt;14</p> </li> <li> <p>\u201cStones, bones, thrones, belly groans, and psychiatric overtones\u201d</p> <ul> <li> <p>Bone pain</p> </li> <li> <p>Polydipsia/polyuria- due to nephrogenic DI</p> </li> <li> <p>Nausea/constipation</p> </li> <li> <p>Depressed mood/cognitive impairment</p> </li> <li> <p>Decreased level of consciousness</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypercalcemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Measure PTH</p> <ul> <li> <p>Normal or \u2191 PTH</p> <ul> <li> <p>Primary hyperparathyroidism: \u2191 Ca+2 and \u2193 PO4-3</p> </li> <li> <p>Tertiary hyperparathyroidism (autologous secretion of PTH in     CKD/ESRD)</p> </li> <li> <p>Familial hypercalciuric hypercalcemia (often asymptomatic, no     treatment required).</p> </li> <li> <p>Li toxicity</p> </li> </ul> </li> <li> <p>\u2193 PTH</p> <ul> <li> <p>Humoral hypercalcemia of malignancy (PTHrP)</p> </li> <li> <p>Malignancy (boney metastases)</p> </li> <li> <p>Excess vitamin D intake</p> </li> <li> <p>Granulomatous disease: 1,25 dihydroxy vitamin D, 25     hydroxyvitamin D, or ACE level</p> </li> <li> <p>Milk-alkali syndrome</p> </li> <li> <p>Medications (classically HCTZ)</p> </li> <li> <p>Thyrotoxicosis</p> </li> <li> <p>Adrenal insufficiency</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypercalcemia/#management","title":"Management","text":"<ul> <li> <p>If Ca+2 \\&lt; 12 and asymptomatic</p> <ul> <li> <p>Encourage PO hydration</p> </li> <li> <p>Normal saline if hypovolemic</p> </li> <li> <p>Evaluate for underlying cause</p> </li> </ul> </li> <li> <p>If Ca+2 &gt; 12 with symptoms or Ca &gt; 14</p> <ul> <li> <p>Trend Ca q8 hrs, EKG, monitor on telemetry; strict I/Os \u00b1 foley     catheter</p> </li> <li> <p>Volume expansion w/ NS bolus followed by continuous infusion at ~     200cc/hr</p> <ul> <li>Goal UOP 100-150cc/hr</li> </ul> </li> <li> <p>Add loop diuretic (Lasix) once patient is volume expanded</p> </li> <li> <p>Bisphosphonates</p> <ul> <li>Zoledronic acid 4mg IV (EGFR &gt;60), Pamidronate 90mg IV (EGFR     15-60)</li> </ul> </li> </ul> </li> <li> <p>If Ca+2 &gt;14 or neurologic symptoms, consider subq (not intranasal)     calcitonin</p> <ul> <li> <p>VUMC: requires approval from an oncology or endocrine attending</p> </li> <li> <p>Tachyphylaxis after ~48H</p> </li> </ul> </li> <li> <p>Additional Information</p> <ul> <li> <p>In CHF pt, consider early addition of a loop diuretic, especially if     volume overloaded</p> </li> <li> <p>In ESRD pt with hypercalcemia (rare), patient with oliguric AKI not     responsive to IVF, or pt with severely elevated Ca 16-18, consult     endocrine and nephrology early</p> </li> <li> <p>In pts with sarcoidosis or lymphoma, consider glucocorticoids</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hyperkalemia/","title":"Hyperkalemia","text":"<p>Mengyao Tang and Amanda Morrison</p>"},{"location":"nephrology/nephrology-hyperkalemia/#background","title":"Background","text":"<ul> <li> <p>Causes:</p> <ul> <li> <p>Cellular shifts: Acidemia, Rhabdomyolysis, TLS, beta blockade</p> </li> <li> <p>Aldosterone deficient states: T4 RTA, Primary adrenal insufficiency</p> </li> <li> <p>Decreased distal tubular delivery: Volume depletion</p> </li> <li> <p>Decreased clearance: AKI, CKD, ESRD</p> </li> <li> <p>Excessive intake</p> </li> <li> <p>Medication-related: ACEi, ARB, MRA, NSAIDs, TMP/SMX, digoxin,     heparin</p> </li> </ul> </li> <li> <p>Pseudo-Hyperkalemia: hemolysis, severe leukocytosis</p> </li> <li> <p>Symptoms are rare, but usually manifest as cardiac dysrhythmias</p> </li> </ul>"},{"location":"nephrology/nephrology-hyperkalemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Confirm hyperkalemia with repeat BMP</p> </li> <li> <p>Check EKG for hyperkalemic changes (sensitivity for EKG findings in     hyper K is poor)</p> <ul> <li> <p>K+ 5.5-6.5: peaked T waves, prolonged PR interval</p> </li> <li> <p>K+ 6.5-8: prolonged QRS, loss of P wave, ST elevation, ectopic beats</p> </li> <li> <p>K+ &gt;8: sine wave pattern, asystole, PEA, VF</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hyperkalemia/#management","title":"Management","text":"<ul> <li> <p>If EKG changes or signs of instability</p> <ul> <li> <p>Calcium gluconate 1g IV (effective within 3-5 min)</p> <ul> <li> <p>Stabilizes cardiac membrane for ~60mins</p> </li> <li> <p>SHOULD BE REPEATED HOURLY while hyperkalemic</p> </li> </ul> </li> </ul> </li> <li> <p>Shift K+ (temporizing measures)</p> <ul> <li> <p>D50 w/ regular insulin 10 units (can order using Adult Hyperkalemia     order set in epic)</p> <ul> <li> <p>Use 5 units if there is renal impairment</p> </li> <li> <p>Lasts for 4-6hrs (can be longer in renal impairment)</p> </li> </ul> </li> </ul> </li> <li> <p>Correct acidosis- Consider using isotonic bicarb</p> </li> <li> <p>Beta Agonists (e.g. high-dose albuterol nebulizer); lasts 2-4 hrs</p> <ul> <li>Note that typical albuterol nebulizer is 2.5mg, need 10-20mg to     have an effect</li> </ul> </li> <li> <p>Increase K+ Excretion</p> <ul> <li> <p>Loop diuretic- if the kidneys work, use them</p> <ul> <li>If there is AKI or a volume deficit can administer with IVF</li> </ul> </li> <li> <p>Volume expansion with IVF: Increases distal Na delivery and K     excretion. NS and LR are likely equally effective.</p> </li> <li> <p>GI cation exchangers</p> <ul> <li> <p>Kayexalate (Polystyrene sulfonate)- only effective if having     BMs. 60g PO q2h until bowel movement (If using oral, ensure     patient is having bowel movements and is not obstructed, could     cause bowel injury/ necrosis). PO can take up to 6hrs to work.     Consider per rectal administration for faster action but DO NOT     GIVE WITH SORBITOL per rectum</p> </li> <li> <p>Lokelma (Sodium-zirconium-cyclosilicate) 10 g PO TID for 48 H.     Actively exchanges K for other cations within the small bowel     and works within 2 hours. Remember to stop once the K is normal     since can cause hypokalemia. Also keep in mind the high Na     content of Lokelma (400mg/5g dose of lokelma)</p> <ul> <li>Needs approval from Nephrology</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Hemodialysis: Consult nephrology early if severe hyper K+</p> </li> </ul>"},{"location":"nephrology/nephrology-hypernatremia/","title":"Hypernatremia","text":"<p>Lauren Chan</p>"},{"location":"nephrology/nephrology-hypernatremia/#overview-of-dysnatremias","title":"Overview of dysnatremias","text":"<ul> <li> <p>Fluctuations in serum Na reflect fluctuations in plasma free water</p> </li> <li> <p>Sodium is the major driver of tonicity. The clinical signs and     symptoms of serum Na fluctuations are related to changes in tonicity     with most profound effects on cerebral tissue</p> </li> <li> <p>Two major mechanisms maintain plasma osmolarity between 275 and 290:     Thirst and secretion of ADH. When these mechanisms malfunction,     dysnatremias occur</p> </li> </ul>"},{"location":"nephrology/nephrology-hypernatremia/#background","title":"Background","text":"<ul> <li> <p>Definition: Na+ &gt;145</p> </li> <li> <p>Hypernatremia = decreased free water</p> </li> <li> <p>Almost always due to inadequate free water intake (ICU patients,     dementia, limited mobility, tube feeding/TPN, impaired     thirst/adipsia from hypothalamic stroke). Hospital acquired     hypernatremia is iatrogenic and correlates with poor outcomes</p> </li> <li> <p>Can also occur from: Na+ overload (salt poisoning, iatrogenic from     NS infusion, over correction), osmotic diuresis (hyperglycemia,     SGLT-2 inhibitors, urea, mannitol), diabetes insipidus</p> </li> </ul>"},{"location":"nephrology/nephrology-hypernatremia/#presentation","title":"Presentation","text":"<ul> <li> <p>Lethargy, irritability, confusion</p> </li> <li> <p>Seizures, coma, hemorrhagic stroke, or subarachnoid hemorrhage (from     the effects of hypertonic serum on cerebral vasculature)</p> </li> </ul>"},{"location":"nephrology/nephrology-hypernatremia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Step 1: Treat underlying cause (vomiting, hyperglycemia,     medications)</p> </li> <li> <p>Step 2: Determine volume status: If severely hypovolemic, the     patient will need IV crystalloid to restore volume in addition to     free water</p> </li> <li> <p>Step 3: Estimate and replace free water deficit (FWD):</p> <ul> <li>FWD = TBW x [(serum Na/140) - 1]</li> </ul> </li> <li> <p>Step 4: Account for ongoing insensible losses and electrolyte free     water clearance</p> <ul> <li> <p>Rule of thumb for accounting for electrolyte free water clearance. This is in addition to replacing free water deficit</p> <ul> <li> <p>0-1 Liter of urine output: Ignore, no need to replace</p> </li> <li> <p>1-3 Liters of urine output: Replace half of the losses</p> </li> <li> <p>&gt;3 liters of urine output: Replace all urine losses</p> </li> </ul> </li> </ul> </li> <li> <p>No evidence that overcorrecting hypernatremia is harmful. In fact,     there is increased mortality with overly cautious correction or     under correction</p> </li> <li> <p>If able, replace free water enterally. Otherwise, administer D5W     intravenously</p> </li> </ul>"},{"location":"nephrology/nephrology-hypernatremia/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Pts w/ suspected DI: Consult Nephrology (may require desmopressin or     may receive desmopressin once stabilized to differentiate between     central and nephrogenic DI)</p> </li> <li> <p>Pts with hypokalemia: giving K decreases total amount of free water     you are giving the pt</p> </li> </ul>"},{"location":"nephrology/nephrology-hyperphosphatemia/","title":"Hyperphosphatemia","text":"<p>Peter Thorne and Amanda Morrison</p>"},{"location":"nephrology/nephrology-hyperphosphatemia/#background","title":"Background","text":"<ul> <li> <p>Phosphate (PO4-3) &gt;4.5mg/dL</p> </li> <li> <p>Etiologies:</p> <ul> <li> <p>Cellular shifts: Cellular lysis (TLS, Rhabdomyolysis), Acidemia</p> </li> <li> <p>Increased intake/absorption or iatrogenic hyperphosphatemia (Over     repletion, Vitamin D toxicity, use of Fleet\u2019s enemas, etc.)</p> </li> <li> <p>Decreased phosphate clearance (Acute or chronic renal disease,     hypoparathyroidism, pseudohypoparathyroidism)</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hyperphosphatemia/#presentation","title":"Presentation","text":"<ul> <li> <p>Symptoms are usually secondary to coexistent hypocalcemia     (psychosis, seizure, perioral paresthesia\u2019s, muscle weakness)</p> </li> <li> <p>Can cause acute phosphate nephropathy with phosphate containing     laxatives</p> </li> <li> <p>Calciphylaxis if concurrent hypercalcemia (high Ca+2 x PO4-3product)</p> </li> </ul>"},{"location":"nephrology/nephrology-hyperphosphatemia/#evaluation","title":"Evaluation","text":"<ul> <li>Labs: BMP (calcium, creatinine), VBG, Vit D, PTH, PTHrP, lactate</li> </ul>"},{"location":"nephrology/nephrology-hyperphosphatemia/#management","title":"Management","text":"<ul> <li> <p>Acute</p> <ul> <li> <p>If renal function normal, can often treat with IVF (promote PO4-3     excretion)</p> </li> <li> <p>Consider need for calcium supplementation (see hypocalcemia section)</p> </li> <li> <p>If renal function impaired and severe hypocalcemia present =     consider hemodialysis</p> </li> </ul> </li> <li> <p>Chronic</p> <ul> <li> <p>Usually secondary to chronic renal failure, goal PO4-3 3.5-5.5 in     CKD patients</p> </li> <li> <p>Renal diet (low PO4-3)</p> </li> <li> <p>PO4-3 binders: Ca+2 containing (calcium carbonate and calcium     acetate) and non Ca+2 containing (sevelamer, lanthanum, and iron     based such as ferric citrate)</p> <ul> <li> <p>Sevelamer is significantly more expensive than calcium     containing binders</p> <ul> <li> <p>Given 3 times daily with meals, started at 800mg (Can be \u2191     to 1,600mg TID)</p> </li> <li> <p>Should not be given if pt is not eating</p> </li> </ul> </li> <li> <p>Calcium acetate: started at 1334mg TID with meals</p> </li> </ul> </li> <li> <p>Limit dose changes to chronic binders upon discharge</p> </li> <li> <p>Need to avoid calcium containing binders in patients with     calciphylaxis</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypocalcemia/","title":"Hypocalcemia","text":"<p>Trey Richardson</p>"},{"location":"nephrology/nephrology-hypocalcemia/#background","title":"Background","text":"<ul> <li> <p>Can be divided into low parathyroid hormone and high parathyroid     hormone states</p> </li> <li> <p>Low PTH</p> <ul> <li> <p>Magnesium deficiency</p> </li> <li> <p>Post-operative for parathyroidectomy</p> </li> <li> <p>DiGeorge syndrome</p> </li> <li> <p>Medications: Bisphosphonates, denosumab, aminoglycosides,       gadolinium</p> </li> <li> <p>Acidemia (Serum Ca is inversely proportional to pH)</p> </li> <li> <p>Infiltrative disease: sarcoid, hemochromatosis, malignancies</p> </li> <li> <p>Autoimmune hypoparathyroidism</p> </li> <li> <p>CRRT (if using regional citrate anticoagulation)</p> </li> </ul> </li> <li> <p>High PTH</p> <ul> <li> <p>Late-stage CKD</p> </li> <li> <p>Hyperphosphatemia</p> </li> <li> <p>Vitamin D deficiency</p> </li> <li> <p>Pseudohypoparathyroidism/Parathyroid resistance</p> </li> <li> <p>Consumption/deposition: Pancreatitis, rhabdomyolysis, some       osteoblastic metastases</p> </li> <li> <p>Sepsis or critical illness</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypocalcemia/#presentation","title":"Presentation","text":"<ul> <li> <p>Chvostek and Trousseau\u2019s signs, laryngospasm, seizures, widened QRS     and arrhythmias</p> </li> <li> <p>Hemodynamic instability</p> </li> </ul>"},{"location":"nephrology/nephrology-hypocalcemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Check PTH, albumin, iCal, VBG, Vitamin D</p> </li> <li> <p>Review medications for possible offenders</p> </li> </ul>"},{"location":"nephrology/nephrology-hypocalcemia/#management","title":"Management","text":"<ul> <li> <p>Under most circumstances there is no need to replace calcium.     Instead, focus on correcting the underlying perturbation (e.g.     acidemia, hypomagnesemia, treating pancreatitis, etc. )</p> </li> <li> <p>If hemodynamic instability, cardiac electrical instability, seizures     then aggressive intravenous replacement is warranted.</p> <ul> <li> <p>Also consider preemptive repletion for patients requiring     high-volume of blood transfusions (citrate in blood products can     cause hypocalcemia)</p> </li> <li> <p>1 g of CaCl is equivalent to 3 grams of Ca Gluconate</p> </li> </ul> </li> <li> <p>Avoid treatment in hyperphosphatemia, advanced CKD/ESRD, and rhabdomyolysis</p> </li> </ul>"},{"location":"nephrology/nephrology-hypokalemia/","title":"Hypokalemia","text":"<p>Peter Thorne and Patrick Steadman</p>"},{"location":"nephrology/nephrology-hypokalemia/#background","title":"Background","text":"<ul> <li> <p>Potassium (K+) \\&lt; 3.5 mEq/L</p> </li> <li> <p>98% of total body K+ is intracellular (majority in muscle cells)</p> </li> <li> <p>Goal: prevent life threatening complication (e.g. arrhythmia),     replace deficit, elucidate cause</p> </li> <li> <p>Insulin and catecholamines (Beta adrenoreceptors) are key drivers of     transcellular shifts</p> </li> <li> <p>H+ and K+ will trade places to maintain electroneutrality</p> </li> </ul>"},{"location":"nephrology/nephrology-hypokalemia/#presentation","title":"Presentation","text":"<ul> <li> <p>Malaise, weakness, myalgias, decreased gastrointestinal motility</p> </li> <li> <p>EKG changes:</p> <ul> <li> <p>Mild: ST segment depression, decreased T wave amplitude</p> </li> <li> <p>Severe: U-waves (most commonly seen in precordial leads V2 and V3)</p> </li> </ul> </li> <li> <p>Severe hypokalemia can lead to rhabdomyolysis</p> </li> </ul>"},{"location":"nephrology/nephrology-hypokalemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>History: decreased K+ intake, increased entry into cells (ex:     elevated beta-adrenergic activity, hypothermia), GI losses, urinary     losses (diuretics, hypomagnesemia, RTA, tubular defects,     hyperaldosteronism)</p> </li> <li> <p>If concomitant metabolic alkalosis: Normal/low BP suggests diuretic     use, vomiting or Gitelman/Bartter syndromes</p> </li> <li> <p>Hypertension suggests renovascular disease or primary     mineralocorticoid excess</p> </li> <li> <p>Labs: BMP, CBC, VBG, urine electrolytes, magnesium, POC glucose, CK.     Possibly aldosterone, renin, cortisol pending clinical context</p> </li> <li> <p>Imaging: Renal US, CT AP</p> </li> </ul>"},{"location":"nephrology/nephrology-hypokalemia/#management","title":"Management","text":"<ul> <li> <p>Check Mg+2, replete to 2; Give empirically while waiting for serum     Mg+2</p> </li> <li> <p>K+ preparation (route); replete to 4</p> </li> <li> <p>Choice of agent:</p> <ul> <li> <p>KCl is used for repletion in the hospital</p> <ul> <li> <p>PO tablets for mild asymptomatic hypokalemia</p> </li> <li> <p>IV can be given through peripheral (rate is 10mEq/hr, may have     burning sensation) or central access</p> </li> </ul> </li> <li> <p>K+ bicarbonate can be dissolved and put through G tube</p> <ul> <li>Useful in pts with hypokalemia and metabolic acidosis</li> </ul> </li> </ul> </li> <li> <p>Dose:</p> <ul> <li> <p>Normal renal function: 10 mEq K+ is expected to raise serum [K+]     by 0.1 mEq/L</p> </li> <li> <p>Significant CKD or AKI: at risk of overcorrection</p> <ul> <li> <p>Shortcut: multiply the mEq by the Cr = how much K+ expected to     rise</p> </li> <li> <p>Once K+ higher than 5.5, K+ increases much faster and rules     above do not apply</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypomagnesemia/","title":"Hypomagnesemia","text":"<p>Mike Tozier</p>"},{"location":"nephrology/nephrology-hypomagnesemia/#background","title":"Background","text":"<ul> <li> <p>Definition: Mg2+ \\&lt; 1.8 mg/dL, most pts asymptomatic until \\&lt;1.2     mg/dL. Severe [Mg+2] \\&lt; 1 mg/dL</p> </li> <li> <p>Causes:</p> <ul> <li> <p>GI losses: Diarrhea, malabsorption, acute pancreatitis, EtOH use,     TPN, vomiting, NG suction, GI fistulas, anorexia, short gut     syndrome, small bowel bypass</p> </li> <li> <p>Drugs: PPIs, loop diuretics, thiazides, digoxin, amphotericin,     aminoglycosides, foscarnet, cisplatin, calcineurin inhibitors,     laxatives, pentamidine</p> </li> <li> <p>Kidney losses: post-ATN diuresis, Bartter syndrome and Gitelman     syndrome</p> </li> <li> <p>Cellular shifts: DKA treatment/recovery, refeeding, hungry bone     syndrome, correction of metabolic acidosis, pancreatitis, EtOH     withdrawal</p> </li> <li> <p>Other: DM, hyper Ca, hyperthyroid, hyperaldosteronism, burns,     lactation, Vit D deficiency, heat, prolonged exercise, mitral valve     prolapse, pseudohypomagnesemia 2/2 EDTA tube, lactation</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypomagnesemia/#presentation","title":"Presentation","text":"<ul> <li> <p>Refractory hypocalcemia or hypokalemia, arrhythmias, muscle weakness</p> </li> <li> <p>Severe symptoms: seizures, drowsiness, confusion, coma, arrhythmias</p> </li> <li> <p>Vertical nystagmus, tetany (Chvostek sign, Trousseau), tremors,     fasciculations</p> </li> </ul>"},{"location":"nephrology/nephrology-hypomagnesemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>EKG: Initially wide QRS, peaked Ts. Progresses to wide PR,     diminished T, arrhythmias</p> </li> <li> <p>Labs: Ca+2, K+, can use FEMg (order urine Mg+2 and Cr, serum Cr and     Mg) or 24-hour urine for Mg to distinguish renal vs GI etiology     (FEMg&gt;2% renal, \\&lt;2% GI)</p> </li> </ul>"},{"location":"nephrology/nephrology-hypomagnesemia/#management","title":"Management","text":"<ul> <li> <p>Correct underlying cause, replete based on severity (Dosing below     for normal GFR)</p> </li> <li> <p>Oral: asymptomatic pts, can cause GI symptoms, not well absorbed</p> <ul> <li> <p>Sustained release (Mg Chloride or Mg L-lactate) better tolerated and     absorbed, though standard preparations (Mg oxide) are faster acting</p> </li> <li> <p>Mg chloride: 3-4 tabs BID (total 30 to 56 meq [15 to 28 mmol]) for     severe hypo Mg</p> </li> <li> <p>2-4 tabs daily (total 10 to 28 meq [5 to 14 mmol]) for mild hypo     Mg</p> </li> <li> <p>Mg oxide: 400-800 mg BID (20 to 40 mmol [40 to 80 meq]) for     mod-severe hypo Mg</p> </li> </ul> </li> <li> <p>Intravenous: for symptomatic patients or if GI intolerance to oral</p> <ul> <li> <p>Mg \\&lt;1 mg/dL: 4 to 8g of MgSO4 (32 to 64 meq [16 to 32 mmol]) over     12 to 24 hrs</p> </li> <li> <p>Mg 1 to 1.5 mg/dL: 4 g MgSO4 (16 to 32 meq [8 to 16 mmol]) over 4     to 12 hrs</p> </li> <li> <p>Mg 1.6 to 1.9 give 1 to 2 grams MgSO4 (8 to 16 meq [4 to 8 mmol])     1-2 hrs</p> <ul> <li>VUMC only has 4g bags of IV mag so would need to ask nurses to     only infuse \u00bd bag</li> </ul> </li> <li> <p>Infusion rate should not exceed 2 g/hr to minimize urinary excretion</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypomagnesemia/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Renal impairment: replete with caution, reduce dose by 50-75% and     monitor closely</p> </li> <li> <p>If persistent hypo Mg in pts requiring diuresis, try K-sparing     diuretic (e.g. Amiloride)</p> </li> <li> <p>Treat concomitant hypokalemia, hypocalcemia or hypophosphatemia</p> </li> <li> <p>In pts with concomitant hypophos and hypocalcemia, IV Mg alone -&gt;     worse hypophos</p> </li> </ul>"},{"location":"nephrology/nephrology-hyponatremia/","title":"Hyponatremia","text":"<p>Lauren Chan</p>"},{"location":"nephrology/nephrology-hyponatremia/#background","title":"Background","text":"<ul> <li> <p>Definition:</p> <ul> <li> <p>Mild: Na+ 130-134</p> </li> <li> <p>Moderate: Na+ 125-129</p> </li> <li> <p>Severe: Na+ \\&lt;125</p> </li> </ul> </li> <li> <p>Hyponatremia occurs when free water reabsorption (i.e. ADH is on) or     intake exceeds free water excretion</p> </li> </ul>"},{"location":"nephrology/nephrology-hyponatremia/#presentation","title":"Presentation","text":"<ul> <li> <p>Mild to moderate symptoms: lethargy, N/V, dizziness, confusion,     fatigue, cramping</p> </li> <li> <p>Severe symptoms: obtundation, coma, respiratory arrest, seizure</p> </li> </ul>"},{"location":"nephrology/nephrology-hyponatremia/#evaluation-and-management","title":"Evaluation and Management","text":"<ul> <li> <p>Step 1: Serum osm\u00a0</p> <ul> <li> <p>&gt;295: Hyper-osmolar, presence of other molecules that contribute to     serum osmolarity\u00a0</p> <ul> <li> <p>Glucose, mannitol, iodinated contrast</p> </li> <li> <p>If hyperglycemic, corrected serum Na+ = measured Na+ +     1.6*[(glucose \u2013 100)/100]\u00a0\u00a0</p> <ul> <li> <p>If corrected Na+ is normal, treat hyperglycemia; not a water     balance problem\u00a0</p> </li> <li> <p>If corrected Na+ is low, there is hypotonic hyponatremia +     coexisting hyperglycemia\u00a0</p> </li> </ul> </li> <li> <p>Renal failure (urea) and ethanol: Ineffective osmoles that can     freely diffuse across cells and do NOT lead to hyponatremia</p> </li> </ul> </li> <li> <p>275-295: Iso-osmolar\u00a0</p> <ul> <li>Pseudohyponatremia 2/2 hypertriglyceridemia, paraproteinemia, or     lipoprotein X: Serum Na not actually low, due to how the lab is     calculated\u00a0</li> </ul> </li> <li> <p>\\&lt;275: Hypo-osmolar \u00e0 Step 2\u00a0</p> </li> </ul> </li> <li> <p>Step 2: Urine Osm</p> <ul> <li> <p>Surrogate for ADH activity</p> </li> <li> <p>Uosm \\&lt;100 or Uosm \\&lt; Sosm correlates with low ADH</p> <ul> <li> <p>Primary polydipsia: Free water intake&gt;output \u00a0</p> </li> <li> <p>Tea and toast: Lack solute to effectively concentrate urine\u00a0</p> </li> <li> <p>Beer drinkers\u2019 potomania: Mixture of the two above</p> </li> </ul> </li> <li> <p>Uosm &gt;100 or Uosm &gt; Sosm correlates with high ADH Step 3\u00a0</p> </li> </ul> </li> <li> <p>Step 3: Urine Na</p> <ul> <li> <p>Is ADH on in the setting of decreased effective arterial bloodvolume     (EABV) or decreased mean arterial pressure (i.e. appropriate ADH)?</p> </li> <li> <p>UNa \\&lt;20: Low EABV \u00e0 RAAS upregulation w/ Na avidity-&gt; appropriate     ADH release</p> <ul> <li> <p>If true volume depletion, then trial 500cc-1L NS bolus and     monitor serum Na. IVF bolus-&gt;Increase EABV \u00e0 \u2193 ADH release \u00e0 \u2191     free water excretion</p> </li> <li> <p>If edematous state (e.g. heart failure or cirrhosis), then     decongestion with diuretics may improve serum Na</p> </li> </ul> </li> <li> <p>UNa\u00a0&gt;40: Euvolemic with no stimulus for ADH-&gt; SIADH</p> <ul> <li> <p>SIADH from: n/v, malignancy, meds, surgery, pulmonary disease,     hormones, pain, bladder distension: \u2191 ADH out of proportion to     stimulus\u00a0\u00a0</p> <ul> <li> <p>Treat with water restriction. Can add NaCl or urea tabs if     fluid restriction is severe\u00a0</p> </li> <li> <p>Water restriction (L/day) = 600 / uosm\u00a0(600 mEq Na in     American diet/day)</p> </li> <li> <p>Salt wasting: diuretics, cerebral salt wasting (aka     hypovolemic SIADH), SSRIs</p> </li> <li> <p>Other: Hypothyroidism, adrenal insufficiency\u00a0</p> </li> </ul> </li> </ul> </li> </ul> </li> <li> <p>If still stumped, can check a FeNa and measure a serum uric acid</p> <ul> <li> <p>FeNa \\&lt;0.5 % suggests appropriate ADH activity.</p> </li> <li> <p>High uric acid suggests some degree of volume depletion and     appropriate ADH activity.</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hyponatremia/#rate-of-correction","title":"Rate of correction","text":"<ul> <li> <p>Acute (\\&lt;48 hrs)</p> <ul> <li> <p>If symptomatic, give 150 cc bolus 3% NaCl up to two times.</p> </li> <li> <p>Monitor Na+ q1-2 hr</p> </li> <li> <p>Goal is an initial rapid 4-6 mEq/L correction and then hold</p> <ul> <li>May require Hypertonic Saline infusion with DDAVP clamp if at     risk of over-correcting</li> </ul> </li> </ul> </li> <li> <p>Chronic (&gt;48 hrs or unknown, higher risk for osmotic demyelination     if corrected too quickly):</p> <ul> <li>Goal Na+ correction rate 4-6 mEq/L over 24 hrs (Max 8mEq/L)</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hyponatremia/#when-to-call-nephrology","title":"When to call Nephrology","text":"<ul> <li> <p>If you are worried about rapid over-correction:</p> <ul> <li> <p>High risk patients are those with rapidly reversible causes</p> <ul> <li> <p>Low solute states (Beer drinker\u2019s potomania, psychogenic     polydipsia, tea-toast)- as soon as they decrease their excess     free water intake, they will rapidly clear free water</p> </li> <li> <p>Volume depletion- as volume is replaced and the stimulus for ADH     release is switched off, then they will rapidly clear the excess     free water if they have normal underlying kidney function</p> </li> </ul> </li> <li> <p>High risk for ODS includes: chronic liver disease, Na \\&lt;105 meq/dL,     alcoholism, and malnutrition.</p> </li> </ul> </li> <li> <p>Consideration of DDAVP clamp</p> </li> </ul>"},{"location":"nephrology/nephrology-hypophosphatemia/","title":"Hypophosphatemia","text":"<p>Peter Thorne</p>"},{"location":"nephrology/nephrology-hypophosphatemia/#background","title":"Background","text":"<ul> <li> <p>Required for metabolic pathways (ATP production!)</p> </li> <li> <p>Most renal reabsorption occurs in proximal tubule via     sodium-phosphate cotransporter</p> </li> <li> <p>Common causes</p> <ul> <li> <p>Internal redistribution, reduced intestinal absorption</p> </li> <li> <p>Refeeding syndrome</p> </li> <li> <p>Alkalemia</p> </li> <li> <p>Phos binders on purpose or inadvertently (calcium, aluminum,     magnesium antacids)</p> </li> <li> <p>Excessive loss (diarrhea, CRRT, increased urinary excretion)</p> </li> <li> <p>Proximal tubular dysfunction such as in Fanconi Syndrome</p> </li> <li> <p>Hyperparathyroidism causes renal phos wasting</p> </li> <li> <p>Post-parathyroidectomy leading to hungry bone syndrome</p> </li> <li> <p>Vitamin D deficiency or resistance</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypophosphatemia/#presentation","title":"Presentation","text":"<ul> <li> <p>Mild Hypophosphatemia (serum &gt;2.0) rarely symptomatic</p> </li> <li> <p>PO4-3\\&lt; 2.0: Muscle weakness</p> </li> <li> <p>PO4-3\\&lt; 1.0: Heart failure, respiratory failure, rhabdomyolysis,     seizures</p> </li> <li> <p>Failure to wean from ventilator</p> </li> </ul>"},{"location":"nephrology/nephrology-hypophosphatemia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Urine PO4-3 level if cause not readily apparent</p> </li> <li> <p>Calculate Fe PO4-3 ([U PO4-3 x PCr x 100]/[P PO4-3x UCr])</p> <ul> <li> <p>Fe PO4-3 \\&lt; 5% = normal renal response to hypophos: redistribution     or \u2193 absorption</p> </li> <li> <p>Fe PO4-3 &gt; 5% = renal phos wasting</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-hypophosphatemia/#management","title":"Management","text":"<ul> <li> <p>Caution replacing in pts with impaired renal function: start with     half suggested dose</p> </li> <li> <p>If K+ &gt; 4 and patient requires IV repletion, may need to use sodium     PO4-3 in place of K+ PO4-3 IV; po preferred unless severe or     symptomatic, or patient cannot take po</p> <ul> <li> <p>K-Phos neutral: oral, each 250mg tablet has 8 mmol of PO4-3 and     1.1mEq of K+</p> </li> <li> <p>K+ PO4-3: IV, each mL has 3mmol PO4-3, 4.4 meq K+</p> </li> <li> <p>Na+ PO4-3: IV, each mL has 3mmol PO4-3</p> </li> </ul> </li> <li> <p>PO4-3&gt;1.5: PO: 40 \u2013 80 mmol K+Phos neutral (aim for 1 mmol/kg)     divided into 3-4 doses/day</p> </li> <li> <p>PO4-3 1.25 - 1.5: oral 100 mmol K+ PO4-3neutral in 3-4 divided doses     if asymptomatic</p> <ul> <li>IV: 30 mmol K+ PO4-3over 6 hours (aim for 0.4mmol/kg) if symptomatic</li> </ul> </li> <li> <p>PO4-3\\&lt;1.25: IV: 80mmol K+Phos over approximately 12 hours (aim for     0.5mmol/kg)</p> <ul> <li>Check serum PO4-3 2-12 hrs after last dose of PO4-3 to determine if     additional needs</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-intravenous-fluids/","title":"Intravenous Fluids","text":"<p>Chandler Montgomery</p>"},{"location":"nephrology/nephrology-intravenous-fluids/#indications-for-intravenous-fluid","title":"Indications for intravenous fluid","text":"<ul> <li> <p>Restoration or maintenance of tissue perfusion</p> </li> <li> <p>Correction of electrolyte abnormalities</p> </li> <li> <p>Nutritional supplementation in those without reliable enteric access</p> </li> </ul>"},{"location":"nephrology/nephrology-intravenous-fluids/#categorized-into-crystalloids-and-colloids","title":"Categorized into crystalloids and colloids","text":"<ul> <li> <p>Crystalloid = water + electrolytes</p> </li> <li> <p>Colloid = water + proteins/large molecules</p> </li> </ul>"},{"location":"nephrology/nephrology-intravenous-fluids/#terms","title":"Terms","text":"<ul> <li> <p>Osmolarity: osmoles of solute per L of solution</p> </li> <li> <p>Tonicity: ability to induce movement of water across a membrane</p> </li> <li> <p>Buffer: anions such as lactate, acetate, gluconate which are     metabolized to bicarbonate in vivo with the goal of sustaining     normal plasma pH</p> </li> </ul>"},{"location":"nephrology/nephrology-intravenous-fluids/#crystalloids","title":"Crystalloids","text":"<ul> <li>Isotonic fluids used for volume resuscitation</li> <li> <p>After ~ 30 mins, redistribute such that only 25% remains w/in       intravascular space</p> </li> <li> <p>Balanced solutions (ex: Lactated Ringer\u2019s, Plasma-Lyte)= have     electrolytes concentrations similar to plasma</p> </li> <li> <p>NS may lead to renal vasoconstriction, AKI, hemodynamic instability,     increased mortality</p> <ul> <li>SMART and SALT-ED: balanced solutions had lower rates of death,     new renal replacement therapy, or persistent renal dysfunction     compared to NS</li> </ul> </li> <li> <p>Situations where NS may be preferred:</p> <ul> <li> <p>Cerebral edema/traumatic brain injury</p> </li> <li> <p>Hypovolemic hyponatremia</p> </li> <li> <p>Pre-existing hypochloremic metabolic alkalosis (e.g. after     vomiting or over diuresis)</p> </li> </ul> </li> <li> <p>Notes on LR</p> <ul> <li> <p>The small amount of K in LR (~4 mEq/L) is unlikely to     significantly exacerbate hyperkalemia</p> </li> <li> <p>Lactate in LR is sodium lactate. No hydrogen ions are being     added to plasma</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-intravenous-fluids/#common-crystalloid-solutions","title":"Common crystalloid solutions:","text":"Fluid Na Cl K Ca Mg Glucose Buffer Osmolarity Tonicity Plasma ~140 ~100 ~4 ~2.4 1.0 ~0.85 Bicarb ~24 ~290 NA Normal 0.9% saline 154 154 0 0 0 0 0 308 Isotonic Lactated Ringer\u2019s 130 109 4.0 2.7 0 0 Lactate 28 273 Isotonic <p>Plasma-Lyte/</p> <p>Normosol</p> 140 98 5.0 0 3.0 0 <p>Gluconate 23</p> <p>Acetate 27</p> 295 Isotonic D5W + 150 mEq HCO3- 150 0 0 0 0 50 Bicarb 150 300 Isotonic 3% Saline 513 513 0 0 0 0 0 1026 Hypertonic D5W 0 0 0 0 0 50 0 252 Hypotonic"},{"location":"nephrology/nephrology-intravenous-fluids/#colloids","title":"Colloids","text":"<ul> <li> <p>Albumin: extracted from human plasma</p> </li> <li> <p>5% - Used after plasma exchange</p> </li> <li> <p>25% - raises oncotic pressure and restore intravascular volume</p> <ul> <li> <p>Uses: Post-LVP, diagnosis and treatment of hepatorenal syndrome,     SBP (see Hepatology)</p> </li> <li> <p>Evidence base for use outside of above indications is poor (SAFE     trial)</p> </li> </ul> </li> <li> <p>Blood Products: Packed RBCs, FFP, cryoprecipitate, etc</p> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/","title":"Renal Replacement Therapy (RRT) Basics","text":"<p>Daniel Motta-Calderon </p>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#backgroundterminology","title":"Background/Terminology","text":"<ul> <li> <p>Dialysis (diffusive clearance)- solutes diffuse down     concentration gradients through a semipermeable membrane separating     blood and dialysate</p> </li> <li> <p>Dialysate (dialysis bath)- electrolyte solution used to create     concentration gradient for dialysis. Customizable to treat specific     electrolyte and acid-base derangements</p> </li> <li> <p>Effluent- Fluid removed during dialysis or ultrafiltration</p> </li> <li> <p>Ultrafiltration- Hydrostatic pressure \u201cpushing\u201d water through a     membrane. There is no dialysate solution used during     ultrafiltration. Solutes are removed through the process of solvent     drag. The effluent in this case is isotonic to plasma</p> </li> <li> <p>Total ultrafiltration (UF) - overall ultrafiltration volume     produced during treatment</p> </li> <li> <p>UF net - net ultrafiltrate volume removed from the patient by     the machine. The overall volume can be completely replaced (net     even), partially replaced, or not replaced at all. UF net is the     difference between UF and the volume replaced in the circuit</p> </li> <li> <p>Timing of dialysis- There are several studies in this space     (IDEAL, IDEAL-ICU, AKIKI, STARRT, ELAINE). In both the outpatient     and the inpatient setting, there is no compelling evidence that     early start dialysis improves mortality compared to later starts</p> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#outpatient-modalities","title":"Outpatient Modalities","text":"<ul> <li> <p>Intermittent hemodialysis (iHD)</p> </li> <li> <p>In home hemodialysis</p> </li> <li> <p>Peritoneal dialysis</p> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#if-someone-with-esrd-is-admitted","title":"If someone with ESRD is admitted:","text":"<ul> <li> <p>Urgent ESRD consult if acute need, otherwise can consult them     routinely</p> </li> <li> <p>Routine orders include MWF phos checks and a renal diet</p> </li> <li> <p>For peritoneal dialysis pts, their diet can be more liberal and     include low phos only or even regular diet (Can just ask what diet     he/she follows at home)</p> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#acute-setting","title":"Acute Setting","text":"<ul> <li> <p>Indications: AKI leading to life-threatening changes in fluid,     electrolyte, and acid-base balance or toxic ingestion [AEIOU]</p> <ul> <li> <p>Acidosis: Severe metabolic acidosis (serum pH\\&lt;7.1) refractory to correcting volume status or other electrolyte derangements</p> </li> <li> <p>Electrolytes: Severe hyperkalemia &gt;6.5 despite medical management     (e.g. loop diuretics, IV fluids, GI cation exchangers, correcting     acidemia, etc.)</p> </li> <li> <p>Intoxication: Dialyzable toxins and medications</p> <ul> <li> <p>Alcohols: ethylene glycol, methanol, isopropyl alcohol,     diethylene glycol, and propylene glycol</p> </li> <li> <p>Medications: lithium, salicylates, valproic acid, phenytoin,     barbiturates, carbamazepine, vancomycin, aminoglycosides, etc.</p> </li> </ul> </li> <li> <p>Overload: Severe fluid overload (e.g., pulmonary edema) refractory     to diuretics</p> </li> <li> <p>Uremia: Uremic complications: encephalopathy, pericarditis, platelet     dysfunction</p> </li> </ul> </li> <li> <p>Can perform furosemide stress test to help predict who is likely to     recover their kidney function</p> <ul> <li> <p>If Lasix na\u00efve, administer 1mg/kg as a bolus. If on a loop diuretic,     administer 1.5 mg/kg as a bolus</p> </li> <li> <p>If within the hour they have made 200 cc of urine, then they are     likely to regain kidney function</p> </li> </ul> </li> <li> <p>Modalities</p> <ul> <li> <p>iHD: Ideal for removal of toxins (e.g. alcohols, dialyzable meds).     Use with caution in hypotensive patients</p> </li> <li> <p>CRRT: Set a rate of volume removal (typically 0-200 cc/hr) less rapid fluid/electrolytes shifts -&gt; better tolerated in patients with hemodynamic instability</p> <ul> <li>Anti-coagulation options- to prevent clotting of circuit<ul> <li>None</li> <li>Heparin (preferred). Can be either within the circuit or systemic if indicated for another reason (e.g. DVT/PE).</li> <li>Citrate (need to monitor calcium frequently)</li> </ul> </li> <li>Complications of CRRT: Infections, hypophosphatemia</li> </ul> </li> </ul> </li> <li> <p>Access</p> <ul> <li> <p>Dialysis catheter (aka: Vascath)</p> <ul> <li> <p>Non-tunneled catheter (Trialysis) used for acute dialysis</p> </li> <li> <p>Different lengths depending on site (see procedures section)</p> </li> </ul> </li> <li> <p>Tunneled dialysis catheter (ex: Permcath)</p> <ul> <li> <p>Typically used as a bridge to fistula/graft placement</p> </li> <li> <p>Placed by IR</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#peritoneal-dialysis-peritonitis","title":"Peritoneal Dialysis Peritonitis","text":""},{"location":"nephrology/nephrology-renal-replacement-therapy/#background","title":"Background","text":"<ul> <li> <p>Typically occurs due to contamination with pathogenic skin bacteria     during exchanges or due to exit-site/tunnel infection</p> </li> <li> <p>Usually presents with cloudy effluent fluid and abdominal pain. Can     also be asymptomatic</p> </li> <li> <p>Important history to obtain: recent contamination, accidental     disconnection, endoscopic or gynecologic procedure, as well as the     presence of constipation or diarrhea</p> </li> <li> <p>Definitive diagnosis requires 2 of the following:</p> <ul> <li> <p>Clinical features consistent with peritonitis</p> </li> <li> <p>Positive dialysis effluent culture</p> </li> <li> <p>Dialysis effluent with WBC &gt; 100 with PMN &gt; 50%</p> <ul> <li>Even if WBC count \\&lt; 100, presence of &gt; 50% PMNs is still     strong evidence of peritonitis in pts with rapid cycle PD</li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Examine catheter exit site</p> </li> <li> <p>Culture peritoneal fluid (requires specific technique, done by     nephrology)</p> </li> <li> <p>Peritoneal cell count with diff, gram stain and culture</p> </li> <li> <p>Obtain peripheral blood cultures if there is concern for sepsis</p> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#management","title":"Management","text":"<ul> <li> <p>All PD orders, intraperitoneal antibiotics, and prescription     adjustments should be directed by ESRD consult service (page them     overnight if concerns)</p> </li> <li> <p>Treatment with intraperitoneal antibiotics should be started     immediately after specimens have been obtained if there is high     clinical suspicion</p> </li> <li> <p>Empiric antibiotics regimen should cover both gram-positive and     gram-negative organisms, typically with vancomycin and third     generation Cephalosporin</p> </li> <li> <p>Systemic antibiotics are generally not necessary unless pts have     systemic signs of sepsis</p> </li> <li> <p>Pts with relapsing, recurrent or repeat peritonitis will likely need     catheter removal</p> </li> </ul>"},{"location":"nephrology/nephrology-renal-replacement-therapy/#secondary-prevention","title":"Secondary prevention","text":"<ul> <li> <p>Treatment with intraperitoneal OR IV antibiotics (for any infection     requiring &gt; 1 dose of antibiotics) requires prophylaxis for fungal     peritonitis with either:</p> <ul> <li> <p>Nystatin\u00a0400,000 to 500,000 units orally TID</p> </li> <li> <p>Fluconazole\u00a0200 mg every other day or 100 mg qdaily</p> </li> </ul> </li> <li> <p>Dialysate should be drained the day of endoscopies or gynecological     procedures</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-aki/","title":"Acute Kidney Injury of Kidney Transplant","text":""},{"location":"nephrology/nephrology-transplant-aki/#background","title":"Background","text":"<ul> <li>Most patients admitted to medicine services with kidney transplants     are &gt;3 months post-op. Therefore, we are typically not managing     perioperative complications such as delayed graft function, or     hyper-acute rejection. Below are the most common causes of acute     kidney injury in kidney transplant recipients.</li> </ul>"},{"location":"nephrology/nephrology-transplant-aki/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Signs and symptoms of UTI?</p> </li> <li> <p>Assess volume status</p> </li> <li> <p>Review meds for recent medication changes</p> <ul> <li> <p>Common offenders: NSAIDs, ACE, diuretics, azole antifungals</p> </li> <li> <p>Medication non-adherence</p> </li> </ul> </li> <li> <p>Tacrolimus (FK) or cyclosporine (CsA) level</p> <ul> <li> <p>FK levels increase with n/v, diarrhea due to alterations in     p-glycoprotein expression within inflamed GI tract</p> </li> <li> <p>FK toxicity also causes diarrhea and volume depletion</p> </li> </ul> </li> <li> <p>Proteinuria:</p> <ul> <li>Transplant patients with 1 g/day proteinuria usually get biopsies</li> </ul> </li> <li> <p>Review donor characteristics (CMV status, PRA, % HLA antibodies     present, DSAs)</p> </li> <li> <p>BK PCR: consider only if unclear source of AKI and no recent titers</p> <ul> <li>Serum PCR is test of choice</li> </ul> </li> <li> <p>Renal transplant U/S (costly and not always warranted)</p> <ul> <li> <p>\\&lt; 1 week post-transplant: If acute graft dysfunction, look for     thrombosis, urine/ureter leak</p> </li> <li> <p>&gt; 1 week post-transplant:</p> <ul> <li> <p>Cr does not respond to 48 hours of current management</p> </li> <li> <p>Lack of clear, reversible causes</p> </li> <li> <p>Hydronephrosis (can occur after stent removal 4-6 wks after     transplant or due to perinephric fluid collection)</p> </li> <li> <p>Arterial stenosis (\u2191 velocities in renal artery -- very     concerning when velocity &gt;300), tardus parvus waveforms)</p> </li> <li> <p>Perinephric abscess with recurrent UTI/pyelonephritis</p> </li> <li> <p>Urinoma (usually first 2-3 weeks), hematoma (after a biopsy)</p> </li> </ul> </li> <li> <p>Unique findings:</p> <ul> <li>Resistive indices: reflect central renal vascular compliance.     High indices in transplant patients signify parenchymal problem     (rejection, infection, ATN)</li> </ul> </li> </ul> </li> <li> <p>Biopsy</p> <ul> <li> <p>To differentiate ATN vs rejection vs BK nephropathy vs recurrent         disease (FSGS, lupus, etc.)</p> </li> <li> <p>Post Biopsy Care:</p> <ul> <li> <p>Watch for bleeding and HTN</p> </li> <li> <p>Blood can get into collecting system, then the capsule, and into     the perinephric space causing Page Kidney (aka Pressure     Tamponade)</p> </li> <li> <p>Compressed renal vessels-&gt; RAAS surge --&gt; rapid, severe     HTN (STAT page the renal fellow)</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/","title":"Kidney Transplant Medicine","text":"<p>Trey Richardson</p>"},{"location":"nephrology/nephrology-transplant-medicine/#introduction","title":"Introduction","text":"<ul> <li>The goal of this section is to serve as a guide for tackling the     most common transplant complications as well as offer a few tips for     managing immunosuppression while kidney transplant patients are     admitted to the hospital</li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#alphabet-soup","title":"Alphabet soup","text":"<ul> <li> <p>PRA: panel reactive antibodies</p> </li> <li> <p>DSA: donor specific antibodies</p> </li> <li> <p>CMV (-/+): indicates the CMV status of both the recipient and the     donor</p> </li> <li> <p>FK506 or FK: another name for tacrolimus</p> </li> <li> <p>KDPI: Kidney donor profile index used to \u201cgrade\u201d the quality of the     donated organ</p> </li> <li> <p>X/6 MM: indicates the number of HLA subtypes that are mismatched     between donor and recipient</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#infections-in-kidney-transplant-recipients","title":"Infections in Kidney Transplant Recipients","text":""},{"location":"nephrology/nephrology-transplant-medicine/#background","title":"Background","text":"<ul> <li> <p>Infections in a kidney transplant recipient can be divided into 3     phases:</p> </li> <li> <p>\\&lt;1-month post-transplant</p> <ul> <li>Surgical site infections, nosocomial infections (e.g. C. Diff,       CAUTIs, and CLABSIs), and donor-derived infections/reactivation       of latent recipient infections predominate</li> </ul> </li> <li> <p>1-6 months post-transplant</p> <ul> <li>Depleted immune-system regenerates increased risk for       disseminated fungal (e.g. PJP, histo/blasto) and viral       infections (HSV, adenovirus)</li> </ul> </li> <li> <p>&gt;6 months post-transplant</p> <ul> <li>Risk for atypical infections persists, but common community       acquired syndromes should still be on the differential</li> </ul> </li> <li> <p>This section will focus on the most common infection in kidney     transplant recipients- infections of the urinary tract</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#evaluation","title":"Evaluation","text":"<ul> <li> <p>UA with culture\u00a0</p> </li> <li> <p>Examine the native kidneys (CVA tenderness) AND the allograft     (almost always in RLQ, denervated so the graft itself will not be     tender, but the surrounding soft-tissue may)</p> </li> <li> <p>Renal U/S (of both allograft and native kidneys) or CT AP if:</p> <ul> <li> <p>Early post-op (1 month)</p> </li> <li> <p>Recurrent (2+ episodes in year)</p> </li> <li> <p>History of nephrolithiasis or if sepsis/bacteremia</p> </li> </ul> </li> <li> <p>Blood cultures if systemic signs/symptoms</p> </li> <li> <p>Consider testing for C. urealyticum, and sending fungal and AFB     urine cultures if UA is recurrently positive but culture negative</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#management","title":"Management","text":"<ul> <li> <p>Remove or replace indwelling catheters</p> </li> <li> <p>Review prior culture susceptibilities (if available)</p> </li> <li> <p>Empiric antibiotic regimens:</p> <ul> <li> <p>Asymptomatic bacteriuria: treat with FQ or beta lactam for 5-7 days     if \\&lt;3 mos post-transplant</p> </li> <li> <p>Simple cystitis: Fluoroquinolones (ciprofloxacin 250 BID or Levaquin     500 mg daily), Augmentin (500 mg BID), 3rd gen cephalosporin     (cefpodoxime 100 mg BID or cefixime 400 mg daily) or nitrofurantoin     100 mg BID (if GFR&gt;30, only treats cystitis since drug only     concentrates in the urine)</p> <ul> <li> <p>\\&lt; 6 mos post-transplant: treat for 10-14 days</p> </li> <li> <p>&gt;6 mos post-transplant: treat for 5-7 days</p> </li> </ul> </li> <li> <p>Complicated UTI/Pyelonephritis (cover Pseudomonas, gram negatives     and Enterococcus): Ceftriaxone 2g daily (preferred), Cefepime 2g     q8hrs (add Vancomycin when using cephalosporin if suspicious for     enterococcus) or Pip-tazo 3.75g q6hrs, can also use meropenem 1g q8h     (need ID approval)</p> <ul> <li> <p>Treat for 14-21 days</p> </li> <li> <p>For stable pts with mild complicated UTI, can consider giving     more narrow empiric antibiotics: Augmentin 875 mg BID or     ciprofloxacin 500 mg q12h</p> </li> </ul> </li> <li> <p>MDR UTI: Consult transplant ID</p> <ul> <li>Options: meropenem-vaborbactam, ceftolozone-tazobactam,     ceftazidime-avibactam</li> </ul> </li> <li> <p>In pts w/PCKD, include lipophilic antibiotic (such as ciprofloxacin)     to penetrate cysts</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#prevention","title":"Prevention","text":"<ul> <li> <p>Bactrim used for PJP prophylaxis during first 6 mos post-transplant     also prevents UTIs</p> </li> <li> <p>Basic infection prevention measures for all comers (e.g. hydration,     frequent voiding, wiping front to back, voiding after sexual     intercourse)</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#rejection-see-kidney-transplant-rejection-section","title":"Rejection - See Kidney Transplant Rejection section","text":""},{"location":"nephrology/nephrology-transplant-medicine/#aki-see-aki-of-kidney-transplant-section","title":"AKI - See AKI of Kidney Transplant Section","text":""},{"location":"nephrology/nephrology-transplant-medicine/#kidney-transplant-immunosuppression","title":"Kidney Transplant Immunosuppression","text":""},{"location":"nephrology/nephrology-transplant-medicine/#background_1","title":"Background","text":"<ul> <li> <p>Most patients with kidney transplants are on triple therapy with an     anti-metabolite (azathioprine or mycophenolate compound) or mTOR     inhibitor + calcineurin inhibitor + prednisone</p> </li> <li> <p>You may also come across patients who are on monthly infusions with     belatacept, a selective T-cell co-stimulation blocker</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#calcineurin-inhibitors","title":"Calcineurin inhibitors","text":"<ul> <li> <p>Tacrolimus (FK), cyclosporine (CsA)</p> </li> <li> <p>Envarsus XR is a once a day long acting formulation of tacrolimus</p> <ul> <li> <p>Common side-effects</p> <ul> <li> <p>Worsening kidney function: mediated by vasoconstriction to the     afferent arterioles</p> </li> <li> <p>Hypertension- treat with CCBs</p> </li> <li> <p>Diabetes</p> </li> <li> <p>Hand tremors, headache, nausea</p> </li> <li> <p>Thrombotic microangiopathy</p> </li> <li> <p>T4 RTA- hyperkalemia</p> </li> <li> <p>Gingival hyperplasia</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#mtor-inhibitors","title":"mTOR Inhibitors","text":"<ul> <li> <p>Sirolimus, everolimus</p> <ul> <li>Major side effects: Poor wound healing, rarely pneumonitis</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#anti-metabolites","title":"Anti-metabolites","text":"<ul> <li> <p>Azathioprine</p> </li> <li> <p>Mycophenolate preparations: Mycophenolate mofetil (Cellcept, MMF),     Mycophenolic acid (Myfortic)</p> </li> <li> <p>Side effects: Bone marrow suppression- hold for lymphopenia; GI     upset- hold for diarrhea</p> </li> </ul>"},{"location":"nephrology/nephrology-transplant-medicine/#additional-information-for-overnight-admits","title":"Additional Information for Overnight Admits:","text":"<ul> <li> <p>Do not change immunosuppression</p> <ul> <li>Exception: If pt has severe diarrhea, can hold night tacro dose and inform the day team</li> </ul> </li> <li> <p>Daily tacrolimus or cyclosporine level (order qam at 5:00). Always     order tacrolimus or cyclosporine dose at 6:00 am and 6:00 pm     (regardless of what time patient takes at home, lab can only run am     tacro levels at a certain time in batches)</p> <ul> <li>EXCEPTION: If late afternoon admission, consider paging the fellow     (since its early) and ask if they want the evening dose held until     the am level comes back</li> </ul> </li> <li> <p>Transplant patients with normal kidney function can have regular     diet</p> </li> </ul>"},{"location":"nephrology/nephrology-ua/","title":"Approach to Urinalysis","text":"<p>Laura Binari, Patrick Steadman</p>"},{"location":"nephrology/nephrology-ua/#background","title":"Background","text":"<ul> <li> <p>3 components: Gross Evaluation, Dipstick Analysis, Microscopic Exam</p> </li> <li> <p>Indications: dysuria, gross hematuria, fever + GU symptoms, AKI,     volume overload</p> </li> <li> <p>If Foley, obtain sample from catheter, not the urine bag</p> </li> <li> <p>Spinning Urine</p> <ul> <li> <p>At VUMC, take sample to lab on 4th floor to centrifuge the sample at     1500 rpm for 5 minutes, remove supernatant and then resuspend     sediment, place drops of urine on the slide, examine with microscope</p> </li> <li> <p>At the VA, there is a microscopy room where you can spin urine as     well</p> </li> <li> <p>Ideally, the specimen should be a fresh catch (\\&lt;2-4 hours old);     Beware: casts like to migrate to the edges of the coverslip!</p> </li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-ua/#gross-evaluation","title":"Gross Evaluation","text":"<ul> <li> <p>Turbid: Infection, precipitated crystals, or chyluria</p> </li> <li> <p>Color: Red Urine (broad DDx, see Hematuria section, includes certain     meds such as rifampin/phenytoin), White (polyuria, phosphate     crystals), Green (methylene blue), Pink (uric acid crystals,     post-propofol infusion), Black (hemoglobinuria/myoglobinuria)</p> </li> </ul>"},{"location":"nephrology/nephrology-ua/#dipstick-analysis","title":"Dipstick Analysis","text":"<ul> <li> <p>Quality of sample: should have zero squamous epithelial cells</p> <ul> <li> <p>Specific gravity: normal = 1.010</p> </li> <li> <p>Surrogate for urine osmolality &amp; hydration: can have falsely high     specific gravity if large particles (contrast, glucose) present</p> </li> <li> <p>Trick: Last 2 digits of S.G. x 30 = Uosm. For example: S.G. is     1.013; 13 x 30 = 390 mOsm/L</p> </li> </ul> </li> <li> <p>Urinary pH: normal pH is 5.5-6.5</p> <ul> <li> <p>Alkaline pH: bicarb suppl, vegan diet, urease producing organisms     (staghorn calculi)</p> </li> <li> <p>Acidic pH: uric acid stones, appropriate response to acidemia</p> </li> </ul> </li> <li> <p>Proteinuria: dipstick detects albumin ONLY (not paraproteins)</p> <ul> <li> <p>Mild albuminuria (30-300 mg/day) not detected by standard dipsticks</p> </li> <li> <p>F/u with spot protein to Cr ratio or 24 hr urine collection     (nephrotic range &gt;3.5 g/day)</p> </li> <li> <p>Transient: due to volume depletion, CHF, fever, postural,     exercise-induced</p> </li> <li> <p>Ddx: primary glomerular dx, secondary glomerular dx (DM, amyloid,     infxn, sickle cell, etc.) vs tubular vs overflow (multiple myeloma)</p> </li> </ul> </li> <li> <p>Heme (see hematuria section): False(+) if semen, false(-) w/     ascorbic acid</p> </li> <li> <p>WBC:</p> <ul> <li> <p>False(+) 2/2 contamination with squamous cells. If bacteria -&gt;     consider UTI/pyelo w/hematuria -&gt; inflammation; May have sterile     pyuria</p> </li> <li> <p>Ddx includes chlamydia, ureaplasma, TB, malignancy, viral infxn,     kidney stones, GN, urethritis, steroid, cyclophosphamide use</p> </li> </ul> </li> <li> <p>Ketones:</p> <ul> <li> <p>Never normal in urine; only detects acetic acid</p> </li> <li> <p>Ddx: DKA, starvation ketoacidosis, pregnancy, keto diet</p> </li> </ul> </li> <li> <p>Glucose: max threshold at proximal tubule exceeded (~serum glucose     180 mg/dL)</p> <ul> <li>DM, Cushing\u2019s, liver/pancreatic dx, SGLT2i use; or a primary defect     of proximal reabsorption (w/phosphaturia, uricosuria, amino aciduria     think Fanconi syndrome)</li> </ul> </li> <li> <p>Leukocyte esterase: enzyme released by lysed neutrophils,     macrophages</p> <ul> <li>Associated with pyuria and infections; false(-) from hematuria or     glucosuria</li> </ul> </li> <li> <p>Nitrites: reduction of urinary nitrates by nitrate reductase</p> <ul> <li>Certain bacteria (e.g. Enterobacteriaceae) express, others (e.g.     Enterococci) do not</li> </ul> </li> <li> <p>Bilirubin: conjugated = water soluble (passes through glomerulus),     unlike unconjugated</p> <ul> <li>Liver dysfunction and biliary obstruction</li> </ul> </li> <li> <p>Urobilinogen: end product of conjugated bilirubin, normally     ~1.0mg/dL is normal</p> <ul> <li>Can be elevated due to hepatocellular dx or hemolysis</li> </ul> </li> </ul>"},{"location":"nephrology/nephrology-ua/#microscopic-examination-of-the-urine-sediment","title":"Microscopic Examination of the Urine Sediment","text":"<ul> <li> <p>Cells:</p> <ul> <li>Dysmorphic RBCs (sign of GN), squamous epithelial cells     (contamination), tubular cells (abnormal, indicates renal dx),     neutrophils (UTI, AIN, TB, sterile pyuria), eosinophils (think AIN,     not sensitive thus cannot exclude diagnosis)</li> </ul> </li> <li> <p>Casts:</p> <ul> <li>Hyaline (pyelo; CKD, normal subjects), RBC (GN), WBC (GN, pyelo,     interstitial dx, inflammation), epithelial - renal tubular cells     (ATN, interstitial nephritis, nephritic sx, heavy metal ingestion),     granular or waxy (presence of kidney disease, but nonspecific),     muddy brown casts (ATN); fatty (nephrotic syndrome)</li> </ul> </li> <li> <p>Crystals:</p> <ul> <li> <p>Ca++ oxalate (envelope/dumbbell shape), uric acid (rhombic/rosette     shaped, classically formed in acidic urine), cystine (hexagonal,     found in cystinuria), Mg ++ ammonium phosphate (aka struvite stones,     from increased ammonia production, in setting of urease producing     bacteria such as Proteus or Klebsiella UTIs)</p> </li> <li> <p>Calcium oxalate crystals + AKI, consider ethylene glycol     intoxication</p> </li> <li> <p>Uric Acid crystals + AKI, consider tumor lysis syndrome</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-aidp/","title":"Acute Inflammatory Demyelinating Polyneuropathy (AIDP)","text":""},{"location":"neurology/neurology-aidp/#background","title":"Background","text":"<ul> <li> <p>Rapid onset polyneuropathy that manifests most often with ascending     weakness and numbness that can involve the respiratory and facial     musculature</p> </li> <li> <p>Usually preceded by infectious illness a few weeks prior</p> </li> <li> <p>Patients are much more likely to get AIDP from an infection than     any vaccine, weak vaccine links to AIDP are an addition 1-2 cases     per million flu vaccines.</p> </li> </ul>"},{"location":"neurology/neurology-aidp/#presentation","title":"Presentation","text":"<ul> <li> <p>Acute, progressive extremity weakness, weak or absent reflexes, and     potentially subjective sensatory changes, especially back pain</p> <ul> <li> <p>There are a TON of variants of AIDP, with some having cranial nerve     weakness early, proximal weakness, sensory ataxia, primarily sensory     loss, or rapid muscle weakness; do not use lack of classic ascending     weakness to dismiss the idea of AIDP</p> </li> <li> <p>Sensory loss is common in an ascending pattern too</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-aidp/#evaluation","title":"Evaluation","text":"<ul> <li> <p>LP \u2013 albuminocytologic dissociation = high protein with normal cell     count</p> <ul> <li>One exception is HIV, which can cause AIDP but also have a high cell     count and high protein count</li> </ul> </li> <li> <p>EMG/NCS</p> <ul> <li> <p>Demyelinating pattern (temporal dispersion and decreased conduction     velocities).</p> </li> <li> <p>This can be normal in the first few days, and is most useful 2+     weeks out if the diagnosis is still unclear</p> </li> </ul> </li> <li> <p>Differential diagnosis: spinal cord lesions, LEMS, MG, acute HIV or     HCV, viral myelitis (entero/West Nile)</p> </li> </ul>"},{"location":"neurology/neurology-aidp/#management","title":"Management","text":"<ul> <li> <p>ABCs! NIF at baseline then Q4-6 hours</p> <ul> <li>NIF \\&lt; -30 with good effort generally warrants ICU monitoring</li> </ul> </li> <li> <p>IVIG or PLEX</p> </li> <li> <p>Can get worse with steroids</p> </li> </ul>"},{"location":"neurology/neurology-als/","title":"Amyotrophic Lateral Sclerosis (ALS)","text":""},{"location":"neurology/neurology-als/#background","title":"Background","text":"<ul> <li> <p>Progressive weakness, often asymmetric and profound with no sensory     loss</p> </li> <li> <p>Combination of LMN and UMN findings</p> <ul> <li> <p>LMN findings: weakness, flaccidity, absent/decreased reflexes,     fasciculations</p> </li> <li> <p>UMN findings: weakness, spasticity, hyperreflexia, pathologic     reflexes (e.g. extensor plantar response), slow movements</p> </li> </ul> </li> <li> <p>Pts with bulbar symptoms may complain of difficulty swallowing,     changes in their voice, or increased saliva production (they just     aren\u2019t swallowing it)</p> </li> <li> <p>Tongue fasciculations are fairly uncommon in other disorders and is     a good clue for ALS if present (these can be hard to be certain of \u2013     tongue movements that are symmetric are typically not     fasciculations)</p> </li> <li> <p>Pseudobulbar affect \u2013 inappropriate laughing or crying; relatively     common in ALS</p> </li> <li> <p>FVC is an important marker for function</p> </li> </ul>"},{"location":"neurology/neurology-als/#evaluation","title":"Evaluation","text":"<ul> <li> <p>EMG/NCS is gold standard; El Escorial Criteria looks for evidence of     UMN and LMN findings at cranial, cervical, thoracic and lumbosacral     levels to determine if ALS or not</p> </li> <li> <p>Exclude mimicking lesions, which may be treatable (see below)</p> </li> </ul>"},{"location":"neurology/neurology-als/#management","title":"Management","text":"<ul> <li> <p>Patients with ALS are ideally treated with a multidisciplinary team     of Neurologists, Pulmonologists, Speech therapists, PT, OT and     mobility</p> </li> <li> <p>Two medications have been shown to add a few months to survival:</p> <ul> <li> <p>Riluzole - PO med; have to track CBC/LFTs. Side effects: GI and     general weakness</p> </li> <li> <p>Edaravone (Radicava) \u2013 IV, given daily for 2 weeks every month. SE =     HA, bruising</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-als/#mimics-of-als","title":"Mimics of ALS","text":"<ul> <li> <p>High cervical spine lesions \u2013UMN changes in upper extremity with LMN     pattern in LE</p> </li> <li> <p>Primary Lateral Sclerosis \u2013 UMN-only disease, much less common with     much slower progression. Many transition to ALS in the first 1-2     years, which then is likely a spectrum of the same disease</p> </li> <li> <p>Multifocal Motor Neuropathy \u2013 rare autoimmune disorder that looks     like ALS with LMN signs only, responds to IVIG. Can have anti-GM1 Ab     in blood. EMG/NCS pattern is different with conduction block</p> </li> <li> <p>Kennedy Disease \u2013 X-linked genetic disorder with progressive LMN     pattern of weakness and endocrine disorders w/androgen resistance     profile (gynecomastia, defective spermatogenesis)</p> </li> <li> <p>Inclusion Body Myositis \u2013 can be asymmetric with grip weakness and     quadriceps weakness. Biopsy and atrophy pattern usually     distinguishes it. CPK 500-800.</p> </li> <li> <p>Polymyositis/dermatomyositis \u2013 proximal weakness in arms/legs, CPK     &gt; 1000, usually younger onset (30-40s), no UMN signs</p> </li> </ul>"},{"location":"neurology/neurology-ams/","title":"Altered Mental Status (AMS)","text":""},{"location":"neurology/neurology-ams/#background","title":"Background","text":"<ul> <li> <p>Definition: Change in a patient\u2019s baseline cognition</p> <ul> <li>Can be hypoactive (lethargic) or hyperactive (agitated)</li> </ul> </li> <li> <p>Risk factors: Functional impairment, age &gt; 75, dementia,     depression, ETOH/substance use disorder, sensory impairment, recent     surgery</p> </li> </ul>"},{"location":"neurology/neurology-ams/#etiologies-consider-move-stupid-mnemonic","title":"Etiologies: Consider MOVE STUPID mnemonic","text":"<ul> <li> <p>Metabolic\u00a0(Hypo/hypernatremia, Hypercalcemia)</p> </li> <li> <p>Oxygen\u00a0(Hypoxia)</p> </li> <li> <p>Vascular\u00a0(CVA, Bleed, MI, CHF)</p> </li> <li> <p>Endocrine\u00a0(Hypoglycemia, Thyroid, Adrenal)</p> </li> <li> <p>Seizure\u00a0(postictal state)</p> </li> <li> <p>Trauma</p> </li> <li> <p>Uremia</p> </li> <li> <p>Psychiatric</p> </li> <li> <p>Infection</p> </li> <li> <p>Drugs \u2013\u00a0intoxication, withdrawal, or medications</p> </li> <li> <p>Delirium \u2013 see \u201cDelirium\u201d section in psychiatry</p> </li> </ul>"},{"location":"neurology/neurology-ams/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Consider broad toxic, metabolic, and infectious workup as     appropriate</p> <ul> <li>TSH, Vitamin B12, CBC, CMP, UA, CXR, VBG, blood Cx, glucose, UDS</li> </ul> </li> <li> <p>Review of medications</p> <ul> <li>Sedatives, anticholinergics, benzos/EtOH toxicity or withdrawal</li> </ul> </li> <li> <p>Head imaging in the setting of focal neurologic findings</p> <ul> <li> <p>Start with head CT \u2013 note strokes take up to 24 hours to show up on     CT</p> </li> <li> <p>Consider MRI if high concern for stroke, inflammatory changes or     infection</p> </li> </ul> </li> <li> <p>LP should be performed if there is any concern for meningitis</p> </li> <li> <p>EEG is reasonable with fluctuating mental status or seizure-like     activity</p> </li> </ul>"},{"location":"neurology/neurology-ams/#management","title":"Management","text":"<ul> <li> <p>Management of underlying etiology </p> </li> <li> <p>See \"Delirium\" in section in psychiatry for nonpharmacologic and pharmacologic management</p> </li> </ul>"},{"location":"neurology/neurology-basic-seizures/","title":"Seizure without Status Epilepticus","text":""},{"location":"neurology/neurology-basic-seizures/#background","title":"Background","text":"<ul> <li>Risk factors: birth trauma, prematurity, TBI with loss of     awareness &gt; 1 hour, strokes/tumors/abscesses, history of     meningitis/encephalitis</li> <li>Key for seizures: stereotyped event with sudden onset/offset<ul> <li>Generally, if full body systems are involved (e.g., jerking or     tonic activity, then there will also be loss of awareness)</li> </ul> </li> </ul>"},{"location":"neurology/neurology-basic-seizures/#evaluation","title":"Evaluation","text":"<ul> <li>A clear description or recording of seizure semiology is helpful</li> <li>Provoked seizures can develop with medications, hypo/hyperglycemia,     significant electrolyte abnormalities (e.g. hyponatremia), and CNS     infections</li> <li>EEG is necessary for spell capture</li> <li>MRI brain with and without contrast once stable</li> </ul>"},{"location":"neurology/neurology-basic-seizures/#management","title":"Management","text":"AED Side effects Levetiracetam (Keppra) (PO/IV) <p>Sedation and agitation, worsening of underlying mood disorders.</p> <p>Can trial B6 supplementation to help with mood effects</p> Valproic acid (Depakote) (PO/IV) Sedation, hirsutism, PCOS, P450 inhibitor, nausea, liver injury, hyperammonemia Phenytoin (Dilantin) (PO/Fosphenytoin IV) Sedation, gingival hyperplasia Lacosamide (Vimpat) (PO/IV) Heart block, dizziness, ataxia Topiramate (Topamax) (PO) Kidney stones, metabolic acidosis, paresthesias, weight loss, cognitive slowing Carbamazepine (Tegretol) (PO) Hyponatremia, SJS (in Han Chinese check HLA), bone marrow suppression (rare) Oxcarbazepine (Trileptal) (PO) Similar to carbamazepine Lamotrigine (Lamictal) (PO) SJS/TEN, nausea. Least sedating Zonisamide (Zonegran) (PO) Sedation, ataxia, nausea, confusion"},{"location":"neurology/neurology-basic-seizures/#non-epileptic-spells-aka-pnes-psychogenic-non-epileptic-spells","title":"Non-Epileptic Spells (aka PNES, psychogenic non-epileptic spells)","text":"<ul> <li> <p>Can be very difficult to distinguish from epileptic seizures</p> </li> <li> <p>Features more common in PNES</p> <ul> <li> <p>Retained awareness with bilateral extremity \u201cseizing\u201d</p> </li> <li> <p>Opisthotonus (arching the back)</p> </li> <li> <p>Talking during a spell</p> </li> <li> <p>Excessively long spells (e.g. lasts hour or days)</p> </li> <li> <p>Forced eye closure</p> </li> <li> <p>Coachability during a spell or reacting to external stimuli</p> </li> <li> <p>Heavy breathing during a spell with lots of rigorous movement</p> </li> <li> <p>Immediately returning to normal after a spell</p> </li> </ul> </li> <li> <p>Features more common in epileptic seizures:</p> <ul> <li> <p>Seizures arising out of sleep</p> </li> <li> <p>Highly stereotyped</p> </li> <li> <p>Incontinence</p> </li> <li> <p>Severe injuries (e.g. burns)</p> </li> </ul> </li> <li> <p>Management</p> <ul> <li> <p>Try to avoid excessive BZD use</p> </li> <li> <p>This requires good clinical judgement as you wouldn't want to     withhold Ativan and discover that the pt was having true atypical     seizures. The compromise would be: do not repeatedly administer BZDs     when there is suspicion for PNES as well as no evidence of response     to prior BZD administration.</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-basic-seizures/#syncopal-convulsions","title":"Syncopal Convulsions","text":"<ul> <li> <p>Very common, can present with posturing and tonic-clonic movements     happening for a few moments after syncope</p> <ul> <li> <p>Should not last for more than 30 seconds</p> </li> <li> <p>These are just related to syncope and do not typically require     seizure medications</p> </li> <li> <p>Workup:</p> <ul> <li> <p>Two-hour EEG and MRI (with and without contrast)</p> </li> <li> <p>Infectious workup, BMP, CBC, blood glucose, toxicology/drug     screen</p> </li> <li> <p>If there is concern for convulsive syncope, (carefully) check     orthostatic vitals</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-brain-masses/","title":"Brain Masses","text":""},{"location":"neurology/neurology-brain-masses/#background","title":"Background","text":"<ul> <li> <p>Neoplasm is the biggest concern</p> <ul> <li> <p>90% of malignant brain masses are metastatic</p> <ul> <li> <p>Most commonly: lung, RCC, breast, melanoma</p> </li> <li> <p>Highest bleeding risk: melanoma, thyroid, choriocarcinoma, RCC</p> </li> </ul> </li> <li> <p>Primary brain tumors</p> <ul> <li> <p>Gliomas: WHO Grade I-IV</p> <ul> <li> <p>Glioblastoma multiforme (GBM) \u2013 WHO Grade IV; large     heterogenous masses with edema; heterogenous contrast     enhancement; can cross the corpus callosum</p> </li> <li> <p>Lower grade gliomas \u2013 include oligodendrogliomas and     astrocytomas</p> </li> </ul> </li> <li> <p>Meningioma: usually low grade</p> <ul> <li> <p>Can be left alone and monitored with yearly MRI</p> </li> <li> <p>If symptomatic, may need resection/radiation</p> </li> </ul> </li> <li> <p>Ependymoma: uncommon. Can cause CSF outflow obstruction</p> </li> <li> <p>CNS lymphoma \u2013 diffuse WM involvement, with mass effect,     restricts diffusion on MRI with prominent contrast enhancement.     Can also cross the corpus callosum</p> <ul> <li>Usually B-cell, initially responds significantly to steroids</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-brain-masses/#presentation","title":"Presentation","text":"<ul> <li> <p>A significant number of brain lesions are detected incidentally</p> </li> <li> <p>If a patient has a first-time seizure, brain mass needs to be ruled     out</p> </li> <li> <p>HA (usually constant, severe), seizure, and focal neurologic     deficits</p> </li> </ul>"},{"location":"neurology/neurology-brain-masses/#evaluationmanagement","title":"Evaluation/Management","text":"<ul> <li> <p>Imaging: MRI w/ and w/o contrast provides the most information</p> <ul> <li>Findings suggesting malignant lesions: marked edema, multifocal     lesions, or presence at gray-white junctions</li> </ul> </li> <li> <p>LP may be indicated if herniation risk is low, particularly if     concerned for infection</p> </li> <li> <p>Biopsy will ultimately be needed in most cases, which is done by     NSGY</p> </li> </ul>"},{"location":"neurology/neurology-brain-masses/#management","title":"Management","text":"<ul> <li> <p>Work up for primary malignancy, CT C/A/P + PET</p> </li> <li> <p>Steroids are generally indicated for treatment of edema</p> <ul> <li>Decadron 10 mg IV to start; then transition to 4mg IV q6h with SSI</li> </ul> </li> <li> <p>Symptomatic tumors need eval by NSGY for resection consideration and     radiation oncology</p> </li> </ul>"},{"location":"neurology/neurology-elevated-icp-and-hydrocephalus/","title":"Elevated Intracranial Pressure (ICP) and Hydrocephalus","text":""},{"location":"neurology/neurology-elevated-icp-and-hydrocephalus/#background","title":"Background","text":"<ul> <li> <p>Communicating hydrocephalus (i.e. non-obstructive)</p> <ul> <li>Causes: subarachnoid granule scarring after subarachnoid hemorrhage     or meningitis, ependymoma producing excess CSF, venous sinus     thrombosis</li> </ul> </li> <li> <p>Non-communicating hydrocephalus (i.e. obstructive)</p> <ul> <li>Causes: tumor, abscess, or hematoma in the midline ventricular     structures</li> </ul> </li> <li> <p>Eventually, elevated ICP will cause brain herniation</p> </li> </ul>"},{"location":"neurology/neurology-elevated-icp-and-hydrocephalus/#presentation","title":"Presentation","text":"<ul> <li> <p>Headache, blurred vision, visual field reduction, enlarged blind     spot, nausea, vomiting, syncope, coma</p> </li> <li> <p>Sixth nerve palsies are common</p> </li> <li> <p>Third nerve palsies (blown pupil) are classically associated     with uncal herniation</p> </li> </ul>"},{"location":"neurology/neurology-elevated-icp-and-hydrocephalus/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Good visual exam: visual fields, enlarged blind spot, papilledema     (may not be present if very rapid ICP increase, even with vision     loss), and 6th nerve palsies</p> </li> <li> <p>Stat head CT to look for obstructions, mass lesions</p> <ul> <li>NSGY evaluation if obstructive lesion (removal vs ventricular drain)</li> </ul> </li> <li> <p>CTV or MRV to look for venous sinus thrombosis</p> <ul> <li>Venous sinus thrombosis needs AC, even if there is some degree of     hemorrhagic infarction</li> </ul> </li> <li> <p>If no obstructive lesion LP with opening pressure</p> <ul> <li>If workup is otherwise normal, except for elevated opening pressure     diagnosis = IIH</li> </ul> </li> </ul>"},{"location":"neurology/neurology-elevated-icp-and-hydrocephalus/#management","title":"Management","text":"<ul> <li> <p>Idiopathic intracranial hypertension (IIH)</p> <ul> <li> <p>Diamox and/or topiramate</p> </li> <li> <p>Ophthalmology evaluation emergently for consideration of nerve     sheath fenestrations or urgent VPS placement if severe disc edema</p> </li> <li> <p>If there is clinical concern for herniation:</p> <ul> <li> <p>Mannitol: 50g IV, can be given peripherally. Has risks of renal     injury</p> </li> <li> <p>Hypertonic saline: 3%, 7% or 23% saline can be given, needs     central access</p> </li> <li> <p>Maintain head of bed at least 30\u00b0 and loosen neck obstructions     (c-collars) as able</p> </li> <li> <p>NSGY consult for shunt consideration</p> </li> </ul> </li> <li> <p>Hyperventilation can be done with goal PaCO2 30-34 mm Hg or ETCO2     20-30 mmHg but is only a temporizing measure and risks rebound     edema</p> <ul> <li>After 4-6 hrs, compensatory pH changes in the blood prevent     vasoconstrictive affects</li> </ul> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-inpatient-headache/","title":"Inpatient Headache (HA)","text":""},{"location":"neurology/neurology-inpatient-headache/#background","title":"Background","text":"<ul> <li> <p>Important to distinguish primary and secondary headache</p> </li> <li> <p>Red flags for secondary headaches (SNOOPP): Systemic symptoms,     Neurologic symptoms, Onset that is sudden (thunderclap), Older age     (new headache &gt;40), Progression or evolution in previous headaches,     Postural component</p> </li> <li> <p>Other red flags: preceding trauma, headache awakening patient from     sleep, no headache-free intervals, thunderclap headache (maximal     intensity develops within 11 minutes or less)</p> </li> </ul>"},{"location":"neurology/neurology-inpatient-headache/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Get a good description of where the pain is, when, associated     symptoms, and assess for \u201cred flag\u201d features listed above</p> </li> <li> <p>If there are any red flag features imaging and workup are necessary</p> </li> <li> <p>Imaging depends on highest suspicions, but CTA head/neck is     appropriate to evaluate for aneurysm (including neck to consider     dissection). If any focal signs, MRI is generally preferred; venous     imaging can be beneficial in headaches with features of elevated ICP</p> </li> <li> <p>If no red flag features, then workup is not necessary, and focus is     on treatment</p> </li> </ul>"},{"location":"neurology/neurology-inpatient-headache/#management","title":"Management","text":"<ul> <li> <p>NSAIDs and Tylenol for infrequent headaches, but consistent use     (&gt;2-3 a week) runs the risk of rebound headaches</p> </li> <li> <p>Triptans for migraine, but contraindicated in patients with CAD,     uncontrolled HTN, previous stroke. They must be used within 6 hour     of onset</p> <ul> <li>There are theoretical concerns of serotonin syndrome when used with     SSRI/SNRIs</li> </ul> </li> <li> <p>Migraines:</p> <ul> <li> <p>\u201cMigraine cocktail\u201d: 1L fluid bolus, 4g Mg, IV Compazine(10mg) OR     Phenergan(20mg) with Benadryl (25mg)</p> </li> <li> <p>2nd line: Depakote 1000 mg IV, decadron 10mg IV , \u00b1     toradol 30mg IV, flexeril 10mg PO</p> </li> </ul> </li> <li> <p>Cluster headache:</p> <ul> <li>Triptans, high flow O2 (&gt;10 L), sometimes intranasal lidocaine if     no arrhythmia history</li> </ul> </li> </ul>"},{"location":"neurology/neurology-ms/","title":"Multiple Sclerosis","text":""},{"location":"neurology/neurology-ms/#background","title":"Background","text":"<ul> <li> <p>Progressive inflammatory disorder primarily manifesting with     demyelination of the central white matter</p> </li> <li> <p>Optic neuritis and transverse myelitis (spinal cord lesion) are     common presentations</p> </li> <li> <p>Generally develop over a few days; very uncommon to happen suddenly     (e.g., patients will complain about a dark spot appearing in their     vision that expands over several days)</p> </li> </ul>"},{"location":"neurology/neurology-ms/#evaluation","title":"Evaluation","text":"<ul> <li> <p>MRI w/ and w/o contrast can identify plaques and determine if they     are more acute</p> <ul> <li>\u201cActive\u201d MS plaque will enhance, and continues to for weeks (even     after treatment)</li> </ul> </li> <li> <p>Modified MacDonald Criteria: \u22653 characteristic demyelinating lesions     (&gt;1 cm, periventricular, infratentorial (brainstem/cerebellum/cord)     or juxtacortical in location) with evidence of separation in time     (active and chronic)</p> </li> <li> <p>LP with studies for oligoclonal bands, IgG index, cell count and     protein, anti-mog, anti-aqp4</p> </li> </ul>"},{"location":"neurology/neurology-ms/#management","title":"Management","text":"<ul> <li> <p>Treat flares and optic neuritis with steroids</p> <ul> <li> <p>Speeds up recovery, but does not improve the degree of recovery</p> </li> <li> <p>Often dosing starts with methylpred 1g</p> </li> </ul> </li> <li> <p>If a patient with known MS has worsening symptoms that are not new,     then recrudescence is the likely cause infectious/toxic/metabolic     workup and imaging is needed</p> </li> <li> <p>There are several long-term medications; common side effects listed     below:</p> <ul> <li> <p>Interferon (SQ injections) \u2013 flu-like symptoms, injection site     reactions</p> </li> <li> <p>Glatiramer acetate (SQ) \u2013 injection site reactions</p> </li> <li> <p>Fingolimod (PO) \u2013 macular edema, liver injury, increased risk of     skin cancer</p> </li> <li> <p>Teriflunomide (PO) \u2013 liver injury, hair loss, immunosuppression,     teratogenic</p> </li> <li> <p>Dimethyl fumarate (PO) \u2013 GI side effects, lymphocytopenia, liver     injury</p> </li> <li> <p>Natalizumab (IV) \u2013 PML concern, immunosuppression</p> </li> <li> <p>Ocrelizumab (IV) \u2013 contraindicated in active HBV infection, cannot     give live vaccines</p> </li> <li> <p>Alemtuzumab (IV) \u2013 autoimmune disease, rash, headache</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-ms/#neuromyelitis-optica-and-spectrum-disorder","title":"Neuromyelitis Optica and Spectrum Disorder","text":"<ul> <li> <p>Demyelinating disease due to Ab against aquaporin-4 (on     oligodendrocytes)</p> </li> <li> <p>Classically causes optic neuritis and longitudinally extensive     transverse myelitis</p> <ul> <li>Can be more aggressive than MS</li> </ul> </li> <li> <p>Diagnose with NMO antibodies and MS workup as above</p> </li> <li> <p>Treated with steroids, but in severe or refractory cases may require     PLEX</p> </li> </ul>"},{"location":"neurology/neurology-myasthenia-lambert-eaton/","title":"Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS)","text":""},{"location":"neurology/neurology-myasthenia-lambert-eaton/#background","title":"Background","text":"<ul> <li> <p>Disorders of the neuromuscular junction</p> </li> <li> <p>MG affects the post-synaptic cleft at the acetylcholine receptor</p> </li> <li> <p>LEMS affects the pre-synaptic cleft at the calcium channels</p> <ul> <li>Many cases are paraneoplastic (classically small cell lung     carcinoma)</li> </ul> </li> </ul>"},{"location":"neurology/neurology-myasthenia-lambert-eaton/#presentation","title":"Presentation","text":"<ul> <li> <p>Double vision, ptosis, dysarthria, dysphagia</p> </li> <li> <p>Dyspnea looks different than in other conditions: air hunger,     usually also with dysphagia</p> </li> <li> <p>Initially, the patient may not look sick or distressed, but may have     a short inspiratory time or difficulty speaking in complete     sentences due to shallow breathing</p> </li> <li> <p>Most pts have a known history of myasthenia, but up to 20% present     initially with crisis</p> </li> </ul>"},{"location":"neurology/neurology-myasthenia-lambert-eaton/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Exam</p> <ul> <li> <p>Look closely for ptosis, nasal speech, weak neck flexion/extension     (same nerve roots as diaphragm), interrupted speech to take extra     breaths</p> </li> <li> <p>These patients do not exhibit \u201chuffing and puffing\u201d like in     COPD/asthma exacerbations</p> <ul> <li>Patients with NMJ disease can go from talking to intubated     within several hours!</li> </ul> </li> <li> <p>LEMS: less ocular weakness, but do have extremity weakness and     absent reflexes.</p> </li> <li> <p>Pulmonary compromise is very rare in LEMS</p> </li> </ul> </li> <li> <p>EMG/NCS</p> <ul> <li> <p>MG: decremental response to repetitive stimulation</p> </li> <li> <p>LEMS: increased amplitude in response to repetitive stimulation</p> </li> </ul> </li> <li> <p>Labs</p> <ul> <li>Myasthenia antibody panels (send prior to IVIG/PLEX being given)</li> </ul> </li> <li> <p>Imaging</p> <ul> <li>Consider chest CT to look for thymic hyperplasia</li> </ul> </li> </ul>"},{"location":"neurology/neurology-myasthenia-lambert-eaton/#management","title":"Management","text":"<ul> <li> <p>Monitor NIF (negative inspiratory force) at baseline and q4h</p> <ul> <li> <p>Measure of diaphragmatic strength</p> </li> <li> <p>Normal is \\&lt;-60</p> </li> <li> <p>If below -30, consider elective intubation</p> </li> <li> <p>Note that patient effort will affect NIF values</p> </li> </ul> </li> <li> <p>IVIG or PLEX</p> <ul> <li> <p>Both have similar supportive evidence; IVIG is usually easier to do</p> </li> <li> <p>PLEX has the risks you would expect with dialysis (e.g. fluid     shifts) and coagulopathy</p> </li> <li> <p>IVIG -&gt; check IgA levels. Can increase risk of DVT, has risk of     aseptic meningitis and provides significant fluid load so not ideal     for pts with CHF</p> </li> </ul> </li> <li> <p>Steroids</p> <ul> <li> <p>Usually up-titrated SLOWLY (by 10-20 mg prednisone daily)</p> </li> <li> <p>Rapid increases in steroids can worsen patients with MG**, so talk     to neuro before adjusting**</p> </li> </ul> </li> <li> <p>Pyridostigmine</p> <ul> <li> <p>Typically continue at their home dose</p> </li> <li> <p>Too much pyridostigmine can make patients worse (more secretions),     so for those doing poorly on &gt;90 mg per dose, consider lowering the     dose</p> </li> </ul> </li> <li> <p>Treat underlying causes of exacerbations: usually infections or     other toxic/metabolic insults</p> </li> <li> <p>Remove/avoid exacerbating medications: fluoroquinolones,     aminoglycosides, beta blockers, and magnesium</p> </li> <li> <p>LEMS specific management:</p> <ul> <li> <p>3,4-diaminopyridine</p> </li> <li> <p>Can respond to IVIG or pyridostigmine</p> </li> <li> <p>Workup for underlying neoplasm</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-outpatient-headache/","title":"Outpatient Headache","text":"Type Presentation First line meds Tension type (most common) Generally bilateral, pressure/tightness, mild/moderate pain, no significant photophobia, phonophobia, or nausea Acetaminophen, TCAs, SNRIs Migraine <p>Unilateral, pulsating, moderate-to-severe pain, lasts 4-72hr, worse with activity and improves with sleep</p> <p>Associated with nausea, photophobia or phonophobia</p> <p>\u00b1 Aura</p> <p>Acute: triptans</p> <p>Preventive: TCAs, propranolol, topiramate, VPA</p> Cluster Severe, often extreme unilateral orbital/supra-orbital/temporal pain, often with lacrimation, rhinorrhea, sweating, swelling of face, visual changes Acute: 100% FiO2 at 12L/min for at least 15 mins, triptans, Indomethacin Medication Overuse HA at least \u00bd the days of the month, w/medication intake at least \u00bd the days of the month; often presents as worsening HA despite increased intake of medication. Often seen with meds that include caffeine (Excedrin, fioricet) \\*STOP offending medication, typically via taper. HA will worsen before it gets better, start concurrent daily prophylactic headache medication"},{"location":"neurology/neurology-outpatient-headache/#medication-overview","title":"Medication Overview:","text":"<ul> <li> <p>Abortive</p> <ul> <li> <p>Triptans (e.g. sumatriptan or rizatriptan)</p> <ul> <li> <p>Cannot be used more than 10 days/month</p> </li> <li> <p>Avoid in pts with hypertension/CAD</p> </li> </ul> </li> </ul> </li> <li> <p>Preventative</p> <ul> <li> <p>Amitriptyline: indicated for both migraine and tension-type. Helps     with sleep and comorbid depression. Most common side effects (SE) =     dry mouth, sedation</p> </li> <li> <p>Topiramate: has the best evidence among migraine meds. Can     theoretically help with weight loss. Most common SE = sodas taste     bad, sedation, parasthesias</p> </li> <li> <p>Propranolol: useful for relative lack of interactions. Mild     cardiac/blood pressure effects compared to other beta-blockers. Most     common SE = drowsiness</p> </li> <li> <p>Magnesium oxide: reduces headache frequency with almost no SE. Start     400mg daily, can go up to 800mg BID. Patients can increase dose     until they get diarrhea.</p> </li> <li> <p>Riboflavin (vitamin B2): mild effect but effectively has no side     effects. 400mg daily.</p> </li> <li> <p>Gabapentin: can be useful if HAs have stabbing/electric quality.     Main SE = sedation</p> </li> <li> <p>Venlafaxine: useful for migraines with significant vestibular     symptoms (dizziness). SE = hypertension/tachycardia.</p> </li> <li> <p>Verapamil: can be used for migraine and cluster headaches. Can use     ER formulation</p> </li> <li> <p>Botox: can be administered every 3 months. Can be very effective,     but pts generally will have had to fail multiple medications for     insurance to approve refer to neuro resident clinic</p> </li> <li> <p>CGRP receptor modulators (mostly injections) such as Rimegepant are     newer options</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-parkinson/","title":"Parkinson\u2019s Disease","text":""},{"location":"neurology/neurology-parkinson/#clinical-presentation","title":"Clinical Presentation","text":"<ul> <li> <p>Resting tremor is typically a very early symptom, often worse on one     side</p> </li> <li> <p>Cogwheel rigidity; can be confused for paratonia, which is seen in     demented or encephalopathic patients who have involuntary variable     resistance movements during passive ROM assessment</p> </li> <li> <p>Speech changes (low volume), hand-writing changes (slow small     movements)</p> </li> <li> <p>Gait changes</p> <ul> <li> <p>Festination \u2013 slow start with movements that gradually build up     speed</p> </li> <li> <p>En bloc turning \u2013 taking multiple steps to turn around</p> </li> </ul> </li> <li> <p>Anosmia and REM behavior sleep disorders are very common</p> </li> </ul>"},{"location":"neurology/neurology-parkinson/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Clinical diagnosis; there are some supportive imaging studies like     DaTscan that looks for activity of substantia nigra (usually not     necessary)</p> </li> <li> <p>Clinical response to dopamine replacement is so typical that if a     patient does not respond, it is important to consider a Parkinson     plus syndrome (see below)</p> </li> </ul>"},{"location":"neurology/neurology-parkinson/#management","title":"Management","text":"<ul> <li> <p>Dopamine replacement \u2013 carbidopa/levodopa; dosed at regular     intervals several times a day. These generally do not need to be     held on admission.</p> <ul> <li>If pt is altered, can hold anticholinergics, MAO-B inhibitors or     COMT inhibitors</li> </ul> </li> <li> <p>Dopamine agonists \u2013 can cause confusion, hallucinations, dyskinesias</p> </li> <li> <p>MAO-B inhibitors (MAOIs): can cause confusion, hallucinations,     insomnia and dyskinesias</p> </li> <li> <p>COMT inhibitors \u2013 can cause confusion, hallucinations, insomnia, and     dyskinesias</p> </li> <li> <p>Anticholinergics \u2013 useful for tremor when there is not much     bradykinesia or gait disturbances. In older pts cognitive changes     are a bigger concern along with hallucinations</p> </li> <li> <p>PD medications are rarely titrated in the hospital because acute     medical illness makes PD symptoms worse and everything will need to     be re-adjusted as an outpatient</p> </li> <li> <p>Be cautious with PRN anti-emetics in patients with PD. Many work via     dopamine antagonism. Zofran is generally the safest option.</p> </li> <li> <p>Similarly, many antipsychotics have dopamine antagonism. Safest     option is seroquel</p> </li> </ul>"},{"location":"neurology/neurology-parkinson/#parkinson-plus-syndromes","title":"Parkinson Plus Syndromes","text":""},{"location":"neurology/neurology-parkinson/#evaluation_1","title":"Evaluation","text":"<ul> <li>Consider if atypical features such as bilateral symmetric onset,     early cognitive/personality changes, cerebellar findings, or     prominent autonomic dysfunction early</li> </ul>"},{"location":"neurology/neurology-parkinson/#types","title":"Types","text":"<ul> <li> <p>Progressive Supranuclear Palsy</p> <ul> <li> <p>PD symptoms with early falls and minimal tremor</p> </li> <li> <p>Vertical eye movement abnormalities</p> </li> </ul> </li> <li> <p>Multisystem Atrophy</p> <ul> <li> <p>Profound orthostatic hypotension without any increase in HR</p> </li> <li> <p>Three types:</p> <ul> <li> <p>MSA-A \u2013 autonomic features prominent (previously Shy-Drager     Syndrome)</p> </li> <li> <p>MSA-P \u2013 prominent atypical Parkinsonism features</p> </li> <li> <p>MSA-C \u2013 prominent cerebellar dysfunction</p> </li> </ul> </li> </ul> </li> <li> <p>Lewy Body Dementia</p> <ul> <li>Parkinsonism with prominent early cognitive impairment and     hallucinations</li> </ul> </li> </ul>"},{"location":"neurology/neurology-status-epilepticus/","title":"Status Epilepticus","text":""},{"location":"neurology/neurology-status-epilepticus/#background","title":"Background","text":"<ul> <li>Either a single seizure &gt;5 minutes or     \u2265     2 seizures occurring without a return to baseline in between     [previous guidelines used 30 minutes as a marker, but this has been     updated]</li> <li>Differentiating convulsive seizures from non-epileptic events     (\u201cpseudoseizure\u201d):<ul> <li>Features that suggest non-epileptic/psychogenic event include     moaning or talking throughout the event, \u201cno-no\u201d head shake,     repetitive movements of opposing muscle groups, very arrhythmic     or purposeful-looking movements, or seizures that have been     ongoing for \u201chours\u201d</li> </ul> </li> </ul>"},{"location":"neurology/neurology-status-epilepticus/#evaluation","title":"Evaluation","text":"<ul> <li>Fingerstick     glucose, BMP/CBC, and UDS</li> <li>Consult Neurology</li> <li>EEG (start with 2hr) to determine if it is seizure or not and for     titration of medications</li> <li>Consider a non-contrasted head CT; MRI cannot be obtained while EEG     is attached</li> <li>Up to half of pts presenting in status epilepticus have no history     of seizure, so they need urgent head imaging, consideration for     lumbar puncture, infectious and toxic workup, tox screen, and     sometimes rheumatologic or paraneoplastic workup</li> <li>If HX of seizure or on Antiseizure meds (ASMs) please order trough levels </li> </ul>"},{"location":"neurology/neurology-status-epilepticus/#management","title":"Management","text":"<ul> <li> <p>ABCs! Start with benzos:</p> <ul> <li> <p>2 mg lorazepam IV then repeat q1-3 minutes up to 0.1 mg/kg OR</p> </li> <li> <p>5 mg of diazepam IV every minute (takes longer to give diazepam so     would give concurrent ASM)</p> </li> <li> <p>10 mg IM midazolam if no IV access</p> </li> </ul> </li> <li> <p>After 2 rounds of benzos, would shift to antiepileptics if still in     status (neurology should be contacted here if not already):</p> <ul> <li> <p>IV fosphenytoin 20 mg/kg</p> </li> <li> <p>IV levetiracetam 30-60 mg/kg (generally 3g, up to 4.5g max)</p> </li> <li> <p>IV valproic acid 30 mg/kg</p> </li> </ul> </li> <li> <p>If still seizing at this point, the patient will likely need     intubation</p> </li> <li> <p>These pts MUST be placed on EEG if they get paralyzed or sedated     because convulsive status often continues as nonconvulsive status,     which still damages the brain!</p> <ul> <li> <p>If still seizing, patients should be on midazolam, propofol or     barbiturate infusions</p> </li> <li> <p>Focal seizures, such as arm or face twitching with retained     awareness do not always need to be treated to the point of     initiating coma</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-stroke-0/","title":"Stroke","text":""},{"location":"neurology/neurology-stroke-0/#background","title":"Background","text":"<ul> <li> Preferred term: Stroke (CVA is like saying heart attack instead of STEMI) </li> <li> <p>Sudden onset, focal (usually one-sided) neurologic deficits: weakness, sensory loss, vision loss, ataxia/unsteadiness, vertigo, double vision, facial droop, dysarthria, aphasia</p> </li> <li> <p>Differential:</p> <ul> <li> <p>stroke (ischemic or hemorrhagic)</p> </li> <li> <p>seizure or post-ictal paralysis</p> </li> <li> <p>headache phenomena (complex migraine)</p> </li> <li> <p>cervical spinal cord lesions, though these more commonly cause bilateral symptoms</p> </li> </ul> </li> <li> <p>Stroke-like symptoms can also develop as recrudescence \u2013 previous stroke or brain lesion symptoms worsening with systemic toxic/metabolic/infectious processes or hypotension</p> </li> </ul>"},{"location":"neurology/neurology-stroke-0/#evaluation","title":"Evaluation","text":"<p>-Critical decision-making information: last known normal (LKN), time symptoms first observed, anticoagulation status, recent surgeries, history of bleeding (severe GIB or ICH), recent medications, platelet count, and baseline neuro exam</p> <ul> <li> <p>If symptoms developed with LKN within 24 hours -&gt; stroke alert!</p> </li> <li> <p> If &gt; 24 hours, can request Neuroalert Instead  </p> <ul> <li> <p>VUMC: call 11111 and tell the operator stroke alert and current patient location</p> </li> <li> <p>NAVA: call an RRT and stat page 835-5137, include in the page 911 at the end of the call back number to signal it is a stroke alert</p> </li> </ul> </li> <li> <p>Stat head CTP (order CTH/CTA) for consideration of tPA or endovascular therapy</p> <ul> <li> <p>If renal function is abnormal, discuss with neurology</p> </li> <li> <p>Generally, go for CTA if the patient is a thrombectomy candidate (within 24 hrs of onset)</p> </li> <li> <p>MRI/MRA is an option but takes longer (MRAs are also better with Gadolinium)</p> </li> <li> <p>Neurology service should be leading this portion</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-stroke-0/#management","title":"Management","text":"<ul> <li> <p>Blood pressure goals</p> <ul> <li> <p>Ischemic stroke:</p> <ul> <li> <p>In general aim for SBP &lt;220</p> </li> <li> <p>Patients with intracranial atherosclerosis may require higher BP to maintain perfusion</p> </li> </ul> </li> <li> <p>Hemorrhagic stroke:</p> <ul> <li> <p>SBP &lt; 140 (BP management is key)</p> </li> <li> <p>These pts are managed in Neuro ICU</p> </li> <li> <p>Reverse coagulopathies and keep platelets &gt;100,000</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-vertigo/","title":"Vertigo","text":""},{"location":"neurology/neurology-vertigo/#background","title":"Background","text":"<ul> <li> <p>Clinical Presentation</p> <ul> <li> <p>Sensation of the room spinning or moving, or themselves spinning or     moving</p> </li> <li> <p>Must distinguish from orthostasis/presyncope via history</p> </li> </ul> </li> <li> <p>Causes: most easily differentiated based on chronicity and triggers     rather than description of symptoms</p> <ul> <li> <p>BPPV - short duration, very positional, classically nystagmus is     horizontal and torsional with the posterior canal being most     commonly involved</p> </li> <li> <p>Vestibular neuronitis/labyrinthitis \u2013 typically follows URI or ear     infections; often self-limited, but can be severe/prolonged, in     which case it is treated with steroids</p> </li> <li> <p>Meni\u00e8re\u2019s Disease \u2013 tinnitus and low range frequency hearing loss,     generally progressive and treated with diuretics, meclizine and     sometimes surgeries or intratympanic injections</p> </li> <li> <p>Endolymphatic Leak \u2013 usually following trauma or concussive blasts,     requires ENT eval and management. Classically a loud sound will     cause vertigo and nystagmus</p> </li> <li> <p>vertiginous migraine: usual migraine triggers, may have aura.     Episodic nature and often positive family hx of migraine or even     vertiginous migraine.</p> </li> <li> <p>Stroke \u2013 sudden onset, ask about vascular risk factors, rare cause     of isolated vertigo</p> </li> </ul> </li> </ul>"},{"location":"neurology/neurology-vertigo/#evaluationmanagement","title":"Evaluation/Management","text":"<ul> <li> <p>Careful exam of vertigo will be more helpful than random scans, but     pt has to be symptomatic for exam to mean anything:</p> <ul> <li> <p>HINTS Battery \u2013 Head Impulse test, Nystagmus pattern, Test of skew</p> <ul> <li> <p>Central pattern \u2013 no corrective saccade, multidirectional     nystagmus, skew present</p> </li> <li> <p>Peripheral pattern \u2013 corrective saccade, unidirectional     nystagmus, no skew present</p> </li> </ul> </li> <li> <p>Dix-Hallpike Test</p> </li> <li> <p>Cerebellar testing: FNF, HKS, mirroring, gait</p> </li> <li> <p>Outpatient Vestibular function testing with ENT</p> </li> </ul> </li> <li> <p>Central patterns will need head and vessel imaging (looking for     vertebral dissection or basilar clots)</p> <ul> <li>Often, central vertigo is due to centrally acting medications</li> </ul> </li> <li> <p>Peripheral causes are varied and often require eval by ENT as an     outpatient</p> </li> <li> <p>Treatment with anticholinergics like meclizine or scopolamine is     often helpful</p> </li> <li> <p>Vestibular therapy with OT is also very beneficial</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-approach-anisocoria/","title":"Anisocoria","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-approach-anisocoria/#background","title":"Background","text":"<ul> <li> <p>Anisocoria = unequal pupil size</p> </li> <li> <p>Constriction of the pupil is driven by parasympathetic innervation;     Dilation by sympathetic innervation</p> </li> <li> <p>Physiological anisocoria = pupil sizes differ by \\&lt;1mm. Normal.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-approach-anisocoria/#conditions-that-can-cause-anisocoria","title":"Conditions that can cause anisocoria:","text":"<ul> <li> <p>Benign episodic mydriasis</p> <ul> <li>Intermittent episodes of pupillary dilation and possible association     with migraine. No other significant neurologic or ocular symptoms     present. Important to exclude other causes of mydriasis prior to     this diagnosis.</li> </ul> </li> <li> <p>Horner\u2019s syndrome</p> <ul> <li> <p>Pupillary miosis + ipsilateral upper lid ptosis</p> </li> <li> <p>May be congenital or acquired</p> </li> <li> <p>Acquired causes include: trauma involving sympathetic pathway,     carotid dissection, cavernous sinus pathology, stroke, neck or     thoracic surgery, or Pancoast / mediastinal tumor (rare).</p> </li> <li> <p>If suspect new onset Horner\u2019s, consider Neurology and Ophthalmology     consult.</p> </li> </ul> </li> <li> <p>CN3 Palsy</p> <ul> <li> <p>Pupillary mydriasis (\u201cblown pupil\u201d) + adduction, supraduction,     infraduction deficit, \u201cdown and out position\u201d, upper lid ptosis.     Must rule out a compressive lesion on CN3.</p> </li> <li> <p>If new onset, consider head imaging and Neurology and Ophthalmology     consult</p> </li> </ul> </li> <li> <p>Medications (especially anticholinergics)</p> <ul> <li>Commonly seen in young patients with scopolamine patches who forget     to wash hands after handling the patch; dilation can last one day to     a couple weeks.</li> </ul> </li> <li> <p>Trauma</p> <ul> <li>Damage to the iris sphincter after eye trauma can cause a dilated     pupil that is poorly reactive to light.</li> </ul> </li> <li> <p>Eye surgery</p> <ul> <li>Patients who have undergone intraocular surgery (like cataract     surgery) may have an irregularly shaped, less reactive, and slightly     dilated pupil as compared to the other eye due to damage or     stretching of the iris during the operation.</li> </ul> </li> <li> <p>Infections</p> <ul> <li> <p>Viral infections and syphilis can cause parasympathetic denervation,     resulting in a relatively mydriatic pupil that is poorly reactive to     light. However, the accommodative pupillary response (i.e.,     constriction at focusing on an object at near) may be intact.</p> </li> <li> <p>\u201cAdie\u2019s Tonic Pupil\u201d = Idiopathic cause of parasympathetic     denervation presenting similarly as above. However, viruses (HSV)     are sometimes thought to be behind idiopathic cases.</p> </li> </ul> </li> <li> <p>Acute angle closure glaucoma</p> <ul> <li>During an acute attack, the pupil may be mid-dilated and sluggish to     light. However, patients will also have symptoms of acute angle     closure (e.g., headaches, nausea/vomiting, eye pain, etc. See     Glaucoma section for more info).</li> </ul> </li> </ul>"},{"location":"ophthalmology/ophthalmology-approach-blurry-vision/","title":"Approach to Blurry Vision","text":"<p>Jonathan A. Barnett</p> <p></p> <p>Approach to Blurry Vision Flowchart</p>"},{"location":"ophthalmology/ophthalmology-approach-blurry-vision/#key-points","title":"Key Points","text":"<ul> <li>This flowchart is meant to serve as a guide. Bear in mind that there     are always exceptions.</li> <li>Many ocular problems are not urgent and can be dealt with     outpatient. Assessing the acuity of onset is the first step.</li> <li>In general, the top differential for blurry vision is Dry Eye,     Cataract, or Uncorrected refractive error.</li> <li>If the symptoms are acute and just in one eye, it is more likely to     be ocular and warrants further investigation (likely ophthalmology     consult).</li> </ul>"},{"location":"ophthalmology/ophthalmology-approach-double-vision/","title":"Approach to Double Vision (Diplopia)","text":"<p>Jonathan A. Barnett</p> <p></p> <p>Approach to Double Vision Flowchart</p>"},{"location":"ophthalmology/ophthalmology-approach-double-vision/#key-points","title":"Key Points","text":"<ul> <li>This flowchart is meant to serve as a guide. Bear in mind that there     are always exceptions.</li> <li>Most important question to ask with any patient complaining of     double vision is whether it goes away when covering one eye. If it     does, then it is an ocular misalignment issue (= true binocular     diplopia).</li> <li>If the diplopia is acute and constant, this requires more urgent     evaluation than if intermittent.</li> <li>Look at the pupil and eye movements:<ul> <li>If the eye is dilated (\u201cblown pupil\u201d), abducted and infraducted (\u201cdown and out position\u201d), and ptotic, this is classic for a complete CN3 palsy and requires immediate neuroimaging (e.g. CTA head) to rule out an enlarging aneurysm.</li> </ul> </li> </ul>"},{"location":"ophthalmology/ophthalmology-approach-flashes-floaters/","title":"Approach to Flashes, Floaters, Spots","text":"<p>Jonathan A. Barnett</p> <p></p> <p>Approach to Flashes, Floaters, Spots Flowchart</p>"},{"location":"ophthalmology/ophthalmology-approach-flashes-floaters/#key-points","title":"Key Points","text":"<ul> <li>This flowchart is meant to serve as a guide. Bear in mind that there     are always exceptions.</li> <li>Scintillating or colorful lights/spots, especially if bilateral, are     likely migrainous in nature.</li> <li>A patient may say they see a visual disturbance in the left eye,     when in reality it is in the left visual field of both eyes     (indicating that it is a neurological issue, e.g., migraine). Ask if     the patient has tried closing one eye to see if the visual     phenomenon is actually in one eye.</li> <li>Rapid onset of floaters, often preceded by a peripheral     crescent-shaped light flash, is classic for posterior vitreous     detachment. A black curtain or veil that comes down in the vision is     classic for retinal detachment.</li> </ul>"},{"location":"ophthalmology/ophthalmology-approach-red-eye/","title":"Approach to a Red Eye","text":"<p>Jonathan A. Barnett</p> <p>When the conjunctiva is vasodilated, or \u201cinjected,\u201d the eye looks red. The more inflamed the conjunctiva, the angrier-looking the eye.</p>"},{"location":"ophthalmology/ophthalmology-approach-red-eye/#differential-for-red-eye","title":"Differential for Red Eye:","text":"<ul> <li> <p>Dry Eye</p> <ul> <li>Trace diffuse injection, blurry vision that fluctuates, gritty     sensation, clears with blinking</li> </ul> </li> <li> <p>Corneal abrasion / ulceration / exposure keratopathy</p> <ul> <li>Unilateral, moderate to severe injection, may be diffuse or     sectoral, pain, blurry vision, mucus discharge, history of poor     blink rate, intubated/sedated status.</li> </ul> </li> <li> <p>Subconjunctival hemorrhage</p> <ul> <li>Patch of bright red, often with sharp borders. Due to rupture of     conjunctival vessel. Whole conjunctiva can be involved and may be     bright red. Looks scarier than it is. Common in patients on     anticoagulation or after a Valsalva event (e.g., coughing). Will     resolve spontaneously.</li> </ul> </li> <li> <p>Allergic conjunctivitis</p> <ul> <li>Chemosis, mild to moderate injection, blurry vision, very itchy,     watery discharge, hx of allergies/atopy</li> </ul> </li> <li> <p>Viral or Bacterial conjunctivitis</p> <ul> <li>Moderate to severe injection, scattered subconjunctival hemorrhages     or petechiae, itchy or burning/painful eyes. If viral, look for     preauricular adenopathy or recent URI.</li> </ul> </li> <li> <p>Acute angle closure glaucoma</p> <ul> <li>Severe eye pain with nausea/vomiting, rock-hard eye, mid-dilated and     fixed pupil, blurry vision</li> </ul> </li> <li> <p>Uveitis/Episcleritis/Scleritis</p> <ul> <li>Eye pain, perilimbal injection (\u201cciliary flush\u201d), blurry vision, may     have history of autoimmune disease. Episcleritis vs Scleritis can be     difficult to discern. Scleritis may have a deeper, violaceous hue.</li> </ul> </li> <li> <p>Endophthalmitis</p> <ul> <li>Eye pain, history of trauma or eye surgery, severe vision loss,     history of immunocompromise and systemic infection (if endogenous)</li> </ul> </li> <li> <p>Carotid-cavernous fistula</p> <ul> <li>Engorged and tortuous conjunctival vessels, recent history of     trauma, resistance to retropulsion (pushing the globe back in)</li> </ul> </li> </ul>"},{"location":"ophthalmology/ophthalmology-basic-eye-anatomy/","title":"Basic Eye Anatomy","text":"<p>Jonathan A. Barnett</p> <ul> <li> <p>Sclera - White wall of the eye</p> </li> <li> <p>Conjunctiva - Translucent, vascularized tissue that covers     the anterior sclera (bulbar conjunctiva) and lines the inner aspect     of the eyelids (palpebral conjunctiva). When the eyes get \u201cred,\u201d it     is usually the conjunctiva, and not the sclera, that is irritated     (conjunctival vessels dilate).</p> </li> <li> <p>Cornea - Transparent, bubble-like structure in front of the     eye.</p> </li> <li> <p>Iris - \u201ccolored\u201d part of the eye that dilates and constricts     the pupil to let in more or less light</p> </li> <li> <p>Pupil - the central hole in the iris</p> </li> <li> <p>Anterior Chamber (AC) - the space between the cornea and the     iris</p> </li> <li> <p>Aqueous Humor - clear fluid that fills the anterior and     posterior chambers, produced by the ciliary body. Nourishes the     cornea. The balance of aqueous production and drainage dictates the     intraocular pressure (IOP).</p> </li> <li> <p>Iridocorneal angle (or just, the Angle) - angle between the     iris and the cornea and site of the Trabecular Meshwork, which     drains aqueous humor from the anterior chamber into the ocular     venous system.</p> </li> <li> <p>Lens - transparent structure located behind the iris that     helps focus light onto the retina; also responsible for     accommodation (focusing at near). Located behind the iris. A     cataract is an opacification of the lens.</p> </li> <li> <p>Ciliary body - ring structure that sits behind the iris.     Produces aqueous humor and suspends the Lens via filaments called     Zonules.</p> </li> <li> <p>Posterior chamber- the space between the iris and the lens</p> </li> <li> <p>Vitreous chamber - the space between the lens and the retina</p> </li> <li> <p>Vitreous humor - thick, jelly-like transparent substance that     fills the vitreous chamber</p> </li> <li> <p>Retina- tissue that lines the inner back wall of the eye,     contains photoreceptors and interneurons that absorb light and     convert it into visual electrochemical signals</p> </li> <li> <p>Macula - area of the retina responsible for central vision.     The fovea is the center of the macula.</p> </li> <li> <p>Choroid - highly vascularized layer of tissue posterior to     the retina</p> </li> <li> <p>Optic disc - head of the optic nerve; the optic nerve is     composed of the axons of the retinal ganglion neurons, transmitting     visual electrochemical signals from the retina to the brain.</p> </li> <li> <p>Uvea - iris + ciliary body + choroid. These 3 tissues are     actually connected and collectively make up the vascular layer of     the eye.</p> </li> <li> <p>The Anterior segment - all structures that make up the     \u201cfront\u201d of the eye, i.e., anterior to the vitreous chamber (cornea,     iris, iridocorneal angle, lens, ciliary body, aqueous humor)</p> </li> <li> <p>The Posterior segment - all structures that make up the     \u201cback\u201d of the eye, i.e., the vitreous chamber and all structures     contained within it (vitreous humor, retina, choroid, optic nerve)</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-cataracts/","title":"Cataracts","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-cataracts/#background","title":"Background","text":"<ul> <li>Opacification of the eye\u2019s natural lens</li> <li>Primary cause is normal aging, occurs bilaterally and symmetrically</li> <li>Other causes include congenital, trauma, and medications (esp     chronic / long-term steroid use</li> </ul>"},{"location":"ophthalmology/ophthalmology-cataracts/#presentation","title":"Presentation","text":"<ul> <li>Most common symptoms include progressive decreased vision over     years, increased glare, increased difficulty with night vision</li> </ul>"},{"location":"ophthalmology/ophthalmology-cataracts/#evaluation-and-management","title":"Evaluation and Management","text":"<ul> <li>Unless the cataracts are dense enough, it is difficult to appreciate     without a slit lamp exam</li> <li>Please place an outpatient referral.</li> </ul>"},{"location":"ophthalmology/ophthalmology-common-abbreviations-in-ophtho/","title":"Common Abbreviations in Ophthalmology","text":"<p>Jonathan A. Barnett</p> <ul> <li> <p>OD = Right eye | OS = Left eye | OU = Both eyes</p> </li> <li> <p>VA = Visual Acuity | VAcc = with correction [glasses or contact     lenses] | VAsc = without correction</p> </li> <li> <p>PH = Pinhole acuity</p> </li> <li> <p>PHNI = No Improvement of vision with a pinhole</p> </li> <li> <p>Gtt = drop</p> </li> <li> <p>Ung = ointment</p> </li> <li> <p>EOM = Extraocular Muscles</p> </li> <li> <p>IOP = Intraocular Pressure</p> </li> <li> <p>CVF = Confrontational Visual Fields</p> </li> <li> <p>CF = Count Fingers</p> </li> <li> <p>HM = Hand Motion</p> </li> <li> <p>DFE = Dilated Fundus Exam | SLE = Slit Lamp Exam | PLE = Pen Light     Exam</p> </li> <li> <p>RAPD = Relative Afferent Pupillary Defect</p> </li> <li> <p>KED = corneal epithelial defect (i.e., abrasion)</p> </li> <li> <p>PEE / SPK = corneal punctate epithelial erosions / superficial     punctate keratopathy</p> </li> <li> <p>FBS = Foreign body sensation</p> </li> <li> <p>PFATs = Preservative-Free Artificial Tears</p> </li> <li> <p>SCH = Subconjunctival hemorrhage</p> </li> <li> <p>DD = Disc Diameters in size</p> </li> <li> <p>W&amp;q = Conjunctiva is white and quiet (normal)</p> </li> <li> <p>D&amp;q = Anterior chamber is deep and quiet (normal, without     inflammation)</p> </li> <li> <p>AC = Anterior Chamber</p> </li> <li> <p>ON = Optic Nerve | ONH = Optic Nerve Head</p> </li> <li> <p>RD = Retinal Detachment</p> </li> <li> <p>PVD = Posterior Vitreous Detachment</p> </li> <li> <p>DR = Diabetic Retinopathy | NPDR: Nonproliferative DR | PDR:     Proliferative DR</p> </li> <li> <p>CNV = Choroidal Neovascularization</p> </li> <li> <p>NVI = Neovascularization of the Iris | NVA = Neovascularization of     the Angle | NVD = Neovascularization of the optic Disc | NVE =     Neovascularization elsewhere (usually peripheral retina)</p> </li> <li> <p>CE/IOL = Cataract Extraction with IntraOcular Lens insertion (i.e.,     cataract surgery)</p> </li> <li> <p>IV = Intravitreal (as usually in \u201cIV injection\u201d)</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-conjunctivitis/","title":"Conjunctivitis","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-conjunctivitis/#background-and-presentation","title":"Background and Presentation","text":"<ul> <li> <p>Allergic, viral, or bacterial cause</p> </li> <li> <p>All forms present with red and irritated conjunctiva</p> </li> <li> <p>In practice it can be difficult to distinguish between the types of     conjunctivitis. However, these are rough guidelines:</p> <ul> <li> <p>Allergic: hx of allergies/atopy, bilateral, chemosis, watery/mucoid     discharge, itchiness predominant symptom</p> </li> <li> <p>Viral: hx of recent URI or exposure, unilateral first then     bilateral, itchy/burning, subconjunctival hemorrhages or petechiae,     watery/mucoid discharge, tender preauricular lymph nodes</p> </li> <li> <p>Bacterial: itching less prominent, burning/aching/stabbing     discomfort predominates, unilateral first then bilateral,     mucoid/purulent discharge (and more copious)</p> </li> </ul> </li> <li> <p>Blurry vision is common, but loss of vision should not occur if     disease limited to conjunctiva.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-conjunctivitis/#management","title":"Management:","text":"<ul> <li> <p>Allergic: eliminate allergen, artificial tears,     antihistamine/mast-cell stabilizer drops (olopatadine, ketotifen),     oral antihistamine (diphenhydramine, loratadine)</p> </li> <li> <p>Viral: 4-8x/day artificial tears, cold compresses, isolation     precautions.</p> </li> <li> <p>Bacterial: culture/swab the ocular discharge, isolation precautions,     moxifloxacin drops (Vigamox) QID or trimethoprim/polymyxin B     drops/ointment for 5-7 days</p> </li> <li> <p>Consult ophthalmology if concern for worsening</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-corneal-injury/","title":"Corneal Abrasion, Exposure Keratopathy, Ulceration","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-corneal-injury/#background","title":"Background","text":"<ul> <li> <p>Corneal abrasion = corneal epithelial defect (KED): an area of     missing corneal epithelium. This is akin to a scratch on the skin.     Most common causes include trauma, excessive surface dryness,     infection, and neurotrophic disease</p> </li> <li> <p>Exposure keratopathy = development of corneal epithelial defects     secondary to incomplete closure of the eyelids (i.e., prolonged     exposure of the cornea to air). Most often occurs in patients who     are intubated/sedated, have poor orbicularis tone/paralysis (Bell     palsy), or have abnormal blink rate (e.g., Parkinson\u2019s).</p> </li> <li> <p>Corneal ulceration = the injury extends past the corneal epithelium     and \u2018ulcerates\u2019 into the underlying stroma. Ulcerations are often     infectious and develop after untreated abrasions (abrasions are     essentially open wounds). In rare cases ulcerations can also be     sterile (autoimmune/inflammatory).</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-corneal-injury/#presentation-and-evaluation","title":"Presentation and Evaluation","text":"<ul> <li> <p>Abrasions and ulcerations are often extremely painful. May be     exacerbated by blinking.</p> </li> <li> <p>Conjunctival injection; but sometimes the eye can appear normal, or     only have trace redness, and the pain may seem out of proportion to     external appearance.</p> </li> <li> <p>Mucus discharge /crusting</p> </li> <li> <p>Photophobia and tearing</p> </li> <li> <p>Blurry vision</p> </li> <li> <p>Ulcerations will present with the above, but also have a whitish     infiltrate in the cornea. The conjunctival injection and discharge     will often be a lot worse.</p> </li> <li> <p>1 drop of Proparacaine 0.5% will improve pain</p> <ul> <li>Note: Proparacaine is used only for diagnostic, and not therapeutic,     purposes. Do not administer proparacaine on a scheduled or PRN basis     for pain. The duration of action is only 15 minutes, and repeated     chronic use can lead to corneal melt/ulceration.</li> </ul> </li> <li> <p>1 drop of Fluorescein followed by shining a blue light (or Wood\u2019s     lamp) will reveal the KED.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-corneal-injury/#management","title":"Management","text":"<ul> <li> <p>VUMC Perioperative Corneal Abrasion Protocol</p> <ul> <li> <p>If patient is recently postop, or underwent recent extubation, and     presents with eye pain/burning, blurry vision, redness, photophobia,     VUMC has a periop corneal abrasion protocol (do not place     ophthalmology consult):</p> <ul> <li> <p>Erythromycin ophthalmic ointment TID into the lower fornix of     eye x5 days</p> </li> <li> <p>If the pain and redness do not improve within 48 hours, then     consult ophthalmology</p> </li> </ul> </li> </ul> </li> <li> <p>Corneal Abrasion</p> <ul> <li> <p>If patient\u2019s signs and symptoms are consistent with a corneal     abrasion, try erythromycin ophthalmic ointment TID as above.</p> </li> <li> <p>If the pain and redness do not improve within 48 hours, or have     other concerns, consult ophthalmology</p> </li> </ul> </li> <li> <p>Exposure Keratopathy</p> <ul> <li> <p>If patient is intubated and sedated, or cannot otherwise fully close     his/her eyes, take the following measures to prevent development of     corneal abrasion or ulceration:</p> <ul> <li> <p>Moisture chambers (aka bubble shields) to eyes at all times</p> </li> <li> <p>Copious amount of lubricating ophthalmic ointment (e.g.,     Lubrifresh) in eyes TID</p> </li> </ul> </li> </ul> </li> <li> <p>Corneal Ulceration</p> <ul> <li>If you see whitish material in the cornea itself, this is likely a     corneal ulceration and warrants an ophthalmology consult.</li> </ul> </li> </ul>"},{"location":"ophthalmology/ophthalmology-dry-eye/","title":"Dry Eye","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-dry-eye/#background","title":"Background","text":"<ul> <li>Most common ocular complaint, especially amongst patients admitted     to the hospital!</li> <li>Due to insufficient tear production and/or imbalance in the     components that make up the tear film</li> <li>Etiology is vast and can include aging, eye strain/overuse, contact     lens use, systemic and topical medications, post eye surgery,     nutritional deficiencies, autoimmune disease, or concomitant with     other ocular conditions.</li> </ul>"},{"location":"ophthalmology/ophthalmology-dry-eye/#presentation","title":"Presentation","text":"<ul> <li>Blurry vision bilaterally that comes and goes (very common\u2013if the     patient complains of fluctuating blurriness, Dry Eye should be at     the top of your differential!)</li> <li>Excessive tearing/watery eyes</li> <li>Stinging, burning, soreness, discomfort, gritty/foreign body     sensation</li> <li>Discomfort with eye movements</li> <li>Trace/mild conjunctival injection</li> </ul>"},{"location":"ophthalmology/ophthalmology-dry-eye/#evaluation-and-management","title":"Evaluation and Management","text":"<ul> <li>If a patient's symptoms sound like Dry Eye, order some     preservative-free (PF) artificial tears at least 4x/day and     lubricating eye ointment at bedtime to see if the patient's symptoms     improve.</li> <li>Polyvinyl alcohol-povidone PF (Refresh Classic)</li> <li>Lubricating ophthalmic ointment (Lubrifresh)</li> <li>Order them SCHEDULED. Do not order these eye drops PRN (patients     will not ask for them).</li> <li>If a patient's symptoms fail to improve or worsen on artificial     tears, consider paging ophthalmology for additional assistance. If     there is no apparent imminent threat to vision, you can place an     ophthalmology outpatient referral upon discharge.</li> </ul>"},{"location":"ophthalmology/ophthalmology-fungemia/","title":"Fungemia and Intraocular Involvement","text":"<p>Jonathan A. Barnett</p> <p>The American Academy of Ophthalmology currently does NOT recommend routine Ophthalmology consults for visually asymptomatic patients with systemic candidemia. The incidence of candidemia-related endophthalmitis detected from routine screenings is &lt;1%.</p> <p>By contrast, if the patient has visual symptoms, an Ophthalmology consult is warranted.</p> <ul> <li>Breazzano MP et al. American Academy of Ophthalmology     Recommendations on Screening for Endogenous Candida Endophthalmitis.     Ophthalmology. 2022 Jan;129(1):73-76.</li> </ul>"},{"location":"ophthalmology/ophthalmology-fungemia/#giant-cell-arteritis-role-of-ophthalmology","title":"Giant Cell Arteritis: Role of Ophthalmology","text":"<p>If a patient has systemic symptoms suspect of GCA (see \u201cRheumatology section\u201d), when is it appropriate to consult Ophthalmology?</p> <ul> <li> <p>If patient HAS visual symptoms (acute vision loss, new onset     diplopia), consult ophthalmology.</p> </li> <li> <p>If patient DOES NOT have visual symptoms, DO NOT consult     ophthalmology (e.g., to rule out \u201cretinal vasculitis.\u201d)</p> </li> <li> <p>It is extremely unlikely that Ophthalmology will find a pertinent     ocular finding in the absence of visual symptoms to support a     diagnosis of GCA.</p> </li> <li> <p>Bottom line: If you suspect GCA given the other systemic symptoms     (regardless of visual status), treat promptly with high dose     steroids!</p> </li> <li> <p>Temporal Artery biopsies are typically performed by Vascular     Surgery.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-glaucoma/","title":"Glaucoma","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-glaucoma/#background","title":"Background","text":"<ul> <li> <p>Glaucoma is a disease of the optic nerve that follows a     characteristic pattern of optic nerve fiber degeneration.</p> </li> <li> <p>High intraocular pressure (IOP) is believed to be the main etiology     of the disease.</p> </li> <li> <p>While the \u201cnormal\u201d IOP range is between 11 and 21 mmHg, there are     individuals who have a pressure above 21 that do NOT develop     glaucoma. Conversely, there are individuals who have a pressure in     the normal range that DO develop glaucoma (= Normal Tension     Glaucoma).</p> </li> <li> <p>Aqueous humor fills the anterior chamber and drains through a     sieve-like structure called the trabecular meshwork (TM), located in     the angle between the iris and the cornea. After passing through TM,     aqueous drains into the eye\u2019s venous system. Impediment to aqueous     flow will cause elevated IOP.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-glaucoma/#presentation","title":"Presentation","text":"<ul> <li> <p>All glaucomas generally cause progressive peripheral visual field     loss that ultimately encroaches on central fixation and leads to     irreversible blindness if left untreated.</p> </li> <li> <p>A glaucomatous optic nerve is often described as \u201ccupped\u201d</p> </li> <li> <p>Presents in an acute or chronic fashion:</p> </li> </ul> <ul> <li> <p>Acute Angle-Closure Glaucoma</p> <ul> <li> <p>The iridocorneal angle rapidly closes, blocking aqueous drainage     and causing a sudden rise in IOP (usually &gt;40mmHg).</p> </li> <li> <p>Symptoms and Signs: intense eye or orbital pain, headache,     nausea/vomiting, blurred vision, halos around lights, fixed and     mid-dilated pupil, rock-hard eye, conjunctival redness, cloudy     cornea.</p> </li> <li> <p>Usually unilateral, but occasionally can be bilateral.</p> </li> <li> <p>Classic trigger is a pupil-dilating factor (e.g., dark     environment or anticholinergic medications) in a person with     anatomically narrow angles.</p> </li> <li> <p>If IOP is not lowered within hours, permanent optic nerve damage     and vision loss will likely occur.</p> </li> </ul> </li> <li> <p>Primary Open Angle Glaucoma (POAG)</p> <ul> <li> <p>The iridocorneal angle is open, but due to inadequately     functioning TM (or other mechanism) aqueous does not drain     properly and IOP is chronically elevated.</p> </li> <li> <p>POAG is often painless and without noticeable vision changes in     the early stage of disease. Individuals can go undiagnosed for     years, sitting at an IOP of say 30mmHg, without being aware they     are losing vision until the vision loss is severe.</p> </li> <li> <p>POAG is the most common glaucoma in the US. When a patient says     they have a history of glaucoma, they probably have POAG.</p> </li> </ul> </li> </ul>"},{"location":"ophthalmology/ophthalmology-glaucoma/#evaluation-and-management","title":"Evaluation and Management","text":"<ul> <li>Primary Open Angle:</li> </ul> <ul> <li> <p>Continue the patient\u2019s home glaucoma drops; caution if they develop     a medical condition that results in a contraindication (See table     below)</p> </li> <li> <p>No need to officially place an Ophthalmology consult to order a     patient\u2019s home glaucoma drops; feel free to page Ophthalmology if     you have questions.</p> </li> <li> <p>Pro tip: Often patients will remember the cap color of the drops     they take but not the names!</p> </li> </ul> Name (brand) Cap color Class Dosing Possible side effects Relative contraindications Timolol (Timoptic) Yellow Nonselective beta-blocker BID Bradycardia, bronchospasm, hypotension Heart conditions (CHF, heart block), asthma/COPD <p>Latanoprost</p> <p>(Xalatan)</p> Teal Prostaglandin analogue QHS Flulike symptoms, joint pains Pregnancy (category C), uveitis <p>Brimonidine</p> <p>(Alphagan)</p> Purple Alpha-2 agonist BID-TID Allergic conjunctivitis, CNS depression, bradycardia Infants and young children <p>Dorzolamide</p> <p>(Trusopt)</p> Orange Carbonic anhydrase inhibitor BID Acidosis, hypokalemia, malaise, GI upset, metallic taste Renal insufficiency, Hepatic cirrhosis, Sickle cell disease, caution when using with other K-wasting drugs <p>Acetazolamide</p> <p>(Diamox) PO</p> PO tablet Carbonic anhydrase inhibitor <p>250mg</p> <p>BID-QID</p> Same as dorzolamide, but side effects more likely to occur given PO Same as dorzolamide, but side effects more likely to occur given PO <p>Cosopt (Blue cap) = dorzolamide + timolol</p> <p>Combigan (Purple cap) = brimonidine + timolol</p> <ul> <li>Acute Angle Closure:</li> </ul> <ul> <li> <p>If suspect acute angle closure given the signs described above,     consult Ophthalmology ASAP.</p> </li> <li> <p>The goal is to lower the IOP ASAP. Target is \\&lt;30mmHg.</p> </li> <li> <p>Administer frequent rotating rounds of all the IOP-lowering drops: 1     drop of Cosopt (then wait 5 minutes), followed by Brimonidine (then     wait 5 minutes), followed by Latanoprost (then wait 5 minutes)--then     keep repeating the cycle until the IOP goes down.</p> </li> <li> <p>Concurrently, administer one dose of IV Diamox 500mg if not     contraindicated (e.g., renal insufficiency or hepatic cirrhosis).     Ophthalmology will recheck the IOP every hour or so to ensure that     the IOP is responding (usually it does).</p> </li> <li> <p>If the IOP does not respond, patient will need a bedside AC tap to     offload aqueous and lower the pressure.</p> </li> <li> <p>Patient should ultimately get a Laser Peripheral Iridotomy (LPI) to     avoid future angle-closure attacks, which is typically performed as     an outpatient procedure.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-optic-neuritis/","title":"Optic Neuritis","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-optic-neuritis/#background","title":"Background","text":"<ul> <li>Optic neuritis is inflammation of the optic nerve. Often caused by     demyelinating disease (e.g., Multiple sclerosis). Less often, can be     caused by infection (viral etiology, bartonella, Lyme, syphilis, TB,     toxoplasmosis) or infiltrative process (e.g., sarcoidosis,     malignancy).</li> </ul>"},{"location":"ophthalmology/ophthalmology-optic-neuritis/#presentation","title":"Presentation","text":"<ul> <li> <p>Symptoms include scotoma, constant blurry vision or blurred spot,     pain with eye movements, along with other systemic neurologic     symptoms (if demyelinating process)</p> </li> <li> <p>If patient is of age 20s-40s and female, autoimmune/demyelinating     disease is at top of the differential</p> </li> <li> <p>If patient is older, consider other causes</p> </li> <li> <p>If patient is immunocompromised, infectious etiology becomes more     likely</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-optic-neuritis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Consult both Ophthalmology and Neurology if concerned for an optic     neuritis</p> </li> <li> <p>MRI brain and orbits with and without contrast, thin slices, fat     suppression</p> </li> <li> <p>If no contraindications to imaging, obtain LP with CSF studies     (glucose, protein, cell count, Gram stain, bacterial/viral cultures,     RPR/VDRL, oligos, consider NMO/AQP4)</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-optic-neuritis/#management","title":"Management","text":"<ul> <li> <p>High dose IV methylprednisolone</p> </li> <li> <p>If vision continues to worsen and/or presence of other systemic     neurologic symptoms despite steroid treatment, consider escalation     to PLEX therapy with assistance of neurology</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-orbital-and-preseptal-cellulitis/","title":"Orbital vs Preseptal Cellulitis","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-orbital-and-preseptal-cellulitis/#background","title":"Background","text":"<ul> <li> <p>The septum is a fibrous, membranous structure that divides the     anterior from the posterior orbit.</p> </li> <li> <p>Preseptal cellulitis = infection is bound anterior to the septum</p> </li> <li> <p>Orbital cellulitis (AKA postseptal cellulitis) = infection extends     posterior to the septum</p> </li> <li> <p>Common risk factors/etiologies: URI, acute or chronic sinusitis,     trauma, tooth abscess, stye or other local/adjacent skin     infection/condition, local/adjacent bug bite, immunocompromised     state, underlying systemic infection</p> </li> <li> <p>Often bacterial cause (gram positive Staph or Strep species, and/or     gram negative anaerobic species like Peptococcus or Bacteroides).     Consider fungal infection (Aspergillus, Mucor) in immunocompromised     or diabetic patients.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-orbital-and-preseptal-cellulitis/#presentation","title":"Presentation","text":"Preseptal Cellulitis Can be Present in Either Orbital Cellulitis <p>-Patient less toxic appearing</p> <p>No visual compromise</p> <p>-Mild conjunctival injection, no to minimal chemosis</p> <p>-No or minimal limitation of eye movements</p> <p>-No or minimal proptosis</p> <p>-Symptoms improving with PO antibiotics</p> <p>-Erythema and Edema of eyelids (upper and/or lower) and periorbital skin</p> <p>-Fever (although more likely in Orbital cellulitis)</p> <p>-Difficulty opening the eye d/t swelling</p> <p>-Blurry vision</p> <p>-Tearing/ocular discharge</p> <p>-Patient more toxic appearing</p> <p>-Pain with eye movements</p> <p>-Limitation of eye movements +/- diplopia</p> <p>-Proptosis</p> <p>-Severe conjunctival injection + chemosis</p> <p>-Vision may be compromised</p> <p>-Symptoms not improving after course of PO antibiotics</p>"},{"location":"ophthalmology/ophthalmology-orbital-and-preseptal-cellulitis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Vital signs</p> </li> <li> <p>Labs: CBC, CMP, ESR, CRP, blood cultures, wound culture if any open     draining areas</p> </li> <li> <p>Imaging: CT orbits with and without contrast</p> </li> <li> <p>Daily or BID photographs to track progression</p> </li> <li> <p>You can use the LRINEC scale to help assess whether the infection is     necrotizing:</p> </li> <li> <p>https://www.mdcalc.com/lrinec-score-necrotizing-soft-tissue-infection.     Necrotizing soft tissue infections should be addressed immediately     and undergo surgical debridement ASAP.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-orbital-and-preseptal-cellulitis/#management","title":"Management","text":"<ul> <li> <p>Preseptal cellulitis can usually be managed on an outpatient basis     with PO antibiotics (e.g. augmentin) with close followup.</p> </li> <li> <p>However, if condition is worsening, if there is failure to improve     on PO antibiotics, or if concerned for postseptal extension (i.e.,     that the preseptal cellulitis has evolved into an orbital     cellulitis), management generally includes:</p> <ul> <li> <p>IV broad spectrum antibiotics (usually Unasyn + Vancomycin to start     if no intracranial extension; could also do Vancomycin +     Ceftriaxone + Flagyl)</p> </li> <li> <p>Ophthalmology Consult</p> </li> <li> <p>Consider ID consult</p> </li> <li> <p>Consider ENT consult if concomitant sinus disease (most of the time     there is)</p> </li> <li> <p>Consider OMFS consult if suspect etiology is odontogenic</p> </li> <li> <p>Tobradex eye drops QID to affected eye</p> </li> <li> <p>Nasal toilet (afrin, flonase, nasal saline)--usually dictated by ENT</p> </li> <li> <p>Warm compresses at least QID to affected eye</p> </li> <li> <p>Trend daily CRP</p> </li> </ul> </li> <li> <p>If there is failure to improve on the above regimen, a large orbital         abscess, optic nerve stretch on CT scan, evidence of necrotizing         infection, or visual compromise, the patient may need to undergo         surgical drainage.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-papilledema/","title":"Papilledema","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-papilledema/#background","title":"Background","text":"<ul> <li> <p>Papilledema refers to edema of the optic nerve due to increased     intracranial pressure</p> </li> <li> <p>Ophthalmology is often consulted to rule out papilledema in patients     who fit the \u201cIdiopathic Intracranial Hypertension (IIH)\u201d profile, or     with patients with other reasons for high ICP</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-papilledema/#presentation","title":"Presentation","text":"<ul> <li> <p>Symptoms of increased ICP: headaches that vary with position (often     worse with bending over), nausea, vomiting, neck     stiffness/meningismus, pulsatile tinnitus, fevers/chills</p> </li> <li> <p>Visual symptoms of papilledema: transient visual obscurations,     dimming of vision, blurry vision, loss of color vision/red     desaturation, loss of peripheral vision, scotoma.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-papilledema/#evaluation-and-management","title":"Evaluation and Management","text":"<ul> <li> <p>Consult Ophthalmology and Neurology if concerned for papilledema.     Neurosurgery should be involved if there is concern for shunt     failure or other neurosurgical problem.</p> </li> <li> <p>Ophthalmology / Neurology will advise on what imaging to order     (usually MRI / MRV brain with and without contrast, + MRI Orbits     with and without contrast and fat suppression)</p> </li> <li> <p>If no contraindications after imaging, obtain LP with opening     pressure, with CSF sent for cells, protein, glucose, and     infectious/neoplastic workup where appropriate</p> </li> <li> <p>Ophthalmology / Neurology may recommend initiation of PO or IV     acetazolamide (Diamox). These may be contraindicated or need to be     renally dosed if the patient has chronic kidney disease.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-retinal-detachment/","title":"Retinal Detachment and Posterior Vitreous Detachment","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-retinal-detachment/#background","title":"Background","text":"<ul> <li> <p>Retinal detachment (RD) = detachment of retinal tissue from the back     of the eye. Risk factors include trauma, high myopia     (nearsightedness), older age, history of RD in the other eye, prior     eye surgery, and family history.</p> </li> <li> <p>Posterior Vitreous Detachment (PVD) = detachment of vitreous (jelly)     from the retina. PVDs eventually will happen to all adults as the     vitreous liquefies and shrivels with age. Some are asymptomatic.</p> </li> <li> <p>PVDs can lead to RDs, but not always. As the vitreous peels away     from the underlying retina, vitreous can pull a piece of retina with     it, causing a retinal tear. The retinal tear, if not treated, can     evolve into an RD.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-retinal-detachment/#presentation-and-evaluation","title":"Presentation and Evaluation","text":"<ul> <li> <p>Both can present with acute flashes and floaters</p> </li> <li> <p>However, RDs will often present with a black curtain or veil that     comes down somewhere in the patient\u2019s field of vision. PVDs may     result in blurriness, but will not present with veils, scotomas, or     severe loss of vision.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-retinal-detachment/#management","title":"Management","text":"<ul> <li> <p>If patient presents with acute flashes, floaters, and/or black     curtains in field of vision in one eye, consult ophthalmology.</p> </li> <li> <p>If not acute, or if symptoms occur in both eyes simultaneously,     chances are this is not a PVD or an RD. See Approach to Flashes,     Floaters, Spots.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-taking-a-good-history/","title":"Taking a Good Ocular History","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-taking-a-good-history/#history-of-present-illness","title":"History of Present Illness:","text":"<ul> <li> <p>Duration/Onset/Timing of visual or eye symptoms</p> </li> <li> <p>Eye pain? Quality/Severity?</p> </li> <li> <p>Symptoms constant or intermittent?</p> </li> <li> <p>Has this happened to you before?</p> </li> <li> <p>Any flashes/floaters/curtains/veils coming down in your field of     vision? Timing of these?</p> </li> <li> <p>Any associated systemic symptoms (nausea/vomiting, fever/chills,     headaches, neurologic deficits)</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-taking-a-good-history/#past-ocular-history","title":"Past Ocular History:","text":"<ul> <li> <p>Do you wear glasses? For distance or reading or both? Contact     lenses?</p> </li> <li> <p>When was the last time you saw an eye doctor?</p> </li> <li> <p>History of eye surgeries?</p> </li> <li> <p>History of any other eye conditions? Cataracts, glaucoma, macular     degeneration, diabetic retinopathy?</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-taking-a-good-history/#family-history","title":"Family History:","text":"<ul> <li>Family history of any eye diseases? Glaucoma, macular degeneration,     diabetic retinopathy?</li> </ul>"},{"location":"ophthalmology/ophthalmology-taking-a-good-history/#social-history","title":"Social History:","text":"<ul> <li>Use of tobacco, alcohol, illicit drugs?</li> </ul>"},{"location":"ophthalmology/ophthalmology-uveitis/","title":"Uveitis (includes Iritis, Cyclitis, Retinitis, Choroiditis)","text":"<p>Jonathan A. Barnett</p>"},{"location":"ophthalmology/ophthalmology-uveitis/#background","title":"Background","text":"<ul> <li> <p>\u201dUvea\u201d = iris + ciliary body + choroid (these 3 tissues are     connected and make up the vascular layer of the eye)</p> </li> <li> <p>Uveitis = inflammation of either or all of these structures.     However, \u201cuveitis\u201d is a bit of a misnomer, since it is used to     denote inflammation of any ocular component</p> </li> <li> <p>Uveitis is usually associated with autoimmune conditions, but     infections can also cause uveitis.</p> </li> </ul> Anterior Uveitis Intermediate Uveitis Posterior Uveitis Panuveitis Practical synonyms Iritis Pars planitis, Cyclitis Retinitis, Choroiditis, Chorioretinitis Diffuse uveitis Definition Inflammation localized to the anterior segment Inflammation localized to the vitreous cavity and pars plana Inflammation localized to choroid and retina Inflammation involving the anterior, intermediate, and posterior structures Symptoms <p>Vision loss</p> <p>Usually painful</p> <p>Perilimbal redness</p> <p>Vision loss</p> <p>Pain varies</p> <p>Vision loss</p> <p>Pain varies</p> <p>Vision loss</p> <p>Pain varies</p> Common etiologies <p>Idiopathic</p> <p>HLA-B27</p> <p>IBD, psoriatic arthritis, ankylosing spondylitis, reactive arthritis</p> <p>Spillover from anterior uveitis</p> <p>Multiple sclerosis</p> <p>Lymphoma</p> <p>Sarcoid</p> <p>Syphilis</p> <p>TB</p> <p>Immunocompromised (HIV, transplant)</p> <p>CMV, HSV, VZV</p> <p>Vasculitis</p> <p>Sarcoidosis</p> <p>Toxoplasmosis</p> <p>Syphilis</p> <p>TB</p> <p>Lymphoma</p> <p>Behcet\u2019s disease</p> <p>Sarcoid</p> <p>Syphilis</p> <p>TB</p> <p>Toxoplasmosis</p>"},{"location":"ophthalmology/ophthalmology-uveitis/#management","title":"Management","text":"<ul> <li> <p>If you suspect a patient has uveitis, consult ophthalmology for     evaluation.</p> </li> <li> <p>Patients with any of the above associated systemic conditions (e.g.,     IBD) do not need an inpatient Ophthalmology consult unless the     patient has visual symptoms. Referral to outpatient Ophthalmology is     appropriate for routine screening.</p> </li> </ul>"},{"location":"ophthalmology/ophthalmology-wilsonsdisease/","title":"Wilson\u2019s Disease: Ophthalmic Manifestations","text":"<p>Jonathan A. Barnett</p> <ul> <li> <p>The two classic ophthalmic manifestations of Wilson\u2019s disease are     the \u201cKayser-Fleischer ring\u201d (copper deposition around the corneal     limbus) and the \u201cSunflower cataract\u201d (copper deposition in the     lens).</p> </li> <li> <p>Wilson\u2019s disease rarely affects vision (unless the sunflower     cataract is very advanced).</p> </li> <li> <p>Unless the disease is very advanced/has been present for years, it     is impossible for one to detect subtle copper deposition in the     cornea, iridocorneal angle, or lens without an office-based slit     lamp exam and gonioscopy (only available in the outpatient setting).</p> <ul> <li> <p>Furthermore, the presence or absence of a Kayser-Fleischer ring does     not rule in or rule out the disease</p> </li> <li> <p>Testing for decreased ceruloplasmin, urinary copper levels, and     genetic testing are more effective diagnostic methods.</p> </li> </ul> </li> <li> <p>If concerned about the visual impact of a developing sunflower     cataract, an outpatient ophthalmology referral is appropriate.</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/","title":"Asthma","text":"<p>Jared Freitas</p>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/#background","title":"Background","text":"<ul> <li>Typically diagnosed in childhood, but occupational asthma,     aspirin-induced asthma and eosinophilic asthma are more commonly     diagnosed in adults</li> <li>Three most common symptoms: wheezing after trigger, nighttime cough,     and associated dyspnea</li> <li>COPD-asthma overlap syndromes: newer entity that typically involves     intermittent symptoms<ul> <li>Obstruction is present but does not fully resolve with     bronchodilator</li> <li>Consider this diagnosis in a pt w/significant smoking history who is     dx\u2019d with asthma at age &gt;40yo</li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/#evaluation","title":"Evaluation","text":"<ul> <li>Ask about triggers: cold, exercise, URIs, allergens, inhaled         irritants</li> <li>Ask about family history or personal history of atopy, eczema,         allergic rhinitis</li> <li>Exam: wheezing, prolonged expiratory phase; nasal polyps, rhinitis,         eczema</li> <li>Spirometry (PFT\u2019s) with reversible obstruction<ul> <li>FEV1/FVC &lt;0.7; FEV1 12% and 200 mL after bronchodilator</li> </ul> </li> <li>\u201cAll That Wheezes Is Not Asthma\u201d. Must rule out alternative         diagnoses:<ul> <li>Panic attacks, upper airway obstruction, foreign body, vocal cord     dysfunction, CHF (cardiac asthma), COPD, ILD</li> </ul> </li> <li>Consider CBC w/diff to screen for significant anemia and     eosinophilia (associated w/allergic asthma or eosinophilic     pneumonia)</li> <li>If concerned for allergic asthma or allergic bronchopulmonary     aspergillosis, consider measuring total serum IgE levels</li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/#classify-severity-and-assess-for-symptom-control-with-the-rule-of-2s","title":"Classify Severity and Assess for Symptom Control with the RULE OF 2s","text":"<ul> <li>Does the patient have symptoms or require rescue inhaler \u22652 times     per week?</li> <li>Does the patient endorse nighttime symptoms \u2265 2 times per month?</li> <li>Does the patient have to refill rescue inhaler \u2265 2 times per year?</li> <li>Does the patient ever have to limit activity due to asthma symptoms?</li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/#initial-assessment-of-severity","title":"Initial Assessment of Severity","text":"<ul> <li>Intermittent: No to all of the above and FEV1&gt; 80% predicted. Start     at step 1</li> <li>Persistent: Yes to any question above. Start at Step 2<ul> <li>Mild: Less than daily symptoms, less than weekly nighttime symptoms,     minor limitation to activities. FEV &gt;80% predicted</li> <li>Moderate: Daily symptoms, weekly nighttime symptoms, some limitation     to activities. FEV 60-80% predicted</li> <li>Severe: More severe symptoms than above, FEV1 &lt;60% predicted</li> <li>Consider referral to pulmonary</li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/#management","title":"Management","text":"<ul> <li>Aim to use the lowest possible step to maintain symptom control.     Also consider stepping down therapy if pt has been well-controlled     for &gt;3 months</li> <li>Prior to escalating therapy, consider:<ul> <li>Adherence to therapy (including inhaler technique), uncontrolled     comorbidities (allergies, GERD, OSA, etc), and alternative diagnoses</li> <li>Ensure patients receive MDI and spacer teaching for full effect</li> </ul> </li> <li>Updated Guidelines: prn ICS - LABA &gt; prn SABA Step 1 (mild     intermittent) and Step 2 (mild persistent)<ul> <li>Reduces exacerbations, easier to schedule does in future if needed</li> <li>SYGMA Trial showed rescue/prn Budesonide-formoterol (ICS - LABA)     non-inferior to daily ICS-LABA + prn SABA in preventing     exacerbations</li> </ul> </li> <li>Follow-up<ul> <li>Repeat PFTs q3-6 mos after beginning therapy and q1-2 yrs thereafter</li> <li>Regular follow up at least q6 mos for all patients with asthma</li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-asthma/#va-specific-guidance","title":"VA specific guidance","text":"<ul> <li>Mometasone is the formulary ICS and Wixela (fluticasone-salmeterol)     is the formulary ICS/LABA</li> <li>Ordering PFTs: Refer to Pulm section on PFTs for VUMC and VA     specifics</li> <li>Please see above text for updated guidance on using prn ICS \u2013 LABA     for step 1/step 2</li> </ul> <p>Image by National Heart, Blood, and Lung Institute. Distributed under a CC BY 2.5 license.   </p>"},{"location":"outpatient-medicine/outpatient-medicine-chronic-rhinosinusitis/","title":"Chronic Rhinosinusitis","text":"<p>Jared Freitas</p>"},{"location":"outpatient-medicine/outpatient-medicine-chronic-rhinosinusitis/#background","title":"Background","text":"<ul> <li> <p>Inflammatory syndrome of the paranasal sinuses, with objective     evidence of inflammation for &gt; 12 weeks, typically in young to     middle aged adults</p> </li> <li> <p>Symptoms: typically need two of the following:</p> </li> <li> <p>Anterior/posterior mucopurulent nasal drainage</p> </li> <li> <p>Presence of nasal fullness/congestion</p> </li> <li> <p>Facial pain/pressure, sometimes accompanied by headache (most       prevalent but least specific)</p> </li> <li> <p>Reduction in sense of smell</p> </li> <li> <p>Red flag symptoms that require more emergent evaluation by ENT or     NSGY</p> </li> <li> <p>Double vision</p> </li> <li> <p>Proptosis</p> </li> <li> <p>Ophthalmoplegia</p> </li> <li> <p>Severe headache</p> </li> <li> <p>Any focal neurologic deficits</p> </li> <li> <p>In addition to clinical history, patients need objective evaluation     with nasal endoscopy or non-contrasted CT of sinuses (gold standard     imaging modality) to confirm presence of inflammation and presence     of nasal polyps</p> </li> <li> <p>Other conditions to consider on differential:</p> </li> <li> <p>Rhinitis without sinusitis (vasomotor, gustatory, allergic,       idiopathic)</p> </li> <li> <p>Headache and facial pain syndromes</p> </li> <li> <p>Laryngopharyngeal reflux syndrome</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-chronic-rhinosinusitis/#management","title":"Management","text":"<ul> <li> <p>Daily sinus rinses with saline can clear sinuses of secretions,     irritants and allergens</p> </li> <li> <p>Utilizing daily intranasal corticosteroid sprays improve symptoms,     better control when used in conjunction with sprays</p> </li> <li> <p>Short courses of macrolide antibiotics less than 3 weeks duration     along with short course oral corticosteroids for acute exacerbations</p> </li> <li> <p>When to refer to specialist:</p> </li> <li> <p>ENT: Refractory symptoms necessitating rhinoscopy to look for nasal       polyps, anatomical source of obstruction, ability to get direct       culture from sinuses, or for sinus surgery as treatment</p> </li> <li> <p>Allergy/immunology: treatment of causal allergen or associated       immunodeficiency that contributes to recurrent infections</p> </li> <li> <p>10-14 days of oral corticosteroids can also help in patients with     nasal polyps shrink inflamed tissue and decrease obstructive     symptoms but require ongoing nasal steroids to prevent recurrence</p> </li> <li> <p>Daily antileukotriene agents and antihistamines can provide benefit     in patients with an allergic component</p> <p>Smoking cessation can lead to symptom relief in CRS pts with and w/o nasal polyps</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-fatigue/","title":"Fatigue","text":"<p>Thomas Horton</p>"},{"location":"outpatient-medicine/outpatient-medicine-fatigue/#background","title":"Background","text":"<ul> <li>21-33% of primary care patients describe fatigue as an important     problem (even if not CC)</li> <li>Obtain a thorough history and validate the patient's concerns</li> <li>Assess impact on daily life and accommodations the patient has made       to cope</li> <li>Description of fatigue: mental vs. physical; sleepiness/tiredness     vs. \"low energy\"</li> <li>Assess Chronicity: Acute &lt;1 month; subacute 1-6 months; Chronic &gt;6     months</li> <li>Review medication list, age -elated cancer screening, prior lab     values, imaging findings if applicable</li> <li>Brief Fatigue Inventory or Fatigue Assessment Scale can be used for     quantification</li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-fatigue/#common-etiologies","title":"Common Etiologies","text":"System Differential Cardiopulmonary CHF, CAD/Angina, PVD, Obstructive lung disease, OSA, other sleep-related disorders Endocrine Diabetes, hypothyroidism, adrenal insufficiency, electrolyte abnormalities Hematologic/Neoplastic Anemia, occult malignancy Infectious Disease HIV, Mononucleosis, Hepatitis, other viral, TB, fungal, parasitic Medication Use Opioids, benzodiazepines, antihistamines, muscle relaxants, anti-depressants, beta-blockers, GABA analogues, substance use (ETOH, THC, Cocaine) Psychological Depression, anxiety, somatization disorder, dysthymia Rheumatologic Fibromyalgia, PMR, SLE, RA, Sj\u00f6gren's"},{"location":"outpatient-medicine/outpatient-medicine-fatigue/#evaluation","title":"Evaluation","text":"<ul> <li>Complete physical exam</li> <li>Lab tests to order if &gt;1 month duration: CMP, CBC w/ diff, HIV,     Hepatitis B/C, TSH</li> <li>Autoimmune, inflammatory, pregnancy, CK, PPD tests based on       clinical context</li> <li>Assess for mood disorder (PHQ-9; GAD7)</li> <li>Assess for sleep disturbance (STOP-BANG, Epworth Sleepiness Scale)</li> <li>Age appropriate cancer screening if applicable</li> <li>Diagnostic imaging studies based on history and physical exam     findings</li> <li>Screen for domestic violence, housing insecurity, substance use</li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-fatigue/#management","title":"Management","text":"<ul> <li>Treatment is largely specific to underlying etiology of fatigue (if     found)</li> <li>Etiology may never be identified</li> <li>Consider diagnosis of myalgic encephalomyelitis/chronic fatigue       syndrome (ME/CFS) if other causes have been ruled out</li> <li>Continue a supportive relationship with patient</li> <li>Consider empiric trial of antidepressant therapy in those with     residual/idiopathic fatigue with depressed mood even if patient does     not meet MDD criteria</li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/","title":"Hypertension (HTN)","text":"<p>Daniel Motta-Calderon</p>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#background","title":"Background","text":"<ul> <li> <p>Elevated systolic blood pressure and diastolic blood pressure are     associated with increased cardiovascular disease (CVD) risk</p> </li> <li> <p>HTN is the most prevalent modifiable risk factor for premature CVD</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#definitions","title":"Definitions","text":"<ul> <li> <p>ACC/AHA definition of HTN: taking antihypertensive medication or     having a systolic pressure \u2265130 mmHg and/or a diastolic pressure \u226580     mmHg</p> </li> <li> <p>Resistant HTN**:** Uncontrolled BP despite taking 3 antihypertensive     medications including a diuretic OR 4 total medications</p> </li> <li> <p>Whitecoat HTN: Mean BPs lower than threshold of HTN based on     out-of-office measurements (falsely elevated measurements during     visits). If SBP &gt; 130 but \\&lt; 160, consider screening for white coat     HTN with home monitoring</p> </li> <li> <p>Masked HTN: Mean BP at/above threshold for hypertension based upon     out-of-office measurements (falsely decreased measurements during     visits). If office SBPs consistently 120-129, consider screening for     masked HTN with home monitoring</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#screening","title":"Screening","text":"<ul> <li>Grade A USPTF rec: Screen all adults &gt;18. Screen adults at least     semiannually if have risk factors for HTN (obesity, AA), or if     previously measured SBP 120-129</li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#diagnosis","title":"Diagnosis","text":"<ul> <li> <p>Proper BP measurement:\u00a0 legs uncrossed, supported arm at level of     heart, after 5 minutes of rest and with empty bladder; avoid     caffeine or tobacco 30 minutes prior</p> </li> <li> <p>Ideally, primary detection in clinical setting (BP \u2265130/80) followed     by confirmation with ambulatory blood pressure monitoring (ABPM):\u00a0</p> <ul> <li> <p>24hrs mean of systolic \u2265125 or diastolic \u226575mmHg\u00a0</p> </li> <li> <p>Daytime mean systolic \u2265130mmHg or diastolic \u226580mmHg\u00a0\u00a0</p> </li> <li> <p>Nighttime mean systolic \u2265110 mmHg or \u226565 diastolic mmHg\u00a0</p> </li> </ul> </li> <li> <p>If ABPM not possible, 2-3 outpatient measurements at 1-4 week     intervals are required to confirm diagnosis\u00a0\u00a0</p> </li> <li> <p>BP &gt;160/100mmHg in the outpatient setting with evidence of     end-organ damage (ischemic CMP, CVA, hypertensive retinopathy, LV     hypertrophy, CKD)\u00a0</p> </li> <li> <p>Any patient presenting with hypertensive emergency or severe     asymptomatic hypertension (&gt;180/120mmHg)\u00a0</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Assess target organ damage as pertinent: CVA, retinopathy, LV     hypertrophy/dysfunction, HF, CAD, CKD, PAD.\u00a0\u00a0</p> <ul> <li> <p>BMP, CBC, lipid panel, UA, TSH, EKG. Consider additional testing     including TTE, urine Alb:Cr ratio, or uric acid, ABI\u00a0</p> </li> <li> <p>Calculate ACSVD 10y risk</p> </li> </ul> </li> <li> <p>Distinguish between primary (90% incidence) and secondary HTN     (10%):\u00a0</p> <ul> <li> <p>Suspect 1\u00ba if gradual onset, family hx, associated with weight gain     &amp; lifestyle factors\u00a0</p> </li> <li> <p>Suspect 2\u00ba if drug-resistant, abrupt onset, onset \\&lt;30yo,     exacerbation of previously controlled HTN, onset of diastolic     hypertension in older adults &gt;65yo, unprovoked or excessive     hypokalemia</p> </li> </ul> </li> </ul> Common 2o Causes Suggestive Features Diagnostic Testing Primary Kidney Disease Hypervolemia, \u2191 Cr, abnormal UA, family history of PKD UA, Urine Alb:Cr ratio, Renal US Renovascular disease (RAS or FMD) Renal bruit, \u2191 Cr after ACE-I or ARB, young age Doppler renal US OSA Apneic events, somnolence, obesity Polysomnography Primary Hyperaldosteronism Hypokalemia, metabolic alkalosis, resistant HTN, etc. Start with plasma aldosterone/renin levels Drug or Alcohol Induced H/o substance use (cocaine, caffeine, nicotine, medications) UDS, BP improvement after withdrawal of suspected agent Uncommon 2o causes: Pheochromocytoma, Cushing\u2019s syndrome, thyroid dysfunction, aortic coarctation, primary hyperparathyroidism, acromegaly, congenital adrenal hyperplasia"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#management","title":"Management","text":"ACA-AHA guidelines (2017) (based on SPRINT trial) Elevated BP systolic 120-129 mmHg AND diastolic \\&lt;80 mmHg Non-pharmacological interventions and reassess in 3-6 months Stage 1 systolic 130-139 mmHg OR diastolic 80-89 mmHg If 10-y CVD risk \u226510%, non-pharm intervention + BP-lowering medication. Reassess monthly until BP goal met, then every 3-6 months Stage 2 systolic \u2265140 mmHg OR diastolic \u226590 mmHg Non-pharmacological intervention + BP lowering medication. Reassess monthly until BP goal met, then every 3-6 months"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#non-pharmacological-interventions-regardless-of-stage","title":"Non-pharmacological interventions: regardless of stage","text":"<ul> <li> <p>8-14 mmHg \u2193: DASH diet (fresh produce, whole grains, low-fat dairy)\u00a0</p> </li> <li> <p>5-10 mmHg \u2193: Weight loss (10 kg or 22 lbs), expect 1mm Hg for every     1kg reduction in body weight\u00a0</p> </li> <li> <p>3-9 mmHg \u2193: Na+ restriction (1.5 g / day), aerobic exercise for     90-150 min/week, increased intake of K+ rich foods\u00a0</p> </li> <li> <p>2-4 mmHg \u2193: Moderate EtOH (2 drinks/day for men; 1 drink/day for     women)\u00a0</p> </li> <li> <p>Consider deprescribing or switching amphetamines, antidepressants     (MAOi, SNRIs, TCAs), atypical antipsychotics (clozapine,     olanzapine), caffeine, decongestants (phenylephrine,     pseudoephedrine), cyclosporine, oral contraceptives, NSAIDs,     steroids</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#pharmacologic-therapy","title":"Pharmacologic therapy","text":"<ul> <li> <p>Three main classes of drugs use for initial monotherapy for primary     hypertension include: ACE-Is/ARBs, CCBs (most frequently a     dihydropyridine), and thiazide diuretics</p> </li> <li> <p>Note that there is wide variability among patients as some will     respond to one antihypertensive drug but not another</p> </li> <li> <p>Black patients often respond best to CCBs or thiazides</p> </li> <li> <p>Individualize therapy depending on comorbidities</p> </li> </ul> Drug Class Common Drugs Side effects/ comments Thiazide diuretics HCTZ 12.5-50 mg\u202f\u00a0 Chlorthalidone 12.5-25 mg: preferred agent based on RCT evidence though inc risk electrolyte abnormalities <p>HypoNa, HypoMg, HypoK, increased uric acid, hypovolemia,\u00a0</p> <p>Orthostatic hypotension\u00a0</p> ACE-I <p>Lisinopril, benazepril, fosinopril, quinapril (all 5-40 mg daily)</p> <p>Ramipril, 2.5-20 mg in 1-2 doses\u00a0</p> Angioedema (more common in AA) AKI, hyperkalemia, cough\u00a0 ARBs <p>Losartan 25-100 mg in 1-2 doses\u00a0</p> <p>Candesartan 8-32 mg in 1-2 doses\u00a0</p> <p>Irbesartan 150-300 mg\u00a0 Valsartan 80-320 mg\u00a0</p> AKI, hyperkalemia\u00a0 Angioedema\u00a0(less frequent than ACE-I)\u00a0 CCB <p>Dihydropyridine:\u00a0 Amlodipine 2.5-10 mg 1-2 doses Nifedipine 30-120 mg in 1-2 doses\u00a0</p> <p>Nondihydropyridine:\u00a0</p> <p>Diltiazem ER 120-480 mg Verapamil ER 100-480 mg\u00a0</p> <p>Dihydropyridine:\u202f\u00a0 Peripheral edema\u202f\u00a0 Worsening proteinuria\u00a0</p> <p>\u202fNondihydropyridine:\u202f\u00a0 Constipation\u00a0 Heart block if used with BB\u202f\u00a0 Contraindicated in HFrEF\u00a0</p> Aldosterone receptor antagonists Spironolactone 12.5-50 mg\u202f\u00a0 Eplerenone 25-50 mg\u00a0 <p>Good choice for resistant HTN\u00a0</p> <p>AKI, hyperkalemia\u00a0 Spironolactone\u2014gynecomastia\u00a0&amp; sexual side effects\u00a0</p> BB Carvedilol 6.25-25 mg bid\u202f\u00a0 Metoprolol succinate 25-200 mg qd\u00a0 Nebivolol 5-10 mg\u00a0 Labetalol 100-300 bid\u00a0 Reserve for CHF/CAD\u202f\u00a0 Hyperglycemia, fatigue,\u202f\u2193\u202fHR\u00a0 \u03b2\u202f1-selective may be safer in pts with COPD, asthma, diabetes\u00a0 Vasodilators Hydralazine 25-100 mg bid or tid\u202fMinoxidil 5-10 mg\u00a0 Reflex tachycardia, fluid retention\u00a0 Centrally- acting agents (alpha 2 agonists) <p>Clonidine 0.1-0.2 qd,\u00a0(Weekly transdermal patch is preferred to avoid non- compliance and subsequent reflex HTN)\u00a0</p> <p>Methyldopa 250-500 mg qd\u00a0</p> Rebound hypertension, withdrawal -Reserved for resistant hypertension due to unfavorable side effect profile\u00a0 **Conditions\u00a0** **Drug Class\u00a0** Heart failure\u00a0 ACE-I/ARB or ARNI + BB + spironolactone + diuretics\u202f\u00a0 CAD ACE-I or BB\u00a0 Diabetes\u00a0 All first line agents, ACE-I/ARB if presence of albuminuria\u202f\u00a0 CKD\u00a0 ACE-I/ARB Recurrent stroke prevention\u00a0 ACE-I, thiazide diuretic\u202f\u00a0 <p>If not meeting goals, combination therapy &gt; doubling single agent (more effective, less side effects)\u00a0</p> <ul> <li> <p>Preferred combinations\u00a0</p> <ul> <li> <p>ACEi/ARB + CCB </p> </li> <li> <p>ACEi/ARB + CCB + thiazide.\u00a0</p> </li> <li> <p>ACEi/ARB + CCB + MRA\u00a0</p> </li> <li> <p>Do not combine beta-blockers with non-dihydropyridines.\u00a0</p> </li> </ul> <p>Therapy goals\u00a0</p> <ul> <li> <p>General population: \\&lt;130/80mmHg\u00a0</p> </li> <li> <p>Frail patients with orthostatic hypotension, limited life     expectancy: consider less aggressive goal \\&lt;140/90\u00a0</p> </li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#additional-information","title":"Additional Information","text":"<ul> <li> <p>VA Specific Guidance:     https://www.healthquality.va.gov/guidelines/CD/htn/</p> </li> <li> <p>Agents that require PADR:</p> <ul> <li> <p>ACEIs - Quinapril</p> </li> <li> <p>ARBs \u2013 Candesartan, Irbesartan, Olmesartan, Telmisartan</p> </li> <li> <p>Beta blockers \u2013 Labetalol, Nebivolol</p> </li> <li> <p>DHP \u2013 Nifedipine SA</p> </li> <li> <p>Aldosterone Receptor Antagonist \u2013 Eplerenone</p> </li> <li> <p>Alpha2 Agonist \u2013 Clonidine patch</p> </li> </ul> </li> <li> <p>How to get BP cuff at the VA</p> <ul> <li>Prosthetics consult BP Cuff TVHS. *Must answer all questions in the     consult, including blood pressure cuff size</li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-hypertension/#low-cost-options","title":"Low-cost options","text":"<ul> <li> <p>Publix: Free (amlodipine, lisinopril), $7.50 x 90 days (losartan,     metoprolol tartrate, HCTZ)</p> </li> <li> <p>Walmart: $4/month (amlodipine, carvedilol, enalapril, hydralazine,     HCTZ, irbesartan, lisinopril, losartan, ramipril)</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/","title":"Lipids","text":"<p>Brittany Saldivar</p>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#background","title":"Background","text":"<ul> <li> <p>1\u00ba Prevention: pts at increased risk who have not yet had a vascular     event</p> </li> <li> <p>2\u00ba Prevention: pts with pre-existing occlusive vascular disease or     ASCVD (e.g., stroke, TIA, CAD + angina, ACS, coronary or arterial     revascularization, PAD)</p> </li> <li> <p>Screening: USPSTF 2016 Guidelines: q5years for adults 40-75yrs</p> <ul> <li> <p>ACC/AHA 2019 Guideline: adults 20-39 q 4-6yrs; &lt;21yrs if strong fam     hx; 40-75 \u201croutinely\u201d assess CV risk and calculate 10 yr ASCVD risk     (lipid pnl q3-12 months)</p> </li> <li> <p>Dot phrase: .ASCVD2013</p> </li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Fasting vs Non-Fasting Lipid Panel</p> <ul> <li>Triglycerides are most impacted by non-fasting testing which can     artificially lower LDL-C depending on how the laboratory     measures/calculates LDL. Consider fasting lipid panels when     triglyceride levels are high</li> </ul> </li> <li> <p>Consider 2\u00ba causes of HLD in initial workup: hypothyroidism, DM,     EtOH use, smoking, liver disease, nephrotic syndrome, CKD, meds     (e.g., thiazide, glucocorticoids)</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#management","title":"Management","text":"<ul> <li> <p>Lifestyle changes:</p> <ul> <li> <p>Heart Healthy Diet: \u2193 trans/saturated fats, choose skim milk,     low-fat dairy products</p> </li> <li> <p>Emphasizes fruits, vegetables, whole grains, poultry, fish, nuts and     olive oil, while limiting red and processed meats, sodium and     sugar-sweetened foods and beverages</p> </li> <li> <p>Promote a healthy weight, regular exercise, smoking cessation, limit     EtOH</p> </li> </ul> <p>Statin Therapy</p> <ul> <li> <p>Initiate as outlined in the following algorithms</p> </li> <li> <p>Check AST/ALT prior to initiation</p> </li> <li> <p>Note that PCE used to estimate ASCVD risk is best validated for     non-Hispanic whites and blacks. Consider use of additional risk     prediction tools/factors in other patient populations</p> </li> </ul> </li> </ul> <p> </p> <p>Figure from 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease</p> <p> </p> <p>Figure from 2018 ACC/AHA Guideline on Management of Blood Cholesterol</p> High Intensity (Decr LDL-C by &gt; 50%) Moderate Intensity (Decr LDL-C by 30% - 49%) Low Intensity (Decr LDL-C by &lt;30%) <p>Atorvastatin (40mg) 80mg</p> <p>Rosuvastatin 20mg (40mg)</p> <p>Atorvastatin 10mg (20mg)</p> <p>Rosuvastatin (5mg) 10mg</p> <p>Simvastatin 20 - 40mg</p> Simvastatin 10mg <p>Pravastatin 40mg (80mg)</p> <p>Lovastatin 40mg (80mg)</p> <p>Fluvastatin XL 80mg</p> <p>Fluvastatin 40mg BID</p> <p>Pitavastatin 1-4mg</p> <p>Pravastatin 10-20mg</p> <p>Lovastatin 20 mg</p> <p>Fluvastatin 20-40mg</p> *Bold denotes dosing with RCT proven LDL lowering benefit"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#statin-options","title":"Statin Options","text":""},{"location":"outpatient-medicine/outpatient-medicine-lipids/#statin-side-effects","title":"Statin Side effects:","text":"<ul> <li> <p>Spectrum of statin associated muscle symptoms (SAMS) include     myalgias, myopathy, rhabdomyolysis, autoimmune myopathy</p> <ul> <li>Myalgias: bilateral involving large muscle groups, onset within     weeks of initiation of therapy and should resolve within weeks of     cessation; CK should be normal</li> </ul> </li> <li> <p>Consider evaluation with CK, BMP, TSH, and vitamin D</p> </li> <li> <p>ACC has a \u201cStatin Intolerance Calculator\u201d to help assess etiology of     symptoms</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#additional-information","title":"Additional Information","text":"<ul> <li> <p>If patient is not tolerating a statin, consider:</p> <ul> <li> <p>Holding statin until symptoms resolve and trialing lower dose or     alternative statin (Pravastatin and Fluvastatin may have lower risks     of myopathy)</p> </li> <li> <p>Every other day dosing with atorvastatin and rosuvastatin (longer     half-lives)</p> </li> </ul> </li> <li> <p>If repeated failed attempts, consider alternative agents: Ezetimibe,     PCSK9 inhibitor</p> </li> <li> <p>PCSK9 inhibitor requires referral to Lipid Clinic</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#hypertriglyceridemia","title":"Hypertriglyceridemia:","text":"<ul> <li> <p>Moderate: TG 175-499 mg/dL; Moderate-severe 500 - 999; Severe: TG &gt;     1000</p> </li> <li> <p>Focus on addressing lifestyle factors and stopping medication that     increase TG\u2019s (HCTZ, some BB\u2019s, estrogens, some ART, antipsychotics)</p> </li> <li> <p>Consider medical therapy when TG&gt; 500mg/dL (increased risk of     pancreatitis):</p> <ul> <li> <p>Omega-3-fatty acids (icosapent ethyl) 4gm daily or Vascepa 4gm     daily</p> </li> <li> <p>Fibrates: Fenofibrate 120 mg daily (avoid in CKD), Gemfibrozil 600mg     bid (increased risk of myopathy with concomitant statin)</p> </li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-lipids/#va-specific-guidelines","title":"VA-Specific Guidelines","text":"<ul> <li> <p>https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp</p> </li> <li> <p>Lowest LDL goal recognized for VA Criteria for Use is 100</p> </li> <li> <p>Preferred statins: Atorvastatin, Simvastatin, Lovastatin</p> </li> <li> <p>Statins that require PADR: Pravastatin, Rosuvastatin (2nd line high     intensity statin)</p> <ul> <li>Must have documented intolerances or drug-drug interaction to all     preferred statins</li> </ul> </li> <li> <p>Other agents that require PADR:</p> <ul> <li> <p>Ezetimibe</p> <ul> <li> <p>Pt has tried and failed or not tolerated all statins (allergy,     AE, etc.)</p> </li> <li> <p>Pt not meeting goal on max dose of statin PLUS bile acid     sequestrants or niacin</p> </li> </ul> </li> <li> <p>Fenofibrate</p> <ul> <li> <p>Pt has tried all formulary alternatives or has contraindication     to use of formulary alternatives (statin, niacin, gemfibrozil,     cholestyramine, fish oil)</p> </li> <li> <p>If TG &gt; 500 mg/dL, fenofibrate should be approved</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-obesitynutrition/","title":"Obesity/Nutrition","text":"<p>Mackenzie Samson</p>"},{"location":"outpatient-medicine/outpatient-medicine-obesitynutrition/#background","title":"Background","text":"<ul> <li> <p>BMI = Body Weight (kg) / Height (meters)2</p> </li> <li> <p>Underweight = BMI \\&lt;18.5</p> </li> <li> <p>Normal = BMI 18.5-24.9</p> </li> <li> <p>Overweight = BMI 25.0-29.9</p> </li> <li> <p>Obesity:</p> <ul> <li> <p>Class I 30-34.9</p> </li> <li> <p>Class II 35-39.9</p> </li> <li> <p>Class IIIA 40-44.9</p> </li> <li> <p>Class IIIB 45-49.9</p> </li> <li> <p>Class IIIC 50+</p> </li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-obesitynutrition/#management","title":"Management","text":"<ul> <li> <p>Goals: Target initial weight loss of 5-7% body weight, schedule     frequent follow up to assess progress. Request pts send 48 hr food     log. Encourage accountability \u201cbuddies.\u201d Consider weight loss apps:     My Fitness Pal, Lose it, Noom</p> </li> <li> <p>Dietary options:</p> <ul> <li> <p>Calorie restriction &gt; macronutrient composition (e.g., low fat, low     carb)</p> </li> <li> <p>Mediterranean: high in unsaturated fats, fruit/veg, legumes, grain,     moderate dairy &amp; EtOH, less meat. Adherence leads to decreased     overall mortality and CV mortality; may decrease diabetes incidence     independent of weight loss</p> </li> <li> <p>Dot phrases below for pictoral representation of cultural diets     adapted to fit Mediterranean guidelines (Asian, African, Latin     American)</p> </li> <li> <p>DASH: High in fruits/vegetables, moderate dairy, \\&lt; 25% caloric     intake from fat (decreases SBP/DBP)</p> </li> </ul> </li> <li> <p>Exercise: &gt;30 min, 5-7 days per week, ideally a combo of aerobic +     resistance training.</p> <ul> <li>Exercise alone is not sufficient for weight loss</li> </ul> </li> <li> <p>Medications: If BMI \u226530 or BMI \u226527 with \u22651 comorbidity. Significant     short term weight loss (~ 5-15 lbs), but weight is typically gained     back when stopped. See table below</p> </li> <li> <p>Referral to medical weight loss: If BMI \u2265 30 or BMI \u226527\u00a0with     comorbid conditions (fatty liver disease, diabetes mellitus, HTN,     OSA)</p> </li> <li> <p>Referral to surgical weight loss: If BMI \u226540 or BMI \u226535 with     comorbid conditions</p> </li> <li> <p>VA: consider referral to MOVE program (in person/telehealth options)</p> </li> </ul> Medication Mechanism Common Side Effects Orlistat (Xenical) Reduces fat adsorption Diarrhea, gas, leakage of oily stools, stomach pain Phentermine-topiramate (Qsymia) Phentermine: appetite suppression  Topiramate (anticonvulsant, migraine txt): ?appetite suppression, ?altered satiety perception Constipation, dizziness, dry mouth, taste changes, tingling of hands and feet, insomnia Naltrexone-bupropion (Contrave) Naltrexone (partial opioid antagonist; used for alcohol dependence): ?altered satiety perception  Bupropion (antidepressant): ?altered satiety perception Constipation, diarrhea, dizziness, dry mouth, headache, BP, tachycardia, insomnia, liver damage, nausea/vomiting Liraglutide (Saxenda) Appetite suppression; quickens satiety  (Victoza: lower dose formulation, FDA-approved for T2DM) Nausea, diarrhea, constipation, abdominal pain, headache, tachycardia Phentermine (Ionamin) Reduces appetite Note: FDA-approved only for short-term use\u2014up to 12 weeks Dry mouth, constipation, insomnia, dizziness, nervousness/ restlessness headache, HTN, tachycardia Semaglutide (Ozempic/Rybelsus) Glucagon-like peptide-1 receptor agonist; reduces appetite Nausea, vomiting, diarrhea, abdominal pain, constipation"},{"location":"outpatient-medicine/outpatient-medicine-obesitynutrition/#additional-information","title":"Additional Information","text":"<ul> <li> <p>EPIC Dot phrases:</p> <ul> <li> <p>.NHFOODINSECURITY\u00a0</p> </li> <li> <p>.NHFOODASIANDIET\u00a0</p> </li> <li> <p>.NHFOODLATINDIET\u00a0</p> </li> <li> <p>.NHFOODAFRICANDIET\u00a0</p> </li> <li> <p>.NHFOODHEALTHYPLATE\u00a0</p> </li> <li> <p>.NHOBESITYYMCA\u00a0</p> </li> </ul> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-outpatient-anxiety-depression/","title":"Approach to Outpatient Anxiety/Depression","text":"<p>Kunal Patel</p>"},{"location":"outpatient-medicine/outpatient-medicine-outpatient-anxiety-depression/#background","title":"Background","text":"<ul> <li> <p>Anxiety disorders: generalized anxiety disorder (GAD), panic     disorder (PD), agoraphobia, social anxiety disorder (SAD), specific     phobia</p> </li> <li> <p>Some of the most prevalent psychiatric disorders</p> </li> <li> <p>Age of onset varies: SAD (~teens), PD (~20s), GAD (broad range,       incl. &gt;50)</p> </li> <li> <p>Depression: can refer to a mood state, syndrome, or mental disorder</p> </li> <li> <p>1-year prevalence of 10%; lifetime prevalence of 21%</p> </li> <li> <p>USPTF recommends screening for depression in the general adult       population</p> </li> <li> <p>Average age of onset 30 years</p> </li> <li> <p>More common in females (2:1), younger adults, lower income patients,       and those who are divorced, separated, or widowed</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-outpatient-anxiety-depression/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Anxiety disorders</p> </li> <li> <p>See table for features to elicit in history</p> </li> <li> <p>Labs (not all may be necessary): CBC, BMP, TSH, UA, EKG, UDS</p> </li> <li> <p>Major depressive disorder (MDD)</p> </li> <li> <p>See table for features to elicit in history</p> </li> <li> <p>Labs (not all may be necessary): CBC, BMP, TSH, RPR, hCG, UDS, B12,       Folate, EKG</p> </li> <li> <p>Determine severity: mild, moderate, severe</p> <ul> <li>Degree of functional impairment and disability</li> </ul> </li> </ul> <p>Disorder</p> <p>(Symptom scales)</p> DSM-5 Criteria Symptoms/features <p>Generalized Anxiety Disorder</p> <p>(GAD-7, Hamilton Anxiety Scale)</p> <p>Excessive anxiety/worry with \u22653 of 6 sx occurring most days for &gt;6 months</p> <p>Difficult to control worry</p> <p>Causes clinically significant distress</p> <p>Not attributable to something else</p> <p>Restlessness</p> <p>Fatigued</p> <p>Difficulty concentrating</p> <p>Irritability</p> <p>Muscle tension</p> <p>Sleep disturbance</p> Panic Disorder Recurrent panic attacks with 1 or more attacks followed by &gt;1 month of fear of another panic attack (\u22654 sx) or maladaptive behavior <p>Palpitations</p> <p>Sweating</p> <p>Trembling</p> <p>SOB</p> <p>Feeling of choking</p> <p>Chest pain</p> <p>Nausea</p> <p>Dizziness, lightheaded</p> <p>Chills/heat sensation</p> <p>Paresthesias</p> <p>Derealization/depersonalization</p> <p>Fear of losing control</p> <p>Fear of dying</p> Social Anxiety Disorder Fear of social or performance situations to the point where there is impairment in function <p>Avoidance behavior</p> <p>Anxiety out of proportion</p> <p>Anxiety interfering with living</p> <p>Fear of scrutiny, embarrassment</p> <p>Fear not better explained by other medical condition</p> <p>Major Depressive Disorder</p> <p>(PHQ-9, HAM-D, MDI, Montgomery-Asberg Depression Rating Scale)</p> <p>\u22655 sx during same 2 week period; depressed mood and/or loss of interest/pleasure must be present; exclude sx clearly due to other medical condition</p> <p>+</p> <p>Sx cause significant distress, not attributable to other medical condition or substance, not better explained by other psychotic disorders, no history of manic or hypomanic episode</p> <p>Depressed mood</p> <p>Loss of interest/pleasure</p> <p>Weight gain/loss</p> <p>Insomnia/hypersomnia</p> <p>Psychomotor agitation/retardation</p> <p>Fatigue</p> <p>Feeling worthless/guilt</p> <p>Decreased concentration</p> <p>Thoughts of suicide/death</p>"},{"location":"outpatient-medicine/outpatient-medicine-outpatient-anxiety-depression/#management","title":"Management","text":"<ul> <li> <p>Anxiety</p> </li> <li> <p>Psychotherapy and/or pharmacotherapy</p> </li> <li> <p>Depression</p> </li> <li> <p>Mild: psychotherapy and symptom monitoring</p> </li> <li> <p>Moderate: psychotherapy and pharmacotherapy</p> </li> <li> <p>Severe: psych consult, psychotherapy, pharmacotherapy</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-outpatient-anxiety-depression/#psychotherapy","title":"Psychotherapy","text":"<ul> <li> <p>Cognitive behavioral therapy: identifying and modifying negative     thoughts</p> </li> <li> <p>Behavioral activation: scheduling positive activities and increasing     positive interactions</p> </li> <li> <p>Interpersonal psychotherapy: addressing interpersonal issues in     structured manner</p> </li> <li> <p>Find with psychotherapists through VUMC behavioral health referral     or psychologytoday.com</p> </li> <li> <p>VA specific: First refer to PCMHI (teams for same day assessment,     otherwise consult) and then if needed to BHIP</p> </li> </ul>"},{"location":"outpatient-medicine/outpatient-medicine-outpatient-anxiety-depression/#pharmacotherapy","title":"Pharmacotherapy","text":"<ul> <li> <p>Good starting agents are SSRIs/SNRIs</p> </li> <li> <p>Choose based on patient\u2019s specific symptoms, age, adverse effects,     co-morbidities, and any potential drug-drug interactions</p> </li> <li> <p>Typically, start at low doses and titrate up every 2 weeks as needed     until maximum dose reached</p> </li> <li> <p>Full effects not seen until 8-12 weeks, should wait this time before     switching</p> </li> <li> <p>If no response, switch to another SSRI/SNRI</p> </li> <li> <p>If partial response, augment</p> </li> <li> <p>Anxiety disorders: buspirone or gabapentin/pregabalin</p> </li> <li> <p>MDD: Addition of second agent from different class (e.g. bupropion)</p> </li> </ul> Drug Daily dose Adverse effects Other considerations SSRIs GI, sexual dysfunction, weight gain Citalopram <p>Initial: 20 mg</p> <p>Target: 20-40 mg</p> <p>QTc++ (Most QT prolonging)</p> <p>Sedation</p> Preferred in older adults due to safety profile Black-box for doses &gt;40 for QT prolongation Escitalopram <p>Initial: 10 mg</p> <p>Target: 10-20 mg</p> QTc+ Preferred in older adults due to safety profile the only true serotonin selective so least off target effects, less drug-drug interactions Fluoxetine <p>Initial: 20 mg</p> <p>Target: 20-80mg</p> <p>The only weight neutral SSRI</p> <p>Activating</p> <p>QTc+</p> Long half-life (low withdrawal risk), 1 wk wash-out when switching Fluvoxamine <p>Initial: 50 mg</p> <p>Target: 50-200 mg</p> QTc+ Low SD, good for GAD + MDD but many drug-drug interactions, higher doses require BID schedule Paroxetine (IR) <p>Initial: 20 mg</p> <p>Target: 20-50 mg</p> <p>Anticholinergic sedating</p> <p>Worst SD</p> <p>Least QTc</p> Short half-life (high risk of withdrawal). Not recommended in older adults due to anticholinergic effects. Sertraline <p>Initial: 50 mg</p> <p>Target: 50-200 mg</p> <p>QTc+, high SD</p> <p>Activating</p> Preferred in older adults due to safety profile SNRIs GI, sexual dysfunction, activating Duloxetine <p>Initial: 30-60 mg</p> <p>Target: 60-120 mg</p> Some weight gain Good for attention and low energy, good for pain Venlafaxine <p>Initial: 37.5-75 mg</p> <p>Target: 150-375 mg</p> <p>QTc+</p> <p>Worst SD</p> <p>Some weight gain</p> <p>Diastolic HTN</p> Risk of withdrawal, good for attention and low energy Desvenlafaxine <p>Initial: 25-50 mg</p> <p>Target: 50-100 mg</p> Diastolic HTN Risk of withdrawal, good for attention and low energy TCAs Anticholinergic+++, drowsiness+++, SD+++, weight gain+++ Amitriptyline <p>Initial: 25 mg</p> <p>Target: 150-300 mg</p> QTc+ Greater risk profile than others; not first-line. Clomipramine <p>Initial: 25 mg</p> <p>Target: 75-250 mg</p> QTc++ Greater risk profile than others; not first-line. Others Buspirone <p>Initial: 10-15 mg</p> <p>Target: 15-60 mg</p> Dizziness, HA, nervousness, drowsiness, activating <p>Anxiety disorders,</p> <p>add-on for MDD (off-label)</p> Mirtazapine <p>Initial: 7.5-15 mg</p> <p>Target: 15-45 mg</p> Drowsiness+++, anticholinergic, weight gain, dizziness, QTc Good add-on with SSRI/SNRI for MDD; good for sleep, nightly dosing Trazodone <p>Initial: 100 mg</p> <p>Target: 200-400 mg</p> Drowsiness+++, dizziness, blurred vision, constipation, priapism, QTc++ Good for sleep- typically used at lower doses for insomnia Bupropion <p>Initial: 150 mg</p> <p>Target: 150 mg BID</p> Dry mouth, nausea, activating, dizziness, sweating, QTc, lowers seizure threshold Good add-on with SSRI/SNRI for MDD Pregabalin <p>Initial: 150 mg/day</p> <p>Target: 150-600 mg divided BID or TID</p> Dizziness, drowsiness, resp depression, falls, edema, SJS/rash, DRESS Anxiety disorders as adjunct (off-label), consider if another indication (neuropathic pain) Gabapentin <p>Initial: 100-300 mg/day</p> <p>Target: 2.4g/day divided BID or TID</p> Dizziness, drowsiness, resp depression, falls, edema, SJS/rash, DRESS Anxiety disorders as adjunct (off-label), consider if another indication (neuropathic pain)"},{"location":"outpatient-medicine/outpatient-medicine-preventative-medicine/","title":"Preventive Medicine/Screening: (USPSTF)","text":"<p>Christina Snider</p> <ul> <li> <p>Refer to US Preventative Services Task Force for complete list of     Grade A &amp; B recommendations:     https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-and-b-recommendations</p> </li> <li> <p>Recommend downloading the \u201cCDC Vaccine Schedules\u201d App on your phone     to easily filter by medical condition or look at contraindications</p> </li> </ul> Preventative Measures for ALL patients Cholesterol screening <p>Men &gt;35 or 20-35 with CV risk</p> <p>Women &gt;45 or 20-45 with CV risk</p> UpToDate: Grade 2C Colorectal cancer <p>All adults age 45-75</p> <p>FOBT annually</p> <p>FIT annually</p> <p>FIT-DNA (Cologuard) q1-3 years</p> <p>Colonoscopy q 10 years</p> <p>Flexible sigmoidoscopy q 5 years</p> <p>Screen earlier if: family hx of CRC or adenomatous polyps at age &lt; 60, hx of IBD, a confirmed or suspected hereditary CRC syndrome, or a hx abdominal/pelvic radiation</p> Grade A for ages 50-75; Grade B for ages 45-50 Depression Screen for depression in general adult populations. If screening, must ensure systems are in place for accurate diagnosis, effective treatment, and appropriate follow up Grade B Diabetes screening Adults age 35-70 who are overweight or obese Grade B Falls Provide exercise interventions to prevent falls in community-dwelling adults &gt;65 years old who are at increased risk for falls Grade B Cardiovascular health Blood pressure screening annually adults &gt;18 Grade A Aspirin 81 mg in age 50-59 with ASCVD risk &gt;10% in 10 years, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. Grade B Statin: See section on Lipids Grade B Hepatitis C Adults aged 18 to 79 years (one time screening) Grade B HIV <p>All adolescents and adults 15-65</p> <p>(one time screening)</p> Grade A Lung cancer <p>Low-dose CT adults 50-80 w/20 pack year smoking history and currently smoke or quit within the past 15 years</p> <p>Should discuss risk vs benefits, particularly in pts with serious co-morbidities who may not tolerate/desire surgery or aggressive treatment.</p> Grade B Obesity BMI annually in all adults Grade A Preventative Measures for WOMEN: Cervical cancer <p>Ages 21-29: q 3 yrs with cervical cytology alone.</p> <p>Ages 30-65: q 3 yrs with cervical cytology alone, every 5 years w/ high-risk human papillomavirus (hrHPV) testing alone</p> <p>or q 5 yrs with hrHPV testing in</p> <p>combination with cytology (co-testing)</p> <p>***ACS 2020 guideline change \u2013Age 25-65: preferred HPV test alone q 5 years (or HPV/Pap co-test every 5 years or a Pap every 3 years)***</p> Grade A Breast cancer <p>Women 50-74: q2 years</p> <p>ACS recommends beginning at age 40, Yearly</p> <p>If family or personal history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated BRCA1/2 gene mutations - should assess risk and refer to genetic counseling.</p> Grade B Folic acid All women who are planning or capable of pregnancy should take daily folic acid supplement (0.4 \u2013 0.8 mg daily) Grade A <p>Chlamydia</p> <p>Gonorrhea</p> All sexually active women &lt; 24, older women with increased risk Grade B Osteoporosis (DEXA) Women &gt;65, postmenopausal women &lt;65 with increased osteoporosis risk (can use FRAX tool) Grade B Preventive Measures for MEN Abdominal aortic aneurysm (AAA) screening Men Ages 65-75 who ever smoked (at least 100 cigarettes total): one-time screening by ultrasonography Grade B"},{"location":"pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/","title":"Acute and Chronic Pain","text":"<p>Thomas Horton, Soibhan Kelley</p> <ul> <li> <p>There are physiological AND emotional components to pain.     Biopsychosocial factors must be addressed. Ex: anxiety/depression,     physical debility, and poor social support. Many pts will never be     completely free of pain, so it is important to set realistic     expectations</p> </li> <li> <p>Central sensitization is a phenomenon where the nervous system     persists in a state of high reactivity which lowers the threshold     for pain stimuli. Two characteristics of centralized pain are     allodynia (pain from non-painful stimuli) and hyperalgesia (painful     stimuli perceived as more painful)</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/#pharmacologic-therapy","title":"Pharmacologic Therapy","text":"<p>Acetaminophen: 650mg q6hr or 1g q8h. \\&lt;3g/day. (\\&lt;2g in liver patients)</p> <ul> <li>Avoid if you are worried about masking fevers</li> </ul> <p>NSAIDs: A great option for acute pain, especially musculoskeletal, HA, and nephrolithiasis in eligible patients (ex: IV/po ketorolac, ibuprofen, naproxen, etc.)</p> <ul> <li>Avoid in acute or chronic kidney disease and \u2191 risk of bleeding.     Caution in CAD/PVD</li> </ul> <p>Topical Analgesics: Best for localized pain but utilized frequently as part of a multimodal regimen</p> <ul> <li> <p>Lidocaine ointment, patches (PADR needed at VA for patches. Can get     by saying contraindication to TCA/gabapentinoids/SNRIs due to     sedation risk)</p> </li> <li> <p>Menthol salicylate gel</p> </li> <li> <p>Diclofenac Gel</p> </li> <li> <p>Capsaicin gel</p> </li> <li> <p>Morphine gel (typically limited to oncology patients with tumor     breakdown through skin)</p> </li> </ul> <p>Neuropathic Agents: Best for neuropathic pain but can be tried for other chronic pain or as part of acute pain regimen. SNRIs and TCAs can provide additional benefit if a pt has comorbid depression, anxiety, or insomnia (TCA). Most agents take 6-8 weeks for peak effect.</p> <ul> <li> <p>Gabapentin (Initial: 100 to 300 mg 1 to 3 times daily). Can be used     for acute pain</p> </li> <li> <p>Pregabalin (Initial: 25 to 150 mg/day in 2 to 3 divided doses). Has     better bioavailability. May work in patients who did not tolerate or     did not have success with gabapentin</p> </li> <li> <p>Duloxetine (Initial: 30 mg daily for 1 to 2 weeks, then increase to     60 mg daily as tolerated)</p> </li> <li> <p>Amitriptyline (Initial: 10 to 25 mg once daily at bedtime)</p> </li> </ul> <p>Muscle Relaxants: Should be used temporarily and intermittently but some benefit from longer term use. Great for paraplegia, spinal injury, spasticity.</p> <ul> <li> <p>Methocarbamol (Initial: 1.5 g 3 to 4 times daily for 2 to 3 days     then decrease dose to \u22644.5 g/day in 3 to 4 divided doses). Preferred     initial agent as has least SE.</p> </li> <li> <p>Tizanidine (Initial: 2 to 4 mg every 6 to 12 hours as needed and/or     at bedtime) \u2013 important to watch out for withdrawal in patients that     take frequently at home.</p> </li> <li> <p>Cyclobenzaprine (Initial: 5 to 10 mg once daily before bedtime)</p> </li> <li> <p>Metaxalone (Oral: 800 mg 3 to 4 times daily)</p> </li> </ul> <p>Opioids: Frequently used in hospital for acute pain. Limit use as much as possible in chronic pain as contributes to long-term central sensitization. May benefit some patient populations but should always be used as a component of a comprehensive, multimodal, patient-specific treatment plan.</p> <ul> <li> <p>Refer to section under Opioids: General Principles &amp; Conversions for     OME equivalents</p> <ul> <li> <p>If &gt;80 OME per day, ensure patient is prescribed naloxone</p> </li> <li> <p>If &gt;120 OME per day, refer to pain clinic</p> </li> </ul> </li> <li> <p>Common choices for acute pain in hospital (always start at low end     for opioid na\u00efve):</p> <ul> <li> <p>Oxycodone (PO) 5-10mg q4 to 6 hours prn</p> </li> <li> <p>Hydromorphone (IV) 0.25 to 1mg q2 to 3 hours prn</p> </li> </ul> </li> <li> <p>For pts on opioids at home, should always continue in hospital to     avoid withdrawal unless clinically contraindicated. Can always     titrate dose as needed</p> </li> <li> <p>Tramadol: Has opioid &amp; NSAID properties. Of note, tramadol also     inhibits serotonin and norepinephrine reuptake. Metabolized by     CYP3A4 and CYP2D6 so there is variability between patients. Typical     dose: 25 to 50mg q4 to 6 hours prn</p> </li> </ul> <p>NMDA Antagonists: Usually prescribed by our pain management colleagues but worthwhile to think about as a potential option if a patient\u2019s pain continues to be difficult to control.</p> <ul> <li> <p>Ketamine (IV infusion). SE includes AMS/delirium, hallucinations,     and dissociation.</p> </li> <li> <p>Memantine (PO)</p> </li> </ul> <p>Alpha 2 agonists (central pain): Not commonly utilized in everyday practice, but helpful in certain patients with chronic pain (off-label). Guanfacine vs clonidine</p>"},{"location":"pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/#non-pharmacologic-therapies","title":"Non-pharmacologic therapies","text":"<p>Procedural Intervention: Best utilized when there is a specific, targetable</p> <ul> <li>Referral to chronic/interventional pain management (Nerve blocks or     Radio-ablative therapy)</li> </ul> <p>Adjunct Therapies: Patient\u2019s will have varying opinions and responses on adjunctive therapies, but these can be as important as any pharmacologic therapy. CBT, personalized exercise regimen, PT/OT, chiropractor, acupuncture</p>"},{"location":"pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/#additional-resources-for-residents","title":"Additional Resources for Residents","text":"<ul> <li> <p>Pain Management Center at VUMC</p> </li> <li> <p>Pain Clinic at the VA. Would specify whether or not you are OK with     them initiating opioids.</p> </li> <li> <p>Complementary and Integrative Health consult at VA</p> </li> <li> <p>Osher Center for Integrative Health at Vanderbilt</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/#acute-pain-for-special-populations","title":"Acute pain for special populations","text":"<p>Renal dysfunction: Check that meds are renally dosed and start with non-sedating options. Always avoid NSAIDs, morphine and codeine.</p> <ul> <li> <p>Acetaminophen and topicals</p> </li> <li> <p>Opioids: oxycodone 2.5 to 5 mg, IV hydromorphone 0.25-0.5mg,     fentanyl IV 25 to 50mcg</p> </li> <li> <p>Gabapentin: start with spot 100mg. Be extremely careful with quick     up titration in CKD due to sedation risk.</p> </li> <li> <p>Methocarbamol: no specific renal dosing, try 500-750mg initially</p> </li> </ul> <p>Cirrhosis: Always avoid NSAIDs, morphine, codeine, hydromorphone (may be OK in mild to moderate cirrhosis)</p> <ul> <li> <p>Acetaminophen (2g max/d) &amp; topicals are safe</p> </li> <li> <p>Gabapentin: start with spot 100mg</p> </li> <li> <p>Methocarbamol: no specific hepatic dosing, try 500 mg initially</p> </li> <li> <p>Other options: consider tramadol 25-50 mg vs oxycodone 2.5 mg</p> </li> </ul> <p>History of substance use disorder: Overnight, always review handoff as day team likely has specific plan in place.</p> <ul> <li> <p>With substance use history, typically rely on multimodal agents as     above. Patients who are in recovery may prefer to avoid opioids     themselves</p> </li> <li> <p>However, patients with OUD can and do have acute, severe pain due to     injury, infections, procedures, etc. NEVER withhold opiates if     clinically appropriate, regardless of substance use history</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-code-status-discussion/","title":"Code Status Discussion","text":"<p>Katie Sunthankar</p> <ul> <li> <p>The approach to obtaining someone\u2019s code status should be thoughtful     and pertinent to their current admission or recent change in     clinical status</p> <ul> <li> <p>Ask yourself \u201cWhy would this patient code? Is resuscitation a     reversible treatment in this patient\u2019s case? What are the chances     that this patient will survive to discharge following CPR? Is the     anticipated outcome in line with the patient\u2019s goals?</p> </li> <li> <p>After you have made your assessment, help patient make an educated     decision based on both the efficacy of resuscitation and the     patient\u2019s goals</p> </li> </ul> </li> <li> <p>Below are examples of phrases that can be used in framing code     status.</p> <ul> <li> <p>NEVER say \u201cDo you want us to do everything?\u201d Most patients will     respond yes to this even if they do not want CPR</p> </li> <li> <p>It is more helpful to give examples of when these situations would     arise and make recommendations based on your medical judgment     factoring in patient's goals</p> </li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-code-status-discussion/#admitting-a-patient","title":"Admitting a patient:","text":"<ul> <li> <p>Introduction: Normalize the conversation by stating \u201cthese are     questions we routinely ask everyone when they come into the     hospital. This is a way for us to understand your wishes in the     event you are unable to make your own decisions.\u201d</p> </li> <li> <p>Surrogate: \u201cIf you were unable to make decisions for yourself,     who would you trust to make your decisions? The person you pick     should be able to speak to your wishes and make the same choices you     would make for yourself\u201d</p> </li> <li> <p>-Intubation: Always do this first so you can avoid the sticky     DNI but not DNR situation. Again, normalize the question. \u201cEveryone     has different opinions on what types of medical care they would want     if they became sicker. One of the things we like to talk about are     ventilators or breathing machines. Some tell us to try a breathing     machine for a trial, but they would not want to be kept alive on a     ventilator.\u201d Now make a recommendation. \u201cIn your case I think if you     were to need a ventilator, I think it would [work, not work,]\u201d     Pause and allow them to ask questions. Also remember that if they     say DNI, then they must be DNR because intubation occurs with ACLS     (this is not allowed at VUMC. It is technically allowed at the VA if     the patient specifically requests but would not recommend routinely     providing this option)</p> </li> <li> <p>CPR: Prime this question with \u201cThe next question I have to ask     you can be hard to think about, but it is important that we know     what you would want in an emergency. Specifically, if you had a     cardiac arrest where your heart stops beating and you die, would you     want chest compressions to try and restart your heart? We know based     on the evidence that CPR is not always successful. It really depends     on the situation. In your case, I think CPR would be (make a     recommendation here). Knowing this, would you want us to attempt CPR     to resuscitate you?\u201d</p> <ul> <li>A helpful way to share data about the success of CPR: \u201cCan I share     some numbers about how often CPR can help?\u201d Sometimes using fingers     to show these numbers helps. \u201cIf you take 10 people in this hospital     and all of their hearts stop beating, which would mean they have     died, and we get to them as fast as possible, only 3 of them would     have their hearts restarted and only 1 of them would ever leave the     hospital.\u201d</li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-code-status-discussion/#what-if-you-do-not-think-performing-cpr-is-medically-appropriate","title":"What if you do not think performing CPR Is medically appropriate?\u2026","text":"<ul> <li> <p>At the end of the day, it is their decision (attendings may change     the code status out of medical futility in Tennessee)</p> </li> <li> <p>Code status can be revisited throughout the hospital stay,     especially if the patient was initially overwhelmed or if their     clinical status evolves. Sometimes patients find it helpful to have     a family member or friend present</p> </li> <li> <p>Consider framing the discussion differently and offer your     recommendation: \u201cWhile you are in the hospital, we will support you     with interventions and medications that we think are helpful based     on what you have told us important to you. However, we are worried     that some of the interventions you are asking for may do more harm     than good. Many people think that CPR works like it does on TV.     Unfortunately, we know that most patients who need CPR in the     hospital do not survive like they do on TV. In your case, we do not     think it would bring you back to your current state. I worry that     this is not something that will be helpful to you.\u201d</p> </li> <li> <p>Another phrase that is helpful (and when the discussion occurs with     surrogates leads to higher rates of changing code status than saying     DNR): \u201callow for a natural death\u201d. For example, \u201cI worry that given     how sick your [loved one] is, that the additional interventions of     CPR if she were to die, would prevent her from having a natural     death\u201d</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-death-pronouncement/","title":"The Death Pronouncement","text":"<p>Michael J. Neuss</p> <p>This scenario arises in a variety of contexts, including the units, wards, and cross-cover. You might know the patient and family well, but particularly when cross covering, that may not be the case</p> <ul> <li>This approach to the death pronouncement is based in part on the     AAFP\u2019s \u201cDeath Pronouncement: Survival Tips for Residents\u201d (Am Fam     Physician. 1998 Jul 1;58(1):284-285.)</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-death-pronouncement/#before-entering","title":"Before Entering:","text":"<ul> <li> <p>Familiarize yourself with the most important points of the patient\u2019s     hospitalization and recent events. Be aware of the circumstances of     the patient\u2019s death, particularly whether death was expected or     sudden.</p> </li> <li> <p>Inquire as to which family is present including whether the POA is     currently at bedside</p> </li> <li> <p>In general, it is best to enter accompanied, ideally with the     patient\u2019s nurse. It is rare for the chaplain to be present but that     might also be a consideration.</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-death-pronouncement/#in-the-room","title":"In The Room:","text":"<ul> <li> <p>Especially when cross-covering, make sure to introduce yourself to     family, and allow them time to introduce themselves to you</p> </li> <li> <p>Less is more when it comes to what you say: it can be good to be     empathetic (consider only short statements such as \u201cI am sorry for     your loss\u201d) but focus mainly on the task at hand, allowing time for     families to be present with their loved one</p> </li> <li> <p>Explain that you have been called to examine the patient to confirm     that they have passed. Allow a brief time for questions; it is rare     (but not impossible) that someone may wish to excuse themselves for     the pronouncement</p> </li> <li> <p>Note the location of a working clock when you enter; your watch is     ok too but do make sure to avoid looking at your smartphone to check     the time of death</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-death-pronouncement/#the-exam-and-pronouncement","title":"The Exam and Pronouncement","text":"<ul> <li> <p>Identify the patient by wrist band</p> </li> <li> <p>Confirm that the patient does not respond to stimuli; one discreet     way to confirm a lack of response to tactile stimuli is to hold the     hand, and apply pressure to a nailbed, appearing to hold the hand     while looking at/visually inspecting the face or other part of the     body</p> </li> <li> <p>Confirm the absence of spontaneous respirations and absence of heart     sounds. Listen for a full minute as some patients have extended     periods of apnea</p> </li> <li> <p>Examine the pupils and note the absence of pupillary light reflex</p> </li> <li> <p>Note the time at which your examination is completed. This is the     time of death</p> </li> <li> <p>Make sure to ask if the family would like an autopsy to be     performed. This is often overlooked, and as awkward as it might feel     to ask for this, it is a requirement</p> </li> <li> <p>Make sure you have notified the attending of record</p> </li> <li> <p>Please see further VA- and VUMC-specific guidance below</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-death-pronouncement/#death-process-at-vumc","title":"Death Process at VUMC","text":"<ul> <li> <p>The key thing is to ensure that all components are completed in the     \u201cDischarge as Deceased\u201d tab under the Transfer-Discharge screen</p> </li> <li> <p>EACH AND EVERY component of this tab must be completed before     Decedent Affairs will accept the body</p> </li> </ul> <p>Required steps:</p> <ul> <li> <p>Cardiopulmonary Death Charting -&gt; Select \u201cNew Reading\u201d and     complete.</p> </li> <li> <p>Cardiopulmonary Death -&gt; Select \u201c+Create Note\u201d</p> </li> <li> <p>Medical Examiner Criteria -&gt; Select \u201c+New Reading\u201d; Criteria     requiring notification of ME is listed in a drop down menu in the     navigator. Includes accidental deaths, threats to public health,     suspicion for foul play, etc. The Vanderbilt Operator can assist     with connecting you to the ME; alternatively, you can call     615-743-1800 during business hours (M-F 8am \u2013 4:30pm) or the     after-hours pager at 800-216-0107.</p> <ul> <li>All patients diagnosed with Covid are automatic ME cases</li> </ul> </li> <li> <p>Autopsy Criteria -&gt; Select \u201c+New Reading\u201d</p> </li> <li> <p>Preliminary Cause of Death and Date/Time of Death -&gt;. Rather than     list \u201cCardiopulmonary arrest,\u201d be specific (e.g., Pulmonary     Embolism, Myocardial Infarction, Metastatic Colon Cancer, etc.)</p> </li> <li> <p>Deceased\u2019s Info \u2013 Report of Death</p> <ul> <li> <p>If you need to leave this and return later after collecting     information, you can access your partially complete entries by     clicking on the date/time text that appears under the ribbon. This     is not intuitive because the numbers listing the date/time do not at     all appear as though they act like a hyperlink (but they do).</p> </li> <li> <p>Be specific; TDS will want you to have listed the name of the family     you notified, the TDS Case Number (which the RN typically enters),     and your attending physician\u2019s name (to sign the death certificate;     give their pager number in this subsection).</p> </li> </ul> </li> <li> <p>Report of Death Note -&gt; Select \u201c+New Reading\u201d and complete.</p> </li> <li> <p>Complete Synopsis + Hospital Course and then at the very bottom     under Summary of Death select \u201c+Create Note.\u201d</p> </li> <li> <p>Once all of this paperwork is finished, be sure to touch base with     the patient\u2019s nurse, usually contact Decedent Affairs and assist in     making sure the body is moved</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-death-pronouncement/#death-process-at-the-va","title":"Death Process at the VA","text":"<p>VA death pronouncement process</p>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/","title":"Hospice","text":""},{"location":"pain-and-palliative/pain-and-palliative-hospice/#background","title":"Background","text":"<ul> <li>Hospice: aims to provide aggressive palliative care for patients at     the end of their life, usually when life-prolonging treatment     options have stopped<ul> <li>Eligibility: less than or equal to 6- month life expectancy<ul> <li>Consider: palliative performance scale (PPS) rating of \\&lt;50-60%,     dependence in 3 of 6 ADL\u2019s, alteration in nutritional status, or     documented deterioration in 4-6 months</li> </ul> </li> <li>Levels of Care<ul> <li>General inpatient care: Patients must require skilled nursing     care that could not be provided at home (IV medications,     suction, high flow O2,) No cost to the patient under this level     of care.</li> <li>Home hospice-Patients are discharged to their \"home\u201d: which     could be a long term care facility, assisted living facility, or     their house.</li> </ul> </li> <li>What is covered?<ul> <li>Personnel:<ul> <li>Hospice RN visits at least weekly and as needed; crisis     on-call visits available 24/7</li> <li>SW, Chaplain, Hospice MD oversight</li> <li>CNAs: usually 1 hr, 2-3/wk at most</li> </ul> </li> <li>Medicines for comfort</li> <li>Medical equipment for comfort and safety including oxygen</li> <li>Up to 13 months of bereavement for caregivers after the death</li> <li>Respite care for 5 days, usually in a nursing home</li> <li>Inpatient hospice at hospice facility or at certain hospitals     for symptom control for up to 7 days</li> </ul> </li> <li>Hospice can be offered to patients without insurance</li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#va-specifics-for-hospice","title":"VA Specifics for Hospice","text":"<ul> <li>Main difference compared to VUMC is pt is allowed concurrent care<ul> <li>This means vets can continue to receive some treatments for the     primary condition (e.g., palliative radiation or chemotherapy) and     still receive hospice services</li> </ul> </li> <li>Additionally, all veterans that go on hospice should have any needed     nursing home stay (at a contracted SNF) covered by the VA regardless     of service connection</li> <li>VA Palliative Care team will help with these referrals</li> <li>One (1) F Status at the VA<ul> <li>Designates \u201ctreating specialty\u201d as NA-HOSPICE. Reduces costs for     families, helps quality metrics. Use this if patient qualifies and     agrees to hospice care</li> <li>Write Delayed Transfer Orders: Admit to NA-HOSPICE and Specialty as     \u201cHospice for Acute Care\u201d</li> <li>Write a nursing text order to \u201cChange Patient to 1-F Status\u201d</li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#medications-for-imminently-dying-patients","title":"Medications for Imminently Dying Patients","text":"<p>General recommendations</p> <ul> <li>At VUMC, there is a very helpful order set titled \u201cComfort Care     Orders (Trauma, MICU, SICU, NEURO ICU, Palliative Care\u201d</li> <li>Make sure to remove unnecessary medications, labs, telemetry,     nursing text orders, etc.</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#pain","title":"Pain","text":"<ul> <li>Morphine 2mg IV or SQ q1h PRN (avoid if renal failure)</li> <li>Hydromorphone 0.25 \u2013 0.5mg IV or SQ q1h PRN</li> <li>Write as PRN, as needed for pain &gt; 2/10 or for air hunger</li> <li>If ineffective after 1 hours, increase by 50-100%</li> <li>If given every hour for 3-4 hours, consider an infusion (given PRN     dose as hourly rate)</li> <li>Fentanyl is not a great option in ICU unless it is a continuous     drip. Bolus lasts only 15 mins</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#dyspneatachypnea","title":"Dyspnea/Tachypnea","text":"<ul> <li>Assess for volume overload, considering decrease or stopping IVFs or     tube feeds</li> <li>Opioids are the treatment of choice for dyspnea</li> <li>Consider Benzodiazepines for air hunger not controlled by opiates</li> <li>Supplemental oxygen for comfort (do not base on O2 sat). Consider     use of cool air or fan</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#restlessnessagitationanxiety","title":"Restlessness/agitation/anxiety","text":"<ul> <li>Assess for urinary retention, constipation, pain, other modifiable     factors</li> <li>Lorazepam (Ativan) 0.5 \u2013 1 mg PO or IV q4h PRN (tablet can be made     into slurry if patient is experiencing dysphagia)</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#nausea","title":"Nausea","text":"<ul> <li>Ondansetron (Zofran) 4mg IV q4h or 8mg q8h PRN</li> <li>Promethazine (Phenergan) 25mg PO or PR q6h PRN; caution can be very     sedating</li> <li>Prochlorperazine (Compazine) 10mg PO or IV q4h PRN</li> <li>Haloperidol (Haldol)</li> <li>If felt to be obstructive in etiology, try Dexamethasone 4mg IV or     SQ q8-12h with Octreotide 100-400mcg IV or SQ q8h</li> <li>If felt to be related to anxiety, try Lorazepam; see dosing above</li> <li>Scopolamine is highly anti-cholinergic and takes time to be     effective, so would NOT use in imminently dying patients</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-hospice/#secretions","title":"Secretions","text":"<ul> <li>Remember: the patient is NOT bothered by their own secretions, and     it is often the family and caregivers who are likely disturbed, so     avoid deep suctioning</li> <li>Glycopyrrolate (Robinul) 0.2 \u2013 0.4 mg SQ or IV q6h PRN</li> <li>Atropine 1% Ophthalmic Solution 2 drops sublingual 2-4h PRN</li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/","title":"Opioids: General Principles &amp; Conversion","text":"<p>Eli Cohen</p>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#oral-morphine-equivalent-ome-conversion-table","title":"Oral Morphine Equivalent (OME) Conversion Table:","text":"Drug PO IV APAP IR ER Notes Tramadol\u00a0 0.1x\u00a0 -\u00a0 -\u00a0 Tramadol\u00a0 Ultram ER\u2122\u00a0 NSAID properties\u00a0 Morphine\u00a0 1x\u00a0 3x\u00a0 -\u00a0 Morphine IR\u00a0 MS-Contin\u2122\u00a0 Renally cleared\u00a0 Hydrocodone\u00a0 1x\u00a0 NA\u00a0 Lortab\u00a0 Hydrocodone\u00a0 NA\u00a0 Oxycodone\u00a0 1.5x\u00a0 -\u00a0 Percocet\u00a0 Roxicodone\u2122\u00a0 Oxycontin\u2122\u00a0 Hydromorphone\u00a0 4x\u00a0 20x\u00a0 -\u00a0 IV, Oral\u00a0 -\u00a0 Oral is $\u00a0 Fentanyl\u00a0 300x\u00a0 300x\u00a0 -\u00a0 IV\u2019 Buccal, Nasal\u00a0 Patch\u00a0 Dosed in ug, not mg\u00a0 Abbreviations: ER = extended release; IR = immediate release; APAP = acetaminophen"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#conversion","title":"Conversion:","text":"<ul> <li>Transition between opiates is done using OME.     Each drugs\u2019 potency is compared to oral morphine (see     table). Ex: 1 mg IV morphine = 3 mg PO morphine</li> <li>When transitioning, doses are traditionally reduced by \u00bc to \u2153     due to cross tolerance</li> <li>IR/ER regimens: Consider switching to extended release when     requiring 3-4 doses of intermediate release (IR) medications in a     24-hour period regularly. The ER medication should treat the chronic     pain experienced by a patient. The IR preparation is indicated for     breakthrough pain. The IR dose should be calculated as 10-20% of the     total OME dose a patient takes daily. Fentanyl patches should last     72 hours</li> </ul> <p>Opiate conversions</p>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#patient-controlled-analgesia-pcas","title":"Patient Controlled Analgesia (PCAs)","text":"<ul> <li> <p>Pumps can be programmed to deliver a continuous rate and/or a bolus     dose</p> <ul> <li> <p>Basal rate = a continuous infusion dosed per hour that cannot be     adjusted by the patient</p> </li> <li> <p>Demand dose = a patient-directed bolus that is given at a prescribed     frequency whenever the pt presses the button. Both the dose and     frequency can be adjusted</p> </li> <li> <p>The general rule of thumb is to calculate the total OME delivered     through the demand when a pt is in steady state and convert 75% of     this dose into the total continuous rate.</p> </li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#calculating-initial-doses","title":"Calculating initial doses:","text":"<ul> <li> <p>Basal dose: check what the patient is actually taking at home (may         be different than what is prescribed, use OME). Take the total daily         dose and convert to IV and then divide that by 24 hours to get an         hourly rate. If moderate pain, increase dose by 25-50%; if severe,         by 50-100%</p> </li> <li> <p>Demand doses: The bolus dose should be 10-20% of total daily dose.         The availability is based on half-life of the medication (2hr for         IV). Adjust the availability based on how frequently you want         patient to be able to have a demand dose (ex: if q10min divide by 12         or if q15min divide by 8 for 2 hours)</p> </li> <li> <p>Don\u2019t forget to set lock-outs (maximum dose that can be given over a         certain period of time) that includes both basal and demand doses</p> </li> <li> <p>Remember that the basal rate will not get to steady state for at         least 8 hrs; When you admit pts or are transitioning pts to a PCA,         always initiate the PCA pump with a bolus (or loading) dose</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#how-to-order-pca-at-vumc","title":"How to Order PCA at VUMC","text":"<ul> <li> <p>Select Analgesic:</p> <ul> <li> <p>*Hydromorphone (most common): Order \u201cHydromorphone (DILAUDID) PCA\u201d</p> </li> <li> <p>Fentanyl (if on at home; not a good inpatient PCA): Order \u201cFentanyl     PCA\u201d</p> </li> <li> <p>*Morphine: Order \u201cMorphine PCA\u201d</p> </li> </ul> </li> <li> <p>Select \u201c[Analgesic] PCA syringe\u201d and adjust the following to pt     needs:</p> <ul> <li> <p>PCA Dose (\u201cDemand\u201d): amount the patient gets when s/he presses the     button</p> </li> <li> <p>Lockout Interval: time between which \u201cdemand\u201d doses will not be     administered if s/he presses the button (i.e., the PCA \u201clocks out\u201d)</p> </li> <li> <p>Continuous Dose (\u201cBasal\u201d): amount the pt gets per hr in continuous     infusion</p> </li> <li> <p>Max Dose: maximum amount of analgesic (Basal + Demand) pt can get in     24 hours</p> </li> </ul> </li> <li> <p>Select all \u201cPCA Nursing Orders\u201d</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#how-to-order-pca-at-va","title":"How to Order PCA at VA","text":"<ul> <li> <p>Under Orders, select \u201cPain/Sedation Infusions\u201d</p> </li> <li> <p>Under \u201cPCAs,\u201d select Analgesic of choice (Hydromorphone or Morphine)</p> </li> <li> <p>Adjust the following:</p> <ul> <li> <p>Load: amount the pt will receive on initial set up of PCA</p> </li> <li> <p>Basal: amount the pt gets per hour in continuous infusion</p> </li> <li> <p>Demand: amount the pt gets when s/he presses the button</p> </li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#interrogating-pca-to-determine-amount-of-analgesia-pt-received","title":"Interrogating PCA (to determine amount of analgesia pt received):","text":"<ul> <li> <p>Look at IV pump display and hit \u201cChannel Select\u201d on PCA</p> </li> <li> <p>Select \u201cOptions\u201d in bottom left of IV pump</p> </li> <li> <p>Select \u201cPatient History\u201d on the left of the screen. This shows the         administration history for a certain time period (e.g., 24h, 12h,         4h, etc.)</p> </li> <li> <p>Hit \u201cZoom\u201d on bottom of screen to change time period to 24 hours. Should show:</p> <ul> <li> <p>Total Drug: total amount of drug received in last 24 hours</p> </li> <li> <p>Total Demands: amount of times the pt has pushed the button for     demand dose</p> </li> <li> <p>Delivered: amount of times the pt actually received a demand dose</p> </li> <li> <p>The difference between \u201cTotal Demands\u201d and \u201cDelivered\u201d is the number     of times the patient pushed the button without receiving a dose</p> </li> </ul> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-opiate-principles/#opioid-side-effects","title":"Opioid Side effects","text":"<ul> <li> <p>Constipation: dose-dependent and will not develop tolerance. If pt         has opioids, they need robust bowel regimen (MiraLAX, senna) with         goal of BM \u2265every 3 days</p> <ul> <li>For opioid-specific constipation can do SQ RelistorTM     (methylnaltrexone) but this is expensive and can only be given in     the PCU or oncology floors at VUMC. For patients with chronic     opioid-induced constipation as an outpatient can trial oral agents     like MovantikTM (naloxgeol). Can also consider PO     naloxone but it does have small amount of bioavailability so watch     for systemic reversal</li> </ul> </li> <li> <p>Nausea: occurs with opiate na\u00efve pts. Consider starting an     anti-emetic concurrently. Most pts will develop tachyphylaxis with     this over a day, so the antiemetic can be discontinued</p> </li> <li> <p>Urinary retention: Consider role of opioids in pts with new-onset or     worsening urinary retention. Try to de-escalate opioid dosing if     possible</p> </li> <li> <p>Overdose: In pts with apneic emergency, IV 0.4 mg Naloxone; however,     low threshold for multiple doses until response. For pts prescribed     opioids as outpatient, need naloxone 4 mg intranasal</p> <ul> <li>If a patient with chronic opiate dependence is over sedated but not     in immediate danger of respiratory failure, one can 1) hold the dose     of opioid and let them wake up on their own or 2) give a dose of     naloxone 0.02-0.04mg (1/10 of the usual dose). This latter strategy     prevents opioid withdrawal and precipitation of pain crisis in     patients on chronic opioids</li> </ul> </li> <li> <p>Pruritis: due to histamine release from mast cells; can be treated     with antihistamines. The opioid can also be rotated. Some but not     all pts will develop tachyphylaxis to this symptom</p> </li> <li> <p>Toxicity: hyperalgesia and neuroexcitatory effects (AMS, myoclonic     jerking, seizures). Risk factors for neuroexcitatory effects are     rapid titration, dehydration, and/or renal failure. Treatment is to     rotate to a higher potency opioid and hydrate when possible</p> </li> </ul>"},{"location":"pain-and-palliative/pain-and-palliative-video-examples-navigating-difficult-conversations/","title":"Video Examples for Navigating Difficult Conversations","text":"<p>Mohana Karlekar</p> <p>Navigating difficult conversations with patients can be daunting especially if you have never seen someone do one well before.\u00a0 Conversations should follow a logical and sequential approach, much like any procedure we perform in medicine.\u00a0 Like all procedures, practice makes us better.</p> <p> </p> <p>QR code   link   for Learning Exchange module   \u201cNavigating Difficult Conversations With Patients\u201d   </p> <p>Good communicators have both formulated their message and identified which communication strategy to use before they initiate a conversation</p> <p>Here are some suggestions for \u201cNavigating Difficult Conversations\u201d</p> <ul> <li>Step 1. Determine your message-keep it simple and short</li> <li>Step 2. Identify what type of news you are communicating: breaking     bad news, assessing understanding of information, communicating     prognosis or navigating goals of care</li> <li>Step 3. Pick the video that best suits your purpose</li> </ul> <p></p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/","title":"Acute Back Pain","text":"<p>Christian\u00a0Roehmer</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/#background","title":"Background","text":"<ul> <li> <p>&gt;90% of back pain is nonspecific and musculoskeletal in nature</p> </li> <li> <p>Can\u2019t Miss: Spinal cord compression, cauda equina, cancer, spinal     abscess, discitis, or osteomyelitis</p> </li> <li> <p>Extra-axial causes: Pancreatitis, nephrolithiasis, pyelonephritis,     AAA, zoster</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/#presentation","title":"Presentation","text":"<ul> <li> <p>Lumbar strain: diffuse pain in lumbar muscles, may\u00a0radiate\u00a0</p> </li> <li> <p>Degenerative disk or facet process: localized lumbar pain,\u00a0similar     to\u00a0lumbar strain\u00a0</p> </li> <li> <p>Inflammatory arthritis: morning stiffness, improves with movement,     systemic\u00a0symptoms\u00a0</p> </li> <li> <p>Osteoarthritis: pain with use, improves with rest\u00a0</p> </li> <li> <p>Herniated disk: radiating pain to legs, often below the\u00a0knees\u00a0</p> </li> <li> <p>Compression fracture: older patients, trauma, spine tenderness on     exam\u00a0</p> </li> <li> <p>Spinal stenosis: pain improves with flexion, shopping cart\u00a0sign\u00a0</p> </li> <li> <p>Spondylolysis: pain with extension\u00a0</p> </li> <li> <p>Spondylolisthesis: pain with activity, improves with rest, can be     seen with imaging\u00a0</p> </li> <li> <p>Scoliosis: abnormal spine curvature, seen on physical exam     inspection\u00a0</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Physical Exam:\u00a0</p> <ul> <li> <p>Inspection: Should include posture, Adam\u2019s Forward Bend Test     (screens for scoliosis), and limb length discrepancy \u00e0 kyphosis,     lordosis, or scoliosis\u00a0</p> </li> <li> <p>Palpation/Percussion: Sensitive for identifying spinal infection,     metastases, or compression fractures</p> <ul> <li>Spinous processes, lumbar \u201cstep-offs,\u201d paravertebral muscles and     SI joint</li> </ul> </li> <li> <p>Range of Motion: Pain with extension and relieved by flexion     suggests\u00a0spinal stenosis\u00a0\u00a0</p> </li> <li> <p>Neurologic Examination:</p> <ul> <li> <p>L2: hip flexion; L3: knee extension; L4: dorsiflexion; L5: great     toe flexion\u00a0</p> </li> <li> <p>S1: plantarflexion\u00a0</p> </li> </ul> </li> <li> <p>Waddell\u2019s Signs:\u00a0 Raise suspicion\u00a0of\u00a0non-organic pain\u00a0\u00a0</p> <ul> <li> <p>Superficial tenderness, pain that\u00a0improves\u00a0with     distraction\u00a0(attention diverted)</p> </li> <li> <p>Pain with sham maneuvers (simulation)</p> </li> <li> <p>Overreaction (disproportionate psychomotor responses)</p> </li> <li> <p>Non-physiologic neurologic deficits</p> </li> </ul> </li> </ul> </li> <li> <p>ESR/CRP: Can be used if concern for infection or malignancy</p> </li> </ul> Provocation\u00a0Tests\u00a0of the Lower Back\u00a0 Test Isolates Action Positive if Straight Leg Raise\u00a0 Lumbosacral nerve roots\u00a0 Pt is supine, lift one leg (keep straight) while the other leg is resting flat Positive for radiculopathy if\u00a0pt experiences radiating pain to the leg being\u00a0lifted\u00a0 Slump Test\u00a0 Lumbosacral nerve roots\u00a0 Pt is sitting, have them slump forward w/chin touching chest. Then passively extend knee and dorsiflex foot <p>Positive\u00a0for radiculopathy\u00a0</p> <p>if\u00a0any of the steps reproduces radicular\u00a0pain\u00a0 \u00a0Use with straight leg raise\u00a0\u00a0</p> Gaenslen\u2019s\u00a0Test\u00a0 Sacroiliac Joint\u00a0 Pt supine, brings knee of leg of side not being tested to chest and holds it; examiner extends straight leg being tested over edge of\u00a0bed\u00a0 Reproduction of pain deep in upper buttocks\u00a0 Patrick\u2019s (Fabers) Test\u00a0 Sacroiliac Joint\u00a0 Pt supine, passively flex hip to 90\u00ba, maximally abduct and externally rotate at\u00a0hip\u00a0 Reproduction of pain deep in upper buttocks\u00a0 Sacral Thrust\u00a0 Sacroiliac Joint\u00a0 Pt prone, apply anteriorly directed thrust over\u00a0sacrum\u00a0 Reproduction of pain deep in upper buttocks\u00a0 Distraction\u00a0 Sacroiliac Joint\u00a0 Pt supine, apply pressure directed\u00a0postero-laterally to both anterior and superior iliac\u00a0spine\u00a0 Reproduction of pain deep in upper buttocks\u00a0 Compression\u00a0 Sacroiliac Joint\u00a0 Pt supine, apply pressure directed\u00a0postero-laterally to both anterior and superior iliac\u00a0spine\u00a0 Reproduction of pain deep in upper buttocks\u00a0 <p>Imaging:\u00a0</p> <ul> <li> <p>AP and lateral plain films; Bilateral oblique films (evaluate for     spondylolysis)</p> <ul> <li>Indications: risk of fracture, red flag symptoms, evaluating for     ankylosing spondylitis, no improvement in pain after conservative     therapy after 6-12 weeks</li> </ul> </li> <li> <p>Non-contrasted MRI (Preferred)</p> <ul> <li>Indications: Suspicion for spinal cord/cauda equina compression,     severe neurological deficits, concern for infection, unexplained     inflammatory marker elevation</li> </ul> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/#management","title":"Management","text":"<ul> <li> <p>First line: conservative therapy for 4 to 6 weeks, avoid bedrest</p> <ul> <li> <p>PT</p> </li> <li> <p>NSAIDs: Ibuprofen 600 \u2013 800 mg q 4-6 hr, Diclofenac (topical) 2 g     TID-QID (7 days)</p> </li> <li> <p>Heat, massage, acupuncture</p> </li> </ul> </li> <li> <p>Adjuncts for pain:</p> <ul> <li> <p>Robaxin: 750 mg \u2013 1.5 g 3-4 times daily for 2-3 days, then \\&lt; 4.5     g/day over 3-4 doses</p> </li> <li> <p>Flexeril: 5 mg tid, or 5 once qhs with Tylenol or NSAID</p> </li> </ul> </li> <li> <p>Pts with neuro deficits or spinal cord compression warrant urgent     surgical evaluation</p> </li> <li> <p>Refer to Spine PT program at VUMC</p> </li> <li> <p>Refractory or Severe Pain: Referral\u00a0to orthopedics\u00a0or PM&amp;R\u00a0spine     specialist</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/","title":"Knee Pain","text":"<p>Samuel Lazaroff</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/#background","title":"Background","text":"<ul> <li> <p>Key features of the history include:</p> <ul> <li> <p>Location: have patient point to the area that hurts most</p> </li> <li> <p>Weight bearing, systemic symptoms (e.g. fevers)</p> </li> <li> <p>Trauma and mechanism of injury</p> <ul> <li> <p>High-energy trauma: high risk of bony and/or ligamentous injury</p> </li> <li> <p>Low-Energy Trauma and Atraumatic etiologies organized by     location (see table)</p> </li> </ul> </li> <li> <p>Presence/absence of effusion and swelling</p> </li> </ul> </li> </ul> Knee Location Low-Energy Trauma Atraumatic Anterior\u00a0 <p>Patellar\u00a0subluxation or\u00a0dislocation\u00a0(instability)\u00a0</p> <p>Patellar fracture\u00a0</p> <p>Patellar tendon rupture\u00a0</p> <p>Quadriceps tendon rupture\u00a0</p> <p>Tendinopathy: patellar or quadricep</p> <p>Hoffa\u2019s fat pad syndrome (inflammation of post-patellar fat)\u00a0</p> <p>Bursitis \u00a0</p> <p>OA\u00a0</p> Medial\u00a0 <p>MCL tear\u00a0</p> <p>Acute medial meniscus tear\u00a0</p> <p>Medial meniscus degenerative tear\u00a0</p> <p>Pes anserine bursitis\u00a0</p> <p>OA\u00a0</p> Lateral\u00a0 <p>LCL tear\u00a0</p> <p>Acute lateral meniscus tear\u00a0</p> <p>IT band syndrome\u00a0</p> <p>Lateral meniscus degenerative tear\u00a0</p> <p>OA\u00a0</p> Posterior\u00a0 <p>PCL tear\u00a0</p> <p>Hyperextension\u00a0</p> <p>Baker\u2019s cyst\u00a0</p> <p>Popliteal art. aneurysm/entrapment\u00a0</p> Generalized\u00a0 <p>ACL tear\u00a0</p> <p>PCL tear\u00a0</p> <p>Intra-articular fracture\u00a0</p> <p>Patellofemoral pain syndrome\u00a0</p> <p>OA\u00a0</p> <p>Patellar stress fracture\u00a0</p> <p>Referred from hip or\u00a0ankle\u00a0</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/#presentation","title":"Presentation","text":"<ul> <li> <p>Traumatic Effusion:</p> <ul> <li>DDx: ACL or PCL rupture, meniscus tear, patellar instability     (dislocation of subluxation), bone bruise,\u00a0fracture\u00a0</li> </ul> </li> <li> <p>Atraumatic Effusion:\u00a0\u00a0</p> <ul> <li>Activity related or pain w/activity: Osteoarthritis, Osteochondral     injury</li> </ul> </li> <li> <p>Not activity-related: Consider autoimmune\u00a0causes, crystalline     arthropathy, Lyme disease, Septic arthropathy (including     gonococcal)\u00a0</p> </li> <li> <p>Less common\u00a0causes: primary bone tumor, viral infection     (Parvo),\u00a0hyperparathyroidism, hemochromatosis, syphilis, sarcoid,     Whipple\u2019s\u00a0</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Physical Exam:\u00a0</p> <ul> <li> <p>Inspection, palpation, AROM, PROM, strength, check for effusion,     neurovascular exam (incl. reflexes if applicable), provocation (of     ligaments), gait</p> </li> <li> <p>Examine the back, hip, and ankle as well</p> </li> </ul> </li> <li> <p>Aspirate if effusion present</p> </li> <li> <p>Ottawa Knee Rule = Imaging\u00a0if\u00a01 of following:\u00a0</p> <ul> <li> <p>&gt; 55 y/o\u00a0</p> </li> <li> <p>Isolated tenderness of patella\u00a0</p> </li> <li> <p>Tenderness of fibular head\u00a0</p> </li> <li> <p>Unable to flex 90\u00b0\u00a0\u00ba</p> </li> <li> <p>Unable to ambulate 4 steps at time of injury and at time     of\u00a0evaluation\u00a0</p> </li> </ul> </li> </ul> Provocation Tests of the Knee\u00a0 Test Isolates Action Positive if Anterior Drawer ACL\u00a0 Hip flexed and knee in 90\u00b0 of flexion, pull anteriorly on\u00a0tibia\u00a0 Tibia translates\u00a0forward\u00a0 Pivot Shift ACL\u00a0 With knee extended, internally rotate the foot and apply valgus\u00a0force\u00a0 <p>Translation of femur</p> <p>or tibia\u00a0</p> Lachman\u00a0 ACL\u00a0 With knee flexed 20\u00b0, hold thigh down with one hand while pulling anteriorly on tibia with your other hand (with thumb on tibial joint line)\u00a0 Soft end point of tibial translation\u00a0 Posterior drawer\u00a0 PCL\u00a0 With hip flexed and knee in 90\u00b0 of flexion, push posteriorly on\u00a0tibia\u00a0 Tibia translates\u00a0backwards\u00a0 Joint line tenderness\u00a0\u00a0 Meniscus\u00a0 Palpate\u00a0 Reproduces pain at\u00a0site\u00a0 McMurray Meniscus\u00a0 <p>With hip &amp; knee flexed, apply:\u00a0</p> <p>Medial: valgus force and internal rotate foot\u00a0</p> <p>Lateral: varus force and externally rotate foot\u00a0</p> Click, pop, or reproduces\u00a0pain\u00a0 Noble Compression\u00a0 IT band\u00a0 Patient lies on unaffected side, flex knee while pressure applied to distal IT band (lateral epicondyle)\u00a0 Click, pop, or reproduces\u00a0pain\u00a0 Patellar compression\u00a0 Patello-femoral pain\u00a0 With knee extended and quads relaxed, apply direct pressure to anterior patella as patient tightens\u00a0quads\u00a0 Reproduces\u00a0pain\u00a0 Patellar apprehension Patello-femoral pain\u00a0 With knee flexed to 30\u00b0, displace patella\u00a0laterally\u00a0 Patient grimaces or tries to straighten\u00a0leg"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/#imaging","title":"Imaging","text":"<ul> <li> <p>X-ray: b/l\u00a0AP,\u00a0unilateral,\u00a0lateral,\u00a0b/l\u00a0sunrise\u00a0view</p> </li> <li> <p>Obtain X-rays in standing position (or joint space narrowing may not     be apparent)\u00a0</p> </li> <li> <p>MSK\u00a0U/S:\u00a0allows for dynamic imaging and is \u2248100% sensitive     for\u00a0effusion\u00a0</p> </li> <li> <p>Also visualizes ligaments, muscles/tendons, joint space,     and\u00a0vasculature\u00a0</p> </li> <li> <p>MRI:\u00a0 indicated after failure of conservative management or when     considering surgical\u00a0repair\u00a0</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/#treatment","title":"Treatment:","text":"<ul> <li> <p>RICE (rest, ice, compression, elevation) for acute injuries\u00a0</p> </li> <li> <p>Bracing\u00a0</p> </li> <li> <p>NSAIDs: see prior section for anti-inflammatory dosing</p> </li> <li> <p>PT for 4-6 weeks\u00a0for ligamentous, muscular, or meniscal\u00a0injury\u00a0\u00a0</p> </li> <li> <p>Antibiotics may be appropriate for bursitis if infection     is\u00a0suspected\u00a0</p> </li> <li> <p>Referral to orthopedics/sports medicine if no improvement after     conservative therapy\u00a0</p> <ul> <li>Surgery reserved for young, athletic people with ligamentous\u00a0injury\u00a0</li> </ul> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/","title":"Neck Pain","text":"<p>Samir Khan</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/#background","title":"Background","text":"<ul> <li> <p>Most common cause of neck pain in adults: degenerative changes of     the cervical spine</p> </li> <li> <p>Most atraumatic neck pain does not require\u00a0imaging</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/#presentation","title":"Presentation","text":"<ul> <li> <p>Cervical\u00a0muscle strain:\u00a0\u00a0pain + stiffness with movement\u00a02/2 muscular     injury</p> </li> <li> <p>Degenerative disc disease/osteoarthritis: pain + stiffness with     movement from derangement in disc architecture leads to inability to     distribute pressure in the joint</p> </li> <li> <p>Cervical radiculopathy: neuropathic\u00a0pain, sensory abnormalities,     and/or weakness in an upper extremity (often radiating to\u00a0hand)</p> </li> <li> <p>Cervical myelopathy: spinal cord compression causing neurologic     dysfunction</p> <ul> <li>Earliest symptom is gait disturbance. Pain is uncommon</li> </ul> </li> <li> <p>Non-cervical conditions:\u00a0shoulder pathology, migraine/headaches,     occipital neuralgia, torticollis, thoracic outlet syndrome, angina     pectoris/MI, bony\u00a0metastases, vertebral artery or carotid artery     dissection, fibromyalgia, meningitis, transverse myelitis\u00a0</p> </li> <li> <p>Posterior neck pain\u00a0</p> <ul> <li> <p>Axial only\u00a0\u00e0 MSK\u00a0(sprain vs degenerative disc disease)\u00a0</p> </li> <li> <p>Axial +\u00a0Extremity\u00a0Pain \u00a0Radiculopathy\u00a0</p> </li> </ul> </li> <li> <p>Anterior neck pain\u00a0</p> <ul> <li> <p>Common sources: esophageal, thyroiditis,\u00a0carotidynia, lymphadenitis,     Ludwig\u2019s angina</p> </li> <li> <p>Red flags: recent\u00a0trauma, lower extremity weakness, gait     abnormality, bowel/bladder incontinence, fever, weight loss\u00a0</p> </li> </ul> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/#evaluation","title":"Evaluation","text":"<ul> <li>Determine MSK (axial pain) vs Radiculopathy/Myelopathy vs     Non-spinal\u00a0</li> </ul> \u00a0Provocation Tests of the Neck Test Isolates Action Positive if Spurling\u2019s test\u00a0 Cervical radiculopathy\u00a0 Downward pressure applied to top of head with extended neck and rotates to affected\u00a0side\u00a0 <p>Reproducible pain beyond shoulder</p> <p>Neck pain alone is not specific</p> <p>Elvey's\u00a0upper\u00a0limb\u00a0</p> <p>tension\u00a0test\u00a0</p> Cervical radiculopathy\u00a0 Head turn\u00a0contralaterally, arm is abducted while the elbow\u00a0extended\u00a0\u00a0 Reproduction of symptoms\u00a0 Hoffman\u00a0sign\u00a0 Corticospinal lesion (UMN)\u00a0 Loosely\u00a0hold\u00a0middle finger and\u00a0flick\u00a0the fingernail downward, allowing the middle finger to flick upward reflexively There is flexion &amp; adduction of thumb/index finger on the same hand <ul> <li> <p>Imaging indications: Neuro deficits, Red flags, persistent     pain\u00a0(&gt;\u00a06\u00a0weeks)\u00a0</p> <ul> <li> <p>Cervical\u00a0Plain films, 2-view (AP and lateral)\u00a0</p> </li> <li> <p>Cervical MRI:\u00a0visualizes spinal cord, nerve roots, bone marrow,     discs and soft tissues</p> <ul> <li>Usually w/o\u00a0contrast; can consider contrast if malignancy or     infection suspected</li> </ul> </li> </ul> </li> <li> <p>EMG/Nerve\u00a0Conduction\u00a0Studies: not routinely used for neck pain     evaluation, but can be used to distinguish cervical radicular pain     from peripheral causes of extremity dysesthesia</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/#management","title":"Management","text":"<ul> <li> <p>Cervical strain, Cervical radiculopathy: PT</p> <ul> <li> <p>5 d course of oral prednisone 60-80 mg, followed by 7-14 day taper</p> </li> <li> <p>Anti-spasmodic prn: Flexeril or Robaxin</p> </li> <li> <p>If not improving or progressive symptoms refer to Ortho Spine + PM&amp;R</p> </li> </ul> </li> <li> <p>Cervical myelopathy requires urgent surgical\u00a0evaluation \u00a0</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-pmr-consultation/","title":"PM&amp;R Consultation","text":"<p>Evan Berlin, Scott Miller, Adam Epps, Lauren Massey</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-pmr-consultation/#reasons-for-consultationreferral-to-pmr","title":"Reasons for Consultation/Referral to PM&amp;R:","text":"<ul> <li> <p>If PT/OT recommends Inpatient Rehabilitation (IPR) for post-acute     disposition</p> <ul> <li>Recommended for pts with: Spinal Cord Injuries, Traumatic Brain     Injuries, Poly-trauma, CVA, Amputation, Burns, Critical Illness     /Acute Polyneuropathies or Myopathies, Prolonged Hospitalization</li> </ul> </li> <li> <p>Benefits of PM&amp;R Consults include:</p> <ul> <li> <p>Confirms and facilitates post- acute rehab disposition (SNF vs IPR     refined opinion)</p> </li> <li> <p>Provides comprehensive document for insurance and post-acute     provider resource</p> </li> <li> <p>Facilitates communication between PM&amp;R consultant, primary team,     case management, PT/OT, and post-acute rehab provider</p> </li> <li> <p>Provision of bedside MSK ultrasound-guided injections: joint     injections (small and large), bursa injections, peripheral nerve     injections (lateral femoral cutaneous, carpal tunnel, cubital     tunnel) and diagnostic joint aspirations</p> </li> <li> <p>Co-management for acute or chronic spasticity, neurogenic bowel and     bladder</p> </li> <li> <p>Can be helpful in identifying equipment required for discharge</p> <ul> <li> <p>Gait impairments of uncertain etiology impacting post- acute     care disposition safety</p> </li> <li> <p>Autonomic dysreflexia</p> </li> <li> <p>Paroxysmal sympathetic hyperactivity associated with brain     injury</p> </li> <li> <p>Contracture, pressure wound insight or prevention</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/","title":"Rehabilitation Options","text":"<p>Evan Berlin, Scott Miller, Adam Epps, Lauren Massey</p> <p>Physical medicine and rehabilitation (PM&amp;R) physicians focus on restoring function and quality of life to those with physical impairments or disabilities affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles, and tendons</p> <p>Physiatrists specialize in determining appropriate rehab options for hospitalized patients</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/#acute-inpatient-rehabilitation-ipr-or-inpatient-rehabilitation","title":"Acute Inpatient Rehabilitation (IPR) or Inpatient Rehabilitation","text":"<p>facility (IRF):</p> <ul> <li> <p>IPR involves a multidisciplinary team of physicians, physical     therapists, occupational therapists, speech and language     pathologists</p> </li> <li> <p>Pts admitted to IPR must be able to tolerate a minimum of 3 hours of     rehab per day for 5 days a week</p> </li> <li> <p>Pts must have medical complexity warranting medical supervision by a     physician</p> </li> <li> <p>Physicians are required to evaluate admitted patients at least 3     times a week</p> </li> <li> <p>Average length of stay (LOS) in acute inpatient rehab is 10-12 days</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/#skilled-nursing-facility-snf","title":"Skilled Nursing Facility (SNF):","text":"<pre><code>- Patients admitted to SNF require skilled needs: Wound care, IV\n    therapy, Catheter care, PT, OT, and/or SLP\n\n- There are no minimal requirements for daily therapy, but patients\n    may receive up to 1.5 hours/day, depending on availability at the\n    facility (in practice it is often less than this)\n\n- Physicians are required to evaluate admitted patients at least once\n    every 30 days\n\n- Average length of stay is 26 days\n</code></pre>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/#long-term-acute-care-hospital-ltach","title":"Long-Term Acute Care Hospital (LTACH):","text":"<ul> <li> <p>Pts admitted to LTACH require extended hospitalization and include     pts who will be receiving prolonged mechanical ventilation</p> </li> <li> <p>Pts will be recommended for transfer to an LTACH when no reasonable     functional or medical improvement can be expected in an acute     inpatient stay</p> </li> <li> <p>LTACHs can be within a hospital or may be free-standing</p> </li> <li> <p>Average length of stay must be greater than 25 days</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/#assisted-living","title":"Assisted Living:","text":"<ul> <li> <p>Pts receive a combination of long-term housing, personal care     services, and health care</p> </li> <li> <p>Designed for individuals who need assistance with activities of     daily living</p> </li> <li> <p>Can be provided in freestanding communities, near or integrated with     SNFs, hospitals or retirement communities</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/#outpatient-services","title":"Outpatient Services:","text":"<ul> <li> <p>Can be ordered at discharge with or without official PT/OT     recommendations</p> </li> <li> <p>Home health (HH): wide range of healthcare services provided in     patients home ranging from wound care to IV antibiotics</p> <ul> <li> <p>HH PT/OT: pts can receive therapy at home when unable to attend     outpatient PT/OT</p> </li> <li> <p>HH nursing services: required for IV antibiotics or PICC line     maintenance; consider for wound care, other services include     medication adherence and reconciliation</p> </li> <li> <p>HH non-skilled aide: outside the scope of acute hospitalization, but     helps with ADLs</p> </li> </ul> </li> <li> <p>Outpatient PT/OT: Consider for those who would benefit from therapy     but do not meet the qualifications for other dispositions or would     prefer outpatient therapy</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/","title":"Shoulder Pain","text":"<p>Joseph Nowatzke</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/#background","title":"Background","text":"<ul> <li> <p>Bones:\u202fClavicle, Scapula (Acromion and Coracoid process) and     Proximal\u202fHumerus\u202f\u202f</p> </li> <li> <p>Rotator Cuff: Supraspinatus, Infraspinatus, Teres minor,     subscapularis</p> </li> <li> <p>Neurovascular: anterior and posterior circumflex humeral arteries,     branching off axillary artery; Innervated by axillary,     suprascapular, subscapular nerve off\u202fbrachial plexus\u202f\u202f</p> </li> <li> <p>Labrum is a cup-shaped rim of cartilage lining and reinforces the     shoulder joint by surrounding the glenoid fossa, allowing extra     support to the head of the humerus</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/#presentation","title":"Presentation","text":"<ul> <li> <p>Brachial Plexus Palsies\u00a0</p> </li> <li> <p>Vascular\u00a0Pathology (e.g. thoracic outlet syndrome, thrombus,     atherosclerosis, vasculitis)\u00a0</p> <ul> <li>Typical symptoms are tightness, heaviness, cramping, or weakness     in\u00a0arm\u00a0</li> </ul> </li> <li> <p>Rotator Cuff Injuries:\u00a0\u00a0</p> <ul> <li> <p>Impingement Syndrome: supraspinatus is\u00a0most\u00a0susceptible</p> </li> <li> <p>Tendinopathy: develops after repetitive motions; pain worsens with     active movement</p> </li> <li> <p>Tendon Tear: develop as a progression of tendinopathy; develops     weakness</p> </li> </ul> </li> <li> <p>Labral Tear &amp; SLAP\u00a0(superior labral tear from anterior to     posterior): develop in repetitive overhead motions (swimming,     baseball, tennis); often described as a \u201ccatching\u201d\u00a0sensation\u00a0</p> </li> <li> <p>Adhesive capsulitis: \u201cfrozen\u00a0shoulder\u201d stiffened glenohumeral joint,     loss of both active and passive\u00a0RoM.\u00a0Increased frequency in     diabetics\u00a0</p> </li> <li> <p>AC\u00a0(acromioclavicular) joint pain: joint often affected by OA, RA     and common cause for anterior shoulder pain\u00a0shoulder separations     and\u00a0osteoarthritis\u00a0\u00a0</p> </li> <li> <p>Glenohumeral OA: degeneration of articular cartilage and subchondral     bone with narrowing of the glenohumeral joint. Presents in older     adults with progressively worsening anterior shoulder pain and     stiffness in both passive and active ROM</p> </li> <li> <p>Biceps Tendinopathy: localized anterior shoulder pain, worsened with     overhead lifting; when rupture develops, will often have a \u201clump\u201d     and acute worsening of\u00a0symptoms\u00a0</p> </li> <li> <p>Posterior shoulder pain often related to cervical\u00a0radiculopathy\u00a0</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Physical Exam:\u00a0</p> <ul> <li> <p>Inspection: Symmetry, erythema, ecchymosis, swelling, deformity,     muscle atrophy (deltoid, infraspinatus), scapular winging\u00a0</p> </li> <li> <p>Palpation: warmth, landmarks, tenderness: SC joint, clavicle, AC     joint, acromion, spine of scapula, bicipital groove, biceps tendon,     greater tuberosity of humerus, common myofascial trigger points     (trapezius,\u00a0levator\u00a0scapulae, rhomboids, supraspinatus)\u00a0</p> </li> <li> <p>Passive ROM: performed by the examiner without\u00a0patient assistance</p> <ul> <li>Helps to distinguish motion limitations caused by a structural     constraint (adhesive capsulitis) vs. motion limitations caused     by\u00a0pain\u00a0</li> </ul> </li> <li> <p>Active ROM: performed by the pt on their own. Loss of active motion     usually indicates weakness due to\u00a0either muscular (tears) or nerve     injury\u00a0</p> </li> <li> <p>C-spine: evaluate\u00a0the C-spine as the origin of pain that may be     referred to the\u00a0shoulder\u00a0</p> </li> <li> <p>Provocation tests: see Below</p> </li> </ul> </li> <li> <p>Imaging:\u00a0\u00a0</p> <ul> <li> <p>Not as\u00a0useful\u00a0as\u00a0a thorough physical exam, especially if     non-traumatic pain\u00a0</p> </li> <li> <p>XR: AP\u00a0(Internal Rotation, External Rotation),\u00a0Lateral, Scapular and     axillary views\u00a0</p> </li> <li> <p>CT: often reserved for traumatic fracture and artificial joint     assessment\u00a0</p> </li> <li> <p>MRI\u00a0w/out contrast: used to evaluate soft tissues, tendons, muscle     and bursae</p> </li> <li> <p>Ultrasound: becoming more useful for initial evaluation of rotator     cuff</p> </li> </ul> </li> </ul> Test Isolates Action Positive if Empty Can Test Supraspinatus Place arms at 80\u2070\u00a0abduction, 30\u2070\u00a0forward flexion and pronate hand with thumbs down; exert downward force at\u00a0elbows <p>Pain\u00a0 tendinopathy</p> <p>Weakness + pain\u00a0\u00a0tear</p> Neer sign Subacromial impingement Passively flex arm with hand pronated (similar to\u00a0empty can) If pain subacromial impingement External Rotation Infraspinatus, teres minor Arms at side, flex 90\u2070 elbow,\u00a0exert medial force to distal\u00a0forearm Weakness, pain Lag sign &amp;\u00a0Lift-Off\u00a0test Subscapularis Place dorsum of\u00a0hand\u00a0on\u00a0lumbar area of back and actively and passively move hand\u00a0off of\u00a0back Pain or failure\u00a0to perform\u00a0indicates subscapularis\u00a0pathology Cross arm test AC joint Active abduction of arm across torso Pain AC joint dysfunction Speed\u2019s Test Biceps Tendon Have pt extend arm in\u00a0full supination with the shoulder flexed.\u00a0Ask pt to\u00a0elevate arm while applying\u00a0downward force <p>Pain in the anterior shoulder</p> <p>\u00a0Biceps\u00a0tendon pathology</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/#management","title":"Management","text":"<ul> <li> <p>Fractures: require assessment by orthopedics for\u00a0reduction\u00a0and     surgical intervention</p> </li> <li> <p>Soft Tissue Injuries, Arthritis\u00a0</p> <ul> <li> <p>Conservative management: referral to\u00a0PT\u00a0for\u00a0muscle strengthening,     flexibility, and postural\u00a0improvement.\u00a0\u00a0</p> </li> <li> <p>Consider short course of NSAIDs, 7-10 days\u00a0(meloxicam, diclofenac)     for pain relief</p> </li> <li> <p>Injections can often be diagnostic and therapeutic\u00a0\u2013 refer to\u00a0ortho\u00a0</p> </li> <li> <p>Sports Medicine\u00a0referral for surgical evaluation if pt fails     conservative therapy</p> </li> </ul> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-spasticity/","title":"Spasticity","text":"<p>Doug Bryant and Jake Dovgan</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-spasticity/#background","title":"Background","text":"<ul> <li> <p>Spasticity is a velocity-dependent increase in resistance to passive     stretch.</p> </li> <li> <p>It differs from hypertonia in that hypertonia is resistance to     passive stretch that is not velocity-dependent.</p> </li> <li> <p>Spasticity is believed to result from disruption of descending     inhibitory modulation of the alpha motor neurons by an upper motor     lesion, producing hyperexcitability.</p> </li> <li> <p>Grading (by the Modified Ashworth Scale)</p> </li> <li> <p>0=no increase in tone</p> </li> <li> <p>1=slight increase in muscle tone, manifested by a catch and release       or by minimal resistance at the end of ROM when affected part is       moved in flexion or extension</p> </li> <li> <p>1+=slight increase in muscle tone, manifested by a catch followed by       minimal resistance through the remainder of ROM (less than half)</p> </li> <li> <p>2=more marked increase in muscle tone through most of ROM, but       affected part is easily moved.</p> </li> <li> <p>3=considerable increases in muscle tone; passive movement difficult</p> </li> <li> <p>4=affected part is rigid in flexion or extension</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-spasticity/#management","title":"Management","text":"<ul> <li> <p>Spasticity can have functional benefits, including improving     standing and transfers. However, it can also cause weakness, poor     dexterity, pain, and contractures.</p> </li> <li> <p>If spasticity is having undesirable effects, first line of treatment     is PT/OT and physical modalities such as stretching.</p> </li> <li> <p>Oral Medications</p> </li> </ul> Medication Mechanism of Action Side Effects/Important Considerations Baclofen GABA-B agonist sedation, fatigue, nausea, centrally acting \u2013 risk of withdrawal Tizanidine Alpha-2 agonist sedation, dizziness, xerostomia, weakness, centrally acting \u2013 risk of withdrawal Diazepam/ Benzodiazepines GABA-A agonist sedation, confusion, hypotension, centrally acting \u2013 risk of withdrawal Dantrolene inhibits Ca release from sarcoplasmic reticulum weakness, sedation, nausea, hepatotoxicity, acts directly on skeletal muscle <ul> <li> <p>Intrathecal baclofen: Reserved for patients who have significant     side effects with oral anti-spasticity medications or who have     severe, persistent, and diffuse spasticity despite maximal doses.</p> </li> <li> <p>Injections</p> </li> <li> <p>Botulinum toxin: Blocks the presynaptic release of acetylcholine       from motor endplates of the lower motor neuron at the myoneural       junction. Effect usually lasts 3-8months</p> </li> <li> <p>Alcohol block: Phenol and ethanol are neurolytic agents that can be       used to block nerves with motor function.</p> </li> <li> <p>Surgeries</p> </li> <li> <p>Selective dorsal rhizotomy, osteotomy, muscle tendon lengthening,       release, or transfer</p> </li> </ul> <p>***If a patient experiences worsening of spasticity, it is important to consider other underlying conditions such as infections, pressure ulcers, constipation, or bladder distention***</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-tbi/","title":"Traumatic Brain Injury (TBI)","text":"<p>Jake Dovgan and Doug Bryant</p>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-tbi/#background","title":"Background","text":"<ul> <li> <p>TBI is categorized as a disruption in brain function leading to     decreased consciousness, memory deficits, neurological deficits, or     intracranial lesion.</p> </li> <li> <p>This disruption is a result of an external blow or force.</p> </li> <li> <p>Most common causes of TBI are falls and MVC.</p> </li> <li> <p>Falls are the most common cause of TBI in elderly population.</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-tbi/#assessment","title":"Assessment","text":"<ul> <li> <p>Mechanism of injury</p> </li> <li> <p>Initial GCS</p> </li> <li> <p>Loss of consciousness and duration</p> </li> <li> <p>Other injuries</p> </li> <li> <p>Initial evaluation should include a non-contrasted head CT to rule     out hemorrhage</p> </li> <li> <p>Full neuro exam including but not limited to cranial nerves,     strength, cognition (orientation), memory, reflexes, sensation,     cerebellar testing, range of motion of joints, Babinski, and     Hoffmann's</p> </li> </ul>"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-tbi/#classification","title":"Classification","text":"Severity GCS Post-Traumatic Amnesia Loss of Consciousness Mild 13-15 \\&lt;1 day \\&lt;30 minutes Moderate 9-12 1 day to 7 days &gt;30 minutes and \\&lt;24 hours Severe 3-8 &gt;1 week &gt; 24 hours"},{"location":"physical-medicine-rehabilitation/physical-medicine-rehabilitation-tbi/#evaluation-and-management","title":"Evaluation and Management","text":"<ul> <li> <p>Secondary complications following TBI:</p> <ul> <li>In the acute setting, patients who have had a TBI are at risk for     seizures, agitation, autonomic problems, bowel/bladder, wounds,     vertigo, headaches, and cognitive impairment, venous thrombosis, and     spasticity</li> </ul> </li> <li> <p>If concerned about TBI would consult PM&amp;R and Speech Therapy for     assistance in management of complications and assessment of     cognition.</p> </li> <li> <p>If concerned for spasticity refer to \u201cSpasticity section\u201d for     specific medication recommendations.</p> </li> </ul>"},{"location":"procedures/procedures-about/","title":"About","text":"<p>Kate Heckman, MD</p> <p>This section was adapted from Procedure Service Guidebook by Tyson Heller, MD</p> <p>VUMC Procedure Service video</p> <p>Making an ultrasound note</p>"},{"location":"procedures/procedures-anesthesia/","title":"Anesthesia and Sedation","text":"<ul> <li> <p>May be used when pain or anxiety may impede performance and success</p> </li> <li> <p>Relative Contraindications: old age, dementia, respiratory     difficulty</p> </li> <li> <p>Aim to use local anesthesia with l% to minimize procedural sedation</p> </li> <li> <p>Creating wheal: clean surface w/ chlorhexidine or alcohol swab; with     22-25G needle, advance needle nearly parallel to skin and aspirate     to ensure no blood vessel involved, then inject anesthetic to create     1-2 cm of raised skin; If deeper subcutaneous anesthesia is needed,     advance needle perpendicular to skin, aspirate as advancing then     inject the tract, inject anesthetic as needle is withdrawn</p> </li> <li> <p>Local anesthesia can alter landmarks, always double check anatomy     after injection</p> </li> <li> <p>Minimal Sedation: 0.25mg-2mg Ativan IV or 1mg-2.5mg Midazolam IV</p> <ul> <li> <p>Midazolam (Versed): faster on (2-5 min) and faster off (30-60 min)</p> </li> <li> <p>Lorazepam (Ativan): onset 5-10 min; Duration 4-8 hours</p> </li> </ul> </li> </ul>"},{"location":"procedures/procedures-anticoagulation-parameters/","title":"Anticoagulation and Bleeding Risk","text":"Anticoagulant How Long to Hold Heparin gtt 4-8 hours, ensure PTT wnl LMWH 12-24 hours Dabigatran (Pradaxa) 1-2 days Apixaban (Eliquis) 1-2 day Rivaroxaban (Xarelto) 1-2 days Warfarin (Coumadin) 5-7 days <p>Platelets, INR: refer to individual procedure sections for procedure-specific guidelines</p>"},{"location":"procedures/procedures-arterial-line/","title":"Arterial Line","text":"<p>NEJM Video Guide</p>"},{"location":"procedures/procedures-arterial-line/#indications","title":"Indications","text":"<ul> <li> <p>Continuous, accurate hemodynamic monitoring (pts requiring     vasopressor titration, pts whose BP accuracy is in question)</p> </li> <li> <p>Need for frequent ABGs</p> </li> </ul>"},{"location":"procedures/procedures-arterial-line/#contraindications","title":"Contraindications","text":"<ul> <li>Abnormal Allen's test, thrombosis of selected site, distorted     anatomy at selected site (known prior fistulas, grafts,     malformations), severe PAD at selected site, Raynaud's of selected     limb</li> </ul>"},{"location":"procedures/procedures-arterial-line/#consent","title":"Consent","text":"<ul> <li>Bruising, pain, damage to adjacent structures, infection, bleeding     (possible extension to RP bleed with femoral placement), hematoma     formation, vascular complications (dissection, AV fistula,     pseudoaneurysm), thrombosis, rarely distal ischemia</li> </ul>"},{"location":"procedures/procedures-arterial-line/#pre-procedural-considerations","title":"Pre-procedural considerations","text":"<ul> <li> <p>Bleeding risk guidelines: no definitive guidelines (some suggest     plts &gt; 50K, INR &lt; 3, PTT &lt; 100)</p> </li> <li> <p>Palpate of artery of interest to best understand anatomy and     surrounding structures</p> </li> <li> <p>Allen Test if placing radial artery access: goal to assess     collateral ulnar blood flow to avoid ischemia. Compress both radial     and ulnar artery 10-15 sec to allow blanching of palm, then release     ulnar artery to assess re-perfusion. If blanching quickly resolves,     ulnar artery will allow distal perfusion</p> </li> <li> <p>If attempting radial access, ensure wrist is adequately extended;     use towel roll under wrist and tape hand to bed or table</p> </li> <li> <p>Discuss with fellow prior to brachial a-line placement</p> </li> <li> <p>Ask RN to prepare tubing and waveform monitoring prior to time-out</p> </li> </ul>"},{"location":"procedures/procedures-arterial-line/#procedural-considerations","title":"Procedural considerations","text":"<ul> <li> <p>Types of Kits</p> <ul> <li> <p>Arrow kit: all-in-one device that has arterial catheter over     introducer needle</p> </li> <li> <p>A-line kit: individual introducer needle, guidewires, and sutures;     multiple steps</p> </li> <li> <p>Micropuncture kit: atraumatic guidewire, microcatheter and     introducer sheath</p> </li> </ul> </li> <li> <p>Reconfirm location with US after lidocaine</p> </li> <li> <p>Ensure arterial access (pulsatile flow of bright red blood)</p> </li> </ul>"},{"location":"procedures/procedures-arterial-line/#post-procedural-considerations","title":"Post- procedural considerations","text":"<ul> <li> <p>Immediately connect pressure tubing to catheter while maintaining     sterile technique</p> </li> <li> <p>Observe monitor for arterial waveform to verify appropriate     placement</p> </li> <li> <p>If persistent bleeding, hold pressure for 15 mins</p> </li> </ul>"},{"location":"procedures/procedures-central-line/","title":"Central Line","text":"<p>NEJM Video Guide</p>"},{"location":"procedures/procedures-central-line/#indications","title":"Indications","text":"<ul> <li> <p>Extracorporeal therapies: HD, CRRT, Plasma (PLEX) or RBC exchange     transfusion</p> </li> <li> <p>Venous access for: vasopressors, chemotherapy, parenteral nutrition,     hemodynamic monitoring (CVP, ScvO2) and cardiac parameters (via PA     catheter), inadequate peripheral access</p> </li> </ul>"},{"location":"procedures/procedures-central-line/#relative-contraindications","title":"Relative Contraindications","text":"<ul> <li>Increased bleeding risk, anatomic distortion at site selection,     indwelling vascular hardware (pacemaker, HD access), vascular injury     proximal to site, skin infection overlying selected site</li> </ul>"},{"location":"procedures/procedures-central-line/#consent","title":"Consent","text":"<ul> <li> <p>Immediate complications: bleeding, malposition, arterial puncture,     arrhythmia, pneumo- or hemothorax, air embolism, damage to     surrounding structures (nerves, thoracic duct)</p> </li> <li> <p>Delayed complications: infection, thromboembolism, myocardial     perforation, venous stenosis</p> </li> </ul>"},{"location":"procedures/procedures-central-line/#pre-procedural-considerations","title":"Pre-procedural considerations","text":"<ul> <li> <p>Bleeding risk guidelines: Plts &gt; 20k, INR \\&lt; 3</p> </li> <li> <p>All patients need to have telemetry &amp; pulse oximetry monitoring</p> </li> <li> <p>With every pt, consider LENGTH, LOCATION, LUMENS, and LINE TYPE!</p> </li> </ul> Central Line <p>Recommended Length</p> <p>(for patient height &gt;5\u20195\u201d)</p> Right IJ or Subclavian 15 cm Left IJ or Subclavian 20 cm Femoral 25 cm *Confirm length of catheter in your kit before you open/place the line! Type of Line Uses Special Considerations Triple Lumen (7Fr) Central access for vasopressors, caustic infusions Consider lumens needs; triple lumen is most versatile but can warrant dual lumen MAC or Cordis* \u2018Short and fat\u2019 allowing rapid transfusion; MAC has two parts and can float a PA catheter through it MAC is placed with dilator still in introducer Dialysis Catheter (Trialysis, 12 Fr) Dialysis line with two 12 Ga. Lumens for dialysis with a third 17 Ga. lumen for added access Two serial dilations *Can place triple lumen in MAC for additional ports; lose ability to rapidly transfuse Site Advantages Disadvantages Internal Jugular Vein Minimal risk of PTX; improve target with positioning and use of US; easily compressible if bleeding occurs Risk of carotid puncture, difficult in obese pt; vein collapsibility with hypovolemia Subclavian More comfortable for pts; landmark driven approach; lowest risk infection Increased risk of PTX, harder to control bleeding with pressure, technically more difficult Femoral Easiest to access, no risk of PTX, can be placed during CPR and intubation"},{"location":"procedures/procedures-central-line/#procedural-considerations","title":"Procedural considerations","text":"<ul> <li> <p>Numb pt right after draping, then set up everything to allow time     for lidocaine to work</p> </li> <li> <p>Set supplies up in exactly the order of use to ensure all are     present and functioning</p> </li> <li> <p>Cap side ports with blue claves (not included in Trialysis kit)     prior to flushing</p> </li> <li> <p>For IJ access, place pt in slight Trendelenburg position to engorge     vein</p> </li> <li> <p>While advancing needle, ensure constant negative pressure with     aspiration of plunger and visualization of needle tip with US</p> </li> <li> <p>Designate someone to watch tele while threading guidewire to monitor     for arrhythmias; limit guidewire insertion depth to no more than 16     cm to reduce arrhythmia risk</p> </li> <li> <p>Always ensure guidewire is secured while it is inside a vein</p> </li> <li> <p>Always ensure target for venous cannulation is visualized and     guidewire is placed correctly prior to dilation: 1) Compression of     target vessel 2) Non-pulsatile dark blood return (unless on     100%FiO2, may be brighter red) 3) US visualization or needle and     wire 4) can use pressure tubing and angiocath to confirm CVP or     obtain venous O2 sat</p> </li> </ul>"},{"location":"procedures/procedures-central-line/#post-procedural-considerations","title":"Post-procedural considerations","text":"<ul> <li> <p>Every IJ or subclavian central line needs a confirmation CXR to     confirm no PTX</p> </li> <li> <p>Ideal placement of distal tip: in SVC just outside the right atrium,     approximately near/superior to carina and right tracheobronchial     angle</p> </li> </ul>"},{"location":"procedures/procedures-central-line/#troubleshooting-complications","title":"Troubleshooting Complications:","text":"<pre><code>- Arterial Access or puncture: immediately remove needle and hold\n    pressure for 15 mins to prevent hematoma formation; if uncontrolled\n    bleeding or artery was dilated, STAT vascular surgery consult\n\n- Bleeding: place direct pressure; subclavian access precludes ability\n    to compress and confers highest bleeding risk; if uncontrolled, STAT\n    vascular surgery consult\n\n- Pulmonary Complications: if free air aspirated into syringe,\n    consider PTX vs poor seal of syringe &amp; needle. Close attention to\n    pulmonary complication &amp; STAT CXR to assess PTX. If rapid\n    deterioration, needle decompression and chest tube placement\n    required\n\n- Venous Air Embolism: can occur if air introduced to system during\n    placement, flushing, or if left open to the atmosphere. Effects are\n    variable, but if suspected, place pt in left lateral decubitus\n    position to trap air in right apex and place pt on 100% O2 to speed\n    resorption\n\n- Arrhythmia: rationale for telemetry monitoring as guidewire can lead\n    to atrial or ventricular arrhythmias; immediately withdraw wire to\n    lesser depth; if arrythmia persists, abort procedure and treat\n    patient and determine cause\n</code></pre>"},{"location":"procedures/procedures-consent/","title":"Consent","text":"<ul> <li> <p>When printing consent forms at VUMC, use MedEx (on the virtual     machine/desktop)</p> </li> <li> <p>Telephone consent requires second physician as witness</p> </li> <li> <p>Use CSN (not the MRN) to locate the patient information for that     specific admission or office visit \u2013 ensure patient current room     number on MedEx screen</p> </li> <li> <p>When consenting pts at NAVA, use the COW with pen pad and the IMed     Consent forms</p> </li> <li> <p>Refer to individual procedure sections for procedure-specific risks     to discuss in consent</p> </li> </ul> <p>Informed Consent Video Guide</p>"},{"location":"procedures/procedures-dht/","title":"Dobhoff Tube","text":""},{"location":"procedures/procedures-dht/#indications","title":"Indications","text":"<ul> <li> <p>Enteral feeding and medication administration if unable to swallow</p> </li> <li> <p>DHT v NGT: DHT deliver meds and fluids, NGT provide suction to     decompress (can also deliver meds/fluids); nurses place NGT,     residents (and ICU nurses) place DHT qUh5AJ5uIZo</p> </li> </ul>"},{"location":"procedures/procedures-dht/#relative-contraindications","title":"Relative Contraindications","text":"<ul> <li> <p>Esophageal varices or strictures (most hepatologists say this is not     a contra-indication, but discuss if recent bleed or recent banding)</p> </li> <li> <p>Other altered gastric anatomy that may prevent passage. (i.e.     gastric bypass, esophageal hernias, tumors or other possible     obstructions)</p> </li> <li> <p>SBO or ileus (use NGT instead for suction)</p> </li> </ul>"},{"location":"procedures/procedures-dht/#absolute-contraindications-for-blind-approach","title":"Absolute Contraindications for blind approach","text":"<ul> <li>Facial trauma, basilar skull fracture, pharyngeal or esophageal     trauma</li> </ul>"},{"location":"procedures/procedures-dht/#consent","title":"Consent","text":"<ul> <li>Common risks: malposition (lung -&gt; pneumothorax or pneumonia;     pyriform sinus; coiling anywhere along tract); perforation anywhere     along the tract; aspiration, nasal ulceration, esophagitis,     gastritis, bleeding, vagal response, discomfort</li> </ul>"},{"location":"procedures/procedures-dht/#pre-procedural-considerations","title":"Pre-procedural considerations","text":"<ul> <li> <p>Bleeding risk guidelines: Plts &gt; 10k, no specific INR     guidelines</p> </li> <li> <p>Make sure DHT and bridle sizes correlate</p> </li> <li> <p>Measure expected advancement depth by measuring distance from tip of     nose, around ear, and to xiphoid process</p> </li> <li> <p>Prior to placement, fasten the stylet in the fully-hubbed position     to reduce bending and folding over of the weighted tip while     advancing</p> </li> <li> <p>Apply anesthetic with lidocaine gel (order Lidocaine uro-jet) and     nasal swab to reduce pt discomfort, reduce gag reflex, and assist     with clearance of the nasal passages</p> </li> <li> <p>Consider fluoro-guided placement after 3 failed bedside attempts</p> </li> <li> <p>Post-pyloric placement</p> <ul> <li> <p>Consider in patients with high pulmonary aspiration risk, severe     esophageal reflux/esophagitis, recurrent emesis, impaired gastric     mobility, and pancreatitis</p> </li> <li> <p>Refer for fluoro-guided post-pyloric advancement after 1 failed     bedside attempt</p> </li> </ul> </li> </ul>"},{"location":"procedures/procedures-dht/#procedural-considerations","title":"Procedural Considerations","text":"<ul> <li> <p>Have the patient sit upright with their head tilted toward the chest     to encourage posterior oropharyngeal positioning of the DHT while     advancing</p> </li> <li> <p>Tip: advance horizontally (nose tip to ear lobe), not angled up</p> </li> <li> <p>If pt can participate safely, have the patient swallow in     conjunction with advancement; pt can suck on straw (with small sips     of water if low aspiration risk) to utilize pharyngeal muscles to     position DHT into esophagus</p> </li> <li> <p>Place bridle and dog-bone tape while at the bedside to reduce     dislodgement</p> </li> <li> <p>Excessive coughing, difficulty phonating, or resistance may indicate     tracheal placement; withdraw tube and re-attempt. Consider Duonebs     to reduce bronchospasms</p> </li> <li> <p>Post-pyloric placement has been shown to be up to 90% successful     with intermittent insufflation of 10-20cc of air ~every 10cm of     advancement after 55cm to promote pylorus opening. IV Reglan or     erythromycin may also help</p> </li> <li> <p>When placing bridle (recommend AFTER xray confirmation), keep     alignment markers (marked on both probes) together so magnetic tips     will align once past the nasal septum</p> </li> <li> <p>When placing the bridle, remove the green stylet housed within the     white probe before retracting back and removing the white probe</p> </li> </ul>"},{"location":"procedures/procedures-dht/#post-procedural-considerations","title":"Post-procedural Considerations","text":"<ul> <li> <p>ALWAYS confirm position radiographically via KUB before medications     are given!</p> </li> <li> <p>Insufflation of air and auscultation of bowel sounds over the     gastric area can be reassuring of correct placement of DHT prior to     taping/bridling and leaving the bedside</p> </li> <li> <p>Most mispositioned/coiled tubes have to be removed and re-attempted,     but it is ok to advance or withdraw if Stylet is still in place.     However, once removed, a stylet should not be re-introduced to a     mispositioned/coiled tube due to risk of GI perforation</p> </li> <li> <p>In case of cranial placement, don\u2019t remove, consult NSGY</p> </li> <li> <p>De-clogging: Clog Zapper Kit (can type this into Epic directly);     coca cola</p> </li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/","title":"Lumbar Puncture","text":"<p>NEJM Video Guide</p>"},{"location":"procedures/procedures-lumbar-puncture/#indications","title":"Indications","text":"<ul> <li>Diagnosis of suspected CNS infections, CNS malignancies,     demyelinating diseases, IIH, NPH, autoimmune encephalitis, suspected     SAH with negative imaging</li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/#absolute-contraindications","title":"Absolute Contraindications","text":"<ul> <li>Increased intracranial pressure with risk of herniation (i.e.     space-occupying lesions, cerebral edema, obstructive hydrocephalus),     infection or epidural abscess over puncture site, trauma to lumbar     vertebrae</li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/#relative-contraindications","title":"Relative Contraindications","text":"<ul> <li>\u2191 intracranial pressure, thrombocytopenia, bleeding diatheses</li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/#consent","title":"Consent","text":"<ul> <li> <p>Common risks: back pain (~66%), severe headache</p> </li> <li> <p>Rare risks: spinal hematoma (\\&lt;0.001%), weakness, radicular     pain/numbness, bleeding, brain function problems, CNS infection,     brain herniation</p> </li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/#pre-procedural-considerations","title":"Pre-procedural considerations:","text":"<ul> <li> <p>Bleeding risk guidelines: Plts &gt; 50k, INR \\&lt; 1.6 (stricter     guidelines d/t spinal hematoma risk)</p> </li> <li> <p>CT head not generally needed prior to LP to rule out mass lesion;     consider if presence of focal neurologic signs, papilledema, recent     seizure, or immunocompromise</p> </li> <li> <p>Consider sending to fluoro-guided if: attempts without imaging are     unsuccessful, obese pts with no palpable anatomy, severe scoliosis,     prior spine surgery, borderline low plts and multiple sticks might     be needed, or pt requires heavy sedation</p> </li> <li> <p>Anticoagulation: full dose LMWH must be off 24h, ppx LMWH off 12h,     ppx heparin off 8h, hep gtt off 4-8hrs with repeat lab demonstrating     normalized PT, P2Y12 inhibitors should be off 7 days to avoid     bleeding risks, IR guidelines require Plavix to be off 5 days (ASA     alone is OK)</p> </li> <li> <p>Labs: cell count w/diff, BF culture, glucose, protein; freeze sample     for future/additional labs (order in epic); if infectious or     neurological labs are needed, consider consult first</p> </li> <li> <p>Ensure lateral decubitus position for opening pressure with glass     pressure manometer</p> </li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/#procedural-considerations","title":"Procedural considerations","text":"<ul> <li> <p>US Probe: Linear (can use curvilinear in obese pts) in transverse     axis to establish midline &amp; in sagittal axis to identify spinous     processes</p> </li> <li> <p>Anesthetic use: Lidocaine 1-2% (likely need more than what is     provided in kit; consider empiric anesthetization of 2 spaces \u00b1     Pain-Ease spray</p> </li> <li> <p>Increased number of attempts = increased success rates</p> </li> <li> <p>Higher rate of success if stylet is removed before entering     subarachnoid space to better observe flow of CSF once in the     subarachnoid space. Stylet should be replaced prior to LP needle     removal</p> </li> <li> <p>Aspiration of CSF = increased risk of bleeding. Don\u2019t aspirate!</p> </li> <li> <p>Volume removal for studies: Basic only 2mL per tube in 1-4. Many     studies ordered: 3mL per tube (*consider calling lab to confirm).     Cytology desired: call lab to confirm amount needed (rule of thumb     2/2/6/2mL); Tube 4 is sent for micro to reduce contamination.     Therapeutic high volume: 30mL max</p> </li> </ul>"},{"location":"procedures/procedures-lumbar-puncture/#post-procedural-considerations","title":"Post-procedural considerations","text":"<ul> <li> <p>Post-LP headache (~10%): encourage pt to lay flat to reduce the     intensity of symptoms (but does not prevent it); if prolonged,     consider blood patch (c/s Anesthesia)</p> </li> <li> <p>Neuro changes OR bleeding complications: STAT non-contrast MRI     lumbar spine for epidural hematoma, q1 neuro-checks x4hrs then q2     for 24-48hrs &amp; consult NSGY</p> </li> <li> <p>Sample cannot be tubed; someone must walk fluid to the lab</p> </li> <li> <p>Resuming anticoagulation: 1h UFH, 4h LMWH, 6-8h     rivaroxaban/apixaban, 6h dabigatran/fondaparinux. Longer periods     should be considered after traumatic tap, and post-procedure     monitoring of neurological function is recommended for all pts</p> </li> </ul>"},{"location":"procedures/procedures-paracentesis/","title":"Paracentesis","text":"<p>VUMC Procedure Service Video Guide</p> <p>NEJM Video Guide</p>"},{"location":"procedures/procedures-paracentesis/#indications","title":"Indications","text":"<ul> <li> <p>Diagnostic: Evaluation of new onset ascites or of known ascites with     concern for SBP</p> </li> <li> <p>Therapeutic: tense ascites, refractory to diuretics, causing pt     discomfort</p> </li> </ul>"},{"location":"procedures/procedures-paracentesis/#relative-contraindications","title":"Relative Contraindications","text":"<ul> <li>Significant bowel distension due to ileus or SBO, hemodynamic     instability (due to large fluid shifts with LVP), DIC,     infection/breakdown of skin overlying puncture site</li> </ul>"},{"location":"procedures/procedures-paracentesis/#consent","title":"Consent","text":"<ul> <li>Risks: abdominal wall hematoma (1%), hemoperitoneum, organ puncture     / bowel perforation, infection, ascitic fluid leak</li> </ul>"},{"location":"procedures/procedures-paracentesis/#pre-procedural-considerations","title":"Pre-procedural considerations","text":"<ul> <li> <p>Bleeding risk guidelines: Plts &gt; 20k, INR &lt; 4 (note that     cirrhosis complicates INR interpretation)</p> </li> <li> <p>If therapeutic, determine volume pt typically gets drained so you     have enough bottles (tip: call service center to request bottles be     sent to RN station if you can't find enough)</p> </li> <li> <p>Labs (order before so nurse can print off labels): cell count     w/diff, BF culture, BF &amp; serum albumin, total protein; cytology if     c/f malignancy; BF/serum Hct if bloody</p> </li> <li> <p>Measure skin/subQ depth with US to help choose sufficiently long     needle for diagnostic paras</p> </li> </ul>"},{"location":"procedures/procedures-paracentesis/#procedural-considerations","title":"Procedural considerations","text":"<ul> <li> <p>Ultrasound Probe: curvilinear</p> </li> <li> <p>Identify safe pocket (&gt;2 cm deep), with no nearby bowel or     adhesions</p> </li> <li> <p>Local anesthesia with lidocaine all the way to peritoneum, as this     is most sensitive part</p> </li> <li> <p>Kit: 6 Fr Safe-T-Centesis Kit; gather cx bottles, cx bottle syringe     adaptor, specimen cup</p> </li> <li> <p>If only diagnostic, use 18G needle with 20-50cc syringe rather than     kit</p> </li> <li> <p>If high bleeding risk, use long 18G needle &amp; attach to syringe     instead of 6 Fr. Catheter</p> </li> <li> <p>Avoid surgical scars out of concern for nearby adhesions and     superficial veins</p> </li> <li> <p>Attempt as lateral as possible to avoid inferior epigastric vessels</p> </li> <li> <p>Roll patient to left or right side to promote pooling of fluid for     easier/safer access</p> </li> <li> <p>Inoculate culture bottles at bedside rather than sending fluid     samples to lab for inoculation to increase yield 50% 80% (Note that     VA does not allow bedside inoculation.)</p> </li> <li> <p>If hernia present, have patient reduce it while draining fluid to     prevent incarceration</p> </li> </ul>"},{"location":"procedures/procedures-paracentesis/#post-procedural-considerations","title":"Post-procedural considerations","text":"<ul> <li> <p>Albumin (25%) for large volume (&gt;5L fluid removal): give 8 g per     liter removed, up to 50 g</p> </li> <li> <p>Ascitic leak: Can try skin glue or place 1 figure-of-eight stitch     with 4.0 vicryl</p> </li> <li> <p>Bleeding complication: hold pressure with quick-clot and gauze for     &gt;5-10 mins if persistent bleeding at site; if profuse bleeding or     concern for organ injury, STAT page EGS and/or IR</p> </li> </ul>"},{"location":"procedures/procedures-thoracentesis/","title":"Thoracentesis","text":"<p>NEJM Video Guide</p>"},{"location":"procedures/procedures-thoracentesis/#indications","title":"Indications","text":"<ul> <li> <p>New pleural effusion that has no obvious explanation (not attributed     to HF alone) or concern for pleural space infection</p> </li> <li> <p>Any respiratory symptoms that would positively respond to large     volume thoracentesis (&gt;1L)</p> </li> </ul>"},{"location":"procedures/procedures-thoracentesis/#contraindications","title":"Contraindications","text":"<ul> <li> <p>Skin infection at needle insertion site</p> </li> <li> <p>Large-volume thoracentesis in hepatic hydrothorax (tends to     reaccumulate). Suspected unexpandable lung</p> </li> </ul>"},{"location":"procedures/procedures-thoracentesis/#consent","title":"Consent","text":"<ul> <li> <p>Common risks (&gt; 5%): coughing, fainting, PTX</p> </li> <li> <p>Rare risks (&lt; 1%): hemothorax, re-expansion pulmonary edema,     liver/spleen puncture</p> </li> </ul>"},{"location":"procedures/procedures-thoracentesis/#pre-procedural-considerations","title":"Pre-procedural considerations","text":"<ul> <li> <p>Bleeding risk guidelines: Plts &gt; 50k, INR &lt; 2 (risk/benefit     evaluation outside these)</p> </li> <li> <p>If loculations present on US, high risk, or any question about     indication, refer to Pulm</p> </li> <li> <p>Labs (order before so nurse can print labels): cell count w/diff; BF     culture, BF &amp; serum LDH, BF &amp; serum total protein; BF &amp; serum Hct if     bloody; cytology if c/f malignancy; consider triglycerides if     concerned for chylothorax</p> </li> </ul>"},{"location":"procedures/procedures-thoracentesis/#procedural-considerations","title":"Procedural considerations","text":"<ul> <li> <p>US Probe: Cardiac (or Linear) to identify safe pocket (&gt;2 cm)     between lung and diaphragm (ask Interventional Pulm or IR if sample     is needed of a smaller pocket)</p> </li> <li> <p>Kit: 6Fr Safe-T-Centesis kit</p> </li> <li> <p>Upright position is typically preferred; lateral to mid-scap/mid-ax.     If patient unable to sit upright, refer to procedure team vs     pulmonology</p> </li> <li> <p>Effusion size: if unable to tap above 9th rib, too small; CXR with     costophrenic angle blunting should correlate to ~250-500mL</p> </li> <li> <p>Insert needle superior to rib to avoid neurovascular bundle (bundles     run below)</p> </li> <li> <p>Stop if pt has any new/increased chest discomfort, aggressive     unremitting cough, frank purulence or air on aspiration,     lightheadedness, hypotension, or vagal response</p> </li> <li> <p>Stop fluid removal after 1.5 L of chronic pleural effusion to reduce     re-expansion pulmonary edema</p> </li> </ul>"},{"location":"procedures/procedures-thoracentesis/#post-procedural-considerations","title":"Post-procedural considerations","text":"<ul> <li> <p>If needing cytology, send at least 60 \u2013 100cc</p> </li> <li> <p>Bleeding complication: STAT page Thoracic Surgery</p> </li> <li> <p>PTX: if pt stable &amp; asymptomatic, supplemental O2 and repeat CXR in     4hrs; if unstable/symptomatic STAT page to Thoracic Surgery</p> </li> <li> <p>Re-expansion pulmonary edema: persistent cough, frothy sputum.     Diffuse GGO on side of thoracentesis. Supportive management (oxygen,     monitor); most resolve in 24-48 hrs. If respiratory distress     progresses, may need mechanical ventilation</p> </li> <li> <p>Documentation: Effusion US characteristics (anechoic, layering     debris, septations), reason for ending procedure (stopped early due     to chest discomfort, complication vs tapped dry), presence of lung     sliding, if more than scant residual effusion remains post-procedure</p> </li> <li> <p>A routine chest radiograph after thoracentesis is no longer     indicated for most asymptomatic, non-ventilated patients. Check lung     slide with US in 2D and M-mode</p> </li> </ul>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/","title":"US-Guided PIV","text":"<p>VUMC Video Guide</p>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/#indications","title":"Indications","text":"<ul> <li>Vascular access; large bore (16-18G) is optimal for blood     transfusion and faster than central lines (except MAC/Cordis);     preserves central access (important for ESRD patients)</li> </ul>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/#relative-contraindications","title":"Relative Contraindications","text":"<ul> <li> <p>Infection over the site, severe bleeding diathesis</p> </li> <li> <p>Avoid EJs unless have been trained due to airway compromise if     extravasation occurs</p> </li> </ul>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/#consent","title":"Consent","text":"<ul> <li>Common risks: arterial puncture, nerve irritation/damage, infection,     infiltration, thrombus formation</li> </ul>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/#pre-procedural-considerations","title":"Pre-procedural considerations","text":"<ul> <li> <p>Bleeding risk guidelines: Plts &gt; 10k, no specific INR     guidelines</p> </li> <li> <p>Location selection: anuric AKI or ESRD patients \u2013 d/w renal, avoid     limb with HD access proximal</p> </li> <li> <p>Target selection: Confirm venous choice with compressibility and     lack of doppler flow. Should follow the rule of 2s: vein must be at     least twice the diameter of the catheter being placed, should be no     more than 2 inches in depth from the surface of the skin, and should     have at least 2 inches of straight (non-tortuous) length</p> </li> </ul>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/#procedural-considerations","title":"Procedural considerations","text":"<ul> <li> <p>US Probe: Linear</p> </li> <li> <p>Kit: IV start kit; ideally 18G needle</p> </li> <li> <p>Anesthetic use: Consider EMLA</p> </li> <li> <p>1st choice: basilic, cephalic veins; 2nd choice: brachial vein     (caution adjacent artery)</p> </li> <li> <p>Use tourniquet</p> </li> <li> <p>Start at 45\u00b0 angle, use 45-45-90 rule to determine starting location     (start as far from center of probe as the vessel is deep), flatten     angle once in the vessel to advance (\"walk\" your way through the     vessel by repeatedly identifying needle tip in the lumen and     advancing)</p> </li> <li> <p>Going too shallow could use up too much catheter leaving nothing to     put in the vein.</p> </li> <li> <p>Going too steep can cause catheter kinking at the hub where it     sticks out of the skin</p> </li> <li> <p>Hold probe close to skin, holding probe far from the end allows too     much movement</p> </li> <li> <p>Center the vessel on the ultrasound probe screen prior to sticking,     place midline on US screen</p> </li> <li> <p>Use both short axis and long axis views to ensure correct placement</p> </li> <li> <p>Short axis- Vessel looks round like a target, helps to scout out the     tip, and is best for ensuring the vein is entered as opposed to a     neighboring artery</p> </li> <li> <p>Long axis- The length of the vessel is viewed. This view is intended     for the final few millimeters of catheter advancement into the vein     to ensure both bevel and plastic sheath lumen traverse the     endothelial layer before threading catheter</p> </li> </ul>"},{"location":"procedures/procedures-ultrasound-guided-peripheral-iv/#post-procedural-considerations","title":"Post-procedural considerations","text":"<ul> <li> <p>DON\u2019T FORGET TO REMOVE TOURNIQUET!! Remove before flushing to     prevent blowing vein</p> </li> <li> <p>Bleeding complication: if arterial, remove catheter &amp; hold pressure     at least 5 mins</p> </li> </ul>"},{"location":"psychiatry/psychiatry-agitation-management/","title":"Agitation Management","text":"<p>Jonathan Constant, Jonathan Smith</p>"},{"location":"psychiatry/psychiatry-agitation-management/#background","title":"Background","text":"<ul> <li>Agitation in the hospital result from discomfort, illness,     medication effects or frustrations the patient is unable to     meaningfully communicate</li> </ul>"},{"location":"psychiatry/psychiatry-agitation-management/#presentation","title":"Presentation","text":"<ul> <li> <p>Impulsive aggression: spontaneous, explosive, reactive/reflexive,     not pre-meditated</p> <ul> <li>Delirium, psychosis, cognitive deficits, withdrawal/intoxication,     pain, post-ictal</li> </ul> </li> <li> <p>Instrumental aggression: pre-meditated, controlled, purposeful     behaviors</p> <ul> <li>Personality disorders, secondary gain, delusional thought</li> </ul> </li> <li> <p>Differential diagnosis for aggression:</p> <ul> <li> <p>Psychoses: mania, depression, schizophrenia, delusional disorder</p> </li> <li> <p>Personality disorder: antisocial, borderline, paranoid, narcissistic</p> </li> <li> <p>Substance use disorder: alcohol, PCP, stimulants, cocaine,     synthetics</p> </li> <li> <p>Delirium, dementia</p> </li> <li> <p>Frontal lobe syndromes (TBI, CVA, neoplasm, neurodegenerative     process)</p> </li> <li> <p>Behavior/Developmental: Intermittent explosive, intellectual     disability</p> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-agitation-management/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Examine (when calm) for source of pain, signs of infection,     discomfort (ex: urinary retention or constipation), toxidromes</p> </li> <li> <p>Neurological exam for focal deficits, ataxia, nystagmus, tremor,     rigidity, aphasias</p> </li> <li> <p>Review medication list and perform med reconciliation of home meds</p> </li> <li> <p>UDS + review of CSMD for evaluation of intoxication/withdrawal</p> </li> <li> <p>CBC, CMP, UA</p> </li> <li> <p>CT head + EEG if focal neurologic deficits</p> </li> </ul>"},{"location":"psychiatry/psychiatry-agitation-management/#management","title":"Management","text":"<ul> <li> <p>Environment</p> <ul> <li> <p>Periodic room searches; search personal belongings, VUPD presence if     warranted</p> </li> <li> <p>Virtual or 1:1 sitter placement,</p> </li> <li> <p>Delirium precautions (see delirium section)</p> </li> <li> <p>Disposable trays and utensils (minimize potential weapons in the     room)</p> </li> </ul> </li> <li> <p>De-escalation: Always first line, although impractical if pt is     unable to communicate effectively, is explosive or already engaging     in violent/potentially harmful behavior</p> <ul> <li> <p>Nonverbal:</p> <ul> <li> <p>Maintain safe distance, avoid sudden movements, don't touch the     pt</p> </li> <li> <p>Maintain neutral posture, neutral, sincere eye contact, same     height</p> </li> </ul> </li> <li> <p>Verbal:</p> <ul> <li> <p>Speak in calm, clear tone, avoid confrontation, and offer to     solve problem if possible</p> </li> <li> <p>Do not insist on having the last word</p> </li> </ul> </li> </ul> </li> <li> <p>Tactics</p> <ul> <li> <p>Redirection: Acknowledge pt's frustrations; shift focus on how to     solve the problem</p> </li> <li> <p>Aligning goals: Emphasize common ground and big picture; make small     concessions</p> </li> </ul> </li> <li> <p>Restraints</p> <ul> <li> <p>Should be used only when necessary to protect patient or others from     harm</p> <ul> <li>Mechanically restrained patients cannot be left unmonitored</li> </ul> </li> <li> <p>De-escalate (4 point to 2 point, etc) and remove restraints as soon     as possible</p> </li> <li> <p>Documentation of restraint:</p> <ul> <li> <p>Face-to-face assessment has to be completed within an hour of     violent restraint</p> </li> <li> <p>\u201cRestraint Charting\u201d tab \u2013 typically in rarely used tab drop     down</p> </li> </ul> </li> <li> <p>Mechanical Restraints:</p> <ul> <li> <p>Soft restraints \u2013 most commonly used</p> </li> <li> <p>Hard restraints \u2013 reserved for severe behavioral health (only 2     sets in house)</p> </li> <li> <p>Mittens</p> </li> <li> <p>Posey Vest \u2013 prevents exiting bed, allows limbs to be free</p> </li> <li> <p>Posey Bed \u2013 wandering patient (TBI, severe dementia)</p> </li> </ul> </li> <li> <p>VUMC Orders: \u201crestraint\u201d --&gt; order set</p> <ul> <li> <p>Non-violent non-self-destructive (order lasts up to 48 hrs)</p> <ul> <li>Most pts needing restraint: non-psychiatric, delirium,     dementia, intubation</li> </ul> </li> <li> <p>Restraint violent self- destructive adult</p> <ul> <li> <p>Order lasts up to 24hr with assessment every 4 hours</p> </li> <li> <p>Mainly severe psychiatric symptoms</p> </li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-agitation-management/#pharmacological-management-for-agitation","title":"Pharmacological Management for Agitation","text":"<p>As discussed above, behavioral interventions are first line for agitation management in the hospital. Pharmacologic treatment should only be used when needed for patient and/or staff safety when non-pharmacologic interventions are unsuccessful or impractical</p>"},{"location":"psychiatry/psychiatry-agitation-management/#acute-agitation","title":"Acute Agitation","text":"<ul> <li> <p>Antipsychotics</p> <ul> <li> <p>Widely effective for acute agitation, especially in delirium and     psychotic disorders</p> </li> <li> <p>Monitor EKG if repeated dosing or if used with other QT prolonging     agents</p> </li> <li> <p>Moderate agitation options:</p> <ul> <li> <p>Olanzapine 2.5 - 5mg po q6h prn. Orally disintegrating tab (ODT)     available</p> </li> <li> <p>Quetiapine 12.5 - 25mg q6h po prn for patients at higher risk of     extrapyramidal symptoms (EPS)</p> </li> </ul> </li> <li> <p>Severe agitation</p> <ul> <li> <p>Haldol 0.5 - 1mg IV/IM q6h prn for older/frail individuals</p> </li> <li> <p>Haldol 2-3mg IV/IM q6h prn for other patients</p> </li> <li> <p>Titrate up to 5 mg and can increase frequency as warranted</p> </li> <li> <p>When using IV Haldol obtain daily EKG, Mg and K levels</p> </li> <li> <p>Stop IV Haldol if QTc &gt; 500 msec</p> </li> </ul> </li> </ul> </li> <li> <p>Benzodiazepines</p> <ul> <li> <p>Lacks EPS that can occur with antipsychotics but can worsen delirium     &amp; disinhibit patients with neurocognitive-related agitation</p> </li> <li> <p>Can use alone or in addition to antipsychotic agent</p> </li> <li> <p>Preferred for agitation related to intoxication/withdrawal of     sedatives</p> <ul> <li> <p>Lorazepam preferentially used due to PO, IV and IM availability</p> </li> <li> <p>Lorazepam 2mg PO/IM/IV q6h prn typical starting dose (1mg if     older/frail)</p> <ul> <li>Can increase frequency if warranted. Monitor for respiratory     suppression</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>If severe agitation not responsive to above, may require sedation     with infusion:</p> <ul> <li>Dexmedetomidine, Propofol or Midazolam</li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-agitation-management/#maintenance-medications","title":"Maintenance medications:","text":"<ul> <li> <p>Antipsychotics</p> <ul> <li> <p>Reserve antipsychotics for severe aggression that pose significant     risk and aim to wean as soon as safely possible</p> </li> <li> <p>Adverse effects: metabolic, EPS, increased mortality in dementia</p> </li> <li> <p>Most commonly used: Olanzapine, Quetiapine, Risperidone</p> </li> </ul> </li> <li> <p>Antiepileptic agents</p> </li> <li> <p>May be effective in reduction of impulsive aggression</p> </li> <li> <p>Most commonly used: Depakote</p> <ul> <li>Levetiracetam could worsen aggression/agitation</li> </ul> </li> <li> <p>Beta Blockers and Alpha Agonists</p> <ul> <li> <p>Noradrenergic over-activity implicated in aggression expression</p> </li> <li> <p>Commonly Used: Propranolol, Clonidine, Guanfacine</p> </li> </ul> </li> <li> <p>Serotonergic agents: SSRI/SNRI/buspirone</p> <ul> <li> <p>Useful if co-occurring depression/anxiety disorders</p> </li> <li> <p>Peak onset of action takes weeks</p> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-alcohol-use-disorder/","title":"Alcohol Use Disorder","text":"<p>Barrington Hwang, Kristopher Kast</p>"},{"location":"psychiatry/psychiatry-alcohol-use-disorder/#background","title":"Background","text":"<ul> <li> <p>50% of hospitalized pts drink alcohol; at-risk alcohol use is &gt;14     drinks/week or &gt;5 drinks in a sitting (for men; for women and men     &gt;65, 7 per week, &gt;4 per sitting)</p> </li> <li> <p>Alcohol withdrawal onset occurs 6-12 hours after last drink, with     90% having non-severe course; CIWA score \\&lt;10 at 24-48 hours     indicates low risk of worsening symptoms</p> </li> <li> <p>Risk of seizures greatest at 12-24 hrs, occurring in ~3% of pts;     risk of delirium greatest at 48-72 hrs, occurring in ~5%</p> </li> <li> <p>Risk assessment</p> </li> <li> <p>RF: prior seizures/delirium, co-substance use (especially       benzodiazepines), no abstinent days in past month, presenting BAL       &gt;200, dysautonomia</p> </li> <li> <p>CIWA symptom-triggered protocol appropriate for pts at low risk of       severe withdrawal</p> </li> <li> <p>For non-low risk pts, consider benzodiazepine/barbiturate load and       standing taper;</p> </li> <li> <p>Indications for admission: prior severe withdrawal (withdrawal     seizures or delirium), comorbidities (medical and psychiatric     illness), pregnancy, significant impairment in social/occupational     functioning, communication barriers, social barriers</p> </li> </ul>"},{"location":"psychiatry/psychiatry-alcohol-use-disorder/#presentation","title":"Presentation","text":"<ul> <li> <p>Acute intoxication: disinhibition, slurred speech, ataxia, nystagmus</p> </li> <li> <p>Acute Withdrawal: nausea, vomiting, anxiety, agitation, audio-visual     and tactile hallucinations, headache, diaphoresis, fine motor tremor     while arms and fingers outstretched, autonomic hyperactivity</p> </li> <li> <p>Chronic heavy use: Sequelae of chronic liver disease &amp; malnutrition,     including thiamine deficiency</p> </li> <li> <p>Caine criteria for Wernicke\u2019s encephalopathy:</p> <ul> <li>2 or more: (1) malnutrition, (2) ataxia, (3) oculomotor   abnormalities, (4) AMS</li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-alcohol-use-disorder/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Identify last use, quantity per day/week, other sedative-hypnotic     use, history of withdrawal, social/occupational dysfunction, other     toxic forms of alcohol compounds including methanol, ethylene glycol</p> </li> <li> <p>Acute Alcohol Withdrawal</p> <ul> <li> <p>Labs: Blood alcohol level, urine toxicology (\u00b1 ethyl glucuronide   to detect use in prior 3 days), BMP, CBC, HFTs (AST:ALT elevation   2:1), CK and \u03b2 - hCG</p> </li> <li> <p>CIWA score quantifies severity, though subject to inflation by   subjective symptoms</p> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-alcohol-use-disorder/#management","title":"Management","text":""},{"location":"psychiatry/psychiatry-alcohol-use-disorder/#acute-alcohol-withdrawal","title":"Acute Alcohol Withdrawal","text":"<ul> <li> <p>Most patients are appropriate for diazepam-based protocols:</p> </li> <li> <p>CIWA-based symptom-triggered for low-risk patients</p> </li> <li> <p>Diazepam load + standing taper for non-low risk patients</p> </li> <li> <p>Substitute lorazepam for pts with hepatic impairment (risk of     long-acting accumulation)</p> </li> <li> <p>Benzodiazepine resistance: likely due to poor cross-tolerance, these     pts require phenobarbital load ( 8-12 mg/kg (up to 15 mg/kg) divided     into 3 doses 3 hours apart)</p> </li> <li> <p>Add folate, multivitamin, and electrolyte repletion</p> </li> <li> <p>If &gt;2 Caine criteria, treat empirically for Wernicke\u2019s     encephalopathy with high-dose IV thiamine (500 mg TID IV x 3-5 days)</p> </li> <li> <p>Consider Addiction Psychiatry consultation for complex presentations</p> </li> </ul>"},{"location":"psychiatry/psychiatry-alcohol-use-disorder/#alcohol-use-disorder_1","title":"Alcohol Use Disorder","text":"<ul> <li> <p>After withdrawal stabilization, engage pt in discussion around use     and educate on connection between use and presenting medical     problems</p> </li> <li> <p>All patients with AUD should be initiated on pharmacotherapy (MAUD)     prior to discharge to mitigate risk of relapse, if consistent with     patient\u2019s goals</p> </li> <li> <p>Additional psychosocial treatments effective for AUD include 12-step     groups (AA, SMART Recovery), cognitive behavioral therapy, sober     living facilities, family therapy, contingency management, and     IOP/residential facilities</p> </li> <li> <p>If patient does not have abstinence goal, reduced or controlled     drinking may allow for harm reduction; naltrexone and topiramate     have evidence for non-abstinence outcomes</p> </li> <li> <p>Pharmacologic Interventions:</p> <ul> <li> <p>Naltrexone (cannot be on opioid agonist):</p> <ul> <li> <p>Need 7-10 days since last opioid before starting</p> </li> <li> <p>25 mg x1 day, then titrate up to 50 mg daily; also available in     q30d IM</p> </li> <li> <p>Monitor liver enzymes; AST/ALT must be \\&lt; 3-5x ULN</p> </li> </ul> </li> <li> <p>Acamprosate (cannot be used in severe renal impairment)</p> <ul> <li> <p>Head-to-head, inferior to naltrexone (see COMBINE trial)</p> </li> <li> <p>333 mg TID, titrating to 666 mg TID dosing</p> </li> </ul> </li> <li> <p>Disulfiram</p> <ul> <li> <p>Infrequently used outside of extreme motivation (e.g.     professional under monitoring); would not use outside specialist     care</p> </li> <li> <p>Must abstain from alcohol ~2 weeks after last dose, given risk     of disulfiram-ethanol reaction (DER), which can be fatal     depending upon disulfiram and ethanol doses</p> </li> </ul> </li> <li> <p>Topiramate</p> <ul> <li> <p>Not FDA-approved for AUD, but has significant supporting     evidence</p> </li> <li> <p>Useful for individuals without abstinence goal</p> </li> <li> <p>Titrate slowly over 8 weeks to 200-300 mg/d</p> </li> </ul> </li> <li> <p>Gabapentin</p> <ul> <li> <p>Not FDA-approved for AUD, but with some evidence</p> </li> <li> <p>Useful for post-acute withdrawal anxiety, insomnia, or     co-occurring neuropathy</p> </li> <li> <p>Titrate to 900-1800 mg/d divided into TID dosing, monitoring for     sedation</p> </li> <li> <p>Risk of sedation/apnea if concomitant alcohol use</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-delirium/","title":"Delirium","text":"<p>Julian Raffoul, reviewed by Wesley Ely and Jo Ellen Wilson</p>"},{"location":"psychiatry/psychiatry-delirium/#background","title":"Background","text":"<ul> <li> <p>Definition: acute fluctuating disturbance of attention and awareness     due to an underlying medical condition</p> </li> <li> <p>Presentation: deficits in attention, orientation, or memory;     hallucinations or delusions; sleep-wake disturbances; psychomotor     changes (hyperactive, hypoactive, or mixed); language impairment;     and/or emotional lability (agitation)</p> <ul> <li> <p>Think about the ABC\u2019s of Delirium</p> <ul> <li> <p>Affect (anxiety, paranoia, irritability, apathy, mood shifts,       personality changes)</p> </li> <li> <p>Behavior (hallucinations, restlessness or agitation, psychomotor       abnormalities, sleep disturbances)</p> </li> <li> <p>Cognition (impaired memory, disorientation, disturbances in       speech)</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-delirium/#evaluation","title":"Evaluation","text":"<ul> <li>Use screening tools to assess for delirium: Brief Confusion     Assessment Method (bCAM). See critical care section for the ICU     version, CAM-ICU</li> </ul> <ul> <li> <p>Once delirium is diagnosed, evaluate for the underlying cause.     Delirium has many etiologies and may occur alone or in combination     (in ~10% of cases, no clear cause is found)</p> <ul> <li> <p>Mnemonic for common causes of delirium:</p> <ul> <li> <p>D- Drugs/toxins (use of benzodiazepines, opiates,     anticholinergics, steroids, etc., withdrawal from ETOH, benzos,     etc.)</p> </li> <li> <p>E- Eyes/ears (sensory deficits)</p> </li> <li> <p>L- Low perfusion states (MI, PE, heart failure, sepsis)</p> </li> <li> <p>I- Infection</p> </li> <li> <p>R- Retention (urine, stool)</p> </li> <li> <p>I- Intracranial events (trauma, seizure, stroke, hemorrhage)</p> </li> <li> <p>U- Undernutrition/dehydration</p> </li> <li> <p>M- Metabolic, endocrine (Hypo or hyper Na, hyperCa, uremia,     thyroid, hypoglycemia)</p> </li> </ul> </li> <li> <p>See neurology chapter for approach and work-up to AMS in general</p> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-delirium/#management","title":"Management","text":"<ul> <li> <p>Treat underlying cause as above</p> </li> <li> <p>See critical care section for prevention in the ICU (ABCDEF bundle)</p> </li> <li> <p>Cognitive impairment or disorientation: provide clock, calendar, and     appropriate lighting. Regular reorientation. Provide cues from a     familiar environment (pictures, calls or visits from family members)</p> </li> <li> <p>Encourage mobilization</p> </li> <li> <p>Review medications, eliminate sedatives and anticholinergics as able     (review agents on Beers Criteria medication list)</p> </li> <li> <p>Remove medical support devices as able (foley catheters, telemetry)</p> </li> <li> <p>Maintain normal sleep-wake cycle. Keep lights on in the day and     avoid excessive naps</p> </li> <li> <p>Ensure adequate bowel regimen and hydration</p> </li> <li> <p>Assess for pain and treat appropriately</p> </li> <li> <p>Ensure hearing aids, glasses, and dentures are available</p> </li> <li> <p>Note on pharmacologic management: There is no pharmacologic     intervention known to prevent or treat of delirium. Reserve for     agitation impairing patient safety when non-pharmacologic     interventions alone are unsuccessful. See agitation section for     medication approach</p> </li> </ul>"},{"location":"psychiatry/psychiatry-inpatient-insomnia/","title":"Inpatient Insomnia","text":"<p>Julian Raffoul, Jose Alberto Arriola Vigo</p>"},{"location":"psychiatry/psychiatry-inpatient-insomnia/#background","title":"Background","text":"<ul> <li> <p>Sleep disturbances in the hospital are multifactorial</p> </li> <li> <p>Consequences of sleep disturbances include changes in cognition,     behavior, anxiety, pain perception, respiratory function,     inflammation, and metabolism</p> </li> <li> <p>Goals while inpatient: optimize sleep environment, minimize     stimulating or sleep-related side effects of concomitant     medications, utilize non-pharmacologic strategies</p> </li> </ul>"},{"location":"psychiatry/psychiatry-inpatient-insomnia/#management","title":"Management","text":"<ul> <li> <p>Non-pharmacologic interventions:</p> <ul> <li> <p>Noise reduction: (ear protection, white noise, etc.)</p> </li> <li> <p>Keeps lights on during the day and off at night</p> </li> <li> <p>Reducing nighttime interruptions: Retime VS checks and lab draws</p> </li> <li> <p>Minimize devices (ex: telemetry) and lines as able</p> </li> </ul> </li> <li> <p>Pharmacotherapy:</p> <ul> <li> <p>Minimize medications such as sedatives/hypnotics, opioids,     glucocorticoids, beta blockers, and certain antibiotics that disturb     sleep architecture</p> </li> <li> <p>Melatonin: 1-5 mg PO qhs</p> <ul> <li>First-line choice based on mild side-effect profile, low     potential for drug-drug interactions, and improves circadian     rhythms; Dose 2-3hrs before bedtime</li> </ul> </li> <li> <p>Trazodone: 25-50 mg PO qhs (max 200 mg/day)</p> <ul> <li> <p>Side effects: headache, dry mouth, and nausea</p> </li> <li> <p>Monitor for orthostasis and infrequent atrial arrhythmias; use     lowest effective dose</p> </li> </ul> </li> <li> <p>Mirtazapine: 7.5-15 mg PO qHS</p> <ul> <li> <p>A primary alpha-2 antagonist with 5-HT2 and H1 antagonism</p> </li> <li> <p>Consider when insomnia appears to be related to primary     depression</p> </li> <li> <p>Can increase appetite and cause weight gain</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-inpatient-insomnia/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Avoid the following in the inpatient setting:</p> <ul> <li> <p>Benzodiazepines</p> <ul> <li>Reduces sleep latency and increases total sleep time but avoided     due to significant adverse effects: respiratory depression,     cognitive decline, delirium, daytime sleepiness, and falls,     particularly in hospitalized older adults</li> </ul> </li> <li> <p>Non-benzodiazepines benzodiazepine receptor agonists (e.g.,     zolpidem, eszopiclone/zopiclone, zaleplon)</p> <ul> <li>Commonly used in the outpatient setting but associated with     cognitive dysfunction, delirium, and falls in hospitalized     patients</li> </ul> </li> <li> <p>Diphenhydramine</p> <ul> <li> <p>Trials evaluating their effectiveness as sleep aids are limited     and show mixed results</p> </li> <li> <p>Many potential side effects that are enhanced in the inpatient     setting: impaired cognition, anticholinergic effects     (constipation, urinary retention)</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-medical-decision-making-capacity/","title":"Medical Decision-Making Capacity","text":"<p>Chelsea Sprick, Neil Phillips, Jonathan Smith</p>"},{"location":"psychiatry/psychiatry-medical-decision-making-capacity/#background","title":"Background","text":"<ul> <li> <p>Capacity is a patient\u2019s ability to make a specific medical decision     at a specific point in time and can be assessed by any physician</p> </li> <li> <p>Competency: \u201cglobal decision-making capacity,\u201d a legal determination     made by a judge</p> </li> </ul>"},{"location":"psychiatry/psychiatry-medical-decision-making-capacity/#four-key-components-to-assess-medical-decision-making-capacity","title":"Four key components to assess medical decision-making capacity","text":"<ol> <li> <p>Choice: patient must clearly indicate a consistent choice</p> </li> <li> <p>\u201cHave you decided whether to follow the recommendation for the     treatment?\u201d</p> </li> <li> <p>\u201cCan you tell me what your decision is?\u201d</p> </li> <li> <p>Understand: Patient must grasp the fundamental meaning of the     &gt; information communicated by the medical team</p> </li> <li> <p>\u201cPlease tell me in your own words what you were told about:</p> <ul> <li> <p>The problem with (1) your health now and (2) the recommended     treatment</p> </li> <li> <p>The risks/benefits of (3) treatment, (4) alternative treatments     and (5) no treatment\u201d</p> </li> </ul> </li> <li> <p>Appreciate: the medical condition and likely consequences of     &gt; treatment options</p> </li> <li> <p>\u201cWhat do you believe is wrong with your health now?\u201d</p> </li> <li> <p>\u201cWhat is treatment likely to do for you?\u201d</p> </li> <li> <p>\u201cWhat do you believe will happen if you\u2019re not treated\u201d</p> </li> <li> <p>\u201cWhy do you think this treatment was recommended?\u201d</p> </li> <li> <p>Reason: patient must rationally manipulate relevant information</p> </li> <li> <p>\u201cWhat makes the chosen option better than the alternative?\u201d</p> </li> <li> <p>\u201cHow did you decide to accept or reject the recommended treatment?\u201d</p> </li> </ol> <p>If the patient does not have medical decision-making capacity:</p> <ul> <li> <p>Identify and remedy cause of impairment if possible (if decision is     non-urgent)</p> </li> <li> <p>Identify surrogate decision maker</p> </li> </ul>"},{"location":"psychiatry/psychiatry-medical-decision-making-capacity/#documenting-medical-decision-making-capacity","title":"Documenting medical decision-making capacity:","text":"<ul> <li>Use a dot phrase .Capacity that lists the four components and     document your thought process citing evidence from your interview</li> </ul>"},{"location":"psychiatry/psychiatry-medical-hold/","title":"Medical Holds","text":"<p>Soibhan Kelley, MD</p>"},{"location":"psychiatry/psychiatry-medical-hold/#background","title":"Background","text":"<ul> <li> <p>6401 vs. 6404</p> <ul> <li> <p>\"6401\": process to detain someone who has a high likelihood of     posing harm to themselves or others due to mental illness. Purpose     is short-term detention until a prompt psychiatric assessment can be     performed</p> <ul> <li> <p>One person completes this. Can be law enforcement officers,     psychologists, physicians</p> </li> <li> <p>Must document justification for why the hold is needed (progress     note, assessment form, etc)</p> </li> </ul> </li> <li> <p>\"6404\": 6404= Certificate of Need. Legal document used for emergency     involuntary psychiatric admission</p> <ul> <li> <p>Pt must have mental illness or serious emotional disturbance     (excluding intellectual/developmental disabilities) and pose an     immediate substantial likelihood of serious harm because of this     based on a face-to face assessment by a qualified psychiatric     professional</p> <ul> <li>Treatment must be necessary for symptom reduction and lack     of treatment would lead to deterioration, with no less     drastic alternative to inpatient hospitalization</li> </ul> </li> <li> <p>Two certificates needed: the first to transport a patient to a     psychiatric facility and the second for an involuntary admission</p> </li> <li> <p>Two different qualified persons must each complete a form</p> <ul> <li>Psychiatry residents can write these due to their special     training licenses</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>No AMA Medical Hold: used when a patient does not have capacity to     leave the hospital against medical advice due to a medical     condition and needs to remain in the hospital</p> <ul> <li>Can be ordered by any physician Medical Hold Order Set</li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-medical-hold/#vuh-specific-procedures","title":"VUH specific procedures","text":"<ul> <li>A physical copy of the first 6404 is required to accompany the     patient when they are transported to a psychiatric facility after     medical discharge. The form is completed by the psychiatry team</li> </ul>"},{"location":"psychiatry/psychiatry-motivational-interviewing/","title":"Motivational Interviewing","text":"<p>Motivational Interviewing (MI) \u2013 Barrington Hwang, Jose Arriola Vigo</p> <p>Background</p> <ul> <li>MI:\u00a0 an evidence-based form of non-judgmental, pt-centered     counseling that elicits change in pt behavior by guiding pt through     own motivations for change</li> <li>For inpatients, MI is most useful for encouraging medication     compliance before discharge or substance use cessation</li> <li>Assumptions/principles:<ul> <li>Pt is in state of ambivalence, whether outwardly expressed or     not</li> <li>Ambivalence is expressed with conflict between multiple courses     of action</li> </ul> </li> <li>Pt may go between stages of change at any given time, some pts may     benefit from explaining this model of behavior change</li> <li>Techniques to identify ambivalence:<ul> <li>Focus     on reasons to change (\"why\") as opposed to specific actions     (\"how\")</li> <li>Express empathy: discussion about values, hopes, emotions, and     goals surrounding behavior</li> <li>Empower self-efficacy: ask about other times they have made     changes in life</li> <li>Develop discrepancy - between current and desired behavior</li> <li>Avoid argument and authoritarian mentality - consider \"asking\"     for permission to give your own thoughts, don't \"give advice\"</li> <li>Defuse resistance to change - emphasize pt autonomy and reflect     on resistance</li> </ul> </li> </ul> <p>Evaluation</p> <ul> <li>Stages of behavior change:<ul> <li>Precontemplation - pt does not intend to change and has not     taken action toward behavior change; could be related to     demoralization from prior attempts</li> <li>Contemplation - pt intends to change, but has not taken action,     usually related to awareness of risks vs benefits of change</li> <li>Preparation - pt intends to change, has taken steps to create     plan and mental action, but no current physical action toward     behavior change</li> <li>Action - pt intends to change, currently following through on     plan</li> <li>Maintenance - pt intends to change, has changed, and is taking     steps to prevent relapse</li> </ul> </li> <li>Continuing the Conversation:<ul> <li>May be effective to have SMART goal-setting if pt is in any     stage except precontemplation: Specific, Measurable, Attainable,     Realistic, Time-limited</li> <li>Pts may benefit from discussion on specific defense mechanisms</li> <li>\"OARS\" interviewing skills: Open-ended questions, Affirm,     Reflect, Summarize</li> <li>Most effective in conjunction with other treatments, when pts     are willing, and when pts express ideas for change themselves</li> <li>Least effective in     group format and when pt feels change comes from authority</li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/","title":"Opioid Use Disorder","text":"<p>Rita Hurd, David Marcovitz</p>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#background","title":"Background","text":"<ul> <li> <p>Standard of care is opioid stabilization with buprenorphine or     methadone (in OUD) or other full agonist opioids (in chronic opioid     therapy)</p> </li> <li> <p>Methadone and buprenorphine can be ordered by any physician for     inpatients</p> </li> <li> <p>Maintenance agonist therapy should be offered to every patient, with     preference for an \u201copt-out\u201d approach (even for uninsured patients     through state grant funding)</p> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#presentation-withdrawal","title":"Presentation (Withdrawal)","text":"<ul> <li> <p>Restlessness/psychomotor activation, anxiety, irritability, nausea,     abdominal cramping, loose stool, diffuse musculoskeletal pain,     chills, insomnia, yawning</p> </li> <li> <p>Pupillary dilation, piloerection, tearing, nasal congestion,     diaphoresis, restless legs</p> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Clinical Opioid Withdrawal Scale (COWS): quantifies severity of     opioid withdrawal and allows for safer buprenorphine inductions</p> </li> <li> <p>Asking about opioid exposure: \u201cYou\u2019re uncomfortable. I work with a     lot of people in the hospital, and some come with regular exposure     to opioids from a lot of different places (their doctors, friends),     should we be treating any withdrawal for you?\u201d</p> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#medications-for-opioid-use-disorder-moud","title":"Medications for Opioid Use Disorder (MOUD)","text":""},{"location":"psychiatry/psychiatry-opioid-use-disorder/#buprenorphine","title":"Buprenorphine","text":"<ul> <li> <p>Partial agonist at the mu opioid receptor with high binding affinity</p> </li> <li> <p>Long half-life (24-36 hours) allows for daily dosing</p> </li> <li> <p>TID dosing is more effective for acute pain (as the analgesic effect     is shorter-lived)</p> </li> <li> <p>OK to use in renal failure/HD; may reduce dose in hepatic injury</p> </li> <li> <p>All non-pregnant pts should receive buprenorphine-naloxone (e.g.     Suboxone) formulations to mitigate risk of diversion/injection</p> </li> <li> <p>Induction:</p> </li> <li> <p>Hold all opioid medication 12+ hours prior to first buprenorphine       dose (typically, this opioid-free period is overnight from 9 PM to 9       AM), with a recorded COWS score &gt;8-10;</p> </li> <li> <p>4 mg is given SL, monitoring for oversedation; additional 4 mg is       given in 1 hour, and final 4 mg at 4 hours (total of 12 mg in first       day)</p> <ul> <li>Only sedation or hypopnea should prevent a full 12 mg dose</li> </ul> </li> <li> <p>Typical starting dose: 12-16 mg/day</p> </li> <li> <p>Maintenance: 4-32 mg daily; 16mg and above to suppress opioid use</p> </li> <li> <p>Requires waivered-provider</p> </li> <li> <p>Acute Pain Management in pts using Buprenorphine:</p> </li> <li> <p>There is no contraindication to full-agonist opioid analgesia for       breakthrough pain</p> <ul> <li>If the etiology of pts pain would require opioid therapy in a       non-OUD patient, do not avoid opioids; these may be used safely       in the hospital</li> </ul> </li> <li> <p>Peri-operative pain management: continue buprenorphine at reduced       and split doses (4 mg BID or TID); will prevent withdrawal and       cravings, but NOT manage new pain</p> </li> <li> <p>Post-operatively: reduce opioid requirements and increase       buprenorphine to home dose</p> <ul> <li>If buprenorphine was discontinued, will require induction       procedure</li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#methadone","title":"Methadone","text":"<ul> <li> <p>Full mu opioid agonist with additional NMDA-receptor activity</p> </li> <li> <p>Better option for individuals who cannot tolerate the buprenorphine     induction procedure, with significant chronic or escalating pain</p> </li> <li> <p>Long t\u00bd: 12-36 hrs; max 10 mg/d q7d, to prevent dose-stacking and       delayed overdose</p> </li> <li> <p>Safe in renal failure; dose reduction for hepatic injury</p> </li> <li> <p>Potential for QT prolongation at higher doses, warrants QTc     monitoring</p> </li> <li> <p>Induction:</p> </li> <li> <p>In the hospital, start at 10 mg TID, holding doses for sedation or       hypopnea; lower doses if concerned for respiratory compromise or       concurrent CNS depressant therapy</p> </li> <li> <p>Limit 40 mg in first 24 hours; then titrate 5 mg/d q3d while       admitted</p> </li> <li> <p>Maintenance:</p> </li> <li> <p>Must confirm dose with methadone clinic before restarting outpatient       dose; until then, do not give more than initial doses (30 mg in       single dose, 40 mg in first 24 hours)</p> </li> <li> <p>After confirming home dose, continue as single daily dose</p> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#naltrexone","title":"Naltrexone","text":"<ul> <li> <p>Mu opioid antagonist; Half-life oral ~4 hours but clinically active     ~24 hrs</p> </li> <li> <p>IM maintains clinically effective levels up to 30 days</p> </li> <li> <p>High affinity for mu receptor --&gt; CAN precipitate withdrawal     requiring 7-10 days opioid abstinence prior to initiation</p> </li> <li> <p>If due for monthly injection while admitted, may substitute oral     formulation until discharged to outpatient provider to receive     injection</p> </li> </ul>"},{"location":"psychiatry/psychiatry-opioid-use-disorder/#additional-information","title":"Additional Information","text":"<ul> <li> <p>Psychosocial Interventions that complement MOUD:</p> </li> <li> <p>Consider referral to SUD counseling, mutual help (self-help,       12-step, AA), intensive outpatient, and short- or long-term       residential treatment</p> </li> <li> <p>Use of other drugs NOT a contraindication to MOUD, however should     encourage abstinence from other drugs during therapy (especially     benzodiazepines)</p> </li> <li> <p>Prescribe intranasal naloxone for overdose prevention to all OUD     patients discharging from hospital, regardless of MOUD status</p> </li> </ul>"},{"location":"psychiatry/psychiatry-personality-disorders/","title":"Personality Disorders","text":"<p>Personality Disorders \u2013 Jonathan Constant, Jonathan Smith</p> <p>Background</p> <ul> <li>Caring for pts with personality disorder symptoms can result in pt     and provider frustration, delays in treatment and at times,     sub-optimal care and AMA discharges</li> <li>An understanding of personality disorders can mitigate some of these     barriers</li> <li>How do personality disorders develop?<ul> <li>Genetic/temperament component, early traumatizing and shaping     experiences</li> <li>Development of maladaptive perceptions and responses to other     individuals</li> <li>Pathological interaction styles and response to stressors (fear     of abandonment, dependence, rejection) are developed and become     self-fulfilling and re-enforced leading to pervasive     interpersonal difficulties</li> </ul> </li> </ul> <p>Presentation</p> <ul> <li>Borderline Personality Disorder:<ul> <li>Unstable and intense relationships; \u201csplitting\u201d between     idealization and devaluation</li> <li>Frantic efforts to avoid real or imagined abandonment</li> <li>Impulsivity: substance use, binge eating, reckless behavior</li> <li>Recurrent suicidal behavior or gestures</li> <li>Mood instability: quick onset and short-lived intense dysphoria,     irritability, anxiety</li> <li>Difficulty controlling anger (displays of temper, aggression)</li> </ul> </li> <li>Narcissistic Personality Disorder:<ul> <li>Grandiosity: exaggerates achievements and expects to be     recognized as superior</li> <li>Preoccupied with unlimited power, success, brilliance</li> <li>Sense of entitlement: expects favorable treatment and compliance     with expectations</li> <li>Exploits others and lacks empathy</li> </ul> </li> <li>Antisocial personality disorder:<ul> <li>Failure to conform to social norms with respect to lawful     behavior</li> <li>Deceitfulness, lying, conning others for personal profit or     pleasure</li> <li>Impulsivity and reckless disregard for others</li> <li>Irritability, aggressiveness and lack of remorse</li> </ul> </li> </ul> <p>Management</p> <ul> <li>Consult Psychiatry</li> <li>Create a behavioral plan<ul> <li>Outline the pt, as well as the team\u2019s, responsibilities and     goals of care with identification of the concerning behavior and     a firm plan for if the agreement is broken</li> <li>Ideally, the pt should sign this plan and consider it as a     contract</li> <li>Dot Phrase/Sample:     .IMBehavioralPlan (go to dot phrases under user Joseph Quintana)<ul> <li>Adjust, add and remove content based on patient</li> </ul> </li> </ul> </li> <li>Behavioral interventions:<ul> <li>Aim for consistency w/ providers &amp; nursing; limit consultants to     \u2193     splitting behaviors</li> <li>Acknowledge pt's grievance/frustrations and shift focus on how     to solve the problem</li> <li>Align goals by emphasizing common ground and find ways to make     small concessions</li> <li>Be aware of progress and know when to disengage (if behaviors     are escalating)</li> <li>Monitor countertransference (the emotions the pt is eliciting in     the provider): irresponsible and child-like behavior may prompt     the provider to become angry or act in ways to limit the pt's     control in their care, further perpetuating the behavior</li> </ul> </li> <li>Gold standard = Psychotherapy<ul> <li>Dialectical Behavioral therapy, Cognitive behavioral therapy,     Psychodynamic</li> <li>If the patient is willing, SW should assist with establishing at     discharge</li> </ul> </li> <li>Pharmacotherapy :<ul> <li>Unclear benefit in pharmacological management of Personality     Disorder</li> <li>Treatment of comorbid psychiatric disorders if present would be     most appropriate</li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-substance-use-disorder/","title":"Substance Use Disorder (SUD)","text":"<p>Barrington Hwang, Kristopher Kast</p>"},{"location":"psychiatry/psychiatry-substance-use-disorder/#background","title":"Background","text":"<ul> <li> <p>SUDs are common, complex, and chronic neuropsychiatric disorders     with well-described inherited risk, dysregulated neurophysiology,     and multiple effective treatment modalities</p> </li> <li> <p>Pts w/SUD face significant stigma, prior traumatic experiences in     healthcare environments</p> <ul> <li> <p>Using the term \u201cabuse\u201d undermines the disease model of addiction</p> </li> <li> <p>Person-centered, specific terminology: \u201cperson with opioid and     alcohol use disorders\u201d</p> </li> </ul> </li> <li> <p>Avoid the qualifier \u201cPolysubstance.\u201d Instead, clarify specific     diagnoses for each substance category</p> </li> <li> <p>DSM 5 Criteria (same for most substance categories): Requires 2+     criteria met in past year; use must cause clinically significant     impairment and/or distress:</p> <ul> <li> <p>Loss of control \u2013 larger amounts, longer time, ongoing use despite     consequences, efforts/desire to reduce use</p> </li> <li> <p>Physiologic changes -- tolerance, withdrawal (these 2 alone do not     necessarily imply a disorder if they result from prescribed     therapy), craving</p> </li> <li> <p>Consequences \u2013 hazardous use, interpersonal problems, medical     problems, failed role obligations, lost activities</p> </li> </ul> </li> </ul>"},{"location":"psychiatry/psychiatry-substance-use-disorder/#general-management","title":"General Management:","text":"<ul> <li> <p>First priority in the inpatient medical setting is to identify and     stabilize withdrawal states</p> <ul> <li> <p>Mitigate risks of severe sequelae (seizure, delirium)</p> </li> <li> <p>Avoid unintended iatrogenic harm (ex: opioid abstinence leading to     lost tolerance and post-discharge overdose)</p> </li> <li> <p>Avoid distress-driven AMA discharge</p> </li> </ul> </li> <li> <p>Consider Addiction Psychiatry consultation for management of complex     withdrawal states, substance use disorders and co-occurring     psychiatric diagnoses, assistance with risk stratification for     hospital misuse and/or hospital discharge with PICC lines for     outpatient antibiotics, and differentiation of pain requiring opioid     therapy and opioid use disorder</p> </li> <li> <p>If in the emergency room and not admitted, consult PAS</p> </li> </ul>"},{"location":"pulmonary/pulmonary-acute-asthma-exacerbation/","title":"Acute Asthma Exacerbation","text":"<p>Stacy Blank</p>"},{"location":"pulmonary/pulmonary-acute-asthma-exacerbation/#presentation","title":"Presentation","text":"<ul> <li> <p>History of asthma or a history concerning for asthma</p> </li> <li> <p>Progressive worsening of symptoms: dyspnea, chest tightness,     wheezing, and cough</p> </li> <li> <p>Physical exam with wheezing, poor air movement, tachypnea, increased     work of breathing, hypoxemia</p> </li> <li> <p>Often use of peak flows is cited in the literature (PEF \\&lt;200 L/min     or PEF \\&lt;50% predicted indicates severe obstruction, PEF \\&lt;70%     predicted indicates moderate exacerbation)</p> <ul> <li>May be useful although often does not change management acutely</li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-acute-asthma-exacerbation/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Generally aimed at ruling out causes for exacerbation and other     diagnoses; these are not required but should be considered in pts     being admitted for inpatient management:</p> <ul> <li> <p>EKG, trop, BNP, D-dimer to assess for cardiac cause (ACS, CHF, PE)</p> </li> <li> <p>CXR to rule out underlying process (PNA, PTX, atelectasis)</p> </li> <li> <p>ABG/VBG not routinely needed unless ill-appearing, tachypneic, or     lethargic/altered</p> </li> </ul> </li> <li> <p>Dangerous signs and possible ICU if:</p> <ul> <li> <p>Tachypnea &gt;30 and/or significantly increased work-of-breathing</p> </li> <li> <p>Hypercapnia or even normocapnia (these pts are usually     hyperventilating; a normal CO2 in a severe asthma exacerbation could     indicate impending respiratory failure)</p> </li> <li> <p>Altered mental status</p> </li> <li> <p>Requiring continuous nebulizers</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-acute-asthma-exacerbation/#management","title":"Management","text":"<ul> <li> <p>Continuous pulse ox with oxygen therapy to maintain O2 &gt;92 %</p> </li> <li> <p>Continuous albuterol nebulizer or Duonebs until able to space to     q1h&gt;&gt;q2h, etc</p> </li> <li> <p>Steroids with dosing based on severity of illness (there is no data     behind exact dosing of steroids).</p> <ul> <li> <p>Start with IV methylpred 125mg q6h in severe exacerbation/ICU     patients</p> </li> <li> <p>Can start with oral prednisone 60mg q12h in less severe     exacerbation/floor pts</p> </li> <li> <p>Plan to transition from IV to PO and then likely to send pt home to     finish course of 40-60 mg pred daily for 5-7 days.</p> </li> </ul> </li> <li> <p>IV mag sulfate 4g over 20 minutes for severe exacerbation</p> </li> <li> <p>Keep pt NPO until off continuous nebs/respiratory effort is     improved. Consider IV fluids with pt\u2019s comorbidities (HFrEF, renal     disease) vs. increased insensible losses with resp effort</p> </li> <li> <p>If pt is not responding to therapies, has worsening respiratory     status, or blood gas concerning for respiratory acidosis needs ICU     care for BiPAP vs mechanical ventilation</p> </li> <li> <p>Note: We do not start empiric antibiotics unless there is concern     for bacterial infection</p> </li> </ul>"},{"location":"pulmonary/pulmonary-acute-asthma-exacerbation/#prior-to-discharge","title":"Prior to discharge:","text":"<ul> <li> <p>Ensure that pt is on appropriate controller medications (see     outpatient management)</p> </li> <li> <p>Evaluate for causes of acute exacerbation to prevent future events     (noncompliance, resp viruses, allergies, exposures, etc.)</p> </li> </ul>"},{"location":"pulmonary/pulmonary-airway-clearance/","title":"Airway Clearance Therapy","text":"<p>Patrick Barney</p>"},{"location":"pulmonary/pulmonary-airway-clearance/#indications","title":"Indications","text":"<pre><code>- Cystic fibrosis, advanced COPD, chronic bronchitis, bronchiectasis,\n    chronic neuromuscular weakness, prolonged ventilator-dependence\n\n- Goal is to assist patients with removing/expectorating mucus from\n    lungs to decrease risk of atelectasis, mucus plug, increased airway\n    resistance, infection\n</code></pre>"},{"location":"pulmonary/pulmonary-airway-clearance/#chest-physiotherapy-cpt","title":"Chest Physiotherapy (CPT)","text":"<pre><code>- Use: pathologies w/ retained secretions and mucous plugging (CF,\n    bronchiectasis)\n\n- RT helps patient go through sequence of positions aimed at\n    \u201cdraining\u201d each of the lobes of the lung by gravity. Sometimes\n    combined with percussion.\n\n- Finding in Epic: chest physiotherapy &gt; CPPD panel \u2013 will initiate\n    RT bronchial hygiene protocol and order TID CPT\n</code></pre>"},{"location":"pulmonary/pulmonary-airway-clearance/#high-frequency-chest-wall-compression-hfcwc","title":"High Frequency Chest Wall Compression (HFCWC)","text":"<pre><code>- Use: pathologies w/ retained secretions (CF, bronchiectasis, chronic\n    bronchitis) or mucociliary clearance problems (lung transplant)\n\n- RT wraps patient in inflatable vest, compressor rapidly inflates and\n    deflates vest to \u201cbreak up\u201d thickened mucus from airway wall so it\n    can be suctioned or expectorated\n\n- Finding in Epic: vest &gt; Facility List &gt; vest physiotherapy or vest\n    physiotherapy for CF under Procedures\n</code></pre>"},{"location":"pulmonary/pulmonary-airway-clearance/#positive-expiratory-pressure-pep","title":"Positive Expiratory Pressure (PEP)","text":"<pre><code>- Use: pathologies w/ retained secretions as discussed above\n\n- Patient exhales against fixed or fluttering resistor that allows air\n    to get behind mucus, helps move mucus from airway walls, and holds\n    airways open longer for improved ventilation\n\n- Trade names- Flutter, Acapella, AerobikA\n\n- Finding in Epic: PEP &gt; Facility List &gt; PEP therapy panel or\n    Oscillatory PEP therapy panel under Order Sets\n\n    - Can also find in a supply closet on 8S and bring to patient, be\n        sure to teach them how to use it\n</code></pre>"},{"location":"pulmonary/pulmonary-airway-clearance/#cough-assist","title":"Cough Assist","text":"<pre><code>- Use: most effective in patients with neuromuscular weakness\n    affecting diaphragmatic strength \u2013 muscular dystrophy, myasthenia\n    gravis, spinal cord lesions, SMA\n\n- Via mask or trach/vent connection \u2013 applies positive pressure to\n    fill the lungs, then quickly switches to negative pressure to\n    produce a high expiratory flow rate to simulate a cough that is\n    intended to produce expectorant\n\n- Finding in Epic: cough assist &gt; Facility List &gt; cough assist\n    treatment panel under Order Sets\n</code></pre>"},{"location":"pulmonary/pulmonary-blood-gases/","title":"Basics of Blood Gases","text":"<p>Lexi Haugh</p>"},{"location":"pulmonary/pulmonary-blood-gases/#did-you-order-an-abg-or-vbg","title":"Did you order an ABG or VBG?","text":"<ul> <li> <p>Need to assess oxygenation ABG</p> </li> <li> <p>Need to assess hypoventilation May use VBG. ABG if shock, severe     hypercapnia</p> </li> <li> <p>pH VBG usually correlates with an ABG (venous pH is ~0.04 lower     than arterial pH)</p> <ul> <li>Less accurate in shock or severe acid-base disturbance</li> </ul> </li> <li> <p>ABGs are obtained by respiratory both at VUMC and the VA</p> </li> <li> <p>VBGs can be ordered like other labs on the floor. Ran as point of     care test (iSTAT) in the ICU</p> </li> </ul>"},{"location":"pulmonary/pulmonary-blood-gases/#assessing-oxygenation","title":"Assessing Oxygenation:","text":"<ul> <li> <p>A-a gradient = PAO2 (alveolar O2) \u2013 PaO2 (arterial O2)</p> <ul> <li> <p>PAO2 = FiO2 (Pbarom - PH2O) - PaCO2/R</p> <ul> <li> <p>FiO2 = 0.21 on room air otherwise obtain from ventilator</p> </li> <li> <p>Pbarom = 760, PH2O = 47</p> </li> <li> <p>R (respiratory quotient) = 0.8</p> </li> <li> <p>PaCO2 = arterial CO2 measured on ABG</p> </li> <li> <p>Normal A-a gradient = (Age +10)/4</p> </li> </ul> </li> <li> <p>See hypoxia section for ddx of increased A-a gradient</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-blood-gases/#assessing-acidbase-status-and-ventilation","title":"Assessing Acid/Base Status and Ventilation:","text":"<ul> <li> <p>Look at the pH (normal = 7.35 \u2013 7.45): pH \\&lt; 7.35 = acidosis; pH &gt;     7.45 = alkalosis</p> </li> <li> <p>Look at the pCO2 (normal = 35-45 mmHg)</p> </li> </ul> Primary Disorder pH pCO2 Respiratory Acidosis \\&lt; 7.35 &gt;45 Respiratory Alkalosis &gt; 7.45 \\&lt;35 Metabolic Acidosis \\&lt; 7.35 \\&lt;45 Metabolic Alkalosis &gt; 7.45 &gt;35 <ul> <li> <p>Is the primary disorder acute vs. chronic?</p> </li> <li> <p>Is the primary disorder appropriately compensated?</p> </li> <li> <p>If not appropriately compensated, what additional process is     present?</p> </li> </ul>"},{"location":"pulmonary/pulmonary-blood-gases/#primary-respiratory-acidosis","title":"Primary Respiratory Acidosis:","text":"<ul> <li> <p>Acute versus chronic</p> <ul> <li> <p>Acute respiratory acidosis and hypercarbia will often present with     somnolence or AMS</p> </li> <li> <p>Similarly, if a PCO2 is 80, and the patient is talking to you, it is     most likely chronic</p> </li> </ul> </li> <li> <p>Acute Causes: Decreased respiratory drive (opiates, intoxication),     respiratory muscle weakness (i.e., myasthenia gravis)</p> </li> <li> <p>Chronic Causes: COPD, sleep apnea</p> </li> </ul> <p>Primary Respiratory Alkalosis</p> <ul> <li> <p>Acute Causes: Mechanical ventilation, anxiety/panic attack, pain, PE</p> </li> <li> <p>Chronic Causes: Pregnancy, CNS disorder, hormones (thyroid,     progesterone)</p> </li> </ul>"},{"location":"pulmonary/pulmonary-blood-gases/#compensation-for-primary-respiratory-disorders","title":"Compensation for primary respiratory disorders","text":"Respiratory Acidosis Respiratory alkalosis Acute 10:1 10:2 Chronic 10:3.5 10:4 For every \u2191of 10 in pCO2, HCO3 \u2191 by 1 or 3.5 For every \u2193 of 10 in pCO2 HCO3 \u2193 by 2 or 4"},{"location":"pulmonary/pulmonary-blood-gases/#primary-metabolic-alkalosis","title":"Primary Metabolic Alkalosis","text":"<ul> <li> <p>Appropriate Respiratory Compensation?</p> <ul> <li>Expected pCO2 = 0.7*(HCO3) + 20 (\u00b15)</li> </ul> </li> <li> <p>Etiologies: Associated with high aldosterone (either appropriate or     inappropriate)</p> <ul> <li> <p>Chloride Responsive = appropriate hyperaldosteronism, can usually be     fixed with Cl administration/ volume resuscitation</p> <ul> <li> <p>Etiologies: Volume contraction i.e., vomiting, over-diuresis)</p> </li> <li> <p>Urine Cl \\&lt;20</p> </li> </ul> </li> <li> <p>Chloride Unresponsive = inappropriate hyperaldosteronism, cannot fix     with NaCl administration/ volume resuscitation</p> <ul> <li> <p>Etiologies: Steroids, Cushing\u2019s, Conn\u2019s, RAS, CHF, cirrhosis</p> </li> <li> <p>Urine Cl &gt;20</p> </li> </ul> </li> </ul> </li> </ul> <p>Primary Metabolic Acidosis: See nephrology section, \u201cMetabolic Acidosis\u201d</p>"},{"location":"pulmonary/pulmonary-cf-exacerbation/","title":"Cystic Fibrosis (CF) Exacerbation","text":""},{"location":"pulmonary/pulmonary-cf-exacerbation/#background","title":"Background","text":"<ul> <li>Presentation: acute worsening of pulmonary symptoms such as     new/increased cough, sputum production (or change in sputum     quality), dyspnea. May have constitutional symptoms including     fatigue, poor appetite</li> </ul>"},{"location":"pulmonary/pulmonary-cf-exacerbation/#evaluation","title":"Evaluation","text":"<ul> <li> <p>\u201cCystic Fibrosis\u201d Admission order set in epic is useful and contains     most of the work-up and management listed below</p> </li> <li> <p>Labs: Sputum culture (specify CF culture), RPP</p> </li> <li> <p>CXR PA and lateral</p> </li> <li> <p>Always ask about coughing up blood and amount -- see 'Hemoptysis'     section if present</p> </li> </ul>"},{"location":"pulmonary/pulmonary-cf-exacerbation/#management","title":"Management","text":"<ul> <li> <p>All patients need a cystic fibrosis pulmonary consult (unless on     Rogers Pulmonary if attending specializes in CF). FYI there is no     fellow so don\u2019t worry when you have to page an attending</p> </li> <li> <p>All CF pts are placed on contact precautions</p> </li> <li> <p>Antibiotics</p> <ul> <li> <p>Check CF notes, recent hospitalizations, culture data \u2013 MRSA, MSSA,     and Pseudomonas are the most common</p> </li> <li> <p>If they were recently admitted and improved on that antibiotic     regimen, it is usually a good empiric choice. CF team will     ultimately guide regimen</p> </li> </ul> </li> <li> <p>General coverage:</p> <ul> <li>MRSA vancomycin (Bactrim or linezolid for allergies)</li> </ul> </li> <li> <p>Pseudomonas Penicillin class (cephalosporin, carbapenem, extended     penicillin) AND aminoglycoside or Ciprofloxacin (double coverage)</p> </li> <li> <p>Be aware that the antibiotic doses are not the typical doses used     for other indications. Use Epic Order Adult Cystic Fibrosis order     set for Antibiotic/dosing (or consult with CF team, pharmacy)</p> </li> <li> <p>Continue tobramycin nebs (if on that month) and MWF Azithromycin     unless otherwise contraindicated if they are on these therapies at     home</p> </li> <li> <p>Airway/sputum clearance</p> <ul> <li>Albuterol nebs, pulmozyme (if on at home), hypertonic saline (if on     at home), Vest, positive end expiratory pressure valve (PEP, ex:     Flutter, Acapella), chest percussive devices (the wand) as last     choice (not as effective)</li> </ul> </li> <li> <p>CF modulators (e.g., ivacaftor/tezacaftor/elaxacaftor): continue if     on at home, needs a non-formulary order so pt can use own supply;     time with fat rich meal for absorption</p> </li> <li> <p>Nutrition/GI</p> <ul> <li> <p>Pancreatic enzymes (most pts are on them), order at bedside for pt     administration</p> </li> <li> <p>Always continue ADEK vitamins</p> </li> <li> <p>Daily to 3 times a week weight checks</p> </li> <li> <p>Nutrition consult</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-cf-exacerbation/#dios-distal-intestinal-obstruction-syndrome","title":"DIOS - Distal Intestinal Obstruction Syndrome","text":"<ul> <li> <p>Acute obstruction (complete or incomplete) in ileocecum by     inspissated intestinal contents. Presents with abdominal     pain/distension, constipation, poor appetite, possibly vomiting     often looks like mechanical obstruction</p> </li> <li> <p>Treat with Miralax and/or Golytely</p> </li> <li> <p>RARELY surgery, try medical management first</p> </li> </ul>"},{"location":"pulmonary/pulmonary-chest-tubes/","title":"Chest Tubes","text":"<p>Pakinam Mekki</p>"},{"location":"pulmonary/pulmonary-chest-tubes/#background","title":"Background","text":"<ul> <li>Nomenclature: Small bore chest tubes= Pigtail Catheters (Often 8-12     Fr) placed via Seldinger technique. \u201cChest Tube\u201d technically denotes     a large bore, surgical thoracostomy tube (Often 24-40 Fr)</li> <li>Indications: Pneumothorax, hemothorax (more often surgical chest     tubes), empyema, malignant effusion (patient specific), chylothorax,     penetrating chest trauma</li> <li>Contraindications: No absolute contraindications. Relative     contraindications include hepatic hydrothorax, large emphysematous     blebs, and anticoagulation or coagulopathy</li> </ul>"},{"location":"pulmonary/pulmonary-chest-tubes/#procedure","title":"Procedure","text":"<ul> <li>Consult pulmonology for patients who may need pigtail chest tube</li> <li>Placement and Sizing</li> <li>The location and size of the chest tube is related to the pathology<ul> <li>Pneumothorax anterior near the apex of the lung in the 2nd       intercostal space, midaxillary line</li> <li>Fluid (water, pus, blood), posterior near the base of the lung       (fifth or sixth intercostal space, midaxillary line</li> <li>Hemothorax surgical chest tube is placed to prevent clot       formation</li> </ul> </li> <li>Potential complications: Laceration of an intercostal vessel, organ     perforation (lung, heart, diaphragm, intraabdominal), trauma of the     intercostal neurovascular bundle, subcutaneous emphysema,     pneumothorax, infection, re-expansion pulmonary edema.</li> <li>Smaller size results in less tissue disruption but more likely to       clog or kink</li> </ul>"},{"location":"pulmonary/pulmonary-chest-tubes/#understanding-the-atrium","title":"Understanding the Atrium","text":"<p>After the chest tube is placed, it is connected to the Atrium which can be connected to the wall for suction. (See Diagram below)</p> <p></p> <p>Atrium Diagram</p> <ul> <li>(A) Dry suction control - determines the level of suction out of the chest tube and is set by the provider. It is important to note that while the atrium is linked to the wall suction via suction port (F) the level of wall suction is determined by (A)</li> <li>(B) Water seal chamber - if the atrium is disconnected from the wall suction, it is on \u201cwater seal\u201d (i.e., to gravity). This allows for the one-way flow of pleural space contents out of the chest.</li> <li>(C) Air leak monitor - if air bubbles are present in the water seal chamber, then that indicates the presence of air in the pleural space. The presence of air is different from normal \u201ctidaling,\u201d within the water seal and requires troubleshooting (see below). Tidaling is normal; it is the movement with respiratory variation in water seal chamber. The water should rise with inspiration and fall with expiration.</li> <li>(D) Collection chamber - drains the pleural fluid contents via the chest tube.</li> <li>(E) Suction verification window - will be orange if suction is on and atrium is functioning appropriately</li> </ul>"},{"location":"pulmonary/pulmonary-chest-tubes/#troubleshooting","title":"Troubleshooting","text":"<ul> <li>Air leaks: If bubbles are present in the water seal chamber, this     indicates air in the pleural space. This is an expected finding in a     pneumothorax; over time, the air leak should disappear as the lung     re-expands. This contrasts with normal tidaling present with     respiratory variation</li> <li>There are two major causes of air leaks:<ul> <li>Persistent air in the pleural space, seen in alveolar-pleural       fistula or pneumothorax (new or old)</li> <li>Leak in the chest tubing at its insertion site or in the tubing       system. To identify the etiology of a new air leak, try clamping       the chest tube at various points, obtain a CXR</li> </ul> </li> <li>Clogging: Would see debris in the collection chamber and lack of     tidaling in the water seal camber</li> <li>In patients with viscous fluid output (ex- empyema), important to       flush the chest tube with normal saline flushes at least twice daily       to prevent clogging</li> <li>For clog - try flushing 10cc of sterile saline toward the pt or       \u201cstripping\u201d the chest tube by pressing the chest tube with your       fingers and pulling towards the drainage system.</li> <li>May require tPA or dornase for fibrinolysis, discuss with team that       placed the tube</li> </ul>"},{"location":"pulmonary/pulmonary-chest-tubes/#chest-tube-removal","title":"Chest tube removal","text":"<ul> <li>Generally, chest tubes are removed when there is \\&lt; 150cc of     drainage in 24 hrs (if placed for pleural effusion)</li> <li>For pneumothorax, there is typically a step-wise approach to     removal. The team that placed the chest tube will guide removal</li> <li>Suctionwater seal \u00b1 clamp trial. CXR obtain after each transition       to monitor for reaccumulation</li> <li>Chest tube should be removed while patient hums (to prevent     inhalation during removal that could introduce air into pleural     space). Pigtail catheters have to be \u201cunlocked\u201d prior to removal to     release the pigtail</li> </ul>"},{"location":"pulmonary/pulmonary-copd-exacerbation-management/","title":"COPD Exacerbation","text":"<p>Taylor Coston</p>"},{"location":"pulmonary/pulmonary-copd-exacerbation-management/#background","title":"Background","text":"<ul> <li> <p>Presentation: increased dyspnea, cough, and sputum production or     purulence, diffuse wheezing, distant breath sounds, tachypnea,     tachycardia</p> </li> <li> <p>Severe respiratory insufficiency: accessory muscle use, fragmented     speech, inability to lie supine, profound diaphoresis, agitation,     asynchrony between chest and abdominal wall with respiration,     failure to improve with initial emergency treatment</p> </li> <li> <p>Impending respiratory arrest: Inability to maintain respiratory     effort, cyanosis, hemodynamic instability, and depressed mental     status</p> </li> <li> <p>Remember that patients with COPD can have other causes of     respiratory distress including acute coronary syndrome,     decompensated heart failure, PE, PNA, PTX, sepsis, acidosis</p> </li> </ul>"},{"location":"pulmonary/pulmonary-copd-exacerbation-management/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Initial Assessment: ABCs</p> <ul> <li> <p>Airway/Breathing: Ensure patient is protecting airway</p> <ul> <li> <p>If obtunded or in severe respiratory distress intubation</p> </li> <li> <p>BiPAP typically appropriate for severe COPD exacerbation unless     contraindication (vomiting, obtundation, facial trauma)</p> <ul> <li>BiPAP is ordered as IPAP and EPAP, 12/5 is often a good     start</li> </ul> </li> </ul> </li> <li> <p>Circulation</p> <ul> <li>For hemodynamic instability immediate rapid sequence intubation.     Pt\u2019s can be hypotensive for a host of reasons (pneumothorax,     sepsis, circulatory collapse from hypoxia and bradycardia, etc)</li> </ul> </li> </ul> </li> <li> <p>Subsequent Workup:</p> <ul> <li> <p>Continuous pulse oximetry, ABG/VBG, EKG, CXR, CBC, BMP, troponin,     BNP, sputum cx, RPP, blood cultures if hemodynamically unstable</p> </li> <li> <p>Lung ultrasound to differentiate COPD from pulmonary edema when a pt     presents with wheezing and respiratory failure (pulmonary edema will     have B lines)</p> </li> <li> <p>Consider trigger: viral infection (70%), PNA, PE (have a high index     of suspicion for PE)</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-copd-exacerbation-management/#management","title":"Management","text":"<ul> <li> <p>Bronchodilators</p> <ul> <li> <p>Order \u201cRespiratory Care Therapy Management Protocol\u201d at VUMC</p> <ul> <li>RT evaluates the pt and based on physical exam will give a     duoneb. Continues to assess the pt and treats based on severity     of the exacerbation</li> </ul> </li> <li> <p>If ordering bronchodilators individually:</p> <ul> <li> <p>Albuterol 2.5 mg diluted to 3 mL via nebulizer or 4 to 8     inhalations from MDI every 4 hours while awake (RT) or more     frequently if needed</p> </li> <li> <p>Ipratropium 500 mcg via nebulizer, or 4-8 inhalations from MDI     q4 hrs while awake</p> </li> <li> <p>Can additionally order Duoneb (albuterol and ipratroprium) q4-6     hours at VUMC</p> </li> <li> <p>There is no respiratory order protocol at the VA, order     individually as above</p> </li> </ul> </li> </ul> </li> <li> <p>Steroids</p> <ul> <li> <p>For severe exacerbation give methylprednisolone 125 mg IV BID (or     60mg IV q6h)</p> </li> <li> <p>For moderate to mild COPD exacerbations give prednisone 40mg PO     daily for 5 days (including the initial IV dose if pt received one     in the ER)</p> </li> </ul> </li> <li> <p>Antibiotics</p> <ul> <li> <p>For moderate to severe exacerbations</p> </li> <li> <p>Azithromycin (500mg x 1 then 250mg daily x 4 or 500mg daily x 3) or     doxycycline 200 mg BID if concern for QT prolongation. Can consider     respiratory fluroquinolone in certain high-risk patients but     typically too broad</p> </li> <li> <p>Refer to Pneumonia in Infection Disease chapter if treating     concomitant pneumonia</p> </li> </ul> </li> <li> <p>Discharge Planning:</p> <ul> <li> <p>Controller medications/inhalers (see COPD in Outpatient chapter)</p> <ul> <li> <p>Make sure any new inhalers are covered by insurance prior to     discharge</p> </li> <li> <p>Provide inhaler education and consider use of a spacer</p> </li> </ul> </li> <li> <p>Vaccinations (influenza, COVID, pneumococcal)</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-cxrs/","title":"CXRs","text":"0 How to Interpret Chest Radiographs (CXR) \u2013 Gautam Babu <p>An X-ray is a density-gram where \u201cwhite\u201d is \u201cdense\u201d and \u201cblack\u201d is \u201cnot dense\u201d.\u00a0 Determine a systematic method you use every time you interpret a CXR to ensure you don\u2019t miss anything.</p> <ul> <li> <p>Start every CXR you interpret by assessing the quality of the film:</p> <ul> <li>Penetration: You should be able to see vertebral bodies through     the cardiac silhouette but not into the abdomen. If you cannot     see them through the heart the film is \u201cunder-penetrated\u201d and     everything will appear more \u201cwhite.\u201d If you can see them through     the abdomen the film is \u201cover-penetrated\u201d and everything will     appear more \u201cblack\u201d</li> <li>Rotation: The spinous processes should be in the middle of the     clavicular heads, if not then the film is rotated</li> </ul> </li> <li> <p>Two Different Systematic Methods:</p> <ul> <li>ABCDE method<ul> <li>Airway \u2013 Trachea midline and patent</li> <li>Bones \u2013 Bone density and obvious fractures</li> <li>Cardiac Silhouette \u2013 You should be able to see the L and R     heart border, if not there may be an adjacent opacity (Right     Middle Lobe, Lingula)</li> <li>Cardiomegaly defined as heart size     \u2265     \u00bd width of the hemithorax on a PA film</li> <li>Diaphragm \u2013 Look for pleural effusions at the costo-phrenic     angle. If you cannot see the diaphragm along the way there     may be an adjacent opacity (Lower Lobe)</li> <li>\u201cEverything else\u201d \u2013 Refers to the lung fields but if you     wanted to continue the alphabet mnemonic</li> <li>Extra-Thoracic Soft Tissue \u2013 Subcutaneous emphysema</li> <li>Fields and Fissures \u2013lung fields should appear symmetric and     \u201cblack.\u201d Asymmetry suggests there is an issue on one side.</li> <li>Great Vessels \u2013 Tortuosity of the aorta and the outlines of     the pulmonary vessels</li> <li>Hilum \u2013 Hilar masses, LAD and pulmonary arteries, the left     hila is higher than the right normally because of the heart</li> </ul> </li> </ul> </li> <li> <p>Working around the film method:</p> <ul> <li>Imagine the entire CXR film as a square and an inner \u201cbox\u201d as     the pleural lining</li> </ul> </li> <li> <ul> <li>Outside the box: Looking for lines, tubes, EKG/tele leads,         subcutaneous emphysema, stomach bubble, sub diaphragmatic air</li> <li>The edge of the box: Looking for pleural thickening, pleural     effusion, pneumothorax, visualization of the diaphragm</li> <li>The middle of the box: aka Mediastinum -&gt; trachea, vascular     pedicle, hila, heart borders, great vessels, retrocardiac space</li> <li>The lung fields</li> </ul> </li> </ul> <p>One important concept to know is the silhouette sign: Two things of different densities will show a clear border on a chest x-ray. In the contrapositive, the loss of a border you expect to see suggests there has been</p> <p>a change in density of one of the structures. For example, the heart and the lung are different densities and as such you have a sharp border. Loss of this border suggests that the adjacent lung \u201cincreased\u201d in density from a PNA (in the right clinical scenario).</p> <ul> <li>Often try to distinguish PNA from pulmonary edema, as these are two     of the most common causes of abnormal opacities seen on CXR<ul> <li>PNA<ul> <li>\"fluffy\" opacities and air bronchograms frequently indicate     alveolar filling</li> <li>typically asymmetric</li> </ul> </li> <li>Pulmonary Edema<ul> <li>linear opacities, fluid in the fissure, Kerley B lines,     cephalization, bilateral pleural effusions</li> <li>Typically symmetric</li> <li>atypical or viral PNA can similarly present with linear     opacities</li> </ul> </li> </ul> </li> </ul> <p>Web Resources:</p> <ul> <li>UVA Department of Radiology \u201cIntroduction to Chest Radiology\u201d<ul> <li>https://www.med-ed.virginia.edu/courses/rad/cxr/index.html</li> <li>Website includes specific examples of lung pathology as well as     CXR interpretation exercises in the \u201cpost test\u201d section</li> </ul> </li> <li>Life in the Fast Lane CXR Self-Assessment Quiz:     https://litfl.com/top-100/cxr/</li> </ul>"},{"location":"pulmonary/pulmonary-hemoptysis/","title":"Hemoptysis","text":"<p>Henry Brems</p>"},{"location":"pulmonary/pulmonary-hemoptysis/#background","title":"Background","text":"<ul> <li> <p>Distinguish between massive (&gt;600cc/24hr or &gt;100cc/hr) and     non-massive hemoptysis. Can be difficult to quantify expectorated     blood volume and volume that is retained in lungs</p> </li> <li> <p>Massive is potentially life-threatening due to impaired ventilation</p> </li> <li> <p>Remember UGIB (hematemesis) and nasopharyngeal bleeds can easily     mimic hemoptysis</p> </li> <li> <p>Presentation based on source of bleed:</p> </li> </ul> Structure Etiologies Airways Bronchitis (common cause of non-massive), bronchiectasis (especially in CF pts), neoplasm <p>Alveolar/</p> <p>Parenchymal</p> Infectious (bacterial PNA, abscess, TB, fungal, aspergilloma), Rheumatic (Goodpasture\u2019s, GPA, Behcet\u2019s) Vascular PE, AVM, CHF, mitral stenosis Other Coagulopathy, traumatic, foreign-body, iatrogenic, cocaine-induced"},{"location":"pulmonary/pulmonary-hemoptysis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Check for anticoagulation on med list</p> </li> <li> <p>Labs: CBC, BMP, Coags, UA (for hematuria), ABG (evaluate     oxygenation), type and screen</p> <ul> <li>Consider ANA, ANCA, Anti-GBM, sputum culture (bacteria, fungal,     AFB), sputum cytology depending on clinical context</li> </ul> </li> <li> <p>Imaging: CXR first (to evaluate etiology and to localize the source     to a side). Chest CT depending on prior workup, severity of bleed,     and stability of patient</p> </li> <li> <p>Bronchoscopy is sometimes indicated to localize bleeding source</p> </li> </ul>"},{"location":"pulmonary/pulmonary-hemoptysis/#management","title":"Management","text":"<ul> <li> <p>Urgent evaluation if any hemodynamic compromise, hypoxia,     hypercarbia, or respiratory distress</p> </li> <li> <p>Ensure a secure airway: massive hemoptysis may require intubation     and MICU transfer</p> </li> <li> <p>Reverse underlying coagulopathy if present. Consider trending HCT</p> </li> <li> <p>If unilateral bleed, place bleeding lung down (i.e. if the source is     left lung, place pt on left side) to prevent filling 'good' lung     with blood (include this info in sign-out if known)</p> </li> <li> <p>Urgent pulmonary consult if clinical instability: Bronchoscopy is     diagnostic and therapeutic</p> </li> <li> <p>Obtain CT Bronchial Artery Protocol if concern for bronchial artery     source (especially in CF patients) so embolization can be planned</p> <ul> <li>Order this at VUMC with a CTA Chest (NOT a CTA PE as that will be     timed incorrectly) and include \"bronchial artery protocol\" in     comments for the study</li> </ul> </li> <li> <p>Consider IR consult for angiography as diagnostic and therapeutic         option</p> <ul> <li>Consult early if there is massive hemoptysis; If bronchoscopy is     attempted but fails to stop the bleed, they can get to angiography     fastest if IR has already been made aware</li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-home-oxygen-therapies/","title":"Home Oxygen Therapies","text":"<p>Mackenzie Samson</p>"},{"location":"pulmonary/pulmonary-home-oxygen-therapies/#summary-of-medicare-part-b-guidelines-for-home-oxygen","title":"Summary of Medicare Part B Guidelines for Home Oxygen:","text":"<ul> <li> <p>Conditions for which oxygen therapy may be covered</p> <ul> <li> <p>Severe lung disease including COPD and ILD, CF, bronchiectasis,     widespread neoplasms</p> </li> <li> <p>Hypoxia related symptoms or findings expected to improve with O2:     pulmonary hypertension, cor pulmonale, erythrocytosis, impaired     cognition, nocturnal restlessness, morning headache</p> </li> </ul> </li> <li> <p>Qualifying Tests and Requirements:</p> <ul> <li> <p>Testing must be performed with a pt in chronic stable condition or     within two days of discharge from an inpatient hospital stay (after     treatment of acute exacerbating conditions)</p> </li> <li> <p>Criteria: Resting SpO2 \u2264 88% (or PaO2 &lt;55) or SpO2 &lt;88%     with ambulation</p> <ul> <li>Must be documented in chart</li> </ul> </li> </ul> </li> <li> <p>Special Considerations:</p> <ul> <li> <p>Medicare requires an additional walk on 4L/min showing desaturation     if the patient needs a flow rate of 5L/min or higher</p> </li> <li> <p>Because of the risk of desaturation with exertion and the intrinsic     error in the pulse ox (around 3%), patients with resting SpO2 \u2264 92%     should have amb sats checked</p> </li> <li> <p>Patients with Raynaud\u2019s or poor circulation may have inaccurate     finger pulse oximeter readings. Consider using a head saturation     monitor</p> </li> </ul> </li> <li> <p>VA Specific Guidance: Will need to document ambulatory saturations     in notes as above. Call the Oxygen Clinic (number listed in all team     rooms) and talk with your case manager</p> </li> </ul> <p>Summary of Medicare Part C Guidelines for Home Respiratory Assist Devices i.e. CPAP/BiPAP:</p> <ul> <li> <p>Restrictive thoracic disorders, covered if the following criteria     are met:</p> <ul> <li> <p>Documentation of a neuromuscular disease/severe thoracic cage     abnormality AND one of the following:</p> <ul> <li> <p>PaCO2 \u2265 45mmHg on ABG, performed while awake and on home O2     requirement</p> </li> <li> <p>Sleep oximetry demonstrates oxygen saturation \u2264 88% for \u2265 5     minutes of nocturnal recording time performed while on home O2     requirement</p> </li> <li> <p>For a neuromuscular disease (only), either: Maximal inspiratory     pressure \\&lt; 60cm H2O or forced vital capacity \\&lt; 50% predicted     and COPD may not contribute significantly</p> </li> </ul> </li> </ul> </li> <li> <p>Severe COPD, covered if the following criteria are met:</p> <ul> <li> <p>PaCO2 \u2265 52mmHg on ABG, performed while awake and on patient\u2019s     prescribed home O2</p> </li> <li> <p>Sleep oximetry demonstrates oxygen saturation \u2264 88% for \u2265 5 minutes     of nocturnal recording time, performed while breathing oxygen at     2LPM or patient\u2019s prescribed FiO2 (whichever is higher). Also     requires that OSA had been considered and ruled out (formal sleep     testing not required)</p> </li> </ul> </li> <li> <p>Hypoventilation Syndrome: covered if criteria 1, 2, AND either 3 or     4 are met:</p> <ul> <li> <p>PaCO2 \u226545 mm Hg on ABG, performed while awake and on home O2     requirement, AND</p> </li> <li> <p>Spirometry shows an FEV1/FVC \u2265 70% AND</p> </li> <li> <p>ABG PaCO2, performed during sleep or immediately upon awakening that     demonstrates worsening PaCO2 of \u2265 7mm Hg compared to the original     result in criterion 1 OR</p> </li> <li> <p>A facility-based PSG or HST demonstrates oxygen saturation \u2264 88% for     \u2265 5 minutes of nocturnal recording time that is not caused by     obstructive upper airway events</p> </li> </ul> </li> <li> <p>OSA:</p> <ul> <li> <p>An initial screening for OSA in the hospital is nocturnal pulse     oximetry. The distinct \u201csaw-tooth\u201d pattern representing intermittent     hypoxia is suggestive of OSA, and a formal NPSG or home sleep test     is recommended to evaluate for OSA. \u00a0This is done on an outpatient     basis only once acute issues have fully resolved</p> </li> <li> <p>Home CPAP/BiPAP covered IF:</p> <ul> <li> <p>The diagnosis of central sleep apnea or complex sleep apnea and</p> </li> <li> <p>Significant improvement of the sleep-associated hypoventilation     occurs with the use of the device</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-hypoxia/","title":"Hypoxia","text":"<p>Henry Brems</p>"},{"location":"pulmonary/pulmonary-hypoxia/#background","title":"Background","text":"<ul> <li> <p>Two major ways to measure oxygenation, which are similar but     distinct:</p> </li> <li> <p>SpO2 or \"pulse ox\" - most common, measures the O2 saturation of Hgb     at capillary level</p> <ul> <li>\\&lt;95% is abnormal, but do not need supplemental O2 unless     \\&lt;90-92% in most pts</li> </ul> </li> <li> <p>PaO2 - the partial pressure of oxygenation measured on an ABG</p> <ul> <li>\\&lt;80 mmHg is abnormal</li> </ul> </li> <li> <p>The relationship between SpO2 and PaO2 is the classic S-shaped     curve.</p> <ul> <li>SpO2 of \\&lt;88% PaO2 begins to fall off dangerously fast</li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-hypoxia/#mechanisms-of-hypoxia","title":"Mechanisms of Hypoxia","text":"Mechanism Pathophysiology Decreased barometric pressure <p>Normal A-a gradient</p> <p>Unlikely to be seen except at high altitudes</p> Hypoventilation <p>Normal A-a gradient</p> <p>Hypoxia easily correctable with supplemental O2</p> V/Q Mismatch <p>Increased A-a gradient</p> <p>Processes that lead to areas of lung where V/Q &lt;1</p> <p>Common examples include PNA, ARDS, pulmonary edema</p> Right-to-left Shunt <p>Increased A-a gradient</p> <p>Can be anatomic (e.g. intracardiac, AVMs) or physiologic (water/pus/blood filling alveoli)</p> <p>Classically does not easily correct with supplemental O2</p> Diffusion Limitation <p>Increased A-a gradient</p> <p>Often related to diseases affecting the interstitium -- e.g., ILD</p>"},{"location":"pulmonary/pulmonary-hypoxia/#differential-diagnosis-for-hypoxia-based-on-anatomical-location","title":"Differential diagnosis for hypoxia based on anatomical location","text":"Anatomical Location Differential Diagnosis Airways <p>COPD most common, Asthma in very severe cases</p> <p>CF, bronchiectasis in patients with appropriate history</p> Alveoli <p>Blood</p> <p>Pus: infection from bacterial, viral, fungal agents</p> <p>Water: pulmonary edema</p> <p>Protein/Cells/Other: ARDS, pneumonitis (e.g., aspiration, drug-induced)</p> Interstitium/Parenchyma Interstitial Lung Disease Vascular <p>Pulmonary Emboli</p> <p>Suspect in patients with significant hypoxia and a clear CXR</p> <p>Pleural Space and</p> <p>Chest Wall</p> <p>Pleural Effusions, Pneumothorax, Neuromuscular weakness, tense ascites</p> <p>More likely to cause dyspnea, need to be severe to cause hypoxia</p>"},{"location":"pulmonary/pulmonary-hypoxia/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Confirm true hypoxia with good pleth</p> </li> <li> <p>CXR</p> </li> <li> <p>Labs: CBC, BMP, BNP, troponin, ABG/VBG</p> </li> <li> <p>EKG</p> </li> <li> <p>TTE: obtain with bubble if shunt on ddx</p> </li> <li> <p>Lung US: B lines, lung sliding, effusions, consolidations     (hepatization), diaphragm paralysis</p> </li> <li> <p>Chest CT without contrast for evaluation of lung parenchyma</p> </li> <li> <p>CTA chest if suspicion for PE (see PE section)</p> </li> <li> <p>Outpatient PFTs if suspected obstructive or restrictive disease</p> </li> </ul>"},{"location":"pulmonary/pulmonary-hypoxia/#management","title":"Management","text":"<ul> <li> <p>Should be directed at underlying cause</p> </li> <li> <p>If acutely decompensating, Duonebs, IV lasix, antibiotics depending     on clinical picture</p> </li> <li> <p>Supplemental O2 for goal SpO2:</p> <ul> <li> <p>&gt;90-92% for most patients (There is generally no need to make SpO2     100%)</p> </li> <li> <p>Between 88-92% for patients with chronic hypoxia from COPD (i.e., on     home O2)</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/","title":"Interstitial Lung Disease","text":"<p>Pakinam Mekki</p>"},{"location":"pulmonary/pulmonary-ild/#background","title":"Background","text":"<ul> <li> <p>Heterogenous group of parenchymal lung diseases that involve     scarring or fibrosis, affecting the lung interstitium, alveoli, and     pulmonary capillaries</p> <ul> <li>Leads to loss of lung volume and compliance and impaired gas     exchange</li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/#etiologies","title":"Etiologies","text":"<ul> <li> <p>ILD is divided into primary (idiopathic) causes and secondary causes</p> </li> <li> <p>Idiopathic: idiopathic pulmonary fibrosis, eosinophilic pneumonia,     idiopathic NSIP, organizing pneumonia, acute interstitial pneumonia,     etc</p> </li> <li> <p>Secondary</p> <ul> <li> <p>Systemic:</p> <ul> <li> <p>Connective tissue disease: RA, Sjogrens, dermatomyositis,     polymyositis SLE, MCTD, scleroderma</p> </li> <li> <p>Granulomatous disease: sarcoidosis, TB</p> </li> <li> <p>Vasculitis: granulomatosis with polyangiitis, eosinophilic     granulomatosis with polyangiitis, amyloidosis,     lymphangioleiomyomatosis</p> </li> </ul> </li> <li> <p>Exposure</p> <ul> <li> <p>Pneumoconiosis (inorganic) \u2013 exposure to coal mines, silica,     asbestos, organic solvents, heavy metals, solder, hair dressing     chemicals</p> </li> <li> <p>Hypersensitivity pneumonitis (organic)- farm exposures, chicken     coops, pesticide, stored grains, mold (ex: water damage in home,     hot tubs)</p> </li> <li> <p>Iatrogenic \u2013 amiodarone, immunotherapies, TKI, TNF-a inhibitors,     nitrofurantoin, radiation</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Dry cough is the most common symptom of ILD. Productive coughs are     uncharacteristic</p> </li> <li> <p>History:</p> <ul> <li> <p>Duration, timing, severity of respiratory symptoms</p> </li> <li> <p>Exposures \u2013 pets, occupation, residence, smoking, drugs, travel,     hobbies, dust, hay, grass,</p> </li> <li> <p>Screen for autoimmune symptoms (arthritis, myalgia, rash, Raynaud\u2019s     phenomenon</p> </li> <li> <p>Screen for vasculitis symptoms: hematuria, hemoptysis, mononeuritis     multiplex</p> </li> <li> <p>Medication history</p> </li> <li> <p>Family history \u2013 premature aging, myelodysplastic syndrome (most     common familial IPF association with telomerase mutations)</p> </li> </ul> </li> <li> <p>Chest Imaging:</p> <ul> <li> <p>CXR \u2013 could find peripheral reticular opacities</p> </li> <li> <p>HRCT protocol is used for diagnosis: evaluates the lung parenchyma     while pt is supine, prone, with inspiratory and expiratory cuts</p> </li> <li> <p>There are two morphologic features on HRCT</p> <ul> <li> <p>Usual Interstitial Pneumonia (UIP): basilar predominant     fibrosis, honey combing, and traction bronchiectasis. Minimal     GGOs. Pattern seen in IPF.</p> </li> <li> <p>Non-Specific Interstitial Pneumonia (NSIP): Marked by subpleural     sparing, increased reticular patterns, and mosaic attenuation     due to air trapping. Minimal or absent honeycombing</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/#labs","title":"Labs","text":"<ul> <li> <p>Rule out infection: CBC, RPP, sputum Cx, Histo antigen, Blasto antigen, Aspergillus galactomannan, 1,3-\u03b2-D-Glucan, sputum GMS, consider NTM, HIV</p> </li> <li> <p>Rheumatologic workup: ANA w/ reflex ENA, ESR, CRP, CK, aldolase,             consider full myositis panel, RF, anti-CCP</p> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/#bronchoscopy","title":"Bronchoscopy","text":"<ul> <li> <p>BAL is not diagnostic ILD (except eosinophilic PNA), may be helpful         to rule out infection</p> </li> <li> <p>Transbronchial biopsy is the gold standard for diagnosis. Surgical         lung biopsy may be helpful in cases where the clinical evaluation         and imaging are not effective (uncommon)</p> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/#misc","title":"Misc:","text":"<ul> <li> <p>PFTs with 6-minute walk test (prognostic value)</p> </li> <li> <p>TTE to evaluate for pHTN</p> </li> <li> <p>SLP evaluation for indolent aspiration</p> </li> </ul>"},{"location":"pulmonary/pulmonary-ild/#management","title":"Management","text":"<ul> <li> <p>Acute flare \u2013 all non- UIP = may respond to steroids. Consult     rheumatology if CTD origin for further options.</p> </li> <li> <p>Chronic therapy</p> <ul> <li> <p>Consider tyrosine kinase inhibitor (nintedanib; INPULSIS trial) and     antifibrotics (pirfenidone; ASCEND trial) \u2013 reduces FVC decline but     no change in mortality</p> </li> <li> <p>There is increased mortality in IPF with azathioprine/pred/NAC     (PANTHER-IPF); steroids are not indicated</p> </li> <li> <p>Immunosuppression for autoimmune related ILD</p> </li> <li> <p>Antigen avoidance for hypersensitivity pneumonitis</p> </li> </ul> </li> <li> <p>Consider lung transplant evaluation for severe disease</p> </li> </ul>"},{"location":"pulmonary/pulmonary-inhaler-therapy/","title":"Inhaler Therapy","text":"<p>Patrick Barney</p>"},{"location":"pulmonary/pulmonary-inhaler-therapy/#inhaler-therapy_1","title":"Inhaler therapy","text":"<ul> <li> <p>Current inhaler device delivery options</p> <ul> <li> <p>MDI \u2013 typical handheld inhaler</p> <ul> <li> <p>Pro is same dose of medicine each time you use them \u2013 if used     correctly.</p> </li> <li> <p>Con is that it requires coordination. Patient must be able to     time 3-5s slow inhalation and 5-10s breath hold w/ release of     medicine, can be helped w/ spacer.</p> </li> </ul> </li> <li> <p>SMI \u2013 \u201csoft mist inhaler,\u201d handheld. Creates cloud of medicine that     is inhaled without propellant.</p> <ul> <li>Pros are more medicine gets into lungs than w/ MDI so lower dose     can be used, does not require coordination.</li> </ul> </li> <li> <p>DPI - handheld inhaler, delivers medicine whenever patient breathes     in through the device, requiring less coordination.</p> <ul> <li>Pro is lack of need to coordinate breath; Con is inconsistent     dose delivery.</li> </ul> </li> </ul> </li> <li> <p>Nebulizers</p> <ul> <li> <p>Saline</p> <ul> <li>Hypertonic saline, NS, 3% and 7%. Can be used to thin secretions     and produce deep cough in patients who need to expectorate as     part of treatment. For CF, chronic tracheostomy, NM weakness. No     evidence for benefit in COPD.</li> </ul> </li> <li> <p>Enzymatic Agents</p> <ul> <li>Dornase alpha \u2013 Pulmozyme \u2013 \u201cDNAse\u2019 - enzyme that breaks down     polymerized DNA in high concentrations in CF airways, indicated     specifically for patients with CF</li> </ul> </li> <li> <p>Anticholinergics</p> <ul> <li> <p>COPD exacerbation, asthma exacerbation \u2013 bronchodilation and     secretion inhibition in acute setting</p> </li> <li> <p>Ipratropium (Atrovent) intermittent nebulizer or     Ipratropium-albuterol (Duo-Neb) intermittent or continuous     nebulizer</p> </li> </ul> </li> <li> <p>Disulfide Disrupters</p> <ul> <li> <p>Sever disulfide bonds of glycoproteins in mucus, lowering its     viscosity and making it more amenable to suction, expectoration</p> </li> <li> <p>N-acetylcysteine (Mucomyst) - nebulized form available in \u201cadult     burn inhalation injury protocol\u201d when search \u201cmucomyst\u201d</p> </li> </ul> </li> </ul> </li> <li> <p>Antibiotics</p> <ul> <li> <p>May be indicated in patients w/ CF, non-CF bronchiectasis, VAP     as salvage therapy</p> </li> <li> <p>Tobramycin \u2013 only nebulized antibiotic available at VUMC</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-inhaler-therapy/#categories-of-inhaled-medications","title":"Categories of inhaled medications","text":"<ul> <li> <p>Short-acting beta agonist (SABA): beta-2 agonism of bronchial smooth     muscle to achieve bronchodilation; also decrease mast cell mediator     release. Ex: albuterol, levalbuterol</p> </li> <li> <p>Long-acting beta agonist (LABA): - beta-2 agonists, same as SABAs     but have lipophilic side chains that allow longer binding but also     slow the onset of action. Ex: formoterol, salmeterol, olodaterol</p> </li> <li> <p>Long-acting muscarinic antagonist (LAMA): - non-specific muscarinic     receptor antagonists, leads to bronchodilation and reduced     secretions. Ex: tiotropium, umeclidinium, glycopyrrolate</p> </li> <li> <p>Inahled corticosteroid (ICS): - suppress airway inflammation. Ex:     budesonide, fluticasone, mometasone</p> </li> </ul>"},{"location":"pulmonary/pulmonary-inhaler-therapy/#vumc-inpatient-options","title":"VUMC Inpatient Options","text":"<ul> <li> <p>SABA : Albuterol (Proventil/Ventolin/Proair) - MDI, neb, continuous     aerosol available</p> </li> <li> <p>SABA/SAMA: Ipratropium-albuterol (Duo-Neb) - neb and continuous neb     available</p> </li> <li> <p>LABA \u2013 only available in combination w/ ICS. LABA/ICS:     vilanterol-fluticasone (Breo Ellipta), salmeterol-fluticasone     (Advair Diskus/HFA)</p> </li> <li> <p>LAMA: Tiotropium (Spiriva Respimat)</p> </li> <li> <p>ICS: Budesonide inhaler (Pulmicort) or neb, fluticasone furoate     (Arnuity Ellipta)</p> </li> </ul>"},{"location":"pulmonary/pulmonary-lung-masses/","title":"Lung Masses","text":"<p>Chandler Montgomery</p>"},{"location":"pulmonary/pulmonary-lung-masses/#background","title":"Background","text":"<ul> <li> <p>Definitions: lesion \\&lt; 3 cm = pulmonary nodule. Lesion &gt; 3 cm =     lung mass</p> <ul> <li> <p>Pulmonary nodules are common and often benign, but presence of lung     mass (&gt;3cm) should prompt workup as chance of malignancy is high     (&gt;50%)</p> </li> <li> <p>For nodules, refer to the Fleischner Society guidelines (incidental     nodules) or Lung-RADS (detected on lung cancer screening) for     surveillance/management recommendations</p> </li> <li> <p>Note that in TN, prior histoplasmosis is a very common cause of     pulmonary nodules</p> </li> </ul> </li> <li> <p>Differential diagnosis:</p> <ul> <li> <p>Malignant:</p> <ul> <li> <p>Primary non-small cell lung cancer (NCSLC): adenocarcinoma,     squamous cell (SCC), large cell carcinoma</p> </li> <li> <p>Metastatic: commonly melanoma, sarcoma, colon, breast, renal,     testicular</p> <ul> <li>Often multiple nodules/masses (e.g., cannonball)\u00a0</li> </ul> </li> <li> <p>Neuroendocrine: small cell lung cancer (SCLC), carcinoid, large     cell neuroendocrine</p> </li> </ul> </li> <li> <p>Infectious:</p> <ul> <li> <p>Granulomatous: TB, non-TB mycobacterium, endemic fungal (histo,     blasto, coccidio)</p> <ul> <li>May have component of calcification</li> </ul> </li> <li> <p>Abscess: Staph aureus, Klebsiella, anaerobes, polymicrobial     (aspiration)</p> </li> <li> <p>Septic emboli, hydatid cyst, aspergilloma</p> </li> </ul> </li> <li> <p>Other: hamartoma, AVM, pulmonary infarct, inflammatory nodule (GPA,     RA), sarcoidosis</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-lung-masses/#evaluation","title":"Evaluation","text":"<ul> <li> <p>History: smoking, cough, hemoptysis, dyspnea, chest pain, weight     loss, fevers, night sweats, hoarseness, bone pain, neuro deficits</p> <ul> <li>Lung cancer should always be considered in a patient with smoking     history &amp; new cough or hemoptysis</li> </ul> </li> <li> <p>Exam: cachexia, lymphadenopathy, bone pain, hepatomegaly, neuro     deficits</p> </li> <li> <p>Imaging:</p> <ul> <li> <p>CXR has poor sensitivity for lung nodules, may show large mass or     malignant effusion</p> </li> <li> <p>CT chest (with contrast if possible - better evaluation of     mediastinum/LNs)</p> <ul> <li> <p>Review prior chest imaging to assess age and growth pattern of     lesion(s)</p> </li> <li> <p>Benign features: small (sub-centimeter), calcified, fat     attenuation, stable over 2 years, multiple nodules</p> </li> <li> <p>Concerning features: large, growth, spiculation, upper lobe     location, thick-walled cavitation, mediastinal invasion</p> </li> <li> <p>Location- adenocarcinoma often more peripheral, SCC often more     central, SCLC associated with massive LAD, mediastinal invasion,     large hilar masses</p> </li> </ul> </li> </ul> </li> <li> <p>Look for paraneoplastic syndromes:</p> <ul> <li> <p>SCLC: SIADH, Lambert-Eaton, Cushing\u2019s syndrome</p> </li> <li> <p>SCC: hypercalcemia (PTHrP)</p> </li> <li> <p>Dermatomyositis, polymyositis, hypertrophic osteoarthropathy</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-lung-masses/#stagingdiagnosis","title":"Staging/Diagnosis","text":"<ul> <li> <p>Imaging: CT chest (with contrast if possible)m CTAP w/contrast vs.     PET/CT to assess for metastasis, consider MRI brain if clinical     stage III or IV disease</p> </li> <li> <p>Biopsy: careful planning is key</p> <ul> <li> <p>For metastatic disease, obtain tissue from least invasive site</p> <ul> <li>FNA or excision of palpable lymph node (cytology department,     US-guided procedure, or EGS)</li> </ul> </li> <li> <p>If uncertain how to best obtain tissue, consult IR, interventional     pulm, and/or oncology to discuss approach</p> <ul> <li> <p>Surgical Bx: Wedge resection/lobectomy often preferred if     solitary nodule amenable to both diagnostic and therapeutic     resection in good surgical candidate</p> </li> <li> <p>Bronchoscopy with EBUS (endobronchial US) often used to obtain     biopsy of mediastinal tissue or central/peri-bronchial lesion</p> </li> <li> <p>Trans-thoracic needle aspiration (TTNA): peripheral lesions not     amenable to bronchoscopy</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-lung-masses/#management","title":"Management","text":"<ul> <li> <p>Planning is complex, usually discussed at multidisciplinary tumor     board</p> </li> <li> <p>NSCLC</p> <ul> <li> <p>Stage I/II: surgical resection \u00b1 adjuvant chemotherapy</p> </li> <li> <p>Stage III: more complex requiring multidisciplinary approach</p> </li> <li> <p>Stage IV: chemo \u00b1 targeted therapy depending on PD-L1 expression,     presence of driver mutations for EGFR, ALK, ROS-1, BRAF, MET, RET,     others</p> </li> </ul> </li> <li> <p>SCLC: usually widely metastatic at time of diagnosis, treated with     systemic chemo/radiation</p> </li> </ul>"},{"location":"pulmonary/pulmonary-pfts/","title":"Pulmonary Function Tests (PFTs)","text":"<p>Peter Edmonds</p>"},{"location":"pulmonary/pulmonary-pfts/#full-pfts-include","title":"Full PFTs include:","text":"<ul> <li> <p>Spirometry: FVC, FEV1, with or without bronchodilator</p> <ul> <li>Patients with new shortness of breath, chronic cough, or upper     airway obstruction</li> </ul> </li> <li> <p>Plethysmography: TLC, RV</p> <ul> <li>Evaluation of restrictive diseases (ILD, neuromuscular) or     hyperinflation (COPD, asthma)</li> </ul> </li> <li> <p>Diffusion (DLCO) can be added to plethysmography</p> </li> <li> <p>'Full PFTs' = Spirometry + Plethysmography + DLCO</p> </li> </ul>"},{"location":"pulmonary/pulmonary-pfts/#tips-for-ordering","title":"Tips for ordering:","text":"<ul> <li> <p>Initial diagnostic workup: Full PFTs with bronchodilator challenge</p> </li> <li> <p>Chronic Lung disease: Spirometry to track FEV1/FVC over time \u00b1     DLCO to evaluate ILD</p> </li> </ul>"},{"location":"pulmonary/pulmonary-pfts/#interpretation","title":"Interpretation:","text":"<ul> <li> <p>Distinguish between obstructive and restrictive disease</p> <ul> <li> <p>FEV1/FVC \\&lt; 0.7 indicates obstructive disease</p> <ul> <li>Normal to increased FVC &amp; TLC is consistent with isolated     obstructive disease</li> </ul> </li> <li> <p>TLC \\&lt; 80% is diagnostic of restrictive disease</p> <ul> <li> <p>Reduced FVC is suggestive, but not diagnostic of restrictive     disease</p> </li> <li> <p>FEV1 commonly too but FEV1/FVC ratio is normal in isolated     restrictive disease</p> </li> </ul> </li> <li> <p>Decreased FEV1/FVC and TLC suggests a mixed obstructive and     restrictive picture</p> </li> </ul> </li> <li> <p>Assess DLCO -- abnormal is \\&lt;75%</p> <ul> <li>Decreased DLCO can help differentiate between causes of obstructive     or restrictive PFTs</li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-pfts/#causes-of-common-abnormalities","title":"Causes of common abnormalities:","text":"<ul> <li> <p>Obstruction</p> <ul> <li> <p>Decreased DLCO: COPD, CF, bronchiectasis</p> </li> <li> <p>Normal DLCO: asthma, early stages of COPD or CF</p> <ul> <li>Asthma: spirometry may be normal, +bronchodilator response (an     increase in FEV1 by 12% and 200ml after bronchodilator),     +methacholine challenge</li> </ul> </li> <li> <p>Though we use FEV1/FVC to diagnose, we track disease severity using     FEV1</p> </li> </ul> </li> <li> <p>Restriction:</p> <ul> <li> <p>Decreased DLCO: ILD</p> </li> <li> <p>Normal DLCO: pleural disease, chest wall (obesity, scoliosis),     neuromuscular disorders</p> </li> </ul> </li> <li> <p>Decreased DLCO: If PFTs otherwise normal consider pulmonary vascular     disease, pulmonary edema, or mixed obstructive/restrictive disease     (pseudo-normalization of PFTs)</p> </li> </ul>"},{"location":"pulmonary/pulmonary-pleural-effusions/","title":"Pleural Effusions","text":"<p>Eddie Qian</p>"},{"location":"pulmonary/pulmonary-pleural-effusions/#background","title":"Background","text":"<ul> <li> <p>There is a normal influx of fluid into the pleural space due to     leaky capillary membranes and the pleural space\u2019s negative pressure.     This fluid is constantly reabsorbed by lymphatics. An imbalance in     the system will result in accumulation.</p> </li> <li> <p>Some examples:</p> <ul> <li> <p>Increased influx: increased filtration from the capillaries from     high intravascular hydrostatic pressure (i.e., heart failure, renal     failure) or low intravascular oncotic pressure</p> </li> <li> <p>Other liquid entry into the pleural space through anatomic deficits:     CSF, chyle, urine, blood, ascites (the diaphragm is naturally     porous)</p> </li> <li> <p>Decreased efflux: obstruction of the parietal pleural stoma (from     protein or cellular debris in exudative pleural effusions)</p> </li> <li> <p>Increased systemic venous pressure (lymphatic system drains into the     systemic venous circulation so high venous pressure prevents     lymphatics from draining appropriately)</p> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-pleural-effusions/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Imaging:</p> <ul> <li> <p>CXR: lateral decubitus position (if effusion moves with gravity,     suggests free flowing)</p> </li> <li> <p>Ultrasound: assess size, location, loculations</p> </li> <li> <p>CT Chest with contrast (not always indicated; helpful to eval     septations)</p> </li> </ul> </li> <li> <p>Thoracentesis (see Procedures section):</p> <ul> <li> <p>Will it change management?</p> </li> <li> <p>Pleural LDH, protein, cell count/diff, culture (don\u2019t forget to     order serum LDH &amp; protein)</p> </li> <li> <p>Consider: pleural cytology, hematocrit, triglycerides, glucose,     amylase</p> </li> <li> <p>If septated or empyema, consider pulm consult for chest tube</p> </li> </ul> </li> <li> <p>Interpretation of pleural studies:</p> <ul> <li> <p>Lights criteria: 1 of the following to be considered an exudative     effusion</p> <ul> <li> <p>Pleural to serum protein ratio &gt; 0.5</p> </li> <li> <p>Pleural to serum LDH ratio &gt; 0.6</p> </li> <li> <p>Pleural LDH &gt; \u2154 upper limit of normal range of serum LDH</p> </li> </ul> </li> <li> <p>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis     (caused by increased intrapleural negative pressure),     hypoalbuminemia, renal failure</p> </li> <li> <p>Exudative: infections (bacterial, TB, fungal), malignant,     rheumatologic, PE</p> </li> </ul> </li> <li> <p>Other tips:</p> <ul> <li> <p>Protein: &gt;5 think TB or malignancy, \\&lt; 0.5 think urine, CSF,     peritoneal dialysate</p> </li> <li> <p>Glucose: \\&lt; 60 think about malignancy, TB, or rheumatologic,     less likely hemothorax or parapneumonic</p> </li> <li> <p>Cell count/differential: polys represent an acute process,     monocytes represent a chronic process, lymphocytes think about     TB or malignancy, eosinophils think about air/blood, TB,     malignancy, asbestos, drugs</p> </li> </ul> </li> <li> <p>Two separate processes may co-occur, and a transudate may mask an     exudative effusion; if concerned for this and you have clinical     stability, trial diuresis prior to thoracentesis</p> </li> </ul>"},{"location":"pulmonary/pulmonary-pulmonary-hypertension/","title":"Pulmonary Hypertension","text":"<p>Pakinam Mekki</p>"},{"location":"pulmonary/pulmonary-pulmonary-hypertension/#background","title":"Background","text":"<ul> <li> <p>Symptoms: insidious dyspnea, exertional chest pain, orthopnea, PND,     edema</p> </li> <li> <p>Exam: JVD, increased P2, split S2, RV heave, TR murmur,     hepatomegaly, ascites, edema</p> </li> <li> <p>Signs of RV failure: low cardiac output (hypotension, renal failure,     hepatic congestion), arrhythmias, refractory hypoxemia (R\u2192L shunt),     effusions (pericardial &gt; pleural)\u00a0</p> </li> <li> <p>WHO Groups and Causes:\u00a0</p> <ul> <li> <p>Group 1: Pulmonary arterial hypertension (PAH): obliteration of     blood vessels in the lung\u00a0</p> <ul> <li> <p>Idiopathic, heritable\u00a0</p> </li> <li> <p>Drugs/toxins (methamphetamine)\u00a0</p> </li> <li> <p>Associated with CTD, HIV, portal HTN, congenital heart disease,     schistosomiasis\u00a0</p> </li> <li> <p>Pulmonary veno-occlusive disease (PVOD), pulmonary capillary     hemangiomatosis\u00a0</p> </li> </ul> </li> <li> <p>Group 2: Left heart disease: back pressure and passive congestion\u00a0</p> <ul> <li>HFrEF, HFpEF, valvular disease, LA stiffness\u00a0</li> </ul> </li> <li> <p>Group 3: Chronic lung disease: chronic hypoxemia, chronic pulmonary     vasoconstriction\u00a0</p> <ul> <li>COPD, ILD, OSA, chronic high-altitude, developmental lung     disorders\u00a0</li> </ul> </li> <li> <p>Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)\u00a0</p> </li> <li> <p>Group 5: Multifactorial</p> <ul> <li>Hematologic disorders, chronic hemolytic anemia, sarcoidosis,     pulmonary Langerhans cell histiocytosis, fibrosing     mediastinitis, metabolic disorders\u00a0</li> </ul> </li> </ul> </li> </ul>"},{"location":"pulmonary/pulmonary-pulmonary-hypertension/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Most common reason for admission with a known diagnosis of pHTN is     volume overload/RV failure and hypoxia</p> <ul> <li>Consider etiology of decompensation: Progression of underlying     disease, medication/dietary nonadherence, infection, arrhythmia,     myocardial infarction/RV ischemia, shunting via opening a PFO as a     release valve, pulmonary embolism</li> </ul> </li> <li> <p>Consult pulmonary hypertension with any questions or assistance with     workup</p> </li> <li> <p>Studies to consider ordering to determine etiology of pulmonary     hypertension</p> <ul> <li> <p>Labs: BNP, liver enzymes, rheumatologic serologies (ANA w/ reflex     ENA, RF/CCP, ANCA, Scl-70, Ro/LA)</p> </li> <li> <p>EKG: R-axis deviation, RBBB, increased P wave in lead II</p> </li> <li> <p>CXR: increased PA and R heart border, vascular pruning</p> </li> <li> <p>TTE w bubble: RVSP &gt;35-40, RV dilation and dysfunction, RA     dilation, septal flattening, pericardial effusion, evaluate for L     heart disease and shunt</p> </li> <li> <p>PFT (outpatient): isolated decrease in DLCO in group I PH, TLC \\&lt;     50%, FEV/FVC \\&lt; 70%</p> </li> <li> <p>V/Q scan or CTA chest to evaluate for CTEPH</p> </li> <li> <p>6-minute walk test is prognostic, can be used to monitor response to     therapy</p> </li> <li> <p>\u00b1 CT chest to evaluate for parenchymal lung disease</p> </li> <li> <p>\u00b1 sleep study to evaluate for OSA</p> </li> <li> <p>Right heart catheterization (RHC) is the gold standard test for PH     diagnosis and determines pre-vs post-capillary HTN (See RHC section     in Cardiology)\u00a0\u00a0</p> <ul> <li> <p>Nitric oxide challenge to assess for drug response</p> </li> <li> <p>Fluid challenge with 500cc LR to assess left heart compliance     `</p> </li> </ul> </li> </ul> </li> </ul> Definitions Characteristics Causes Pre-capillary PH <p>mPAP &gt; 20 mmHg</p> <p>PAWP \u2264 15 mmHg</p> <p>PVR \u2265 3 WU</p> Groups 1, 3, 4, 5 Post-capillary PH <p>mPAP &gt; 20 mmHg</p> <p>PAWP &gt; 15 mmHg</p> <p>PVR &lt; 3 WU</p> Group 2 <p>Combined pre- and post-</p> <p>capillary PH</p> <p>mPAP &gt; 20 mmHg</p> <p>PAWP &gt; 15 mmHg</p> <p>PVR \u2265 3 WU</p> Group 2, 5"},{"location":"pulmonary/pulmonary-pulmonary-hypertension/#poor-prognostic-indicators-for-phtn","title":"Poor Prognostic Indicators for pHTN","text":"<ul> <li> <p>NYHA Functional Class (FC III-IV) - 6-minute walk test \\&lt; 300</p> </li> <li> <p>AKI - Hyponatremia</p> </li> <li> <p>Low SBP (SBP \\&lt; 90) - CTD or liver disease as etiology</p> </li> <li> <p>Poor hemodynamics on RHC (RAP &gt; 20; cardiac index \\&lt; 2)</p> </li> <li> <p>TTE findings - TAPSE \\&lt; 1.8, pericardial effusion, severe RV     dysfunction</p> </li> </ul>"},{"location":"pulmonary/pulmonary-pulmonary-hypertension/#management","title":"Management","text":"<ul> <li> <p>Goal of hospitalization is to understand and optimize hemodynamics</p> </li> <li> <p>Overall goal- improve NYHA functional class, RV function, 6-minute     walk test, quality of life</p> </li> <li> <p>General management: treat underlying cause, diuretics for right     heart failure, goal SpO2&gt;90%</p> </li> <li> <p>PAH medicines: Consult pulmonary hypertension if considering     starting of changing meds</p> </li> <li> <p>Oral treatments may be used as monotherapy or in combination\u00a0</p> <ul> <li> <p>Calcium-channel blockers \u2192 patients with + vasoreactive challenge\u00a0</p> </li> <li> <p>NO-cGMP enhancers: PDE5-inhibitors sildenafil or tadalafil,     riociguat\u00a0</p> </li> <li> <p>Endothelin receptor antagonists (ERAs): Bosentan, macitenatan,     ambrisentan \u2013</p> </li> </ul> </li> <li> <p>Prostacyclin analogs</p> <ul> <li> <p>Prostacyclin analogs increase cAMP-mediated pulmonary     vasodilation. Side effects include jaw pain, flushing,     arthralgia, diarrhea.</p> </li> <li> <p>IV formulations are administered through a continuous pump.     Never stop IV prostacyclins, even brief pauses can cause rebound     vasoconstriction and death. In an emergency, can run temporarily     through PIV</p> <ul> <li> <p>Epoprostenol: IV (Veletri) or inhaled (Flolan), half-life 4     minutes.</p> </li> <li> <p>Treprostinil: IV/subcutaneous/inhaled/PO, half-life 4 hours\u00a0</p> </li> <li> <p>Iloprost: inhaled, half-life minutes\u00a0</p> </li> <li> <p>Selexipag (Uptravi): PO, half-life hours\u00a0</p> </li> </ul> </li> </ul> </li> <li> <p>Treatment based on NYHA functional classification:\u00a0</p> <ul> <li> <p>Class I: no treatment or monotherapy\u00a0</p> </li> <li> <p>Class II: monotherapy or combination oral therapy\u00a0</p> </li> <li> <p>Class III: combination oral therapy or prostacyclin\u00a0</p> </li> <li> <p>Class IV: prostacyclin \u00b1 oral therapy\u00a0</p> </li> </ul> </li> <li> <p>Lung transplant for patients who are candidates and failing maximal     medical therapy\u00a0</p> </li> <li> <p>VA ECMO can be used as bridge to medical therapy or lung transplant\u00a0</p> </li> <li> <p>Atrial septostomy- serves as \u201cpop-off\u201d valve and allows for     decompression of failing RV; used as definitive palliative procedure     or bridge to transplant\u00a0</p> </li> </ul>"},{"location":"radiology/radiology-consults-radiology-procedures/","title":"Consults for Radiology Procedures","text":"<ul> <li>Radiology Procedures are performed by 3 separate consult services     depending on the procedure requested.</li> <li>These pagers are covered 24/7, often by the same person for up to a     week at a time (home call, not night float), so kindly reserve     overnight pages for true urgent/emergent indications and save     non-emergent communications until the morning</li> </ul> Consult Service Vascular IR CT/US Procedures Fluoro/Neuro/MSK fluoroscopy EPIC Order \u201cInpatient Consult to Interventional Radiology\u201d \u201cInpatient Consult for Adult Image-Guided Procedures (CT/US)\u201d Call 20878 (Fluoroscopy) for scheduling &amp; orders. Contact Number (weekdays) <p>#20840</p> <p>(MD desk)</p> <p>#20120</p> <p>(MD desk)</p> <p>#20878</p> <p>(Fluoro techs)</p> Contact Number (nights &amp; weekends) Pager only Pager only <p>#37185</p> <p>(ER reading room)</p> Service Pager 835-5105 835-0770 N/A Procedure Requested <p>-Active bleeding Embolizations</p> <p>-Cholecystostomy</p> <p>-PTC (biliary drains)</p> <p>-Nephrostomy</p> <p>-Tunneled lines</p> <p>-Dialysis interventions</p> <p>-G-tube placement</p> <p>-IVC Filter</p> <p>-Drain repositioning</p> <p>-Abscess drainage</p> <p>-Biopsies</p> <p>-Paracentesis**</p> <p>-Thoracentesis**</p> <p>-Dobhoff tube placements**</p> <p>-Lumbar punctures**</p> <p>-Joint injections / aspirations</p> <p>-Esophograms</p> <p>-Upper GI Series</p> <p>-Small bowel follow-through</p> <p>-Contrast enemas</p> <p>**Requires failed bedside/Inpatient medicine procedures service attempt</p> <p>Specific Procedural Questions</p> <p>Pre-Procedure (contact consult services for case-specific requirements, guidelines below):</p> <ul> <li> <p>NPO @ MN prior to procedure if sedation is to be used (majority of     cases). Local only cases do not require patient to be NPO (see IR or     CT/US procedures consult note for details).</p> </li> <li> <p>Labs required within 1 month of procedure or sooner if there is a     clinical situation that can affect those lab values. Think Warfarin     and INR, for example.</p> </li> </ul> <ul> <li> <p>INR (\\&lt;1.5 for most procedures)</p> </li> <li> <p>Platelets (&gt;50K)</p> </li> </ul> <ul> <li>Anticoagulation</li> </ul> <ul> <li> <p>Google \u201cSIR anticoagulation guidelines 2019\u201d</p> </li> <li> <p>VUMC IR guidelines based on SIR 2019 guidelines are included at end     of section</p> </li> </ul> <p>Inpatient biopsies for malignancy: Inpatient biopsies are lowest priority on the CT/US procedures service given resource availability and will more than likely get bumped. We recommend that these get scheduled outpatient.</p> <ul> <li>Place an outpatient consult to image guided procedures at time of     discharge/through discharge tab in EPIC to facilitate outpatient     biopsies.</li> </ul> <p>Drain Management</p> <ul> <li>Best to discuss directly with service that placed the drain (IR vs.     CT/US vs. surgery)</li> </ul> <ul> <li>Flush with 10 mL sterile saline q shift while inpatient (flush into     drain towards the patient and then place back to gravity or     accordion suction bag)</li> </ul> <ul> <li>If drain output decreases, either:</li> </ul> <ul> <li> <p>The collection (e.g., abscess) has been drained</p> </li> <li> <p>The drain is clogged/malfunctioning/mispositioned</p> <ul> <li> <p>Start with making sure there are no kinks in the drain, the 3     way is not clogged, and that the accordion drain is functioning.</p> </li> <li> <p>Next, ensure the drain flushes appropriately. What this means     is: you can flush the drain with 10 ml of saline and when you     place back to gravity/accordion drainage bag you get back what     you flushed in. There should be no leakage around the drain at     the skin at baseline or during flushing.</p> </li> <li> <p>If the drain is functioning, and there is still no output,     obtain a CT w/ IV contrast to evaluate the collection and     ongoing need for drainage,</p> </li> <li> <p>If the collection remains, and drain is appropriately positioned     within the drain, it is likely clogged/malfunctioning. First     ensure proper suction/3-way direction. If this is not the issue,     you can consider instilling tPA into the catheter for 2 hours</p> <ul> <li> <p>Would avoid in the setting of therapeutic anticoagulation     given increased risk of bleeding unless discussed with     procedural service).</p> </li> <li> <p>Epic order: Alteplase (TPA) injection/infusion options     Percutaneous drainage 2mg or 4mg</p> </li> </ul> </li> <li> <p>If this doesn't improve output in 48 hours, consider     repositioning drain (VIR consult)</p> </li> </ul> </li> </ul>"},{"location":"radiology/radiology-consults-radiology-procedures/#anticoagulation-for-ir-procedures","title":"Anticoagulation for IR Procedures","text":"<p>Based on 2019 SIR Consensus Guidelines. JVIR 2019; 1168-1184. The length of time anticoagulation is held may differ from these guidelines in certain clinical circumstances at the discretion of the proceduralist. Generally, may resume anticoagulation 24 hours after the procedure.</p> <p>Low Risk Procedures</p> <ul> <li>Screening coagulation laboratory tests</li> </ul> <ul> <li>PT/INR, platelet count, Hgb not routinely needed</li> </ul> <ul> <li>Suggested laboratory thresholds for most patients</li> </ul> <ul> <li> <p>INR: correct to \\&lt;3.0</p> </li> <li> <p>Platelets: transfuse if \\&lt;20,000</p> </li> </ul> <ul> <li>Suggested laboratory thresholds in patients with chronic liver     disease</li> </ul> <ul> <li> <p>INR: n/a</p> </li> <li> <p>Platelets: transfuse if \\&lt;20,000</p> </li> <li> <p>Fibrinogen: cryoprecipitate if \\&lt;100</p> </li> </ul> List of Low-Risk Procedures Medication Action <p>Vascular</p> <p>- Central venous catheter non-tunneled/tunneled line placement, removal and exchanges (e.g. port)</p> <p>- Dialysis assess interventions (e.g. shuntograms)</p> <p>- Gonadal vein embolization</p> <p>- IVC filter placement and retrieval</p> <p>- Laser ablation and phlebectomy</p> <p>- Lymphangiogram</p> <p>- Sclerotherapy for venous malformation</p> <p>- Transjugular liver biopsy</p> <p>- Venography and select venous interventions (e.g. adrenal vein sampling)</p> <p>Nonvascular</p> <p>- Superficial abscess drainage</p> <p>- Catheter exchanges (e.g. biliary, nephrostomy, abscess)</p> <p>- FNA/superficial biopsy</p> <p>- Gastrostomy and GJ exchanges</p> <p>- Appendicular skeleton bone biopsy, joint injections, peripheral nerve blocks</p> <p>- Thoracentesis</p> <p>- Paracentesis</p> <p>- Tunneled drainage catheter placement</p> Anticoagulants Warfarin (Coumadin) Target INR &lt;3.0. Withhold 5 days for MSK procedures only. Bridging per PCP/cardiology Heparin (unfractionated) Do not withhold LMWH (therapeutic) Do not withhold LMWH (prophylactic) Do not withhold Rivaroxaban (Xarelto) Do not withhold Edoxaban (Savaysa) Do not withhold Fundaparinux (Arixtra) Do not withhold Apixaban (Eliquis) Do not withhold Argatroban Do not withhold Bivalirudin (Angiomax) Do not withhold Dabigatran (Pradaxa) Do not withhold Antiplatelets Aspirin (81 or 325 mg) Do not withhold Clopidogrel (Plavix) Do not withhold Prasugrel (Effient) Do not withhold Ticagrelor (Brilinta) Do not withhold Cangrelor (Kengreal) Do not withhold NSAIDs <p>Short-acting</p> <p>- Ibuprofen</p> <p>- Diclofenac</p> <p>- Ketoprofen</p> <p>- Indomethacin</p> Do not withhold <p>Intermediate-acting</p> <p>- Ibuprofen</p> <p>- Diclofenac</p> <p>- Ketoprofen</p> <p>- Indomethacin</p> Do not withhold <p>Long-acting</p> <p>-Meloxicam</p> Do not withhold Glycoprotein IIb/IIIa Inhibitors <p>Long-acting</p> <p>- Abciximab (ReoPro)</p> Withhold 24 hours <p>Short-acting</p> <p>- Eptifibatide (Integrilin)</p> <p>- Tirofiban (Aggrastat)</p> Withhold 4 hours <p>High Risk Procedures</p> <ul> <li>Screening coagulation laboratory tests</li> </ul> <ul> <li>PT/INR, platelet count, Hgb</li> </ul> <ul> <li>Suggested laboratory thresholds for most patients</li> </ul> <ul> <li> <p>INR: correct to \\&lt;1.8 (\\&lt;1.5 if neuro procedure)</p> </li> <li> <p>Platelets: transfuse if \\&lt;50,000</p> </li> </ul> <ul> <li>Suggested laboratory thresholds in patients with chronic liver     disease</li> </ul> <ul> <li> <p>INR: \\&lt;2.5. (\\&lt;1.5 if neuro procedure)</p> </li> <li> <p>Platelets: transfuse if \\&lt;30,000</p> </li> <li> <p>Fibrinogen: cryoprecipitate if \\&lt;100</p> </li> </ul> List of High-Risk Procedures Medication Action <p>Vascular</p> <p>- Angiography and arterial interventions (e.g. chemoembolization, renal embolization, uterine embolization)</p> <p>- BRTO/BATO</p> <p>- Catheter directed thrombolysis (e.g. DVT, PE, portal vein)</p> <p>- Complex IVC filter removal</p> <p>- Lymphangiogram with thoracic duct embolization</p> <p>- Portal vein interventions</p> <p>- Pulmonary artery malformation embolization</p> <p>- Transjugular intrahepatic portosystemic shunt (TIPS)</p> <p>Nonvascular</p> <p>- Ablations (e.g. cryoablation, microwave ablation, radiofrequency ablation)</p> <p>- Deep abscess drainage</p> <p>- Biliary interventions (new placement e.g. cholecystostomy)</p> <p>- Deep non-organ biopsy (e.g. retroperitoneal, pelvic, intra-abdominal)</p> <p>- New Gastrostomy and GJ tube placement</p> <p>- Axial skeleton biopsy, bone marrow biopsy</p> <p>- Neuro: epidural injection, facet block, LP, myelogram, vertebral biopsy</p> <p>- Solid organ biopsy (e.g. liver, kidney, lung)</p> <p>- Spine procedures</p> <p>- Urinary tract interventions (nephrostomy tube placement, ureteral dilation)</p> Anticoagulants Warfarin (Coumadin) Withhold 5 days, goal INR &lt;1.8. Bridging per PCP/cardiology Heparin (unfractionated) <p>Withhold IV for 4 hours</p> <p>Withhold SQ for 6 hours</p> LMWH (therapeutic) Withhold for 24 hours LMWH (prophylactic) Withhold for 12 hours Rivaroxaban (Xarelto) <p>Withhold:</p> <p>2 days (CrCl&gt;30)</p> <p>3 days (CrCl&lt;30)</p> Edoxaban (Savaysa) Withhold 2 days Fundaparinux (Arixtra) <p>Withhold:</p> <p>2 days (CrCl&gt;50)</p> <p>3 days (CrCl&lt;50)</p> Apixaban (Eliquis) <p>Withhold:</p> <p>2 days (CrCl&gt;50)</p> <p>3 days (CrCl&lt;50)</p> Argatroban Withhold for 2 hours Bivalirudin (Angiomax) Withhold for 2 hours Dabigatran (Pradaxa) <p>Withhold:</p> <p>2 days (CrCl&gt;50)</p> <p>3 days (CrCl&lt;50)</p> Antiplatelets Aspirin (81 or 325 mg) <p>81mg: Do not withhold</p> <p>325mg: Withhold 5 days unless angiography or neuro procedure</p> Clopidogrel (Plavix) Withhold 5 days unless angiography/embolization Prasugrel (Effient) Withhold 7 days Ticagrelor (Brilinta) Withhold 5 days Cangrelor (Kengreal) Avoid; if emergent withhold 1 hour NSAIDs <p>Short-acting</p> <p>- Ibuprofen</p> <p>- Diclofenac</p> <p>- Ketoprofen</p> <p>- Indomethacin</p> No recommendation <p>Intermediate-acting</p> <p>- Ibuprofen</p> <p>- Diclofenac</p> <p>- Ketoprofen</p> <p>- Indomethacin</p> No recommendation <p>Long-acting</p> <p>-Meloxicam</p> No recommendation Glycoprotein IIb/IIIa Inhibitors <p>Long-acting</p> <p>- Abciximab (ReoPro)</p> Withhold 24 hours <p>Short-acting</p> <p>- Eptifibatide (Integrilin)</p> <p>- Tirofiban (Aggrastat)</p> Withhold 4 hours"},{"location":"radiology/radiology-consults-radiology-procedures/#contrast-allergies-or-extravasation","title":"Contrast Allergies or Extravasation","text":"<p>See ACR contrast manual for additional Information:</p> <p>https://www.acr.org/Clinical-Resources/Contrast-Manual</p> <p></p> <p>From the ACR contrast manual</p>"},{"location":"radiology/radiology-cxr/","title":"Basic Chest X-ray Interpretation","text":"<p>Gautam Babu</p> <p>An X-ray is a density-gram where \u201cwhite\u201d is \u201cdense\u201d and \u201cblack\u201d is \u201cnot dense.\u201d Determine a systematic method you use every time you interpret a CXR to ensure you don\u2019t miss anything</p> <ul> <li>Start every CXR you interpret by assessing the quality of the film:</li> <li>Penetration:<ul> <li>Should see vertebral bodies through the cardiac silhouette but     not into the abdomen</li> <li>If you cannot see them through the heart, the film is     \u201cunder-penetrated,\u201d and everything will appear more \u201cwhite.\u201d</li> <li>If you can see them through the abdomen the film is     \u201cover-penetrated\u201d and everything will appear more \u201cblack.\u201d</li> </ul> </li> <li>Rotation: Spinous processes should be in the middle of the     clavicular heads</li> <li>Two Different Systematic Methods:</li> <li> <p>ABCDE method</p> <ul> <li>Airway \u2013 Trachea midline and patent</li> <li>Bones \u2013 Bone density and obvious fractures</li> <li>Cardiac Silhouette \u2013 Should see L &amp; R heart border, if not there     may be an adjacent opacity (Right Middle Lobe, Lingula)<ul> <li>Cardiomegaly = heart size \u2265 \u00bd the width of the hemithorax     on a PA film</li> </ul> </li> <li>Diaphragm \u2013 Look for pleural effusions at the costo-phrenic     angle. If you cannot see the diaphragm along the way, there may     be an adjacent opacity (Lower Lobe)</li> <li>\u201cEverything else\u201d \u2013 Refers to the lung fields<ul> <li>Extra-Thoracic Soft Tissue \u2013 Subcutaneous emphysema</li> <li>Fields and Fissures \u2013lung fields should appear symmetric and     \u201cblack\u201d</li> <li>Great Vessels \u2013 Tortuosity of the aorta and the outlines of     the pulmonary vessels</li> <li>Hilum \u2013 Hilar masses, LAD and pulmonary arteries</li> </ul> </li> </ul> </li> <li> <p>Working around the film method:</p> <ul> <li>Imagine the entire CXR film as a square and an inner \u201cbox\u201d as     the pleural lining</li> <li>Outside the box: Lines/tubes, subq emphysema, gastric bubble,     subdiaphragmatic air</li> <li>Edge of the box: Look for pleural thickening, pleural effusion,     pneumothorax, visualization of the diaphragm</li> <li>Middle of the box: Trachea, vascular pedicle, hila, heart     borders, great vessels, retrocardiac space</li> <li>The lung fields</li> </ul> </li> </ul> <p>Silhouette sign</p> <ul> <li>Two things of different densities will show a clear     border on a chest x-ray</li> <li>Loss of a border you expect to see suggests a change in density of     one of the structures.</li> <li>Ex: heart &amp;l lung have different densities with sharp border. Loss     of this border suggests that the lung \u201cincreased\u201d in density<ul> <li>Ex: Pneumonia (fluffy opacities, air bronchograms, asymmetric)     and pulmonary edema (linear opacities, fluid in fissures, Kerley     B lines, cephalization)</li> </ul> </li> </ul> <p></p> CXR example <ul> <li>1,2-10: first rib, posterior aspect of ribs 2 to 10</li> <li>AK: aortic knob</li> <li>APW: aortopulmonary window</li> <li>BS: breast shadow</li> <li>C, T: carina, tracheal air column</li> <li>CA, GA: colonic air, gastric air</li> <li>CPA: costophrenic angle</li> <li>DA: descending aorta</li> <li>LHB: left heart border (most of which represents the left ventricle,     the superior aspect represents the left atrial appendage)</li> <li>LPA: left pulmonary artery</li> <li>RC: right clavicle</li> <li>RHB: right heart border (represents the right atrium)</li> <li>PHB: posterior heart border</li> <li>RHD, LHD: right hemidiaphragm, left hemidiaphragm</li> <li>RPA: right pulmonary artery</li> <li>S: scapula</li> <li>RA: retrosternal space</li> <li>RMF: right lung fissure (left major and minor fissures are not     always visualized)</li> </ul> <p>Chapter 15. Imaging Studies. Gomella L.G., &amp; Haist S.A. (Eds.), (2007). Clinician's Pocket Reference: The Scut Monkey, 11e. McGraw Hill. https://accessmedicine.mhmedical.com/content.aspx?bookid=365&amp;sectionid=43074924</p>"},{"location":"radiology/radiology-kub/","title":"Basic Abdominal X-ray Interpretation","text":"<p>Gautam Babu</p> <p>As with chest radiographs, use a systematic approach. Here are some important reminders:</p> <ul> <li>Patient positioning (marked by tech):</li> <li>Supine films poorly evaluate for free air, but are fine for     evaluating bowel gas pattern, tube positioning</li> <li>Upright or left lateral decubitus are more sensitive for free air</li> <li>NGT films<ul> <li>Film will not include the lower abdomen so cannot fully evaluate     bowel gas pattern. If you don't see your NGT, confirm that the tube     is not coiled in the oropharynx, esophagus or airway (check CXR if     necessary).</li> <li>Post pyloric placement should be to the right of the midline with     the tube resembling the \u201cC-loop\u201d of the duodenum.</li> </ul> </li> <li>Bowel caliber \u2013 small bowel distension more than 3cm caliber may be     abnormal, is there distal gas? Recent operative intervention?     Differential: ileus vs SBO</li> <li>Colon \u2013 identify by haustration. Cecum and rectum can be distended     up to 9cm. Remainder of colon should be under 6cm. Stool burden?     Twist/volvulus?</li> <li>Gas (where it shouldn't be) \u2013 look for lucency against straight     lines (diaphragm, liver, falciform).<ul> <li>Large volume air can also outline bowel wall against intraluminal     air</li> <li>Bowel wall shouldn't have gas (pneumatosis)</li> <li>Liver gas can be pneumobilia (prior ERCP/stent) or portal venous gas     (from ischemic bowel)</li> </ul> </li> <li>Bladder \u2013 foley projecting in right location?</li> <li>Soft tissues \u2013 may faintly see kidney margins, psoas. No big/obvious     soft tissue mass?</li> <li>Bones \u2013 rib fractures, spine compression deformities, pelvic/hip     fractures</li> </ul> <p></p> <p>KUB example</p>"},{"location":"radiology/radiology-radiology-exams-diagnosis/","title":"Common Radiology Exams by Suspected Diagnosis","text":"<p>Ryan Adams, Leah Brown</p> Musculoskeletal Fracture X-rays, CT (extremity) without contrast Soft tissue infection <p>CT (extremity) with contrast</p> <p>MRI (extremity) with and without contrast</p> Osteomyelitis <p>X-ray (extremity)</p> <p>MRI (extremity) with and without contrast</p> Bone or soft tissue tumors MRI (extremity) with and without contrast DVT Ultrasound doppler (extremity) venous (laterality) Chest Pulmonary embolism CT angiogram chest pulmonary embolism with contrast Lung mass, metastases CT chest with contrast Pulmonary nodule CT chest without contrast Pneumothorax X-ray chest portable (or 2 view), SPECIFY UPRIGHT Abdomen/Pelvic Cholecystitis Ultrasound abdomen limited (specify cholecystitis) Pancreatitis CT abdomen pelvis with contrast Appendicitis CT abdomen pelvis with contrast Bowel obstruction X-ray abdomen 1 view, CT abdomen pelvis with contrast HCC <p>CT abdomen with contrast, specify HCC in comments</p> <p>MRI abdomen with contrast, specify HCC in comments</p> Mesenteric ischemia/AAA CT angiogram abdomen and pelvis Crohn\u2019s/IBD CT abdomen pelvis enterography with contrast Neurologic Brain mass/metastases MRI brain with and without IV contrast Stroke MRI brain without contrast Multiple sclerosis MRI brain with and without contrast Aneurysm or vascular injury CT angiogram head and neck with and without contrast Dural venous sinus thrombosis CT venogram head Intracranial hemorrhage CT head without contrast Spine trauma CT (c/t/l) spine without contrast, MRI spine wo contrast Spine tumor, infection, post-op MRI (C/T/L) spine with and without contrast Urogenital Ovarian/testicular torsion <p>Ultrasound scrotal with complete doppler</p> <p>Ultrasound pelvic transvaginal</p> Ectopic pregnancy Ultrasound transvaginal and pelvic Kidney stones <p>Ultrasound renal</p> <p>CT abdomen pelvis without contrast</p> Pyelonephritis <p>Ultrasound renal</p> <p>CT abdomen pelvis with contrast</p> <p>See ACR appropriateness criteria for additional Information. (https://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria)</p>"},{"location":"rheumatology/rheumatology-antiphospholipid/","title":"Anti-Phospholipid Syndrome","text":"<p>Gautam Babu</p>"},{"location":"rheumatology/rheumatology-antiphospholipid/#background","title":"Background","text":"<ul> <li> <p>Antiphospholipid antibodies (aPLs) =\u00a0a heterogenous group of     autoantibodies which\u00a0interact with endothelial cells\u00a0through binding     of \u03b22GPI receptor</p> </li> <li> <p>APLs induce a procoagulant and proinflammatory endothelial\u00a0phenotype     arterial, venous, small vessel thromboembolic events, or pregnancy     losses</p> </li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#presentation","title":"Presentation","text":"<ul> <li> <p>Unexplained/recurrent venous, arterial, and/or small vessel     thromboembolic events</p> </li> <li> <p>Venous: DVT most common</p> </li> <li> <p>Arterial: cerebral, renal, mesenteric, coronary, PE</p> </li> <li> <p>Pregnancy morbidity: recurrent, unexplained spontaneous abortions,     fetal loss, preterm birth due to preeclampsia, placental     insufficiency</p> </li> <li> <p>Other features: nonbacterial vegetations (Libman-Sachs     endocarditis), thrombocytopenia, livedo reticularis</p> </li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#evaluation","title":"Evaluation","text":"<ul> <li>Revised Sapporo classification criteria: At least one of the     clinical criteria and one of the laboratory criteria are met:</li> </ul> <ul> <li> <p>Vascular thrombosis (arterial, small vessel, or venous)</p> </li> <li> <p>Pregnancy morbidity</p> </li> <li> <p>Antiphospholipid lab testing: must be present on two or more     occasions at least 12 weeks apart (NOT TESTED INPATIENT) Lupus     anticoagulant, anticardiolipin antibody (IgG or IgM, medium or high     titer) anti-beta-2 glycoprotein-I antibody (IgG or IgM)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#management","title":"Management","text":"<ul> <li> <p>Mainstay is anticoagulation for treatment and secondary prevention</p> </li> <li> <p>Acute thromboembolism: Heparin gtt with bridge to warfarin</p> </li> <li> <p>Secondary thrombosis prevention, anticoagulation with warfarin is     preferred</p> </li> </ul> <ul> <li> <p>Studies suggest that DOACs are less effective than warfarin</p> </li> <li> <p>Goal INR 2-3 regardless of whether arterial or venous     thromboembolism present</p> </li> </ul> <ul> <li>ASA 81 mg + warfarin for pts w/arterial events and risks for ASCVD</li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#catastrophic-anti-phospholipid-syndrome-caps","title":"Catastrophic Anti-phospholipid Syndrome (CAPS)","text":"<p>Gautam Babu</p>"},{"location":"rheumatology/rheumatology-antiphospholipid/#background_1","title":"Background","text":"<ul> <li>Rapid development of thromboses in multiple small blood vessels in     various organs resulting in multi-organ failure. Occurs in a small     subset of patients with APS</li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#presentation_1","title":"Presentation","text":"<ul> <li> <p>Similar presentation to APS, but multiple organs are involved in a     short period of time</p> </li> <li> <p>Renal (hypertension, proteinuria, hematuria, acute renal failure),     Pulmonary (ARDS, PE), Central Nervous System (encephalopathy,     stroke, cerebral venous thrombosis), Cardiac (coronary thrombosis),     and Cutaneous (livedo reticularis, acrocyanosis, purpura,     ecchymosis, splinter hemorrhages, and necrosis resulting in     ulceration)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>Exclude other causes of small vessel occlusion: HIT, DIC or TMA</p> </li> <li> <p>Definite dx= all 4 criteria met, probable dx=combination of criteria     present</p> </li> </ul> <ul> <li> <p>Evidence of involvement of three or more organs, systems, and/or       tissues</p> </li> <li> <p>Development of manifestations simultaneously or in less than a week</p> </li> <li> <p>Confirmation by histopathology of small vessel occlusion in at least       one organ or tissue</p> </li> <li> <p>Laboratory confirmation of the presence of antiphospholipid       antibodies</p> </li> </ul>"},{"location":"rheumatology/rheumatology-antiphospholipid/#management_1","title":"Management","text":"<ul> <li> <p>Anticoagulation: Heparin acutely. Warfarin once stable &amp; no bleeding     or recurrent thromboses</p> </li> <li> <p>Pulse steroids with methylprednisolone x 3 days followed by     prednisone</p> </li> <li> <p>Severe cases may require PLEX/IVIG. Refractory CAPS may require     rituximab or eculizumab</p> </li> </ul>"},{"location":"rheumatology/rheumatology-arthrocentesis-quick-look/","title":"Arthrocentesis Quick Look","text":"<p>Raeann Whitney</p>"},{"location":"rheumatology/rheumatology-arthrocentesis-quick-look/#when-in-doubt-tap-it","title":"When in doubt, tap it!","text":"<ul> <li> <p>Send synovial fluid for Gram stain/culture and cell count</p> </li> <li> <p>Beware: Inflammatory / crystal arthropathies can have very high     leukocyte counts!</p> <ul> <li>The presence of crystals does NOT exclude septic arthritis</li> </ul> </li> <li> <p>A fever or concern for infection in a prosthetic joint is a surgical     emergency; ortho will come in the middle of the night to tap a joint</p> </li> <li> <p>Contraindications to tap: overlying cellulitis or psoriatic plaque</p> <ul> <li>Anticoagulation / DVT ppx is OK (no need to hold)</li> </ul> </li> </ul> \u200bArthritis Type Appearance\u00a0\u200b Total WBC\u00a0\u200b PMNs\u00a0\u200b Non-inflammatory\u00a0\u200b Straw like / yellow\u00a0\u200b \\&lt;2000\u200b \\&lt;25%\u200b Inflammatory /\u00a0Crystalopathies\u00a0\u200b Yellow / cloudy\u00a0\u200b &gt;2000\u200b (often 20-50K+) &gt;50%\u200b Septic\u00a0\u200b Purulent\u00a0\u200b &gt;50,000\u200b (often &gt;100K) &gt;75%\u200b"},{"location":"rheumatology/rheumatology-arthrocentesis-quick-look/#crystals","title":"Crystals","text":"<ul> <li> <p>Monosodium urate: needle-shaped, negatively birefringent</p> <ul> <li>Sensitivity is generally good (&gt;90s%)</li> </ul> </li> <li> <p>Calcium pyrophosphate dihydrate: rhomboid-shaped, positively     birefringent (weakly)</p> <ul> <li>Weak birefringence significantly reduced sensitivity</li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-biologic-overview/","title":"Biologic Overview","text":"<p>Hannah Lomzenski</p>"},{"location":"rheumatology/rheumatology-biologic-overview/#background","title":"Background","text":"<ul> <li> <p>\"-cept\" refers to fusion of a receptor to the Fc part of human     immunoglobulin G1 (IgG1)</p> </li> <li> <p>\"-mab\" indicates a monoclonal antibody (mAb)</p> </li> <li> <p>\"-ximab\" indicates a chimeric mAb</p> </li> <li> <p>\"-zumab\" indicates a humanized mAb</p> </li> <li> <p>\"-umab\" indicates a fully human mAb</p> </li> <li> <p>\u201c-tinib\u201d indicates a tyrosine kinase inhibitor (small molecule     inhibitors, not true biologics)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-biologic-overview/#selected-biologics","title":"Selected biologics","text":""},{"location":"rheumatology/rheumatology-biologic-overview/#kinase-inhibition","title":"Kinase inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Tofacitinib</p> <p>(Xeljanz)</p> JAK-1 and JAK-3 inhibitor RA, UC, JIA, psoriatic arthritis nasopharyngitis, skin rash, GI sx, GU sx; &lt;1% lymphoma <p>Baracitinib</p> <p>(Olumiant)</p> JAK-1 and JAK-2 inhibitor RA; off-label: COVID-19 URI, nausea, \u21d1AST/ALT; &lt;1% lymphoma <p>Upadacitinib</p> <p>(Rinvoq)</p> non-specific JAK inhibitor RA URI, nausea, neutropenia, \u21d1AST, \u21d1CPK"},{"location":"rheumatology/rheumatology-biologic-overview/#il-1-inhibition","title":"IL-1 inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Anakinra</p> <p>(Kineret)</p> IL-1 receptor antagonist IL-1 receptor antagonist deficiency, gout flares, FMF, HLH HA, vomiting, infections, nasopharyngitis, Ab development; in RA: eosinophilia, decreased WBC <p>Canakinumab</p> <p>(Ilaris)</p> mAb against IL-1\u03b2 Cryoporin-associated periodic syndromes (CAPS), FMF, hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare Weight gain, GI sx, HA, vertigo, serious infections"},{"location":"rheumatology/rheumatology-biologic-overview/#il-17-inhibition","title":"IL-17 inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Secukinumab</p> <p>(Cosentyx)</p> human IgG1 mAb against IL-17A AS, psoriasis nasopharyngitis, GI, IBD (&lt;1%) <p>Ixekizumab</p> <p>(Taltz)</p> human IgG4 mAb against IL-17A AS, psoriasis neutropenia, Ab development, URI, Crohn\u2019s (&lt;1%)"},{"location":"rheumatology/rheumatology-biologic-overview/#il-6-inhibition","title":"IL-6 inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Tocilizumab</p> <p>(Actemra)</p> IL-6 receptor antagonist cytokine release syndrome, giant cell arteritis, RA, JIA \u21d1 serum cholesterol, \u21d1 AST/ALT, infusion rxn, HSV infection (&lt;2%) <p>Sarilumab</p> <p>(Kevzara)</p> IL-6 receptor antagonist (soluble + membrane-bound) RA \u21d1 AST/ALT, HSV infection (&lt;2%)"},{"location":"rheumatology/rheumatology-biologic-overview/#il-1223-inhibition","title":"IL-12/23 inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Ustekinumab</p> <p>(Stelara)</p> mAb against IL-12 + IL-23 IBD, psoriasis nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx <p>Guselkumab</p> <p>(Tremfya)</p> human IgG1 mAb against IL-23 psoriasis URI, tinea, GI sx"},{"location":"rheumatology/rheumatology-biologic-overview/#costimulation-blockade","title":"Costimulation blockade","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Abatacep</p> <p>(Orencia)</p> inhibits T-cell activation by binding CD80 and CD86 on APCs, thus blocking the required CD28 ixn between APCs and T cells. RA, psoriasis, JIA nausea, UTI, HA, URI, Ab development"},{"location":"rheumatology/rheumatology-biologic-overview/#b-cell-depletion-and-inhibition","title":"B-cell depletion and inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Rituximab</p> <p>(Rituxan)</p> mAb against the CD20 antigen on surface of B-lymphocytes CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG, neuromyelitis optica) HTN, peripheral edema, night sweats, fever, weight gain, angioedema, arthralgias, \u21d1 ALT, hypophosphatemia, hematologic abnormalities <p>Belimumab</p> <p>(Benlysta)</p> IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes lupus nephritis, SLE GI symptoms, hypersensitivity reaction, infections, psychiatric disturbances"},{"location":"rheumatology/rheumatology-biologic-overview/#tnf-inhibition","title":"TNF-inhibition","text":"<p>Generic Name</p> <p>(Brand Name)</p> Mechanism of Action Common Uses Common Side Effects <p>Adalilumab</p> <p>(Humira)</p> mAb against TNF\u03b1 RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa skin rash, HA, URI, \u21d1 CPK, +ANA titer (12%), Ab development (3-26%) <p>Certolizumab</p> <p>(Cimzia)</p> humanized mAb Fab fragment against TNF\u03b1 RA, Crohn\u2019s, AS, psoriasis; \\*approved for use during pregnancy skin rash, nausea, URI <p>Etanercept</p> <p>(Enbrel)</p> tumor necrosis factor receptor linked to Fc portion of IgG1; binds TNF RA, AS, psoriasis, JIA <p>skin rash, diarrhea,</p> <p>+ANA titer (11%)</p> <p>Infliximab</p> <p>(Remicade)</p> chimeric mAb against TNF\u03b1 RA, IBD, AS, psoriasis abd pain, URI sx, anemia, \u21d1 ALT, Ab development (10-50%) <p>Golimumab</p> <p>(Simponi)</p> mAb against TNF\u03b1 RA, UC, AS, psoriasis, JIA URI, Ab development (16-38%), +ANA titer (4-17%)"},{"location":"rheumatology/rheumatology-crystal-arthropathy/","title":"Crystalline Arthropathies","text":"<p>Thomas Horton</p>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#gout","title":"Gout","text":""},{"location":"rheumatology/rheumatology-crystal-arthropathy/#presentation","title":"Presentation","text":"<ul> <li> <p>Red, hot, swollen joint (classically affects 1st metatarsal     phalangeal joint [podagra])</p> </li> <li> <p>May progress to involve ankles, knees, elbows, and small joints of     hand if untreated</p> <ul> <li>Flares may also become polyarticular over time</li> </ul> </li> <li> <p>Gout is diagnosed with combination of clinical presentation and     arthrocentesis results</p> </li> <li> <p>Lifestyle factors:</p> <ul> <li> <p>Protective: Low fat dairy, hydration, weight loss, smoking cessation</p> </li> <li> <p>Promoting: Meat, seafood, alcohol, high fructose corn syrup,     medications that lead to hyperuricemia (ex: thiazides)</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Synovial Fluid Analysis:\u00a0</p> <ul> <li> <p>Cell count and differential: WBC 20,000-100,000, &gt; 50% neutrophils</p> </li> <li> <p>Order gram stain/culture (It is possible to have septic arthritis     and gout)</p> </li> <li> <p>Examination for crystals under polarizing light microscopy: (order     \u201cSynovial Fluid Eval\u201d so the lab knows to look for crystals)</p> <ul> <li>Monosodium urate crystals: needle-shaped and negatively     birefringent and appear yellow when parallel to the polarizer</li> </ul> </li> </ul> </li> <li> <p>Imaging: generally unnecessary</p> <ul> <li> <p>MSK ultrasound: \"Double contour sign\" (hyperechoic band = urate     crystals deposits)</p> </li> <li> <p>Radiographs: Punched out erosions or lytic areas with overhanging     edges</p> </li> <li> <p>Dual energy CT scan: gout crystal aggregates appear green. Not     routinely necessary; Do not order without rheumatology consult</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#management","title":"Management","text":"<p>Acute:</p> <ul> <li> <p>Do not discontinue allopurinol during an acute gout attack</p> </li> <li> <p>NSAIDs (if not contraindicated): Short course (2-5 days) at full     anti-inflammatory dose: ibuprofen 800 mg TID, indomethacin 50 mg     TID, naproxen 500 mg BID</p> </li> <li> <p>Colchicine (avoid if GFR \\&lt;10 mL/min. Dose reduce by 50% if GFR \\&lt;50     mL/min)</p> <ul> <li> <p>Best if used within the first 36 hours of\u00a0an attack. Much less     effective if started later.</p> </li> <li> <p>Dosing: 1.2 mg then 0.6 mg one hour later, then 0.6 mg daily until     clinical improvement</p> <ul> <li>Note drug interactions that may require dose adjustment of     colchicine: Statins, diltiazem, fluconazole, cyclosporine,     tacrolimus, clarithromycin, etc.</li> </ul> </li> </ul> </li> <li> <p>Steroids:</p> <ul> <li> <p>Ideally intra-articular if single joint affected and infection has     been ruled out</p> </li> <li> <p>Oral prednisone, dose 0.5mg/kg/day until clinical improvement then     taper over 7-14 days</p> </li> </ul> </li> <li> <p>Anakinra (IL-1 receptor antagonist): 100mg once daily for three days     (or QOD for CrCl \\&lt;30). Requires rheumatology consult. For patients     with contraindications to all other treatments</p> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#chronic","title":"Chronic:","text":"<ul> <li> <p>Urate Lowering Therapy (ULT)</p> <ul> <li> <p>Indications: Strong: &gt;2 attacks/year, one or more subcutaneous     tophi, radiologic changes. Conditional: CKD 3 or worse,     urolithiasis, serum urate &gt;9</p> </li> <li> <p>Goal serum urate: \\&lt;6.0 mg/dL, or \\&lt;5.0 mg/dL in patients with tophi</p> </li> <li> <p>ULT can precipitate an acute gout flare and should always be started     with low-dose NSAIDs, colchicine (0.6 mg) or prednisone (5 mg daily     or QOD)</p> <ul> <li>Prophylaxis should be continued for at least 6 months until uric     acid is at goal and tophi have resolved</li> </ul> </li> <li> <p>Allopurinol (xanthine oxidase inhibitor): Start low at 100 mg per     day (sometimes even 50mg daily in those with advanced CKD) and     increase as needed for target uric acid \\&lt;6 (most patients will need     400-800 mg daily)</p> <ul> <li> <p>Adjust dose monthly (3-4 weeks). In kidney dysfunction go     slower.</p> </li> <li> <p>Titration of allopurinol \u2193 both the risk of acute gout attacks     and DRESS syndrome</p> </li> <li> <p>Genetic testing (HLA-B*5801) recommended prior to starting for     pts of Asian and African descent given \u2191 incidence of     allopurinol hypersensitivity if + positive allele</p> </li> </ul> </li> <li> <p>Febuxostat: alternative xanthine oxidase inhibitor that is     metabolized by the liver for pts at risk for DRESS or SJS related to     allopurinol. Black box warning for \u2191 cardiovascular risk; more     expensive than allopurinol</p> </li> </ul> </li> <li> <p>Consider Rheumatology consult for patients with refractory serum     urate levels &gt;6.0 on XOI</p> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#additional-pearls","title":"Additional pearls","text":"<ul> <li> <p>There is a microscope in the rheumatology clinic at VUMC (TVC 2);     You can page the rheumatology fellow and they are happy to help you     use it</p> </li> <li> <p>Uric acid level is often normal during acute gout flare</p> </li> <li> <p>Shifts in uric acid may be the trigger of the flare: Diuresis,     dietary changes, hospital stays</p> </li> <li> <p>Eliminating uric acid from the diet only reduces uric acid by ~1     mg/dL. Urate lowering therapy will be needed in most patients even     if diet changed</p> </li> <li> <p>VA specific guidance:</p> <ul> <li> <p>Colchicine is non-formulary but is easily approved</p> </li> <li> <p>For steroid intra-articular injections triamcinolone is the     formulary option</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#pseudogout-calcium-pyrophosphate-dihydrate-crystal-deposition-disease-cppd","title":"Pseudogout- Calcium pyrophosphate dihydrate crystal deposition disease (CPPD)","text":""},{"location":"rheumatology/rheumatology-crystal-arthropathy/#presentation_1","title":"Presentation","text":"<ul> <li> <p>Red, hot, swollen joint usually in the wrists, knees, or MCP joints</p> </li> <li> <p>Cannot distinguish from gout based on clinical features alone. Like     gout, diagnosis is based on exam and arthrocentesis</p> </li> <li> <p>More prevalent in the elderly populations</p> </li> </ul> <p>Evaluation</p> <ul> <li> <p>Synovial Fluid:</p> <ul> <li> <p>Cell count and differential: WBC 20,000 to 100,000, &gt;50%     neutrophils</p> </li> <li> <p>Order gram stain/culture (It is possible to have septic arthritis     and CPPD)</p> </li> <li> <p>Examination for crystals under polarizing light microscopy</p> <ul> <li>CPPD crystals: rhomboid-shaped, weakly positively birefringent     and appear blue when parallel to the polarizer</li> </ul> </li> </ul> </li> <li> <p>Imaging:\u00a0</p> <ul> <li>XR: chondrocalcinosis (thin calcified line present in     fibrocartilage) in the joint space (easiest to see in knee and     wrists)</li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#management_1","title":"Management","text":"<ul> <li> <p>Typically follows the same treatment used for acute gout attacks     (see above, little evidence)</p> </li> <li> <p>Some patients may develop Chronic CPP Crystal Inflammatory     Arthritis.</p> <ul> <li> <p>Resembles RA in presentation</p> </li> <li> <p>Treatment base on symptoms and ranges from NSAIDs (1st line) to Colchicine, HCQ, and steroids. Can also use anakinra in acute cases, with consult to rheumatology</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-crystal-arthropathy/#additional-information","title":"Additional Information","text":"<ul> <li> <p>CPPD can be associated with other disorders: hyperparathyroidism,     hemochromatosis, hypomagnesemia, hypophosphatemia, and familial     hypocalciuric hypercalcemia</p> <ul> <li>Consider further workup for these conditions, especially in a   younger patient.</li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-inflammatory-myopathies/","title":"Inflammatory Myopathies","text":"<p>Greg Jackson</p>"},{"location":"rheumatology/rheumatology-inflammatory-myopathies/#background","title":"Background","text":"<ul> <li> <p>Inflammation and damage of skeletal muscle primarily leading to     weakness</p> </li> <li> <p>Subtypes: Dermatomyositis, polymyositis, antisynthetase antibody     syndrome associated myositis, immune-mediated necrotizing myositis,     inclusion body myositis</p> </li> <li> <p>Additional myopathies: statin-induced myopathy, metabolic     (hypothyroid, electrolyte), viral/infection myositis, diabetic     myonecrosis</p> </li> <li> <p>Important point: PMR= painful, preserved strength vs inflammatory     myopathy = painless weakness</p> </li> <li> <p>Hypomyopathic (or amyopathic) variants: skin and/or lungs are     affected &gt;&gt; muscles</p> </li> </ul>"},{"location":"rheumatology/rheumatology-inflammatory-myopathies/#presentation","title":"Presentation","text":"<ul> <li> <p>Proximal, symmetric muscle weakness in upper and lower extremities     in all but inclusion body myositis which is typically more distal     and asymmetric</p> </li> <li> <p>Dermatomyositis: skin involvement can include heliotrope rash of     upper eyelids, Gottron\u2019s papules (on MCP, PIP), \u201cmechanic\u2019s hands,\u201d     and shawl sign</p> </li> <li> <p>Raynaud\u2019s and arthralgias can also be present</p> </li> </ul>"},{"location":"rheumatology/rheumatology-inflammatory-myopathies/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Labs: BMP, TSH, CK level, anti Jo-1 antibody</p> </li> <li> <p>EMG: findings indicate myopathy</p> </li> <li> <p>MRI extremity/affected muscle group: muscle edema</p> </li> <li> <p>Skin biopsy in dermatomyositis: \u201cinterface dermatitis.\u201d</p> </li> <li> <p>Muscle biopsy (do not do biopsy in same muscle as EMG done)</p> <ul> <li> <p>Polymyositis, inclusion body myositis: T cell mediated muscle injury</p> </li> <li> <p>Dermatomyositis: immune complex/B cell mediated muscle injury</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-inflammatory-myopathies/#management","title":"Management","text":"<ul> <li> <p>Prednisone 1 mg/kg/day for 4-6 weeks with subsequent taper</p> </li> <li> <p>Consult Rheumatology</p> </li> <li> <p>MTX or AZA used if refractory to steroids, may need IVIG, rituximab</p> </li> <li> <p>If statin induced: stop statin or switch to lower intensity</p> </li> <li> <p>If dermatomyositis: evaluate for underlying malignancy</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatoid-arthritis/","title":"Rheumatoid Arthritis","text":"<p>Raeann Whitney</p>"},{"location":"rheumatology/rheumatology-rheumatoid-arthritis/#background","title":"Background","text":"<ul> <li> <p>Inflammation and proliferation of synovial tissue, loss of articular     cartilage, erosion of juxtarticular bone</p> </li> <li> <p>Female predominant (~3:1), mostly child-bearing age at onset</p> </li> <li> <p>Chronic, inflammatory polyarthritis affecting the small joints of     the hands (MCPs, PIPs, classically spares DIPs), wrists, feet,     ankles - typically symmetric</p> </li> <li> <p>Ulnar deviation, swan neck, boutonniere deformities are late     findings of untreated disease</p> </li> <li> <p>Morning stiffness lasting &gt;30 min (often 1 hr+) suggests     inflammatory arthritis (not specific)</p> </li> <li> <p>Extra-articular manifestations include: sicca symptoms, scleritis,     ILD, pulm nodules, serositis, constrictive pericarditis, anemia,     mononeuritis multiplex, rheumatoid nodules, rheumatoid vasculitis.     Increased risk of lymphoma, osteoporosis</p> </li> <li> <p>C1-C2 instability: pts need evaluation with imaging prior to     surgical procedure/intubation</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatoid-arthritis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Clinical diagnosis + positive RF, anti-CCP. Note up to 15-20%     patients have seronegative RA</p> <ul> <li> <p>RF is more sensitive but not specific; can be + in HBV/HCV,     cryoglobulinemia</p> </li> <li> <p>CCP is less sensitive but more specific</p> </li> </ul> </li> <li> <p>CBC, CMP, CRP, ESR, HIV, Hepatitis B and C screening; Quantiferon     Gold (biologics)</p> </li> <li> <p>Obtain hand and foot films to assess for periarticular osteopenia &amp;     typical marginal erosions</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatoid-arthritis/#management","title":"Management","text":"<ul> <li> <p>The majority of joint damage occurs early in the disease so early     treatment paramount</p> </li> <li> <p>DMARDs: typically start with MTX; may require biologics such as TNF     inhibitors</p> <ul> <li> <p>MTX dosed weekly; required daily 1 mg folic acid supplement</p> <ul> <li>Toxicities: oral ulcers, bone marrow suppression, liver     toxicity, pneumonitis, teratogenic (contraception required)</li> </ul> </li> </ul> </li> <li> <p>Symptomatic/Flare treatment (no impact on disease progression):</p> </li> <li> <p>Steroids at low-moderate dosage (e.g., prednisone 15-20mg/day);     NSAIDs (high doses required for anti-inflammatory effects)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/","title":"Rheumatology Lab Testing","text":"<p>Raeann Whitney</p> Lab Test Quick Associations ANA SLE, many others (NOT specific) dsDNA SLE Anti-Smith SLE Anti-SSA / Ro Sjogrens (fetal heart block) Anti-SSB / La Sjogrens Anti-RNP Mixed Connective Tissue Disease Anti-Scl70 Scleroderma (diffuse) Anti-Centromere Scleroderma (limited) Anti-Jo Dermatomyositis Anti-histone Drug-induced lupus RF RA (not specific; also HBV/HCV, cryoglobulinemia, etc.) Anti-CCP RA C3/C4 SLE (hypocomplementemia) ANCA Granulomatosis with polyangiitis, microscopic polyangiitis <p>Serologic testing must be interpreted in the clinical context. ANA, ANCA, and even specific antibodies without typical manifestations of the disease are of unclear clinical significance</p>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#anti-nuclear-antibodies-ana","title":"Anti-nuclear Antibodies (ANA)","text":"<ul> <li> <p>Always send with reflex (if \u2265 1:80, will check for dsDNA, Sm, SSA,     SSB, Scl70, RNP)</p> <ul> <li> <p>At VUMC, 1:80 is considered \u201cpositive\u201d; a higher titer is more     specific for ANA-associated rheumatologic disease</p> <ul> <li>~30% of the general population has a \u201cpositive\u201d ANA at 1:40,     most clinically significant ANAs are at least 1:160</li> </ul> </li> </ul> </li> <li> <p>Common Patterns</p> <ul> <li> <p>Smooth/homogenous \u2013 associated with Anti-dsDNA and Anti-histone     antibodies</p> </li> <li> <p>Speckled \u2013 associated with Anti-RNP, Anti-Smith, Anti-SSA/Ro,     Anti-SSB/La</p> </li> <li> <p>Nucleolar \u2013 associated with Anti-Scl-70</p> </li> </ul> </li> <li> <p>Specific types of ANAs:</p> <ul> <li> <p>Anti-dsDNA: High levels (&gt;150) are usually specific for SLE. Can     correlate with disease activity, a/w renal disease</p> </li> <li> <p>Anti-Smith (Qualitative): Very specific for SLE but not sensitive</p> </li> <li> <p>Anti-SSA/Ro</p> <ul> <li> <p>Classic for Sjogren\u2019s but non-specific; can also be seen in SLE,     MCTD, myositis, etc</p> </li> <li> <p>Maternal positivity for SSA is associated with congenital heart     block in infants</p> </li> </ul> </li> <li> <p>Anti-SSB/La: Similar profile to Anti-SSA/Ro but less common</p> </li> <li> <p>Anti-Scl-70: Specific for systemic sclerosis, most associated with     diffuse cutaneous disease</p> </li> <li> <p>Anti-RNP: Required for MCTD diagnosis, can also be seen in SLE</p> </li> <li> <p>Anti-histone: drug-induced lupus</p> </li> <li> <p>Anti-centromere: limited scleroderma, a/w pulmonary HTN</p> </li> <li> <p>Anti-RNA polymerase III: increased risk of scleroderma renal disease</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#anti-neutrophil-cytoplasmic-antibodies-anca","title":"Anti-neutrophil Cytoplasmic Antibodies (ANCA)","text":"<ul> <li> <p>Qualitative: p-ANCA, c-ANCA, negative, or indeterminate</p> </li> <li> <p>Quantitative titers: anti-proteinase 3 (PR3), anti-myeloperoxidase     (MPO) IgG antibodies</p> </li> <li> <p>See vasculitis section for further details</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#c3-and-c4","title":"C3 and C4","text":"<ul> <li> <p>Hypocomplementemia in active SLE (due to increased consumption)</p> </li> <li> <p>Complement may also be low in diseases that decreases the liver\u2019s     synthetic function</p> </li> <li> <p>\u2193 C3/C4 in other diseases that form immune complexes, activating the     classic complement pathway: mixed cryoglobulinemia, Sjogren\u2019s, MPGN,     and antiphospholipid syndrome</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#c-reactive-protein-crp-and-erythrocyte-sedimentation-rate-esr","title":"C-reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)","text":"<ul> <li> <p>Both tests are non-specific markers of inflammation</p> </li> <li> <p>CRP measures a specific acute phase protein made by the liver</p> <ul> <li> <p>IL-6 dependent (pts anti-IL6 therapy will have falsely decreased     CRP)</p> </li> <li> <p>Typically changes more rapidly than ESR as it is a direct measure of     acute phase reactant</p> </li> </ul> </li> <li> <p>ESR is the rate at which RBCs settle to the bottom of a test tube</p> <ul> <li> <p>Presence of positively charged proteins disrupt the self-repelling     negative charges of RBCs clumping (rouleaux formation) increased     rate of sedimentation</p> <ul> <li>ESR will increase in states with increased antibodies, acute     phase proteins, etc</li> </ul> </li> <li> <p>Falsely low ESR: low fibrinogen states (DIC, HLH), sickle cell,     polycythemia</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#creatinine-kinase-ck","title":"Creatinine Kinase (CK)","text":"<ul> <li> <p>CK can be elevated by vigorous exercise, rhabdomyolysis,     endocrinopathy, cardiac disease, renal disease, malignancy,     medication effect, neuromuscular disease, connective tissue disease</p> </li> <li> <p>Consider inflammatory myopathies if there is elevated CK and     objective proximal muscle weakness</p> </li> <li> <p>Notably, CK is normal in polymyalgia rheumatica</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#extended-myositis-panel","title":"Extended Myositis Panel","text":"<ul> <li> <p>Ordered as \u201cMyositis extended Pnl-ARUP\u201d; includes 19 separate Abs</p> </li> <li> <p>Can be sent when suspecting various forms of myositis such as     dermatomyositis, polymyositis, anti-synthetase syndrome (ex- ILD     work-up)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-rheumatology-lab-testing/#cryoglobulins","title":"Cryoglobulins","text":"<ul> <li> <p>Cryoglobulins are immunoglobulins that spontaneously precipitate at     low temperatures and become soluble again with rewarming</p> </li> <li> <p>Reported as qualitative (positive or negative) and quantitative     (percentage = \u201ccryocrit\u201d)</p> <ul> <li> <p>Cryoglobulin last test is highly prone to collection error; must be     collected in pre-warmed tubes and maintained at body temperature     during collection and delivery to the lab;</p> </li> <li> <p>At VUMC can only be obtained at certain times M-F; lab &amp; nursing     staff can coordinate</p> </li> </ul> </li> <li> <p>Cryoglobulins are classified into three types: Type I, II, and III</p> <ul> <li> <p>Type I Cryoglobulins: Monoclonal immunoglobulins (IgM or IgG)</p> <ul> <li>A/w lymphoproliferative disorders (Waldenstr\u00f6m\u2019s, MM, CLL, B     cell lymphomas)</li> </ul> </li> <li> <p>Types II and III are Mixed Cryoglobulins (they contain polyclonal     components)</p> </li> <li> <p>Essentially all mixed cryoglobulinemias will be RF+ *</p> </li> <li> <p>Commonly associated with HCV (~90%); also CTD</p> </li> <li> <p>Type II: monoclonal Ig with RF activity against polyclonal Igs</p> </li> <li> <p>Type III: polyclonal Ig with RF against polyclonal Igs</p> <p>*RF activity by definition is the reactivity of an IgM component with the Fc portion of an IgG</p> </li> </ul> </li> <li> <p>Cryoglobulinemic vasculitis: small vessel vasculitis, vascular         deposition of cryoprecipitates</p> <ul> <li> <p>Skin most common: palpable purpura, usually in lower extremities     (colder areas), immune-complex mediated leukocytoclastic vasculitis     on biopsy</p> </li> <li> <p>Additional manifestations include: Arthralgias, peripheral motor or     sensory neuropathy, sicca, glomerulonephritis (usually MPGN)</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-sarcoidosis/","title":"Sarcoidosis","text":"<p>Jared Freitas</p>"},{"location":"rheumatology/rheumatology-sarcoidosis/#background","title":"Background","text":"<ul> <li> <p>Multisystem disordered defined by forming noncaseating granulomas in     different tissues</p> </li> <li> <p>Cardiac and neuro manifestations can be isolated</p> </li> </ul>"},{"location":"rheumatology/rheumatology-sarcoidosis/#presentation","title":"Presentation","text":"<ul> <li> <p>Constitutional symptoms: fatigue, night sweats, weight loss, fevers,     arthralgias, myalgias</p> </li> <li> <p>Pulmonary symptoms (most common): dyspnea, cough, and wheezing</p> </li> <li> <p>Extrapulmonary manifestations:</p> <ul> <li> <p>Cutaneous: Highly variable, but present in 25% of patients</p> <ul> <li> <p>Papules, macules, or plaques commonly involving neck, upper     back, extremities</p> </li> <li> <p>Lupus pernio: indurated, violaceous bumps on nose, lips, cheeks,     ears</p> </li> <li> <p>Erythema nodosum</p> </li> </ul> </li> <li> <p>Neuro</p> <ul> <li> <p>Affects 5-10% pts; involving any part of CNS or PNS</p> </li> <li> <p>CN palsies, hypothalamic/pituitary dysfunction, seizures,     myelopathy or radiculopathy, hydrocephalus, aseptic meningitis</p> </li> </ul> </li> <li> <p>Cardiac</p> <ul> <li>Granulomas can affect pericardium, myocardium and endocardium     resulting in valvular disorders, conduction system and     cardiomyopathy</li> </ul> </li> <li> <p>Liver/Spleen</p> <ul> <li>Granulomas in liver and spleen can lead to elevated LFTs,     cirrhosis, anemia, leukopenia and thrombocytopenia (splenic     sequestration)</li> </ul> </li> <li> <p>Ocular</p> <ul> <li>Uveitis, secondary glaucoma, retinal vasculitis,     keratoconjunctivitis</li> </ul> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-sarcoidosis/#work-up","title":"Work Up","text":"<ul> <li> <p>Combination of clinical features, radiographic manifestations,     exclusion of other similarly presenting diseases, and noncaseating     granulomas on pathology</p> <ul> <li> <p>CXR: hilar and mediastinal lymphadenopathy \u00b1 pulmonary infiltrates</p> </li> <li> <p>High-Resolution Chest CT</p> <ul> <li>Lymphadenopathy (bilateral and symmetric), with micro or     macronodules, fibrotic changes (reticular opacities, traction     bronchiectasis, volume loss)</li> </ul> </li> <li> <p>PFTs</p> <ul> <li>May show restrictive disease (decreased TLC &amp; VC) and diffusion     impairment (reduced DLCO). Occasionally obstructive with     endobronchial disease.</li> </ul> </li> <li> <p>Labs: CBC w/ diff, CMP, UA, quant-gold for TB. ACE level is of     limited clinical use</p> </li> <li> <p>Biopsy</p> <ul> <li> <p>Important to rule out mimics. The differential for \u201cnoncaseating     granulomas\u201d is extensive, including lymphoma and fungal     infections.</p> </li> <li> <p>Not required for pts w/ asymptomatic bilateral hilar adenopathy     or Lofgren syndrome (fever, erythema nodosum, arthralgias, and     bilateral hilar LAD)</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-sarcoidosis/#management","title":"Management","text":"<ul> <li> <p>Most pts do not require therapy: monitor symptoms, CXR, PFTs at 3-6     month intervals</p> </li> <li> <p>Indications for treatment: progressive disease or severe disease at     presentation</p> </li> <li> <p>Mainstay of treatment is oral steroids:</p> <ul> <li> <p>Dosing usually 0.3-0.6 mg/kg daily for 4-6 weeks</p> </li> <li> <p>If only symptoms is cough, could consider inhaled glucocorticoids</p> </li> </ul> </li> <li> <p>If unresponsive or unable to tolerate steroids may require     alternative agents (MTX, AZA)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-scleroderma/","title":"Scleroderma (Systemic Sclerosis)","text":"<p>Eva Niklinska and Raeann Whitney</p> <p>Background</p> <ul> <li> <p>Distinguish from localized scleroderma (morphea or linear     scleroderma) = dermal fibrosis w/o internal organ involvement)</p> </li> <li> <p>2 Major Subtypes of Generalized / Systemic Scleroderma (SSc):</p> <ul> <li> <p>Limited Cutaneous (lcSSc): skin thickening limited to the neck,     face, or distal to elbows and knees; spares the truck and proximal     extremities</p> <ul> <li> <p>Limited does not equal mild, limited refers to distribution of     skin involvement</p> </li> <li> <p>Renal crisis is rare</p> </li> <li> <p>Patients with + ACA (anticentromere Ab) are at high risk for     developing PAH</p> </li> <li> <p>Patients with + Anti-Scl-70 Ab are also at high risk for     progressive ILD</p> </li> </ul> </li> <li> <p>Diffuse Cutaneous: skin thickening extends proximal to the     elbows/knees or trunk</p> <ul> <li> <p>Typically more abrupt onset and rapid progression compared to     lcSSc</p> </li> <li> <p>High risk for progressive ILD</p> </li> <li> <p>+ RNA polymerase III Ab = high risk of renal crisis, higher     risk for malignancy</p> </li> </ul> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-scleroderma/#presentation","title":"Presentation","text":"<ul> <li> <p>CREST: Calcinosis cutis, Raynaud phenomenon, Esophageal dysmotility,     Sclerodactyly, Telangiectasia (CREST syndrome is no longer a     discrete diagnosis)</p> </li> <li> <p>Systemic: fatigue, weight loss</p> </li> <li> <p>Vascular: Raynaud\u2019s \u00b1 digital tip ulcers, telangiectasias,     nailfold capillaroscopy w/ dilated capillary loops</p> </li> <li> <p>Skin: Loss of facial wrinkles, decreased oral aperture</p> </li> <li> <p>MSK: arthralgias, myalgias, flexion contractures</p> </li> <li> <p>GI: Esophageal or intestinal dysmotility, GERD, GAVE (watermelon     stomach)</p> </li> <li> <p>Pulm: ILD (NSIP, UIP), pulmonary arterial hypertension (PAH)</p> </li> <li> <p>Cardiac: pericardial effusions, myocarditis, cardiomyopathy,     conduction system disease</p> </li> <li> <p>Renal: renal crisis (onset of malignant HTN, greatest risk in first     5 years)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-scleroderma/#evaluation","title":"Evaluation","text":"<ul> <li>2013 ACR/EULAR Classification Criteria weight-based symptom     scoring\u00a0\u00a0</li> </ul> Items Sub-items Weight Skin thickening of fingers of both hands extending proximal to metacarpophalangeal (MCP) joints 9 Skin thickening of fingers (only count the highest score) Puffy fingers Whole finger, distal to MCP 2 4 Fingertip lesions (only count the highest score) Digital tip ulcers Pitting scars 2 3 Telangiectasia 2 Abnormal nailfold capillaries 2 Pulmonary arterial hypertension and/or interstitial lung disease 2 Raynaud\u2019s phenomenon 3 Scleroderma-related antibodies (any of anti-centromere, anti-topoisomerase I [anti-cL 70], anti-RNA polymerase III) 3 Patients with a total score of \u22659 are classified as having definite systemic sclerosis (sensitivity 91%, specificity 92%) <ul> <li> <p>Labs: ANA w/ Reflex, Scl70, anticentromere, RNA pol III (separate     order in Epic)</p> </li> <li> <p>Imaging/Procedures: Baseline PFTs, Lung HRCT, TTE, EKG, 6-minute     walk test</p> </li> <li> <p>Skin biopsy: Not often used for dx, may be required to differentiate     other rare disorders (eosinophilic fasciitis, scleroderma,     scleromyxedema)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-scleroderma/#management","title":"Management","text":"<ul> <li> <p>Organ-Based Symptomatic Therapy</p> <ul> <li> <p>Raynauds: CCB (amlodipine, nifedipine), topical nitroglycerin</p> </li> <li> <p>GERD: PPI</p> </li> <li> <p>Renal: Monitor BP; Cr</p> </li> <li> <p>ILD: Periodic PFTs, monitor for new respiratory symptoms, pulm     referral</p> </li> <li> <p>Cardiac/PAH: annual TTE, cardiology referral</p> </li> </ul> </li> <li> <p>Systemic Immunosuppression (if progressive skin thickening or organ     involvement)</p> <ul> <li>MTX, MMF, cyclophosphamide, if refractory rituximab, IVIG\u00a0</li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-scleroderma/#scleroderma-renal-crisis","title":"Scleroderma Renal Crisis","text":"<ul> <li> <p>Typically presents early in disease course (can even precede skin     thickening)</p> </li> <li> <p>Abrupt onset of hypertension and renal dysfunction</p> </li> <li> <p>Labs: Elevated Cr, proteinuria, microangiopathic hemolytic anemia,     elevated renin</p> </li> <li> <p>Treatment: short acting ACE (captopril or enalapril, titratable),     may require HD</p> </li> </ul>"},{"location":"rheumatology/rheumatology-sle/","title":"Systemic Lupus Erythematous","text":"<p>Eva Niklinska</p>"},{"location":"rheumatology/rheumatology-sle/#background","title":"Background","text":"<ul> <li> <p>Characterized by multisystem inflammation, activation of complement,     autoantibody formation</p> </li> <li> <p>Presentation:</p> <ul> <li> <p>Constitutional: fatigue, fevers, weight loss</p> </li> <li> <p>Neurologic: cerebritis, myelitis, mononeuritis multiplex, psychosis</p> </li> <li> <p>Skin: malar rash (spares nasolabial folds), discoid lesions     (scarring), photosensitivity</p> </li> <li> <p>Hematologic: leukopenia, anemia, thrombocytopenia</p> </li> <li> <p>Pulmonary: pleuritis, pleural effusion, ILD</p> </li> <li> <p>Cardiac: pericarditis/myocarditis, increased risk for CAD,     Libman-Sacks endocarditis</p> </li> <li> <p>Renal: nephritic/nephrotic syndrome</p> </li> <li> <p>MSK: arthralgias, myalgias, arthritis (nonerosive, often symmetric)</p> </li> <li> <p>Ophtho: keratoconjunctivitis sicca 2/2 concurrent Sjogren\u2019s</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-sle/#evaluation","title":"Evaluation","text":"<ul> <li> <p>Labs to check upon admission: dsDNA (don\u2019t re-send ANA/ENA panel if     known ddx), C3/C4, ESR, CRP, CBC w/ diff, CMP, UPC</p> </li> <li> <p>2019 EULAR/ACR classification criteria for diagnosis:</p> <ul> <li> <p>ANA (\u2265 1:80) + additive scoring\u00a0(classify as SLE if score is 10+)</p> </li> <li> <p>Do not count criteria if there is a more likely explanation for it</p> </li> <li> <p>Occurrence of a criterion on one occasion is sufficient. Criteria do     not need to occur simultaneously. At least one criterion must be     clinical</p> </li> </ul> </li> <li> <p>Ddx: RA, MCTD, SS, Sjogren\u2019s, Vasculitis (Behcet\u2019s), PM/DM,     Fibromyalgia\u00a0</p> </li> <li> <p>* Note + ANA is now entry criteria [ANA only needs to be + once]</p> </li> </ul> Clinical Criteria Weight Laboratory Criteria Weight <p>Constitutional</p> <p>Fever</p> 2 <p>Antiphospholipid antibodies</p> <p>(Lupus AC, CL, \u03b22GP1)</p> 2 <p>Hematologic</p> <p>Leukopenia</p> <p>Thrombocytopenia</p> <p>Autoimmune hemolysis</p> <p>3</p> <p>4</p> <p>4</p> <p>Complement proteins</p> <p>Low C3 OR C4</p> <p>Low C3 AND C4</p> <p>SLE-specific antibodies</p> <p>3</p> <p>4</p> <p>Neuropsychiatric</p> <p>Delirium</p> <p>Psychosis</p> <p>Seizure</p> <p>2</p> <p>3</p> <p>4</p> <p>Anti-dsDNA OR</p> <p>Anti-Smith</p> 6 <p>Mucocutaneous</p> <p>Non-scarring alopecia</p> <p>Oral ulcers</p> <p>Subacute cutaneous OR discoid lupus</p> <p>Acute cutaneous lupus</p> <p>2</p> <p>2</p> <p>4</p> <p>6</p> <p>Serosal</p> <p>Pleural or pericardial effusion</p> <p>Acute pericarditis</p> <p>5</p> <p>6</p> <p>Musculoskeletal</p> <p>Joint involvement (2+ joints)</p> 6 <p>Renal</p> <p>Proteinuria (&gt;0.5g/24h)</p> <p>Renal Bx Class II or V lupus nephritis</p> <p>Renal Bx Class III or IV lupus nephritis</p> <p>4</p> <p>8</p> <p>10</p>"},{"location":"rheumatology/rheumatology-sle/#management","title":"Management","text":"<ul> <li> <p>Hydroxychloroquine mainstay of treatment, 200-400 mg/day; dose 5     mg/kg/day for long term to decrease risk of retinal toxicity</p> <ul> <li> <p>Safe in pregnancy; decreases VTE/HLD risk\u00a0</p> </li> <li> <p>Annual ophtho exam for retinal toxicity\u00a0</p> </li> <li> <p>NOT immunosuppressive</p> </li> </ul> </li> <li> <p>Glucocorticoids for flares: Usually started with hydroxychloroquine     and tapered once hydroxychloroquine has taken effect</p> </li> <li> <p>Other immunosuppressive medications (MTX, MMF, AZA, RTX) used with     rheumatology consultation: MMF, cyclophosphamide or other advanced     therapies used in SLE with renal involvement or severe end organ     involvement</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/","title":"Vasculitis","text":"<p>Hannah Angle</p>"},{"location":"rheumatology/rheumatology-vasculitis/#background","title":"Background","text":"<ul> <li> <p>Large vessel vasculitis (aorta and its major branches)</p> <ul> <li> <p>Takayasu arteritis:</p> <ul> <li> <p>Most commonly &lt;30 years old, 80-90% cases in females, greatest     prevalence in Asia</p> </li> <li> <p>Branches of aorta/aortic arch (subclavian, innominate, carotid     arteries)</p> </li> </ul> </li> <li> <p>Giant cell Arteritis:</p> <ul> <li> <p>Most commonly &gt;50 years old, slight F &gt; M predominance</p> </li> <li> <p>Cranial arteries (temporal artery), aorta and its branches</p> </li> </ul> </li> </ul> </li> <li> <p>Medium vessel vasculitis (muscular arteries that supply visceral     organs)</p> <ul> <li> <p>Polyarteritis nodosa (PAN):</p> <ul> <li> <p>Most often middle age/older adults (peaks in 5th decade of life)</p> </li> <li> <p>Necrotizing vasculitis of muscular arteries (renal, mesenteric,     arteries supplying neurons and skin)</p> </li> </ul> </li> <li> <p>Kawasaki\u2019s: not addressed here- most often children</p> </li> </ul> </li> <li> <p>Small Vessel Vasculitis (arterioles, capillaries, and venules)</p> <ul> <li> <p>ANCA-associated vasculitis:</p> <ul> <li> <p>GPA: granulomatous; classically involves nasopharynx, lungs, kidneys</p> </li> <li> <p>MPA: affects multiple organs but predilection for lungs and kidneys; in contrast to GPA, no nasopharynx involvement or granulomas</p> </li> <li> <p>EGPA: granulomatous; predilection for heart and lungs; associated with eosinophilia, chronic rhinosinusitis, asthma; uncommon &gt; 65 years old</p> </li> </ul> </li> </ul> </li> <li> <p>Immune-complex vasculitis: not addressed here</p> <ul> <li> <p>Cryoglobulinemic vasculitis (see lab section)</p> </li> <li> <p>IgA vasculitis</p> </li> <li> <p>Anti-GBM disease</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#takayasus-arteritis","title":"Takayasu's Arteritis","text":""},{"location":"rheumatology/rheumatology-vasculitis/#presentation","title":"Presentation","text":"<ul> <li> <p>Subacute constitutional symptoms (fevers, arthralgias, myalgias,     rash, weight loss), limb claudication, neuro symptoms from     carotid/vertebral arteritis (vertigo, headaches, syncope, strokes),     GI symptoms from mesenteric ischemia, angina from coronary arteritis</p> </li> <li> <p>HTN (renal artery involvement), discrepant BP between arms (arterial     stenosis), diminished or absent pulses (\u201cpulseless disease\u201d),     arterial bruits, carotidynia (tenderness of carotid artery)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#evaluation","title":"Evaluation","text":"<ul> <li> <p>ESR/CRP (often elevated, though can be normal during active disease)</p> </li> <li> <p>Arteriography: MRA or CTA of head/neck, chest, and abdomen/pelvis</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#management","title":"Management","text":"<ul> <li> <p>New arterial stenosis or aorta/carotid artery involvement: 1mg/kg     prednisone daily (max 60-80mg) for 2-4 weeks followed by steroid     taper</p> </li> <li> <p>Organ threatening disease (coronary artery involvement, critical     stenosis of carotid/vertebral arteries): 500-1000mg IV     methylprednisolone daily for 1-3 days, then 1mg/kg prednisone daily     for 2-4 weeks followed by steroid taper</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#giant-cell-arteritis","title":"Giant Cell Arteritis","text":""},{"location":"rheumatology/rheumatology-vasculitis/#presentation_1","title":"Presentation","text":"<ul> <li> <p>Always consider in pts &gt;50 years old with new headache, abrupt     vision changes (diplopia, amaurosis fugax), jaw claudication,     temporal artery tenderness</p> </li> <li> <p>Polymyalgia rheumatica will often accompany GCA; classically with     bilateral shoulder and hip pain/stiffness (with elevated ESR, but     normal CK)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#evaluation_1","title":"Evaluation","text":"<ul> <li> <p>ESR/CRP (almost always elevated), CK, TSH</p> </li> <li> <p>Evaluate for any temporal artery abnormalities (tenderness to     palpation, presence of nodules)</p> </li> <li> <p>Ophthalmology evaluation if any concern for ocular involvement</p> </li> <li> <p>Temporal artery biopsy by vascular surgery</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#management_1","title":"Management","text":"<ul> <li> <p>Start glucocorticoids as soon as GCA is suspected, do not delay     while awaiting biopsy</p> <ul> <li> <p>No vision loss: prednisone 1mg/kg daily (max 60 mg) for 2-4     &gt; weeks followed by steroid taper</p> </li> <li> <p>Vision loss/diplopia: 500-1000mg IV methylprednisolone daily for     &gt; 3 days, followed by prednisone 1mg/kg daily (max 60mg) for 2-4     &gt; weeks followed by steroid taper\u00a0\u00a0</p> </li> </ul> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#polyarteritis-nodosa-pan","title":"Polyarteritis Nodosa (PAN)","text":""},{"location":"rheumatology/rheumatology-vasculitis/#presentation_2","title":"Presentation","text":"<ul> <li> <p>Constitutional symptoms: fatigue, weakness, fevers, arthralgias,     myalgias, rash, weight loss</p> </li> <li> <p>Evidence of multisystem involvement:</p> <ul> <li> <p>Asymmetric polyneuropathy with motor and sensory deficits (foot     &gt; drop, radial/ulnar neuropathy)</p> </li> <li> <p>Skin manifestations: livedo reticularis, palpable purpura,     &gt; ulcers, tender erythematous nodules, bullae, vesicles</p> </li> <li> <p>HTN (renal arteritis)</p> </li> <li> <p>Abdominal pain and melena (mesenteric arteritis)</p> </li> <li> <p>Ischemic cardiomyopathy (coronary arteritis)</p> </li> <li> <p>Testicular pain (orchitis)</p> </li> </ul> </li> <li> <p>Classically spares the lungs (consider other dx if pulmonary     complaints)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#evaluation_2","title":"Evaluation","text":"<ul> <li> <p>ESR/CRP, CK, TSH</p> </li> <li> <p>Hepatitis panel (HBV/HCV can cause secondary PAN)</p> </li> <li> <p>Arteriography: MRI, CT, or angiogram with classic \u201cstring of pearls\u201d     appearance\u00a0</p> </li> <li> <p>Biopsy: segmental transmural inflammation of muscular arteries,     fibrinoid necrosis of arterial wall (no granulomas, presence     suggests another process)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#management_2","title":"Management","text":"<ul> <li> <p>Mild disease (ex: isolated cutaneous disease): prednisone 1mg/kg     daily (max 60-80mg) for 4 weeks followed by steroid taper</p> </li> <li> <p>Moderate disease: cyclophosphamide + prednisone 1mg/kg daily (max     60-80mg) for 4 weeks followed by steroid taper</p> </li> <li> <p>Severe/life-threatening disease (renal failure, significant     proteinuria, GI/cardiac/neurologic involvement): cyclophosphamide +     500-1000mg IV methylprednisolone daily for 3 days, followed by     prednisone 1mg/kg daily (max 60mg) for 4 weeks followed by steroid     taper\u00a0\u00a0</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#granulomatosis-with-polyangiitis-gpa","title":"Granulomatosis with Polyangiitis (GPA)","text":""},{"location":"rheumatology/rheumatology-vasculitis/#presentation_3","title":"Presentation","text":"<ul> <li> <p>Constitutional symptoms (fevers, fatigue, weight loss) + evidence of     glomerulonephritis (hematuria, proteinuria), upper respiratory tract     involvement (nasal crusting, rhinorrhea, epistaxis, sinusitis), and     pulmonary involvement (dyspnea, cough, hemoptysis)</p> </li> <li> <p>Less commonly affects eyes (scleritis), skin (palpable purpura), and     peripheral nerves (mononeuritis multiplex)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#evaluation_3","title":"Evaluation","text":"<ul> <li> <p>ANCA + (typically PR3-cANCA)</p> </li> <li> <p>ESR/CRP, ANA, anti-GBM, C3/C4, cryoglobulins, HBV/HCV, HIV</p> </li> <li> <p>UA with microscopy (hematuria, proteinuria, RBC casts, dysmorphic     RBCs)</p> </li> <li> <p>CT chest if pulmonary symptoms</p> </li> <li> <p>Biopsy: necrotizing granulomatous vasculitis, pauci-immune     glomerulonephritis</p> </li> <li> <p>Clinical Pearl: If you suspect renal disease based (elevated Cr,     hematuria) ask renal fellow or rheum fellow to help spin the urine     to evaluate for RBC casting or dysmorphic cells. Quick way to     confirm active GN, renal biopsy takes time to arrange</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#management_3","title":"Management","text":"<ul> <li> <p>Mild-moderate disease: MTX + prednisone 0.5 mg/kg/day followed by     steroid taper</p> </li> <li> <p>Severe disease: rituximab or cyclophosphamide + prednisone     1mg/kg/day (60-80mg max)</p> <ul> <li>For pts with RPGN, pulmonary hemorrhage, mononeuritis multiplex,     &gt; or optic neuritis: IV methylprednisolone 7-15mg/kg/day (1000mg     &gt; max) x 3 days for induction therapy</li> </ul> </li> <li> <p>DVT ppx (high risk for DVT/PE)</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#microscopic-polyangiitis-mpa","title":"Microscopic Polyangiitis (MPA)","text":""},{"location":"rheumatology/rheumatology-vasculitis/#presentation_4","title":"Presentation","text":"<ul> <li>Similar to GPA, but without upper respiratory tract involvement;     classically only involves lungs and kidneys</li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#evaluation_4","title":"Evaluation","text":"<ul> <li> <p>ANCA + (typically MPO-pANCA)</p> </li> <li> <p>ESR/CRP, ANA, anti-GBM, C3/C4, cryoglobulins, HBV/HCV, HIV</p> </li> <li> <p>UA with microscopy (hematuria, proteinuria, RBC casts, dysmorphic     RBCs)</p> </li> <li> <p>CT chest if pulmonary symptoms</p> </li> <li> <p>Biopsy: necrotizing vasculitis (no granulomas), pauci-immune     glomerulonephritis</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#management_4","title":"Management","text":"<ul> <li>Same as GPA, see above</li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#eosinophilic-granulomatosis-with-polyangiitis-egpa","title":"Eosinophilic Granulomatosis with Polyangiitis (EGPA)","text":""},{"location":"rheumatology/rheumatology-vasculitis/#presentation_5","title":"Presentation","text":"<ul> <li> <p>Similar to GPA/MPA + atopic symptoms such as asthma (&gt;90%),     rhinosinusitis, and peripheral eosinophilia</p> </li> <li> <p>Cardiac involvement (accounts for 50% deaths from EGPA): coronary     arteritis, myocarditis, heart failure, arrhythmias</p> </li> <li> <p>Skin involvement (&gt;50%): tender subcutaneous nodules</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#evaluation_5","title":"Evaluation","text":"<ul> <li> <p>ANCA + (typically MPO-pANCA), peripheral eosinophilia</p> </li> <li> <p>IgE, ANA, RF, C3/C4</p> </li> <li> <p>Biopsy: necrotizing granulomatous vasculitis, eosinophilic     infiltrates with fibrinoid necrosis, pauci-immune glomerulonephritis</p> </li> </ul>"},{"location":"rheumatology/rheumatology-vasculitis/#management_5","title":"Management","text":"<ul> <li> <p>Mild-moderate disease: prednisone 0.5-1 mg/kg/day for 6-12 weeks     followed by steroid taper</p> </li> <li> <p>Severe disease: cyclophosphamide + prednisone 0.5-1 mg/kg/day for     6-12 weeks followed by steroid taper</p> <ul> <li>For pts with life-threatening multiorgan involvement (cardiac,     &gt; pulmonary, renal, neurologic): IV methylprednisolone 1000mg     &gt; daily x 3 days for induction therapy</li> </ul> </li> <li> <p>DVT ppx (high risk for DVT/PE)</p> </li> </ul>"},{"location":"toxicology/toxicology-brown-recluse-loxoscelism/","title":"Brown Recluse Bites (Loxoscelism)","text":"<p>Ashley Zeoli</p>"},{"location":"toxicology/toxicology-brown-recluse-loxoscelism/#background","title":"Background","text":"<ul> <li>Only a handful of spiders are truly harmful to humans</li> <li>The brown recluse (a member of the Loxoceles genus) is widespread in     the South, West, and Midwest US</li> <li>They are often found in homes (attics, basements, cupboards) and     outdoors (rock piles and under tree bark)</li> <li>Their numbers increase in association with humans (i.e.     synanthropic)</li> <li>Appearance/identification:<ul> <li>Brown recluses have three pairs of eyes, a monochromatic abdomen and legs, and very fine hairs on its legs</li> <li>Using the \u201cviolin\u201d pattern on its body is a poor way to identify this spider, as other harmless spiders can have similar markings.</li> </ul> </li> <li>Loxocelism is the medical manifestation of the brown recluse spider     bite</li> <li>Venom contains insecticidal toxins, metalloproteases, and     phospholipases</li> </ul>"},{"location":"toxicology/toxicology-brown-recluse-loxoscelism/#presentation","title":"Presentation","text":"<ul> <li>Bites are most common on the upper arm, thorax, or inner thigh</li> <li>Local signs:<ul> <li>Sometimes painless, but can cause burning sensation with two small cutaneous puncture marks with surrounding erythema. Pain can increase over the first 8 hours</li> <li>Usually appears as a red plaque or papule with central pallor and can sometimes present with vesiculation</li> <li>Usually self-resolves in 1 week</li> </ul> </li> <li>Skin necrosis:<ul> <li>In some, skin lesion can progress to necrosis overall several days</li> <li>An eschar will form that eventually ulcerates</li> <li>Usually will heal over several weeks to months</li> </ul> </li> <li>Systemic signs:<ul> <li>The degree of systemic effects does not correlate with the appearance of the bite</li> <li>Symptoms may develop over several days, and include nausea, vomiting, fever, rhabdomyolysis, malaise, acute hemolytic anemia, significant swelling from head/neck bites that can compromise the airway, DIC and renal failure</li> </ul> </li> </ul>"},{"location":"toxicology/toxicology-brown-recluse-loxoscelism/#evaluation","title":"Evaluation","text":"<ul> <li>Presumptive diagnosis is based clinical presentation of the     bite/wound</li> <li>DDx includes vasculitis, pyoderma gangrenosum, cellulitis, or other     arthropod bites</li> <li>Definitive diagnosis is based upon observing a spider bite in     combination identification by an entomologist. There is an assay for     Loxoceles venom, but it is not commercially available</li> <li>Patients with local symptoms do not need any further workup</li> <li>Patient with any systemic symptoms require lab evaluation for more     serious disease:<ul> <li>CBC, UA to eval for blood, CMP, CK</li> <li>If anemia: Type and Screen, peripheral smear, reticulocyte count, LDH, haptoglobin, coags to evaluate for hemolysis or DIC</li> </ul> </li> </ul> <p>Loxocelism flowchart</p>"},{"location":"toxicology/toxicology-brown-recluse-loxoscelism/#management","title":"Management","text":"<ul> <li>Local signs:<ul> <li>Wound care (soap/water, elevation)</li> <li>Pain management</li> <li>Tetanus vaccine/prophylaxis if indicated</li> <li>Antibiotics only if signs of concurrent cellulitis</li> </ul> </li> <li>Skin necrosis:<ul> <li>Symptomatic and supportive care</li> <li>Surgical intervention can worsen cosmetic outcomes and is rarely indicated in the acute care setting. Skin grafting is occasionally needed for a very large ulcerative wound that is not healing. Infection is rare, Furthermore, the ulcerative base of the wounds often have a yellow stringy material that is not pus or infection. Please call Toxicology with any questions regarding brown recluse bites</li> </ul> </li> <li>Systemic signs: Targeted at treatment of symptoms that develop (Consult toxicology)<ul> <li>Hemolytic anemia: transfuse for Hgb &lt;10 + consult heme</li> <li>Rhabdomyolysis: LR for UOP &gt;200-300cc/hr</li> <li>If patient develops chest pain, obtain EKG and check a troponin; if     either is abnormal please obtain echo and call Toxicology as heart     effects (i.e. myocarditis) is something we have been seeing at VUMC</li> <li>DIC: supportive care</li> </ul> </li> </ul>"},{"location":"toxicology/toxicology-overdose-management/","title":"Management of Specific Overdoses","text":"<p>Lauren Chen</p>"},{"location":"toxicology/toxicology-overdose-management/#overview","title":"Overview","text":"<p>There are 5 main classes of drugs/toxins that induce bradycardia and hypotension (ABCDO)</p> <ul> <li>Alpha-2 agonist</li> <li>Beta-blockers</li> <li>Calcium channel blockers</li> <li>Digoxin and cardiac glycosides</li> <li>Acetylcholinesterase inhibitors (Organophosphates)</li> </ul> <p>Key Points:</p> <ul> <li>Physical exam, labs, and ECG can be helpful in determining the class     of drug/toxicant</li> <li>Ensure physical exam includes vitals (including RR) pupils,     heart/lung exam, abdominal exam including bowel sounds, and     peripheral pulses</li> <li>Obtain a blood glucose to differentiate beta blocker (hypoglycemia     or normoglycemia) versus calcium channel blocker (hyperglycemia)     toxicity</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#alpha-2-agonists","title":"Alpha-2 Agonists","text":""},{"location":"toxicology/toxicology-overdose-management/#background","title":"Background","text":"<ul> <li>Examples: Clonidine, dexmedetomidine, guanfacine, tizanidine,     methyldopa</li> <li>Mechanism: Centrally acting inhibition of norepinephrine release     decreased noradrenergic activity</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation","title":"Evaluation","text":"<ul> <li>Physical Exam: Early/transient HTN, attenuated sympathetic response     (decreased HR, BP), opioid toxidrome (pinpoint pupils, CNS     depression, respiratory depression)</li> <li>Laboratory abnormalities: None associated with overdose</li> <li>ECG: Sinus bradycardia</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management","title":"Management","text":"<ul> <li>IVF and high dose naloxone</li> <li>Naloxone may reverse the CNS and respiratory depression as well as     hypotension</li> <li>Vasopressors such as norepinephrine/epinephrine are used if naloxone     does not work</li> </ul> <p>Quick dosing reference:</p> <ul> <li>Naloxone 10mg IVP followed by 5 mg/hr if there is no response</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#beta-blockers-bbs","title":"Beta blockers (BB\u2019s)","text":""},{"location":"toxicology/toxicology-overdose-management/#background_1","title":"Background","text":"<ul> <li>Mechanism: Competitively block catecholamines at beta-adrenergic     receptors decreased inotropy and chronotropy; impaired     gluconeogenesis and glycogenolysis</li> <li>Lipophilic BB\u2019s (propranolol, metoprolol): Cross the blood brain     barrier -&gt; CNS depression</li> <li>Membrane stabilizing BB\u2019s (propranolol): QRS prolongation,     dysrhythmias, and seizures</li> <li>Sotalol: Potassium channel blocking properties QTc prolongation and     dysrhythmias</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_1","title":"Evaluation","text":"<ul> <li>Physical Exam: CNS depression, seizures, myocardial depression,     respiratory depression</li> <li>Laboratory abnormalities: Hypoglycemia or normoglycemia</li> <li>ECG: Sinus bradycardia, AV block (low grade), QRS widening     (propranolol), QTc prolongation (sotalol)</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_1","title":"Management","text":"<ul> <li>IVF, Calcium</li> <li>Glucagon: Stimulates adenylcyclase increased cAMP increase HR and BP</li> <li>Epinephrine or Norepinephrine should be first line vasopressors</li> <li>Intralipid infusion if refractory HoTN or pt codes from a lipophilic     BB (i.e. Propranolol)</li> <li>BB induced arrhythmias: Sodium bicarbonate (adjunct QRS widening)     and Mg for QTc prolongation induced Torsades de pointes</li> <li>Hemodialysis for significant sotalol toxicity</li> </ul> <p>Quick dosing reference:</p> <ul> <li>Calcium: 3g calcium gluconate</li> <li>Glucagon:<ul> <li>10 mg over 10 min (vomiting occurs if administered too fast)</li> <li>Infusion 3-5 mg/h (need infusion as half-life is 6 minutes)</li> </ul> </li> <li>Atropine: 0.5-1mg q3-5min</li> <li>Intralipid (Lipid Emulsion) 20% infusions: 1.5 cc/kg bolus followed     by 0.25 cc/kg/min for 60 minutes (for 70 kg adult: 1 liter over 1     hour) for refractory hypotension or if patient codes), max dose is     10 ml/kg or 1200 ml whichever is greater however, there is limited     guidance on a max dose - if using lipid emulsion therapy, please     call Toxicology or Poison Control immediately</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#calcium-channel-blockers-ccbs","title":"Calcium channel blockers (CCB\u2019s)","text":""},{"location":"toxicology/toxicology-overdose-management/#background_2","title":"Background","text":"<ul> <li>Two categories: Dihydropyridines (DHP) and non-dihydropyridines     (Non-DHP)</li> <li>DHP (amlodipine, nifedipine): Peripheral &gt; central channels,     selectivity is lost in overdose</li> <li>Non-DHP (diltiazem, verapamil): Primarily cardiac calcium channels</li> <li>Mechanism:<ul> <li>DHP: arterial vasodilation reflex tachycardia</li> <li>Non-DHP: peripheral vasodilation, decreased inotropy, bradycardia. Calcium mediated insulin inhibition in the pancreas hyperglycemia</li> </ul> </li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_2","title":"Evaluation","text":"<ul> <li>Physical Exam: Markedly preserved mental status until patient is     about to code</li> <li>Labs: Hyperglycemia (elevated serum glucose concentrations are     associated with severe overdose and sequelae)</li> <li>ECG: Bradyarrhythmia, high-degree heart block (3rd degree)</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_2","title":"Management","text":"<ul> <li>IVF, vasopressors if needed</li> <li>Bradycardia: Atropine (not effective for second- or third-degree     block), calcium, glucagon</li> <li>Hypotension + bradycardia:<ul> <li>High dose insulin/euglycemic therapy (HIE)</li> <li>Give with dextrose. Titrate insulin like a pressor. Blood     pressure may take up to 20 minutes to change</li> <li>May increase contractility through increasing the cardiac     utilization of glucose. Not likely to help with vasodilation or     bradycardia</li> </ul> </li> <li>Vasopressors (norepinephrine or epinephrine). May consider     phenylephrine for DHT induced vasoplegic shock with tachycardia</li> <li>Intralipid should be used in code/refractory hypotensive situations     for lipophilic CCB\u2019s (verapamil, amlodipine, diltiazem)</li> <li>Methylene blue for refractory distributive shock can be considered,     but consult toxicology prior to using</li> </ul> <p>Quick dosing reference:</p> <ul> <li>Calcium: 3g calcium gluconate</li> <li>Glucagon<ul> <li>10 mg over 10 min (vomiting occurs if administered too fast; max 10 mg/hr)</li> <li>Infusion 3-5 mg/h (need infusion as half-life is 6 minutes)</li> </ul> </li> <li>Atropine: 0.5-1mg q3-5min</li> <li>If hypotensive and bradycardic:<ul> <li>High-dose insulin 0.5-1 unit/kg bolus followed by 0.5-1     unit/kg/hour infusion titrated to up to 10 units/kg/ hour.     Call Toxicology immediately if exceeding 3 units/kg/hour.</li> <li>Intralipid infusions: 20% infusions: 1.5 cc/kg bolus followed by     0.25 cc/kg/min for 60 minutes (for 70 kg adult: 1 liter over 1     hour) for refractory hypotension or if patient codes), max     dose is 10 ml/kg or 1200 ml whichever is greater however,     there is limited guidance on a max dose - if using lipid     emulsion therapy, please call Toxicology or Poison Control     immediately.</li> </ul> </li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#digoxin-and-cardiac-glycosides","title":"Digoxin and Cardiac Glycosides","text":""},{"location":"toxicology/toxicology-overdose-management/#background_3","title":"Background","text":"<ul> <li>Examples: Digoxin, yellow oleander, lanatoside C, foxglove, lily of     the valley, bufo toads</li> <li>Mechanism: Blockade of Na/K ATPase increased intracellular calcium     increased contractility and may delay after depolarizations/shorten     repolarization of the atria and ventricles trigger arrhythmias;     increased vagal tone</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_3","title":"Evaluation","text":"<ul> <li>Physical Exam: Lethargy, nausea, vomiting, reported yellow halos in     visual fields (chronic)</li> <li>Laboratory abnormalities: Hyperkalemia (marker of acute toxicity     although does not cause; correlates with mortality)</li> <li>ECG: Any abnormality (though Afib RVR is unlikely, more likely to     have a regular pulse due to 3rd degree block in the     setting of Afib), biventricular tachycardia is classic but rarely     seen</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_3","title":"Management","text":"<ul> <li>Digoxin fab fragments<ul> <li>Indications: Hemodynamic instability, significant unstable arrhythmia, end organ damage secondary to hypoperfusion (renal failure), or potassium \u22655.0 mEq/L</li> <li>It can also be indicated for pts with high post distribution digoxin levels even if they are asymptomatic. However, please contact poison control/toxicology for guidance.</li> </ul> </li> <li>For pts with severe symptomatic bradycardia when digoxin fab     fragments are not available, atropine is recommended but will likely     not be effective</li> <li>Given the sensitivity of the myocardium with digoxin, pacers can     trigger significant dysrhythmias and only recommended if no access     to digoxin fab fragments or fab fragment failure</li> </ul> <p>Quick reference dosing:</p> <ul> <li>Digoxin fab fragments: Number of vials = [(serum level times the     weight of the patient)/100] rounded up. Empiric treatment 10 vials.     NOTE: In acute on chronic toxicity or chronic toxicity, please     contact the Poison Center or Medical Toxicology for guidance as less     vials may be recommended to try to avoid adverse events from     worsening heart failure or atrial fibrillation<ul> <li>Unclear dosing for natural toxins (often empirically 10 vials for an adult)</li> </ul> </li> <li>Atropine (if digoxin fab fragments are not available): 0.5-1mg     q3-5min</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#acetylcholinesterase-inhibitors","title":"Acetylcholinesterase Inhibitors","text":""},{"location":"toxicology/toxicology-overdose-management/#background_4","title":"Background","text":"<ul> <li>Examples: Organophosphates (e.g. insecticides), carbamates,     physostigmine, rivastigmine, donepezil</li> <li>Mechanism: Inhibition of the breakdown of acetylcholine increased     acetylcholine stimulation of muscarinic and nicotinic receptors</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_4","title":"Evaluation","text":"<ul> <li>Physical Exam:<ul> <li>Muscarinic: Diarrhea/Diaphoresis, Urination, Miosis, Bronchorrhea/Bronchospasm, Bradycardia, Miosis, Emesis, Lacrimation, Salivation (DUMBBELS mnemonic)</li> <li>Nicotinic: Fasciculations, muscle weakness, and/or muscle paralysis</li> <li>Intermediate syndrome: Neurologic syndrome after resolution of cholinergic excess, decreased DTR, proximal muscle weakness, respiratory insufficiency, neck flexion weakness, CN abnormalities</li> </ul> </li> <li>Laboratory abnormalities: Standard lab tests are not helpful.</li> <li>ECG: Sinus bradycardia, QTc prolongation</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_4","title":"Management","text":"<ul> <li>Atropine, Pralidoxime, Benzodiazepines</li> <li>Secretions: Titrate atropine to dry secretions (can require large     amounts i.e. 50 mg).</li> <li>Bronchorrhea: Atropine as below; excessive watery mucous from the     lungs can cause patients to drown in their own secretions</li> <li>Organophosphate poisoning: Pralidoxime to reactivate the     acetylcholinesterase enzyme</li> <li>Seizures: Benzodiazepines</li> </ul> <p>Quick dosing reference</p> <ul> <li>Atropine: 1-2 mg (mild-moderate symptoms) vs 3-5mg (severe) IV     repeated every 2-20 minutes or 1mg followed by doubling doses every     5 minutes until bronchorrhea is no longer present followed by an     infusion 10-20% of the loading dose per hour (max 2 mg/hour)</li> <li>Pralidoxime: 30mg/kg (max 2g) loading dose followed by 8-10 mg/kg/hr     (max 650mg/hr); WHO dosing is 2000 mg bolus followed by 500 mg/hr     infusion. Pralidoxime use for other acetylcholinesterase inhibitors     should be used only with Poison Control/Medical Toxicology guidance</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#alcohol","title":"Alcohol","text":""},{"location":"toxicology/toxicology-overdose-management/#background_5","title":"Background","text":"<ul> <li>One standard drink = 12oz regular beer = 5oz wine = 1.5oz 80%     distilled spirit</li> <li>Absorption primarily in duodenum/small intestine (80%) with 80-90%     of absorption in \\&lt;60 min in ideal conditions (i.e. empty stomach)</li> <li>Mechanism: Metabolism via alcohol dehydrogenase. Withdrawal due to     CNS overactivity from decreased inhibitory tone (GABA) and     unregulated excess excitation (glutamate binding to NMDA, dopamine)</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_5","title":"Evaluation","text":"<ul> <li>Physical Exam:<ul> <li>Intoxication: Slurred speech, disinhibition, incoordination, unsteady gait, memory impairment, nystagmus, stupor, coma, hypotension, tachycardia</li> <li>Wernicke encephalopathy: Encephalopathy, oculomotor dysfunction, gait ataxia</li> <li>Withdrawal: Anxiety, agitation, restlessness, insomnia, tremor, diaphoresis, palpitations, HA, n/v, hallucinations (onset 12-24h after last drink), seizures (12-48hr), DTs (72-96hr)</li> </ul> </li> <li>Laboratory abnormalities: EtOH level, Peth, UDS, hypoglycemia,     hyperlactatemia, hypoK, hypoMg, hypoCa, hypophos</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_5","title":"Management","text":"<ul> <li>Intoxication: Supportive care</li> <li>Withdrawal: Thiamine, folate, multivitamin, IV fluid for     intravascular depletion</li> <li>Psychomotor agitation: Benzodiazepines (long-acting preferred)     including diazepam, lorazepam, and chlordiazepoxide. Lorazepam for     acute alcoholic hepatitis/liver dysfunction.</li> <li>Seizures: CIWA scoring and benzodiazepines. If h/o DTs, consider     phenobarbital taper. If status, consider escalation to propofol</li> </ul> <p>Quick dosing reference:</p> <ul> <li>Diazepam: 5-10mg IV every 5-10min until appropriate sedation     (severe) or per CIWA protocol</li> <li>Lorazepam: 2-4mg IV every 15-20min or per CIWA protocol</li> <li>Thiamine: Administer before glucose containing fluids. WE prevention     100mg IV QD x3d. For WE 500mg IV TID x3d followed by 250mg QD x3d,     then 100mg QD.</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#opioids","title":"Opioids","text":""},{"location":"toxicology/toxicology-overdose-management/#background_6","title":"Background","text":"<ul> <li>Examples: Natural opiates (morphine, codeine), semi-synthetic     (hydrocodone, hydromorphone, oxycodone, oxymorphone, heroin,     buprenorphine), synthetic opioids (fentanyl, meperidine, tramadol)</li> <li>Mechanism: Multiple receptors with wide range of clinical effects     including sedation, analgesia, respiratory depression, GI     dysmotility, bradycardia, miosis, anxiolysis</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_6","title":"Evaluation","text":"<ul> <li>Physical Exam<ul> <li>Intoxication: AMS, miosis, hypoventilation, decreased bowel     sounds, seizures, coma</li> <li>Withdrawal: Mydriasis, yawning, piloerection, diaphoresis,     rhinorrhea, increased BS</li> </ul> </li> <li>Laboratory abnormalities: None specific to opioid toxicity</li> <li>ECG: QT prolongation (loperamide, methadone, very large doses of     oxycodone), QRS widening (loperamide)</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_6","title":"Management","text":"<ul> <li>Intoxication: Supplemental oxygenation/ventilation support,     naloxone, ACLS<ul> <li>IV naloxone preferable. However, if no IV access, apneic, or     patient in critical condition, can use intranasally or IM.     Switch to IV when able</li> <li>Consider alternative etiologies of respiratory depression if no     response after 10mg</li> </ul> </li> <li>Withdrawal: COWs scoring and protocol<ul> <li>Symptom control: ondansetron (nausea, vomiting), loperamide     (diarrhea), hydroxyzine (anxiety), methocarbamol (cramps),     dicyclomine (abdominal cramps)</li> <li>Acute, severe: Methadone or buprenorphine, do NOT use for     iatrogenic withdrawal (i.e following naloxone administration)</li> <li>Iatrogenic or patients trying to overcome addition: Clonidine     taper</li> </ul> </li> </ul> <p>Quick dosing reference</p> <ul> <li>Intranasal naloxone: 4 or 8mg as single dose in one nostril. Repeat     q2-3min, alternating nostrils</li> <li>IV naloxone: 0.4-2mg q2-3min. Consider initial lower dose     (0.04-0.2mg) in patients with opioid dependence to avoid withdrawal     or if concerned for concomitant stimulant overdose. However, if     apneic, use higher doses, if mildly bradypneic in a known chronic     user, can try smaller doses repeated every 2 minutes until patient     is breathing at a normal rate while using bag mask ventilation to     support the patient</li> <li>Methadone 10mg IM or 20mg PO. Usually need to discuss with psych to     give.</li> <li>Buprenorphine 4-8mg sublingual. If symptoms persist after 60min, can     give subsequent dose. Maximum 24mg in 24hr. Usually need to discuss     with psych to give.</li> <li>Clonidine 0.1-0.3mg every hour until symptom resolution, maximum     0.8mg per 24hr</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#sodium-channel-blockers","title":"Sodium Channel Blockers","text":""},{"location":"toxicology/toxicology-overdose-management/#background_7","title":"Background","text":"<ul> <li>Examples: Class I antiarrhythmics, tricyclic antidepressants     (amitriptyline, imipramine) anticonvulsants (carbamazepine,     lamotrigine), cocaine, insecticides</li> <li>Mechanism: decreases depolarization of non-nodal cardiac myocytes</li> <li>Consider other concomitant effects (e.g. TCA with anticholinergic     and K channel blockade)</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#evaluation_7","title":"Evaluation","text":"<ul> <li>Physical Exam: Depends on ingestion</li> <li>Pure Na channel blockade: classically bradycardia but sodium channel     blocking drugs often have anticholinergic properties resulting in     tachycardia</li> <li>TCAs: typically tachycardia, cardiogenic shock, hypotension, AMS,     seizures, respiratory depression, anticholinergic symptoms</li> <li>Laboratory abnormalities: No specific abnormalities</li> <li>ECG: QRS widening, QTc prolongation, ventricular dysrhythmia (Vfib,     Vtach, TdP), new right axis deviation</li> </ul>"},{"location":"toxicology/toxicology-overdose-management/#management_7","title":"Management","text":"<ul> <li>Sodium bicarbonate (mainstay)<ul> <li>Indications: hypotension, QTC &gt;100ms, QT prolongation</li> <li>Mechanism: increases serum pH and extracellular Na to help offload Na channels</li> <li>Goal pH: 7.5-7.55</li> </ul> </li> <li>Magnesium if arrhythmias refractory to sodium bicarb</li> <li>IVF and vasopressor support as needed</li> <li>TCA toxicity: consider lipid emulsion (discuss with poison control     prior)</li> </ul> <p>Quick dosing reference</p> <ul> <li>Sodium bicarb: Initial 1-2mEq/kg bolus q5min until pH is 7.45 to     7.55, QRS will hopefully narrow to less than 120 msec at this pH but     it may remain prolonged. Then recommend infusion 150mEq in 1L D5W at     150ml/h (contact poison control or toxicology for guidance on     discontinuation</li> <li>Intralipid infusions: 20% infusions: 1.5 cc/kg bolus followed by     0.25 cc/kg/min for 60 minutes (for 70 kg adult: 1 liter over 1 hour)     for refractory hypotension or if patient codes), max dose is 10     ml/kg or 1200 ml whichever is greater however, there is limited     guidance on a max dose - if using lipid emulsion therapy, please     call Toxicology or Poison Control immediately</li> </ul>"},{"location":"toxicology/toxicology-qtc/","title":"Drug-Induced QTc Prolongation","text":"<p>Mohamed Salih</p>"},{"location":"toxicology/toxicology-qtc/#background","title":"Background","text":"<ul> <li>QT is measured from the start of the Q-wave to the end of the T-wave     (use the lead with the longest measurement) and is the time of     ventricular depolarization + repolarization</li> <li>QTc is the corrected estimate of QT assuming a rate of 60 bpm since     QT decreases with tachycardia and increases with bradycardia</li> <li>QTcF (Fridericia) + QTcB (Bazett) on ECG are different equations and     either may be used</li> <li>QTcB tends to overestimate QT</li> <li>A 2016 Meta-analysis (PMID 27317349) recommended QTcF over QTcB</li> <li>Prolongation is defined as a QT &gt; 440 ms in males or &gt;460 in     females</li> <li>Usually not very high concern until QTcF &gt; 500 ms.</li> <li>Life threatening risk of prolonged QTcF &gt;500ms = Torsades de pointes     (TdP) (see \u201cWide Complex Tachycardias\u201d in the Cardiology section for     evaluation and management of TdP).</li> <li>Two main causes of prolonged QT:<ul> <li>Congenital/Hereditary (long QT syndrome/channelopathies)</li> <li>Acquired (Drug induced, anorexia, bradycardia, MI/BBB, hypothermia, hypothyroidism, hypokalemia, hypomagnesemia, hypocalcemia, increased ICP)</li> <li>Think of ABCDE for common offenders:<ul> <li>A: Anti\u201dA\u201drrythmics (think class IA (procainamide,     disopyramide) and class III (amiodarone, sotalol,     dofetilide))</li> <li>B: Anti\u201dB\u201diotics: (azoles, macrolides, quinolones)</li> <li>C: Anti\u201dC\u201dychotics: 1st gen&gt;2nd gen (chlorpromazine,     haloperidol, risperidone)</li> <li>D: Anti \u201cD\u201depressants: SSRIs, TCAs</li> <li>E: Anti\u201dE\u201dmetics: (5-HT3 antagonists) ondansetron, also     droperidol</li> </ul> </li> <li>Other high risk medications: methadone, Arsenic (chemo),     quinines (antimalarials), hydroxychloroquine</li> <li>Special note on ondansetron (Zofran): Risk IV &gt; PO (ODT). Risk     is greater if using IV dose &gt; 16mg, concomitant QT prolonging     meds, concomitant other congenital and/or acquired QT     prolongation condition</li> <li>Conclusion: Single dosing of IV/PO Zofran without additional     risk factors is safe, but if the patient is on other QTc     prolonged medications or has risk factors for QTc prolongation,     would get ECG prior to giving or before giving another dose of     Zofran within 2 hours</li> </ul> </li> </ul>"},{"location":"toxicology/toxicology-qtc/#presentation","title":"Presentation","text":"<ul> <li>Most commonly asymptomatic</li> <li>Other symptoms include palpitations, seizure, syncope, SCD</li> </ul>"},{"location":"toxicology/toxicology-qtc/#evaluation","title":"Evaluation","text":"<ul> <li>Always evaluate with a recent EKG</li> <li>If pt is at high risk; ie: receiving antibiotics \u00b1 antiemetics     while inpatient with QT &gt;500, can monitor with EKG q 2-3 days</li> <li>It important to add QTc for crossover resident in your handoff</li> </ul>"},{"location":"toxicology/toxicology-qtc/#management","title":"Management","text":"<ul> <li>If stable:<ul> <li>Stop the offending medication (see ABCDE\u2019s above)</li> <li>Aggressive electrolyte repletion (K and Mg especially)</li> <li>Serial EKG monitoring \u00b1 monitor on telemetry</li> <li>If offending medication is needed, think of alternatives regimens (zofran scopolamine patch/alcohol wipe sniff; neutropenic ppx LVQ/fluconazole cefdinir/micafungin, etc.)</li> </ul> </li> <li>If unstable:<ul> <li>ABCs</li> <li>Defibrillation if pulseless</li> <li>Empiric IV magnesium</li> <li>If drug induced, contact cardiology for overdrive pacing as IV magnesium does not work</li> <li>Refer to ACLS protocol</li> </ul> </li> </ul>"},{"location":"toxicology/toxicology-toxidrome-overview/","title":"Toxidrome Overview","text":"<p>Quinton Taylor</p> Toxidrome Agent Symptoms Antidote Cholinergic <p>Insecticides (e.g. organophosphates)</p> <p>physostigmine, neostigmine, pyridostigmine, pilocarpine,</p> <p>nerve agents (e.g. Sarin)</p> <p>Muscarinic: Defecation, Urination, Miosis, Bradycardia, Bronchosecretions, Emesis, Lacrimation, Salivation, Sweating (DUMBBELLS)</p> <p>Nicotinic: Mydriasis, Tachycardia, Weakness, Hypertension, Fasciculations (MTWtHF)</p> Atropine (with pralidoxime if organophosphate poisoning) Anticholinergic Antihistamines, antipsychotics, antidepressants (TCAs), anti-parkinsons, atropine, scopolamine Hyperthermia, dry skin, mydriasis, delirium, hallucinations, tachycardia, urinary retention, seizures (\u201cHot as a hare, red as a beet, dry as a bone, blind as a bat, mad as a hatter\u201d) <p>Supportive care, consider</p> <p>physostigmine with toxicology</p> Sympathomimetic Cocaine, amphetamines, bath salts, synthetic cannabinoids, sedative/hyponotic withdrawal, pseudoephedrine, caffeine Hyperthermia, mydrasis, diaphoresis, tachycardia, arrythmias, hypertension, seizures None, supportive care; benzodiazepines as needed\\* Opioid Morphine, heroin, hydromorphone, fentanyl Miosis, hypoventilation, somnolence, comatose, bradycardia, hypotension Naloxone Sedative-hypnotic Benzos, barbiturates, alcohol, zolpidem CNS depression, confusion, stupor, coma None, supportive care only Hallucinogenic Phencyclidine, LSD, MDMA \u201cEcstasy\u201d Hallucinations, depersonalization, agitation, mydriasis (usually), tachycardia, hypertension, nystagmus None, supportive care only Serotonin syndrome SSRIs, SNRIs, MOAIs Hyperreflexia, myoclonus, diaphoresis, flushing, diarrhea, hyperthermia, tachycardia, confusion, agitation, coma Supportive care; benzodiazepines as needed\\*; contact toxicology prior to using cyproheptadine *for treatment of seizures, tachycardia, hypertension, agitation, and hyperthermia <p>General Workup</p> <ul> <li> <p>ABCs, evaluate vital signs, mental status, pupil size, skin     temperature and moisture</p> </li> <li> <p>Pulse ox, continuous cardiac monitoring, EKG, blood glucose</p> </li> <li> <p>UDS, acetaminophen/salicylate levels, ethanol levels, UA, BMP,     hepatic function panel, blood gas</p> </li> </ul> <p>General Management</p> <ul> <li> <p>Decontamination for topical exposures</p> </li> <li> <p>Antidotes if known ingestions/fits appropriate toxidrome</p> </li> <li> <p>Supportive care</p> </li> <li> <p>Discuss with toxicology, may be ways to enhance elimination of the     toxin (e.g. diuresis, alkalinization, dialysis, etc.)</p> </li> </ul>"}]}